[{"article": "The American Diabetes Association has more about diabetes-related eye complications.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nFor 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.\nThe study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone.\n\"First and most importantly, it provides patients an improved therapy for diabetic macular edema.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None discussed.\u00a0 The NYT reported: \"About 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\"", "answer": 0}, {"article": "In this study, researchers measured blood levels of vitamin D in 1,043 patients enrolled in a phase 3 clinical trial comparing three first-line treatments for newly diagnosed, advanced colon cancer.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\nIt promotes the intestines' ability to absorb calcium and other important minerals, and is essential for maintaining strong, healthy bones, according to the U.S. National Institutes of Health.\nThose patients survived one-third longer than patients with low levels of vitamin D -- an average 32.6 months, compared with 24.5 months, the researchers found.\n\"We found that patients who had vitamin D levels at the highest category had improved survival and improved progression-free survival, compared with patients in the lowest category,\" said lead author Dr. Kimmie Ng, an assistant professor of medicine at Harvard Medical School in Boston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes it clear that patients should not take supplements to increase vitamin levels if they are already normal, thus preventing harms from oversupplementation. However, we wish the story had specifically mentioned potential side effects of high dose vitamin D.", "answer": 1}, {"article": "\u201cAre DORAs the perfect hypnotics?\nOnly long-term use in large numbers of insomnia patients will reveal whether these drugs will be preferred to GABAergic hypnotics, and whether they produce rare complications, including narcolepsy-like symptoms in predisposed individuals,\u201d Mignot wrote.\nMonkeys given GABA inhibitors were much slower in responding to the prompt, and in some cases, missed it altogether, while monkeys given a potent orexin blocker called DORA-22 did not show these attention issues, Renger said.\nMost sleep aids, including Sanofi\u2019s Ambien or Sunovion Pharmaceuticals\u2019 Lunesta, act on a key neurotransmitter in the brain called GABA.\n\u201cWhen you hit those, you don\u2019t just hit the sleep system,\u201d John Renger, executive director and head of neruoscience basic research at Merck and one of the study\u2019s authors, said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is one quote noting that further testing will need to be done to look for rare complications, including narcolepsy-like symptoms, but the story does not mention other side effects, such as sleep walking, balance issues, etc.\u00a0 About a similar drug, Suvorexant, it states that the most common side effects have been headache and sleepiness \u2013 but no data are provided.\nThroughout, the story is not clear in differentiating between Suvorexant and the similar drug tested in the latest trial \u2013 DORA-22.\u00a0 Suvorexant is mentioned in the second sentence but it is NOT the drug studied in the trial being reported on.", "answer": 0}, {"article": "\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\n\"To the extent that the drug may act as an incentive to bring the subject up, that will be a good opportunity,\u2019\u2019 he said.\n\"There\u2019s a huge economic cost to divorce, and this is often cited as one of the main reasons for a divorce,\u2019\u2019 Goldstein said.\nThe condition affects about 10 percent of all pre-menopausal women, according to experts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects of the drug were reported in the story.\u00a0 Safety data reported indicates that potential side effects include dizziness, nausea, fatigue, somnolence, and insomnia. ", "answer": 0}, {"article": "But it may be too early to call this a cure.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nMORE: Babies Should Eat Eggs and Peanuts Early to Avoid Food Allergies\n\nIn the follow-up, which tracked the children for four years after they were treated with the combination therapy, 67% of those who got the combination probiotic and peanut therapy were comfortable eating peanuts, compared to only 4% of those who did not get the treatment.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t mentioned, which is problematic. The type of immunotherapy used in conjunction with probiotics for this study is called peanut oral immunotherapy. In a 2016 research summary document, the American Academy of Allergy, Asthma & Immunology describe this type of immunotherapy as \u201cone of the more promising new treatments\u201d for peanut allergies. Specifically, the summary noted that \u201cMultiple studies have now shown [oral immunotherapy] to be efficacious at desensitizing peanut-allergic children, but this efficacy comes at the expense of high rates of allergic adverse events, and the risk/benefit ratio of [oral immunotherapy] is an area requiring more study.\u201d This is a complex area, and the research summary is worth reading, but the key point here is that there are risks associated with oral immunotherapy \u2014 and this story doesn\u2019t acknowledge them.", "answer": 0}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe trial has moved on to phase II, which is taking place in 50 hospitals in the United States, said Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami's Miller School of Medicine and lead author of the study.\nThe largest national stem cell study for heart disease, sponsored by Baxter Inc., uses this surgical method, and recently announced success in a 12-month phase II trial for patients with severe angina.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story briefly mentions the potential for rejection, it fails otherwise to specify the potential side effects of the stem cell harvesting or infusion. This is surprising, given the fact that the Phase I trial is designed to prove safety. ", "answer": 0}, {"article": "Two small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nHere's how he survived]\n\nPrevious research has reached the same conclusion, but a significant problem with this study and others like it is that they rely on retrospective data, looking back over any number of years, said Michael S. Sabel, the chief of surgical oncology at the University of Michigan, who was not involved in the newly published study.\nWith $45 billion pledge to charity, Mark Zuckerberg and wife imagine \u2018a world without suffering from disease\u2019\n\nThe myth of sugar-free drinks, candy: Study shows they can wreak havoc on teeth, too\n\nModern men tend to overeat like cavemen as a way of showing off to women\n\nFor more health news, you can sign up for our weekly newsletter here.\n\"It's premature to suggest, and it\u2019s a difficult conversation to have with patients, that removing the breast will help them live longer in the face of Stage 4 disease,\" Sabel said.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Breast surgery can lead to complications, such as bleeding and infection, like any major surgery. Patients usually choose between breast-sparing surgery (surgery that takes out the cancer and leaves most of the breast) and a mastectomy (surgery that removes the whole breast).\nAccording to cancer.gov, mastectomies can affect a woman\u2019s psychological well-being due to a change in body image and the loss of normal breast functions. Furthermore, women undergoing total mastectomies lose nipple sensation, which may impede sexual arousal.\nOther breast surgeries could lead to sudden drops in estrogen production, which could induce early menopause in premenopausal women.\nSince harms are not addressed, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Cleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nPeople with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s too early to say exactly what harms might result from the use of this test clinically, but at the very least, we know that some patients would be unnecessarily flagged for\u00a0additional tests and procedures based on a false-positive test. The story should have mentioned this.", "answer": 0}, {"article": "This study received funding from the Divers Alert Network and U.S.\n\"I have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\" Calder-Becker said.\n\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nNone of the participants in either group had heart abnormalities, but the SIPE-susceptible athletes had higher pulmonary arterial pressure and pulmonary artery wedge pressure during the underwater exercise, confirming that SIPE is a form of pulmonary edema caused by high pressure in the blood vessels within the lungs.\nDURHAM, N.C. -- Swimmers and divers who are prone to a sudden and potentially life-threatening form of pulmonary edema in cold water could benefit from a simple and readily available dose of sildenafil, according to findings from a small study by Duke Health researchers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study itself is silent on the potential harms seen in the subjects treated with sildenafil, we think that the story should have noted that explicitly. Are four-hour erections an issue that swimmers need to be concerned about? Harmful side effects of ingesting sildenafil certainly\u00a0exist but are not broached\u00a0here.", "answer": 0}, {"article": "Drinking concentrated blueberry juice improves brain function in older people, according to research by the University of Exeter.\nThe study excluded anyone who said they consumed more than five portions of fruit and vegetables per day, and all participants were told to stick to their normal diet throughout.\nOf the 26 healthy adults in the study, 12 were given concentrated blueberry juice - providing the equivalent of 230g of blueberries - once a day, while 14 received a placebo.\nBefore and after the 12-week period, participants took a range of cognitive tests while an MRI scanner monitored their brain function and resting brain blood flow was measured.\nFlavonoids, which are abundant in plants, are likely to be an important component in causing these effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no statement about harms, not even a statement declaring there are none.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss potential harms. In a story like this, which is about a test that gives parents options, harm is a tricky concept and is very much in the eye of the beholder. Those who are likely to see a harm are those concerned about the slippery slope toward \"designer babies.\" Is there a moral and/or ethical question raised when parents can more easily conduct a test that might lead them to not have children? There is also the potential harm of falsely reassuring or alarming data.", "answer": 0}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\n\u201cIt sounds like opinion and nothing more.\u201d\n\nThe only published data on the tanning pill\u2019s ability to reduce sunburns came out last month in the British Journal of Dermatology.\nDr. Tobias W. Fischer, a dermatologist at the University Lubeck in Germany, offered this rationale for why he didn\u2019t: \u201cI don\u2019t give interviews, criticizing other researchers\u2019 work, even if industrial.\u201d\n\nThe editor of the journal that published the study, Dr. Tanya Bleiker, said it had been reviewed by experts before acceptance, as are all the journal\u2019s reports.\nAccording to Bleiker, \u201cthe authors stated very clearly that there was no conflict of interest.\u201d\n\nHowever, more than half of the authors work for Laboratoires Inneov, as indicated on the cover page of the report.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms found in the trials so far, but then the evidence in the trials so far is being called into question.\u00a0 We\u2019ll give the story credit for exposing the potential harm of consumers (and dermatologists) being misled by unsubstantiated claims. ", "answer": 1}, {"article": "Arriving in New York, you would be synced to the local time after one day, he said.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\n(Reuters Health) - Exposing sleeping people to a series of short flashing lights at night might help them adjust more quickly to time zone changes, according to a new U.S. study.\n\u201cThis clock remains synchronized with the external day through regular exposure to light.\u201d\n\nNighttime flashes change the timing of the circadian clock, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report indicated there was no harm involved: \u00a0\u201cIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality.\u201d This report also indicated helpful additional information from an outside observer, Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study, who said: \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 1}, {"article": "gov.\nThey were given MRI brain scans and a battery of tests to measure memory and thinking abilities; they also had blood drawn to check the level of omega-3 fatty acids in their red blood cells.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nTHE QUESTION Eating fish can be good for the heart, thanks to the presence of omega-3 fatty acids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of eating fish are not in question \u2013 although the story could have mentioned concerns with mercury in some fish at some levels of consumption.", "answer": 2}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nSure enough, in the week when they ate eggs, volunteers had lower acylated ghrelin and higher PYY3-36 compared with the week when they ate cereal.\nSo to assess whether people who ate egg breakfasts were better off than their counterparts who ate cereal, they took blood samples and measured the concentration of two key hunger hormones: acylated ghrelin (which stimulates hunger) and PYY3-36 (which is how the intestines let the brain know that you\u2019re full).\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In just a line, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol), but that\u2019s probably splitting hairs. We\u2019ll call this not applicable since there aren\u2019t really any harms from eating a reasonable amount of eggs. Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "A man whose P.S.A.\n\u201cThere\u2019s a strong case that they should be exempted from screening.\u201d\n\nThe advice is less clear for men with scores between 1.0 and 2.0 at the age of 60.\nThe long-term risk of dying from prostate cancer ranged from about 1 percent to 3 percent for these men, and the decision to screen may depend on their personal views and family histories, Dr. Vickers said.\n\u201cWe need to screen fewer people, screen the right people, and we don\u2019t have to treat every cancer we catch.\u201d\n\nA version of this article appeared in print on September 28, 2010, on page D1 of the New York edition of The Times.\nThe findings also suggest that at least half of men who are now screened after age 60 don\u2019t need to be, the study authors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harm that might occur by a man who stops screening at age 60 because his PSA level was low who might still go on to die from prostate cancer. \u00a0The story provided estimates of this.\u00a0\nWhile presenting interesting insights about prostate cancer risks, the story did not include any information about the accuracy of the PSA test itself. At the very least, it ought to have indicated that there are common factors that can increase an individual\u2019s PSA level which are unrelated to prostate cancer.", "answer": 0}, {"article": "Dupixent is for the hard-core cases that aren\u2019t helped by anything else.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\"People with moderate to severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives,\" Julie Block, president and CEO of the National Eczema Association, said in a statement provided by the company.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cthe drug can cause serious allergic reactions and eye inflammation. \u2018The most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u2019 the FDA notes.\u201d\nThis is sufficient, but one important detail we think is worth noting: The FDA gave the drug \u201cbreakthrough therapy status,\u201d meaning that long-term impacts were not studied.", "answer": 1}, {"article": "So he fears that fat injections for breast enlargement could increase unnecessary biopsies.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nBut Dr. Michael F. McGuire, the president of the American Society of Plastic Surgeons, cautioned: \u201cHow you take the fat, how you process it, how you inject it are all factors in how successful fat survival is going to be.\u201d\n\nIn some cases, radiologists can distinguish between innocuous and suspicious calcifications, said Dr. Sameer A. Patel, a plastic and reconstructive surgeon at Fox Chase Center in .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe body of the story details several potential complications including long-term fat loss that undoes any initial benefits, as well as the appearance of cysts, masses, nodules and scarring. The story also notes concern about fat grafts potentially interfering with breast cancer screening.\nHowever, the story should have at least referred to such problems higher in the story. It also neglected to mention reports of at least one death, as well as strokes and serious infections including septic shock, that were noted in the task force report.\n\n", "answer": 1}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\nHowever, as the disease spreads, it becomes difficult to differentiate healthy brain cells from cancerous glioblastoma stem cells, and the condition is therefore almost impossible to completely remove.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that the Zika virus had no adverse health effects in mice, but that it is possible it might destroy healthy neural tissue in humans. Again, the story needed to caution that we have no idea how this might help\u2013or hurt\u2013humans.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a half-hearted attempt here. It says that new over-the-counter enzymes are made\u00a0by fungi and haven\u2019t been tested in humans. And it suggests that anyone with a fungal allergy should \u201cuse the products with caution.\u201d\u00a0It also passes along a company spokespersons\u2019 observation that \u00a0\u201conly occasional side effects\u201d are reported by customers taking one of their supplements.\nBut the company phone line\u00a0is hardly an accurate tool for assessing possible harms and side effects of these products. And vague warnings about possible allergic reactions don\u2019t qualify as useful information for decision-making.\u00a0If there are safety concerns with any of these products, the story should have spelled them out more clearly and described what the risks are.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned for either of the newer brand-name approaches mentioned \u2013 the drug Solesta or the device InterStim.\nThe Solesta website states:\nThe most common risks of treatment with SOLESTA are mild pain or discomfort in the rectum or anus, (experienced by about 27 out of 100 patients) and minor bleeding or spotting from the rectum following treatment (experienced by about 16 out of 100 patients). Some patients experienced a fever (7 out of 100), abdominal pain (3 out of 100), or diarrhea or constipation (6 out of 100) after treatment.\nMore serious risks including infection and inflammation of the tissues in the anus may occur, but these are not common. In clinical studies, about 4 of 100 subjects experienced infection and 3 of 100 subjects experienced inflammation.\nMedtronic\u2019s InterStim website states:\nThe InterStim Therapy system has risks similar to any surgical procedure, including swelling, bruising, and bleeding. Complications can include pain at the implant site, new pain, infection, lead (thin wire) movement, technical or device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation. Any of these situations may require additional surgery or cause your symptoms to return.", "answer": 0}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nThe researchers found that a troponin threshold of <5 ng/L at presentation identified around two-thirds (61%) of patients at very low risk of heart attack and may have been eligible for early, safe discharge--with a high negative predictive value of 99.6%.\n\"Until now there were no quick ways to rule out a heart attack within the emergency department,\" explains lead author Dr Anoop Shah from the University of Edinburgh in the UK.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of this test \u2014 discharging a patient who may be having a heart attack and be at risk of dying \u2014 can only be adequately assessed in prospective evaluations using this new test as part of routine care. The release doesn\u2019t adequately address this or describe what might happen if the test is wrong. We also think that the release could have done a better job of explaining that this new test is only one part of the assessment of patients presenting with chest pain. Other factors that are likely to be important that could have been mentioned from the paper include changes in the EKG (electrical test of the heart) that is also part of standard care. In addition, the duration of symptoms is also important. For patients who have had pain for less than 2 hours, the test may not be as effective.", "answer": 0}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any potential harms from the procedure, although it appears to involve\u00a0piercing of the eyeball and injecting cells inside.\u00a0 It would also appear that the procedure requires\u00a0a small slice through the cornea to release pressure within the eye from adding the stem cells.\u00a0 And while the eye is well-known to be one of the fastest healing of our organs, any surgery involves potential risks.\u00a0 While the release does point out that the cells, as they multiply, form a kind of protective layer in the back of the eye, it does not mention \u2014 as the actual research paper does \u2014 that that layer may interfere with the supply of nutrients to cells in the eye, leading to their death.\u00a0 Nor does the release mention the potential problem of rejection of the foreign cells, which the research paper explains.", "answer": 0}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n\"I personally think foods [containing soy] are better.\"\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harm.", "answer": 0}, {"article": "Two studies reported nearly 80% of Freespira-treated patients were panic attack free at 12 months post-treatment.\nFreespira is commercially available throughout the U.S. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms.\n(For a tutorial on how unsafe medical devices have been allowed into the marketplace, see our toolkit article.)", "answer": 0}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\nHe is a surgical oncologist at Northwell Health's Imbert Cancer Center in Bay Shore, N.Y.\n\n\"Not only did these patients have a better survival outcome at one year, but they had only one-third the side effects compared to Yervoy,\" Deutsch said.\nAnd at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe study is scheduled for presentation Monday in Madrid, Spain, at the annual meeting of the European Society for Medical Oncology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the most common side effects were fatigue and diarrhea. But the story also offers information about how common any adverse side effects were \u2014 for both Opdivo and Yervoy. That\u2019s valuable information. What\u2019s more, the story notes that Opdivo was less likely to cause adverse side effects than Yervoy, and that those side effects were less severe. Again, that\u2019s useful context.", "answer": 1}, {"article": "About nine years ago, scientists discovered that the tumors of about half of patients with melanoma have a mutation in a gene called BRAF.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\n\"I don't want to say this is going to change survival rates but they're working with the most ill people, so you can't really generalize [to other patient populations],\" said Dr. Alice Pentland, chair of dermatology at the University of Rochester Medical Center.\nWEDNESDAY, Aug. 25, 2010 (HealthDay News) -- By probing deeper into the biological mechanisms that go awry in melanoma, scientists have come up with an experimental drug that has had an effect in a surprising number of patients with advanced melanoma.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in this story \u2014 somewhat shocking when you consider that safety assessment is the primary objective of phase\u00a0I research.\u00a0The suggestion that this drug may substantially increase the risk of another, less invasive type of skin cancer, certainly warrants some attention. The accompanying editorial in the NEJM commented: \"Overall, PLX4032 had moderate toxicity, with rash of grade 2 or 3, fatigue, and arthralgia being the major dose-limiting toxic effects. Somewhat unexpectedly, cutaneous squamous cell carcinomas developed in a significant percentage of patients.\"", "answer": 0}, {"article": "That said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\nDietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nAccording to Stewart, the meaning behind the numbers is clear.\nSource: Stewart RAH, Wallentin L, Benatar J, et al.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this is a story about a study of dietary habits, this is N/A.", "answer": 2}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\n\u201cAlthough this research is only in the lab at the moment, we hope it will move quickly toward clinical trials in patients.\u201d\n\nLeukemia is the most commonly diagnosed cancer in children and accounts for a around a third of all cancers diagnosed in children.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\nAccording to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a news story can speculate about \u201cearly potential\u201d benefits in a headline from such early laboratory results, it can also speculate about potential harms from the pathway this proposed intervention takes.\nWhat could go wrong with this approach?\nWhat will scientists be concerned about as they move into clinical trials?\nThe story talks only about potential benefits.\u00a0 There are always potential harms on the horizon.", "answer": 0}, {"article": "But even that can be helpful.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\nThere are several theories, including changes in how food is processed and children's not being exposed to certain foods early in life.\nCurrently, food-allergic people have only two options: to avoid the substance that causes their reaction or to try to stop a reaction with an injection of epinephrine.\nOnce that is established, the participants are sent home to sprinkle that amount of purified protein on their food for a week or two; then they return to the research center in to see if the dose can be increased.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that 4 individuals in a study of 33 had to withdraw from the study due to allergic reaction.\u00a0 \nThere was also a strong word of caution to readers NOT to try desensitization on their own. \u00a0 ", "answer": 1}, {"article": "The pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nIt is a lifelong condition that occurs when the pancreas does not produce any insulin, while type 2 diabetes \u2013 far more common, especially as obesity rises around the world \u2013 is a condition where the pancreas does not produce enough insulin or the body\u2019s cells do not react to it.\nHaving a hugely expanded supply of lab-grown islets will enable us to significantly extend this established clinical treatment.\u201d\n\nCGT was set up in 2012 and is based on the 12th floor of Guy\u2019s hospital in London.\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\nJohn Casey, consultant transplant surgeon at the Royal Infirmary of Edinburgh and lead clinician for the islet transplantation programme in Scotland, said: \u201cIslet transplantation can transform the lives of patients with type 1 diabetes, and in some cases can result in long-term freedom from insulin injections with excellent glucose control.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0mentions a few times the benefits of being freed from insulin injections, but offers no information on the potential harms of any therapy, including the one being proposed here, which would be invasive. Current islet transplant treatments contain a number of risks.\nThere also should be some discussion about what percentage of transplanted patients would see benefit. The article makes it seem as if all of them would be free from using insulin.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with benefits, the potential harms of red palm oil are just generally summarized. Still, the story points out that this oil and others like it can produce harm (and clearly contain plenty of calories). A nice touch is that the potential harms addressed by the story include environmental damage caused by poor agricultural practices, as well as potential exploitation of workers in developing nations. While those domains are typically outside our scope, they are clearly relevant to consumers looking to make informed purchases.", "answer": 1}, {"article": "The machine costs around $30,000, but would be priced under $20,000 in poor countries, he told the AP.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\n\"The test that we developed finally makes it possible to detect TB in a single clinic visit,\" Dr. David Alland, chief of infectious diseases at the UMDNJ-New Jersey Medical School, said in a university news release.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the new test apparently does a very good job\u00a0of ruling out individuals who don\u2019t have TB, the study reported that 5 out of 609 patients without TB received a false-positive TB diagnosis. These individuals may be subjected to additional tests and treatments that have the potential to cause harm. The story didn\u2019t mention this. ", "answer": 0}, {"article": "The procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\n\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\nBut the first to reach an infant born by cesarean section come mostly from the environment \u2014 particularly bacteria from inaccessible or less-scrubbed areas like lamps and walls, and skin cells from everyone else in the delivery room.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that thus far the procedure \u201chas proved entirely safe,\u201d but we\u2019re talking about only four babies here!\u00a0The article assumes that all the bacteria in the mother\u2019s vaginal secretions are \u201cfriendly.\u201d \u00a0This is clearly not the case in all patients. Significant infections can be transmitted to the newborn from bacteria resident in the mothers vaginal secretions from less than friendly bacteria\u00a0including Chlamydia, Listeria and group B Strep to name a few. Suggesting that the procedure is not recommended but then pointing out that Dr. Brubaker had the procedure done for her newborn supports the notion that this is a harmless procedure \u2014 a potentially dangerous message.", "answer": 0}, {"article": "\u201cAn aneurysm in no way means that you're going to die.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nIf an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nThe deadly condition is called an abdominal aortic aneurysm (AAA) and Berg had not one but two of them \u2014 measuring 5 centimeters and 6.5 centimeters wide \u2014 making surgery dangerous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential risks associated with this procedure or any stent insertions for abdominal aortic aneurysms. Further, there\u2019s no discussion of whether the procedures and devices involved have undergone safety trials.", "answer": 0}, {"article": "\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nIt appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nIt blocks an enzyme crucial to the production of male hormones, which spur the growth and spread of advanced prostate cancers.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nOct. 12, 2010 -- Even when medical or surgical castration fails, a potent drug extends survival by four months in patients with metastatic prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of hormone therapy \u2013 harms that may include osteoporosis, fractures, diabetes and heart disease.\u00a0 This is a significant oversight. ", "answer": 0}, {"article": "Actuarial five-year OS was 95.6 percent for the entire cohort.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\n\u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d\n\nA total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional and academic hospitals across the U.S.\nAlthough prostate tumors generally respond well to radiation therapy (RT), the possibility of radiation exposure to healthy tissue in the genitourinary (GU) and gastrointestinal (GI) systems can be of concern.\nNewswise \u2014 BOSTON, September 26, 2016 -- High dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity and excellent cancer control rates, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that between half and two-thirds of patients experienced low, \u201cusually temporary\u201d rates of toxicities. It also notes that \u201cfewer than 2 percent of patients experienced severe toxicities in their gastrointestinal, reproductive, and urinary systems, and no patients reported life-threatening or fatal toxicity.\u201d A few more details here would be helpful. For example, how many patients experienced a decline in urinary or sexual function, and for what period of time? And what are other potential risks of radiation therapy? The real question is how do these harms compare to other treatments? That was not assessed in this study.", "answer": 1}, {"article": "The protective effect for hip fractures disappeared.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nThe bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\nA new analysis of the landmark Women\u2019s Health Initiative, the federal study that discovered the health risks, indicates that women who stopped using estrogen after the dangers were uncovered are no longer at increased risk for strokes and blood clots about 10 years after they stopped.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe Post tries but fails to do justice to the mixed picture of longer-term outcomes for women who took estrogen-only therapy. There is no quantitative statement about the risks, or the benefits. Some of the findings are misstated: \u201cRisk for heart disease during the follow-up period was similar to that seen while women were taking the hormone.\u201d The point of the study is that there was no increased risk in heart disease in estrogen-alone users (as opposed to findings with estrogen/progestin arm); and longer followup confirmed no increase. As stated, the story seems to imply there was an increased risk for heart disease that did not diminish during followup.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The \u201cgenerally safe\u201d line is too vague for us.\u00a0 There are side effects and risks associated with probiotic use.", "answer": 0}, {"article": "The team then stacked up gray matter changes against dietary consumption as reported in the questionnaire.\n\"One has to wonder if there are other factors associated with fish consumption that they didn't measure that might be protective,\" he said.\nWith that information, the authors found that regardless of age, gender, physical activity routines, and/or educational achievement, race or weight, those who ate baked or broiled fish had larger mass in the hippocampus, precuneus, posterior cingulate and orbital frontal cortex regions of their brains.\nLipton added that \"this group of researchers is really, really good,\" and called the study results \"a very interesting finding, and absolutely worthy of further exploration.\"\nThe study authors found that eating baked and broiled fish -- but not fried -- helps to preserve gray matter neurons, strengthening them in areas of the brain deemed critical to memory and cognition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not as good as the competing WebMD story, which stated:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 0}, {"article": "\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is recommended for optional use in boys and men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides a single comment about the potential harms of the vaccine (\u201c\u2026thus far the vaccine appears to be safe.\u201d). Additional information concerning injection site reactions would have been useful. But we give the story credit for doing a good job of discussing the risks vs. benefits in the wider subject of universal vaccination of young men.", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\n\"This drug has minor effects on normal cells other than neutrophils (white blood cells),\" said the study's senior author, Peter J. O'Dwyer, MD, a professor of Hematology/Oncology at Penn and director of the Developmental Therapeutics Program at the ACC.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\n\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAlso, combining palbociclib with other anti-cancer agents is feasible, and early results in myeloma and some solid tumors have led to more definitive studies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes the drug\u2019s side effects, including the most common one which renders patients more susceptible to infections. However, it needs to be pointed out that the studies involved very small numbers of patients and the emergence of more serious side effects may not be seen until the drug is observed in a larger population.", "answer": 1}, {"article": "He is a neuroscientist at the University of South Florida's College of Pharmacy and Byrd Alzheimer's Institute in Tampa.\nJune 7, 2012 -- Drinking three cups of coffee per day may help turn the tide against Alzheimer's disease among older adults who are already showing signs of memory problems, a new study shows.\nAccording to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nIn the study, blood levels of caffeine were more than 50% lower among people with MCI who developed Alzheimer's during follow-up, when compared with their counterparts who did not worsen.\n\"There is no reason to stop if you are experiencing memory problems.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Caffeine can cause anxiety, poor sleep, irritative bladder symptoms, palpitations, and even arrythmia. \u00a0Older people are at greater risk for each of these problems and should be aware of the adverse effects of caffeine, even at lower levels of intake.", "answer": 0}, {"article": "The authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe study cites the health advantages of breast-feeding. Are there no potential harms or disadvantages? For example, there is some research to suggest that pregnancy and breast-feeding may increase flares of RA.\n", "answer": 0}, {"article": "For most patients the cravings really do disappear.\nIt used to be that roughly one in 100 people died from this operation.\nA big reason the operation works is because it seems to suppress appetite.\nIt can force type 2 diabetes into almost instant remission and it appears to reduce the risk of cancer.\nIt's about one-tenth of cardiac surgery,\" he explains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment mentions some harms of the surgery, including death, depression and suicide. ", "answer": 1}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At first glance, it\u2019s hard to imagine there are any dangers: Chemicals in broccoli are harmless, right? But as revealed by this very study\u2013that\u00a0sulforaphane has the capacity to significantly change blood lab levels\u2013these chemicals can work like medication. That means they\u00a0also may carry harms, too. In this case, specifically, it\u2019s for people taking the blood thinner Coumadin (warfarin), who must be very careful when eating broccoli and other vegetables rich in Vitamin K.", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports the potential health risks linked to the patch, primarily breast cancer.\nThe story does a nice job presenting the actual number of events (breast cancer), 3/264 in patch group and none in the placebo group, and goes on to mention that, although not statistically significant, it does support concerns about breast cancer risk. ", "answer": 1}, {"article": "But after being treated with the immune therapy, his cancer did not grow or recur for nearly eight months.\nIt\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\nAfter surgery to remove the bulk of the brain tumor, Badie and his colleagues directly injected the site with the modified immune cells (called chimeric antigen receptor T cells, or CAR T cells) six times, and the remaining part of this tumor stopped growing.\n\u201cIf we can do the same for other patients, that would be an amazing accomplishment that many decades of work and research on glioblastoma have never done,\u201d says Badie, whose own father passed away a decade ago from glioblastoma.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes that CAR-T cell therapy has potentially dangerous side effects when used the way it was in in this trial, and acknowledges surprise on the part of the investigators as to why the patient did not develop them. The story might have been stronger if it had noted that the treatment is well known for serious side effects in experiments on patients with other forms of cancer. (See our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.)", "answer": 1}, {"article": "For starters, Blank says, circumcision helps baby boys pretty much immediately.\n\"I think that all healthy newborn babies should be circumcised,\" says Edgar Schoen, a professor emeritus at the University of California, San Francisco.\nIt's all the same couple of studies that have been regurgitated and reprogrammed.\n\"They act as though there's this huge body of literature.\nTo do that is a human rights violation and an ethical travesty,\" says Georgeanne Chapin of the anti-circumcision group Intact America.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only specific harm mentioned in the story was critics\u2019 comparison to genital mutilation.\nBut the story didn\u2019t cite what the AAP wrote in its statement:\n\u201cComplications are infrequent; most are minor, and severe complications are rare.\u201d\nOr what appears on the AAP website:\n\u00a0", "answer": 0}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\n\"The ultimate goal is to be able to predict the response of patients to new and existing therapies at an early stage, thereby personalizing their treatment and improving outcomes,\" Michael J. Evans, research fellow in the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, explained in meeting news release.\nBoth methods have their limits and, \"while this study is very preliminary, if this radiotracer technology can prove to detect very early recurrence or metastasis in human patients, it could become extremely useful in either the pre- or post-treatment setting in selecting a treatment algorithm,\" Schwartz said.\nIn studies involving mice with prostate cancer, the researchers had the radiotracer hone in on prostate-specific antigen (PSA), the same prostate cancer marker used in the PSA test.\nBut a team from Memorial Sloan-Kettering Cancer Center in New York City said the technology could help identify cases where prostate cancer has spread to the bone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said nothing about potential harms.\nMedline Plus reminds consumers:\nThe amount of radiation used in a PET scan is low. It is about the same amount of radiation as in most CT scans. Also, the radiation doesn\u2019t last for very long in your body.\nIt is possible, although very unlikely, to have an allergic reaction to the radioactive substance. Some people have pain, redness, or swelling at the injection site.\nHarms also emerge from false positive and false negative test results \u2013 which could lead to unnecessary treatment or undertreatment.", "answer": 0}, {"article": "The study appears in the latest issue of the journal Ophthalmology.\nAbout 3 million Americans and 60 million people worldwide have glaucoma, and the numbers are projected to rise over the next few decades as the population ages.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\n\u201cWe call this disease a \u2018thief of vision\u2019 because most people with it have no idea that they have lost sight until it is too late to bring it back,\u201d Iwach says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 There wasn\u2019t any discussion of potential harms and we can\u2019t think of any \u2013 besides the obvious one of unnecessary glaucoma screening in some cases.", "answer": 2}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of the immunotherapy it describes. Immunotherapy frequently causes a flu-like syndrome. Among the potential complication are devastating infections. The published case study hints at these, observing that the patient\u2019s initial reaction to the therapy was \u201ctransient lymphopenia, low-grade fever, and myalgia.\u201d Other adverse events commonly reported after immunotherapy include diarrhea, rash, adrenal insufficiency, and liver test abnormalities.", "answer": 0}, {"article": "Those deaths were related to the transplants, Saccardi said.\nMONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nTo see how patients did over the long term after stem cell transplants, Saccardi and colleagues followed 281 patients from 13 countries who received stem cell transplants between 1995 and 2006.\nHowever, it can be considered a concrete option for patients showing aggressive MS who have not responded to approved treatments,\" said study co-author Dr. Riccardo Saccardi.\n\"There may be a population of MS patients that could be identified that might do well with transplant,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on one potential adverse outcome: death. The story addresses this using clear, unambiguous language, which is good. In addition, the story notes: \u201cThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\u201d That\u2019s a key point to make. The story could have been stronger if it had addressed the potential for other, nonfatal outcomes, but we give it a satisfactory rating.", "answer": 1}, {"article": "The results were just published online by the medical journal The Lancet.\nA study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\nIt works by keeping the body from breaking down clots.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned there was no increase in deaths due to blood clots in the TXA group. We understand it\u2019s a blog brief \u2013 so this is sufficient. ", "answer": 1}, {"article": "The developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nThe condition is poorly understood and somewhat vaguely defined, so estimates are not very precise.\nSome drugs that treat the pain, including opiates, can make the constipation worse, he said.\n\u201cIt may provide more of a one-stop shop.\u201d\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The visor that allows legally blind people to see is no longer Star Trek fiction.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nA next-generation visor from eSight can improve vision for many legally blind people.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s\u00a0no\u00a0discussion of risks here. Does an eSight cause eye strain? What about headaches? Nausea? Does all-day use impact sleep quality? Is there a feeling of detachment or foggy-headedness that sometimes accompanies use of the virtual reality headsets it takes after? These are but a few of the questions we had on the drawbacks.", "answer": 0}, {"article": "Natural-birth advocates cite a \"cascade of interventions\" caused by hospitals' practice of using the drug Pitocin to stimulate labor.\nThe risk of death for infants delivered via C-section\u2014who are more likely to have a low birth weight\u2014was double that of vaginal births, and C-section babies were more likely to have respiratory problems.\nIf you have customers who sit at a table and don't order anything, you're not making any money,\" says Jennifer Block, author of \"Pushed: The Painful Truth About Childbirth and Modern Maternity Care.\"\nNatural birth\u2014without drugs or interventions\u2014whether at home or in a hospital, remains a rarity (despite the fact that home births don't have an appreciably higher risk rate than hospital births).\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantifies the risk of death in C-section versus vaginal birth. The story could have done more to describe other, more common risks, such as wound complications and infections.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story presented information about one side effect, dizziness, it did not do an adequate job address potential harms associated with treatment.\nFrom the company's own website, it was possible to learn that:\nThe most common adverse events occurring during all controlled clinical trials for patients taking LYRICA vs those taking a placebo were dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention).\nThese might be important to patients or investors. \u00a0", "answer": 0}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the only available preventive treatments are accidental discoveries: A number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too.\n\"There's a big hole to fill, both in prevention and acute therapies,\" says Alexander Mauskop, director of the New York Headache Center in New York City.\nIn women of childbearing age, who are the ones most prone to frequent migraines, \"you can imagine that might have effects on fertility or placental function.\"\nBut then he says that, since I'd previously shown some response to Botox, perhaps I might want to give it another try.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Initially the story says patients \u201creport limited side effects that consist mostly of pain at the injection site. Unlike the current preventive medications, there is no nausea, no fuzzy thinking, no nerve pain, no weight loss or gain.\u201d\nBut it also notes a lack of long-term safety data and \u201cpotential long-term effects on blood pressure or other cardiovascular function\u201d as well as potential effects on fertility or placental function.\nIn the end, the reporter reflects on her own migraines and her own choices: \u201cI think about my two young children and my risk tolerance. Perhaps in ten years I\u2019ll feel differently. For now, however, I pick up the phone and cancel my clinical trial appointment.\u201d\nWe also like this cautionary sentence: \u201cRight now, the longest patients have been on one of these new therapies is one to two years.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note the potential harms of treatment, such as dry and irritated eyes and blurry vision, but we are not told how often these happens. The story only provides one patient's anecdotal evidence that the surgery did not work well for him due to lasting uncomfortable side effects. \n\u00a0\n\u00a0", "answer": 1}, {"article": "So are lycopene packed tomatoes really the magic fruit?\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\n\"This study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\" says study author Jouni Karppi, of the University of Eastern Finland in Kuopio.\n\"Eating tomatoes is a good thing, but we don't know if there is really anything unique about tomatoes apart from other fruits and vegetables that reduce stroke risk,\" explains Dr. Walter Willett, chair of the Department of Nutrition at Harvard School of Public Health in Boston, Massachusetts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know of any harms that can result from eating tomatoes,\u00a0so we\u2019ll rule this not applicable. However, the story could have cautioned against trying to get lycopene from supplements,\u00a0which could have unknown side effects and harms.", "answer": 2}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the selling points of Reiki is how harmless it may be (lack of efficacy notwithstanding).\u00a0 The story could have addressed what might be the greater harm in people choosing Reiki for therapeutic benefit and forgoing other, proven treatment methods.\nWe\u2019ll again give the column the benefit of the doubt.", "answer": 1}, {"article": "\"These are exciting results.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\nWhile the procedure can be potentially life-threatening, none of the 15 patients in the study died or suffered lasting side effects.\nThe study was approved by ethics committees in Brazil, he said, adding that he personally believes it was appropriate to do the research in children as well as adults, as long as the Brazilian ethics panels approved.\nDr. Lainie Ross, a medical ethicist at the University of Chicago, said the researchers should have studied adults first before exposing young teens to the potential harms of stem cell transplant, which include infertility and late-onset cancers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of the new treatment whatsover, including no mention of how serious these harms were or how frequently they occurred.\u00a0\u00a0 ", "answer": 0}, {"article": "\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nThe number of scans has increased at a rate of 10 percent a year recently, jumping from 3 million scans in 1980 to more than 70 million a year today.\n\"It's often said that the radiation dose of a chest X-ray is comparable to flying across the continent,\" Smith-Bindman says, referring to natural radiation exposures at high altitudes.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\n\"For the same body part, the same patient with abdominal pain being evaluated for possible cancer, there can be a profoundly different radiation dose,\" says Dr. Rebecca Smith-Bindman, a radiologist at the University of California at San Francisco who led that study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harm of exposure to radiation due to CT scanning.\u00a0The story could\u00a0have also mentioned\u00a0other\u00a0harms from overuse of scanning, such as follow-up testing\u00a0and procedures to evaluate suspicious findings that\u00a0turn out to be benign.\u00a0", "answer": 1}, {"article": "The Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\nThe most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nBut an analysis of insurance claims for more than 2,200 people with Type 2 diabetes who underwent stomach-reducing surgery found that the vast majority of them were able to drop drugs they had been taking to treat the condition beforehand.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story does report that some patients died and 21 percent had to be readmitted to a hospital within a year after surgery.\u00a0 Since the story was about the study, we\u2019ll give it a satisfactory score for reporting the harms reported in the study.\u00a0 But such stories could (and we wish would) always include even a line about other side effects and complications of stomach-reduction surgery, which include nutritional deficiencies, gallstones, stomach ulcers, hernias, food intolerance, kidney stones, low blood sugar, blood clots, leaks in stomach staples, pneumonia, dumping syndrome (nausea, vomiting, diarrhea, dizziness and sweating caused by food moving too quickly through the small intestine) and other problems.\n", "answer": 1}, {"article": "For the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nFor centuries pathologists have relied on the microscopic examination of tumors to distinguish between atypical moles and melanoma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention potential harms. Like any diagnostic or screening test, IMS carries a risk of a false negative and false-positive tests that could lead to a false sense of security or anxiety/unnecessary treatment. In addition, a biopsy is required to test\u00a0a tissue sample (for both a standard evaluation and IMS). Though generally safe, a biopsy can result in scarring, bleeding, infection or allergic reaction to a topical antibiotic. The release could have mentioned these potential harms.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said reported side effects included reactions at the sites of the infusion and swelling around blood vessels observed with brain imaging, and that the companies \u201csaid they plan to present the results in detail at [an] academic conference.\u201d\nThe story could have been clearer on how common these side effects are and how serious they were. According to the companies\u2019 news release, infusion-related reactions \u201cwere mostly mild to moderate in severity. Incidence of ARIA-E (edema) was not more than 10% in any of the treatment arms, and less than 15% in patients with \u2026 the highest dose per the study protocol safety and reporting procedures.\u201d\nThese are concerning potential harms for which no one knows the long-term consequences.", "answer": 1}, {"article": "MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\nEvery year, 1.3 million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer, the procedure is invasive and results in complications in 18 percent of patients, with 3 percent hospitalized for infection within 30 days.ii,iii,iv Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction.\n\"While biopsy is the only path to prostate cancer diagnosis, no man wants to, nor should have to, go through the uncomfortable, costly procedure if it can be avoided,\" said Dr. Jan Groen, Chief Executive Officer of MDxHealth.\nThe study published in The Journal of Urology, led by researchers at the Vanderbilt University Medical Center, was designed to elucidate the cost-effectiveness of SelectMDx in a population of U.S. men with elevated PSA, a marker of prostate cancer risk.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although providing urine for the test involves little to no risk, choosing not to move forward with a biopsy as a result of the test does bring with it a risk of being wrong, should the cancer be aggressive (a false negative). The likelihood of that error would be an important piece of information.\nThe study cites a reference suggesting that the sensitivity for detecting high-risk cancers was 95.7%.", "answer": 0}, {"article": "Other doctors were not so sure.\nThe difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.\n\u201cI have patients who agonize about this, people who are coming to the end of their tamoxifen.\u201d\n\nEmily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years.\nIn the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantified the risk of endometrial cancer and pulmonary blood clots.\nThis was the only one of the three stories that we reviewed that picked up on the high dropout rate in the study \u2013 an important addition:\n\u201cIn the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\u201d\n\u00a0", "answer": 1}, {"article": "# # #\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nGiven the prevalence of chronic pain, high frequency SCS is an exciting advance for our patients.\u201d\n\n\n\nSCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult to treat chronic pain in the trunk and limbs.\nConversely, only 44 percent of back pain and 56 percent of leg pain patients in the traditional SCS group experienced a 50 percent reduction in pain.\nIn the study, researchers examined 171 patients with chronic back or leg pain who were implanted at 10 comprehensive pain treatment centers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms except to note that the high-frequency group had no paresthesia. The study that\u2019s the basis for the release noted that \u201cnon-serious\u201d study-related adverse events occurred in about 30% of patients in both groups. These included implant site pain and lead migration resulting in \u201csurgical\u00a0revision\u201d (i.e. a second operation). But that begs the question: How can a second surgery be considered \u201cnon-serious\u201d?", "answer": 0}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the text notes that individuals involved in the study experienced no \u201cserious adverse effects,\u201d it doesn\u2019t define what \u201cserious\u201d means. The use of that adjective implies that participants may have experienced some side effects, however modest. And although this prep is too new to have gathered data over time about possible harms, the release claims it is as \u201csafe\u201d as some already available options. These standard preps are purgatives that often come with mild side effects such as stomach pain, nausea and syncope from induced bowel movements, and the inevitable damage to intestinal flora. Those side effects deserved a mention here.", "answer": 0}, {"article": "Probiotic organisms are non-pathogenic bacteria that, when present in the gut flora, are known to improve the overall health of the host.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nIn the case of bipolar disorder and the GBA, previous studies have shown that inflammation, or overstimulation of the body's immune system, is a contributing factor in the disease.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms of probiotics nor the fact that they are not regulated for safety and effectiveness.", "answer": 0}, {"article": "A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cThis is a huge development for men with CRPC that previously did not have many options,\u201d says Isabel Schlaepfer, PhD, CU Cancer Center member, assistant professor in the Division of Medical Oncology and senior author of the study.\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug\u2019s potential harms to people are known and reported in the New England Journal of Medicine. They include \u201cfatigue, constipation, and back and joint pain as well as hypertension.\u201d\nThe release doesn\u2019t tell us if the mice in the study experienced any side effects from the drug.  ", "answer": 0}, {"article": "Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria.\nNoting that he is a scientific advisor to Sirtris, a company developing drugs that activate the sirtuins, Dr. Kahn said, \u201cCertainly, drugs that act on this class of proteins have the potential to have major effects on human disease.\u201d\n\nDr. Auwerx\u2019s study complements one published earlier this month by Dr. David Sinclair of the Harvard Medical School, who found that much more moderate doses of resveratrol protected mice from the metabolic effects of a high-calorie diet.\nDr. Evans described the study as \u201cvery important, because it is rare that we identify orally active molecules, especially natural molecules, that have such a broad-based, positive effect on a problem as widespread in society as metabolic disease.\u201d\n\nDr. Ronald Kahn, director of the Joslin Diabetes Center in Boston, said the research would focus attention on the sirtuins, a recently discovered group of enzymes that resveratrol is believed to affect.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\nDr. Bruce Spiegelman, a Harvard Medical School expert on fat metabolism, said Dr. Auwerx\u2019s paper was \u201cpretty good.\u201d Dr. Auwerx believes resveratrol activates sirtuin, which in turn activates a factor known as PGC1-alpha in a manner first described by Dr. Spiegelman and his colleagues last year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that there were uncertainties about the safety of reservatrol in humans.\u00a0 In fact, to date, no clinical trials with this compound have been completed.\u00a0 At this time, a single trial looking at safety in colon cancer patients is recruiting subjects.\u00a0 The story should have emphasized the need for safety testing humans before any claims can be made. With some nutrients, such as Vitamin A, we know that small doses provide benefit, while large doses can be harmful.\u00a0 The story would have been strengthened by providing more sources with healthy skeptism to balance the overwhelming enthusiasm from other sources, many of whom had ties to the drug companies promoting the substance. ", "answer": 0}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nPeople who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms either \u2013 just vague \u201cincreased risk of potentially fatal bleeding.\u201d\nHow big a deal is this drug?\u00a0 The story never explains with any meaningful detail.\nThe story cites a talk at a recent conference that followed bleeding in patients in Xarelto or warfarin\u2026but never explained how many had bleeds on which drug \u2013 making the citation almost useless.", "answer": 0}, {"article": "After taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any story that discusses the potential benefits of alcohol consumption should say a word or two about the potential harms of overdoing it, since heavier drinking is unequivocally related to a host of health risks. This story didn\u2019t\u00a0include any such warning.", "answer": 0}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\nThe study, presented by Australian heart researcher Philip Barter, who oversaw Pfizer's torcetrapib clinical trials, concluded torcetrapib caused \"off-target\" effects, including deaths, elevated blood pressure, cardiovascular problems and a possible link to cancers.\nThe study suggested a \"clean\" version of torcetrapib could increase so-called good cholesterol without raising blood pressure and causing adverse cardiovascular events.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the increased risk of death, heart disease and elevated blood pressure with the failed drug. However, in the absence of evidence, the story should not be suggesting that a more \"clean\" version of the drug would not have such harms.", "answer": 1}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that none of the patients \"experienced graft rejection or required long term immune suppression \u2014 two potential side effects with human donor corneal transplants.\" It could have discussed what it might mean for these patients if these grafts ultimately fail.\u00a0Does it prevent them from then undergoing a human corneal transplant, which has a more established record of long term success?", "answer": 1}, {"article": "In a recent editorial appearing in the , van der Wall lays out the research in support of sauna bathing as a safe and salubrious habit for healthy people of all ages.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\n\u201cAs infrared heat penetrates more deeply than warmed air, users develop a more vigorous sweat at a lower temperature than they would in traditional saunas,\u201d says Dr. Richard Beever, a clinical assistant professor of family medicine at the University of British Columbia.\nFrom the Jewish to Mesoamerican \u201chouses of heat,\u201d people all over the world have long associated a good sweat with a wide assortment of health benefits.\n\u201cSauna bathing leads to a significant increase in heart rate and reduction in total vascular resistance, thereby decreasing blood pressure,\u201d says Dr. Ernst van der Wall, chief of cardiology at the Netherlands Leiden University Medical Centre.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Effect on sperm count is mentioned. But that\u2019s far from the only risk.\u00a0There are large segments of the population who are generally told not to use saunas\u2013such as pregnant women or people with chronic diseases.\u00a0What makes saunas inherently dangerous for them? Is it also true for infrared saunas?\u00a0We don\u2019t know or learn in this article.", "answer": 0}, {"article": "To learn more about DOs and the osteopathic approach to medicine, visit http://www.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nThe osteopathic philosophy of medicine takes a whole person approach to prevention, diagnosis and treatment, giving its practitioners a distinct model for clinical problem solving and patient education.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\n\"There are significant benefits to early disease detection because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer's.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Without discussing sensitivity or specificity, the news release gives no picture of the potential for false positives or false negatives \u2013 always potential harms with any test.", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nNo one knows exactly how light treatment works, but most experts seem to agree that the body has a master biological clock that responds to or is \u201cset\u201d by natural light fluctuations.\n\u201cThe hormone melatonin, which is secreted at night, can be suppressed by light,\u201d Dr. Rosenthal said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201cSide effects include headaches and hypomania.\u201d And it included the warning: \u201cUsing a light box is not as simple as it may appear. Experts recommend consulting with a knowledgeable health care provider.\u201d\nAnother point the story could have raised is that a person with a disorder that does not respond to light may self-diagnose and fail to seek more effective therapy or advice.", "answer": 1}, {"article": "Nezhat advises women to look for a surgeon experienced in doing minimally invasive surgery.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\n\u201cThe robot will not really decrease human errors but it will make the surgery easier,\u201d Dr. Tommaso Falcone of the Cleveland Clinic, in Ohio, who was also not involved in the study, told Reuters Health in an e-mail.\n\u201cWith minimally invasive surgery by an experienced surgeon\u2019s hands, the incisions are smaller, pain and suffering is less, visualization is better, and recovery is faster than with open surgery,\u201d Dr. Ceana Nezhat of the Emory University School of Medicine in Atlanta who was not involved in the review, told Reuters Health.\nOn the other hand, the newness of the technology could have deterred surgeons from using it for difficult cases, potentially biasing the results in a positive way for the robotic technique.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\u201d\u00a0 The researchers reported a very complete breakdown of intraoperative and post-operative complications \u2013 including what differences were statistically significant or not.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "The trial was funded by Mayo Clinic.\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Presumably, there is little risk to individuals from the blood test itself. However, it\u2019s important to note that among individuals with low LDL and the highest levels of blood ceramides, 83.6% did not experience cardiovascular disease. This raises the concern that use of the blood ceramide test might increase overtreatment, depending on what a patient\u2019s doctor recommends if the test reveals high ceramide levels. It is not clear what, if anything, individuals can do to reduce their blood ceramide levels. While there\u2019s certainly no harm in encouraging people to change their lifestyles to reduce their risk of heart disease and stroke, some health experts now argue that statins, often prescribed to decrease patients\u2019 cholesterol levels, might do more harm than good for individuals at lower risk of heart disease.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\nBut tPA is not indicated and could hurt a patient's chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does raise risks in a meaningful way. It says:\n\u201cBut tPA is not indicated and could hurt a patient\u2019s chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures. That is why patients need a CT scan to confirm the type of stroke before receiving tPA.\u201d\nHowever,\u00a0that statement could have gone further and noted that some patients with a negative CT scan may have a hemorrhage after getting tPA.  ", "answer": 1}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nFor the study, 105 children ages 2-18 with upper respiratory tract infections that kept them awake at night were given either a dose of buckwheat honey, honey-flavored cough syrup or no treatment half an hour before bedtime.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\nHoney has long been used by some parents as an alternative treatment for cough, although it should not be given to children under 1 year old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that honey may cause an allergic reaction and that, rarely, it contains bacteria.", "answer": 1}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nCurrently, the only way to truly separate out those on the road to Alzheimer\u2019s is to conduct expensive imaging tests of the brain, or to do a spinal tap, an invasive procedure that extracts spinal fluid for signs of the amyloid protein that builds up in the disease.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being told you are at increased risk for developing cognitive impairment is potentially distressing news. But as with many new reports on screening for disease, absolutely no mention is made of the potential harms associated with the tests. \u00a0And what about the potential for false alarms? Unnecessary emotional anxiety, increased doctor visits, and drug interventions could potentially have a very negative impact on someone who is experiencing normal aspects of aging.", "answer": 0}, {"article": "\u201cMentally, people feel calmer, sharper, maybe more content.\nWe thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nIf a large national study were done, it could turn out that yoga is just as good and may be a low cost alternative to people with unmet needs.\u201d In the meantime, he says it doesn\u2019t hurt to add yoga to existing treatments so patients can take advantage of any potential benefits.\n\u201cYoga has also become such a cultural phenomenon that it has become difficult for physicians and consumers to differentiate legitimate claims from hype,\u201d researchers from Duke University Medical Center write in their study, published in the journal Frontiers in Psychiatry.\nFor instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While it\u2019s not an invasive treatment and seems to be safe for most people, yoga can cause harm.\u00a0The story, however, doesn\u2019t address this possibility or state whether the studies included in the review assessed potential adverse effects\u00a0of treatment.", "answer": 0}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\n\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\n\"I had no idea what to expect.\u201d\n\nDespite his fears, within a few weeks, Priddy was in the operating room, nervously anticipating the implant surgery on his right ear.\nThey sound different, but that's better than not hearing them at all.\u201d\n\nPriddy said that from his experience as a cochlear implant recipient, he has learned many valuable lessons about himself and the world around him.\nThe pain was so excruciating at that moment.\u201d\n\nBut the deafness typically results after the device is implanted because it has yet to be turned on.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the harms of surgery are few\u2014mainly the dashed hopes of those it doesn\u2019t help and the chance that some people may need a reoperation if the first implant stops working. It\u2019s not completely clear that if the surgery fails, a partially deaf person is likely to be permanently deaf. Can it cause infections or facial paralysis or affect a person\u2019s taste? Yes, it can\u2014but readers will have to do their own research to find out. ", "answer": 0}, {"article": "Sports medicine and pain doctors are also recommending them for problems like tennis elbow, Achilles tendinitis and overuse injuries and strains.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nAnd the three topical Nsaids sold in this country \u2014 Voltaren gel, the Flector Patch and Pennsaid, a liquid \u2014 all contain the Nsaid diclofenac, whose oral version has been linked to liver damage.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story summarizes the reported side effects of topical NSAIDS. What\u2019s more, the reporter points out that the potential risks in people who have other health problems or are taking other drugs have not been well studied. That insight is something we see too rarely.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state \u201cPatients in the study experienced diarrhea, nausea, rash, fatigue decreased appetite, vomiting, itchiness and taste alteration.\u201d But we weren\u2019t told how many of the 97 experienced these.\u00a0 So the true scope of what was seen is not reported.", "answer": 0}, {"article": "He is also founder of Durin Technologies Inc., the company that is developing the test.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nAn estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nIt works by determining the amount of amyloid plaque, associated with the disease, in people's brains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not discuss the potential harms of this sort of test. As mentioned above, some healthy people would be told in error that they have signs of Alzheimer\u2019s Disease. Such a misdiagnosis could have profoundly grave consequences.", "answer": 0}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the potential harms of Brilinta. \nGiven the questions about risks of the reigning anti-platelet blockbuster Plavix it intends to replace, this is a significant omission.\nThe risks linked to Plavix could therefore arguably demonstrate a need for a drug that reduces heart risk without introducing other potential harms. \nThis should have been mentioned, as should have any potential risks early data link to Brilinta.", "answer": 0}, {"article": "Mumford, who's now 30, says he's never felt better.\n\"That can be a critical time interval for a patient who is in remission,\" she said, noting that doctors often fear a patient's relapse while awaiting the transplant.\nBut the registry's more than 12 million donors meet the needs of only about 60 percent of Caucasians in the United States and only 5 to 15 percent of minorities, who are underrepresented.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\nCleveland, Ohio (CNN) -- Diana Tirpak was so sure her leukemia was going to kill her, she bought a suit for her husband, Jake, to wear at her funeral.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "See the larger discussion of the evidence evaluation.\nThe story mentions that the procedure has the same risks as adult bone marrow transplants, and that the procedure requires months of recovery. These risks aren\u2019t quantified \u2014 they\u2019re just \"well worth it,\" according to these two success stories.\u00a0The article makes the procedure seem like a no-brainer.\u00a0There are many other risks with these transplants, none of which are mentioned.\u00a0Detail about any of the risks, including the rates of death due to the procedure, are missing. As that reader who claims to be a transplant nurse, BMTnurse,\u00a0commented on the CNN\u00a0web page: \"Those whose transplants fail tend to die miserably.\"", "answer": 0}, {"article": "TORONTO, May 22, 2018 - A non-surgical procedure, called percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.\nSt. Michael's Hospital provides compassionate care to all who enter its doors.\nNineteen sites across Europe and North America participated in the five-year follow-up.\nFounded in 1892, the hospital is fully affiliated with the University of Toronto.\nThe subsequent two years of follow-up have been academically driven, organized the by the academic steering committee of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms of the PCI procedure. According to the NIH these include:", "answer": 0}, {"article": "It would be, they report in the Journal of the American Medical Association.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\nIn 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nNew guidelines from the American Heart Association and the American College of Cardiology in 2013 broadened the definition of who should get cholesterol-lowering statins, which are among the most widely prescribed drugs in the world.\nBut in the new report, Dr. Thomas Gaziano of the Harvard School of Public Health and colleagues say they\u2019re in fact simpler than the old guidelines, which advised people to aim for a total cholesterol level of less than 200, keeping \u201cbad\u201d LDL cholesterol to 130 for average people and under 100 for those considered at risk of a heart attack.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NBC did a better job than the Times in answering the question about risks. NBC wrote that statins \u201ccan damage muscle in 5 to 15 percent of patients. In 2012, the Food and Drug Administration\u00a0updated labeling on statins to\u00a0include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\u201d This is a nice addition to the overall coverage of the new statin studies and a step we wish more reporters had taken.", "answer": 1}, {"article": "About 3.3 million people are allergic to peanuts or tree nuts.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the last line, the story warns that the children in the studies, who were allergic to peanuts, were under close medical supervision and that \"parents should not try the approach at home.\"\nThis is a satisfactory warning about potential harms. But it should have appeared earlier. \u00a0 \nThe author should also have mentioned whether those in the study who \"did not tolerate\" the exposure treatment needed epinephrine or some other intervention to quell the allergic reaction. ", "answer": 1}, {"article": "For more information, please visit http://www.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nThe first study, published in the journal Hypertension in 2012, found cognitive and cardiometabolic benefits of habitual cocoa flavanol consumption in older adults who had been diagnosed with mild cognitive impairment (MCI).\nDr. Kwik-Uribe went on to speak about Mars' flavanol research program that has spanned over two decades: \"The amount of research showing the beneficial effects of cocoa flavanol consumption is growing and Mars is proud to be a partner in important research like this that highlights the positive role cocoa flavanols may play in supporting healthy aging.\"\nThe high- and intermediate-flavanol cocoa drinks were produced using Mars' patented Cocoapro\u00ae process, while the low-flavanol drink was made with a highly processed, alkalized cocoa powder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms, potential or actual, in the release. Our main concern is that consumers will think these findings apply to your typical chocolate candy bar, which is full of sugar and fat. While the release notes dryly that commercially available chocolate, \u201cgiven its macronutrient profile \u2026 is not recommended as a health food,\u201d we don\u2019t think many readers will find this caveat that\u2019s buried in an editor\u2019s note at the end of the release. And even if they do, they might not understand what it\u2019s getting at.", "answer": 0}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAlthough this story does not go into detail about the potential harms of screening mammography, it does include comments from independent experts who point out that the scans do lead to the diagnosis and treatment of women whose tumors would never have become life-threatening.", "answer": 1}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nThe study was conducted at 14 sites in the United States and Australia and included 162 patients who received different dose combinations of the drugs: two daily 150 milligram (mg) doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nBut the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained.\nThese drugs can be safely combined, and the survival was significantly improved without untoward side effects,\" said Dr. Michele Green, a dermatologist at Lenox Hill Hospital in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u2019s discussion of harms tends to\u00a0downplay their importance.\u00a0It quotes an expert who says there were no \u201cuntoward side effects\u201d with the combination treatment, and\u00a0it reports that\u00a0skin rashes and rates of squamous cell carcinoma were\u00a0\u201csimilar to that typically seen in patients taking only one of the drugs.\u201d\nThat\u2019s one take, we suppose, but the study itself reported much higher rates of drug induced fevers and chills\u00a0in the combination groups, which was serious enough to require hospitalization in 19% of low-dose and 26% of high-dose combination group patients (compared with 2% of monotherapy patients). Other\u00a0side effects reported more frequently in the\u00a0combination groups were\u00a0fatigue (in 53% of patients), nausea (44%), vomiting (40%), and diarrhea (36%).\u00a0Those certainly sound like \u201cuntoward\u201d side effects to us.", "answer": 0}, {"article": "Kisco, N.Y.\nThe second study, conducted in Taiwan and led by Dr. Wei-Jei Lee of the Min-Sheng General Hospital, involved randomly assigning 60 obese (but not morbidly obese) patients with type 2 diabetes to receive gastric bypass surgery or sleeve gastrectomy.\nThe average cost of a bariatric surgery is nearly $30,000, according to a recent study from Johns Hopkins University.\nThere are various theories to explain why gastric bypass may be superior, including one that attributes the success to changes in hormones that control the metabolism of blood sugar.\nAnd certain procedures may still be preferable for certain patient populations, added Roslin, such as bands for patients with lower BMI who don't have so many metabolic challenges.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the LA Times, this story attached a number to the risk of complications observed during the study. It would have been interesting to see some discussion of the seriousness of these problems, as some data suggest that short-term\u00a0complications with gastric bypass are more grave than those with the band, while longer-term complications with the band may be more frequent and serious. This story mentioned that there were no deaths in either group in the bypass vs. band study, but as with the competing coverage, it didn\u2019t explain that there are well established differences in mortality risk associated with each procedure. We\u2019ll award a passing grade, but the story could have done better here.", "answer": 1}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\n\u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d\n\nLung cancer is the second-most-common malignancy in the United States, after breast cancer.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\n\u201cImmunotherapy is rapidly, in combination with other treatments and on its own, dramatically changing the standard of care for lung cancer,\u201d said Leena Gandhi, an oncologist at NYU Langone Health who led the study on the immunotherapy-chemotherapy combination, called Keynote-189.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects were not addressed. About 14% of the patients in the combination group dropped out of the trial due to adverse events, versus about 8% of those in the chemo-only group.\nAcute kidney injury and fever relating to neutropenia, a low white blood cell count, occurred more frequently in patients who received Keytruda.", "answer": 0}, {"article": "Results also show that older patients and those in a higher socioeconomic subgroup had better quality of life measures after PAP therapy.\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\n\"Quality of life is one of the most vital outcomes for patients and often one of the primary reasons to seek medical attention,\" said lead author and principal investigator Dr. Harneet Walia, assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and staff at the Cleveland Clinic's Sleep Disorders Center.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nThe study was funded by a scholar award from the Cleveland Clinic Neurological Institute-Center of Research Outcomes and Evaluation and by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While CPAP therapy is relatively safe, there are still common side effects that were not mentioned in the news release. According to the National Sleep Foundation, most CPAP users will experience some mild side effects including congestion, runny nose, or stomach bloating. Though the harms are only mildly irritating, it would have been helpful if they were included in the release.", "answer": 0}, {"article": "But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes on at some length to talk about the side effects from drugs, yet allows the researcher/inventor to make the claim that there are no side effects from this device. With all the framing about the promise of the approach, we would hope for more discussion of what\u2019s not known about safety profile after such limited experience to date. Even an additional line would suffice. We only hear the one positive patient\u2019s experience.", "answer": 0}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nIn recent years, the medicinal value of curcumin has been the subject of intense scientific studies, with publication numbering in the thousands, looking into the possible beneficial effects of this natural product on many kinds of affliction in humans.\nBased on studies that she has done both in the laboratory and in patients over 25 years, the key to curcumin's effectiveness on burns and scalds is that it is a natural inhibitor of an enzyme called phosphorylase kinase.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen School of Medicine, stresses that use of topical curcumin gel for treating skin problems, like burns and scalds, is very different, and appears to work more effectively, when compared to taking curcumin tablets by mouth for other conditions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Curcumin, the active ingredient of tumeric, is considered to be an alternative therapy. Neither turmeric nor curcumin has been extensively studied in clinical trials, but animal studies have shown that chronic use could lead to stomach ulcers. In addition, the American Herbal Products Association classifies turmeric as a menstrual stimulant. Turmeric should be avoided in patients with bleeding disorders and bile duct obstruction.\nExperts believe tumeric is generally safe, although the quality of the available clinical studies is questionable.\nAn additional potential harm is failure to be treated with appropriate care. We would not want parents of kids with severe burns to forgo appropriate, evidence-based medical care in favor of an alternative over-the-counter product with no scientific evidence to support its use. The last sentence of the news release states that the doctor uses curcumin gel in addition to standard medical treatment. That important bit of information should have been highlighted more prominently in the release so that people skimming the release wouldn\u2019t assume they could attempt to self-treat burns or scalds with curcumin alone.\nSince harms weren\u2019t mentioned in the news release we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "I'll Be Me ,\" Saturday, November 7, at 8 p.m.\nAntioxidant may be most effective in combination\n\nThis is one of the first studies to look not only at these biomarkers, but also the metabolites of resveratrol in spinal fluid, to show that resveratrol is probably getting into the brain, said Dr. Giulio M. Pasinetti, who is the Saunders Family Chair and professor in neurology at the Icahn School of Medicine at Mount Sinai.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nNow, the first study in people with Alzheimer's suggests that the compound, when taken in concentrated doses, may actually have benefit in slowing progression of this disease.\n\"To really get a better feel of how effective this could be you really need to do larger studies for longer periods of time (such as several years),\" said James A. Hendrix, director of global science initiatives at the Alzheimer's Association, a research and advocacy organization.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically discusses the safety of resveratrol, noting that the one concern researchers found was that there appeared to be a slight weight loss (two pounds) in patients taking resveratrol over the course of the one-year study, compared to a one pound weight gain in patients taking placebo. This is significant because weight loss can be a problem for Alzheimer\u2019s patients. The story could also have addressed the concerns raised in some quarters that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners.", "answer": 1}, {"article": "Coffee or tea?\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThere's a growing body of research to suggest that both are probably good for you.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A claim is made in the article that by enjoying tea of the best quality, you are probably doing more good than harm. The article did not mention any potential harms associated with consumption of green tea, even if that would be to say that there are no known risks associated with green tea consumption.", "answer": 0}, {"article": "Kaiser funded the study.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\n\"Even after the rash has healed, the pain can last for months or even years,\" said lead study author HungFu Tseng, a research scientist at the Kaiser Permanente Division of Research and Evaluation in Pasadena, Calif.\n\nZostavax, as the vaccine is called, was approved in 2006, based on the results of clinical trials.\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\nEven though the vaccine is only about 55 percent effective, \"it's better than nothing,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story briefly refers to this vaccine providing protection against shingles \u201cwithout many side effects.\u201d While many stories would stop there (if they even acknowledged the potential for side effects), this report goes further to include the comment from an independent source that \u201cI think it\u2019s a very good vaccine, and it\u2019s a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people.\u201d ", "answer": 1}, {"article": "\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\n\u201cYou can sterilize a hospital room, but not when anyone\u2019s inside.\u201d\n\nAbout five years ago, Brenner says, the Columbia team came up with a potential solution.\n\u201cWe\u2019ve known for a century that UV light is extremely efficient at killing microbes, bacteria, and viruses,\u201d says study leader David Brenner, director of the Center for Radiological Research at Columbia University Irving Medical Center.\n\u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically,\u201d he says.\nThe light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria not exposed to light remained active.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms of far-UVC light are mentioned; in fact, in the opening sentence we read:\u00a0 \u201cresearchers have developed an ultraviolet (UV) lamp that kills influenza virus but isn\u2019t harmful to human skin or eyes\u2026.\u201d\nBut, again, we\u2019re given no data regarding safety.\u00a0We are not told if the previous skin or eye studies (which we\u2019re told prove the safety of this approach) were done in the laboratory or on real humans.", "answer": 0}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\nThe apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\n\"This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease,\" said Emma C. Harte, PhD, a research scientist at Randox Laboratories.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\nReporters can register online here: https://www.xpressreg.net/register/aacc0716/media/landing.asp\n\nScientific Poster B-124: Development of a New Biochip Array for ApoE4 Classification from Plasma Samples Using Immunoassay Based Methods \n\nWednesday, August 3\n\n9:30 a.m. \u2013 5 p.m. (presenting author in attendance from 12:30\u20131:30 p.m.)\n\nScientific Posters A-118, A-119, A-135, and A-180\n\nTuesday, August 2\n\n9:30 a.m. \u2013 5 p.m. (presenting author in attendance from 12:30\u20131:30 p.m.)\n\nAll scientific posters will be on display in the Terrace Ballroom at the Pennsylvania Convention Center in Philadelphia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there are likely no direct harms from drawing a blood sample, the release could have noted the potential harm of any screening tests for AD risk factors \u2014 such as anxiety, depression, misdiagnosis or over-diagnosis\u00a0 \u2014 particularly if screening is conducted on those at potentially very low risk. To its credit, the release includes a quote from one of the investigators who makes it pretty clear that the test is intended for those with probable symptoms and family histories of AD.", "answer": 0}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\n(June 1, 2016) - A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential risks associated with CD34+ treatment. The Cell Transplantation paper did not report significant adverse effects associated with the treatment, but noted that \u201cthe longer-term effects of this treatment are unknown.\u201d Even if there are no additional risks associated with a treatment, a release needs to tell readers that \u2014 and, in this case, the researchers themselves make clear that they do not yet have a clear assessment of potential risks.", "answer": 0}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\n\"You are not putting yourself at risk of death or heart attack if you defer,\" and considering the safety worries about heart stents used to keep arteries open after angioplasty, it may be wise to wait, said Dr. Steven Nissen, a Cleveland Clinic heart specialist and president of the College of Cardiology.\nBut most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\n\"Even though it goes against intuition, the blockages that are severe that cause chest pain are less likely to be the source of a heart attack than segments in the artery that are not severely blocked,\" said Dr. David Maron, a Vanderbilt University cardiologist who helped lead the new study.\nAfter five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the percent of individuals in each group that initially had angina and then compared that with the percent affected at 3 and 5 years.\u00a0 It also mentioned the rates of heart attack and death in both treatment groups.\nWhile the story mentioned 1/3 of those in the medication-only group later went on to have a stent put in or had coronary bypass surgery, it could have compared this with the number of individuals in the stent and medication group who went on to either have an additional stent placed or had bypass surgery.\u00a0(30% vs. 20%)\u00a0", "answer": 1}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\n\"There are many paths to weight loss,\" said registered dietitian Karen Congro, director of the Wellness for Life Program at The Brooklyn Hospital Center in New York City.\nThe researchers found that combining the DASH diet with weight management and exercise resulted in a 16.1 mm Hg drop in systolic blood pressure compared to 11.2 mm Hg on the DASH diet alone.\nMore than one-third of American adults are obese, and the incidence of obesity has gone up 140 percent over the past decade, Kushner notes.\nInsulin and glucose markers improved only in the low-carb group, and there was a significant drop in blood pressure in the low-carb group compared to the orlistat group -- systolic blood pressure (the top number) dropped by 5.9 mm Hg on the low-carb diet vs. 1.5 mm Hg for the orlistat group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any of the known\u00a0adverse effects\u00a0of orlistat, which include gastrointestinal\u00a0upset that can limit the drug\u2019s tolerability.\u00a0It could also have mentioned some of the concerns (such as potential for nutrient deficiencies)\u00a0that many health professionals have about diets that are high in meat\u00a0and protein and very low in carbohydrate.", "answer": 0}, {"article": "Decades later, it became popular as a psychedelic club drug.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\n\"While the science is promising, ketamine is not ready for broad use in the clinic,\" Insel wrote in his blog a few months ago.\n\"If there was even a 1 percent chance that this worked, it would have been worth it to me,\" he says.\nAnd in 2006, a team from the National Institute of Mental Health published a landmark study showing that a single intravenous dose of ketamine produced \"robust and rapid antidepressant effects\" within a couple of hours.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there is a brief mention of possible harms, including abuse and hallucinations, the soft warnings in the story are undercut by statements such as, \u201cketamine\u2019s safety record is so good that it\u2019s often the painkiller of choice for children who arrive in the emergency room with a broken bone.\u201d Again, readers and listeners are given the impression that the drug has been scrutinized far more carefully that it actually has.\nThere is a final cautionary note from a proponent of ketamine treatment of depression that wider use could mean \u201csomething bad will happen to a depressed patient\u201d. However, this risk is cast not as a hazard inherent in the drug, but as worry that a careless doctor will tarnish the drug\u2019s good name.", "answer": 0}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\nBut we have no idea of the prevalence of the abnormality in routine populations.\u201d\n\nNow, as more and more people have scans for everything from headaches to foot aches, more are left in a medical lurch, or with unnecessary or sometimes even harmful treatments, including surgery.\nIt\u2019s one of only two body parts \u2014 the other is the back \u2014 where there are good data on abnormalities that turn up in people who feel just fine, indicating that the abnormalities may not be so abnormal after all.\n\u201cEvery time we get a new technology that provides insights into structures we didn\u2019t encounter before, we end up saying, \u2018Oh, my God, look at all those abnormalities.\u2019 They might be dangerous,\u201d said Dr. David Felson, a professor of medicine and epidemiology at Boston University Medical School.\n\u201cSome are, some aren\u2019t, but it ends up leading to a lot of care that\u2019s unnecessary.\u201d\n\nThat was what almost happened with Mrs. Weinstein, an active, athletic 64-year-old who lives in New London, N.H. And it was her great fortune to finally visit a surgeon who told her so.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions unnecessary surgery\u00a0as the most serious\u00a0harm of scanning, as well as needless worry and potentially, feeling worse about the diagnosis. The story could have mentioned more common problems with MRI (claustrophobia) and CT scans (radiation exposure), but the real concern is that the imaging test makes the patient and physician more likely to chose an invasive treatment such as surgery.", "answer": 1}, {"article": "Tomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nTo raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nothing in this story discusses\u00a0any harms, but the product label tells us that \u201cIn clinical trials, the most common adverse reaction following the use of RESTASIS\u00ae was ocular burning (17%). Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).\u201d \u00a0The label also says: \u201creported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the vial tip touching the eye during administration).\u201d", "answer": 0}, {"article": "Researchers randomly assigned 241 women with urinary incontinence to daily medicine and a placebo injection, or a Botox injection and a daily placebo pill.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does detail the side effects of dry mouth, urinary infections and incomplete emptying of the bladder, but these are never quantified. But language like \u201cmuch more common\u201d or \u201cmore likely\u201d is unhelpful in its lack of specificity.\u00a0 The paper itself revealed:\nDry mouth occurred in significantly more participants in the anticholinergic group than in the onabotulinumtoxinA group (46% vs. 31%, P=0.02). Intermittent catheterization was recommended according to protocol criteria at scheduled visits in the onabotulinumtoxinA group only (in 5% of the participants at 2 months, 3% at 4 months, and 1% at 6 months). However, additional women in both groups performed catheterization off-protocol . More women in the onabotulinumtoxinA group than in the anticholinergic group had a urinary tract infection (33% vs. 13%, P<0.001).\nMaybe 15 percentage point differences\u00a0 or 20 percentage point differences are things we should tell readers about and let them judge.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story could have pointed out that because the significance of telomere length is unclear, people who take the test may either get a false sense of a security from learning they compare favorably to the general population or experience unnecessary anxiety if they get a lower-than-average result.", "answer": 0}, {"article": "Although colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\nPatients must often take time off work and need transportation home from the procedure.\n\"We were pleased by the results of this first clinical study,\" he says.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nOne screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms.", "answer": 0}, {"article": "\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nreports to address the risks of mercury in tuna,\u201d said the consumer organization, \u201cwe are also concerned that both reports dismiss concerns about PCB\u2019s in most fish.\u201d\n\n\u201cThese reports are urging Americans to eat more seafood as if it were a crisis,\u201d Dr. Goldberg said.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\nrecommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presents balanced information about potential harms of fish consumption, though it would have been stronger if it had included more detail about harms.\u00a0For example, it might have noted the effects of mercury on fetal development.", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nIn addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\nThe AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with over 18,000 attendees.\nIn an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nAmong nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, according to a study in Cancer Prevention Research, a journal of the American Association for Cancer Research, by Lori Sakoda, PhD, MPH, research scientist at the Kaiser Permanente Division of Research in Oakland, California.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release about potential harms that may arise with the administration of metformin. The drug is known to produce harmful side effects in more than 10 percent of people taking it, largely affecting the stomach or bowel such as vomiting, diarrhea, and loss of appetite.", "answer": 0}, {"article": "Well, maybe not.\nIn a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are not discussed. The release hints that this benefit is there for \u201chealthy\u201d joints, but says nothing about joints with torn cartilage, already degrading joint surfaces or substantial osteoarthritis. The release notes that researchers plan more do more study of those with anterior cruciate ligament (ACL) injuries, but that is a tendon injury, not a joint injury.\nThere\u2019s a concern that this release could send the wrong message to some runners. What about people who experience pain when they run? Should they continue to run, despite the pain, because running might be \u201cchondroprotective.\u201d", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We get some valuable description of how other oral medications have come into question (even after FDA\u00a0approval) because of side effects, and this context allows the reader to judge that perhaps it is too soon to see the new drug \u2013 Gilenya \u2013 as a complete home run. Side effects mentioned for Gilenya include liver toxicity, infection risk and eye problems.\n\u00a0", "answer": 1}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThe paper's other authors are Qifan Zhu, Liqin Zhu, Zhiping Liu, Rajendra Karki, Ankit Malik, Deepika Sharma, Liyuan Li, R.K. Subbarao Malireddi, Prajwal Gurung, Geoffrey Neale, Scott Olsen, Robert Carter, Daniel McGoldrick, Gang Wu, David Finkelstein, Peter Vogel and Richard Gilbertson, all of St. Jude.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nBoosting the activity of a protective gene and giving patients 'good' gut bacteria could help prevent or slow progression of colorectal cancer, St. Jude Children's Research Hospital scientists have found\n\nMemphis, Tenn., JUNE 19 -- Scientists at St. Jude Children's Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer.\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This work is so far removed from clinical use in human subjects that it may be difficult to adequately assess potential risks for human patients. However, as noted above, the release does mention interferon treatment and transferring \u201cgood\u201d bacteria populations into human patients. Every treatment carries some risks, and those are worth discussing.\nThe human digestive system is awash in colonies of different bacteria, all striving to maintain dominance in their environment.\u00a0 An imbalance between these different strains can cause a host of intestinal problems ranging from simple discomfort to life-threatening conditions.\u00a0 The release\u2019s cavalier mention of possibly transferring \u201cgood bacteria\u201d does readers an injustice by ignoring risks.\u00a0 While fecal transplants have shown some success in early research, they do carry substantial risks, and while some colon cancer patients may be willing to accept that risk, the release should at least mention that it exists.", "answer": 0}, {"article": "Other expert groups have made similar statements.\nFor example, Walmart sells Equate loratadine tablets (the same active ingredient as Claritin) for about $7 for 60 24-hour doses\n\nAntihistamines make perfect sense for someone who suffers a few sneezy days each season and doesn't want to use a spray for weeks or months, Eghrari-Sabet says.\nIf you are allergic to mold spores or to pollen from trees, grasses or ragweed, that means knowing when levels are high (by checking pollen.com or the National Allergy Bureau) and then taking steps such as these recommended by the American Academy of Allergy, Asthma and & Immunology:\n\u2022 Keep windows closed at home and in your car.\nIt's also important to administer the sprays correctly, so that they end up inside your nasal passages, not just your nose, where they might cause irritation, Sublett says.\n\"These are first-line treatments\" that can prevent allergy symptoms, not just treat them, says Jackie Eghrari-Sabet, an allergist in Gaithersburg, Md.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes into the side effects of steroid nasal sprays, antihistamines and decongestants. Although none of these harms are quantified, we\u2019ll give the story the benefit of the doubt.\nThe line that caught our attention was: \u201cLabels caution that some children using the sprays may experience slower growth.\u201d What kind of slower growth (mentally vs. physically)? How many children encountered this side effect? And is it worth the risk to ever use a steroid nasal spray? A few figures here would have been helpful to put this in perspective, because \u201cslower growth\u201d sounds like one of the more serious harms that someone could experience.", "answer": 1}, {"article": "ABOUT CLEARPOP\n\nClearPop for Rapid Earache Relief represents a simple, safe, pediatrician recommended, clinically effective and fun way to treat earaches.\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\nIn light of this, Morehouse developed a lollipop with a patented shape optimized to pull congestion out of the middle ear and into the mouth.\n-is increasingly used by frequent flyers to deal with ear pain that afflicts children disproportionately during air travel.\nClearPop is made by Try This First, Inc. a physician-funded \"small pharma\" organization aimed at reducing the estimated 30 million antibiotics prescriptions written to children yearly for ear infection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no risks mentioned for the lollipop device or for the ingredients but we give them a pass on this criteria since harms appear minimal. It\u2019s worth noting that there can be a harm if persistent ear pain that is not resolved by use of the lollipop is not given medical attention.", "answer": 1}, {"article": "To him, diet underpins longevity.\nAccording to Toribio-Mateas, the results confirm earlier theories that \"some hormone-like growth factors that are required during development to grow, then become promoting agents of aging after development and sexual maturity have been reached\".\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\n\"When you make IGF less active, it reduces risk factors linked to diabetes and cardiovascular disease,\" says Miguel Toribio-Mateas, Chairman of the British Association for Applied Nutrition and Nutritional Therapy.\n\"The results of the study are encouraging and warrant more research in this area,\" says Toribio-Mateas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story should have explained to readers at least a few known potential harms of fasting\u2013which are very real, especially for people with certain health conditions, including common ones like diabetes. All we get is a quote that hints it might be dangerous to fast for more than five days:\n\u201cFive days is safe: going on for longer is difficult to do outside of a clinic,\u201d says Longo.\nBut fasting for 5 days would clearly be harmful for many people.", "answer": 0}, {"article": "This study was presented at a medical conference.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nAlso, 43% of men who didn\u2019t take anticlotting medications had a recurrence of their cancer, compared with 33% of men who did take them.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\nHowever, they need to be confirmed, and the optimal dose, timing, and duration of use needs to be worked out, he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story mentions that the drugs carry risks, including bleeding. However, the story should have been clear that such bleeding can be lethal in some cases and that these drugs also raise the risk of prostate cancer patients suffering complications during treatments.\u00a0", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although this story did mention two side effects of excessive intake of vitamin D, this list downplays the consequence of overdose. \u00a0For this, they could have simply gone to the Time archives and unearthed their piece from 1992: \u00a0http://www.time.com/time/magazine/article/0,9171,975464,00.html\u00a0\nThis is not a trivial point, especially since the clinician quoted in the piece mentioned personal consumption levels above those recommended. \u00a0Taking a supplement to match the intake mentioned, in concert with vitamin D containing foods, multivitamins, and exposure to sunlight \u2013 could result in people ending up with higher than intended levels.\nThere is also no mention of the lack of long term data on supra-therapeutic levels of the vitamin, and we can assume that the effects, good or bad, may be magnified by the longer duration of exposure and more sensitive developing body in the children and adolescents that were the focus of the piece.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only potential harm mentioned with this medication is that it carries a safety warning about increased risk of heart attack and stroke associated with its use. \u00a0The story went on to discuss that salsalate carries this warning because of its drug class but that there isn\u2019t evidence demonstrating that these risks are associated with its use. \u00a0The would seem to be confusing \u2013 does this medication increase the risk of heart attack and stroke or not?\nFurther \u2013 because this drug has been around for a long time, \u00a0a lot is known about its side effect profile at least among people with arthritis.\u00a0 It would have been helpful to at least mention the known major side effects.\u00a0", "answer": 0}, {"article": "The scientists published details of their work online Thursday in the journal Science Translational Medicine.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\nThe success represents an advance that is \"absolutely critical in terms of making prosthetics useful,\" says Mike McLoughlin, an engineer at the Johns Hopkins University Applied Physics Laboratory.\nWhen Copeland touches an object with the robotic hand, he can tell which finger the sensation is coming from and whether an object feels hard or soft, says Robert Gaunt, a bioengineer and assistant professor in the Department of Physical Medicine & Rehabilitation at the University of Pittsburgh.\nAt the moment, they are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any harms that may lurk in future applications of surgical implants to communicate with a potential robotic arm.\u00a0The most obvious way to approach this would be to talk about risks of neurosurgery generally;\u00a0accidental destruction of healthy tissue, for example, or stroke. But there may be others related to the technology\u2013essentially there are a lot of unknowns when the patient test group is one individual.", "answer": 0}, {"article": "In all, 31,567 people were screened.\nA new study has found that it is possible to find a large number of \"silent\" cancers in the lungs of heavy smokers by periodically screening them with CAT scans.\nWhen the tumors are then surgically removed, most people live five years or more, in striking contrast to patients whose cancers are found only after they experience symptoms.\nSuch early lung cancers can usually be cured; the problem is that they are usually found at that \"asymptomatic stage\" only by chance when someone has a CAT scan or chest X-ray for an unrelated reason.\nIn 1994, the study, called the International Early Lung Cancer Action Program, began screening smokers and former smokers, as well as a few nonsmokers exposed to radon, beryllium and other cancer-causing substances.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that abnormal scans can lead to biopsies\u00a0and that the scans may pick up cancers that \"grow so slowly they will never pose a health problem.\"\u00a0 The story should have also mentioned radiation exposure as a potential harm and described the consequences of false positive test results.", "answer": 1}, {"article": "Contributing authors Dr. Farid Saad is a full time employee of Bayer Pharma.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not on this text\u2019s radar screen. Testosterone treatment does have a few side effects including sleep apnea, stimulation of benign growths in the prostate, enlarged breasts and increased risk of blood clots. The study on which this release was based does not appear to discuss these outcomes either, but their inclusion here would have been helpful.", "answer": 0}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did an incomplete job on side effects.\u00a0 It did mention nausea, depressed mood and skin tingling \"which led to a discontiuation rate of 9.4%.\" But the FDA has raised major concerns\u00a0about this drug and rates of depression, and that is not clear from the story.", "answer": 0}, {"article": "WEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nThe benefit was primarily seen among men younger than 65 and the authors estimated that seven men under the age of 65 and 8 over the age of 65 would need to be treated to save one life.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\nBut much remains to be known about how best to treat different types of prostate cancer.\n\"Watchful waiting\" is often recommended when a man is not expected to die of the cancer and would like to avoid the risk of the debilitating side effects associated with prostate cancer treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms associated with various approaches to treating prostate cancer as well as the increased risk of prostate cancer progression and death seen in the cohort of men who followed the watchful waiting approach were discussed.", "answer": 1}, {"article": "The study had some limitations, the authors acknowledged.\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nThis effect may be even more pronounced among people younger than 60, according to the study published in the March issue of Archives of Neurology.\n\"This is a promising avenue for future research,\" said Alcalay, an advisor for the Parkinson's Disease Foundation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for noting the potential side effects of statins up high.\u00a0 And later it reported:\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood. Co-Q10, an antioxidant, is thought to have benefits for people with Parkinson\u2019s disease.\nBut we wish the story had gone the extra step of actually quantifying the harms from this study or other studies.\u00a0 And it could have cited the recent FDA update on the risks associated with statins.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of the \ntreatment were not mentioned", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Irwin Rosenberg was quoted as stating that taking too much vitamin B12 is unlikely to cause harm. \u00a0However \u2013 there are specific conditions where the use of injectable vitamin B12 can be problematic (e.g. in those with Leber\u2019s disease or allergy to cobalt) and any regular injections are associated with risk of blood borne infection.", "answer": 0}, {"article": "This post has been updated.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\nThe ratio of two metabolites, or byproducts, of the body's processing of nicotine allows easy identification of the two groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that side effects of\u00a0varenicline\u00a0include nausea, difficulty sleeping, and abnormal dreams. It also acknowledges that there is harm in pursuing a therapy that does not work if the quitter is discouraged. Excerpt: \u201cEach time somebody fails, it affects their self confidence,\u201d Lerman said. \u201cThe trial and error approach is not optimal.\u201d \u00a0We\u2019ll rate this borderline satisfactory, but ideally we would have liked to see some quantification of these side effects, especially since frequency of side effects is an important part of the rationale for choosing one approach over the other. Moreover, the story should have explored potential harms from the blood test used to classify nicotine metabolism. How accurate is it? And if the test is wrong, what does that mean for your chances of quitting successfully?", "answer": 1}, {"article": "Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\n(Reuters) - Merck & Co\u2019s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.\nThe U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When making decisions about health care treatment options, patients often consider three factors: cost, benefit, and quality of life (i.e., potential harms/side effects). Some patients may decide not to pursue treatment that may extend life for a short period of time if that treatment will also have a significant adverse effect on their quality of life. In short, discussion of potential harms is extremely important. The story notes only that \u201c[s]afety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients.\u201d Given that potential side effects include hepatitis, hypothyroidism, and Type 1 diabetes mellitus, it would have been worth devoting an additional sentence or two to possible harms.", "answer": 0}, {"article": "If that feels a little onerous, consider new findings out of Baylor College of Medicine in Houston suggesting that love of physical activity may start in the womb.\nThe research in question involved mice, not women.\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\n\u201cI think our results offer a very positive message.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of vigorous activity during pregnancy\u00a0were not discussed.", "answer": 0}, {"article": "It\u2019s quite a dramatic response.\u201d\n\nSo dramatic, in fact, that Yuan refers to Young as her \u201cmiracle patient.\u201d\n\n\u201cThis in some ways is pretty unprecedented.\nThey started to go away after the third treatment, she said.\nThis patient is at a late stage of her disease.\nA couple of major drug companies have already expressed interest in his vaccine, he said.\n\u201cI was very frightened when I started out.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of side effects of the combination treatment and only a brief mention that this drug combination showed no clinical benefit in other patients.", "answer": 0}, {"article": "Years later, on the surface.\n\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\n\"I am in a lot less pain today and now it just feels as though I have a sunburn that is a few days old,\" he said.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nNow he's trying something that might seem shocking: an electrical current applied to his head - part of a clinical trial at Beth Israel Medical Center in New York.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment says there is some tingling and a sunburn-like lingering effect linked to the treatment. \nWhile this is accurate, TDCS is relatively new and the real side effect profile is unknown at the moment.\u00a0 There may well be cognitive and motor reflex effects with repeated use.\u00a0 \nA simple statement that there may well be other unrecognized side effects would have put this into context. ", "answer": 0}, {"article": "Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nAcupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention the possible harms of each intervention. While these methods are generally considered safe, no treatment is without risk of harm so we would like to see some discussion.\u00a0 The risks associated with acupuncture generally rest with the acupuncturist and can include soreness, infection, and in rare cases, organ injury if the needle is pushed in too far. Because the Alexander Technique calls for changes to posture and movement, it may cause harms to people with specific spinal injuries that are better left treated by licensed medical experts.", "answer": 0}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nThe type of scans used in this study, PET scans, are expensive and patients have to go to a scanning center, get injected with a radioactive dye, wait for the dye to reach their brain and then have a scan.\n\u201cThe field was taken aback.\u201d\n\nYet there was a problem.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No. There is nothing in this story about what it\u00a0would mean, for example, if everyone over a certain age started having their brains injected with radioactive dye on a regular basis. Everyone has a lifetime radioactive load limit, for one. What else might the dye do to people who have other chronic conditions or are taking medications?", "answer": 0}, {"article": "Remember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\nAs The Early Show medical correspondent Dr. Emily Senay explained Tuesday, calcium provides the building blocks necessary to make sure bones are dense and strong.\nThe study earlier this year also found that women who took supplements regularly reduced their chance of fracture more than those who didn't.\nThe maximum recommended intake of calcium is 2,500 milligrams.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. In the study, the researchers found that constipation was a side effect of taking the calcium supplement", "answer": 0}, {"article": "Others need regular exposure to milk in order to maintain protection against allergic reactions.\nThe results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nOral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify/explain the extent of \u201csignificant reactions during the treatments that make the therapy unfeasible\u201d in the new sublingual approach.", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Radiation treatment can cause secondary cancers and other problems. The story mentions this and clearly explains that the incidence of such cancers is low. But, as noted above, existing studies do not track patients long enough to make a determination of harms feasible.", "answer": 1}, {"article": "Noctiva is the first FDA-approved treatment for this condition.\n\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nThe U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night).\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does well describing harms, providing extensive details on adverse effects, particularly warning that Noctiva can cause a potentially life-threatening drop in blood sodium and shouldn\u2019t be used by those at risk for that condition. The release says the drug will come with a boxed warning and a Medication Guide to draw attention to the risk. It also lists the most common side effects: nasal discomfort, cold symptoms, nasal congestion, sneezing, high or increased blood pressure, back pain, nose bleeds, bronchitis and dizziness.\nIt cautions against use in pregnant women and children as well as patients with symptomatic congestive heart failure or uncontrolled hypertension and patients with certain nasal conditions such as colds or allergies.\nWe would have liked to see the news release mention that 4 percent of patients in the trials stopped therapy due to adverse events. Also, an FDA document expressed concern that the drug could mask symptoms of underlying conditions, which was only alluded to in the news release with an advisory that doctors treat underlying conditions that could cause frequent urination.", "answer": 1}, {"article": "Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear fully within three years of the procedure.\n\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\n\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nThe stent, called Absorb, is made of a plastic similar to dissolving sutures and offers patients an alternative to metal stents currently used to prop open arteries cleared of blockages.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that one clinical study found a higher risk of heart attacks and blood clots in participants, complications that Abbott Labs apparently blames not on the stent but on surgeons\u2019 lack of experience in using it.\nA weakness here, though, as noted in the \u201cbenefits\u201d segment above, is that there apparently have been no clinical trials that have lasted long enough for the stents to dissolve (about three years) in order to assess harms. The story should make that clear to readers.", "answer": 1}, {"article": "The incidence has more than doubled in developed countries in recent decades.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that no adverse events were associated with the intervention. However, the harms assessed by the researchers were things like maternal or infant death, emergency caesarean delivery, and preterm birth. They didn\u2019t assess (and the story didn\u2019t mention) less serious harms like fishy taste, nausea, belching, and heartburn that are commonly associated with fish oil capsules and which might make this regimen burdensome for pregnant women.\nMoreover, it would have been useful if the story had also noted that the reason researchers want to replicate the results in a larger group of women is to make sure these very high doses of fish oil are indeed safe.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not mention side effects of deep brain stimulation, which may include brain bleeding, stroke, seizure, and mood and cognitive changes.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nAs it is now, \"millions of people are being exposed to potential risks associated with a treatment that may or may not offer specific benefit, and the costs are substantial,\" she wrote.\nIt would be quite reasonable to try physical therapy first because the chances are quite good that you'll do quite well,\" said one study leader, Dr. Jeffrey Katz, a joint specialist at Brigham and Women's Hospital and Harvard Medical School.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\nWhen that happens, it's tough to tell if the pain is from the tear or the arthritis \u2014 or whether surgery is needed or will help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only quoted a commentary in the journal that published the paper \u2013 referring to \u201cmillions of people are being exposed to potential risks.\u201d\u00a0 But the specific risks weren\u2019t qualified or quantified.\nThe paper itself reported:\n\u201cThere were no significant between-group differences in the frequencies of overall or specific adverse events. Over the 12-month period of follow-up, serious adverse events occurred in 3 participants assigned to arthroscopic partial meniscec-tomy and 2 participants assigned to physical therapy alone (including one death in each group); adverse events rated as mild or moderate in severity occurred in 15 participants in the arthroscopic-partial-meniscectomy group and 13 participants in the physical-therapy group. Total knee replacement (coded not as an adverse event but rather as an indication for discontinuation from the study) was performed in 5 participants assigned to arthroscopic partial meniscectomy and 3 participants assigned to physical therapy alone.\u201d", "answer": 0}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\n\"I had these two implanted electrodes here.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms or side effects. Because this is an invasive, implantable device, there are risks from the implantation alone. It is also unclear how long the device will last.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job listing the potential harms of the procedure.\u00a0 The story gives appropriate caveats that this stem cell and fat grafting is relatively unstudied in women with a history of breast cancer, a population possibly more vulnerable to long-term harms of fat injections in the breast area. The story notes the potential need for multiple revision surgeries if the fat transfer does not take.\u00a0 The story notes that women looking for increased bresat volume beyond 1 cup size would likely not be candidates.\u00a0 The story appropriately lists potential long-term harms, including obscured mammograms due to nercrosis and calcifications from the fat. ", "answer": 1}, {"article": "But if you prefer something less invasive but more frequent, you can test your poop every year without feeling like you\u2019re opting for, um, No.\nOf the two, Richard Wender, a physician and chief cancer control officer of the American Cancer Society, said the FIT is preferable, both because it\u2019s more accurate and because it requires only one poop sample and no changes in diet.\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\nAnd the drawbacks of colonoscopy \u2014 including the time commitment, not-so-fun preparation, expense and small chance of harm \u2014 are probably keeping some people from participating in colorectal cancer screening.\n\u201cThey were very clear: We\u2019re going to stick to the evidence, and right now we don\u2019t have evidence for colonoscopy,\u201d said Aasma Shaukat, section chief of gastroenterology in the Minneapolis VA Health Care System.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a Satisfactory rating here since it does mention that with colonoscopy, there\u2019s \u201ca small but real risk of harm, such as a perforation\u201d from the screening test.\nBut, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues.\u00a0 We would have liked the story even better had it mentioned these factors.\u00a0 \u00a0", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\n\u201cThe promoters of these are appealing to people who think it\u2019s better to do things outside of the medical establishment,\u201d he said, adding that \u201cthe desire to help people is an extremely strong motivator, but so is money.\u201d He pointed to a section of the National Institutes of Health\u2019s Web site that lists several drugs, including sedatives like clonazepam and birth control pills, whose efficacy might be altered by melatonin.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nStephanie Yao, a spokeswoman at the F.D.A., wrote in an e-mail that any item that uses melatonin \u201cas an additive may be subject to regulatory action.\u201d\n\nThat is why the makers of these new baked goods label them \u201cNot for food use.\u201d They want them to be considered dietary supplements, which do not need the F.D.A.\u2019s premarket approval and are not required to be proved safe or effective.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that dessert makers \u201care marketing their products as a harmless way to promote relaxation.\u201d\nWhile harms are not quantified, it\u2019s clear from the story\u2019s discussions about regulatory questions why that\u2019s impossible to do right now. The harms mentioned are largely hypothetical in that there isn\u2019t good evidence documenting these problems.\nBut the story does a good job in painting, with broad strokes, what might go wrong if one uses these products.", "answer": 1}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\n\u201cThe data shows that it is a safe and well tolerated strategy that stimulates relevant anti-tumor immune responses.\u201d\n\nHowever, the treatment has its downsides: \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four months\u2014which may be too long from some patients with advanced cancer.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\nWhile they are very small scale\u2014one was on six participants, the other 13\u2014the findings mean researchers can move ahead with the vaccines, which could potentially lead to new, more effective cancer treatments.\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for making an important point that waiting for the vaccine to be made might be detrimental to patients with advanced cancer. It says, \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four\u00a0months\u2014which may be too long from some patients with advanced cancer.\u201d\nThe story also notes that \u201cBoth vaccines were deemed safe\u201d but it doesn\u2019t discuss any side effects that may have shown up in the trials. What happened to the five patients who were not tumor free at 25 months?\nThe story does mention that more research is needed to identify potential harms.", "answer": 1}, {"article": "There was still a benefit four weeks later.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\nThe study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.\nThere are still many questions, including whether the drug would benefit people with insomnia due to a health condition, which doctors call secondary insomnia.\n\"The amount of additional sleep was not tremendous,\" said Dr. Carl Bazil, director of the division of epilepsy and sleep at New York-Presbyterian Hospital/Columbia University Medical Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\n\u201cthere were no serious side effects in this study.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\u201d", "answer": 1}, {"article": "The participants completed the same cognitive tests each year during the four-year study, with 92 percent of the college-studies group displaying a significant increase in cognitive capacity, while the remaining 8 percent generally maintained their cognitive capacity.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nFor the control group, 56 percent displayed a significant increase in cognitive capacity, while 44 percent had no change.\n\"We plan to follow these participants as they age to see if college studies could help delay the onset or reduce the debilitating effects of dementia.\"\nAn Australian study called the Tasmanian Healthy Brain Project recruited 359 participants ages 50 to 79 who took a series of cognitive tests before completing at least a year of full-time or part-time study at the University of Tasmania.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were noted in the news release or the paper, and its hard to envision any, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Co-authors include: Drs.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nOTTAWA, ON - August 21, 2017 - Researchers at the Children's Hospital of Eastern Ontario (CHEO) looked at the incidence of and risk factors associated with sedation-related adverse events in pediatric emergency departments as part of a multi-centre observational study published today in JAMA Pediatrics.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did a good job of explaining possible harms that occur in relation to different types of sedation. A few words about the specific adverse events seen with ketamine would have been of value. \u00a0As a dissociative agent, ketamine is known for its ability to produce bizarre dreams, and hallucination as well as excessive salivation.\nHere is an excerpt from the release:\n\u201cThe overall incidence of adverse events in the study population was 11.7%. The most common events were a decrease in oxygen saturation (5.6%) and vomiting (5.2%). Significant interventions in response to an adverse event were rare, occurring in only 1.4% of children. Two other practices \u2013 receiving an opioid prior to sedation and having a laceration repair \u2013 were associated with the occurrence of vomiting, oxygen desaturation and need for significant interventions.\u201d", "answer": 1}, {"article": "Training would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nThe miniature telescope was developed by VisionCare Ophthalmic Technologies Inc. of Saratoga, Calif.\n\n\"This is truly a breakthrough technology for AMD patients as their treatment options have been limited until now,\" says Kathryn A. Colby, MD, PhD, an ophthalmic surgeon at the Massachusetts Eye and Ear Infirmary in Boston and an assistant professor of ophthalmology at Harvard Medical School.\nJuly 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did quantify the harms:\u00a0 \"the IMT is large enough to pose a threat to the cornea of the eye, leading to extensive loss of cells essential for maintaining the clarity of the cornea. In the study, 10 eyes had unresolved corneal edema, or swelling, caused by trapped fluid. Five such cases resulted in corneal transplants. The FDA says the five-year risk for unresolved corneal edema, corneal decompensation, and corneal transplant are 9.2%, 6.8%, and 4.1%, respectively.\"", "answer": 1}, {"article": "Sarah Ellis will never forget her darkest days battling depression and the series of prescriptions the Sioux Falls, South Dakota mother of three endured.\n\"It gave us an answer \u2014 that this was her physiology and her genetics and not something in her head.\u201d\n\nThe Avera Institute for Human Genetics (AIHG) in Sioux Falls, South Dakota is among several institutions exploring the role of pharmacogenomics \u2014 the science of how our inheritance and genetic makeup influences the way we metabolize medications.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nDNA Tests May Be a Guide\n\n'One piece of the puzzle'\n\nAIHG\u2019s pharmacogenomics research has led to the development of Genefolio, a genetic test that uses an individual\u2019s unique DNA to predict how that individual will respond to medications.\nNow the burgeoning field of pharmacogenomics \u2014 how genes affect a person's response to drugs \u2014 is helping more patients avoid debilitating and all-too-common side effects of psychiatric medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any potential harms of genetic testing, and the article also does not discuss the fact that some genetic tests may focus only on a single genetic marker, making them far less useful. Tests that are inaccurate may falsely suggest that patients will or will not respond to a specific drug, delaying effective treatment.\u00a0Moreover, genetic test results can have significant negative social, emotional and financial consequences for patients, including the possibility of employment and insurance discrimination based on the test results.", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\nFor those patients who either fail to respond, or who develop an inadequate response to these drugs over time, a biologic DMARD is an effective add-on treatment option.2 The first choice of biologic therapy is usually a TNFi2 and currently identical dosing regimens of TNFi are used both to induce and then maintain a clinical response.1\n\nOver the first six months of the study, flares (exacerbations of symptoms and signs) occurred in 14% of patients who stayed on the same TNFi dose, compared to a similar figure of 13% in those patients for whom the dose was reduced by one-third.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\nRome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release says: \u201cThere were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.\u201d\u00a0But it is not clear whether self-reported measures of disability are limited to the effects of rheumatoid arthritis, or whether they also include side effects that may have been caused by the drug.\u00a0According to the American College of Rheumatology, those side effects can include \u201can increased risk for all types of infections, including tuberculosis (TB) and fungal infections. Some of these infections may be severe.\u201d\nWhile the potential for side effects should have been mentioned, we\u2019d note that reducing the TNFi dose should theoretically reduce harms. But that is an assumption that needs to be studied. This study is too small to do that.", "answer": 0}, {"article": "The study appears online in the Journal of Clinical Investigation.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the benefit of the doubt here because the story does mention the possibility of unintended harms from brown fat-activating treatments. However, we thought it was worth noting \u2014 as the authors of the study did in their paper \u2014 that the hormones that activated brown fat in this study are elevated during heart failure and cancer-related wasting. Thus, any weight loss they produce may be accompanied by important adverse effects.", "answer": 1}, {"article": "\"They attached, but they were not getting enough food.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\nTo determine whether a woman's endometrium (uterine lining) is healthy and can sustain the embryo, the research team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With any drug treatment related to pregnancy it is absolutely essential to discuss the effects of the drug on both mother and child. This news release doesn\u2019t address safety risks to either.\nThe Mayo Clinic\u2019s website for patients offers a long list of possible side effects from progesterone in adults. Much less information is available about progesterone\u2019s risk to a developing fetus. ", "answer": 0}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We preferred the way the Boston Globe handled this question. It said:\n\u201cVirtual colonoscopy, with or without prep, has some limitations. About one in five patients must undergo a standard colonoscopy after the imaging procedure to have suspicious looking polyps snipped off and biopsied. The CT scan also delivers a dose of radiation that \u2014 while only one-fifth of the dose of an abdominal CT scan \u2014 was significant enough to raise the flags of the US Preventive Services Task Force.\u201d\nIn addition, MedPage Today reported:\nCT imaging picked up indeterminate or potentially clinically important findings outside the colon in 16% and 3% of patients, respectively. Medical record review showed that 5.5% of the cohort ended up getting additional diagnostic work-up due to such incidental findings.\nThat could be a good thing \u2013 but it could bring potential harm in additional workups for some incidentalomas \u2013 things you caught that you really didn\u2019t need to know about.", "answer": 0}, {"article": "Advanced online publication: http://www.\nThe published results showed a gene-dose effect at the high dose of tramiprosate (150 mg, twice daily), with patients with two APOE4 alleles (APOE4/4 homozygotes) showing the largest clinical benefit, those with one APOE4 allele (APOE4 heterozygotes) showing an intermediate benefit, while APOE4 non-carriers showed no benefit from tramiprosate.\nEfficacy Results in APOE4/4 Homozygous Patients from the JPAD Phase 3 Analyses\n\nThe published results showed the largest clinical benefit in the Alzheimer's APOE4/4 homozygous AD patients, who represent approximately 15 percent of patients in the study.3 APOE4/4 homozygous patients who received the high dose of tramiprosate showed efficacy benefit compared to placebo on both cognitive and functional measures in the Phase 3 analyses.\nData published by Alzheon in the Journal of the Prevention of Alzheimer's Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of APOE4 alleles\n\nFRAMINGHAM, Mass., October 24, 2016 - Results published today in The Journal of the Prevention of Alzheimer's Disease (JPAD) describe analyses of Phase 3 data for the investigational amyloid-targeted drug, tramiprosate, in patients with Mild to Moderate Alzheimer's disease (AD).\n\"These newly-published findings form the basis for the design of our Phase 3 program, and further support our company's commitment to advance ALZ-801 into pivotal studies in APOE4/4 homozygous AD patients who represent up to 15% of AD patients1.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contained enough detail about safety issues to give it a satisfactory when it noted: \u201cThe safety profile of tramiprosate in 2,025 AD patients across the two studies was favorable and similar in the APOE4 carriers and non-carriers. The main adverse events were gastrointestinal (nausea, vomiting and weight loss), which were mild or moderate in severity.\u201d\nWe would have liked more discussion of how patients might use the drug and whether there are any other harms that could loom from treatment.", "answer": 1}, {"article": "One such tool is called a CT chest scan, which produces detailed images with high-dose x-rays and is being used in millions of patients every year in the U.S.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nNEW YORK (Reuters Health) - U.S. researchers say they have found clear signs that blood clots in the lungs are being overdiagnosed, exposing patients to potentially dangerous side effects from unnecessary drugs.\nAccording to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\nThe number of deaths caused by the condition dropped only little, however: from 12.3 per 100,000 in 1998 to 11.9 per 100,000 in 2006.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained: \u201cthe blood-thinning drugs used to treat blood clots increase the risk of bleeding in the brain or gastrointestinal tract, for example. According to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\u201d It also reported: \u201cCT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer. And the dyes used to enhance the scan also cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nWhile psychostimulants such as LDX are primarily marketed for the treatment of ADHD, they have been successful in treating cognitive complaints in some patients including postmenopausal women.\nThey work by promoting the release of dopamine, which is impaired in ADHD and other disorders characterized by executive function problems.\nThe researchers found a 41 percent overall improvement in executive functions for women receiving LDX, compared to a 17 percent improvement when taking placebo medication.\nAll participants served as their own controls by being randomly assigned to cross-over to a placebo for an additional four weeks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any harms in this release, although the paper mentions that this drug can raise both heart rate and blood pressure, although not precipitously.", "answer": 0}, {"article": "TUESDAY, Feb. 28, 2012 (HealthDay News) -- Menstrual cramps are the bane of many women, but new research suggests that a form of vitamin D may one day be added to the meager list of pain relievers for the sometimes disabling condition.\nThe vitamin is also known to have anti-inflammatory effects, Rabin added.\nTo find out more about painful menstrual periods, head to the U.S. National Library of Medicine.\nThe study was published Feb. 27 in the Archives of Internal Medicine.\nThe cost of vitamin D supplements would be roughly comparable with both of these remedies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not talk about any harms related to high doses of Vitamin D.\n\u00a0", "answer": 0}, {"article": "The BCG vaccine lowered A1c levels 9 percent to 16 percent.\n(The standard of care is a continuous glucose monitor, in which a probe is inserted into the abdomen, plus an insulin pump.)\nCritics have gone so far as to send letters to newspapers that covered her work apologizing to patients \u201con behalf of Dr. Faustman\u201d for \u201chaving their expectations cruelly raised.\u201d She has also struggled for funding, receiving much of her research support from the private Iacocca Family Foundation, rather than in federal grants.\nIt alters the immune system so as to increase levels of T regulatory cells; T regs keep other immune cells in check, including those that attack the pancreas\u2019s insulin-making cells \u2014 the root cause of type 1 diabetes.\nAlthough many studies of BCG are underway around the world in diabetes and other autoimmune diseases, including multiple sclerosis, there has been little interest among U.S. researchers outside Faustman\u2019s lab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the BCG vaccine, an attenuated form of Mycobacterium bovis that has been used to treat tuberculosis for nearly 100 years, is considered extremely safe.\nThere are some rare side effects of the BCG vaccine (as for any medicine), so the article could have mentioned this, though.", "answer": 0}, {"article": "Gardasil protects against several strains of HPV, which is the leading cause of cervical cancer in women.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\n\"Studies like this underscore the 'human' in human papillomavirus,\" said Fred Wyand, director of the HPV Resource Center at the American Social Health Association.\nAlthough the U.S. Centers for Disease Control and Prevention recommends that 11- and 12-year-old girls begin receiving the vaccine as part of school vaccination efforts, an advisory panel voted against routine use of the vaccine in boys and men.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There wasn\u2019t a single mention of potential harm to any study participants, and there wasn\u2019t a sentence saying, \"Researchers did not find any significant harm for those who received the vaccine.\"\n In the broader social context, there was no mention of whether the vaccine might falsely lead young men to feel they are \"safe\" from a sexually transmitted disease, when the vaccine only covers four types of the human papillomavirus, and there are many more that are not covered.", "answer": 0}, {"article": "Sharif said the excellent short-term outcomes and 100 percent cure rate of HCV in organ recipients should prompt transplant centers to rethink use of HCV-infected kidneys.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\nTUESDAY, Aug. 7, 2018 (HealthDay News) -- Dialysis patients waiting for kidney transplants might safely accept an organ from a donor infected with hepatitis C virus (HCV), a new study finds.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nDialysis can cost more than $88,000 a year, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201csome patients might not want to take the risk associated with an infected kidney,\u201d but we think the potential risks of this strategy warranted more discussion.\nHepatitis C causes inflammation of the liver that can lead to diminished liver function or failure of that organ. According to the study, one patient in the study experienced a serious adverse event, protein in the urine, which indicated liver malfunction and could have been triggered by the HCV infection. The condition improved after treatment, according to the published study.\nModern HCV treatments are not 100% effective at curing the disease and come with \u201cblack box warnings\u201d for side effects such as low blood cell count, nausea, flulike symptoms, feeling tired, headache, and reduced appetite.", "answer": 0}, {"article": "The men, 35 to 79 years old, had systolic blood pressure of 140 or more.\nIn participants assigned to the pharmacist-led program, the average reductions in systolic and diastolic blood pressure were 21.6 and 14.9 greater, respectively, than in those assigned to the control group at six months, the researchers found.\nThe study, published Monday in the New England Journal of Medicine , tested whether pharmacist-led programs in barbershops could significantly lower high blood pressure in black men in the United States.\nAlso, pharmacists aimed to lower blood pressure in the program participants to less than 130/80, whereas the primary care providers of those in the control group probably targeted a blood pressure of less than 140/90.\n\"We know that when it comes to people being receptive to health messages, the setting and the mood that people are in can have an impact on how open they are to receiving those messages,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough one to rate. On one hand, It is hard to envision harms arising from men participating in what appeared to be a safe screening and treatment program for high blood pressure. On the other, the journal paper about this study reported that three individuals experienced acute kidney injury, although that problem disappeared once medications were altered. So, there are risks, and the story would have been stronger had it included them.", "answer": 0}, {"article": "The development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nFor enquiries out of hours, please call 07595 963 613.\nMovember is a registered 501(c)(3) charity.\nFor more information, click here.\nThe ICR's mission is to make the discoveries that defeat cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned.", "answer": 0}, {"article": "For more information, visit http://www.\nThe Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 \"Best Hospitals\" issue of U.S. News & World Report.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nStructured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care.\nThe System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that there was no increase in adverse events reported during the study, nor were there any cases where pneumonia was not appropriately diagnosed. There is the potential for some harms that aren\u2019t addressed, namely missed diagnosis and the identification of small pneumonias that don\u2019t need to be treated (overdiagnosis).\n\u201cIn the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\u201d according to the lead study author. This benefit in terms of harms reduction might have been stressed even more. Ultrasound screening could be safer in the long run for children than X-ray since repeated exposure to radiation presents a cumulative risk for cancer. Radiation oncology experts and the FDA have long called for reduced reliance on routine X-ray and computerized tomography (CT) screening in children unless the benefits outweigh the risks. More than 100 professional organizations including pediatricians, radiation physicists and oncologists have signed on to the \u201cImage Gently\u201d campaign which urges the use of ultrasound instead of radiation when feasible.", "answer": 1}, {"article": "For more information, click on www.hsrxbiopharmaceutical.com\nMeasurements in the level of pain and range of motion in the affected knee were recorded over a 14-day period for each patient.\nAfter 14 days of treatment, average pain reduction was more than twice as large as the competition.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any potential harms of the topical cream or tablet \u2014 or whatever it truly is.", "answer": 0}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nThere was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\nAmong the side effects of the combined treatment, 16 patients experienced neutropenia, a low count of the infection-fighting white blood cells called neutrophils; five patients with neutropenia had fevers; three patients became anemic; and two patients developed thrombocytopenia, a lowered count of blood-clotting platelets.\n\"However, it seemed that patients were responding at all levels of the drug.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The headline is problematic, but we\u2019ll talk about that under the \u201cUnjustifiable Language\u201d criterion. The rest of the release does a good job of describing potential harms. The release discusses eight potential harms, defines them and offers numbers on all of them (e.g., \u201ctwo patients developed thrombocytopenia, a lowered count of blood-clotting platelets\u201d). That\u2019s very good. Two things would have made it even better. First, the release could have included an explanation of what the observed adverse effects actually mean. For example, how severe was the thrombocytopenia? And how much of a risk does that pose to a patient\u2019s health \u2014 are we talking about the potential for bruising easily? Or a high risk of bleeding to death? Second, it wasn\u2019t clear if the dose of guadecitabine was related to observed effects. I.e., were patients who received higher doses of guadecitabine more likely to exhibit adverse effects?", "answer": 1}, {"article": "The agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nThe FDA previously cleared medications containing synthetic versions of THC for nausea for patients getting chemotherapy and for other uses, but it had not approved any drug derived from the plant itself.\nThe Food and Drug Administration on Monday approved the first drug derived from marijuana, which will be used to treat two rare and severe forms of childhood epilepsy.\nNow that Epidiolex is approved by the FDA, cannabidiol is expected to be reclassified by the Drug Enforcement Administration within 90 days.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FDA release about the agency\u2019s approval lists the most serious side effects, many of which are common, including liver damage, depression, suicidal thinking, anorexia and insomnia. But the news story does not mention them.", "answer": 0}, {"article": "George said he believes the approach works by \u201cresetting\u201d electrical activity and restoring normal mood regulation.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nSomething similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\nIn the May issue of the Archives of General Psychiatry, George and his colleagues report the results of their 190-patient study, the most rigorous investigation of TMS for depression so far.\nNEW YORK (Reuters Health) - A daily dose of electricity delivered to a specific part of the brain can lift depression, new research confirms, even for people who\u2019ve already tried multiple antidepressants to no avail.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that people in the TMS and sham treatment groups were equally likely to experience side effects including headache, discomfort at the TMS site, and eye twitching. The story could have pointed out that we don\u2019t know much about long-term adverse effects of this treatment, and that a short-term study of 190 subjects has limited ability to identify rare but potentially serious adverse effects.", "answer": 1}, {"article": "Two patients discontinued therapy because of adverse events related to the drug.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that \u201cTreatment-related side effects included mainly low-grade fatigue, itching, elevated lipase, rash, nausea, joint pain and anemia. Grade 3 or 4 side effects occurred in 20.5 percent of patients. Two patients discontinued therapy because of adverse events related to the drug.\u201d That\u2019s enough to earn a satisfactory rating. However, it could have been better. The release says adverse effects \u201cincluded mainly\u201d manageable problems. But more than 20 percent of patients had \u201cgrade 3 or 4\u201d side effects \u2014 and that is not trivial. The release would have been much stronger if it had offered some insight into those more severe effects, or even explained what \u201cgrade 3 or 4\u201d effects means. Grade 3 effects, according to the National Cancer Institute, are \u201csevere\u201d \u2014 while grade 4 effects are \u201clife-threatening or disabling.\u201d That merits more discussion than it got.", "answer": 1}, {"article": "Depression affects about 20 percent of people at some point in their lives.\nHONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\nThe journal article explained that adverse events (including dizziness, tiredness, nausea, excessive sweating, headache, transient tachycardia, insomnia, vomiting, unsteadiness and somnolence) occurred in at least 5% of the patients in either group and that two patients discontinued due to intolerance of acupuncture stimulation.", "answer": 0}, {"article": "Several of these differences were associated with worse performance months later in cognitive and behavioral tests.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\nFor concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "MRIs are generally deemed to be a safe procedure, since no ionizing radiation is used. Adverse events for MRI scans are rare, but like any medical procedure, they do carry some risk, especially for patients with implants and external and accessory devices \u2014 like artificial joints, insulin pumps and\u00a0ventilators. For these patients, risks include device malfunction or heating of the implanted medical device and the surrounding tissue, which could lead to burns.\nAccording to the FDA, the use of gadolinium-based contrast agents (GBCAs) also carries some risk, including side effects such as allergic reactions. For patients with kidney disease, GBCAs could cause a rare and potentially fatal condition known as nephrogenic systemic fibrosis.\nSince harms are not mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "'Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy' by Xun Liu, Sally Jary, Frances Cowan and Marianne Thoresen in Epilepsia\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nAlso, the severity of cerebral palsy is milder and seven out of ten are able to walk.\nIn this cohort born after 2007, the number of children with poor outcome is lower at 34 per cent (11 per cent death and 23 per cent survived with disability).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Therapeutic hypothermia is widely regarded as safe, if the treatment is provided by practitioners with the right expertise to patients who meet the relevant criteria.\nForcing the human body to the wrong temperature can cause many potentially serious side effects, including bleeding, infection, dehydration and low magnesium. It is relatively safe only because of expert management by ICU personnel familiar with the procedure.\nAll of that needs to be mentioned, whereas the release doesn\u2019t address the risks.", "answer": 0}, {"article": "River Vision Development Corporation licensed the drug from Roche.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\nThe study \u201cincluded some of the worst cases imaginable and we\u2019re now wondering whether the drug might find expanded utility in much-less-severe disease,\u201d Smith told Reuters Health in a telephone interview.\nThe eyes don\u2019t have that bulging appearance, he said, and many of them return to the degree of bulging they had before they got the disease.\nGraves\u2019 disease is the most common cause of overactive thyroid in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that using the new drug brought on double vision among 50 percent of the patients by six months. Only 10 percent of the patients admitted double vision at the start of the trial.\u00a0 Also, the story states that \u201cHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\u201d", "answer": 1}, {"article": "TUESDAY, Aug. 25, 2015 (HealthDay News) -- Needles beat pills for treating hot flashes in breast cancer survivors, according to a new trial that compared acupuncture, \"sham\" acupuncture, the medication gabapentin and a placebo pill.\n\"The placebo effects for both acupuncture and drugs are quite intriguing, as they both seem to persist over time,\" Mao said.\nAcupuncture had the greatest effect on overall hot flash scores at 8 weeks, when all interventions ended, followed by sham acupuncture and then gabapentin.\n\"For patients suffering symptoms, they can look for all kinds of possible solutions and are better off talking to their doctor to find out what's most appropriate for them,\" Deng said.\n\"In fact, in clinical practice, every doctor uses it all of the time,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is likely safe but we have no idea if the women who received it, the sham acupuncture or gabapentin experienced any adverse effects of those treatments.", "answer": 0}, {"article": "In an interview last spring with Psych Congress Network, an Internet news site for mental health professionals, Dr. Timothy Wilens, chief of child and adolescent psychiatry at Massachusetts General Hospital, said \u201cwe have enough data to say they\u2019re actually neuroprotective.\u201d The pills, he said, help \u201cnormalize\u201d the function and structure of brains in children with A.D.H.D., so that, \u201cover years, they turn out to look more like non-A.D.H.D.\nFor most people with A.D.H.D., stimulants can temporarily boost focus, motivation and self-control by increasing the availability of these chemical messengers.\nOne peer-reviewed 2013 study co-authored by Dr. Swanson suggested that the stimulants may change the brain over time so as to undermine the long-term response to the medication and even exacerbate symptoms when people aren\u2019t taking them.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\n\u201cSometimes wishful thinking gives us hope that the impressive short-term relative benefits of medication over other treatments will persist beyond childhood, but I haven\u2019t seen it,\u201d said James Swanson, director of the Child Development Center at the University of California at Irvine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cries out for some details about the downsides of medication. It includes a statement that most children quit taking their medicine. Why? Again, the story seems to assume that readers are ADHD aficianados.", "answer": 0}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nIn addition, there were differences in the measured absolute amounts of exercise performed when comparing objective activity monitoring using a wearable \"device\" and self-report of physical activity.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nThe Lifestyle Interventions and Independence for Elders Study is supported by a National Institutes of Health/National Institute on Aging Cooperative Agreement (U01AG22376) and a supplement from the National Heart, Lung and Blood Institute (3U01AG022376-05A2S), and sponsored in part by the Intramural Research Program, National Institute on Aging, National Institutes of Health.\nFor the LIFE study, the researchers analyzed data from 1,635 men and women age 70-89 over an average of 2.6 years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The release could have noted that harm scores were pretty even among all of the study participants, regardless of the duration of their physical activity, and that the protocol was designed to keep the regimen safe for older, sedentary people.", "answer": 0}, {"article": "Armstrong thinks that a diet rich in folate might be important for brain functioning throughout life.\n\"It's too early to say that everyone should start taking folate,\" he stressed.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\n\"These results provide new information that points to the importance of keeping a closer watch on folate status in childhood and adolescence.\n\"We know that folate plays a really critical role in brain development and brain function,\" said Dr. Daniel Armstrong, associate chair of pediatrics at the University of Miami Miller School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. The story could have mentioned the potential for excessive folic acid intake to interfere with vitamin B12 uptake which, though unlikely in a teen population, could mask symptoms of B12 deficiency. But we\u2019ll give it the benefit of the doubt on this.", "answer": 2}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly lays out some of the ways that testing can go awry. It reports that the CT scans expose people to about the same amount of radiation as a mammogram, implying a level that many people routinely accept, though it does not go into detail about potential radiation effects. The story also explains the risk of \u201cincidentalomas\u201d, things that can pop up on this sort of scan besides coronary artery calcium, such as nodules in lungs, that might lead a person down a path of further testing and treatment. And it spells out the potential consequences of having a scan that reveals high levels of calcium deposits, prompting further testing and treatments, perhaps leading to substantial harms.Overall, we think the harms are admirably covered.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nFor the study, researchers evaluated 37 children ages 9 to 18 who were obese and at high risk for heart disease and Type 2 diabetes.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study sought to hold number of calories constant in order to examine the impact of reduced sugar. \u00a0While many health experts would point out that substituting pizza and bagels does not meet the criteria for an overall healthy diet, that was not a concern of this design.", "answer": 2}, {"article": "SUNDAY, Aug. 28, 2011 (HealthDay News) -- An experimental drug, apixaban (Eliquis), appears better than the old standby warfarin in preventing strokes in people with the abnormal heart rhythm called atrial fibrillation, a new study finds.\nThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns.\nFor the trial, more than 18,000 patients with atrial fibrillation and a heightened risk for stroke were randomly assigned to receive either apixaban or warfarin.\nThe new report was published online Aug. 28 in the New England Journal of Medicine to coincide with its presentation at the European Society of Cardiology Congress in Paris.\nIn that trial, published in July in the New England Journal of Medicine, apixaban's use was associated with raised odds for bleeding -- without providing patients with any reduction in heart attack risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided good insight about possible problems associated with apixabane in patients with coronary artery disease who were simultaneously taking two blood thinners in addition to apixabane.", "answer": 1}, {"article": "But researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\n\u201cIt\u2019s promising that we can see an effect from a single dose,\u201d says researcher Leah Coles, PhD, a research fellow at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss potential harms. We\u2019re not aware of any harms associated with drinking beet root juice, but there are concerns that getting too much nitrate could have have toxic effects, such as increasing the risk for cancer. (That\u2019s why nutritionists often advise against eating meats cured with nitrates such as hot dogs.) The story could also have warned of possible adverse effects from supplements that contain nitrate or nitrite salts, which can be highly toxic.\u00a0There is no information on Medlineplus.gov about beetroot. \u00a0Medication interactions are also possible. Harm is always possible, even with nutritional supplements. We stand by our same hard line as with the \u201ccosts\u201d criterion above.\u00a0 All interventions have potential harms; some discussion is warranted.", "answer": 0}, {"article": "Correction: February 16, 2006, Thursday A front-page article on Feb. 8 about a new study finding that low-fat diets have no effect on the risk of cancer or heart disease misstated the incidence of breast cancer among women in the study.\n\"People are always thinking it's what they ate.\nBut they had just as much breast and colon cancer and just as much heart disease.\nThe women were not trying to lose weight, and their weights remained fairly steady.\n(The difference was deemed statistically insignificant.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes many questions about whether a low-fat diet is worth the trouble.", "answer": 1}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nThey also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did make clear that the OCT device was a light-only probe that carried no need for dyes or invasive procedures; it was \u201cswept\u201d across the tissue so that the microscopic tissue structures could be captured on video and analyzed or compared with the gold standard analyses in the path lab. But the release probably should have said whether the use of OCT added to time under anesthesia or was associated with little or no harm at all to patients.\u00a0In addition, there is the potential for harm in terms of an impact on cosmetic results if tissue is removed based on a positive reading that was found to be a false positive. One of the cases described in the study was a false positive.", "answer": 0}, {"article": "Higher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\n\u201cDoctors at UC San Diego and UCLA now have a non-invasive imaging method to more accurately assess the local extent of the tumor and possibly predict the grade of the tumor, which can help them more precisely and effectively determine appropriate treatment.\u201d\n\nThe current standard of care for detecting and diagnosing prostate cancer is contrast enhanced magnetic resonance imaging (MRI), which involves intravenously injecting patients with a contrast agent to highlight blood flow.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\n\u201cProstate cancer can often be an indolent disease, where a patient may only require surveillance rather than aggressive surgery,\u201d noted co-author Christopher J. Kane, MD, professor of urology at UC San Diego.\nBut diffusion MRI suffers from magnetic field artifacts that can distort the actual location of tumors by as much as 1.2 centimeters or roughly half an inch \u2013 a significant distance when surgeons are attempting, for example, to assess whether a tumor extends beyond the prostate and into adjacent nerve bundles.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. One conceivable concern is that \u201cprovid[ing] a better target for biopsies, especially for smaller tumors\u201d might lead to overdiagnosis \u2014 finding low-risk cancers that would never cause a problem. The patient is subsequently burdened with a cancer diagnosis and complication risks related to ensuing treatment/surveillance protocols.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Tens of thousands of kids may benefit from cholesterol-lowering medication, but no one would know because screening guidelines exclude too many children, U.S. doctors said Monday.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\nBut a third of those children didn\u2019t have relatives with heart disease or high cholesterol, and so wouldn\u2019t have been screened under the current guidelines, issued by the government\u2019s National Cholesterol Education Program.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\nFor example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that cholesterol-lowering drug treatment in children is controversial and the safety of such treatment has not been studied in children. However, the story does not mention any of the specific harms of statin treatment that have been identified in studies of adults.", "answer": 1}, {"article": "heart assocIation Mouth-to-mouth not necessary and seen as deterrent\n\nIn a break from decades-old first aid guidelines, the American Heart Association on Monday endorsed \"hands only\" cardio-pulmonary resuscitation - rapid chest compression without mouth-to-mouth resuscitation - to improve the odds for victims of cardiac arrest.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\n\"If you have access to an AED (Automated External Defibrillator), you want to apply that as early as possible,\" advised San Francisco General's Barton.\nThe message is, if there is any doubt, provide \"hands only\" CPR.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news article explains that when CPR is performed with chest compressions only (without mouth-to-mouth resuscitation) the main harm is rib fractures induced by energetic chest thumping. ", "answer": 1}, {"article": "(CNN) Finding ways to fight the flu just got a tad more ribbeting -- that is, if you ask some researchers who have turned their attention to frogs.\n'It makes the virus particle fall apart'\n\nThe researchers observed how the peptides interacted with influenza viruses under a microscope and in mice.\nIt never gets influenza,\" Jacob said, adding that the peptide fights the flu virus by destroying an important part of the hemagglutinin.\n\"Amphibians, especially certain groups of frogs, produce and store large amounts of antimicrobial peptides in specialized granular glands in the skin,\" said Louise Rollins-Smith, associate professor of pathology, microbiology, and immunology at Vanderbilt University School of Medicine.\n\"You have the message and then you have the little stem that holds it up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given the early nature of the research\u2013which the story makes clear is preliminary\u2013we\u2019ll rate this N/A.\nIdeally, we\u2019d like a statement to the effect that the safety is totally unknown.\u00a0However\u00a0the story does establish that future research might better pin down the harms, i.e.,\u00a0\u201cIf further studies show it has a low level of cytotoxicity\u2026\u201d", "answer": 2}, {"article": "The study's primary endpoint was OS.\n\"With our study, we hypothesized that proton therapy would offer a survival benefit to patients and reduce treatment-associated toxicities, which can be very serious,\" he said.\nThe findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy, said Joe Y. Chang, M.D., professor, Radiation Oncology and the study's corresponding author.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says:\n\u201cAmong the acute and late toxic effects diagnosed in patients were: esophagitis, pneumonitis and cardiac arrhythmia. Of note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\u201d\nSo we give the release credit for talking about harms. Some numbers to show how many of the 64 people enrolled had side effects would have been helpful.", "answer": 1}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about hip replacement.\nRheumatoid arthritis affects about 1.3 million people in the United States, while osteoarthritis affects 27 million Americans aged 25 and older, according to the American College of Rheumatology.\nIn addition, rheumatoid arthritis patients have a higher infection risk after total knee replacement than osteoarthritis patients, the study authors found.\n\"Joint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\" study author Dr. Bheeshma Ravi, from the University of Toronto and Women's College Research Institute, said in a journal news release.\nWEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of joint replacement are the focus of the story, but there is no attempt to put them in perspective for readers.\nThe story does not tell readers how high or low the rates of complications are. It says people with rheumatoid arthritis had higher rates of dislocation and infection after a joint replacement than those with osteoarthritis, but no relative or absolute risk statistics are reported. The story pulls a quote from a news release saying \u201ccomplication rates are low,\u201d but \u201clow\u201d is not defined.", "answer": 0}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n\"The 90 percent detection rate by stool DNA testing is remarkable.\nUnlike common polyps, they tend to be flat and the same color as the colon lining.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of false positives with this method. ", "answer": 0}, {"article": "\u201cWe find a clear benefit.\nIt\u2019s making them fit and healthy.\u201d\n\n\n\nThe UK\u2019s National Health Service recommends that to ward off an early death, people should spend 150 minutes a week performing moderate exercise, or 75 minutes a week doing vigorous exercise.\nFor those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\nAs a rule of thumb, moderate exercise can be done while maintaining a conversation, whereas during vigorous exercise talking at the same time is too hard.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit the story does provide some information on the potential harms before embarking on a \u201cweekend warrior\u201d status. \u00a0The lead author of the paper recommended, \u201c\u2026\u00a0to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury. \u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise.\u201d", "answer": 1}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\n\"This increased connectivity reflects the fact that video gaming experience changed the mode of operation of certain brain structures,\" Dr. De Giglio said.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nResearchers led by Laura De Giglio, M.D., Ph.D., from the Department of Neurology and Psychiatry at Sapienza University in Rome, recently studied the effects of a video game-based cognitive rehabilitation program on the thalamus in patients with MS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While there are no obvious harms that would come from playing the video game/training program used in the study we think addressing harms is applicable for this news release, and there was no mention. It is possible that focusing on training in one part of brain function may lead to lack of attention in other parts, and this imbalance may result in relative gains and losses in brain activity that may have negative impacts in certain cognitive or functional areas. It may also be worth noting that harm may come from overuse. In a controlled setting like this study, overuse may be preventable. But what if this was available at home and the person could use it 24/7?", "answer": 0}, {"article": "Still, some researchers not involved in the study said the topic required more work.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nWe need more studies, funded by someone other than the company that makes the product.\u201d\n\nSmoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year.\nOne got Chantix, the brand name of the drug varenicline, which is taken twice a day by mouth as a pill; the other group got a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically focuses on the use of varenicline, which goes by the trade name Chantix, but does not mention any of the possible adverse health effects associated with the drug. These possible side effects include changes in mood, suicidal thoughts, and cardiovascular problems \u2014 all of which are worth mentioning.", "answer": 0}, {"article": "As Albert, a pseudonym for an AA member in Georgia, previously told me, \u201cThere\u2019s just not a lot of widely advertised options available.\u201d AA and 12-step treatment are \u201cthe most well-known and most recommended option, so that\u2019s kind of where you tend to go.\u201d\n\nZemore\u2019s study begins to peel away at this problem.\nPresumably, you could get those by participating in alternatives to AA.\u201d\n\nIn other words, these alternatives could help the one-third to two-thirds of people who don\u2019t get anything or much out of AA.\nThis is a big part of the 12 steps, with the final step even invoking \u201ca spiritual awakening.\u201d For people who aren\u2019t religious or spiritual, this can be a big turn-off; that\u2019s one reason SMART and LifeRing exist to begin with \u2014 they\u2019re meant to be secular alternatives to the 12 steps.\nThere has been a good amount of research into AA and the 12 steps over the years, broadly finding that about a third of people maintain recovery from alcohol addiction due to 12-step treatment, another third get something out of the treatment but not enough for full recovery, and another third get nothing at all.\nThe study, in short, looked at how people\u2019s self-reported outcomes with AA and 12-step programs compare with the three biggest alternative mutual help groups \u2014 Women for Sobriety, SMART Recovery, and LifeRing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there is no well-established quantification of harms of mutual-help groups, we feel this potential should be borne in mind, just as we would expect reports of negative side effects and adverse events in a medication study. The story doesn\u2019t mention potential downsides to any of these programs.\nFor example, as a ProPublica investigation\u00a0pointed out in 2014, some who participate in AA meetings are forced to do so by the criminal justice system. This group of mandatory members may include violent felons who are trading attendance for a lighter sentence. ProPublica noted that in some cases, this can create \u201ca combustible mix of violent ex-felons and newcomers who assume that others \u2018in the rooms\u2019 are there voluntarily.\u201d\u00a0 These conditions may increase the potential for sexual and financial abuse of AA members.", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports:", "answer": 1}, {"article": "The children were assessed 11 times between birth and the age of 6 years.\n\"This study highlights the fact that in utero exposure can have a profound effect on the fetus that lasts through childhood,\" said Dr. Jennifer Wu, an obstetrician-gynecologist from Lenox Hill Hospital in New York City.\n\"The body composition at age 6 years in children given fish oil supplementation was characterized by a proportional increase in lean, bone and fat mass, suggesting a general growth-stimulating effect,\" the researchers, who were led by Hans Bisgaard, from the University of Copenhagen, wrote in the report.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nHowever, the higher BMI was not due to a higher percentage of fat, but rather to higher percentages of lean muscle and bone mass, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any risks of taking fish oil. But these include belching, bad breath, heartburn, nausea, loose stools, rash, and nosebleeds. For pregnant women who have to be vigilant about even seemingly harmless side effects (nausea can be a serious symptom in the third trimester, for example), these details are important.", "answer": 0}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nThe patches stayed in place and worked even in the challenging outdoor race, and the patches\u2019 biochemical test results agreed with the indoor bikers\u2019 conventional sweat tests, the researchers reported in the journal Science Translational Medicine.\nFor simple fitness purposes, it could give an early warning that it\u2019s time to replenish electrolytes before someone starts to feel dehydrated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study doesn\u2019t contain data on adverse effects, and the story doesn\u2019t touch on potential harms. Have patches been tested for skin irritation, for example? More broadly, could skin patches give athletes a false sense of security, prompting them to ignore physical symptoms, or distract them from the basics of proper training, nutrition and hydration? That\u2019s not addressed.", "answer": 0}, {"article": "The patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nStelara, which brought in sales of $1.34 billion in the second quarter of 2018, is also being tested in autoimmune disease lupus.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that one patient who received Stelara died from \u201cexcessive bleeding\u201d but that overall side effects were similar between Stelara and placebo patients. That\u2019s enough to earn a satisfactory rating here. However, it was fairly glaring to discuss a patient dying without explaining whether or not it was thought that this death was attributed to the treatment or the underlying disease.\nAlso the story would have been stronger if it had noted that Stelara affects the immune system, and can cause a host of other significant side effects. The story doesn\u2019t need to list every single risk, but a sentence addressing the risks would be worthwhile.", "answer": 1}, {"article": "In the study, published in the Proceedings of the National Academy of Sciences, researchers examined the effects of POPG on RSV infection in human lung cells in the lab and in mice infected with the virus.\nRSV is the major cause of hospitalization in young children under age 2 and is an increasingly problematic infection in adults with chronic lung disease, the elderly, and those with weakened immune systems.\n\"Our findings demonstrate that POPG is a potent antiviral agent both as\n\na prophylactic and after infection has occurred,\" researcher Dennis Voelker, PhD, professor of medicine at National Jewish Health in Denver, says in a news release.\nThe findings also suggest that POPG\u2019s role in the lungs may be to help the lungs tolerate the daily barrage of inhaled irritants.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t quantify the harms of something that hasn\u2019t advanced beyond the lab and has not yet been done in humans.\u00a0 Of course, you can\u2019t say much at all at this stage, which raises the question of why the story was published now in a consumer health section that is labeled, \"Health & Parenting.\"\u00a0 ", "answer": 2}, {"article": "About three months later, participants underwent mental-functioning tests and MRI scans that examined brain size and blood supply in the brain.\nAnother possibility is that the slight mental decline that the people in the older brain group were experiencing caused them to eat less healthy omega-3-rich foods, instead of vice versa.\nThis suggests they may play a role in promoting general vascular, or blood vessel, health in the brain, similar to how they are thought to help heart health, rather than acting on just one brain area, Tan said.\nThe researchers took into account various health and lifestyle factors, including age, education and body mass index, to explore whether other differences among the people with low levels of omega-3s could help explain their more rapid brain aging.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of eating fish are not in question, although there is some concern that certain species high in mercury can be harmful for pregnant women and children.", "answer": 2}, {"article": "Another expert, however, said that scenario is likely overoptimistic.\nMONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nTheir systolic blood pressure -- the top number in a blood-pressure reading -- remained dangerously high at 160 millimeters of mercury (mmHg) or above despite having taking three or more drugs to control blood pressure, the researchers noted.\n\"You may have to take less medication and you may have to take lower doses of medication, but we all expect that patients will still have to take some medication,\" he said.\nFor the study, an international team lead by Dr. Murray Esler, professor and senior director of the Baker IDI Heart and Diabetes Institute in Melbourne, Australia, assigned 35 patients to renal denervation and compared them to 47 patients who had already had the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not sufficient to simply act as stenographer when study authors say \u201cthe procedure is safe as well as effective.\u201d In fact, a careful review of the actual journal paper contradicts the safety statement.\u00a0One subject in the crossover group suffered a renal artery dissection (tear) during placement of the guide catheter that required urgent repair. Not important enough to report?\nAnd it certainly isn\u2019t adequate to quote from a news release that \u201cparticipants\u2019 kidneys were not damaged or functionally impaired.\u00a0 We also found no ill effects on long-term health from the procedure.\u201d\u00a0 Would most blood pressure experts consider 6-12 months as \u201clong-term health\u201d?\nCan a procedure be proclaimed \u201csafe\u201d in the hands of one experienced team?\u00a0 What might the learning curve be for this approach?\nThese are not merely academic questions when a researcher \u2013 and a story \u2013 proclaim a tiny study as proof of safety.", "answer": 0}, {"article": "To learn more about Oncotype DX breast cancer tests, visit: www.OncotypeDX.com or www.mybreastcancertreatment.org.\nThe results showed that physician treatment recommendations changed for 31 percent of patients after receiving the DCIS Score result, reducing the number of patients receiving a radiotherapy recommendation by approximately one-third.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\nAbout Genomic Health\n\nGenomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.\n\"The Oncotype DX DCIS Score result was validated in two studies including nearly 900 patients and is the only genomic test for patients with pre-invasive breast cancer,\" said Phil Febbo, M.D., chief medical officer, Genomic Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release emphasizes the potential beneficial effect of test results on refinement of treatment recommendations. It doesn\u2019t contemplate or even mention the possibility that an inaccurate test result could cause harm \u2014 for instance by recommending a conservative course of therapy when a more aggressive approach is warranted, or vice-versa. While the study itself didn\u2019t assess outcomes or potential for harm, as with Benefits we\u2019d expect some nod to the fact that this is an area of uncertainty that requires more research.", "answer": 0}, {"article": "Overall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\n\u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham.\nAt six months, people who took the full dose of Qnexa once daily lost nearly 10% of their body weight; by one year, it was up to 10.4%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned specific side effects of this particular medication combination. \nTo be most informative to readers, the story should have mentioned that the potential for long-term harm is not known. \u00a0And the rate at which people stopped taking the drug due to side effects should have been included.", "answer": 1}, {"article": "Prior to this, Yu\u2019s team had performed targeted MRI biopsies with the patient being moved in and out of the MRI scanner as the needle was guided to the target area \u2014 a sort of stop-motion procedure that could take up to an hour.\nHe ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\n\nMagnetic resonance imaging and targeted biopsy for the prostate have provided relief for patients like Harder who have not been able to get an accurate diagnosis.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nNow, with the support of Massey Cancer Center, Urology and Radiation Oncology, they are doing about 1,200 multiparametric-MRI and 200 imaging guided biopsies per year.\nAfter Harder\u2019s third biopsy, his urologist was ready to throw in the towel, and that\u2019s when Harder was referred to Jinxing Yu, M.D., at VCU Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible side effects of biopsies such as serious infections, pain, and bleeding. There\u2019s also no mention of the\u00a0 harms that can come from a false-positive test that can lead to more tests, mental anguish and unnecessary procedures.\nAlso, it does not mention that MRIs may be inappropriate for patients with kidney disease or implanted devices such as pacemakers, stents and inner ear implants, due to the strong magnetic field used.", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms, which include not only the failure to identify someone who has depression, but also the \u201cfalse positive\u201d misdiagnosis of people who do not have depression. This is the difference between \u201csensitivity\u201d and \u201cspecificity\u201d \u2014 and it\u2019s important. Being told that one has a medical problem that one does not actually have can have implications in people\u2019s personal and professional lives. We did like that the story addressed privacy concerns, which can certainly lead to anxiety and other problems.", "answer": 0}, {"article": "Adverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nMost common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\nFor these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn about a range of adverse effects ranging from blood in the urine to incontinence. \u201cMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure,\u201d we are told.\nWe\u2019ll award a satisfactory grade here because the release at least mentions some adverse effects associated with the procedure. But as with the benefits description, we again receive no sense of what this is compared to (drugs? surgery? watchful waiting?), how common these problems were, or what the release means when it describes them as \u201cmild to moderate in severity.\u201d\nUpdate: This rating has been changed to Not Satisfactory in order to be consistent with how this criterion has been applied in the past. As stated in the description of our review criteria, a news release or story may be rated Not Satisfactory if it:\u00a0", "answer": 0}, {"article": "So Dr. Jianfeng Xu, a professor of epidemiology and cancer biology at Wake Forest University School of Medicine, and his colleagues studied a Swedish population of 2,893 men with prostate cancer and 1,781 men who did not have it.\n\u201cWe can know what diseases we will have to face in the rest of our lives.\u201d\n\nThat worries him, as it does Dr. Edward P. Gelmann, deputy director of the Comprehensive Cancer Center at Columbia University.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nAll this can happen very rapidly.\u201d\n\n\u201cWe have worked with enough families that have a positive family history to know that people are anxious to know their risk of prostate cancer,\u201d he said.\nBut others worry that more frequent testing could exacerbate what is already a major problem: most prostate cancers grow so slowly that they would have been harmless if left alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did include mention of the harms that are associated with treatment of prostate cancer, namely impotence and incontinence, and that the treatment of prostate cancer may not be at all necessary because not all prostate cancers are life threatening. \u00a0As this is a very counter-intuitive thought (that not all cancers are deadly) it might have been emphasized more.\n\u00a0It is critical that people be aware that while a large clinical trial (the PIVOT study) is underway, it is not yet known whether aggressive treatment of early prostate cancer is effective or whether it may cause more harm than good. \u00a0So while the effectiveness of prostate cancer screening remains controversial,it\u2019s important to note that aggressive treatment of early prostate cancer remains controversial too. \u00a0", "answer": 1}, {"article": "Roslin said limiting grains and sugars reduces insulin surges, which sparks water loss, curbs hunger and can boost energy.\nBut the company said Efron is just one person and that more than 100,000 people have tried and succeeded on the plan, including the beauty director of Essence magazine, Mikki Taylor, who lost nine pounds in seven days.\nThe diets have found popularity in Hollywood, and one of the most Googled detoxes is one consisting of cayenne pepper, syrup and lemon juice, made famous by celebrities like Denise Richards and Beyonce Knowles, who reportedly lost 20 pounds for \"Dreamgirls\" using the detox.\n\"I can't believe how wonderful our bodies are, and when we're good, they really respond,\" she said.\nHe warned that staying on the homemade diet long-term can carry health risks, which is why it's wise to speak with a doctor first before embarking on any plan.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms associated with these \u2018treatments\u2019 other than to mention that if you stay on a homemade diet long term (how long is long term?), it can carry health risks (such as? and how commonly?). \u00a0However this cautionary note is not sufficient for a consumer to have any concrete idea about what the risks are or how commonly they occur.", "answer": 0}, {"article": "The effect of the newer-generation medications, gonadotropin-releasing hormones, is similar to bicalutamide, according to other trials.\nMen with medium-grade tumors and those who may not have had their entire cancer removed during surgery also survived significantly longer if they received the drug.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\nMore research will be needed to confirm which men benefit most from taking the drug.\nIn these cases, radiation therapy is usually used.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "STAT does not mention any negative side effects (including hot flashes and sexual problems).", "answer": 0}, {"article": "The Foundation was established in 2007 with the support of the Queensland Government.\n\"Kidney stones are a bit of a mystery, occur frequently in the community and generally affect young, healthy adults,\" Dr Furyk said.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\nDr Furyk's research was recently published in the Annals of Emergency Medicine: http://www.annemergmed.com/article/S0196-0644(16)30364-X/abstract\n\nAbout the Emergency Medicine Foundation - EMF is an Australasian non-profit organisation funds innovative, evidence-based emergency medicine research that will improve clinical practices to save lives, as well as deliver significant economic benefits to the healthcare system.\n\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from the use of tamsulosin mentioned in the news release, although a simple web search reveals a host of minor side effects \u2014 drowsiness, dizziness, blurred vision, lightheadedness, fainting, back pain, cough, decreased sexual ability, diarrhea, headache, runny or stuffy nose, sinus inflammation, trouble sleeping, or weakness \u2014 and possible severe side effects including severe allergic reactions, chest pain or irregular heartbeat, fever or chills, or other conditions.", "answer": 0}, {"article": "Thanks to members Drs.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nNewswise \u2014 LEAWOOD, KS \u2014 Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems intuitive that injection of a solution into the joint space of the knee should have some downsides. Indeed, a 2012 meta-analysis of 89 clinical trials involving over 12,000 subjects published in Annals of Internal Medicine concluded, \u201cIn patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events.\u201d\nCommon side effects of short duration following viscosupplementation include swelling, and feelings of pain and warmth at the injection site. Serious but rare complications include infection, allergic reaction and bleeding.", "answer": 0}, {"article": "Then what, Dr. Nigg asked in series of studies, do orthotics actually do?\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\nThus a flat foot is not something that is bad per se.\u201d\n\nSo why shouldn\u2019t Jason \u2014 or anyone, for that matter \u2014 just go to a store and buy whatever shoe feels good, without worrying about \u201ccorrecting\u201d a perceived biomechanical defect?\n\u201cBut choosing the right one requires a great deal of care.\u201d\n\nYet Scott D. Cummings, president of the American Academy of Orthotists and Prosthetists, says the trade is only now moving toward becoming a science.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article focused largely on the potential upside of shoe inserts\u2014and didn\u2019t explicitly address potential harms from the use of orthotics.\u00a0It mentioned that inserts could increase muscle work requirements but didn\u2019t discuss the significance of this point in terms of pain and function.\nSome of the potential harms\u2014 such as exacerbating injury risk and/or pain and dysfunction\u2014are obvious. There are more subtle harms as well, such as creating the expectation among athletes that they cannot safely exercise, perform normal daily activities, and work\u00a0 without the aid of an orthotic.\n\u00a0\n", "answer": 0}, {"article": "\"We looked at whether we could lower the [repeat surgery] rate by using this device,\" Boolbol said.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nFor the study, Boolbol and her colleagues randomly assigned 495 breast cancer patients to receive the MarginProbe after lumpectomy or not receive it.\n\"This can potentially decrease having to go back to the operating room and with no real effect on your [cosmetic] outcome,\" said study leader Dr. Susan Boolbol, chief of breast surgery at Beth Israel Medical Center, in New York City.\nThe study of nearly 500 patients undergoing breast-conserving surgery found little difference in the volume of tissue removed when the device was used compared to traditional detection methods.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply \u2013 but inadequately \u2013 stated that \u201cresearchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control group patients.\u201d\nIt would be useful to have a more quantitative sense of how much more tissue was removed using the MarginProbe device. What does \u201cnot much more\u201d mean?\u00a0 Would it mean the same thing to all women? That would help the reader balance the benefit of avoiding a second surgery against the risk of removing more breast tissue when the device is used, which could negatively affect\u00a0the appearance of the breast after surgery.", "answer": 0}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\n\u201cPatients are very concerned about loss rates with aminocentesis and CVS and want reassurance about their pregnancies, so we are always looking for a better test,\u201d says Jennifer Wu, an obstetrician/gynecologist Lenox Hill Hospital in New York City.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does quantify potential harms in one way by noting, \u201cThere were no false-negative results with the new test.\u201d We wish the story also spoke about false positives. False positives are certainly part of the stress and harms from any screening test that need to be considered. In this case, it appears the false positives were low but not negligible.", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that \u2018few side effects were reported\u2019.\u00a0 While it is true that \u2018few\u2019 is a subjective term, it would have been useful for readers to know that ~13% of those taking the 200 milligram dose experienced side effects; further \u2013 in order to have some idea about how to value the side effects, it would have been helpful to list that the side effects included fatigue, dry mouth, headache, and drowsiness.", "answer": 0}, {"article": "(Editing by Andrew Roche)\nThree months after treatment, the weight loss began to reverse in some patients, and after nine months, three patients weighed more than before treatment - the longest period of sustained weight increase since they had become ill. Around half also had better moods and less obsessive-compulsive behaviour.\n\u201c(This) will go some way towards reassuring patients that DBS is not just another treatment designed to fatten them up without making them feel better.\u201d\n\nDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain.\n\u201cThe fact that the procedure was associated ... with improvements in affective and obsessional symptoms is of key importance,\u201d they said.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes potential harms, stating \u201cImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur.\u201d\u00a0 There was no other discussion of potential harms.\nIn fact, the researchers reported:\n\u201cDBS was associated with several adverse events, only one of which (seizure during programming, roughly 2 weeks after surgery) was serious. Other related adverse events were panic attack during surgery, nausea, air embolus, and pain.\u201d", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n\u201cBy detecting those individuals who don't have narrowing in their heart arteries, but they are in the process in developing them because the arteries are inflamed, we may be able to intervene early enough to prevent heart disease.\u201d\n\nThat's why surgeons do heart bypasses.\nBut by the time a narrowed artery shows up on a standard scan, \u201cit's likely to be already too late to intervene and reverse the narrowing in the artery that has already occurred over many years,\u201d Channon said.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because there is so little information about the imaging technique and what it requires, it\u2019s hard to say what the harms or benefits might be, but certainly the story might have mentioned the potential risk of drug intervention (or non-intervention) if the inflammatory cell \u201cmarker\u201d is valid as a predictor of heart attack risk.\nAlso, it would have been worth discussing if the new imaging technique exposes patients to radiation, which has been shown to increase the risk of cancer if used repeatedly.", "answer": 0}, {"article": "But they can be deadly in the modern era.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nIt was approved by the FDA in 2003 to treat a form of asthma often triggered by allergens, but Stanford researchers are now testing it on patients with food allergies \u2014 and finding that it might help speed along classic allergy desensitization therapy, in which patients are slowly introduced to escalating quantities of the allergen, via allergy shots or those \u201chome brew\u201d concoctions.\nIt\u2019ll be interesting to see how this translates into making it into a pharmacy, and into the hands of patients.\u201d\n\nCorrection: A previous version of the story misstated some aspects of Aimunne\u2019s work on peanut allergies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Particularly for the new-style food-desensitization therapies under development, the article explains potential (and even deadly) risks associated with them and it alludes to some of the downsides of immunotherapies (\u201callergy shots,\u201d for instance) that can take months or years to work. But it says essentially nothing about the potential or actual adverse effects of a DNA vaccine under development, noting only that it \u201chypothetically decreases the risk for adverse events.\u201d", "answer": 1}, {"article": "Pooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\nShe said in a statement: \u201cTaking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions.\u201d\n\nBut she also urged caution.\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nWhile these results should reassure many people with depression that antidepressants can be effective, \u201cthis does not necessarily mean antidepressants should always be the first line of treatment,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the various side effects that can occur with antidepressant medication, such as weight gain, insomnia, and loss of sexual desire.\nThe study authors looked at which drugs were more or less tolerated, and their analysis did not include adverse effects or withdrawal symptoms. Those facts weren\u2019t included in the story.", "answer": 0}, {"article": "But there is debate about whether the eye movement makes a difference, said Stephen Holland, founder of the Capital Institute for Cognitive Therapy and co-author of the textbook \u201cTreatment Plans and Interventions for Depression and Anxiety Disorders.\u201d \u201cThe question is whether stimulation adds to it.\u201d He does not use it in his practice because he considers it no more effective than cognitive behavioral therapy.\nShe occupied herself with press inquiries and funeral arrangements.\n\u201cDoes EMDR deal with the future?\u201d she asked Kalin.\nKalin nodded, and they began processing memories again.\n\u201cI started getting really interested in it,\u201d she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not broached.", "answer": 0}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\nA little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms associated with deep brain stimulation.\u00a0 There are some minor or temporary problems that may occur as well as risk of brain hemorrhage. There is no mention of complications of foreign material in the brain, of stimulators\u00a0 housed in the chest, \"mild anesthesia\" and of the insertion of wires into the brain.\u00a0 \nHowever \u2013 in its description of the benefit for Parkinson\u2019s disease, the story mentioned that it was not beneficial for end-stage symptoms and indicated that the benefits of treatment were temporary for this degenerative condition.\u00a0 This provides an important perspective about limits of benefits.", "answer": 0}, {"article": "Duchenne muscular dystrophy affects an estimated one in 3,500 males, according to the National Institutes of Health.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story fails to mention any of harms of sildenafil, which include:\u00a0\u00a0\u00a0 * sudden severe loss of vision (see below for more information)\u00a0\u00a0\u00a0 * blurred vision\u00a0\u00a0\u00a0 * sudden decrease or loss of hearing\u00a0\u00a0\u00a0 * ringing in ears\u00a0\u00a0\u00a0 * erection that is painful or lasts longer than 4 hours\u00a0\u00a0\u00a0 * dizziness or lightheadedness\u00a0\u00a0\u00a0 * fainting\u00a0\u00a0\u00a0 * chest pain\u00a0\u00a0\u00a0 * worsening shortness of breath\u00a0\u00a0\u00a0 * itching or burning during urination\u00a0\u00a0\u00a0 * rashSildenafil may also interact with other prescription drugs.\nWhat\u2019s more, the story failed to note that the continual administration of sildenafil over many months used in this study (and the sort of life-long daily treatment that would be envisioned in human patients) is more like the way the drug is used in patients with pulmonary hypertension and completely different from the occasional doses of the Viagra brand form of the drug used by men to treat erectile dysfunction.", "answer": 0}, {"article": "All the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\n(There is also a non-hormonal IUD that is approved for 12 years, but it was not included in the current study.)\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s strongly implied that an unintended pregnancy is a potential harm of keeping\u00a0either one of these prescription devices longer than the FDA-approved length of time. But that\u2019s fairly self-evident. We think the story\u00a0should have addressed other potential harms that come with having an IUD in the first place such as infection, ectopic pregnancy, or expulsion.\u00a0This could have been addressed succinctly in one extra sentence.", "answer": 0}, {"article": "And AbbeVie is in the midst of phase 3 trials for elagolix to treat uterine fibroids and endometriosis, a disorder in which the tissue that lines the inside of the uterus grows outside of it, causing pelvic pain.\nThe cause of fibroids remains unknown, though those with a family history have an increased risk of developing them.\nThe first oral treatment for women with the common condition of uterine fibroids could be available as soon as summer 2018, with two other medications in the pipeline.\nIt\u2019s estimated that as many as 26 million women in the U.S. have one or more such tumors, though less than half experience symptoms.\nThe most common symptom is long and excessive bleeding during menstrual periods, which can lead to anemia and the need for blood transfusions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes the side effects of UA and potentially two other similar drugs in the pipeline. The main concern about these agents is the effects they may have on the endometrium (uterine lining) over time.", "answer": 1}, {"article": "Currently, there are many treatments for primary tumors but they do little to prevent metastasis and stray cancer cells from relocating to another part of the body.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cOur cancer trap works just like a roach motel, where you put in some bait and the roach goes there and dies,\u201d said Liping Tang, UTA bioengineering professor and leader of the research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not addressed. That may be for reasons that we\u2019ll address under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "Nadworny, who now works as a public policy advocate for people with disabilities, had knee replacement surgery last April.\nThe vast majority of joint-surgery patients report much less pain and greater mobility afterward, with success rates topping 95 percent, according to the American Academy of Orthopedic Surgeons, a physicians organization.\n\u201cThe person who struggles is the one who\u2019s done long-distance running for years and just doesn\u2019t want to give it up.\u201d\n\nTechnology could eventually change that.\nBecause of improvements in materials and the way they\u2019re treated and sterilized, implants \u2014 which include polyethylene and titanium alloys \u2014 don\u2019t wear down as fast as they once did.\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned at least some potential harms:\nIn patient-reported surveys, some still complain of pain and tissue inflammation after their procedures. Smaller numbers suffer serious complications, ranging from blood clotting to hospital-acquired infections.\nStill, it could have devoted more attention to risks, including the lax regulation of implantable devices.", "answer": 1}, {"article": "Those who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\nHowever, the team did observe one appreciable difference: patients on gemcitabine were less likely to experience serious side effects as a result of their chemotherapy treatment than those on the fluorouracil/folinic acid treatment (7.5 percent versus 14 percent).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms and tolerability are discussed, and the rates of serious side effects for each group are provided. Specific examples of those serious effects would\u2019ve been ideal, such as were provided in the JAMA editorial: \u201cmore stomatitis and diarrhea [were] observed in the fluorouracil and leucovorin group and more myelosuppression in the gemcitabine group.\u201d", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The anecdotes cited were all glowing. None included any mention of possible drawbacks. This surgery is associated with very significant risks, including risk of death\u2013typically from a blood clot. Now, those risks are with all hip replacements\u2013same day discharge and not\u2013but they are never mentioned and should have been.\nThe story leaves readers with the impression that they might all be going home maybe 10-12 hours after surgery as the 54-year old patient profiled did (no exact timing of his day was provided in the story). How representative was that? Didn\u2019t the age and conditioning of a 54-year old play a big factor here? What might change if he were a 64-year old or 74-year old reader of the WSJ? Or is this what gets hidden when joint replacement surgeries are increasingly marketed to younger and younger people? And when journalism fails to scrutinize that factor?", "answer": 0}, {"article": "Another method involves a specially designed treadmill tank.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\nIt\u2019s also an easy-on-the joints form of exercise for seniors and others who suffer from arthritis, and a recent study shows it can speed recovery from stroke faster than using a traditional treadmill.\n\u201cIt\u2019s a very pleasant way of achieving exactly what you\u2019re trying to do \u2013 allowing a cardio-respiratory response,\u201d Wolfe-Klein told CBS News.\nIf running\u2019s not your thing, but the water looks inviting, Coates said there are also spin bikes that can be used underwater.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss harms. There don\u2019t appear to be any particular health risks associated with the use of underwater treadmills that wouldn\u2019t apply to beginning any exercise or rehabilitation regime \u2014 but that\u2019s actually a point worth making.\nHowever, exercising in a pool poses risks of its own \u2014 particularly for patients who may be recovering from surgery or stroke. As a result, it would be wise\u00a0to explain that these patients (or any patient who is not confident in the water) should have\u00a0supervision. And, this therapy may induce anxiety among people who can\u2019t swim or are anxious around water.", "answer": 0}, {"article": "Asthma on the Rise in U.S.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.\nYoshiteru Shimoide, MD, head of the Yoshiteru Shimoide Clinic of Internal Medicine in Kagoshima City, Japan, presented the results here at the annual meeting of the American Academy of Allergy, Asthma, & Immunology (AAAAI).\nMarch 5, 2012 (Orlando, Fla.) -- A traditional Chinese herbal remedy known as kampo helped to relieve daily asthma symptoms in nearly all of more than 200 people studied, Japanese researchers report.\nIn contrast, about three-fourths of those taking standard asthma medications still had daily wheeze and other symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained:\nThe study did not look at possible side effects of kampo herbs. But a major problem facing kampo medicine is herbal product quality. There have been cases in which poisonous plants found their way into the herbal mix, resulting in kidney damage, for example.", "answer": 1}, {"article": "A typical acupuncture session runs for about $100 and is often not covered by health insurance.\nNEW YORK (Reuters Health) - Acupuncture may help relieve chronic back, joint and shoulder pain, according to a new review of the evidence - but some of its benefit is likely due to the \u201cplacebo effect,\u201d researchers concluded.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\nSome think it has potential as an add-on or alternative to standard treatment, while others argue any acupuncture-related benefits are likely the result of hopeful patients getting treatment they strongly believe will help them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that acupuncture is safe\u00a0when performed by a\u00a0qualified and licensed acupuncturist, which is true. The story didn\u2019t report on the flip side of this statement,\u00a0which was addressed by another\u00a0recent review of the evidence \u2014 i.e. that when acupuncture\u00a0is delivered by unqualified practitioners, there\u00a0are dozens of published cases of\u00a0severe adverse reactions including\u00a0death. Tough call here, but we think the story didn\u2019t quite meet our standard.", "answer": 0}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThis is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).\n\"This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a 'game changer' for future treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s particularly important to note side effects associated with new medications but the release makes no mention of any harms arising from the drug\u2019s use in the study. However, the full research paper (which unfortunately is behind a paywall) includes a table of adverse events experienced by both the experimental group and patients receiving a placebo that include problems such as infections, respiratory disorders, gastrointestinal and nervous system disorders. While these may ultimately have been minor problems, they deserve mentioning.", "answer": 0}, {"article": "Prozac was developed by Eli Lilly and is now available in a cheaper generic form as fluoxetine.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\nSignificantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nIn the largest study yet of the effect of this type of antidepressant on stroke recovery, French researchers found that stroke patients given Prozac improved their scores in motor skills tests more than those given a placebo, or dummy pill.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Generally this isn\u2019t a risky medicine, but we ding the story here for not only failing to quantify harms, but perhaps mischaracterizing the safety data from the study. It quotes the researchers as stating that side effects were rare and mild. But in the actual study,\u00a025% of those taking fluoxetine had transient digestive problems (compared to 11% receiving placebo), and there were two serious side effects, a partial seizure and a serious case of low\u00a0sodium.\u00a0A more accurate summary would\u2019ve been the softer statement that MOST side effects were rare OR mild.", "answer": 0}, {"article": "Most recently, the F.D.A.\nWhile the market for smoking cessation therapies is estimated to be more than $1 billion annually, many smokers continue to fail in their efforts to quit even while using the available products, with long-term success rates generally peaking at about 20 percent.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nThe most widespread therapies currently available are nicotine-replacement products, like nicotine patches and gum, which are designed to wean the smoker by administering trickles of nicotine to the body, replacing the surges delivered by cigarettes.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Early studies of NicVax looked at safety, yet we are given no information on adverse events from these early trials or on the potential harms of the vaccine. The story suggests that NicVax may be used in conjunction with other smoking cessation products, yet this has not been tested in clinical trials thus far.", "answer": 0}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\nThis compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nFiling for approval in the EU has been completed.\nSome 4.9 percent of patients using cabazitaxel died from side-effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned that:", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nThe drug also reduced major osteoporotic fractures by 55% compared with teriparatide and increased bone density to a greater extent in the hip region compared with teriparatide.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A serious omission, the release is essentially silent about potential harms, which, according to other sources, may include \u201cback pain, arthralgia, upper-respiratory-tract infection, hypercalciuria, and dizziness.\u201d A mid-term post-marketing surveillance study of Forteo (teriparatide), a related drug on the market, observed an association but not causation with osteosarcoma (a rare malignant bone cancer) in people taking the drug. Osteosarcoma had been observed in animal trials of the drug that were dependent on dose and treatment duration. ", "answer": 0}, {"article": "The American Academy of Pediatrics currently recommends 400 units a day for infants.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\n\"There's overwhelming evidence ... that increasing your vitamin D intake can make substantial improvement in your overall health and welfare,\" says Dr. Michael Holick of Boston University.\nWhen skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While Dr. Holick is quoted in this story as commenting that \u00a0\u00a0\"\u2026there is no downside to increasing your vitamin D intake\",\u00a0he is also a co-author on a 1992 paper in the New England Journal of Medicine documenting a series of deaths due to accidental overdose of vitamin D.\u00a0\u00a0 The story did not give any weight to the potential for problems with over-consumption of vitamin D.\n.\u00a0", "answer": 0}, {"article": "The Alzheimer's Society has more about cannabis and Alzheimer's disease.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\n\"We would love to see this study done in a larger group of people, to see if it continues to be effective in a larger group, and how worried we need to be about this sedation side effect,\" Fargo said.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A major strength of this news release is that it favors cautious, rather than hyped language.\nIt\u2019s clearly stated:\nAbout 45 percent of patients experienced sedation with nabilone, compared with 16 percent for placebo.\nWe very much appreciated how the story also anticipated that some readers might take the study findings as justification for self medicating with marijuana, and why that might be risky.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided accurate information about a potential harm of excess consumption of vitamin B-6.", "answer": 1}, {"article": "But this is where it gets more complicated.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nBut there are conflicting views on who meets that \u201chigh risk\u201d definition\n\nChemoprevention should not be confused with chemotherapy.\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We grant a passing grade for the inclusion of statements about increased risk of uterine cancer and other serious side effects. But we have to wish for some discussion of sexual side effects in more common language. Not everyone knows that \u201chot flashes\u201d and \u201cvaginal dryness\u201d are part of the menopause-like state that chemoprevention creates in some women. We suspect those potential side effects influence women\u2019s decisions.", "answer": 1}, {"article": "New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThey're not harmful to your health, but many people are bothered by their appearance.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nDraelos has served as a consultant to Merz.\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that women experienced no side effects from the cream.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the potential side effects associated with daily use of a nonsteroidal anti-inflammatory drug. Potential harms of ibuprofen taken for years can be substantial and include increased risk of stroke, heart attack, gastrointestinal bleeding and kidney disease.\nNo mention is made of the potential harms associated with either false-positive, or false-negative, tests for Abeta42.", "answer": 0}, {"article": "Right now, for a lot of children, that means 3 years old.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- By analyzing patterns in the brain's electrical activity, researchers say they've been able to assess autism risk in children as young as 6 months of age.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\nAnd unlike MRIs, they require no sedation, so testing could be put to widespread use, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were quantified. Instead, readers were told that the EEG is \u201cpainless and safe.\u201d The story presses the idea that \u201cearly intervention is extremely important\u201d even though the study did not detect autism in any way that would warrant treatment. What would be the next step for these children? Should they be put into behavioral therapy, put on a restrictive diet, given drugs of some kind? All of these options have potential consequences that could, indeed, prove harmful to the children, especially if they are falsely diagnosed as having autism. And, like most screening tests, there is the additional potential harm of unnecessary worry for some parents, as it is likely that at least some kids will \u2018screen positive\u2019 and then develop normally.\nScreening tests have harms.\u00a0 It is a common journalistic pitfall to overlook this fact.", "answer": 0}, {"article": "Stein said.\nSoon, we can expect more human trials in which investigators will dissect the properties of different PCSK9 antibodies and assess the effect of these agents.\u201d\n\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, Young and Fong caution that it will remain unclear how important this class of drugs will be.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\nWith statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the researchers found that the drug was safe and \u201cNone of the subjects who received REGN727\u00a0discontinued the study because of adverse effects.\u201d While true, it does not give the whole picture.\u00a0 Here\u2019s what the investigators said:\n\u201cThe proportions of subjects who had at least one treatment-emergent adverse event were similar among subjects who received intravenous REGN727 and those who received placebo. As compared with subjects who received placebo, a higher proportion of subjects who received subcutaneous REGN727 had an adverse event in the single-dose and the multiple-dose studies. Headache was the most common adverse event.\u201d\nIt didn\u2019t include the caveat that the MedPage Today story did:\n\u201cGiven the small number of subjects and the short duration of exposure, our ability to evaluate the safety profile of REGN727 in these trials was limited,\u201d the researchers cautioned.\nBut it did report:\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, (two editorial writers) caution that it will remain unclear how important this\u00a0class of drugs will be.", "answer": 1}, {"article": "\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThis often triggers unnecessary biopsies and, sometimes, unnecessary surgery.\nIf a man has any type of damage to the prostate, his PSA level can go up.\nThe PCA3 test isn\u2019t a replacement for PSA testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of any possible harms such as diagnosing prostate cancers that won\u2019t affect the health of the individuals or missing prostate cancers that should have been treated. ", "answer": 0}, {"article": "This practice isn't totally harmless.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that taking large doses of supplements (above 4,000 IUs) can increase your risk of kidney stones, calcification of blood vessels and cardiovascular disease. Vitamin D toxicity is rare, but given the current enthusiasm for supplementation, it\u2019s good for stories to voice some caution.", "answer": 1}, {"article": "Yorkshire Cancer Research; Prostate Cancer UK; The British Columbia Cancer Agency Strategic Priorities Fund.\n\"Cancers that are contained in the prostate, however, have the potential to be 'actively monitored' which is not only cheaper, but has far fewer negative side-effects in patients with non-life threatening cancer.\"\nProfessor Norman Maitland, from the University of York's Department of Biology, said: \"Unnecessary prostate treatment has both physical consequences for patients and their families, but is also a substantial financial burden on the NHS, where each operation will cost around \u00a310,000.\nDr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release says that unnecessary radiotherapy and surgery is harmful, but it does not explain any harms of the new tests. Although biopsies are minimally invasive, the Mayo Clinic says that prostate biopsies can cause bleeding and risk of infection.\nIn this test, the tissue was collected only from prostatectomy specimens. \u00a0Therefore, to actually be useful for preventing over treatment, the test must be assessed in biopsy specimens. \u00a0The harm would be misclassification \u2014 mistakenly telling someone that treatment is unnecessary because the tumor appears to be low-risk when in fact it\u2019s aggressive and would benefit from treatment.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\nAccording to study author Wang, trans fats have been almost eliminated from the food supply, so what is needed next is more taxation on sugary drinks and more regulations requiring salt to be reduced in food.\nTo get insight into the answer, they analyzed the results of seven health and nutrition surveys including almost 34,000 adults aged 20 and older between 1999 and 2012.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s certainly possible that attempts to promote healthier diets could result in unintended harms. For example, some might argue (erroneously, in our view), that a tax on sugar-sweetened beverages, intended to promote healthier drink choices, would be regressive (i.e. disproportionately costly to lower income consumers). But we think a discussion of such issues is beyond the scope of this article, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\n\"It's reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children's Medical Center of New York.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\nA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants' Gas Relief.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify the potential harms, but it makes it clear that the remedies most often used by parents have no significant side effects. It says, \u201cBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents. \u2018It\u2019s reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\u2019 said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children\u2019s Medical Center of New York.\u201d", "answer": 1}, {"article": "His father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained in terms of the side effects of the dialysis, the pain, nausea and feeling \u201cdizzy, washed out.\u201d \u00a0It was good that the article explained that the harms of dialysis are also measured in other ways: the disruption to a person\u2019s life, the need to travel and go in and out of facilities, and the effects on their independence, which can be debilitating for older people.", "answer": 1}, {"article": "Water jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\nSchools with water dispensers saw a modest weight drop among students, according to the study by researchers from NYU Langone Medical Center, New York University's Institute for Education and Social Policy, and the Center for Policy Research at Syracuse University's Maxwell School of Citizenship and Public Affairs.\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Students in New York City schools had access to water through drinking fountains before this intervention study. This study looked at a new way to deliver New York city tap water to kids, which may have encouraged them to opt for water instead of sugary beverages, like soda.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "The surgery worked.\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\nAt the same time, hormonal changes that reduce the appetite and take effect immediately after the surgery begin to decline.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects should be clearly stated. The randomized study notes that the majority of people who had the surgery (including, interestingly, those who underwent a sham procedure) had side effects including nausea and vomiting. The story states simply that there were \u201cno significant side effects.\u201d", "answer": 0}, {"article": "The manufacturer of the sleep aid Snooz'n says its 2.5-ounce \"shots\" contain five milligrams of melatonin; Unwind, a \"relaxation blend,\" has three milligrams per 12-ounce can.\nIn a statement, Drank inventor Peter Bianchi says \"the safety of Drank's consumers remains a top priority\" and the company is working to modify the product's packaging and marketing \"to reflect its classification as a dietary supplement.\"\nHowever, a study published in January in the Journal of the American Geriatrics Society found that a pre-bedtime cocktail of magnesium, zinc and a five-milligram dose of melatonin significantly improved sleep among a group of 43 elderly Italian insomniacs.\nIt's typically released by the pineal gland around 10 p.m.; secretion stops around 4 or 5 a.m., helping to trigger the body to wake up, Scharf says.\n\"The issue is this: Some of them probably have some biologic effect, but they haven't been as well studied as you'd like,\" Scharf says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story raises the general issue of safety, suggests that\u00a0pregnant/nursing women\u00a0and children should not take\u00a0these drinks,\u00a0and warns against mixing these drinks with alcohol. It also suggests that people with certain health conditions check with their doctor before taking any of these drinks. We think that\u2019s thorough enough.", "answer": 1}, {"article": "One was a low-fat diet that included lots of fruits, low-fat dairy, poultry, whole grains and small amounts of red meat.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that eating avocados is linked to decreases in LDL cholesterol levels, but also clearly notes that eating avocados in conjunction with tortilla chips (as guacamole lovers are wont to do) would lead to a significant increase in calorie consumption.", "answer": 1}, {"article": "\"If you are a patient and someone says, 'There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,' you're not going to be so excited.\"\nAll improve survival by a few months.\nNone of the new drugs works for everyone.\nPatients with a limited time to live may not be so positive, Turnham says.\nFor the first time, however, patients such as Herry have options.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate discussion of potential harms from a couple of the drugs.\u00a0 Excerpts:", "answer": 1}, {"article": "The Progensa test looks for a genetic material called PCA3.\nWASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\nThey said Gen-Probe\u2019s Progensa PCA3 test caught about half the actual cases of prostate cancer in men who had abnormal PSA levels or digital rectal exams, and had about a 20 percent \u201cfalse positive\u201d rate.\nIf you had precursors such as high grade PIN (prostatic intraepithelial neoplasia) your score was about 38 to 40 and men who had cancer scored about 50 to 55.\u201d\n\nThe test had a specificity of 78 percent, meaning that 78 percent of the men who had cancer indicated by the test actually did.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did include sufficient information to conclude that with this test, there were still both false positive and false negative results. \u00a0There was, however, no discussion about whether this test had any role in helping men who really didn\u2019t require treatment to avoid such treatment. ", "answer": 1}, {"article": "Neither Hologic nor Rovers had input into the research design, analysis or interpretation of results.\nThe home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\nThe researchers compared the results from self- and clinician-samples - which were tested for high-risk HPV strains that are linked to cervical cancer - to the Pap results and the results of cervical biopsies collected during colposcopy, which is a secondary diagnostic test that confirms the presence of cervical pre-cancerous lesions among women with abnormal Pap smear results.\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\nThey reported this screening approach detected high-risk HPV in all of the cases of women who were found to have high-grade, abnormal cervical precancerous growths, showing that self-collection at home for HPV may be a viable method to identify women at high-risk for cervical cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address two key potential harms, namely the failure to identify someone who has high-risk HPV, and the \u201cfalse positive\u201d misdiagnosis of people who did not have high-risk HPV. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d\u00a0It\u2019s particularly relevant in this instance because HPV screening has a track record of problems with both specificity and sensitivity\u2014 and because the release itself makes clear that there were people diagnosed as at high risk in some of the screening tests, but not others. Missing someone who is at high risk is clearly problematic. But being told that one faces significant medical risks that one does not actually face can also have ramifications for future healthcare, with consequences both physical and financial.\nAnother potential harm could be having a certain rate of patients sending in the test but not following up, leaving clinicians with positive tests and patients lost to follow up which would skew the impact of the screening effort.", "answer": 0}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\n\"There are some clear benefits to circumcision,\" he said.\n\"These may be considered unacceptable for an elective procedure,\" she said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\nTwo studies involved neonatal circumcision, and six involved older males, roughly 14 to 49 years old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information about potential harms of the surgery (requiring general anesthesia) or of the device once implanted.\u00a0 The study reported ongoing adverse events related to the device and the surgery including dizziness, taste disturbances, facial weakness/paralysis, ear pain, tinnitus (ringing in the ear) and middle ear effusions (build up of fluid).", "answer": 0}, {"article": "Can these tiny tumors affect the lymph nodes and spread cancer to other areas of the body?\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nAnd the only patients with positive lymph nodes had microinvasive tumors that were associated with relatively large non-invasive tumors (ductal carcinoma in situ or DCIS).\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The results of this study support forgoing routine axillary (armpit)\u00a0sentinel lymph node biopsy to evaluate for cancer spread in cases where the invasive breast cancer is less than 1mm in size.\nA potential harm of this approach is missing metastatic cancer. This is not mentioned in the release.\nApropos of this, how long the patients were followed (the mean follow-up was 4.6 years, according to the published study) is a key piece of information and was also not included in the release.", "answer": 0}, {"article": "\"Great.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor years, all Siravo and her husband, David, wanted was a good night's rest \u2013 and now they're finally getting it.\nAn estimated 22 million Americans suffer from sleep apnea, putting them at greater risk for diabetes, heart disease, stroke and memory loss.\nA treatment is offering hope for millions of patients with sleep apnea, a disorder that causes people to stop breathing when they're asleep.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that \u201clike any surgery, there is risk of infection\u201d when Inspire is implanted.\nThat isn\u2019t enough.\u00a0A check of FDA\u2019s MAUDE database reveals patient complaints of slurred speech, difficulty breathing, and the device suddenly activating itself, among other problems.\nIn addition, there are questions particular to the use of an electrical device implanted in the chest \u2014 especially for a condition that is most common among patients who are \u201colder, overweight and male\u201d (as the story puts it). For example, can patients with pacemakers also use Inspire, or would they interfere with each other?", "answer": 0}, {"article": "Other studies are further along.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nHowever, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.\nSo it's possible, Gorodeski explained, that the \"modest\" symptom improvements would have happened anyway.\nIn an early study of 27 patients, Japanese researchers used patients' own muscle stem cells to create a \"patch\" that was placed on the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that the study was designed primarily to determine whether the technique was safe, and the researchers said it was. That\u2019s consistent with the relevant paper, which reports that patients showed \u201cno procedural-related complications.\u201d\nHowever, that does not mean the procedure is risk free and carries no harms. This is effectively heart surgery\u2013what are the risks? That needed at least a passing mention.", "answer": 0}, {"article": "For more information about the Cranberry Institute, along with the health benefits of cranberries and current scientific research, visit http://www.\nThe comprehensive meta-analysis and assessment of human clinical trials, published in the official journal of the American Urological Association, The Journal of Urology\u00ae, assures practitioners and their patients that cranberry products are a low cost, low risk and effective way to help prevent recurrent UTIs.1\n\nTo answer the question, \"Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections?\"\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that taking cranberries as a health supplement is \u201clow risk.\u201d And that\u2019s true. But that doesn\u2019t mean that it\u2019s no risk. For example, the University of Maryland notes that one of the chemicals found in cranberries can increase the risk of kidney stones for some people \u2014 that\u2019s valuable information for readers who have a history of kidney stones. Even if the harms are minimal, it is important to note that fact explicitly.\u00a0", "answer": 0}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\nIt is estimated that the condition affects one in 110 children in the United States, according to the U.S. Centers for Disease Control and Prevention.\nTUESDAY, May 31, 2011 (HealthDay News) -- At the moment, a diagnosis of autism is based on subjective evaluations, but a new way of using MRI might be an objective way of spotting the disorder, Columbia University researchers report.\nWhile the children were undergoing the fMRI, the researchers played recordings of their parents talking to them and watched for brain activity in areas of the brain responsible for hearing and understanding language.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms quantified or even mentioned, which is disappointing. The harms from an inaccurate diagnosis of autism or any other disorder can be real and devastating.", "answer": 0}, {"article": "The effect, however, typically lasts only about seven months before the cancer starts to grow again, though some patients benefit for more than two years.\nBecause it unleashes the immune system, ipilimumab can have serious side effects.\nVemurafenib is the latest so-called targeted therapy, which inhibits the effects of genetic mutations that spur tumor growth and spread.\n\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nAfter three years, 20.8 percent of those who got that new drug were alive, compared with 12.2 percent of those in the control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job explaining signifcant potential harms of both drugs \u2013 something competitors didn\u2019t do at all.", "answer": 1}, {"article": "But the results do merit further research.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\nIn the study, published in the Annals of Internal Medicine, researchers randomly assigned 108 people with type 2 diabetes to receive 3, 3.5, or 4 grams per day of salsalate or a placebo in addition to their current diabetes therapy for 14 weeks.\n\"We are conducting a larger trial involving more patients with type 2 diabetes to further establish whether a salsalate dosage of 3.5g/day provides durable and safe control of blood glucose in this population.\"\nMore recently, inflammation has been implicated in development of the insulin resistance that leads to elevated blood sugar levels associated with type 2 diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms were not quantified, we give the story the benefit of the doubt for discussing potential safety issues prominently in the study, including a very early mention of proteinuria and the need for more long-term safety data.", "answer": 1}, {"article": "\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\n\"There are still plenty of people who can't achieve adequate LDL levels with existing drugs, including statins,\" he noted.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\n\"This new shot may provide a more long-lasting approach, especially if it could be given once a month,\" Sacco said.\n\"Even though statins are so effective at lowering cholesterol and reducing risk for heart disease and stroke, they do need to be taken every day and they can have certain side effects in some people,\" said Sacco, who is also chairman of neurology at the University of Miami.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that researchers reported\u00a0no \u201cserious\u201d side effects with the drug. OK, but\u00a0\u00a0we wish the story had mentioned that this study was really much too small\u00a0to even estimate adverse effects. In the past, other monoclonal antibodies\u00a0have produced rare but serious adverse effects- something that could have provided meaningful context for readers.", "answer": 0}, {"article": "Doctors from the University of Cambridge and the University of Li\u00e8ge in Belgium collaborated on the research.\nThe journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nThe chances that an unresponsive, brain-damaged patient will eventually emerge depend on the type of injury suffered, and on the length of time he or she has been unresponsive.\nThe imaging techniques used in the new study could help identify which patients are most likely to emerge \u2014 once the tests are studied in larger numbers of unconscious people, said Dr. Joseph Fins, chief of the medical ethics division of New York Presbyterian Hospital-Weill Cornell Medical Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the imaging technique, either from the risks of the technique itself or from the implications of false positive or negative results. The article does imply that it isn\u2019t clear whether such findings would predict long-term cognitive improvement and the degree of improvement. However, little information is given about the test itself. It involves the use of a short-acting radioactive substance but is probably safe. The greater harm would be around providing false hope of recovery to family members.", "answer": 0}, {"article": "In 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nIt is believed that the stimulation aids in plasticity, the ability of the brain to gradually form new neural connections to take on functions previously performed by damaged areas.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nThe study reported at the INS 12th World Congress builds on observations that electrical motor cortex stimulation\u2019s effectiveness in relieving central post-stroke pain can be predicted by rTMS, suggesting the techniques share similar pain-relief mechanisms.\nNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Quoting from the release: \u201cNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold. Two patients reported transient, slight scalp discomfort after rTMS.\u201d", "answer": 1}, {"article": "They\u2019re also studying the cost difference.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cWomen experience urinary incontinence twice as often as men,\u201d the National Institute of Diabetes and Digestive and Kidney Diseases, part of the NIH, says on its website.\nAnd, according to the National Institutes of Health, between 25 percent and 45 percent of all women have some degree of urinary incontinence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Urinary tract infections were three times more common in the women who received Botox shots, and the reader is informed of this. But a lot is left out. We would have also liked to see noted other side effects of Botox for urinary incontinence, such as blood in the urine, fatigue, insomnia, and\u00a0inability to completely empty the bladder (in about 17% of people) \u2014 and the need to self-catheterize to relieve the problem.\nAnd then there are the more general side effects left out of the story, including \u201cdry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes,\u201d according to botoxforincontinence.com. And what of the harms of a neurostimulator implant? There\u2019s no mention of this, and the side effects are numerous.", "answer": 0}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story.\u00a0The adverse effects of the drugs in question would be key information\u2013do they outweigh the benefits put forth in this story?", "answer": 0}, {"article": "But not all mothers were equally likely to take folic acid supplements.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nThe fact that autism cases have been on the rise in the U.S. even after folic acid supplementation became mandatory is a puzzle, according to three researchers from the Centers for Disease Control and Prevention\u2019s Division of Birth Defects and Developmental Disorders.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\nOn the other hand, pregnant women here are also far more likely to consume a healthy amount of the B vitamin because the Food and Drug Administration has required manufacturers of enriched breads, cereals and other grains to fortify them with folic acid since 1998.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough call.\nThe US Preventive Services Task Force and other expert bodies state that there is no evidence of potential harm from recommended levels of folic acid supplementation. But there are hypothetical, yet plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story could have mentioned this.\nThe point is that there are always potential harms.\u00a0 This is not a risk-free substance.\u00a0 Stories may not always find the time/space to delve into hypothetical/plausible potential harms, but we wish they would.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are mentioned at different points in the report: maternal deaths; interventions and complications, such as cesarean sections, forceps delivery, infections and hemorrhage compared with hospital births; \u201ccomplications\u201d for the babies. But the story does not really explore the difference (if any) between risks that would be of potentially greater concern during home birth versus hospital birth \u2014 or vice versa. The story does note that the U.K. study behind the guidance found that there was a slightly increased risk of complications for babies born at home if it was the mother\u2019s first birth. We\u2019ll rule this Satisfactory with suggestions noted for next time.", "answer": 1}, {"article": "MK-4305 belongs to a new class of sleep drugs that inhibits production of orexins in the brain, blocking stimulation of the brain\u2019s arousal system.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\nThe improvement was 11.6 percent at 40 mg, 6.6 percent at 20 mg and 6.2 percent at the lowest dose.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentions side effects, but it does not put any number to them. The press release, at least, notes that the incidence of these side effects was 3% or less, but, again, a little more context would be nice. And what about drug dependence? What about contraindications with other drugs, vitamins, foods? What about withdrawal problems? \nOne of the problems was drowsiness upon awakening. \u00a0Last time we checked, insomniacs don\u2019t need the help of a drug to achieve this result. \u00a0\u00a0It is unclear whether these adverse events are observed only during the active (pill taking) phase of the study or after. \u00a0It is also important that the effects of chronic use are not mentioned, and the reader will be interested in these (as the problem is chronic) and the harms may multiply over time. \u00a0Finally, because orexins, the brain chemical on which the drug is supposed to work, are involved in appetite and food-consumption, the occurrence of problems, or lack thereof, in this arena are particularly relevant and merit a mention.", "answer": 0}, {"article": "The distorted valve functions poorly, its flaps swinging apart.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms of this device nor mention that medical devices are not required to provide robust safety data to go on the market in the U.S. According to the study, 3.4% of patients experienced complications related to the device within one year. It\u2019s important to keep in mind that this adverse event rate is under ideal conditions\u2013where patients are closely monitored by physicians because of clinical trial enrollment.\nWhile there may be smaller surgical incisions than standard surgery, is it still quite invasive to insert a metal clip into a heart valve. Post-surgery, the device can malfunction, and cause a host of problems, including death.", "answer": 0}, {"article": "So why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nThe multidisciplinary Stanford team is now working on developing a panel that could be used commercially, that would test for around five of the 17 cytokines and would likely involve the doctor first classifying patients by severity in order to interpret the results.\nIndeed, a major drug trial is now being conducted in Norway investigating whether the immune-modifying drug rituximab alleviates ME/CFS symptoms, after preliminary studies suggested that it did in some patients.\nThe symptoms can range from mild to extremely severe, with about a quarter of patients so ill they're mostly or completely confined to bed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms of testing. Notably, since the researchers noted broad overlaps between cases and healthy controls in the levels of almost all the cytokines measured, it seems likely that test results could be easily misinterpreted to either label healthy people as sick or sick people as health.", "answer": 0}, {"article": "The study started in August 2010.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\nVaccine efficacy was maintained across the various age groups included in the study, ranging between 90% in people aged 70-79 years (95% confidence interval: 83-94%) and 89% in those aged 80 years and above1 (95% confidence interval: 74-96%)1.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release notes that serious adverse reactions occurred with about equal frequency among study participants who received the vaccine and those who had placebo injections.\u00a0Although the release acknowledges the most common injection site\u00a0and systemic adverse reactions, most commonly mild-to-moderate\u00a0pain at the injection site and fatigue, it could have been more forthcoming about how common these reactions were. The article on which the release is based states that 79% of participants who received the vaccine, versus 29.5% of placebo recipients, reported local and/or systemic side effects.", "answer": 1}, {"article": "Evivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nThe liquid will remain pink if a sample has low levels of acetate and lactate, indicating that Bifidobacterium is missing and that key nutrients from breast milk, human milk oligosaccharides (HMO), are being wasted.\nIdentifying a Disappearing, Yet Critical Piece of Gut Health\n\nDr. Henrick's previously published findings, which are the basis for the Evivo test, show an inverse correlation between rising infant fecal pH, reduced acetate and lactate, and lower levels of beneficial Bifidobacterium, proving that the infant gut microbiome has been rapidly changing over the last three generations.\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\n\"Currently there is no way to easily determine whether a baby is colonized with healthy bacteria,\" said Mark Underwood, M.D., Chief of Neonatology at UC Davis Medical Center.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The test itself is described as \u201cquick and non-invasive.\u201d However, the release transitions to the Evivo probiotic product, which is a live culture of Bifidobacterium\u00a0bacteria that\u2019s designed to augment such microbes in a baby\u2019s gut. There are no potential harms discussed here.\nHowever, the CDC\u2019s website states about probiotics (generally): \u201cIn healthy people, probiotics usually have only minor side effects, if any. However, in people with underlying health problems (for example, weakened immune systems), serious complications such as infections have occasionally been reported.\u201d", "answer": 0}, {"article": "The results showed no differences in IQ.\n\"There is growing evidence from a number of studies that all infants, those born at term and those born early, benefit from receiving extra blood from the placenta at birth,\" said Dr. Heike Rabe, a neonatologist at Brighton & Sussex Medical School in the United Kingdom.\n\"The extra blood at birth helps the baby to cope better with the transition from life in the womb, where everything is provided for them by the placenta and the mother, to the outside world,\" Rabe said.\nLorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\n\"Polycythemia can have medical consequences for the infant, including blood clots, respiratory distress and even strokes in the worst-case scenario,\" Lorch said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hooray for this story including two potential harms and reporting with experts outside of the study authors. The story calls the potential for harms \u201cunclear\u201d and that is one of way of giving the reader some balance even if there isn\u2019t much information available. Both jaundice and polycythemia are listed as potential harms.", "answer": 1}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\nWhile it did not prove a cause-and-effect connection, the study of nearly 1 million cancer patients found that those taking statin drugs such as Lipitor and Crestor appeared to have:\n\u2022 and a 30 percent lower risk of dying from colon cancer.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins have been identified with some serious side effects, including memory loss, muscle pain, and a condition known as rhabdomyolysis, and the story should have made some reference to this. In this article, the FDA\u00a0explains risks.", "answer": 0}, {"article": "Those studies are expected to launch later this year, including two at Penn.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\n\"This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before,\" Alley said.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that \u201cthe most common side-effects reported were fatigue, nausea, loss of appetite, and dry mouth,\u201d but we have no idea of magnitude of those effects or whether more serious, less common effects may have occurred.\nThe study reported that 64% of the patients had a treatment related adverse effect, but this wasn\u2019t mentioned in the news release. Side effects directly relate to quality of life and could be a deal-breaker for many patients. \nWe\u2019ve outlined some of the common challenges in writing about harms from immunotherapy drugs in this guide for journalists.", "answer": 1}, {"article": "Dr. Lars Marquardt,a professor of surgery at the University of Erlangen-Nuremberg in Germany and co-author of an accompanying journal editorial, said surgery for people with asymptomatic carotid steno sis is done too frequently.\n\"It is also unclear how optimal medical management [lifestyle changes in addition to anti-platelet medication and statins] would affect overall stroke and cardiovascular risk, and stroke-free survival,\" he said.\n\"Only a small minority of patients with carotid stenosis will suffer a stroke,\" said lead researcher Dr. Raffi Topakian, from the Academic Teaching Hospital Wagner-Jauregg in Linz, Austria.\n\"Patients with symptomatic carotid stenosis don't get the surgical procedure early enough, and patients with asymptomatic carotid stenosis have too many surgical interventions,\" Marquardt said.\nThis can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported that 10 individuals in the study of 435 had TIAs. \u00a0While transient ischemic attacks is one outcome of interest, the study presented the number of study participants that had strokes, and died of either stroke or cardiovascular death.\nThe story reported the likelihood that individuals with one or another of the problems visualized with ultrasound would have a stroke \u2013 but did not report the absolute increase in stroke that was actually observed. \u00a0This information is essential for understanding the magnitude of benefit possible. \u00a0And although the story included quotes from clinicians indicating that the risk of stroke is higher with carotid endarterectomy, there should have been some number provided to enable readers to understand the risks associated with the intervention that might result from having undergone the tests.", "answer": 0}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\nAdmissions for heart attacks and strokes declined in all counties, going from more than 800 to less than 700 per 100,000 people, but the drop was steeper in counties that enacted bans.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\n\u201cPolicies such as these when adapted on a nationwide level will be good for our entire population,\u201d said Creager, director of Dartmouth-Hitchcock Medical Center\u2019s heart center in Lebanon, New Hampshire.\nThey were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "Women who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nThough the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\nBut researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms.\u00a0 Aside from the fact that walnuts carry a significant amount of fat and protein and should be eaten in moderation, we don\u2019t know of other harms worthy of mention.", "answer": 2}, {"article": "But you can't make any conclusions about definite health benefits\" based on the study findings, said lead author Suzanna M. Zick, a naturopathic physician and research associate professor at University of Michigan Medical Center, Ann Arbor.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\n\"We know there are anti-inflammatory drugs like aspirin that appear to have anti-cancer properties.\nThe researchers found that the level of inflammation in the subjects who took the ginger pills fell by an average of 28 percent, while staying about the same in those who took the placebo.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Barely satisfactory.\nThe story only says that previous animal research showed ginger \u201cisn\u2019t potentially toxic to the stomach like aspirin.\u201d\nWhat about in people?\nThe story states that the National Library of Medicine that ginger is \u201clikely safe\u2026although some people may develop side effects.", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\nAlthough the treatment of DCIS is debated among experts, Kopans said, \"In my mind, it is always worth it to find additional cancers.\"\nHowever, among the women who did have invasive cancer, computer-aided detection was linked with a greater likelihood of finding the cancer while it was stage 1 or 2 compared to stage 3 or 4, they found.\n\"It's an add-on and now is used in probably three-quarters of U.S. mammograms,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Beginning with the headline \u201cAre Pricey Computer-Aided Mammograms Worth It?\u201d and continuing throughout the piece, the potential problems with CAD are noted. \u00a0The article includes several quotes from Dr. Joshua Fenton, lead author of the study, on three key problems with CAD. \u00a0Dr. Fenton observed that \u201cthe (overall) rate of invasive breast cancer diagnosis was no different with or without CAD.\u201d \u00a0 In addition, \u201cCAD was also associated with increased diagnostic testing among women who turned out not to have breast cancer.\u201d \u00a0These women had additional mammography, or ultrasound, or biopsies. \u00a0Finally, because CAD led to increased diagnosis of DCIS, Dr. Fenton observed that \u201cIf you are an older woman, (there is) the risk of over-treatment of noninvasive lesions.\u201d", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer\u2019s and Parkinson\u2019s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\nBy 2050, it\u2019s estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any potential risks of any aspect of the protocol. Since we do not really know what the protocol consists of we have no way of assessing potential risk.", "answer": 0}, {"article": "TUESDAY, June 5, 2012 (HealthDay News) -- A simple blood test may help gauge prognosis and tailor treatments for women who have been diagnosed with early stage breast cancer.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nCommenting on the findings, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"We are moving into a state where we're looking at a person's individual tumor and this is another way to do that, potentially leading to treatment.\"\nAlthough the test may not be far off in terms of clinical practice, \"we need additional studies,\" Lucci said.\nAccording to Bernik, though, \"it makes sense that women who have circulating tumor cells would potentially be at higher risk of distant disease at some later date.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quotes from experts not connected with the study give readers valuable perspective on the current usefulness of the test.\u00a0 Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, notes that the presence of circulating tumor cells may not be sufficient predictive information.\nJustin Sebbing, a professor in the department of surgery and cancer at Imperial College in London, cautioned that it\u2019s currently uncertain \u201c\u2026how this information can be integrated into present practice.\u201d\nThe writer also notes that the American Society of Clinical Oncology does not recommend that clinicians measure circulating tumor cells in patients.\nThese three cautions should help readers understand that if accuracy is not established, use of a test to guide therapy decisions could lead people down the wrong path.", "answer": 1}, {"article": "Might non-opioid painkillers work just as well as these addictive drugs?\nThe study involved 416 adults (average age, 37) who had gone to an emergency department with an extremity injury causing moderate to severe pain (averaging 8.7 on a scale of 1 to 10).\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\nFor pain, they were randomly assigned to take acetaminophen along with a non-opioid \u2014 ibuprofen \u2014 or with one of three commonly prescribed opioids: oxycodone, hydrocodone or codeine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not delve into potential harms \u2014 but it does note that the study itself did not collect information on side effects. In a case like this one, simply reminding readers that there are potential side effects for all the drugs studied, and that the study did not address them, is sufficient for a Satisfactory rating.", "answer": 0}, {"article": "Associate Professor Michael Buckland is Head of the Molecular Neuropathology at the University of Sydney and Head of the Department of Neuropathology at Royal Prince Alfred Hospital.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\n\"This is the first demonstration that micro-RNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,\" said Associate Professor Michael Buckland, Head of the Department of Neuropathology at RPA Hospital and the Brain and Mind Centre, University of Sydney.\nIn addition to identifying biomarkers that distinguish healthy people from those with MS, the researchers identified nine unique micro-RNA molecules that differentiate between two MS sub-types: relapsing-remitting MS (RRMS) and progressive MS.\n\nRelapsing-remitting MS (RRMS) affects 70 percent of people and often evolves into a secondary progressive form of MS. 10-15 percent of people with MS are diagnosed with a progressive form of the disease from the outset known as primary progressive MS.\nExosomes are nano-sized particles shed by almost all cell types in the body and are packed with micro-RNAs and other types of small RNA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The possible debits of this blood test\u2014false positives and false negatives, for example\u2014are not broached. These are very likely to occur in a larger group of subjects.", "answer": 0}, {"article": "No significant side-effects remained after two years.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\nThe VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story regurgitates nearly word-for-word what\u2019s in the news release:\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said. No significant side-effects remained after two years.\nAs we mentioned in our review of the news release, it\u2019s a disservice to patients to downplay harms with the word \u201conly.\u201d\nThe story does not give the proportion of patients on VTP who experienced adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, both the story and the news release gloss over the fact that over 1/3 of patients needed repeat treatment within 2 years, and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\nThe study, which retrospectively tracked more than 43,000 men for an average of 3.3 years, found that men prescribed phosphodiesterase-5 (PDE5) inhibitors--the type of erectile dysfunction drug sold under the names Viagra, Levitra, Cialis and others--after their first heart attack were 33 percent less likely to die from any cause.\nThe ACC's Annual Scientific Session, which in 2017 will be March 17-19 in Washington, brings together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study was designed to determine if there is an\u00a0association between treatment for ED and death or cardiovascular outcomes after a first heart attack. Other side effects more commonly seen were not measured.\nWe\u2019d still like to see at least some mention of the common harms from ED drugs in a news release distributed to a wide audience, particularly one that touts its safety and potential benefits.", "answer": 0}, {"article": "This version has been corrected.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nThe first procedure carries a 15 percent risk of collapsing a lung (pneumothorax), as well as infection.\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nCorrection: The original version of this post incorrectly named the company that is distributing the Bronchial Genomic Classifier.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the additional maneuvering of the bronchoscope to collect cells for the genomic testing adds less than a minute to a bronchoscopy procedure. But it doesn\u2019t make clear that bronchoscopy itself carries some risks (mainly of infections). In addition, a company news release reports that the test has a relatively low specificity of 47%, which means there will be many false positive results. The story doesn\u2019t explore this beyond saying that there will still be biopsies. These false positives will result in unneeded surgical or needle biopsies in those who turn out not to have cancer.\u00a0Any story about a new test \u2013 rather than dwelling on \u201caccuracy\u201d \u2013 should explain both the sensitivity and specificity of the test.", "answer": 0}, {"article": "Dr. Warren was puzzling over how to recreate that synaptic traffic cop when, because of a scheduling conflict, he showed up in 2001 at the wrong scientific conference and happened to sit next to Mark F. Bear, a neuroscience professor at M.I.T.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nIf authenticated in further, larger trials, the results could also become a landmark in the field of autism research, since scientists speculated that the drug may help some patients with autism not caused by fragile X, perhaps becoming the first medicine to address autism\u2019s core symptoms.\n\u201cThis is perhaps the most promising therapeutic discovery ever for a gene-based behavioral disease,\u201d said Dr. Edward M. Scolnick, former research chief at Merck and now director of the Stanley Center for Psychiatric Research at the Broad Institute at Harvard and the Massachusetts Institute of Technology.\n\u201cBut I\u2019m not going to have kids for at least 10 years anyway, and they\u2019ll have a cure for by then.\u201d\n\nShe paused, looked at her mother and said: \u201cYou\u2019ve got 10 years.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the big problems of reporting on research that hasn\u2019t been published or peer-reviewed is that harms don\u2019t get adequately quantified\u2013a\u00a0 drawback that was on\u00a0full display in this story. The report\u00a0didn\u2019t\u00a0even mention the possibility of patients being harmed by this experimental drug. \u00a0", "answer": 0}, {"article": "Khalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"Science is showing that meditation and spiritual fitness can be an important dimension in battling Alzheimer's, and Kirtan Kriya is a safe, affordable, fast, and effective way to keep the brain spiritually fit.\"\nAbout the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nThe print edition is scheduled to be published in August.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not addressed in the release but meditation is not associated with any common health risks. We\u2019ll rule this Not Applicable.", "answer": 2}, {"article": ".\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\n\"The visualized portion of a skin lesion can be just the tip of the iceberg, and most dermatologists operate 'blindly' beyond what they can see on the surface,\" Siegel said.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n\"Consequently,\" he said, \"many benign lesions are needlessly biopsied in order to avoid the risk of missing a potentially deadly melanoma.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned no harms of elastography, which are similar to conventional ultrasonography. Excessive false positive results could lead to needless biopsies in the case of both skin and breast lesions.\u00a0 Alternatively, false negative results of the new test could lead to undiagnosed breast or skin cancer.\u00a0 The story focuses on the reduced likelihood of biopsy in both cases failing to comment on the potential downside. ", "answer": 0}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nThe heart quits pumping blood, leaving vital organs depleted of oxygen -- a situation that can cause significant damage to the brain, kidneys and other organs, or death if quick emergency action is not taken.\n\"My goal is to get back to a normal life,\" he said, noting he hates cold weather and is surprised he withstood hypothermic therapy.\n\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\nFor 24 hours, his body temperature was kept at 91 degrees Fahrenheit, which put him in a state of hibernation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms associated with this treatment or the frequency with which these are typically observed.\nThe person used as an example of the benefits of the treatment developed pneumonia in the course of his recovery from his cardiac arrest and his hypothemia treatment, which may be a side-effect of the treatment. ", "answer": 0}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nSimilar types of stimulation treatment are used in some patients with depression or during spinal surgery, according to Barrett.\nThe \u201creal\u201d magnetic stimulation group improved by about 16 percent right after the treatment and 23 percent at the later time point, while there was no significant benefit seen in patients given the fake stimulation.\nPatients in both groups started out with an average mark of about 170 on the tests, which are scored from 0 to 227 combined.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention potential adverse effects of TMS or state whether any adverse effects were seen in the study.", "answer": 0}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\nResults showed that the implanted stem cells didn\u2019t survive very long in the brain, disappearing about one to two months after injections; however, patients still showed significant motor recovery at six and 12 months post-surgery.\nIn addition to setting the stage for an expanded trial of the procedure, the promising results also change \u201cour notion of what happens after a stroke,\u201d Steinberg explained.\nIn other words, they are the precursors to muscle, fat, bone, and tendon tissue.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly noted side effects.\u00a0 It\u2019s worth pointing out that the study only followed patients for about a year, and long-term effects are unknown and could be more severe.", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nCurrently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nThe most common reason men seek testosterone therapy is waning sexual desire or performance, although the ability of the hormone to relieve sexual symptoms is unpredictable.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0notes that a recent study was halted because of an unexpectedly high rate of cardiac problems in the testosterone group. It also mentions the possibility that testosterone therapy can result in thickening of the blood and may increase the risk of prostate cancer.\nThe story isn\u2019t precise about\u00a0how often these harms occur, and it also\u00a0didn\u2019t mention\u00a0some of the \"minor\" side effects associated with testosterone use, including acne, hair loss on the scalp, hair growth on the face, increased breast size, and testicular atrophy.\nA close one here. Overall, we felt the story called appropriate attention to the harms and did not try to minimize them \u2014 enough\u00a0to earn a satisfactory.\u00a0\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Papa and her team expanded on that work by studying how levels of these two proteins, or biomarkers, change immediately after head trauma.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\nMORE: Concussion Expert: Over 90% of NFL Players Have Brain Disease\n\nIn all people, regardless of the type of injury they had, the levels of the proteins, called GFAP and UCH-L1, rose within the first hour after the injuries.\nThere\u2019s growing evidence that concussions may have more lasting effects than previously thought, and that monitoring people with head injuries, no matter how apparently minor, is crucial to ensuring they receive proper treatment and minimize the effects of the trauma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any harms, but all screening tests have harms associated with false positive and negative results. In athletes, for example, a false positive test keeps you off the field and creates\u00a0unnecessary anxiety. A false negative result\u00a0means you go back on the field with a concussion and potentially suffer another head injury that could have catastrophic consequences.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nThe government has approved use of growth hormone for a limited array of conditions in adults and children, Dr. Merriam said.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\n\"There are no short-term fixes,\" he said, saying diet and exercise remain preferred approaches to avoiding many health problems associated with aging.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that further study of growth hormone in otherwise healthy older adults is needed due to a lack of safety information, however none of the potential harms are mentioned. We do not know the long-term effects of growth hormone in older adults; however, it may pose an increased risk of prostate cancer for older men and decrease longevity (Vance, M. L. (2003). Can growth hormone prevent aging? N Engl J Med, 348(9), 779-780.).", "answer": 0}, {"article": "Chemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\nImportantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\nThe same can be true of molecules, and in some cases, having the wrong handed molecule can have profound biological consequences.\nProfessor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nLed by Professor Peter J. Sadler from Warwick's Department of Chemistry, researchers have developed a new line of attack against cancer: an organic-osmium compound, which is triggered using a non-toxic dose of sodium formate, a natural product found in many organisms, including nettles and ants.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched\u201d (emphasis added). What does \u201clargely untouched\u201d mean? Was there some level of harm or change induced in healthy cells? In the context of human health, vague statements like that make us nervous. That\u2019s particularly true when a release does not disclose what sort of testing has been done \u2014 and remains to be done \u2014 for a potential treatment. It\u2019s always a good idea to point out that in research this preliminary, we have almost no idea what kind of adverse effects might occur when the compound is actually administered to patients.\nThis also plays to the popularity of terms like \u201cprecision oncology\u201d and \u201cselective\u2019 or \u201ctargeted\u201d\u00a0 cancer treatment.\u201d We are finding more and more that lots of our targeted treatments still can and do have \u201coff target\u201d harms. Gleevec and subsequent generation molecules are examples (prototypes) of great \u201ctargeted therapies\u201d but they still have other common side effects. Also, always comparing targeted molecules to chemotherapy is becoming less fair these days given that we have a better understanding of how to anticipate and manage side effects in general.", "answer": 0}, {"article": "For that reason, Dr. Jacobson of Emory gives the prescription drug, \u201coff label,\u201d to cardiac patients, even though the F.D.A.\nThe American College of Cardiology now advises patients with coronary artery disease to increase their consumption of omega-3 acids to one gram a day, but it does not specify if this should be achieved by eating fish or by taking capsules.\n\u201cIn other countries, uptake may be harder because doctors think of it as just a dietary intervention.\u201d\n\nIn the largest study of fish oil \u2014 conducted more than a decade ago \u2014 Italian researchers from the Gissi Group (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto), gave 11,000 patients one gram of prescription fish oil a day after heart attacks.\nBut the landmark Gissi-Prevenzione trial of fish oil had methodological weaknesses: the patients treated with prescription fish oil pills were compared with untreated patients, rather than with patients given a dummy pill.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms, side effects, or anticoagulation effects with excess doses. The story also failed to mention that fish oil can be a source of mercury with its potential neurologic risks (although there was a brief mention of mercury without context). ", "answer": 0}, {"article": "The patients were selected at random from a national database.\nWithin a year of the blood test, the team found that cancer was more common among those who had thrombocytosis: 11.6% of men and 6.2% of women were found to have cancer compared to 4.1% of men and 2.2% of women without a raised platelet count.\nPrevious studies have suggested a link between thrombocytosis and various cancers, with recent guidelines from the National Institute for Health and Care Excellence advising high platelet counts could be a sign of cancer of the oesophageal, stomach, lung or uterus.\nWhile many different types of cancer were present in both groups, the team found that breast and prostate cancers were less common among those with thrombocytosis than in the general population, while lung and colorectal cancers were more common.\nOf the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have stated more explicitly the significant potential downsides (clinical and financial) of mass use of primary thrombocytosis screening, and even the harm that can potentially occur when an \u201cincidental\u201d finding of elevated platelet levels must be further investigated in the absence of other cancer risk factors or symptoms. It could raise anxiety levels of people who may have elevated platelet counts due to other reasons or younger people feeling they need to be tested because the results by age weren\u2019t mentioned.", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif. (The study was sponsored by SI-BONE, manufacturer of the SIJ implants.)\nThe implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\nAfter one year, subjects assigned to SIJ fusion still had significant reductions in pain and disability, as well as improved quality of life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some harms are mentioned but in insufficient detail. The published study cites a small number of serious complications. Although the adverse events are rare, they should still be mentioned. The most common side effects among those receiving the procedure were leg and pelvic pain within the first year, according to the study.", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included past warnings about alcohol consumption for \u201cwomen intent on warding off breast cancer.\u201d", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms beyond mention that the tracer was radioactive.\u00a0 What is the radiation burden? ", "answer": 0}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nFurthermore, there were greater severe acute toxic effects from the chemoradiotherapy treatments compared with radiotherapy alone,13 but no significant differences in severe late toxic effects were noted in the comparison of the 3 treatment arms.14 Unfortunately, the concomitant chemoradiotherapy arm had an increase in deaths not attributable to cancer compared with the other 2 arms; this finding needs to be explored further to determine whether undetected fatal late treatment toxic effects are greater with concomitant regimens.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nThe TREMPLIN (Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation) trial compared the efficacy and safety of induction chemotherapy using docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy with cisplatin (n = 60) or cetuximab (n = 56), for laryngeal preservation.33 No differences were found in laryngeal preservation, laryngeal function preservation, or overall survival between the 2 regimens.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This comes back to cetuximab. As noted above, cetuximab is already sold under the trade name Erbitux. And Erbitux\u2019s own website notes that it can cause significant adverse health effects, including heart attacks and allergic reactions that resulted in death. We don\u2019t expect a news release to include a thorough recounting of every possible adverse health effect associated with a treatment, but we do expect there to be at least an acknowledgment of known health risks \u2014 and especially so when the relevant risks are so severe.", "answer": 0}, {"article": "Once that occurs, the team hopes to work with cardiologists to quickly move the research into clinical trials, involving chemotherapy and heart transplant patients.\n\"This is something that nobody has ever seen before,\" says Marek Michalak, co-principal investigator and a distinguished professor in the Department of Biochemistry at the University of Alberta's Faculty of Medicine & Dentistry.\n\"It offers hope to those who are living with heart failure,\" adds Luis Agellon, co-principal investigator and a professor at McGill University's School of Dietetics and Human Nutrition.\n\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\n\"If cardiac fibrosis can be stopped, then that could substantially improve the outcome for people at risk,\" says Agellon.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The research paper does not include any statement about potential toxicity other than to point out that none of the 162 mice died prior to the conclusion of the study. The release is silent on the issue. A\u00a0few words about the potential toxicity (or the absence of risk if that\u2019s the case) of TUDCA which is commercially available and has been studied\u00a0for the treatment of biliary cirrhosis would have been in order.", "answer": 0}, {"article": "WEDNESDAY, April 20, 2011 (HealthDay News) -- Researchers have developed a blood test that they say could help physicians predict whether pregnant women will deliver their babies prematurely.\nAbout 10 percent of births are premature, and the rate rises to 30 percent among women who have already had a baby prematurely, Graves said.\nOne option is to provide drugs that dampen the immune system so the baby's lungs develop faster, said Dr. Jennifer Wu, an obstetrician-gynecologist at Lenox Hill Hospital in New York City.\n\"If you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that's truly the case.\"\nThe researchers developed a screening method that looked for so-called peptide biomarkers in the blood that -- in tandem with several other proteins -- predicted 80 percent to 90 percent of the premature births at 28 weeks of gestation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentioned that the false positive rate was 20%, so we\u2019ll give it a passing grade. We wish, though, that it had included some expert comment on the significance of a false positive rate that high.", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the drug is associated with \u201cfew significant side effects,\u201d however, the specifics of these side effects are not provided. Six patients in the advanced basel cell carcinoma study experienced 8 grade 3 adverse events, including fatigue, hyponatremia, muscle spasms, and atrial fibrillation. One patient withdrew from the study citing adverse effects.", "answer": 0}, {"article": "This use can sterilize the air in a public space, reducing the spread of respiratory droplets containing flu viruses and other bacteria and viruses.\"\n\"Far-UVC light has a very limited range and cannot penetrate through the outer dead-cell layer of human skin or the tear layer in the eye, so it's not a human health hazard,\" said Brenner, who directs Columbia's Center for Radiological Research.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nHowever, \"because viruses and bacteria are much smaller than human cells, far-UVC light can reach their DNA and kill them,\" he said in a university news release.\nHe noted that the technology's cost \"is not prohibitive, and it is safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Based on earlier in vitro studies by the same authors, it\u2019s mentioned the antiviral effect can be achieved without harming human or mouse skin, or causing cataracts (cataracts and skin cancer are a\u00a0 well-documented side effect of full spectrum UVC exposure). It\u2019s not clear if these results would hold up in live subjects. No other side effects of far-UVC spectrum light are mentioned.", "answer": 0}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nWhile many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\nThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The word \u201charms\u201d does not appear in the news release. During intravenous infusions there are complications that may arise. The release does not mention harm, even to dismiss the probability as rare.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nThe study included 107 healthy but overweight participants, ages 18-75, who were randomly assigned to follow for three months either a low-calorie vegetarian diet, which included dairy and eggs, or a low-calorie Mediterranean diet for three months.\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\nThe vegetarian diet was more effective at reducing LDL (the \"bad\") cholesterol, while the Mediterranean diet resulted greater reductions in triglycerides, high levels of which increase the risk for heart attack and stroke.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Both diets used in the study are generally safe for most people. Food intolerances aside, the only potential harm we could see in the diets used in the study is that the calorie quota (about 2100 calories per day) may not be appropriate for all people.", "answer": 2}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The magnitude of improvement among frail patients increased at 180 and 365 days.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nTo place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nThe absolute reduction in 180-day mortality among frail patients was more than 19 percent, with improvement remaining robust even after controlling for age, frailty, and predicted mortality.\u201d\n\n: This investigation was supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this was a study about a quality improvement initiative, we\u2019ll rate this N/A.\u00a0However, it might have been worth raising the question of whether the time and emphasis placed on this screening test by clinicians detracted from other work they could have been doing to improve patient care and outcomes.", "answer": 2}, {"article": "For more information, visit http://www.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\nThe number of cancers detected in women ages 40-49 was not significantly different from women ages 50-59 or 60-69.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not explain additional harms of earlier mammogram screening, of which there are several. One is radiation exposure; though mammograms involve minimal radiation, the risk of exposure still exists. The larger harm, however, is the possibility of false-positives and false-negatives. Mammograms aren\u2019t foolproof tests; the American Cancer Society estimates that mammograms miss 1 in 5 breast cancers (false negatives). They also estimate that about half of women getting an annual mammogram over a 10-year period will have a false positive (where the screening indicates something abnormal, but in reality there is no cancer). False positives are more common in younger women, and can lead to additional tests, cost and anxiety for women when nothing is wrong. The higher rate of false positives in women ages 40-49 is one of the reasons that the mammogram age is so controversial. For the group 40-49 years of age about 3% of the callbacks resulted in an actual cancer detected while it was about 6% and 7% in the older age groups.", "answer": 0}, {"article": "The drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nAll the participants were counseled about diet and exercise.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nFenfluramine was taken off the market in 1997 after being linked to potentially life-threatening heart valve problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Stronger points: \nWeaker points:\u00a0", "answer": 1}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms at all, which is problematic. The authors of the paper noted the difficulty in identifying true rates of adverse events in the study given the discrepancy in the number of subjects in each treatment group.\u00a0 There was a 6:1 ratio of guselkumab subjects compared to adalimumab in the post placebo phase of the trial.\u00a0 While the true incidence of harm is unclear at the moment, some comment is\u00a0necessary even in a press release.\u00a0 For example, according to the paper, 20 percent of patients who received guselkumab experienced \u201cadverse events of infection\u201d during the first 16 weeks of the trial, as compared to 14 percent among patients receiving a placebo and 12 percent of patients who received adalimumab. A higher rate of infection is certainly worth mentioning. Heck, even a comparable rate of infection is worth mentioning. Overall, patients who received guselkumab had lower rates of all \u201cadverse events\u201d compared to adalimumab over the first 16 weeks of treatment (50 percent versus 56 percent), and over weeks 16 through 52 of the study (49 percent versus 61 percent). But the rates of adverse events were still noteworthy, and the release should have addressed them.", "answer": 0}, {"article": "The remaining women served as a control group.\n\"In addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\" he said.\n\"It is the urine output which is of course the key factor leading to the effect seen in the study,\" said Wessells, chair of the department of urology at the University of Washington School of Medicine in Seattle.\nThe study, conducted in Bulgaria, involved 140 healthy premenopausal women who had at least three UTIs in the past year.\nWhat's more, the amount of time that passed before a woman's next UTI and between recurrent infections was longer in the water group than in the control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Increasing intake of water carries a low risk of causing problems\u2013except for more bathroom trips. For women suffering from incontinence, this could be especially troublesome and a disincentive. The story indirectly addressed that, so we\u2019ll give credit:\n\u201cIn addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\u201d he said.", "answer": 1}, {"article": "He is vice president for health care outcomes and policy at Roswell Park Cancer Institute in Buffalo, N.Y.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n\"The new guidelines say there is clear evidence that the benefit of [post-mastectomy radiation therapy] extends to women with limited lymph node involvement,\" said Dr. Stephen Edge.\nFor instance, he explained, ''a woman 65 who has microscopic involvement in a single lymph node and an estrogen-receptor positive cancer would be very different from a 38-year-old who has three lymph nodes involved and so-called triple-negative breast cancer.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does address the need to \u201cweigh the risks and benefits.\u201d The story notes: \u201cSide effects can include redness of the skin, swelling and skin breakdown severe enough to compromise future breast reconstruction.\u201d Those are important points, and we\u2019re glad the story made them.\nWe wish the story had also discussed that there can also be more serious health effects from radiation, including the possibility of increased risk of a second cancer. Also, surgical complications may be increased in patients who require radiation therapy.", "answer": 1}, {"article": "Thousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cThe difficulty is identifying which patients will benefit from these drugs,\u201d said Professor Robert Coleman, emeritus professor of medical oncology who led the new study.\nSheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2016 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any of the possible side effects of taking a bisphosphonate. For some women, those side effects are significant and thus they should be included.\nAdditionally, we\u2019re wondering how the genetic test is performed since there was no description offered. Is it a blood test or is it more invasive, complex and risky, requiring acquisition of tumor tissue?", "answer": 0}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\n\"What I foresee is in five years, each person will know this risk number, this 'polygenic risk score,' similar to the way each person knows his or her cholesterol,\" said Dr. Sekar Kathiresan, who led the research team from the Broad Institute, Massachusetts General Hospital and Harvard Medical School.\nFor example, when the researchers tested the system using a DNA database from Britain, less than 1 percent of people with the lowest risk scores were diagnosed with coronary artery disease, compared with 11 percent of people with the highest risk score.\n\"There are things you can do to lower the risk,\" Kathiresan said \u2014 the usual advice about diet, exercise, cholesterol medication and not smoking helps.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention in the story about possible false positives or false negatives although both represent considerable concerns for individuals. False positives can cause patients unnecessary concern\u00a0while false negatives may embolden persons to be careless in controlling other risk factors that can lead to disease.\nFor example, people with a high score may want to take cholesterol-lowering medications, which will have costs and potential side effects, without knowing whether they are effective. There also can be psychological harms of telling someone that that they have a high risk for cardiovascular disease or other diseases.", "answer": 0}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nThe following related elements from this issue of JAMA are also available on the For The Media website:\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity\n\n-- Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A , LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study\n\n-- Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities\n\n-- Editorial: Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity\n\nFor more details and to read the full study, please visit the For The Media website.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss any potential harms associated with bariatric surgery \u2014 and there are several. While the focus of this study was on rates of death, not on other outcomes, any discussion of this surgery that might sway a reader to try it needs to include a summary of potential complications and risks.\nThe issue of harms might have been included in the \u201climitations\u201d section of the release.", "answer": 0}, {"article": "\"Are there people gaming the system?\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\n\"Many people don\u2019t have adequate space in their jaw for the teeth to come into full position, but that alone isn\u2019t justification of having them all removed,\" says Dr. Scott Tomar of University of North Carolina's School of Dentistry.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\nSome think of removing the wisdom teeth early on as a way to lessen the crowding of other teeth\n\n\"You might not have symptoms now, but you can't assume it's gonna be that way for the rest of your life,\" says Dr. Ray White, an oral surgeon working at University of North Carolina.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks associated with wisdom tooth extraction are clearly spelled out in the story. These include \u201cpoor wound healing, infection, pain, and uncontrolled bleeding\u201d along with nerve injury which can, in rare cases, leave people with permanent facial numbness. As noted above, some quantification of these results would have been ideal.", "answer": 1}, {"article": "The difference?\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nIt\u2019s no longer that you need to stay away from hormone replacement therapy, it\u2019s that you need to use it wisely.\u201d\n\nThat wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.\nIf a doctor won\u2019t work with you, then find another doctor,\u201d says Dr. Marina Johnson, a Dallas endocrinologist and pharmacist and author of Outliving Your Ovaries: An Endocrinologist Weighs the Risks and Rewards of Treating Menopause With Hormone Replacement Therapy.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that conclusions of the Women\u2019s Health Initiative have been discredited by subsequent studies but fails to state any of these studies or acknowledge potential side effects of HRT. \u00a0The article instead points out some of the limitations of the Women\u2019s Health Initiative, but we don\u2019t think \u201cdiscredit\u201d is appropriate in this case.\u00a0 It was further analysis of the WHI data \u2013 not new studies \u2013 that showed that risks are different in the younger postmenopausal women (women in their 50s) compared with the older population.", "answer": 0}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nJust because a drug doesn\u2019t measure up in that way, he says, \u201cdoesn\u2019t mean the drug is not effective.\u201d\n\nBut even if the FDA agrees to overlook some of the negative data about ataluren, insurers may not.\nIn an e-mailed statement, FDA spokesperson Sandy Walsh confirmed that the FDA\u2019s decisions are all \u201cbased on an assessment of the available data and whether the benefits of the drug outweigh its risks.\u201d That data can include the experience of patients like Max, Rowan and Charlie.\n\u201cIf the evidence isn\u2019t good, then insurance companies won\u2019t pay for [drugs],\u201d said National Center for Health Research (NCHR) president Diana Zuckerman.\nYou could use it for your child, too.\u201d\n\nPTC Therapeutics has tried to get FDA approval for the drug twice before.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text briefly mentions side effects associated with the drug, increases in blood pressure and cholesterol levels, an assertion contested by the drug\u2019s manufacturer, PTC Therapeutics. However, it would have been more helpful to quantify and more clearly describe these side effects, and tap independent experts for their viewpoints. We found the NCHR\u2019s testimony about the risks of combining this drug with other drugs these kids commonly take to be important, for example.", "answer": 0}, {"article": "The researchers are continuing to evaluate that.\nThe dual-drug approach greatly boosted the chances of eliminating microscopic signs of early cancer by the time a woman was due to have surgery, said researcher Dr. Jose Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School.\nThe two drugs, he said, \"affect the same pathway but do it in a different way.\"\nThe study is well done and important, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.\nIn another study, published online Jan. 17 in The Lancet Oncology, researchers from Germany reported that Tykerb is less beneficial than Herceptin as a single-drug therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a high level description of possible side effects from these drugs.\u00a0 But no sense of the scope of these problems was provided.\nMore diarrhea?\u00a0 More frequent liver-enzyme alterations?\u00a0 Deaths have been reported?\nHow much more?\u00a0 How many deaths?\nIf you can quantify ill-described \u201cresponse,\u201d you can quantify the harms.", "answer": 0}, {"article": "D'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nBut many patients and their families aren't comfortable waiting and opt to have surgery before it's deemed medically necessary.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nWhen the prostate gland was examined after their surgery, researchers found that many who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms from taking vitamin D supplements were not mentioned (nor were those of surgery). \u00a0While toxicity is rare, studies suggest that long-term intakes of high doses are associated with adverse health effects. Perhaps more importantly, what about men possibly taking vitamin D when they really ought to have surgery because they have an aggressive tumor type?", "answer": 0}, {"article": "The ASNR was founded in 1962 and is headquartered in Oak Brook, Illinois.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Procedures almost always carry risks, and MRI is no exception. Some physicians are concerned with \u201cMRI abuse,\u201d pointing out that MRIs often pick up abnormal \u2013 but harmless \u2013 findings that muddy up the clinical picture. These so-called \u201cincidentalomas\u201d can lead to more tests and treatments that cause harm and add to costs. Unnecessary imaging is a major contributor to spiraling health care costs in the US, since a single scan on average in the US costs $2,611, according to Medicare data.", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of Erbitux are accurately presented.", "answer": 1}, {"article": "The researchers did not observe any side effects.\n\u201cWe certainly have a technology that can change the medical field by being able to program and generate strong immune responses that are specific and effective,\u201d he said.\nStudy authors say the vaccine is formulated to work against all cancers caused by HPV types 16 and 18, including cervical, anogenital (anal and genital), and head and neck cancers.\nIt uses the immune system of the treated women to fight off cancer, said Joseph Kim, president and CEO of Inovio Pharmaceuticals and study co-author.\nBut there are a lot of people out there who still have HPV, and nothing protects against all 130 strains of the virus.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cThe researchers did not observe any side effects.\u201d\u00a0 But the Philadelphia Inquirer reported: \u201cMost side effects of the vaccine were minimal and deemed unrelated to the treatment, the paper reported.\u201d", "answer": 0}, {"article": "Decipher was developed in partnership with the Mayo Clinic.\nThe Decipher results increased agreement in treatment recommendations between urologists and radiation oncologists, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the Decipher test were made available.\nIn addition, the 19% of the patients with the highest risk based on Decipher had a nearly 10-fold higher risk of distant metastases by 5 years.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t explain what sorts of risks a patient faces from radiation, hormone, and other \u201cadjuvant\u201d therapies after surgery, and avoiding these seems to be a key point of the Decipher test.\u00a0We also don\u2019t get\u00a0any words on how reliable the test actually test is and how often it might return inaccurate results, which is its own kind of risk.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All drugs come with some kind of risk profile. And, in this case, we are talking about treating patients with diabetes who, presumably, already are managing that disease with prescription medication. At a minimum, the release should mention any side effects or harms observed in the study.", "answer": 0}, {"article": "Reuters - A nicotine addiction pill can help smokers quit gradually when they can\u2019t go cold turkey, a study finds, suggesting that it may be time to revisit practice guidelines that focus primarily on immediate cessation.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\n\u201cThis is the first study of its kind to enroll a group of smokers who are not traditionally enrolled in clinical trials because they are not ready to quit,\u201d said Dr. Caryn Lerman, professor of psychiatry and deputy director of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends several paragraphs discussing potential side effects associated with Chantix \u2014 including the fact that the FDA has placed its black box warning on the drug in light of its possible neuropsychological effects. The story does not mention concerns related to possible cardiovascular health effects that were raised by the FDA in 2012.", "answer": 1}, {"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nStudy published in the Journal of the American Osteopathic Association finds OMT plus antibiotics reduces risk of death for the most severely ill patients\n\nCHICAGO--August 29, 2016-- An analysis of multicenter randomized controlled clinical trial found osteopathic manipulative treatment (OMT) for pneumonia reduced length of hospital stay in adults 50 to 74 years old and lowered in-hospital mortality rates for patients 75 and older.\nThe data were analyzed by intention-to-treat analysis of all participants and by per-protocol analysis of participants who finished the study without missing any protocol treatments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it\u2019s commonly accepted that osteopathic manipulation is \u201charmless,\u201d the release should have addressed any potential complications, discomforts, cost issues or other side effects.", "answer": 0}, {"article": "The study followed more than 1,600 people over the age of 60 for five years.\n\"It seems as though the statins because they lower cholesterol reduce production of these plaques,\" said Dr. Gayatri Devi.\n\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\nA patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study should have mentioned whether the studied group that took statins showed any side effects compared to the group not taking the statins. \nThe story is implictly about the potential benefits of long-term, prophylactic use of statins for people at high risk for dementia and some vascular diseases. The possiblity of side effects in this group should have been mentioned.\u00a0\nThe journal\u2019s press release says \"the most common side effects of statins are headaches, nausea, fever and muscle pain.\" ", "answer": 0}, {"article": "The main limitation of the study is the underlying weakness of the studies evaluated.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\n\u201cWe need treatments to address it, and it should be treated with equal seriousness as erectile dysfunction.\u201d\n\nThe prevalence of premature ejaculation is difficult to measure because of the differing definitions of the problem and some men\u2019s reluctance to report it.\n\u201cThere are a range of treatments available for premature ejaculation, including drug treatments, behavioral techniques and counseling, however, some men may not want to visit the doctor, take drugs long-term or be on a long wait list for counseling,\u201d said lead author Katy Cooper of the University of Sheffield in the UK.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report helpfully mentioned that \u201csome studies, but not all, discussed side effects such as gastrointestinal discomfort, dizziness, mild pain and decreased libido. When they were reported, the adverse effects were generally mild.\u201d\nIt would have been useful to note that the off-label use of SSRIs also involves some rate of adverse effects and that some foreign-sourced herbal treatments have been found to be adulterated with compounds from prescription drugs, and that quality control of herbal treatments is sometimes a problem.", "answer": 1}, {"article": "Newswise \u2014 HOUSTON \u2015 For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs).\nWhen ICI-associated colitis is severe, guidelines require a patient to stop ICI treatment until the colitis is in remission.\nThe first patient\u2019s colitis resolved within two weeks following a single FMT treatment; the second patient experienced a partial recovery after the first treatment, followed by complete recovery after a second FMT.\n\u201cThe resolution of colitis in these patients can be confirmed clinically and endoscopically after FMT treatment,\u201d said Wang.\n\u201cIf the patient is a good responder to immunotherapy, that means you\u2019ve taken their effective treatment away,\u201d said Wang.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Risks of these transplants are not mentioned.\u00a0 Fecal material produced without careful screening could introduce microbes, including those linked to MS and Parkinson\u2019s.", "answer": 0}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nWhen it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\nLess than 1 percent of patients treated with cryoablation were hospitalized for a recurrence of the disease, compared with 6 percent in the drug group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention several of the harms associated with the use of this device along with the incidence with which they were observed.", "answer": 1}, {"article": "This can be made from their own vessels.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nIn this most recent study, published Friday in the medical journal Lancet, scientists reported on the new blood vessels in those same patients and 4 others.\nFrom those, scientists made sheets of tissue that were rolled into blood vessels 6 to 8 inches (15 to 20 centimeters) long.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the new approach made it \"easier and safer\" for dialysis.\u00a0 But such a statement can\u2019t be made definitively in a lead sentence of a story on such early research.\u00a0 Indeed, the story presented the picture of harms unevenly, stating that artificial vessels are \"prone to infection and inflammation,\" without explaining how often that happens.\u00a0 We don\u2019t think it helps reader comprehension to paint an existing approach with such a broad negative brush while painting the new and uNPRoven approach with such a broad positive brush. ", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\nThe U.S. has one of the highest rates of pre-term and low-weight births \u2014 about one in 12 births, according to the March of Dimes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention, although the story does note the finding that children given standard incubator care had higher math and language scores in school even though IQ levels were similar in both groups.\nA 2012 Cochrane review of multiple studies found no negative outcomes associated with skin-to-skin contact for healthy newborns except for one study\u2019s report of longer duration of breastfeeding in a control group.", "answer": 1}, {"article": "For more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nDenver, CO. (February 17, 2016) - U.S. children are not consuming enough vegetables, resulting in an inadequate intake of key nutrients, including potassium and dietary fiber, which are important for growth, development and overall health.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\nStorey ML, Anderson PA. Nutrient Intake and Vegetable and White Potato Consumption by Children 1 to 3 Years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most troubling thing about this study and about the release is the inclusion of french fries and potato chips in the study as if they were equal in health value to other forms of potatoes. There is no discussion of the potential harms that come from foods high in sugar, salt, fat, and calories.", "answer": 0}, {"article": "URBANA, Ill. - Nearly every American who has become a parent in the last decade has heard the slogan, \"breast milk is best,\" and has likely been encouraged to offer breast milk to newborns.\nIf they spent more time with the new toy, that was an indication that the piglet recognized it as new and preferred it.\nThe preference for novel objects, an indication of natural curiosity, is a sign of healthy brain development and points towards positive development of learning and memory.\n\"There are so many ways we can alter the composition of the microbiota and they can have very strong benefits.\nOne way to tell is by looking at metabolic end-products - volatile fatty acids (VFAs) - excreted by bacteria during digestion of prebiotic fibers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known disadvantages of formula over breast milk so harms should be included in any discussion of changing infant nutrition patterns.", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\nFebruary 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nThe results strongly support its use, especially in infants with deformities and less-severe malformations.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly addresses the vast majority of the complications discussed in the journal article, which is enough to earn it a satisfactory rating. However, the release does not mention the possibility of infection. There was only one case identified in the article, but it is also the most significant of the complications that cropped up over the course of the (retrospective) study.", "answer": 1}, {"article": "Tumors or other abnormalities show up in red.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\nThe patented real-time radiofrequency scanner uses computer tomography and works by using the same technology as a mobile phone, but with only a tiny fraction of its power.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed. If it\u2019s too early to tell the rates of false positives, we need to know that. The article draws a picture of a tool with no potential downsides.", "answer": 0}, {"article": "What would that look / sound / smell like?\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some forms of weight loss can pose risks for patients, such as various fad diets or when people with a sedentary lifestyle suddenly begin engaging in rigorous exercise. But this study does not appear to have evaluated how people tried to lose weight, instead focusing on the extent to which they were motived to make changes based on the intervention. Because of the nature of the study, we\u2019ll rate this as not applicable. However, it would have been valuable to include language encouraging people to talk to a health care provider before making abrupt changes to their lifestyle.", "answer": 2}, {"article": "Previous studies indicated that chemicals in green tea called polyphenols are absorbed and alter the energy metabolism in the liver.\n\"It was known that green tea polyphenols are more effective and offer more health benefits than black tea polyphenols since green tea chemicals are absorbed into the blood and tissue,\" said Susanne Henning, the study's lead author and an adjunct professor at the UCLA Center for Human Nutrition, which is part of the David Geffen School of Medicine at UCLA.\n\"The results suggest that both green and black teas are prebiotics, substances that induce the growth of good microorganisms that contribute to a person's well-being,\" she said.\nHowever, only the mice that consumed black tea extract had an increase in a type of bacteria called Pseudobutyrivibrio, which could help explain the difference between how black tea and green tea change energy metabolism.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of consuming black tea were mentioned. Black tea contains caffeine, which can cause a range of adverse effects in high doses.\nOf course, the manuscript that\u2019s the basis of the release specifies that the study tested decaffeinated black tea. However, the release doesn\u2019t mention this. Clarifying this point would have been helpful.", "answer": 0}, {"article": "Federal grants helped pay for the work.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nSaline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\nThe difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this study is all about safety, we think the story should have provided more detail on the known harms of saline vs balanced fluids. The AP story does mention the kidney disease risk with saline, but doesn\u2019t explore why physicians might be leery to use balanced fluids. As CNN explained:", "answer": 0}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nIn his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nSaid Tracy, \"We were told that I should prepare myself for the loss of functionality below the waist \u2013 including bowel, bladder and sexual functions.\nThe proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release tells readers that proton beam treatment poses fewer risks than other forms of radiation therapy, but doesn\u2019t explain what those risks are \u2014 or what risks proton treatment does pose. As the Mayo Clinic notes on its site, \u201cProton therapy can cause side effects as the cancer cells die or when the energy from the proton beam damages healthy tissue.\u201d Common side effects range from headaches and fatigue to soreness and digestive problems.\nSide effects from proton beam are likely the same as photon beam radiation but the selling point of proton is that it is more precise and thus the overlapping side effects should be fewer. But there have been few, if any, trials to compare proton and photon therapies which would supply the needed evidence to support the claim.", "answer": 0}, {"article": "Raji presented the findings here at the annual meeting of the Radiological Society of North America.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing HealthDay story, at least WebMD reminded readers:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 1}, {"article": "Hitachi has delivered the first hospital based spot scanning system in May 2008 and has treated over 1,500 patients to date.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nToshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nGiven the growing demand for technical and clinical advancements in the treatment of cancer, interest in proton therapy is on the rise, with more and more hospitals and cancer treatment facilities venturing into this area.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release gives the briefest mention of side effects, but we\u2019ll give it the benefit of the doubt.\u00a0The statement that PBT brings \u201cvery few side effects\u201d is understood to be true since proton beams deposit less radiation outside the tumor area than do photon-based treatments. However, there are few (if any) reports of clinical studies comparing the side effects of protons with those from photon treatments.\nIn addition, claiming that patients \u201cexperience no pain\u201d when undergoing proton therapy is slightly misleading, since the same can be said for photon-based radiation therapy.\nIt\u2019s important to point out that proton facilities don\u2019t typically use an advanced imaging technique (such as CT or MR) to verify the patient\u2019s position prior to administering radiation; whereas this is standard practice for photon IMRT techniques. That is troublesome, because the consequences of a geometric miss in proton therapy are expected to be greater than they would be for photon IMRT.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions potential harms associated with older sunscreen formulations (e.g. ashy color, ineffective when exposed to light)\u2014but says nothing about potential harms of the newer versions that are the story\u2019s focus. Do they cause allergic or photoallergic reactions? Could they give sun-lovers unwarranted confidence in the lotions\u2019 prowess? In an apparent paradox, increased use of sunscreen has been associated with the spiraling incidence of skin cancer. Is this because sunscreens are used improperly (as the article suggests)? Or do sunscreens have inherent weaknesses as well? ", "answer": 0}, {"article": "To test whether the bacteria could help fight cancer, researchers injected the tumors of 24 patients with a single dose of Clostridium novyi-NT, ranging from 10,000 to 3 million spores.\n\"Patients only had one week of exposure to the bacteria, but even with that limited exposure we saw quite interesting and, in some patients, clinically meaningful activity,\" Janku said.\nIn 2000, the U.S. Centers for Disease Control and Prevention reported that a handful of drug users in the United Kingdom fell ill or died after their injection sites became infected with the bacteria.\nYou would expect that the injected lesion would have some type of response because you're disrupting the tumor cells,\" Gnjatic said.\n\"What would be interesting is if this could prime an immune response that would eventually also take care of the non-injected tumors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that two patients in the trial who received the highest doses fell ill with sepsis and gangrene. It also mentioned a need to \u201ckeep an eye on potential side effects\u201d in future trials.", "answer": 1}, {"article": "The approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n\"These are patients who have been on drugs and may have had multiple angioplasties or CABG surgeries,\" AHA President Gordon Tomaselli, MD, tells WebMD.\n\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\nBlood was collected and processed to collect the stem cells, and then, using a catheter threaded into the heart, the researchers injected the CD34+ cells into areas of the muscle that had been identified as oxygen-deprived areas.\nThe new treatment came from the discovery about a decade ago that CD34+ stem cells stimulate the formation of new blood vessels, study researcher Douglas W. Losordo, MD, of Chicago's Northwestern University tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit for the following \u2013 although we think it was incomplete:\n\u201cAbout one in three patients had elevations of a cardiac enzyme that is associated with heart attacks. While the elevations did not appear to be clinically significant, Losordo says the researchers will continue to closely monitor cardiac enzymes in patients who receive the treatment.\u201d\nWhat does that mean?\u00a0 \u201cAssociated with heart attacks\u201d?\u00a0 How? Why? How often? In what past research?\u00a0 And what does \u201cdid not appear to be clinically significant\u201d mean?\u00a0 Did it cause any problems or didn\u2019t it?", "answer": 1}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\n\u201cThey throw up their hands and think, \u2018that\u2019s not for me.\u2019 But everyone does light physical activity, and the idea that doing more of it can have substantial health benefits should be welcome news.\u201d\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the NIH has noted, the benefits of physical activity far outweigh the risks. For that reason, we won\u2019t ding this story for not going into details regarding the risks associated with light physical activity. Nonetheless, it would have been nice to see the story mention that older adults may want to consult with a health professional to determine what types of activity they should (or should not) engage in.", "answer": 2}, {"article": "The majority of cases are caught at around 66.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nAlthough prostate cancer is the second leading cause of cancer death in the U.S. after lung, few risk factors have been found, and it is difficult to accurately diagnose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned PSA tests. which detects antigens that can be present in men without the cancer and \u201ccarries a risk of returning a false positive that can kick-start unnecessary, life-changing treatment.\u201d\nHowever, the story didn\u2019t explain that a genetic test would not necessarily prevent these harms, without a better test to detect actual cancers. While men found to be at low risk might be spared additional testing, those with genetic markers for prostate cancer might be subject to more aggressive interventions that could harm them.", "answer": 0}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\n\"In our analysis, daily aspirin use was associated with about a 16% lower risk of dying from cancer overall,\" Jacobs says.\nAmong them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201ceven low-dose aspirin can lead to problems such as serious gastrointestinal bleeding.\u201d\n\u00a0", "answer": 1}, {"article": "Russo says, \"One of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses, except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight or obese.\"\nThe researchers conclude that \"these findings provide positive evidence for the benefits of physical activity in women attempting pregnancy, especially for walking among those with higher BMI.\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nWhitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\n- Results of a recent study to better understand modifiable factors such as physical activity that may affect a woman's ability to conceive a child suggest that walking may help women to improve their chances of becoming pregnant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms from walking are likely not significant enough to warrant mention here.\nHere\u2019s a minor point:\u00a0 since vigorous activity is noted as beneficial to conception, this might warrant mention as something that a woman with other health concerns might consider consulting her doctor about.\nOtherwise, the issue of harms seems negligible enough to consider this N/A.", "answer": 2}, {"article": "The ChemMedChem study is available at http://dx.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\nThe RB analogs inhibited the ATPase activities of two SecA isoforms identified in S. aureus, SaSecA1 and SaSecA2, as well as the SaSecA1-dependent protein-conducting channel.\nBecause of the widespread resistance of bacteria to antibiotics on the market, there is an urgent need for the development of new antimicrobials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Any new drug developed from this research would have side effects. But whereas the release is optimistic in forecasting that such drugs would be effective treatments for MRSA, it doesn\u2019t also caution that such drugs might cause harm. At the very least, a statement about the fact that potential harms are unknown would have been helpful.", "answer": 0}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nHowever, in the elderly the differences between the treatment and placebo groups were much smaller, and the researchers calculated that 17 older patients would have to be treated with Prozac for one to gain from it.\n\u201cMore than 80 percent of the patients are not getting a significant benefit from the drug \u2014 either they\u2019re not getting better or they would get the same benefit with placebo,\u201d he told Reuters Health.\nIf five or more patients need to be treated with an antidepressant for one to substantially improve, most don\u2019t get much out of it, he pointed out.\nMost of those trials were funded and run by the pharmaceutical companies that manufacture Prozac and Effexor \u2014 Eli Lilly and Wyeth, respectively.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was at least the acknowledgement that these drugs do carry side effects \u2013 but none was specified nor quantified.", "answer": 0}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nAs a result, consumption of folic acid has been adopted by expectant mothers worldwide, and the addition of folate to our food supply has led to a 70% decrease in the number of babies born with neural tube defects.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\nVitamin B3 is required to make NAD and is typically found in meats and green vegetables as well as vegemite.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release made no mention of harms of niacin supplements. Niacin supplements are used clinically and have side effects when used in high doses. According to WebMD, these include a hot \u201cflush\u201d reaction that can be frightening. As dosage increases, other side effects may occur, including liver problems, ulcers, loss of vision, and irregular heartbeat. \nThere have been enough people worried about niacin side effects that the British Columbia Drug and Poison Information Centre has an FAQ page\u00a0about the supplement. ", "answer": 0}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nResults of those tests show lab rats that received the cardiosphere-derived cells:\n\u2022 Demonstrated longer heart cell telomeres, compound structures located at the ends of chromosomes that shrink with age\n\u2022 Improved their exercise capacity by an average of approximately 20 percent\n\u2022 Regrew hair faster than rats that didn't receive the cells\n\n\"This study didn't measure whether receiving the cardiosphere-derived cells extended lifespans, so we have a lot more work to do,\" said Lilian Grigorian-Shamagian, MD, PhD, co-primary investigator and the first author of the study.\n\"Our previous lab studies and human clinical trials have shown promise in treating heart failure using cardiac stem cell infusions,\" said Eduardo Marb\u00e1n, MD, PhD, director of the Cedars-Sinai Heart Institute and the primary investigator of the study.\n\"We have much to study, including whether CDCs need to come from a young donor to have the same rejuvenating effects and whether the extracellular vesicles are able to reproduce all the rejuvenating effects we detect with CDCs.\"\nThe CDCs, manufactured by Capricor Inc. (NASDAQ: CAPR) as their product CAP-1002, have been used in other human clinical trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of stem cell therapy are not mentioned, and it\u2019s impossible to know for sure what the risks of this intervention might be. Safety data appears to be limited. The published study states that cardiosphere-derived cells \u201care already in advanced clinical testing and have proven safe to date,\u201d but it cites just one article that was written by one of the same researchers, Eduardo Marban, who developed and owns a financial interest in the technology.", "answer": 0}, {"article": "The results so far are very promising.\nBased on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren's disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren's nodule tissue.\nThe trial was run by the UKCRC accredited Oxford Clinical Trials Research Unit (OCTRU), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s mentioned the researchers \u201cfound the drug to be safe and well tolerated.\u201d\u00a0 The associated research paper mentions \u201cthere were two serious adverse advents, both considered unrelated to the study drug.\u201d\u00a0 But no further information is provided. The release could have been more informative regarding potential harms from the drug.\nHumira has been documented to cause a host of side-effects. It carries a black box warning for compromising immunity, and has been reported to make people more prone to tuberculosis and skin cancer.\nOf note, these side effects were noted in patients given subcutaneous Humira. The Humira in this study was administered locally in the hand, which could be less likely to cause systemic side effects.", "answer": 0}, {"article": "TUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nSo, patients scoring at the lower end of risk for colon cancer might be able to have less invasive screening tests (such as the fecal occult blood test), while those at higher risk would require a colonoscopy, Imperiale's team concluded.\nAnd while some areas of the United States have rates of compliance with colonoscopy guidelines of 75 percent or more, \"many areas have poor colon cancer screening rates,\" he added.\nThe system might also make colon cancer screening more efficient and boost the number of people who get checked for the disease, said a team led by Dr. Thomas Imperiale of Indiana University Medical Center, in Indianapolis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm of a screening test such as this really is \u201cgetting it wrong\u201d in terms of predicting someone to be at low risk and finding them to have a higher risk polyp or malignancy. As noted above, the story cautions that \u201clow- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\u201d", "answer": 1}, {"article": "But if the beta-amyloid plaques that are the disorder's key physical hallmark could be detected before memory loss and cognitive troubles were evident to all, would you want to know?\nUntil recently, the diagnosis of Alzheimer's disease could be made only after a patient's death, when a pathologist could find physical evidence of amyloid plaques and neurofibrillary tangles.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nAmong patients diagnosed with mild cognitive impairment, about 60% have amyloid plaques and will go on to develop dementia that is likely Alzheimer's disease, said Dr. Michael W. Weiner of the Department of Veterans Affairs' Center for Imaging of Neurodegenerative Diseases.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story hints at the potential harm of receiving a positive test result at a time when there are no effective treatment options for Alzheimer\u2019s. However, harms were not addressed directly enough to merit a satisfactory rating, in our opinion. As with any diagnostic test, this test may cause harm from a false-positive result, which may create unnecessary anxiety, or a false-negative reading, which may create a false sense of security and delay appropriate management steps. The test is also radioactive and contributes to the patient\u2019s lifetime radiation exposure and cancer risk. None of these downsides is discussed in the story.", "answer": 0}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\n\"I cannot prove and I don't think anyone can prove that alcohol consumption can prevent anyone from dying or prevent heart attacks,\" says Kenneth Mukamal, an associate professor of medicine at Harvard Medical School, Boston.\nAnd heavy drinking is not good for anyone: It has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\n\"At those ages, any benefit we get from moderate drinking is only to the extent that someone who is moderately drinking is not heavily drinking,\" Mukamal says.\nBut, if you do drink, groups including the American Heart Association and U.S. Centers for Disease Control and Prevention recommend:\n\u2022 No more than two drinks a day for men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes a variety of potential harms associated with moderate drinking: excess calorie intake, increased blood pressure (among those with hypertension), and increased breast cancer risk in women.\nThe article also pointed out that heavy drinking is not good for anyone: \u201cIt has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\u201d", "answer": 1}, {"article": "What's lacking are clinical studies.\n\"It was the most amazing and grace-filled experience to finally have that moment of having my baby be placed on my chest,\" Caminiti says.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did not address specific harms per se, it did mention that there was a lack of clinical studies on this topic \u2013 implying that nobody really understands the potential risks of this approach compared to a typical C-section. The piece also pointed out that infection control is a potential concern with family-centered C-sections, and that hospitals would be slow to change their routines without hard evidence on infection rates. We think that\u2019s enough to merit a satisfactory rating here.", "answer": 1}, {"article": "Fried said sensory experiences that eventually become memories pass through this hub before they are stored in the hippocampus, the brain\u2019s chief memory center.\n\u201cThe entorhinal cortex is the golden gate to the brain\u2019s memory mainframe,\u201d Dr. Itzhak Fried, professor of neurosurgery at the David Geffen School of Medicine at UCLA, who worked on the study, said in a telephone interview.\nPacemaker devices known as deep brain stimulators made by Medtronic and St. Jude Medical are already used to calm muscle tremors in patients with Parkinson\u2019s disease and other movement disorders, and are being tested for a host of other conditions such as treatment-resistant depression.\nDespite costly efforts, no drug has been found that can keep Alzheimer\u2019s from progressing, and policymakers are growing increasingly worried about the swelling ranks of dementia patients as the population ages.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While this story (unlike the HealthDay story we reviewed) at least mentions that deep brain stimulation is \u201cvery invasive,\u201d it should have listed at least some of the major risks of implanting electrodes into the brain connected to stimulation devices under a patient\u2019s skin, including bleeding, strokes and infections.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nA larger part is at this point, we just don't fully understand what the genetic mechanism that leads to autism is.\"\nIf a parent is also found to have the abnormality, geneticists conclude that the couple is at higher risk of having a child with autism.\n\"CMA should be added to first-tier genetic testing for autism spectrum disorders.\"\nThe U.S. National Institute of Neurological Disorders and Stroke has more on autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion regarding the emotional or social ramifications associated with receiving genetic testing results.\u00a0 ", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Older adults are susceptible to sexually transmitted diseases like anyone else. Increased sexual activity might increase those risks.\nWe acknowledge that we\u2019re holding the bar high here, but unapologetically, especially with recent studies showing rising rates of STDs in seniors.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nBut, when the researchers looked at the dietary compounds individually, it was clear that berries could benefit both men and women, lowering the risk of Parkinson's disease by about 25 percent for those who had at least two servings of berries a week.\nDr. Michael Okun, medical director of the National Parkinson Foundation, said, \"It is exciting to see research emerging about modifiable dietary issues that may affect the risk of getting diseases such as Parkinson's.\"\nWhen researchers compared those who ate the most flavonoids with those who ate the least, they found that only men saw a statistically significant benefit, lowering their risk of Parkinson's by 40 percent.\nGao said it wasn't clear why only men benefited from the extra flavonoid intake, but he noted that other studies have also found differences between men and women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends most of its time discussing the potential health benefits of berries. We\u2019re not aware of any harm attributable to berry consumption (provided they are the edible kind).\nAnd the story included this quote from the author:\n\u201cThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\u201d Gao added.", "answer": 1}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThat is the same receptor in the brain targeted by the weight loss drug Fen-phen, which was popular in the 1990s.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nThe company plans to announce results of the first Phase 3 clinical trial of the drug at the end of March, Chief Executive Jack Lief said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although mentioning the heart valve problems which were seen to occur with the use of a different weight loss medication, there was no mention in this story of the side effects (headache, nausea, and dizziness) which were seen to occur with this medication during the relatively short period of time it was used. \u00a0The story also failed to mention whether weight re-gain was common after use of the medication was stopped. Harm is of particular concern with obesity drugs, particularly given the experiences with Fen-Phen which had a similar mechanism of action.", "answer": 0}, {"article": "Brooks hopes that more health workers will consider incorporating pets into care plans for people with mental illness.\n\"I think it's really hard when you haven't had a mental illness to know what the actual experience is [like],\" said one participant.\n\"I think there's significant value in considering the common everyday pet to be as important as the relationships one has with one's family in the course of their treatment,\" says Longsjo.\n\"There's like a chasm, deep chasm between us ... [Other people are] on one side of it, and we're on the other side of it.\n\"When I'm feeling really low they are wonderful because they won't leave my side for two days,\" one study participant with two dogs and two cats, \"They just stay with me until I am ready to come out of it.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. It is important to recognize that the patients reporting positive influences of pets are having a good experience already. Giving a pet to someone with a major mental illness, who has not previously cared for an animal, could go very poorly without the right support systems in place.", "answer": 0}, {"article": "Published online 29.10.2018. https:/\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nThe Kuopio Ischaemic Heart Disease Risk Factor Study ongoing at the University of Eastern Finland explored the associations of fermented and non-fermented dairy products with the risk of incident coronary heart disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since readers might interpret this study\u2019s results as supporting consuming more fermented dairy (much of which contains saturated fats), not mentioning the potential harms of consuming too much saturated fats is a shortcoming.", "answer": 0}, {"article": "Newswise \u2014 Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\nThis is why most doctors recommend \u2018active surveillance\u2019 for low-risk cancers,\u201d he said.\n- Radiation patients had similar urinary irritative symptoms to men on active surveillance, which is an improvement from previous studies with older radiation techniques.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study compared benefits and harms for three different situations: surgery, radiation and surveillance.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any effects, either positive or negative, of decreasing or eliminating cola consumption.", "answer": 0}, {"article": "Pain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\n\"You need to pay attention when you put them on, to see if you have any kind of skin reaction to the compounds that are contained in the patch,\" Rosenquist said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are quantified. Instead, the story relies on quotes that merely mention side effects. Interestingly, the story gives more space to the possibility of a skin reaction from the patches than it does the more serious potential harm. In one sentence it says, \u201cOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\u201d\u00a0 The story should have given some estimate of how often that\u2019s happened.", "answer": 0}, {"article": "But scientists at Stanford University say there may be a way to prevent jet lag without medication or adjusting your sleep schedule.\nThrough light therapy, the technique Zeitzer is experimenting with, a person's brain can be tricked into adjusting more quickly to disturbances in sleep cycles by increasing how long he or she is exposed to light prior to traveling to a new time zone.\nA team of researchers led by neurobiologist Jamie Zeitzer is working on a technique that exposes people to short flashes of light while they sleep to help them adjust more quickly to time zone changes.\nIt will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nOr they do nothing and suffer the exhausting consequences; the body eventually adjusts at a slow pace of about one hour a day, taking up to three days to catch up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0were no harms expressed in the article, nor was the word \u2018harm\u2019 mentioned in the published study. This is where an outside expert may have shined some light. As an expert quoted in a Reuters article stated, \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 0}, {"article": "Newswise \u2014 The first laser treatments used to treat skin conditions such as benign vascular birthmarks and port-wine stains were developed more than 40 years ago.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release refers to \u201csafety concerns\u201d of existing laser devices, including eye damage, but there are no details about the level of risk presented by this new device. Oddly, the abstract of the conference presentation and the upcoming journal article in Lasers in Surgery and Medicine that were mentioned in the release both highlighted concerns about discoloring or burning skin, something not mentioned at all in the release.\nNote: The conference abstract was behind a paywall which requires a journal subscription. A draft of the accepted journal article was provided upon request, but we urge those who send out news releases to automatically include primary source material.", "answer": 0}, {"article": "Here's the scientific proof.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nWith the widespread availability of marijuana in recent years thanks to its legalization in a growing number of states, there has been increasing concern about the long-term health consequences on teens who might be able to get easier access to it illegally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides\u00a0a list of the potential harms associated with marijuana use but it over-emphasizes the importance of this relatively small study in downplaying them \u2013 calling it \u201csurprising news\u201d that is \u201call good\u201d in the headline. And the second sentence says the study \u201cshould alleviate some of the worst fears.\u201d \u00a0That is too big a leap.\nThe story tried to describe the context of previous studies on marijuana but used this language \u201cother studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations.\u201d\u00a0As readers, we want to ask \u2013 did previous studies conclude there were risks? How can a study \u201cseem to allude?\u201d\nA recent review (N Engl J Med 2014; 370:2219-222) cited 69 publications examining the potential harms of marijuana use by the general population. \u00a0This one study is simply an addition to the growing body of evidence.", "answer": 0}, {"article": "Over the 18-year period, the number of breast cancers diagnosed at very early stages increased 66 percent, while the number of more advanced cancers (stage 3) decreased by 66 percent.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nIt also suggests that women aged 40 to 49 at average risk discuss the pros and cons with their doctors and decide on an individual basis if and when to start screening.\nWhile 4 percent of women whose cancer was found on mammogram died during a follow-up period that ranged from one to 20 years, 11 percent of those whose cancers were found by the doctor or the women died.\nThere was a decrease found in cancers being diagnosed at later stages in those whose cancers were found on mammograms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss why mammography in younger women is not always beneficial and described several of the harms that the US Preventive Services Task Force discussed.", "answer": 1}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\nNot a huge dent, but a significant one.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nIn 1956, the FDA approved 17-HP for the treatment of certain cancers and other hormonal disorders, under the brand name Delalutin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good discussion of concerns and ongoing monitoring of the drug\u2019s safety.", "answer": 1}, {"article": "\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\nThe women were matched on such factors as age and breast density, a risk factor for cancer, with higher density increasing risk.\n\"That helps explain the false positives,\" Audeh said.\nHe reviewed the study but was not involved in it.\nAfter surgery and radiation, he said, a woman's breasts have changed, and there is a greater chance that a radiologist will think that something is abnormal simply because of the changes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0discusses false positives & interval cancers & provides explanations of both of these problems associated with screening mammography.", "answer": 1}, {"article": "MORE: You Asked: Should I Take Probiotics?\n\u201cThe evidence at this point is promising,\u201d says McIntyre, \u201cbut it is not sufficient to justify recommending to patients as a viable treatment strategy.\u201d\n\nBut McIntyre says the results are encouraging.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\nIt\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0states that no serious side effects of the probiotic were reported, and this is sufficient for Satisfactory rating.\nIdeally it would have provided additional\u00a0information about\u00a0what would\u00a0constitute\u00a0a \u201cserious\u201d side effect. With\u00a0the way the story is\u00a0worded, it\u2019s possible that other side effects were reported by study participants. This is important information to have in order to\u00a0compare to other treatments for depression or IBS.", "answer": 1}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\n\"Some harms are mentioned, but it's entirely unclear how they were considered when coming up with the recommendations,\" says Milo Puhan, a physician and epidemiologist at the University of Zurich and senior author of the new study.\nYet both the new guidelines and the latest study agree on an important point: Doctors and patients should spend more time reviewing the benefits and risks of statins, with attention paid to each person's particular circumstances.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\n\"I think for me, as a physician,\" says Ilana Richman, an internist at the Yale School of Medicine, \"this kind of data suggests that if we give more weight to the potential for adverse events, then maybe it's reasonable to hold off for lower-risk patients.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a service by highlighting the harms of statins. It explains: \u201cThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines. People taking statins are also at a higher risk of developing diabetes, which is harder to reverse.\u201d\nIt also mentions the potential for overtreatment with the use of coronary calcium scans.\nHowever, we wish it had included absolute numbers. The story says harms are \u201cuncommon,\u201d but provides no data to back that up.\nRates of adverse effects with statins have been measured at 1 to 10%, which makes them \u201ccommon\u201d in the definition of the European Medicines Agency. Also noteworthy is that some contend that adverse effects of statins have not been reliably reported.", "answer": 1}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the harms of hormone pills. ", "answer": 1}, {"article": "He is also the co-founder of Neuro-Luminance Ketamine Infusion Centers.\nThe study, \"Practical application of the neuroregenerative properties of ketamine: real world treatment experience,\" addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\n\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nCiting over 60 published scientific research studies, the new research article also reviews the molecular mechanisms by which ketamine invokes a robust activation of the brain's own repair mechanisms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible side effects in the news release, other than to challenge the broader psychiatric community\u2019s belief that ketamine is addictive. The author is quoted saying, \u201cOur patients get better after a few infusions and from there treatments can be discontinued.\u201d\nIn contrast to the release, the study did point out some side effects, which should have been included in the PR release. It states, \u201cThe most common side effects in doses used for depression treatment include: dizziness, nausea, and a slight sense of dissociation. The side effects clear generally within 15-30 minutes after the infusion.\u201d", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out that a major side effect of the new drugs is anemia, and more than 40% of patients in the boceprevir studies required erythropoietin to combat it; however, the story should have noted that over 20% of patients in the control groups also became anemic. In addition, there was a high drop-out rate in the two trials, which should have been mentioned. Why did so many drop out? \n ", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that mild heartburn was the only side effect seen in the study, and that larger long-term studies are needed to establish safety. \u201cI would tell a patient the caveat is, \u2018If you want to try it, you need to be aware that we don\u2019t really know its side effects,'\u201d a researcher says.\nWe\u2019d also add that the herbal supplement industry is not regulated or controlled in the same way as the pharmaceutical industry, i.e. there are fewer restrictions and enforcement, so relying on supplements to treat a condition can pose additional risks from potentially poor-quality or contaminated products.", "answer": 1}, {"article": "Funding for HAB comes from Hass avocado producers and importers in the United States.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nAs we head into American Heart Health Month (February) it's important to remind people that they have the power to help control their risk factors for developing heart disease by exercising regularly, knowing cholesterol levels and keeping them under control and maintaining a healthy weight.\nCardiovascular disease is responsible for one out of every four deaths; it is the number 1 killer of American women and men, and it is a leading cause of disability.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It could have been noted that adding an avocado or two a day to one\u2019s diet would also add to daily caloric intake. An average avocado has around 250 calories and 21 grams (about one-third of the recommended daily allowance) of fat.\u00a0Additional caloric intake can result in weight gain and stored fat, which in turn impacts metabolic markers (such as increased insulin production and inflammatory markers) and cardiovascular risk.", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes sources claiming \u201cYou\u2019re going to be sparing individuals side effects\u201d and it describes Xalkori as \u201ca pill with relatively minor side effects compared to the hair loss and nausea that chemotherapy can cause\u201d. The drug label and FDA news release are less dismissive of the problems experienced by patients in the preliminary trials so far.\nWhile few trial participants reported symptoms severe enough to cause serious harm, hospitalization or symptoms so bad they couldn\u2019t carry on routine activities, most of the patients did report problems with vision and more than half reported nausea, diarrhea, vomiting or other gastrointestinal symptoms, including some that may have required treatment. Treatment was interrupted in 36 percent of the patients in one of the trials and 45 percent of the patients in the other trial. Five percent of patients had neutropenia, abnormally low white blood cell counts. (See http://labeling.pfizer.com/showlabeling.aspx?id=676) \nThe FDA news release included a list of side effects and warned of potentially life-threatening reactions. \u201cThe most common side effects reported in patients receiving Xalkori included vision disorders, nausea, diarrhea, vomiting, swelling (edema), and constipation. Vision disorders included visual impairment, flashes of light, blurred vision, floaters, double vision, sensitivity to light, and visual field defects. Xalkori use has also been associated with inflammation of the lung tissue (pneumonitis), which can be life-threatening. Patients with treatment-related pneumonitis should permanently stop treatment with Xalkori. The drug should not be used in pregnant women.\u201d (See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm)\nThe story should have summarized these side effects and warnings. It should have also noted that since the trials reported by Pfizer included only 255 patients, little is known about the potential risk of rare, but serious, side effects.", "answer": 0}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nMark Thomas, who researches addiction at the University of Minnesota Health Sciences, says that a vaccine like this could help a former heroin abuser, \u201cforge a path to abstinence.\u201d Thomas, who was not involved with the study, explains that he was initially wary of the vaccine approach.\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\nBut in light of the growing drug abuse epidemic, for which, he says, \u201cwe have so few tools,\u201d adding a vaccine to the available treatments could help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes\u00a0\u201cThe researchers did not observe any harmful side effects from the intervention.\u201d Having said that, again the study was conducted in four monkeys under highly controlled lab conditions\u2013not in humans. The comment of one of the authors, \u201cWe believe this vaccine candidate will prove safe for human trials,\u201d feels premature. On what grounds does he believe this?\nTo have passed this criteria, the story should have said the harms are\u00a0unknown.", "answer": 0}, {"article": "TUESDAY, Aug. 16, 2016 (HealthDay News) -- An experimental drug appears to reduce the risk of bone fractures in postmenopausal women with osteoporosis better than a placebo and the currently available drug, a new study finds.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\nAlong with building bone density, they are the only ones that increase bone quality, he said.\nAmong the nearly 2,000 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo, the researchers found.\n\"I am hoping that having a second drug available, that it will help reduce the cost,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists nausea and heart palpitations among the serious side effects of both abaloparatide and Forteo.", "answer": 1}, {"article": "Although the difference between the treated patients and those given the placebo in the trial might appear modest, Dr. Joan T. Merrill, a lupus expert at the Oklahoma Medical Research Foundation, said Benlysta\u2019s safety and its ability to reduce steroid use would make it attractive to doctors.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nMore patients on the drug had the required improvement in symptom severity.\nOn Friday, it closed at $3.32 a share.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not include any insight about potential harms or side effects that have been seen to date with the use of this drug.", "answer": 0}, {"article": "The drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nShe said Geier plans to continue the Lupron for several months to see if it helps Marco's other autistic behavior.\nGeier could not be reached for comment despite several attempts by phone.\nIt's not recommended for people with heart disease, kidney disease, asthma, depression or seizures because it can worsen those conditions.\n\"We were basically under seige in this house,\" Badillo said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job dedicating quite a bit of discussion to potential harms from this approach \u2013 both known and unknown. ", "answer": 1}, {"article": "\u201cI hope insurance companies will look at this and realize that early detection and surgery, if appropriate, will ultimately save them money in the long term.\u201d\n\nSOURCE: bit.ly/2gVClQv The New England Journal of Medicine, online October 25, 2017.\nBehavior and quality of life also improved.\n\u201cThe results are impressive,\u201d he told Reuters Health by phone.\nThe surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\n\u201cThe child may not be able to ambulate by his- or herself.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained but again without much quantification.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that deep breathing may cause people with asthma or panic disorders to hyperventilate and that a different breathing pattern is often recommended for these patients. The story could have mentioned exercise or psychological techniques for reducing stress and improving health, many of which are supported by stronger evidence.", "answer": 1}, {"article": "And 52 received lower doses averaging between 400-1,000 units daily.\nThe falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\n\"After studying these patients for a year, we found a 40 percent reduction in acute respiratory illness among those who took higher doses of vitamin D,\" said the study's lead author, Adit Ginde, MD, MPH, professor of emergency medicine at the University of Colorado School of Medicine.\n\"If our results are confirmed by a larger trial, high dose vitamin D, ideally using daily dosing to minimize fall risk, has the potential for substantial public health benefit through ARI prevention for the large and growing population of long term care residents,\" Ginde said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the higher doses of vitamin D also had unintended side effects. It reports that the number of falls in the high dose\u00a0group was significantly increased, although according to the study, the number of hip fractures was not different in the two groups.\nThe release meets our standard here, but the finding of more falls should arguably have received more emphasis. Falls might lead to more hip fractures, which could cancel out any \u201clifesaving\u201d benefits from reduced rates of respiratory infection. ", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\nThe presentation has taken place within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) that has been held from the 29th of April to the 3rd of May in Honolulu, Hawaii.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Likewise, there is no mention of potential harms that use of tivanisiran might cause to patients. Since one of the earlier studies was a safety trial it would have been appropriate to include those results in the release.\u00a0\u00a0", "answer": 0}, {"article": "While the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\n\"There are a number of cancers which are not localized,\" he said.\nProton treatment is limited on Britain's National Health Service.\nThe other drawback is that the cyclotron is not cheap.\nOnce the proton beam has been generated, it's piped into a treatment room where patients receive a powerful dose of targeted radiation that kills only those cancerous cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm that is suggested is the lack of availability of the treatment.", "answer": 0}, {"article": "For more information, visit http://www.\n\"Prostate cancer still represents one of the main causes for cancer-related deaths among men,\" said Matthias Eder, PhD, co-author of the study and a researcher in the division of radiopharmaceutical chemistry at the German Cancer Research Center in Heidelberg, Germany.\nThe current clinical methods are not sensitive enough for detecting disease beyond the prostate, but we are convinced that this novel theranostic radiotracer represents a significant step forward that could have a major impact on the future of prostate cancer care.\"\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is not really addressed \u2014 or addressable \u2014 given that only one patient has been treated. The release discusses previous drugs of this type that had problems, and mentions \u201cadverse effects\u201d associated with existing therapies. The suggestion is that this drug does not have those problems and would be a safer alternative to existing therapies. But there\u2019s no way we can assess the safety of this approach based on results in only patient. So the release is incomplete and potentially misleading in its discussion on this point.", "answer": 0}, {"article": "For now, he suggested that people choose olive oil and other unsaturated fats over saturated fats (found largely in meat and dairy) and trans fats (found in some processed foods, like crackers, cookies and chips).\nAnd after they did, olive oil was still linked to a lower stroke risk.\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nOlive oil is a key ingredient in the so-called Mediterranean diet.\n\u201cWe need to remember that this is an observational study,\u201d said Dr. Nikolaos Scarmeas, a neurologist at Columbia University Medical Center in New York who wrote an editorial published with the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "2018;59:160-172.\nThe researchers speculate that it may be due to the polyphenols (anthocyanins and other flavonoids) in Montmorency tart cherries, the varietal of tart cherries grown in the U.S. Polyphenols in plant-based foods are broken down by microbes to stimulate growth of good bacteria.\nIn the human trial, the microbiome was positively altered (primarily measured by the increase in good bacteria) after just five days of drinking Montmorency tart cherry concentrate, although there were strikingly different responses due to the participants' initial microbiome composition.\nLANSING, Mich. August 7, 2018 - Montmorency tart cherries may play a role in improving gut health, suggests a first-of-its kind human trial of nine adults combined with a parallel laboratory study published in the Journal of Nutritional Biochemistry.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned.\nSeveral tart cherry juices on the market contain substantial amounts of sugar. This is germane since \u2014 among the host of diseases cherry juice is claimed to be good for \u2014 there are claims that tart cherry juice is actually \u201cgood for diabetes.\u201d\nAlthough the amounts used in this study were modest, it\u2019s worth noting that some readers might think \u201cmore is better\u201d and drink enough to substantially elevate their blood sugar.\nFurther, most physicians do not recommend juice as a source of nutrition, but rather the whole fruit.", "answer": 0}, {"article": "So what is it about tai chi that works?\nSince it is a low-impact, gentle, non-threatening, accessible activity, it may be a perfect exercise for debilitated patients with fibromyalgia who otherwise cannot or choose not to do other forms of exercise,\" Yeh said.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\nAbout 10 million Americans have fibromyalgia, and about 75 percent to 90 percent of them are women, according to estimates from the National Fibromyalgia Association.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not identify any possible harms. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The NEJM authors clearly state: \"No adverse events were noted during the study interventions.\" The study did not consider worse muscle soreness to be an adverse event so long as it resolved before 3 days\u2019 time, so we don\u2019t know how much of that occurred in either arm of the study. So why not drop in a line about the lack of adverse events? Wouldn\u2019t a reader be interested that this exercise appears safe?", "answer": 0}, {"article": "The patient blows a single breath into a specialized balloon.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\nThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels in the control group.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that the test could potentially reduce harms by reducing a patient\u2019s repeat exposure to radiation from CT scans. However, the harms of the test itself \u2014 i.e. false positive screens that cause substantial anxiety and necessitate additional testing \u2014 are not addressed. \nAs noted above under \u201cWhy This Matters,\u201d the concern is that using this test to guide surveillance testing (whether to order the CT) could be a problem if the test is not actually very accurate when used in that role \u2014 false positive and particularly false negative results could lead to harms. We have no data (certainly not from the study in question) that could address these concerns.", "answer": 0}, {"article": "the bigger issue though is, is the increased costs associated with protons worth it to society?\nHuge magnets direct the beam of radiation the length of a football field into treatment rooms.\nThe massive facility at the University of Pennsylvania - soon to be the world's largest - will cost $140 million.\n\"The beam will travel thru these magnets and that will steer the beam into the different rooms.\"\nThat's because proton beam radiation is highly targeted - delivering its dose only to the tumor and sparing the surrounding tissue, which is important for certain rare cancers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of proton beam therapy.", "answer": 0}, {"article": "\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\nAmid all the debate, many specialists are wondering if women on bisphosphonates should take a \"holiday\" from the drug from time to time.\nLast fall the Food and Drug Administration issued a \"safety update\" urging doctors and patients to be on the lookout for the problem.\nMoreover, the study verified that long-term use of bisphosphonate drugs reduces the risk of typical osteoporosis fractures by 24 percent.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NPR does a good job of parsing the harm described in the JAMA article. Extra credit for including the notion of a \u201cdrug holiday\u201d that is a practical reaction from treating physicians to a confusing landscape of discoveries about these drugs.", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The risk of harm in elective c-sections is the focus of the study, and the news report explains them well. ", "answer": 1}, {"article": "Scientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nBased on our discovery, the already approved drug Denosumab or other future drugs that will block RANKL/RANK, could be used for breast cancer prevention in BRCA mutation carriers,\" explains Verena Sigl.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Denosumab \u2014 as well as carrying out genetic testing \u2014 comes with harms, none of which are mentioned in the release. Denosumab is described as \u201can antibody with very few side effects,\u201d but this does not accord with the results of a online drug database\u00a0which\u00a0shows a lengthy side\u00a0effects list, some of which are serious.\nDenosumab was approved by the FDA for osteoporosis in postmenopausal women in 2010 and for giant cell tumor of the bone in 2013. It carries an increased risk of osteonecrosis (a painful condition caused by reduced blood flow to the bone which causes it to die) of the jaw and femoral hip fractures, increased infection susceptibility, and low calcium levels in the blood, among others. Women at risk might be expected to take such a drug for decades.", "answer": 0}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\nWhile it\u2019s not certain how the mineral curbs colds, it appears to have antiviral properties that prevent the cold virus from replicating or attaching to nasal membranes.\nWhen taken within 24 hours of the first runny nose or sore throat, zinc lozenges, tablets or syrups can cut colds short by an average of a day or more and sharply reduce the severity of symptoms, according to the Cochrane Database of Systematic Reviews, a respected medical clearinghouse.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nA March 2008 report in The Journal of Infectious Diseases, for example, found that zinc lozenges cut the duration of colds to four days from seven days, and reduced coughing to two days from five.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pointed out that nasal zinc products, associated with loss of smell, were not evaluated in the Cochrane review and it\u00a0quotes one of the authors of the study suggesting that the potential harms of zinc products are limited to a bad taste and some nausea. However, the full listing includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. \u00a0\u00a0 \n\u00a0", "answer": 0}, {"article": "\u201cThat was the biggest drawback.\u201d\n\nDr. Neil Spielholz, of Nova Southeastern University in Fort Lauderdale, was involved with the initial study submitted to the FDA - the same one that showed the success of laser treatment in UK smokers.\nThose in the three treatment group, in turn, had better success rates than a control group that was given fake laser treatments.\nThe lack of any drugs involved in laser therapy \u201cwould be the beauty of this,\u201d he said.\nIn response, Laser Therapeutics is designing another study to address those comments, he said.\nIn that session, the laser is pointed at spots on the face, hands and wrist, with the aim of relieving withdrawal symptoms and preventing cravings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address the potential harms of laser therapy, which was surprising given how careful the story is in other regards.", "answer": 0}, {"article": "Studies in 2007 and 2008 suggested that stented arteries faced a higher risk of blood clots, potentially triggering heart attack a year or more down the road.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\n\"We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,\" said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb.\nThe Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text offers a list of complications found with the new device, apparently recorded in the clinical trial: allergic reactions, infections, internal bleeding. And it gives us quantified information on \u201cheart-related complications\u201d for both the dissolvable and metal stents.\nBut the story\u2019s main message is that we simply do not know if these stents cause complications over the long term.\u00a0 It does quote a source who helped conduct the clinical trial for Abbott and who describes the \u201ctheoretical\u201d reason for the new stents as allowing arteries to return to their \u201cnormal\u201d shapes after the stents dissolve and, thus, prevent the kinds of problems that afflict permanent mesh stents, including a higher risk of blood clots.\u00a0 But the only study mentioned by the story, and by Abbot Labs in a news release, lasted a single year, while the stents are designed to completely dissolve over the course of three years.", "answer": 1}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\n\u201cThe prototype dressing mimics this physiological process, and while it has proven to create an optimal environment where chronic wounds can heal, we are always looking for new ways to keep pathogens under better control.\u201d\n\nRoy notes that chronic wounds are particularly susceptible to infection because bacteria, which at times are free floating within a wound \u2013 can sometimes mobilize, creating colonies covered by a thick sticky coating called a biofilm.\n\u201cA wound naturally produces its own electrical fields that help reduce bacteria and promote cell regeneration; however, this function is likely impaired in chronic wounds,\u201d said Sashwati Roy, PhD, an Associate Professor in the Department of Surgery at Ohio State\u2019s College of Medicine.\n\u201cWe\u2019re hoping this new design may allow electric fields and currents to penetrate more deeply into wounds, and really get to where these biofilms may be hiding,\u201d said Subramaniam, chair of the Department of Mechanical and Aerospace Engineering at Ohio State.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from the technology.\nAccording to an article in DermatologyTimes, \u201cPatients who are allergic or sensitive to silver, zinc and/or polyester should avoid using Procellera. In addition, patients undergoing magnetic resonance imaging, electrocardiogram or electroencephalogram should avoid using Procellera.\u201d The information was provided by a physician-consultant to the manufacturer. ", "answer": 0}, {"article": "\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nPeople who drank three to four cups per day had about a 25% lower risk than those who drank two or fewer cups per day.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of the potential harms of drinking large quantities of coffee or tea.\u00a0 ", "answer": 0}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\nCommon symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nClinical remission was defined as a CDAI score down to 150.\nThose who received 1 mg/kg had a 36.6 percent response rate and the 3 mg/kg dose led to a 34.1 percent response rate.\nMany Crohn\u2019s patients require surgery when medicines no longer control symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "WASHINGTON -- Bacteria live on everyone\u2019s skin, and new research shows some friendly germs produce natural antibiotics that ward off their disease-causing cousins.\nBut those good bugs are rare in the skin of people with atopic dermatitis, Gallo said.\nThose patches of dry, red, itchy skin are at increased risk of infections, particularly from a worrisome germ known as Staphylococcus aureus.\nThis community \u2014 what scientists call the microbiome \u2014 plays critical roles in whether we stay healthy or become more vulnerable to various diseases.\n\u201cWe\u2019re encouraged that we see the Staph aureus, which we know makes the disease worse, go away,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have explained that the harms are unknown\u2013more testing must be done before a better understanding of the risks and benefits emerge.", "answer": 0}, {"article": "The German analysis found only five such studies.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\n\"This article holds no surprises whatever,\" said Dr. Uwe Joseph Schoepf, a professor of radiology and cardiology at the Medical University of South Carolina.\nTUESDAY, Feb. 2, 2010 (HealthDay News) --When a doctor wants to assess the condition of heart arteries without putting a gadget into those blood vessels, the X-ray technology called computed tomography -- more commonly called a CT scan -- is better than magnetic resonance imaging, or MRI, a German review of studies has found.\n\"For ruling out coronary artery disease, CT is more accurate than MRI,\" researchers from Humboldt University in Berlin said in a report in the Feb. 2 issue of the Annals of Internal Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story highlights the presumed advantages of CT scans, there isn\u2019t a single word about potential harms. That includes the radiation exposure leading to risks for cancer, which are acknowledges in the introduction to the\u00a0published study. (According to the most recent estimates, the risks may be in the neighborhood of one case of cancer for every 800 individuals scanned.)\u00a0The story also leaves out\u00a0the specificity results of this research, ignoring the rates of false positives and their potential harms.", "answer": 0}, {"article": "\u201cI\u2019ll never forget that feeling,\u201d said Ms. DiGiusto, 65, a speech pathologist in Braintree, Mass.\n\u201cThe feeling that I\u2019m never going to see my kids or husband again and that asthma is finally going to get me.\u201d\n\nTwo years ago, Ms. DiGiusto\u2019s doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.\n\u201cThere will not be millions of thermoplasty patients.\u201d\n\nStill, even patients with severe asthma often are denied insurance coverage for the procedure.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nAnd researchers at Washington University School of Medicine found that compared with a control group, bronchial thermoplasty patients saw their asthma attacks drop by a third, their emergency room visits fall by 84 percent, and the number of days they lost from work and school drop by 66 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers to 5-year studies suggesting that the procedure is safe, and suggests that short-term problems consist of\u00a0\u201ctemporary coughing, mucus and other respiratory symptoms brought on by irritation of airways.\u201d This understates the severity of adverse effects\u00a0seen\u00a0while patients are receiving active treatment. In the trial mentioned above, 16 patients\u00a0in the bronchial thermoplasty group had to be hospitalized for asthma-related complications during treatment,\u00a0compared with only 2 patients in the control group.", "answer": 0}, {"article": "At the top of the list?\nThis means that a single 200-calorie sugary drink may be OK for a person who typically consumes a 2,000 calorie-per-day diet.\nEating More \u2014 Or Less \u2014 Of 10 Foods May Cut Risk Of Early Death\n\nAbout half of all U.S. deaths from heart disease, stroke and Type 2 diabetes are linked to poor diets, according to a new study published in the Journal of the American Medical Association.\n\"This is a remarkable burden, nearly 1,000 deaths each day\" linked to dietary habits, says senior study author Dariush Mozaffarian, dean of the Friedman School at Tufts.\n\"Our research suggests that nearly half of the risk can be reduced [by] eating a healthy diet,\" Mozaffarian says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The likelihood of suffering harm from adopting any of this diet advice seems low, though concerns have been raised about the health effects of cutting sodium to very low levels. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "But getting the treatment to the right target in the body has presented a challenge.\n\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nIn the approach used by Davis and colleagues, once the particles find the cancer cell and get inside, they break down, releasing small interfering RNAs or siRNAs that block a gene that makes a cancer growth protein called ribonucleotide reductase.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\n\u201cThis is the first study to be able to go in there and show it\u2019s doing its mechanism of action,\u201d said Mark Davis, a professor of chemical engineering, who led the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says this was a phase 1 clinical trial \u2013 the main purpose of which is to determine safety of an experimental intervention.\u00a0 Yet the story says the lead investigator could not say if there were any safety concerns.\u00a0 Huh?\u00a0 We can understand not leaping to conclusions after tests on just three tumor samples (although, as noted,\u00a0 the story tended to do anyway), but shouldn\u2019t the story have at least probed for potential safety concerns with this approach?\u00a0 \nIn fact, the use of siRNA in experiments like this is in its infancy and as such little is known about the existing side effect profile.\u00a0 High on the list is the potential for the agent to have unexpected and non specific effects called off-targeting.\u00a0 Off-targeting is the potential largest liability of the approach, possibly resulting in inadvertent turning off or on of non-targeted genes.\u00a0 This collateral damage is a significant challenge to the use of siRNA even with nano-directed treatments.\u00a0 A more balanced story would have noted the potential downside of the approach.", "answer": 0}, {"article": "Massage therapy increases the activity level of the body's white blood cells that work to combat viruses.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\nTo find a massage therapist near you, the American Massage Therapy Association (AMTA), the most trusted name in massage therapy, offers a free professional massage therapist locator service at www.findamassagetherapist.org.\nThe American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although massage is generally considered a \u201csafe\u201d therapy, it is still an intervention and not free from risk, particularly among those with musculoskeletal issues. Massage can cause soreness and also directly cause new injuries, exacerbate existing problems, distract patients from more appropriate care and mildly stress the body.\nSince harms were not mentioned at all in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "However, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nThe most common side effects patients undergoing viscosupplementation may endure are flare-ups - where the knee becomes hot and swollen within 24 hours after the injection - and effusions, where excessive joint fluid collects inside the knee.\n\"This is most effective in relatively younger patients, 40 to 50 to 60 year olds, and...in people with mild to moderate forms of the disease,\" says Richmond.\nThe effect of the injection used in viscosupplementation is to stimulate cells in the knee to increase production of hyaluronic acid.\n\"We have an epidemic of osteoarthritis of the knee and we have limited treatment options,\" says Dr. Richmond, who was not affiliated with the analysis but who reviewed the same data it was based on.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, the story states that the meta-analysis found \u201cpotential for harm.\u201d\u00a0 Further, it reported:\nThe most common side effects patients undergoing\u00a0viscosupplementation\u00a0may endure are flare-ups \u2013\u00a0 where the knee becomes hot and swollen within 24 hours after the injection \u2013 and effusions, where excessive joint fluid collects inside the knee.\u00a0 The researchers in\u00a0Switzerland reviewed the existing studies and\u00a0concluded\u00a0that\u00a0viscosupplementation was associated with an increase in these and other adverse events.\nBut there was no description of how often this was seen \u2013 making the issue almost useless to readers. Is it 1 in 100 patients?\u00a0 10 in 100?\u00a0 50 in 100?", "answer": 0}, {"article": "\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms mentioned by this story include PPHN, newborn withdrawal from antidepressants, and \u201ca small risk of heart defects.\u201d This is responsible \u2013 and enough for a Satisfactory rating. The story could have gone further by quantifying these harms and mentioning the potential harms of untreated depression, which aren\u2019t noted in the story.\u00a0As noted by the study author in the competing HealthDay story: \u201cUntreated depression or anxiety during pregnancies has been linked to different adverse health outcomes, such as miscarriage, preterm birth, pre-eclampsia and smaller newborns,\u201d Huybrechts said.", "answer": 1}, {"article": "ET, or more than twice their 25-day average trading volume.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "AST OPC-1 just completed its phase 1/2a clinical trial, which essentially evaluates the safety of the therapy. The three patients in the trial have not shown any serious adverse events, and the story reports this. However, we think the story could made it clearer that that is very early data, and that harms resulting from the therapy remain to be seen. This is the first stage of a three-step dose escalation trial and the dose used was the lowest envisioned. It\u2019s certainly possible that adverse events not seen at a low dose will occur more frequently with a higher dose of the therapy.", "answer": 0}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\nIn a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\nThe findings fit with current federal dietary guidelines, which recommend up to one drink per day for women and just to two drinks per day for men.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cautions that higher levels of alcohol intake are not protective, remedying an important\u00a0deficiency in the competing WebMD coverage. But\u00a0it\u00a0doesn\u2019t really address the\u00a0uncertainty about whether moderate alcohol intake might increase the risk for some diseases such as breast cancer or pose other potential harms. As such, it doesn\u2019t fulfill the criterion.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story implies the likelihood of death after two years\u201342 percent. \nIt also cites potential harms that include inability to monitor blood pressure and potential damage to brain, kidneys and other organs. \nYet the story fails to mention other harms that were described in the New England Journal study: stroke [18 percent], infection [35 percent], sepsis [36 percent], transfusions and surgeries for bleeding, and replacements. After implantation, patients were in the hospital for an average of 27 days.\nThese are not insignifiant risks of harm. The story earns a satisfactory under this criterion only barely. ", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the devices can produce ozone which, in some concentrations, can be harmful.\u00a0 It also cites one case where a similar device exploded during an air flight, mentioning that no one was seriously injured.\u00a0 It seems fair to consider the story satisfactory for this criterion.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.To schedule an interview, please contact Krysten Carrera, 301-496-3583, NIDDKMEDIA@niddk.nih.gov.\nThe NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases.\nLed by scientists at the Phoenix Epidemiology and Clinical Research Branch, part of NIH\u2019s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the team studied a total of nine men and women with obesity who resided in the Branch\u2019s metabolic ward on two separate visits, each for eight days.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not contain a single sentence regarding whether there might be harms if this technique were expanded and used in a wider setting as a treatment for obesity. We wondered: Would people get used to the stimulation if it were used on a long-term basis and stop showing the \u201cbenefit?\u201d Are there other cognitive abilities that are in any way muffled by the stimulation? The release should at least acknowledge that there could be potential harms uncovered in further study. The limitations section of the paper itself even states that is was not entirely clear that the treatment reached the targeted brain areas and not other areas. We find this concerning if not a bit alarming.", "answer": 0}, {"article": "\u201cIt might not be people smoking marijuana,\u201d Kaminski said.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\nNewswise \u2014 EAST LANSING, Mich. \u2014 A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is nothing in the release about the harms of ingesting or smoking marijuana. The release (nor the study) never mentions specifically how the HIV patients consumed their marijuana \u2014 whether through smoking, edibles, cannabis oil or other means, or any potential risks associated with any of the methods.\nAnytime we inhale smoke into our lungs we are taking a risk. At a minimum, some of those risks should be mentioned. And, better yet, if the study did not adequately track patients to assess the negative effects of marijuana smoking or otherwise ingesting, that should be acknowledged.\nIt\u2019s likely that the negative impact of marijuana was not mentioned because the study was in vitro (using blood samples). However, that underscores the fact that no true clinical correlation can reasonably be made from this study alone.", "answer": 0}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nThe risk factors measured in the study included elevated blood pressure (above 120/80 mg/Hg), high cholesterol, high insulin levels in the blood and abnormally high levels of C-reactive protein, an indicator of inflammation in the body.\n\"If you have very high blood pressure or lipids [cholesterol] or diabetes, you do see cardiovascular changes even at a very young age,\" Raghuveer says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the weight-reduction procedures \u201ccarry the same risks as any surgical procedure, such as infections, blood clots and bleeding\u201d as well as nutritional and vitamin deficiencies. It also states that gastric banding \u201chas low effectiveness and a risk of the band slipping down the stomach.\u201d Note: The most risky complications (problems arising from general anesthesia) were not mentioned.", "answer": 1}, {"article": "Carl Dieffenbach, AIDS chief at the National Institute of Allergy and Infectious Diseases, agreed.\n\"The overall goal is to not have to take medication, and then hopefully lead maybe to a cure.\"\nEven if the new approach doesn't get rid of HIV completely, it may repair patients' immune systems enough that they can control the virus and not need AIDS medicines - \"what is called a functional cure,\" he said.\nThe cell transplant appears to have cured both problems, but finding such donors for everyone with HIV is impossible, and transplants are medically risky.\n\"The idea is if you take away cells the virus can infect, you can cure the disease.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job in saying:\u00a0\u201cThe only side effect was two days of flulike symptoms. It will take longer to determine safety\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the potential harms of oophorectomy, including heart disease, hip fractures and now, potentially, neurological deficits.", "answer": 1}, {"article": "Johnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys, in which the animals were also found to be protected.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides just enough information to get a flavor for the potential harms without overly dramatizing them. Example: \u201cThe volunteers got one of three doses \u2013 low, medium, or high \u2013 and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\u201d And: \u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish.\u201d", "answer": 1}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nThe use of MDMA in psychotherapy has been studied for decades, but research in the U.S. all but ground to a halt after the drug became illegal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It does not quantify the potential harms. It does, at least, mention a few of the dangerous effects of the drug. \"Don\u2019t try this experiment at home. Ecstasy use can cause depression, severe anxiety, and potential cognitive problems, according to the National Institute on Drug Abuse. And when purchased on the street it can be contaminated.\" The possibility of an overdose would have been a nice mention.", "answer": 0}, {"article": "So researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The downsides of medical screening or diagnostic tools were left unmentioned. \u00a0This is an unfortunate lost opportunity to explain to readers that any diagnostic or screening technology, while potentially lifesaving, could potentially harm as well. What if, for example, it flags someone as sick when they\u2019re not \u2014 leading to unnecessary anxiety or treatment? And what if it detects a disease that would never cause the patient symptoms and yet the patient gets treated anyway? What if it misses someone who is sick and provides them with false reassurance?", "answer": 0}, {"article": "Those drugs could not be used, however, until they received emergency use authorizations from the F.D.A.\n\u201cIf you have a critically ill patient, to delay therapy, it\u2019s just incomprehensible to me,\u201d said Dr. Richard Whitley, a professor at the University of Alabama and the president of the Infectious Diseases Society of America.\nDr. Lurie, the federal official, said there had been 237 requests to use the drug since the emergency use authorization was granted nearly two weeks ago.\nSo far, the order has been far less than some investors had hoped, though the price of the order announced Thursday was higher than expected.\nPeramivir is given intravenously, making it usable by hospitalized patients who are too ill to take two approved flu drugs that work against the virus in similar ways \u2014 Tamiflu by Roche, which is typically given as a pill, or Relenza from GlaxoSmithKline, which is inhaled.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs.\nThese side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers:\n\u201cThe most common side effects of PERAMIVIR are:\n\u2022 diarrhea\n\u2022 nausea\n\u2022 vomiting\n\u2022 white blood cell count decreased\nThese side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time.\nOther medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. \nThese side effects include:\n\u2022 Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior.\n\u2022 Allergic reaction or severe rash\nNot a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot.\u201d\n\n\n\n \nPatient fact sheet available at:\nhttp://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf \nProvider fact sheet available at:\n http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf\u00a0 ", "answer": 0}, {"article": "ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nThe tests are based on the technology platform of Nucleosomics\u00ae, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.\nCommenting on the results, Principal Investigator, Professor Thierry Roumeguere, Head of Urological Services, Erasme Hospital, Brussels, Belgium said \"A non-invasive test to help in the risk stratification of men with suspected or actual prostate cancer will be a major step forward in the management of this disease.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThis suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA, leading to better patient management and fewer unnecessary biopsies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. How might the false positive rate compare with current practice? Even if, as the company hopes, this blood test might reduce the total number of men sent to have biopsies who turn out to have low-grade tumors, could this test send some men to biopsy who would not have been subjected to it based on current practice?\nOn the other hand, what is the false negative risk; that is, the chance that identification of a high-grade tumor might be delayed because a man was not referred for a biopsy based on the results of this blood test?", "answer": 0}, {"article": "The medical approach to treating tonsil infections has evolved over recent decades.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n\"Though a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\" Chinnadurai said.\n\"The decision about whether those children should have tonsillectomy for that temporary benefit is really tied to what those children need or what they're suffering with,\" Chinnadurai said.\nThe researchers decided to review whether the throat infection guidelines are too stringent, ruling out patients who potentially could benefit but don't meet the high threshold of recurring infections, Chinnadurai said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story a satisfactory rating for including the following statements:\n\u201cAbout 3 percent of kids who undergo the procedure experience bleeding during the two-week recovery period, Hackett said. \u201cThough a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\u201d Chinnadurai said.\nThe story would have been stronger if it had named the risk of infection following surgery and that general anesthesia carries its own important risks.", "answer": 1}, {"article": "However, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n\"There has been debate for many years over the safety and efficacy of ACE inhibitors compared to ARBs, with many of them using an 'ACE inhibitor-first' approach, with ARBs regarded as less effective,\" study author Dr. Sripal Bangalore said in a medical center news release.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n\"We believe that our study ends the debate and gives physicians the option to prescribe either drug for their patients,\" added Bangalore, an associate professor in the division of cardiology, in the department of medicine at NYU Langone.\nMONDAY, Jan. 4, 2016 (HealthDay News) -- Newer blood pressure drugs are as safe and effective as older medications, new research suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No specific harms are mentioned, just a reference to tolerability. A Washington Post story on the same study at least mentions the dry cough that ACE inhibitors can cause, information which would be most helpful to readers who have been prescribed these medications. Several other side effects could have and likely should have been mentioned, but we\u2019ll give the benefit of the doubt.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story does not quantify the harms of either the diet plans or of obesity.", "answer": 0}, {"article": "Funding for the study was provided by F. Hoffmann-La Roche and Biogen Idec.\nThe result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.\nBut initial indications suggest that the new antibody drug, called ocrelizumab, successfully targets these renegade cells with hopeful results: a significant reduction in disease-related inflammatory brain lesions.\nInc.\n\nFor more on multiple sclerosis, visit the U.S. National Library of Medicine.\nThe patients were divided into four groups, treated with: a low dose of ocrelizumab (600 milligrams); a high dose of ocrelizumab (2,000 mg); a well-known MS inflammation treatment known as \"intramuscular interferon beta-1a\"; or a sugar pill (placebo).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What does \u201cappears to be safe\u201d and \u201cno serious adverse effects directly attributable to the drug\u201d mean?\nHere\u2019s what the study abstract stated:\u00a0 \u201cWe noted serious adverse events in two of 54 (4%; 95% CI 3\u00b70\u20144\u00b74) patients in the placebo group, one of 55 (2%; 1\u00b73\u20142\u00b73) in the 600 mg ocrelizumab group, three of 55 (5%; 4\u00b76\u20146\u00b73) in the 2000 mg group, and two of 54 (4%; 3\u00b70\u20144\u00b74) in the interferon beta-1a group.\u201d\nWhy didn\u2019t the story report this?\nWhat side effects were seen?\u00a0 Tell readers/patients and let them decide if they are serious or not.\u00a0 And how did researchers know that whatever was seen was not directly attributable to the drug?\nAnd what\u2019s the safety record been of the drug the Mayo expert described that has a longer track record?\nInsufficient information on harms.", "answer": 0}, {"article": "\u201cPrevious versions of these work in a very, very low-resolution range.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThere, engineers have partnered with Nanovision Biosciences Inc. to create a retinal implant that uses silicon nanowires smaller than the width of a cell to sense light entering the eye and stimulate retinal neurons.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\n\"We hope to replicate in humans the excellent results obtained in animal models,\" Pertile said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article makes no\u00a0mention of harms. The story makes clear that the new devices have not been tested in humans, but there must be\u00a0data on the risks of implanting the\u00a0current devices, the FDA-approved artificial retinas mentioned in the article. A brief\u00a0mention of such\u00a0risks would help give readers a sense of the risk-benefit balance should these high-tech devices make it to the market in the coming years.", "answer": 0}, {"article": "Today\u2019s action supports the FDA\u2019s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging\u2014an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,\u201d said FDA Commissioner Scott Gottlieb, M.D.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\n\u201cThe FDA\u2019s review team worked closely with the test developer and the U.S. Department of Defense to expedite a blood test for the evaluation of mTBI that can be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d\n\nThe Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. In any screening test, there is always the harm of missing an injury that exists or finding a false positive that leads to unnecessary and sometime costly followup tests and treatments.", "answer": 0}, {"article": "Doctors delivered Owen at 32 weeks so she could begin chemotherapy and radiation.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\n\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nWhile prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the WSJ article, there was not even a hint that widespread use of these tests might pose harms as well as benefits, as well as higher costs and ethical dilemmas.", "answer": 0}, {"article": "Kudrow is one of hundreds of doctors investigating a new class of drugs that block calcitonin gene-related peptide (CGRP), a molecule that spikes during a migraine attack.\n\u201cIt's not a pill, it's an injection that stays in the system for a long period of time and is continuously blocking that CGRP mechanism of migraine.\u201d\n\nResults from several pharmaceutical trials are expected either later this year or in early 2018.\nShe feels like a different person who no longer has to shy away from social commitments.\nMost migraines are benign, although they can be disabling.\n\u201cIf we can block CGRP, then we can abort a migraine attack,\u201d says Kudrow.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no discussion of the drawbacks of this new experimental class of drugs.\nAt the very least, we know that the need to take injections will be a turn off for some sufferers.", "answer": 0}, {"article": "Sadly, disappointment is part of it, according to Pharr, who typically hears the frustration of people who go through a study that worked for another person but not for them.\nAfter all, ALS is rare, and in up to 90% of all cases, there is no family history and no known risk factors, as was the case with Pharr's father.\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\nImportantly, one patient showed some improvement, though he and his colleagues noted that this outcome \"must be interpreted with caution\" since the study wasn't designed to measure effectiveness of the treatment.\nMost people with ALS die within three to five years after their symptoms begin, though about 10% survive for 10 years or longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a lot of detail on the harms noted in the study, earning it\u00a0a Satisfactory rating in this criterion, albeit with caveats.\nCertainly, the bar for safety may be lower for ALS than for other diseases, but we think the story misleads by calling the treatment \u201cgenerally safe.\u201d As the story explains,\u00a0two of the 15 patients developed \u201csevere complications,\u201d including partial paralysis and \u201cincapacitating pain.\u201d More detail is warranted here. In fact, the 15 patients in the study experienced\u00a0a total of 81 adverse events\u00a0that researchers said were probably or definitely related to the treatment, mainly surgery. While most of these were not serious, they may\u00a0have reduced the quality of life at least temporarily for patients who probably have little time left to live. In addition, these patients spent several days in a hospital going through an uncomfortable procedure.", "answer": 1}, {"article": "UW-Madison radiology professor Weibo Cai is also a senior author on the study.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\n\"Our expectation is that the device will be more effective and convenient to use than other technologies,\" says Wang.\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\nMeasuring less than 1 centimeter across, or about a third of the area of a U.S. penny, the tiny devices -- which are safe for use in the body and implantable via a minimally invasive procedure -- generate gentle electric pulses from the stomach's natural churning motions and deliver them to the vagus nerve, which links the brain and the stomach.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss potential harms, even though the similar, approved device has caused a number of harms, such as:\n\u201cNausea, pain at the neuroregulator site, vomiting and surgical complications were among the serious adverse events reported in the clinical trial. Additionally, some patients experienced pain, heartburn, problems swallowing, belching, mild nausea and chest pain.\u201d\nThe release should have addressed the possibility that this experimental device could present similar risks.", "answer": 0}, {"article": "The average age of the participants was 11.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nMONDAY, Dec. 7, 2015 (HealthDay News) -- Evidence is mounting that a marijuana-derived oil might benefit some children with epilepsy whose seizures aren't controlled by approved medications, two new studies show.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\nOne child remained seizure-free, but 12 of the initial participants dropped out of the study because the cannabidiol didn't seem to do them any good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The subheadline declares that \u201cdrug interactions remain a concern,\u201d and story includes reference to a study that found cannabidiol to interact \u201cbadly\u201d with anti-seizure medications currently approved for epilepsy treatment. It later specifies the drugs that may be affected. We think this nod in the direction of harms is sufficient for a Satisfactory rating, although we\u2019re concerned that the story mentions no other side effects from the treatment. A news release noted that \u201cAdverse events occurred in more than 10 percent of participants with the most common being somnolence, diarrhea and fatigue and led to discontinuation in 4 percent of patients.\u201d", "answer": 1}, {"article": "Feb. 4, 2016.\nTuuli MG, Liu J, Stout MJ, Martin S, Cahill AG, Odibo AO, Colditz GA, Macones GA. A randomized trial comparing skin antiseptic agents at cesarean delivery.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\nWe are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n\nAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries.\nThe study appears online Feb. 4 in The New England Journal of Medicine and coincides with a presentation at the Society for Maternal-Fetal Medicine\u2019s Annual Meeting in Atlanta.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t mention any harms associated with either of the antiseptics used in the study. If there were no skin reactions, or some with one but not the other, it would be good to note that. This is a minor omission.", "answer": 0}, {"article": "Her team reviewed MRI images from 130 patients treated for clot-caused strokes at Sainte-Anne Hospital in Paris between May 2006 and October 2008.\n\"A tool that can estimate the age of stroke would be of great value in cases of unknown stroke onset time,\" said lead researcher Dr. Catherine Oppenheim, professor of radiology at Universite Paris Descartes in France.\n\"It's potentially helpful, and I don't know that it would take years to prove that,\" said Dr. Larry B. Goldstein, director of the Duke University Stroke Center in Durham, N.C.\n\nGoldstein noted that about 40 percent of stroke patients who arrive at his facility within two hours of symptom onset receive tPA.\nThe MRI is \"trying to act as a surrogate clock,\" said Kallmes, who edited Oppenheim's journal article.\n\"This concerns as many as a quarter of all stroke patients who cannot be given tPA because they wake up with stroke symptoms or are unable to say when their stroke began.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated this application of MRI technology.\u00a0 Although the harms would likely be small, the harm that may arise from incidental findings is worth noting.\u00a0 The more you scan \u2013 something being proposed in this study \u2013 the more you find, including things you didn\u2019t need to find. That\u2019s worth at least a line.", "answer": 0}, {"article": "In a landmark medical clash pitting the diagnostic merits of fancy tech versus vintage exercise machines, the new toys and old ways finished in a dead heat, cardiologists reported Saturday.\n\"The remarkable thing about the study is ... these were quite high-risk patients, but the actual [bad] event rate was very low ...\nIt is a real testament to how far we\u2019ve come in the treatment of patients with suspected coronary disease,\" said Dr. Steven Nissen, department chair of cardiovascular medicine at the Cleveland Clinic.\nAs a result, however, David's two brothers, both close to his age, were convinced to undergo CTAs.\nResults of the federally funded trial \u2014 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) \u2014 were presented at the American College of Cardiology\u2019s 64th Annual Scientific Session in San Diego.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential drawbacks of these interventions are not discussed. \u00a0 The press release describing this study did note potential harms of the stress tests: they were associated with more catheterizations, and nuclear stress tests were associated higher levels of radiation exposure compared with CTA. But the story did not pick up on that information. (There was also no mention of the fact, either in the story or press release, that standard exercise electrocardiography involves no radiation exposure, and would presumably be the lowest-risk option as far as radiation is concerned.)\u00a0As noted above, the only hint of possible harm that occurs is an end-of-story anecdote about an individual whose stress tests failed to signal the presence of blocked arteries.\u00a0 The inference here is that stress tests can miss diagnostic signals that CTA will find. \u00a0Oddly, the anecdote seems incongruent with the main message of the story.", "answer": 0}, {"article": "The pill is his blood pressure medication.\n\"If you had a stroke, even a small stroke, your risk of dementia within the next two years was greatly magnified,\" he says.\n\"The good news is that we can control blood pressure now,\" says Maria Carrillo, the group's chief science officer.\nAnd when the heart pushes too hard, as it does when blood pressure is elevated, it can cause damage that can lead to a stroke.\nYou Might Want to Check Your Blood Pressure\n\nEvery day, Dr. Walter Koroshetz, 65, takes a pill as part of his effort to help keep his brain healthy and sharp.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, we wouldn\u2019t expect a story like this to cover all the side effects of the myriad treatments.\nBut we do think it could have noted that one reason blood pressure drugs are prescription-only is because they can cause side effects that may need medical management. Unlike what the story said, it is not as simple and carefree as taking \u201ca pill\u2026 to help keep [your] brain healthy and sharp.\u201d", "answer": 2}, {"article": "\" Hicks says.\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\nSpit Test May Reveal The Severity Of A Child's Concussion\n\nA little spit may help predict whether a child's concussion symptoms will subside in days or persist for weeks.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nAnd, right now, there's no way to know which kids are going to have long-term problems, he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms, which would include false positive and false negative results. For example, if a child\u2019s test result erroneously said he would have prolonged symptoms (a false positive result), he may miss out on school or activities, for no good reason. And if the result instead erroneously said the child wouldn\u2019t have prolonged symptoms (a false negative result), the child may resume school or activities too early.", "answer": 0}, {"article": "\"Being impotent is no fun.\"\nHowever, he added, \"if we can get the thyroid effect in the liver [where cholesterol is metabolized] but not in other organs, we would be OK.\"\n\nFrequent monitoring showed no ill effects on the hearts and bones of those taking the drug, the report said.\nIn the trial, various doses of the drug, eprotirome, a laboratory-engineered version of thyroid hormone, were added to statin treatment for 168 people whose high levels of LDL cholesterol had not been lowered by previous use of statins.\nWEDNESDAY, March 10, 2010 (HealthDay News) -- A thyroid-derived cholesterol-lowering drug that could be an alternative to the widely used statin medications has done well in a small, early trial, Swedish and American researchers report.\n\"The first importance of the trial is that it shows hepatic [liver] targeting of hormonal action,\" Ladenson said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that the drug \" did not cause the feared side effects on the heart and other organs that have plagued similar thyroid-based treatments.\" But can these side effects be expected to show up in a small, short-term trial? \nNonetheless, because of the strength of the concluding comments by the independent expert \u2013 \"But if there is one thing we\u2019ve learned about drugs in this arena, it\u2019s that we need large trials to see how they measure up in terms of risk and benefit\u2026I\u2019m not sure I\u2019d want to sign up for that one before I had longer-term results. Being impotent is no fun.\"- we\u2019ll give this story the benefit of the doubt.\u00a0", "answer": 1}, {"article": "First a drug must get F.D.A.\nWhile Medicare generally pays for drugs that are approved by the Food and Drug Administration, its debate over paying for Provenge has raised concerns among some cancer patients, doctors and investors who say the government is sending a warning shot that it will not automatically pay for high-priced medicines.\nSome analysts have assumed that Medicare will pay for Provenge when used for the patients specified in the drug\u2019s label \u2013 those with advanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention harms. The clinical trials reported that patients treated with Provenge experienced infusion reactions and infections. The review for Medicare also noted that the FDA ordered further study of strokes in people who get Provenge.", "answer": 0}, {"article": "The oral drug targets an enzyme called Syk.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nSept. 28, 2010 -- An experimental rheumatoid arthritis treatment helps two-thirds of patients getting too little relief from methotrexate.\nBut there's an overabundance of Syk in the fluid of arthritic joints, and the enzyme is part of the runaway immune machinery that increases joint inflammation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides more quantification of potential harms than most stories we review. It provides a point by point breakdown of the harms in the same way it breaks down the benefits. It also flags a potentially huge Achilles heel for the drug. \"There\u2019s at least one theoretical concern about R788. Normally, the Syk enzyme helps suppress tumors. Women with breast tumors have low levels of Syk. It\u2019s not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\" This is more than a theoretical concern. Inceased cancer risk is one of the big reasons that drugs end up being pulled from the market after approval.", "answer": 1}, {"article": "And the experimental combined system itself was not fully automated.\n\u201cThis is an important step in diabetes control because it shows that, with this system, people can sleep safely with minimized risk of hypoglycemia,\u201d said Dr. Eric Renard, a professor of diabetology at Montpellier University Hospital in Montpellier, France.\nThe new study in The Lancet, proponents say, represents a proof-of-concept milestone in the quest to develop such a system.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The Times waited until the last 3 paragraphs of an 1,100-word story to hint\u00a0that an automated system could deliver unsafe doses of insulin. It isn\u2019t until the last sentence that\u00a0we learn that the system would need to be \"exquisitely reliable\" in order to be safe. We feel the story should have raised these issues earlier and that it could have done more to emphasize just how difficult it\u00a0will be\u00a0for any device to calculate insulin requirements on the fly. Insulin dosing\u00a0is affected by\u00a0factors\u00a0ranging from how much a\u00a0person has exercised to what\u00a0and how much they have eaten. It\u2019s conceivable that technology can account for all of these variables,\u00a0but there are a lot ways things\u00a0could go wrong, with potentially deadly results. It\u2019s a close call, but\u00a0we don\u2019t feel the\u00a0story\u00a0did enough to call attention to these issues.\u00a0", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\n\"Waitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\" said McRae.\n\"But more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\"\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of midwifery care could include risks both for the health of the baby, as well as the health of the mother.\u00a0 Maternal health outcomes are not addressed in the study, and not mentioned in the release.", "answer": 2}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not cover harms.\u00a0A problem with these drugs is that they can cause amyloid-related imaging abnormalities (ARIAs), which are findings on brain scans that indicate swelling and small hemorrhages in portions of the brain. These were the most frequent adverse events in the Biogen study and occurred in a lot of people, especially at the higher doses.", "answer": 0}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The study comes a month after Gov.\n\u201cDoctors and patients need to think about the cancer risk when ordering this test.\u201d\n\nThe study, published in the new edition of Archives of Internal Medicine, found a small but real risk from the average radiation \u2014 for every 100,000 men between 45 and 75 undergoing the test every five years, there would be 42 cancers; for every 100,000 women ages 55 to 75, there would be 62.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\n\u201cThe bill was written to target those people most likely to benefit from it, not everyone,\u201d said Oliveira, who credits the test for saving his life when it revealed blockages that led to double-bypass surgery two years ago.\nThe scans are sometimes criticized as an example of expensive new technologies being adopted before proof is established that they're better than cheaper existing methods \u2014 an issue at the heart of the health care reform debate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n \nThe potential cancer risk caused by CT screening for signs of heart disease is the point of this story. Also, by highlighting uncertainty about the benefits of the screening and recapping debate over the Texas law mandating coverage of the scans, the story emphasizes the importance of considering potential harms when setting public policy on screening tests. A longer story could have considered other potential harms, including the side effects of treatments prescribed based on screening tests.", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nThe volunteers took pills once a day for six weeks.\nPeople taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Anything we put in our mouths has the potential to cause harm \u2013 a concept not recognized in this story. ", "answer": 0}, {"article": "For more information about our products and the organization, visit http://www.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nAbout The Journal of Bone & Joint Surgery\n\nThe Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field.\nThe company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\nAll had \"massive, irreparable\" tears of the rotator cuff muscles, causing shoulder \"pseudoparalysis,\"with little no ability to lift the arm.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states, \u201cHowever, complications occurred in 39 percent of the shoulders. Further surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\u201d\u00a0 It adds that, \u201cWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\u201d", "answer": 1}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nThe nurses have a success rate in the \"high 90s,\" Miller says, but \"very few\" hospitals have devoted the time or resources to create the discipline.\n\"Once a person presents with septic shock, the catheter is an early aid that can guide the way a patient is managed,\" Dennis says.\n\"It's old technologies put together in a different way to enable established medical treatments to be done earlier,\" Reavill says.\nA venous heart catheter inserted through the neck, the traditional approach, requires painstaking preparation of the insertion area and a \"pseudo-operative field,\" says Dr. Andrew Dennis, attending surgeon at Stroger Hospital's trauma and burn units and a clinical researcher.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in the story. Placing a catheter into the central circulation and measuring pressure is not without the potential for harm.\u00a0 Although the risk of a catastrophic rare neck artery puncture may be avoided with the use of the arm approach, the risks of misplacement and infection may not be reduced.", "answer": 0}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\nThe results of the study were published online March 16 in the New England Journal of Medicine to coincide with a planned presentation of the findings at the American College of Cardiology's annual meeting in San Diego.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\nAmong all the patients, 6.9 percent who had clots removed, and 7 percent of those who didn't, died, had another heart attack or developed heart failure in the 180 days after the procedure.\n\"There has been some controversy about removing blood clots during the treatment of heart attacks,\" said lead researcher Dr. Sanjit Jolly, an associate professor of cardiology at McMaster University in Hamilton, Ontario.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly states that there is no apparent benefit for clot removal and that there is some increased occurrence of strokes with the procedure. The absolute percentage of subjects who had a stroke in each group is also provided, so readers get a very clear picture of how often this occurs and the difference between the groups.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted privacy and data security concerns near the top and expanded on them in the body of the piece. The story would have been more balanced if it had declared more strongly that while these apps could be helpful, until studies are done, it is also just as possible that they could be useless or even harmful in ways that were not discussed in the story, such as diverting patients from proven interventions.", "answer": 1}, {"article": "Newswise \u2014 Lap band surgery has significant benefits for severely obese teenagers and, despite its controversial nature, should still be considered as a first option to manage obesity during adolescence, a new study has found.\n\u201cWe are talking about a group of adolescents with severe obesity and significant health and psychological problems related to their increased weight \u2013 this is not for everyone,\u201d says corresponding author and Paediatric Endocrinologist Dr Alexia Pe\u00f1a, who is a Senior Lecturer with the University of Adelaide\u2019s Robinson Research Institute.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\nThis is not the case for other surgeries currently offered for obesity management.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study on which this release was based did reference \u201cminor complications\u201d and symptoms that required removal of the bands among some participants, the release ignores this information.", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article uses information from an FDA news release to discuss side effects:\nThe most common side effect in the clinical trial was headache, which occurred in 37.5% of the treatment group and 35.3% of the sham treatment group. Other possible side effects were mild, and included temporary jaw or face pain, muscle spasms or twitching, and neck pain.\nThis is enough to rate Satisfactory, but there is certainly more that could be said about side effects. We easily found evidence of short-term memory loss and patient complaints of significant\u00a0anxiety by doing a quick Google search.", "answer": 1}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\nThe apnea can probably be taken care of with these noninvasive techniques, she says, and invasive surgery can be avoided.\nThe only surgery proved effective more than 90 percent of the time is a significant and highly invasive surgery.\n\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nThe \"new\" CPAP machines are more sophisticated, Aurora says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only discusses success rates but doesn\u2019t mention any potential harms. What are the actual problems people encounter when having \u201ca series of surgeries to completely treat apnea\u201d or when they have the more \u201chighly invasive surgery\u201d?\u00a0 And what has been found even in the limited series of robotic procedures?", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself \u2014 using DNA taken from a cheek swab \u2014 carries no physical risks.\nBut the story needed more detail about the potential downsides. As noted in more detail in the TIME coverage of the story, the various \u201cscales\u201d that are used to assess drugs aren\u2019t organized by how effective the drugs might be based on genetics, but instead how many adverse events they might cause. So, a person is told to take certain drugs not because they\u2019ll be more effective than other drugs, they\u2019re just less likely to cause problems.\nCould selecting drugs based on how many problems they cause lead some people to choose drugs that aren\u2019t as effective for treating depression? That would seem to be biggest issue in terms of harms \u2014 that the test would simply be wrong for some people.\nAlso, the test appears to show results for drugs beyond antidepressants \u2014 including some drugs that are known to cause dependency or can be deadly when taken alone, mixed together or with other drugs, such as hypnotics and benzodiazepines (Ambien and Xanax, for example). This is important to consider in a group of people already at higher risk for suicide.\nAll of this means adverse event data is vital \u2014 was it indeed lower in the gene-tested group?\nIf adverse event data were not available from the company or the investigators at the University of Michigan who led the study, the article could have noted the fact.", "answer": 0}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\u201d", "answer": 1}, {"article": "Her study followed 25 children with dyslexia and 20 children without dyslexia over a 2\u00bd-year period.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\nCelebrities including Whoopi Goldberg, Cher and Henry Winkler (the \"Fonz\") have made their dyslexia publicly known, and great artists such as Pablo Picasso are said to have had it.\nThe potential to alarm a child isn't worth it, and he doesn't trust that this method would offer definitive information.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nMRI brain scans are generally considered to present little physical risk, so the issue here is really the potential negative effects of the information the test produces. At least the story raises that issue by including comments from parents who worry that this sort of scanning could further stigmatize children who have trouble reading or writing. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms of treatment in the news story or in the published study. Other research suggests that main harm of taking the supplements is kidney stones.", "answer": 0}, {"article": "Among 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\nDental decay was low in both groups.\nIf not halted or reversed, this leads to a cavity.\nis an evidence-based approach to preventing or treating dental caries at its earliest stages.\nDoing so can change the whole picture of caries control.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms.", "answer": 0}, {"article": "One study published in Psychological Science trained 16 college-aged adults and 16 older adults (around age 71) with Gabor patch exercises for 1.5 hours per day for seven days.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nIf we haven\u2019t yet processed the prior set of information, we can\u2019t understand it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine what harms there might be, but it would have been helpful to know something about the drop-out rate that would have done at least a bit of financial damage to the trainees.", "answer": 2}, {"article": "The study was divided into three parts.\nAccording to Wong, this body of work reveals that, as compared with the currently used Tau tracer, F-18 AV1451, the new tracer, F-18 RO948, does not bind randomly to other tissue, offering greater clarity into quantification of potential tau burden within the human brain.\n\"One of the greatest public health challenges is Alzheimer's disease, for which there currently is no cure and no definitive diagnostic until autopsy,\" says Dean Wong, M.D., Ph.D., professor of radiology and radiological sciences, psychiatry and behavioral sciences, neurology and neuroscience, and director of the Section of High Resolution Brain PET Imaging, Division of Nuclear Medicine at the Johns Hopkins University School of Medicine.\n\"It really takes a village to make progress in biomedical research, and this project was no exception, with the involvement of the PET team at Hopkins, a CRO who helped recruit healthy subjects, colleagues in psychiatry and behavioral sciences, colleagues at the National Institute of Aging and neuroscience imaging experts at Roche,\" says Wong.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there any risks associated with injecting these molecular markers into a study participant or patient? Even if there aren\u2019t, that in itself is worth addressing. The release also doesn\u2019t address two other potential harms (which are common to most, if not all, diagnostics): the failure to identify someone who has Alzheimer\u2019s and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d Missing someone who has Alzheimer\u2019s is problematic. And being told that one has a disease that one does not actually have can also have ramifications for future healthcare, with consequences both physical and financial.", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\nThe story does not mention harms.\n\u00a0\nWhile the researchers reported that there were no adverse events during the trial, it is possible that exercise classes could lead to falls or sports injuries, so the story should have addressed this point.", "answer": 0}, {"article": "But in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any harms that might occur from the use of probiotics. \u00a0Are there specific groups for which these products could be dangerous? \u00a0And if constipation is as serious as the story suggested, is there harm in first attempting self management with ineffectual products?", "answer": 0}, {"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nGrowing Medical Support for Peppermint Oil in the Management of IBS\n\nThe World Gastroenterology Organization (WGO) issued global IBS guidelines in September 2015, which recommended peppermint oil in managing IBS as a first-line therapy option.\nThe researchers also concluded that, \"A novel formulation of peppermint oil, designed to cause sustained release in the small bowel, was superior to placebo in causing a reduction in total symptoms.\"\nThe lead author of the review article, entitled \"Irritable Bowel Syndrome,\"1 was Paul Enck, M.D., Department of Internal Medicine VI (Psychosomatic Medicine and Psychotherapy), University Hospital T\u00fcbingen, T\u00fcbingen, Germany.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms, even though the trial of IBgard that is highlighted in the release specifically tracked adverse events including indigestion, flatulence and reflux. The article summarizing that trial knocked other brands of peppermint oil capsules for causing heartburn, nausea, anal burning and \u201cdose-dumping,\u201d which is the sudden release, rather than slow release, of the drug in the capsule.", "answer": 0}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms of prolonged aspirin use, such as stomach bleeding and gastrointestinal ulcers.", "answer": 0}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\n\"But just being familiar with your breasts should never take the place of regular screenings and mammograms.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\n\"All women should know how their breasts look and feel so they can recognize any changes in them.\n\"I advise women to speak with their physician to determine what is right for them,\" Evers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are potential and actual harms to screenings, including unnecessary biopsies and other tests, anxiety and false negatives. Again, while new technologies have reduced some of these harms, they are not zero. The story doesn\u2019t mention any.", "answer": 0}, {"article": "All had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\nThe use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology.\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses some of the harms associated with the therapy and provides specific numbers\u00a0that are easy for readers to understand. It says, for example, \u201cOf 59 patients who enrolled, 12 died from their tumor during the study period and one from a traumatic brain injury. Significant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\u201d\nThe release didn\u2019t point out that all of the patients had additional treatments \u2014 including surgery and chemotherapy \u2014 so it\u2019s not possible to pinpoint years later where to place the blame for any hearing loss or cognitive deficits.\nWe think some of the harms from the therapy were given short shrift, but we address this in the \u201cQuality of Evidence\u201d measure.", "answer": 1}, {"article": "He said his team is now working with other scientists to try to design a drug which could interrupt the gene\u2019s activity.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nLONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of possible harms that might come from blocking a gene. The story calls the gene a \u201crogue\u201d and a \u201cculprit\u201d but does little to explain what it does. It says it is both inside cancer cells and outside them, destroying \u201ca naturally-occurring protein in the body which normally prevents cancer cells from spreading.\u201d As anyone who has been through cancer treatment knows, knocking out cancer cells through radiation and chemotherapy can take a heavy toll on a person. People can die from infections and other complications. One question might have helped answer the harms question: \u201cWhen you blocked this rogue gene, what happened to all of the normal cells around the cancer cells?\u201d\u00a0Anything that alters cell function in tumors could have powerful effects on normal tissue, too. The researchers noted in their article that they have yet to \u201cestablish normal and disease expression patterns of all three WWP2 isoforms\u201d. If they don\u2019t yet fully understand the normal form and function of WWP2, the potential for unanticipated effects is a serious concern that the story should have addressed.", "answer": 0}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nWith this device, we can see warning signs days in advance, and adjust treatment accordingly.\u201d\n\nThe most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally.\nProduced by Abbott, the CardioMEMS\u00d4 HF System is approved in the United States by the Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No intervention is risk-free, especially ones that are invasive. On page 9 of the CardioMEMS user\u2019s manual, a slew of potential adverse effects is associated with this implantation procedure, including infection, bleeding, arrhythmias, blood clots, heart attacks, stroke and even death.\nSince the news release doesn\u2019t address harms, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "Previous surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed at all. No surgery is completely without risks, so this is not an acceptable oversight. For example, as of 2007, Orthopedics Today was still highlighting the fact that \u201cDisease transmission also remains a worry for surgeons using allografts.\u201d", "answer": 0}, {"article": "Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nIn addition to Tecentriq\u2019s approval for bladder cancer patients whose disease has stopped responding to chemotherapy, the FDA last month approved the Roche drug as an initial treatment for people with a specific type of advanced bladder cancer and in people whose cancer progressed despite at least one prior platinum-containing chemotherapy.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only tells us that:\nSevere side effects were reported in 16.5 percent of the Keytruda patients, compared with nearly half of the chemotherapy group.\nBut what does severe mean? And how often did less severe side effects occur when patients were on Keytruda?\nAs we\u2019ve discussed in 6 tips for writing about immunotherapy, there\u2019s a tendency to underplay the harms of immunotherapy drugs.", "answer": 0}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nWhile noting that many people are reluctant to undergo spinal taps, this story includes only comments that downplay the potential harms, including pain or bleeding. The story fails to discuss the potentially serious consequences of using this sort of test before symptoms appear, such as insurance or employment discrimination.\nFinally, the story downplays that importance of the relative lack of specificity of the method. While testing of apparently healthy older people for the presence of the markers may be appealing, the reality is that based on the study up to a third of those may be falsely labeled as having the disease. This may subject a significant number of older Americans to the potential side effects of newer treatments to say nothing of the financial impact of a third of the population in this age group.", "answer": 0}, {"article": "\u201cThere are a lot of questions.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n\u201cWe don\u2019t know how well these particles are localized to the prostate or if they\u2019re going to the pelvis or other parts of the body.\u201d\n\nMalizia notes that in one serious complication reported in the study, the particles appeared to migrate and kill a small part of the bladder wall.\nWe really don\u2019t know what the short- and long-term success or complication rates are,\u201d says Anthony Malizia Jr., MD, president and director of the Malizia Clinic, a nonprofit urology specialty center in Atlanta.\nIt\u2019s the same kind of growth,\u201d says study researcher Joao Martins Pisco, MD, chief radiologist at Hospital Pulido Valente and director of interventional radiology at St. Louis Hospital, both in Lisbon, Portugal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention that one patient in the study had a serious complication that required surgery to repair the bladder. \u00a0However \u2013 since the study population was small and men were only followed for \u2018an average of nine months\u2019 after the procedure \u2013 the story could have been even more explicit and emphatic that it is too soon to know the harms associated with this procedure. It did include one independent expert\u2019s comments to that effect.\nMore bothersome: the story described the complications of TURP without informing the reader about how often they occur or bothering to note that other, widely available treatments that have been around for a decade or more have reduced risks of these complications.\nAny story whose first words are \u201ca minimally invasive procedure\u201d may paint an unjustified picture of guaranteed safety.\u00a0 Special caution should be taken to counter this.\nOne last point on harms:\u00a0 the major \u201charm\u201d that the study could not address (and the story ignored) is the possible eventual need for requiring additional treatment.", "answer": 0}, {"article": "Cassandra Quave, an Emory University scientist who studies how indigenous people use plants in healing practices, said researchers pulled apart the chemical ingredients of the berries and tested them in mice infected with these superbug strains.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that \u201cthe plant extracts didn\u2019t harm the skin tissues or the normal, healthy bacteria found on skin.\u201d It also wisely cautioned \u201cthe average person shouldn\u2019t try to use the weed to make their own medicine.\u201d\nWe\u2019ll award a satisfactory grade but note that the disclaimer could have been stronger, saying that the injections were prepared under laboratory conditions and could not be prepared by just crushing the berries. We also don\u2019t know how the extract might affect humans.", "answer": 1}, {"article": "It took a year for the company to get clearance for the trial from the F.D.A.\nRegeneron\u2019s drug, which is called VEGF Trap-Eye, \u201cgives us the opportunity to not have to see them monthly,\u201d said Dr. Jeffrey Heier of Boston, an investigator in one of the trials and a consultant to Regeneron.\nMeanwhile, Advanced Cell Technology, of Marlborough, Mass., said it would test its stem cell therapy on 12 adults with severe vision loss caused by Stargardt\u2019s, an inherited disease.\nThe two similar trials involved a total of 2,457 patients who were randomly chosen to receive either Lucentis every four weeks or VEGF Trap-Eye either every four weeks or every eight weeks.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites a company assurance that the new drug is \u201cequally safe\u201d compared with\u00a0its\u00a0FDA-approved competitor. To which we respond:\u00a0How safe is that?\u00a0\u00a0Injecting\u00a0substances into the eye\u00a0is associated with rare but potentially serious risks such as infections of the interior eye. There\u2019s also some evidence that\u00a0Lucentis\u00a0is associated with increased risk of stroke. Does the new drug carry the same\u00a0risks? The story should have provided more details. \u00a0 With over 2000 patients in the trials the company could have reported on the minor and major complications that were observed in the 2 trials.", "answer": 0}, {"article": "The current study included 317 people with moderate to severe psoriasis.\nBriakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\n\"Cancer risk is extremely hard to define, and this study was not powered to detect any difference in the risk of developing a malignancy,\" said Bebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing WebMD story, this story quantified the serious infections and explained the two cancer cases seen in the briakinumab group.\u00a0 It also explained that an earlier trial of the drug showed \u201csome unexplained major adverse cardiac events.\u201d\u00a0 This was a more complete explanation than what WebMD provided.", "answer": 1}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nIt has been shaking for years and they look at it as though, \u2018Hmm, is this really my hand?\u2019 It\u2019s really a remarkable moment.\u201d\n\nFor Samuels, who underwent the procedure on June 29, the recovery has been surprising.\nIt has been developed by InSightec, which is funding the trial along with the Focused Ultrasound Foundation and the Binational Industrial Research and Development Foundation.\nThe therapy, called focused ultrasound thalamotomy, uses the energy generated by sound waves to burn off certain cells in the thalamus, a region of the brain where the essential tremor is thought to originate.\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses adverse effects, and that\u2019s sufficient for a Satisfactory rating.\nWe do wish the story had quantified the harms that were measured in the study. The fourth paragraph says the procedure \u201cbrings lasting side effects in some patients\u201d and later the story quotes a physician who is not involved in the research as saying, \u201cIt\u2019s a pretty high incidence of side effects.\u201d But nowhere do exact numbers appear.\nRather than citing data from the study, the story quotes the physician as saying that \u201cover a third of patients actually experienced either gait disturbance or paresthesia,\u201d or numbness. This information isn\u2019t very useful because the story does not explain when these rates were measured. According to the study, three months after the procedure 36% of patients had gait disturbance and 38% had numbness. After 12 months, the numbers dropped, to 9 percent and 14 percent respectively.\nAlso worth mentioning is that one patient was reported to have permanent diminished sensation of the dominant thumb and index figure, which was categorized as a serious adverse event. That did not appear in the story.", "answer": 1}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\n\"Drug-coated stents have reduced re-stenosis rates compared to bare metal stents, but require prolonged dual antiplatelet therapy to prevent clotting of the drug-coated stent,\" said Dr. Gregg Fonarow, an American Heart Association spokesman.\nThe researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s overlap between harms and benefits here because stents are designed to prevent harm. However, the study identifies the development of blood clots on the stent as a safety outcome (along with the numbers of heart attacks and death). While the article tells us that the rate of clots was significantly lower with one type of stent, it does not quantify the harms.", "answer": 0}, {"article": "(Philadelphia, PA) - Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research.\nIn addition, levels of phosphorylated and insoluble tau, the form of the protein that is known to directly damage synapses, were 50 percent lower in treated animals.\nWhen the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits leukotriene formation by blocking the 5-lipoxygenase enzyme.\n\"Leukotrienes are in the lungs and the brain, but we now know that in addition to their functional role in asthma, they also have a functional role in dementia,\" Dr. Pratic\u00f2 explained.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms in a mouse model do not necessarily translate to humans but we do know what the side effects profile looks like. \u00a0The harms include alteration of liver function, sleep and behavioral disorders \u2014 to name a few.", "answer": 0}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nWomen of child-bearing age are strongly encouraged to take it, because it can prevent birth defects.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nNow, there's new information showing how important folic acid is.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms or lack of harms that are associated with adequate folic acid intake in women of child bearing age.", "answer": 0}, {"article": "\"Is it possible with cosmetic use?\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\n\"This is a new pathway, and we need to think about the implications of this,\" says Edgar Salazar-Grueso, chief medical officer of Solstice Neurosciences, which makes Myobloc.\n\"The discovery was quite serendipitous ... and surprising,\" Matteo Caleo, who led the study, told the journal Science.\nThe FDA didn't do much in response, but since then it has been getting new reports of serious adverse reactions in people receiving Botox, and launched a safety review.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a clear report on the potential harm to rats receiving Botox injection into whisker muscle. But the story went beyond a reasonable argument to suggest a link between the study results and harms to patients. \u00a0 While the implication of the study is that there is the potential of systemic effects following local treatment with botulism toxin, the story didn\u2019t really make clear what this meant.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All patients who undergo knee replacement operations have a small risk of complications (e.g. blood clots, infection, even death). Does the new gender-specific knee implant increase or reduce these or other potential harms? The article does not pose this question. At the moment, no one knows the answer. ", "answer": 0}, {"article": "\u201cWe expected to see some response, but I don\u2019t think we expected to see a 45% significant response,\u201d says Forde.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\nPutting together everything that doctors currently know about lung tumors, \u201cmore than half of people with lung cancer can avoid chemotherapy and get more precision-based treatments,\u201d says Dr. Matthew Hellmann of the Memorial Sloan Kettering Cancer Center (MSKCC), lead author of the study.\nThe medications target a protein called PD-1, its related PD-L1, or CTLA-4, which protect the body\u2019s cells from being killed by immune cells; because tumors are normal cells growing out of control, they take advantage of this molecular security blanket to avoid getting detected by immune cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects are mentioned, and this is a major oversight of the story.\nFor example, it could have mentioned that in the Keytruda study of patients with a common type of advanced disease, called non-squamous non-small-cell lung cancer, those in the immunotherapy group experienced more of certain adverse events, such as kidney problems, and were more likely to drop out of treatment due to side effects that those receiving chemotherapy alone.\nNot to mention that in general, immunotherapy can lead to many inflammatory conditions that can occur throughout the body as a result of treatment, such as colitis.", "answer": 0}, {"article": "For more information, go to http://www.\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\n1 McCann, J. C., Shigenaga, M. K., Mietus-Snyder, M. L., Lal, A., Suh, J. H., Krauss, R. M., Gildengorin, G. L., Goldrich, A. M., Block, D. S., Shenvi, S. V., McHugh, T. H., Olson, D. A., and Ames, B. N. (2015) A multi-component nutrient bar promotes weight loss and improves dyslipidemia and insulin resistance in the overweight/obese: Chronic inflammation blunts these improvements.\n7 McCann, J. C., and Ames, B. N. (2011) Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text extols the benefits of the bars with no mention of possible harms. \u00a0We\u2019d suggest that there is possible harm in replacing actual foods containing a wide variety of nutrients (and many potentially beneficial compounds that we don\u2019t know anything about) with a supplement bar processed in a factory. The peer-reviewed rendition of the study also finds no clear downsides, although it did note that \u201cchronic inflammation [which\u00a0can accompany obesity] blunted most improvements,\u201d suggesting that some folks will be helped far less by the bars than will others.", "answer": 0}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nIn fact, the use of these minimally invasive biopsies increased from 59 percent to 67 percent of all biopsies between 1997 and 2008, a trend which is likely to continue, one expert noted.\n\"We also found that the use of imaging guidance increased over this time period, most likely because the technique enables more efficient and safe targeting of lesions,\" Kwan said in a news release.\nTUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\n\"In time, I would expect 80 to 90 percent of biopsies will be image-guided biopsies,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\"Minimally invasive\" does not equate to \"no harm.\"\u00a0 Yet no discussion of potential harms \u2013 either in traditional biopsies or in the minimally-invasive variety made it into the story.\u00a0 No medical intervention with any level of invasiveness is without harm.\u00a0 So potential harms must be discussed to make the story complete. ", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study does not mention any potential harms of botox injection. While the procedure is safe, there are some risks that would be important to mention and consumers should also be told that they should seek out a practitioner who is skilled and experienced in providing the injections.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No information is included about possible over-diagnosis that may occur if this device is used to determine if very small lumps that are possibly benign or malignant.\u00a0 Recent studies have focused on the harm done by over-diagnosis and the resulting over-treatment of DCIS and early breast cancers.", "answer": 0}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\n\u201cThe findings of our studies, along with clinical findings reported by other groups, indicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases,\u201d Sahebkar said.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\n\u201cTwo key effects of curcumin that account for most of the therapeutic effects of this compound are its strong antioxidant and anti-inflammatory properties,\u201d said Sahebkar researcher at the Mashhad University of Medical Sciences in Iran, in an email.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that pregnant and lactating women should avoid using curcumin supplements, and quotes one of the study authors as saying that \u201cpatients with malabsorption syndrome, gall bladder problems, gastric ulcer, bleeding problems as well as those who are undergoing surgery, and those who have a history of hypersensitivity to herbal products should be cautious and consult with their physician before taking this supplement.\u201d\nWe\u2019ll rate this good enough for a satisfactory, although the story could have noted that many of these warnings seem to relate to the fact curcumin may interfere with iron metabolism (posing problems for those with iron deficiencies), and that curcumin can apparently also cause nausea, dizziness, or diarrhea in some people.", "answer": 1}, {"article": "Professor Bartlett said researchers are constantly looking at new treatment strategies for alcohol abuse and addiction, which is characterised by extended periods of heavy alcohol use, binges and abstinence, and anxiety and depression which contribute to relapse.\n\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\nThe study by Professor Bartlett, Dr Belmer, Dr Patkar and Dr Vanessa Lanoue (Queensland Brain Institute) can be accessed here.\n\"This is not just another drug that shows promise in helping to reduce binge drinking,\" she said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "When it comes to potential harms from using the drug, the release only offers the following:\u00a0 \u201cIt is commonly used there [in Asia] and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\u201d\u00a0 What are those limited effects?\u00a0 How often do they occur?\u00a0 Are they greater or lesser than the side effects of other drugs used in curbing heavy drinking?\nA caution on the the potential toxicity of the drug if taken with alcohol should have been included.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nGrob says work by his group and others has shown that psilocybin can help treat \u201cterminal cancer patients with overwhelming existential anxiety, an area that traditional medicine struggles with.\u201d And a study in late 2014 found that LSD permanently reduced anxiety in a small number of patients.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nBut at the same time, many of these substances were taken in uncontrolled settings by large numbers of people, and certain proselytizers (like Timothy Leary) advocated their widespread use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Obviously the harm potential of these drugs is probably what gave them a bad reputation in the first place\u2013particularly in their potential for abuse\u2013so it would have been useful to hear which adverse effects were experienced by these users in these small experiments. It was good that the story stipulated that the drugs were used under controlled and supervised conditions, and so the obvious question arises: is that how these drugs would be used in the wider population, and if not, would that not alter the harm/benefit potential of the drug?\nAs we circle back to re-evaluating these drugs, focusing on one specific area (anxiety/depression), it seems a little too easy to forget they are powerful drugs that affect multiple chemical and who knows what other\u00a0systems in the brain. Informed consent documents for future studies will be tricky.", "answer": 0}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\n\"My mother left me when I was 26, and it was extremely painful and traumatic for my entire life,\" she says.\nOnly 3 percent of those who had surgery died, compared with 10 percent of those who did not, during the follow-up period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story does not mention any of the harms of treatment. Although it could be assumed that readers understand that mastectomy and ovary removal are traumatic, this story does not inform them about other substantial harms, such as premature menopause. Indeed, most of the women included in this study had decided not to have surgery, presumably because of concerns about the heavy consequences. While the results of this study may lead many women with BRCA1/2 mutations to reevaluate the balance of benefits and harms, the story should have offered at least some overview of the reasons the decision to undergo these preventative procedures is so difficult.\n", "answer": 0}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\n\"We know this is important for physical growth and development, but it may also be important for mental ability,\" she added.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, this story is all about the potential developmental harms of a high-calorie, nutrient poor diet.", "answer": 1}, {"article": "We need to look at dietary patterns rather than individual nutrients or individual food components.\u201d\n\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\nA study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\n\u201cOne of the things we learned is that we need to look at the whole picture,\u201d says Lichtenstein.\nSo Dr. Christopher Ramsden, a clinical investigator at the National Institutes of Health, who was interested in understanding the effects of linoleic acid on heart health, contacted one of the original authors and reviewed data that had not been included in the study.\nFor decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall thrust of the story was about harms of linoleic acid, so we\u2019ll call this satisfactory.", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n\u201cMost clinicians or surgeons feel like if you take the time to do a big operation on someone, you know the area operated on, how the operations went, if there were complications,\u201d lead author Dr. Benjamin S. Brooke of the University of Utah School of Medicine in Salt Lake City told Reuters Health by phone.\nMore than nine million patients underwent one of 12 such surgeries during the study period, and between six and 22 percent, depending on the surgery, were readmitted to the hospital within a month.\n\u201cA lot of readmissions are patients who have time to be transferred or triaged, if they are not bleeding to death or having a heart attack,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of any downside that might be caused by returning patients requiring rehospitalization back to the hospital where the original work was done. It\u2019s conceivable that policies encouraging people to go back to their original hospital could delay treatment of problems that can get worse without immediate care. For example, if someone travels for a procedure, getting back to the hospital for readmission could take longer than going to a local hospital. The story does note that going to the original hospital often results in more timely care, but the flip side was worth mentioning, too.", "answer": 0}, {"article": "If you'd like to find out more about this procedure, please click here\n\"It was like a miracle to me.\n\"I had a guilty feeling.\nIt was an absolute miracle.\"\nLook what I've given her.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were no harms of treatment mentioned.", "answer": 0}, {"article": "Lung cancer is the No.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nPatients who had taken the drugs to control diabetes were much less likely to have lung cancer spread \u2014 which is when it becomes most deadly \u2014 the researchers told a meeting of the American College of Chest Physicians.\nIn April, researchers said a natural supplement derived from food, called myo-inositol, seems to stop the precancerous changes that lead to lung cancer.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study may not have addressed the harms of these drugs during its chart review, but they do have well-known side effects, which could\u2019ve been mentioned.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. ", "answer": 0}, {"article": "Carmichael and Segura collaborated on the study.\n\"We tested this in laboratory mice to determine if it would repair the brain in a model of stroke, and lead to recovery,\" said Dr. S. Thomas Carmichael, Professor and Chair of neurology at UCLA.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\nThis research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\nUnlike some other organs in the body, such as the liver or skin, the brain does not regenerate new connections, blood vessels or new tissue structures.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned and are relevant.\nThe gel is a foreign substance being introduced into the brain. Did it trigger any kinds of reaction in the surrounding normal tissue? Did it cause any systemic symptoms?", "answer": 0}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nIncrease in Drug and Opioid Overdose Deaths\u2014United States, 2000-2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release lists a number of adverse reactions that have been identified during use of naloxone hydrochloride in postoperative patients, including\u00a0hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest.\nWhile we give the release credit for providing an extensive list of potential list of side effects, we question whether including a long laundry list of warnings under \u201cimportant safety information\u201d is sufficient to prevent accidents when untrained individuals are treating people who are suspected of opioid overdose. And yet this product is marketed for individuals without medical experience. In mentioning usability trials involving the product the release states that, on average, \u201cmore than 94% of users can correctly administer EVZIO without training, and 100% with training.\u201d We\u2019d like to know how many volunteers were involved and what is the effect of incorrectly administered Evzio.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nCardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThey are also looking at what they call \"triple hybrid\" imaging, which combines the CCTA/SPECT hybrid with information on coronary artery shear stress.\nThe approach has shown promise in studies focusing on short-term observations, but information is lacking on long-term outcomes.\nInvasive coronary angiography (ICA) is considered the gold standard for determining the percent of stenosis, or narrowing, due to plaque in a coronary artery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t address harms, which at a minimum involve exposure to an additional radiation-based imaging technique that could increase the risk for cancer.", "answer": 0}, {"article": "On Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\nFor some, relief was almost instantaneous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that patients receiving dupilumab reported slightly more cases of conjunctivitis, and swelling around the injection site, than those receiving the placebo injections. The story would have been more complete if it had also noted that a few patients saw their eczema get worse and that many also reported upper respiratory infections, though the rates were similar to those receiving placebo injections.", "answer": 1}, {"article": "Although the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\nFor patients with scores above one, blood thinners are considered necessary, as these patients are judged to be at moderate to high risk, according to the researchers.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThis causes blood to pool, and then it can clot.\nWe shouldn't wait longer than a month to begin treatment,\" Bunch said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because blood thinners work by interfering with blood\u2019s ability to clot, users are at some risk of dangerous heavy bleeding. This issue doesn\u2019t\u00a0make an appearance in the story.", "answer": 0}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\nFor the study, half of the participants were randomly assigned to receive a 0.3 milligrams per kilogram dose of psilocybin while the rest received a vitamin placebo (250 milligrams of niacin) known to produce a \u201crush\u201d that mimics a hallucinogenic drug experience.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is vague here, noting that patients \u201cexperienced no serious negative effects, such as hospitalization or more serious mental health conditions.\u201d But that doesn\u2019t mean they had no side effects. A look at the paper shows that 28 percent of patients, for example, suffered headaches or migraines and 14 percent had nausea. Did the benefits outweigh these effects? Many people might say yes. However, it\u2019s important for research institutions to describe the research \u2014 warts and all \u2014 and let people make informed decisions. If we think that\u2019s true for clinically available treatments, it should also apply to treatments in the earlier stages of testing.", "answer": 0}, {"article": "The process can take several years.\nDespite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.\nThese include medications to lower blood pressure and diuretics to help remove excess fluid that builds up as a result of the heart's labored pumping ability.\n\"This drug, although still in an experimental phase, might be an important way to improve heart function in patients with heart failure,\" he said.\nOne patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly points out that side effects included nausea and headaches, and that one participant did experience abnormal liver function after receiving the highest dose, a side effect that eventually cleared up.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the new drug was found to be \"safe and effective\" but provided no details on its potential harms and no detailed safety comparison with the current standard of treatment. \nIf the trial was small, it may be premature to assume cethromycin is as safe as Biaxin.\u00a0", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not adequately list the harms of this treatment for women with and without polycystic ovarian syndrome (PCO). Instead the story focuses on the potential downsides of IVF and the risks of hormones for some women. \nThe target group, that is, women with subfertility, can enhance their likelihood of conceiving with modest weight loss and conventional medications as needed, but who might be lured into this \"tennis shoe\" treatment out of fear that they won\u2019t conceive rather than doing the harder thing of diet, activity, and physical activity. This is not dicussed. However, IVM requires egg retrieval and embryo transfer, the same as IVF, and these risks should be mentioned\u2013 the former with small risks of bleeding and infection and the latter with small risk of infection and poorer reproductive outcomes. ", "answer": 0}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThis work received no outside or corporate finding, the researchers noted.\nUnfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nAfter looking for other possibilities, those who took statins regularly had a 41 percent lower risk of developing rheumatoid arthritis compared with people who were not taking statins regularly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story does not mention any side effects of statins or other concerns about the long-term use of the drugs.", "answer": 0}, {"article": "Svetsky cautioned that weight gain from eating large amounts of dark chocolate would counteract any benefits on blood pressure.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nEvery day for 18 weeks, the volunteers were instructed to eat one-square portions of a 16-square Ritter Sport bar, or a similar portion of white chocolate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit, this piece did allude to weight gain as a potential problem with advocating consumption of chocolate.\u00a0 It could have mentioned that with the portion of dark chocolate used in the study, no weight gain was seen during the 18 weeks of study.", "answer": 1}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\nThen there are the interventional radiologists, who have extensive experience with stenting in arteries not near the heart, and neurologists, who specialize in treating brain diseases.\napproval late next year.\nBut Dr. Ricotta said that in most cases he would still probably prefer surgery, for which he has had a low complication rate.\nMeanwhile, patient demand for stents is growing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "See above \u2013 the piece does not provide \nabsolute rates for harms or side effects for various treatment options.", "answer": 0}, {"article": "In the nearly year and a half since having the surgery, her condition has improved substantially, she said.\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\nThe six-month study, which involved 255 people, found that those who underwent surgery had 4.6 more hours each day of good control of their symptoms than those who got the best drug therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the \"much greater risk of serious adverse side effects\" in the same sentence that delivers the positive results. Placing the \"bad news\" of side effects right alongside the \"good news\" of improvements is a best practice for which this reporter should be commended.\nLater in the story the reporter lists these side effects and provides data on the number, severity and duration of the side effects. The story also mentions the death that resulted from the surgery.\u00a0\nYet the story fails to mention that the study found consistent, if small, loss of cognitive function in the stimulation group. It also fails to mention that the long-term effect of the sugery is unknown, and that this study, lasting just six months, cannot help answer that question.\u00a0 ", "answer": 1}, {"article": "So, how might the message of this new study linking high-fiber diets to a lower risk of breast cancer be communicated to teenagers?\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nIt's well-known that fiber can prevent constipation and keep the bowel moving by making stools bulkier and absorbing water.\nThe findings are based on a long-term study of 44,000 women who were surveyed about their eating habits in high school.\n\"The recollection of dietary habits more than a decade earlier must be questioned,\" writes Blackwell.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that none of the patients experienced serious side effects or adverse events.\u00a0 It could have emphasized that one can\u2019t draw much of a conclusion on safety after experiments in a few people. ", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story squeaked by on this one by pointing out that there are some sudden deaths associated with sauna use, usually in relation to alcohol use. But the story also mentions that previous studies have suggested that sauna bathing might have some harmful effects. We wonder what those effects were, and why we should trust the new study\u2019s assurance that there are no such effects.", "answer": 1}, {"article": ".\n\"Isoflavones--the component of soy that has estrogen-like properties--have been shown to slow the growth of breast cancer cells in laboratory studies, and epidemiological analyses in East Asian women with breast cancer found links between higher isoflavone intake and reduced mortality; however, other research has suggested that the estrogen-like effects of isoflavones may reduce the effectiveness of hormone therapies used to treat breast cancer,\" explained Fang Fang Zhang, MD, PhD, of the Friedman School of Nutrition Science and Policy at Tufts University.\nThis is because in hormone receptor-positive cancer, the most common form of the disease, there are some concerns that high estrogen levels help cancer cells grow and spread, though this remains controversial.\nFor more information or to obtain a PDF of any study, please contact:\n\nDawn Peters (US) +1 781-388-8408 \n\nsciencenewsroom@wiley.com \n\nFollow us on Twitter @WileyNews\n\nFull Citation: \"Dietary Isoflavone Intake and All-Cause Mortality in Breast Cancer Survivors: the Breast Cancer Family Registry.\"\nIn an accompanying editorial, Omer Kucuk, MD, of the Winship Cancer Institute of Emory University, noted that the United States is the number 1 soy producer in the world and is in a great position to initiate changes in health policy encouraging soy intake.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a competent job of explaining the concerns about soy\u2019s estrogenic properties and the fact that the study was designed to look at overall deaths from any cases among the patients, and not at quality of life or morbidity.\nA careful reader would be able to discern in the release that gobbling up soy supplements is not encouraged by the results of this study or the scientists who conducted it; and that there is a difference between saying something is \u201cnot detrimental\u201d in women treated with hormone therapy and that something is completely safe for all women with breast cancer.\nWe would have liked the release to include a statement noting that women with breast cancer should consult their physicians about their tumor\u2019s potential sensitivity to estrogen and to discuss dietary soy with them. This is particularly important since the release ends by quoting an editorial that encourages wide consumption of soy.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no broad discussion of safety or side effects.\u00a0 But one issue was raised that was not in the NYT story:\u00a0\n\"Women in the fish-oil group had lower rates of pre-term births, particularly births earlier than 34 weeks of gestation. But, there was a trade-off: More women who took the supplement needed their labor to be induced or had caesarean sections because the babies stayed in the womb longer, said Dr. Makrides.\"\nBecause it at least nodded in the direction of a specific potential harm issue, this story gets a satisfactory score on this criterion.", "answer": 1}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\n\u201cBut we have to prove that at certain doses, nobody gets hurt.\u201d\n\nReferring to glioblastoma patients, Dr. Riina said, \u201cEveryone is looking for something to do for these people.\u201d\n\n\u201cEven if you buy someone just a year, that could be a wedding or a graduation,\u201d he continued.\n\u201cSuppose someone said, \u2018I have much better drug.\u2019 Now I can say I at least have a delivery system.\u201d\n\nWith patients, Dr. Boockvar tries to walk a fine line, trying to level with them and yet not rob them of all hope.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\n\u201cYou never know what might happen in the year they hold onto.\u201d\n\nThe study, which began in August, is still in its earliest phase, meaning its main goal is to measure safety, not efficacy \u2014 to find out if it is safe to spray Avastin directly into brain arteries and at what dose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the infusion method has not been proven safe\u2013indeed, that\u2019s what the current study is designed to find out. \nIn addition, the reporter cites the doctor\u2019s estimated risks of the treatment the featured patient faces: a 5 percent chance of becoming \"visibly weak\" and a 1 percent chance of left-side paralysis.\u00a0\n\u00a0", "answer": 1}, {"article": "More women were still using the intrauterine system after two years than were still taking standard medical treatments -- 64 percent compared to 38 percent.\n\"If women suffer with heavy periods and do not want to get pregnant -- as the levonorgestrel intrauterine system is a contraceptive -- then having the levonorgestrel intrauterine system is a very good first-line treatment option that does not require taking regular, daily oral medications,\" said the study's lead author, Dr. Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\nFor women who do want to get pregnant, Gupta said, taking the blood-clotting drug tranexamic acid during periods is an alternate method of treating heavy periods.\nWEDNESDAY, Jan. 9, 2013 (HealthDay News) -- Women with heavy menstrual bleeding may find some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to new research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The explanation of side effects was not satisfactory. \u00a0There are a list of side effects on the manufacturer\u2019s website that were not mentioned in the story.\nAs correctly stated in the story, the most common side effect of Mirena is irregular bleeding. Since the purpose of the study was to compare overall effectiveness and side effects of Mirena vs. other medical therapies, it was adequate to the study\u2019s purpose to simply state that serious adverse effects were no different between the groups. But the story provides little detail provided about adverse effects of the other therapies, as well as Mirena. It would be useful to the reader to have a better sense of the kinds of side effects associated with both types of treatment.\n\u00a0", "answer": 0}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids\n\u201cPhysicians should counsel those with first time injuries on these benefits moving forward.\u201d\n\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is a global leader in orthopaedic sports medicine education, research, communication and fellowship, and includes national and international sports medicine leaders.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nResearch presented today at the American Orthopaedic Society for Sports Medicine\u2019s (AOSSM) Annual Meeting in Colorado Springs, CO, demonstrated that surgery after a first-time shoulder dislocation lowered the re-injury risks and need for follow-up surgery when compared to those who were initially treated non-operatively and experienced a repeat dislocation prior to surgery.\nThe Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether there were any drawbacks associated with undergoing surgery. This quote from the lead author appears to acknowledge their existence:\u00a0\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nBut it does not spell out what those drawbacks might be.", "answer": 0}, {"article": "(Reuters) - Patients who have robot-assisted surgeries on their kidneys or prostate have shorter hospital stays and a lower risk of having a blood transfusion or dying \u2014 but the bill is significantly higher, a study found.\nThe results were similar for people who had kidneys removed.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nOpen and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\nWe were going to get patients out of the hospital quicker, have better potency and incontinence outcomes,\u201d he told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits criterion above, the details provided were adequate.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited one instance of harms, saying: \u201c\u2026\u00a0for people who started out with at least 20 nanograms of vitamin D per milliliter of blood, adding more vitamin D through supplements was associated with a greater risk of hip fractures.\u201d\nWe also wanted to see a mention of potential harms of calcium, such as kidney stones. Another common side effect is excess gas and one potential harm of high doses is cardiovascular complications such as heart attack.", "answer": 0}, {"article": "For more information, visit http://www.\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\n\"Overall, considering the accumulating evidence of fetal benefit and safety, influenza vaccination of pregnant and postpartum women should be a public health priority in accordance with national recommendations,\" the commentary authors wrote.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms at all and that is an important omission considering the strong disagreement over the drug\u2019s side effects and effectiveness. The Centers for Disease Control and Prevention (CDC) and the Mayo Clinic both stress that the risks associated with oseltamivir are far outweighed by the benefits of using it to treat flu during pregnancy. And studies (like this one from 2010 or this one from 2013) have found no evidence that oseltamivir hurts the pregnancy or the unborn child. However, the Cochrane Collaboration, which reviewed numerous trial data found \u201cThe use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children.\u201d\u00a0 The study itself even acknowledged that the health risk to fetuses is unknown. \u201c\u2026the study does not answer the question as to whether early treatment is associated with lower rates of important adverse outcomes such as stillbirths and maternal deaths,\u201d the study states in a section describing limitations.\nThe medical society was remiss in not acknowledging the unknown safety issues and that health experts are in disagreement over oseltamivir\u2019s safety and effectiveness.", "answer": 0}, {"article": "\"The work by [first author] Price et al.\nThe study in rodents found that when mice had a particular gene -- SIRT1 -- knocked out, or turned off, resveratrol had no effect on them.\nThe paper also showed that the AMPK pathway was activated in mice given high doses of resveratrol, yet there was no benefit to mitochondrial function.\nSeveral studies, including work with yeast, worms and flies, have found that resveratrol acts on a class of seven genes known as sirtuins and, in human cells, SIRT1 in particular.\nThere was no effect on AMPK in mice given a lower dose of resveratrol.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms, nor of the concern for potential harms in the leap from mice to humans, nor of how long and widely a substance would need to be tested in people before its safety could be projected.", "answer": 0}, {"article": "P-Cure continues to develop advanced patient-centric solutions with a focus on adaptive therapy and real time motion management.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nIt may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery,\u201d said Michael Marash, Ph.D., founder and CEO of P-Cure.\nThe P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nWith P-Cure, oncologists can develop a compact, gantry-less proton center for significantly less capital and operating costs, essentially making proton therapy more widely available and attainable.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms associated with this therapy. As noted above, it makes passing and not numerically defined, reference to the potential harms of standard proton therapy, meaning radiation hitting parts of the body that don\u2019t need radiation treatment.\nThe release states indirectly who this wouldn\u2019t work for by giving the cancers that may be treated. The question of harm/benefit also depends on what the goal of the device. Is it to help patients already selected for proton beam therapy or to bring in patients who otherwise would be treated using conventional radiotherapy? Consideration of benefits and harms would differ, but neither is addressed.", "answer": 0}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\nLetters were mailed to all participants Monday notifying them of the results so they could consult with their doctors about switching to the less intensive therapy.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about the new finding that more intensive management of sugar levels in high risk patients increases mortality risk. Differences in death rates were given in absolute terms. ", "answer": 1}, {"article": "Over the next decade, 442 women were diagnosed with colon cancer.\nAs a result, experts now advise that while HRT is effective at relieving menopausal symptoms \u2014 like hot flashes and vaginal dryness \u2014 women should take it at the lowest dose and for the shortest time possible.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nThe study, which followed nearly 57,000 California teachers, found that women who were using HRT at the outset were 36 percent less likely to develop colon cancer over the next decade than those who had never used HRT.\nNEW YORK (Reuters Health) - Hormone replacement therapy (HRT) can carry serious health risks, but a new study adds to evidence that menopausal women who use the hormones may have lower odds of developing colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state, \"a large U.S. government study in 2002 found that postmenopausal women given HRT had higher risks of heart attack, stroke, breast cancer and blood clots than women given an inactive placebo.\"\u00a0 And we think that\u2019s sufficient in this case. ", "answer": 1}, {"article": "After a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n\"Are [aromatase inhibitors] better than tamoxifen?\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n\"Aromatase inhibitors are clearly associated with osteoporosis and with bone and joint [conditions].\nBut the [financial] costs are much more expensive.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "For more information visit http://www.\nMore than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.\nToday, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 50,000 NHS and private patients every year.\nSome of the data was presented at 16:25 CEST today (Sunday) at the European Society for Medical Oncology 2016 Congress in Copenhagen.\nProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the release does address side effects, stating: \u201cfewer patients experienced serious side-effects from taking nivolumab than with conventional treatment \u2013 only 13 per cent compared with 35 per cent of patients who received chemotherapy.\u201d However, it doesn\u2019t explain what those \u201cserious side-effects\u201d might be. According to the website for one nivolumab drug, these side effects may include inflammation of the brain or nerve problems that lead to paralysis. Patients, families, and healthcare providers make decisions based on quality of life as well as length of life, and information like this is essential for anyone wanting to make informed decisions about treatment options. It\u2019s not enough to refer to \u201cserious side-effects,\u201d you need to explain what those side effects may include. Vague language does a disservice to the reader.", "answer": 0}, {"article": "Tammy Wade knew she had to try something else to lose weight when she stepped on the scale and saw the number: 203 pounds.\n\"We have two-thirds of all Americans who are overweight or obese, and the costs are nearing $150 billion a year,\" says Christine Ferguson, a health policy professor at George Washington University.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\nYou recall the fen-phen episode where a significant number of people got heart-valve defects,\" says Janet Woodcock, a top FDA official.\nBarbara Troupin of Vivus, the company that is developing Qnexa, says the drug appears to do a lot more than just help people lose weight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story sidebar notes \u2013 from the FDA briefing documents: \u201cThe review noted continued concerns that Qnexa can increase the risk for several possible side effects, including increased heart rate, birth defects and thinking problems such as memory lapses and confusion.\u201d\nIt also included these caveats:\n\u201cThere\u2019s been a long history with obesity drugs that we\u2019ve had to take off the market. You recall the fen-phen episode where a significant number of people got heart-valve defects,\u201d says Janet Woodcock, a top FDA official.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won\u2019t just be obese people taking them.\n\u201cWhen you\u2019re talking about a drug where it could go into literally tens of millions of Americans, there has to be attention to safety,\u201d Woodcock says.\nWhat might look like a rare problem now could turn into another public health disaster, she says.", "answer": 1}, {"article": "For more information, visit http://medicine.\nThe study, \"The Impact of Preoperative Statin Therapy on Open and Endovascular Abdominal Aortic Aneurysm Repair Outcomes,\" recently was published in Vascular, the official publication of the International Society for Vascular Surgery.\n\"Our research showed that patients who took statins before either open or minimally invasive interventions had better outcomes compared to those who did not take statin medications,\" Vogel said.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"This information could be beneficial to patients who are about to have elective endovascular abdominal aortic aneurysm repair,\" Vogel said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Despite the horror show picture painted in the opening sentence, there is no explanation of the harms associated with statin therapy. Some discussion of the impact of giving statins to someone not already taking them would have added value to the release.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit for noting that DXA scans involve radiation, and for explaining exactly how much radiation one may be exposed to during a scan. However, that information could have been placed in a more health-relevant context. The DXA scan, the story says, exposes someone to \u201cabout the same as one day of background radiation\u201d and compares the dose to chest x-rays and mammograms. The story would have have stronger if it had explained whether that means low risk or high. A few more details would have been helpful here.", "answer": 1}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nHe points out that in The New England Journal of Medicine study, only 8 percent of the patients in the first surgical group subsequently tore a meniscus, a fragile pillow of cartilage that can rip if a knee gives way.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\nBut large-scale, randomized controlled studies, the gold standard of medical research, may be difficult to orchestrate, in part because people with shredded A.C.L.\u2019s can balk at being denied surgery.\nIn an important 2009 study published in The British Journal of Sports Medicine, researchers retrospectively compared outcomes after 10 years in competitive athletes who had surgery or had opted for conservative treatment of their torn A.C.L.\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several of the outcomes in this study straddle the line between benefit and harm (or lack of harm), so please see the \"Benefit\" criterion below, too.\u00a0Overall,\u00a0this story\u00a0covers the authors\u2019 key safety messages from the\u00a0published NEJM article, particularly as they refer to the rates of adverse events between the two groups. The piece says in general terms\u00a0that ACL surgery has risks like any surgery.\u00a0It would\u2019ve been better to include some more details.\u00a0A mention, if not quantification, of specific risks would\u2019ve added more balance to the discussion. The study\u00a0itself did consider surgical and anesthetic adverse events in its analysis. \nIt also could have been clearer about the uncertainty about the lack of long-term outcomes. We don\u2019t know how the two treatment groups will compare in terms of development of arthritis and future surgeries (e.g., more meniscectomies) farther out than 2 years. The challenge is that such long-term outcomes may be decades off in this young population.", "answer": 1}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nThe wearing away of cartilage leads to pain and other symptoms.\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that strontium can increase the risk for deep vein thrombosis, but doesn\u2019t indicate whether the drug was associated with any adverse effects in the study.", "answer": 0}, {"article": "For more information, visit www.aao.org.\nFor more information on glaucoma, visit the American Academy of Ophthalmology's EyeSmart\u00ae public information website, www.aao.org/eye-health.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes the authors saying the device is \u201cwell-tolerated and safe\u201d with a retention rate of 89 percent at six months. It also pointed out that some patients experienced itchiness and redness, which it describes as common adverse effects for patients taking glaucoma medication, and that the ring became dislodged in 15 patients, requiring it be replaced so therapy could continue.\nWhile the release adequately covers the known risks, in a study this small it would be good to remind readers that the device has not yet been tested on a large and diverse group of patients who might have different results. We also wonder how the ring would work in practice. Would patients who have difficulty following a treatment regimen in the first place be prompt about getting to a physician\u2019s office promptly to have a ring replaced?", "answer": 1}, {"article": "Oral infections, such as thrush, also may be diminished.\nThe transdisciplinary team, including William Ray, Department of Biochemistry; Andrea Dietrich, of the Charles E. Via Jr. Department of Civil and Environmental Engineering in the College of Engineering; and Glenn Lesser, from Wake Forest Baptist Medical Center, previously identified the role of lactoferrin, a specific milk protein, in diminishing the metallic flavor stimulated by chemotherapy medications.\n\"Our research shows that daily lactoferrin supplementation elicits changes in the salivary protein profiles in cancer patients - changes that may be influential in helping to protect taste buds and odor perception,\" said Duncan.\n\"By suggesting lactoferrin as a dietary supplement, we can reduce TSA for many patients, restoring their ability to enjoy foods during a time in which nutrition can play a key role in their recovery.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of potential harms from lactoferrin.\nReaders might be curious about the potential for intoxication (animal studies have been inconclusive in this area) or intolerance.\nWebMD mentions:\n\u201cLactoferrin can cause diarrhea. In very high doses,\u00a0skin rash, loss of appetite,\u00a0fatigue, chills, and\u00a0constipation\u00a0have been reported.\u201d", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world's most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\"\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\nThis protein, known as alpha-synuclein, can cause the brain's nerve cells to die when in a clustered state and is a hallmark sign of the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug nortriptyline has side effects. These include nausea, rare allergic reactions and liver toxicity in some patients. The release should have made some reference to potential harms, even if these are not well-known for this new therapy yet.", "answer": 0}, {"article": "Wolf notes, however, that chemoradiation often severely damages the larynx, which may cause problems with eating or swallowing years later.\nThe induction approach can be done anywhere, but requires intense collaboration among surgeons, medical oncologists and radiation oncologists.\nFor patients who must go on to receive surgery, by selecting them up front, we can spare them the complications that may occur when the voice box is removed following multiple cycles of chemotherapy with radiation,\" adds study author Francis Worden, M.D., professor of hematology/oncology.\nFor the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative treatment with chemotherapy and radiation to try to avoid surgery.\nBut the head and neck oncology team at the University of Michigan Comprehensive Cancer Center came up with a different approach: Give patients a single dose of chemotherapy and see who responds to it.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states: \u201cEven that single [initial] dose of chemotherapy can be debilitating and toxic for some patients.\u201d That\u2019s enough to earn it a marginal satisfactory mark here. The release would have been better if it had noted that radiation, surgery and chemotherapy all carry serious side effect risks. ", "answer": 1}, {"article": "For more information, go to http://www.\nThe study, published in the American Journal of Clinical Nutrition, was led by CHORI Senior Scientist Janet King, PhD.\n\"We were pleasantly surprised to see that just a small increase in dietary zinc can have such a significant impact on how metabolism is carried out throughout the body,\" says King.\nOakland, CA (January 3, 2017) - A new study by researchers from the UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) shows that a modest 4 milligrams of extra zinc a day in the diet can have a profound, positive impact on cellular health that helps fight infections and diseases.\nUCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We wish the news release mentioned that too much zinc is also harmful. According to the National Institutes of Health, increased zinc intake could lead to nausea, vomiting, loss of appetite, stomach cramps, diarrhea and headaches. When people take too much zinc for a long time, they sometimes have problems such as low copper levels, lower immunity and low levels of HDL cholesterol \u2014 sometimes referred to as the \u201cgood\u201d cholesterol.\nWhile this study was about food fortified with zinc, the news release was vague about how people should acquire their zinc, and this confusion could encourage people to reach for a bottle of zinc supplements.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "In effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\nCardiovascular fitness also improved in all three groups, but the lower-intensity exercisers who went longer did better than those who went shorter, and the higher-intensity group did better still.\n(It's unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.)\nAt the end of the study, members of all three exercise groups lost an average of about 2 inches from their waist circumference.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The high-intensity exercisers in this study had higher rates of musculoskeletal issues (cramping, strains, bone breaks \u2014 several of which required hospitalization) than other groups. Adverse effects caused more people to drop out of the study in the high-intensity group compared with the other groups. The story did not mention this.", "answer": 0}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nAmong the nearly 1,200 people who received the intervention, half as many people had made suicide attempts (or had come very close) as those in the control group.\nBut few of those suicide survivors get the follow-up care they need at a time when they are especially likely to attempt suicide again.\n\"It is a brief intervention that hospital workers, primary care staff, outpatient behavioral health, can all be trained in to utilize,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Patients could be potentially harmed if a hospital relies too heavily on the SPI instead of more thorough and immediate psychiatric care. For example, if a patient with a serious mental illness isn\u2019t diagnosed and treated promptly.", "answer": 0}, {"article": "This article has been updated to include additional comment from Kathryn Cullen.\nResearchers from the University of Minnesota (UM) and the nonprofit Mayo Clinic found that ketamine caused an average decrease of 42 percent on the Children\u2019s Depression Rating Scale (CDRS)\u2014the most widely used rating scale in research trials for assessing the severity of depression and change in depressive symptoms among adolescents.\n\"The purpose of our study was to investigate the effects of ketamine for TRD in younger patients for whom this indication for ketamine administration is not well studied,\" Mark Roback, a professor of pediatrics at the University of Minnesota, told Newsweek.\n\"Adolescence is a very important time for studying depression, first because depression often starts during these years, and second because it is an important time for brain development,\" Kathryn Cullen, from the Department of Psychiatry at UM, told Newsweek.\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story brushed over significant potential harms, including the potential for misuse. It stated that researchers \u201cfound that the treatment was well tolerated,\u201d and contained a quote stating \u201cwe still don\u2019t know about the long-term safety.\u201d\nAccording to the research paper, there were some issues the story ignored.\u00a0 Three participants became nauseous during the infusions, while two others experienced dysphoria (profound unease).\u00a0 One participant reported hand pain from the intravenous site that persisted for several days.\nAlso, with any invasive procedure \u2014 even infusions \u2014 there is always the risk of infections.\nBut most importantly, ketamine use requires considerable caution. It is now considered a misused recreational drug and some research indicates it can cause complications when used long-term.\nIt seems such cautions are particularly warranted due to the existence of clinics where ketamine is used off-label to treat depression.", "answer": 0}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nThey are an implant that slowly releases the hormone etonogestrel over a period of three years, and four IUDs: the copper T that can be used for up to 10 years, and three IUDs containing the hormone levonorgestrel (two approved for use up to three years, and one approved for up to five years).\nIn a paper published two years ago, European experts predicted that \u201cafter decades of dominance by \u2018the Pill,\u2019 it is likely that in the future, long-acting reversible contraceptives will become the first-line contraceptive option, owing to their superior contraceptive effectiveness in real-life use, cost effectiveness as well as their established safety profile.\u201d\n\nHere is a summary of the advantages of LARCs, listed by the committee:\n\n\u25a0 They are independent of the sex act and do not depend on the user\u2019s motivation and reliability.\nUnlike early IUDs no longer in use, \u201cmodern IUDs do not carry an increased risk of pelvic inflammatory disease after the first 20 days following insertion,\u201d Dr. Brooke Winner and her colleagues wrote in The New England Journal of Medicine.\nThe hormone, a form of progesterone, prevents ovulation and thickens the cervical mucus, making it harder for sperm to reach and fertilize an egg.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential side effects of long-acting implants or IUDs. These include \u201cirregular bleeding and cramping\u201d as short-term impacts. We\u2019ll give the benefit of the doubt, but we would have liked an additional comment by someone not connected to the committee report on whether there are any long-term studies underway about downstream potential impacts for women 5 or 10 years after using these. In addition, rare but potentially serious complications of copper IUDs, such as perforation (when the IUD pushes through the wall of the uterus), could have been mentioned.", "answer": 1}, {"article": "For example, over 6 years of follow-up, no ovarian cancer cases were seen among BRCA2 mutation carriers who underwent salpingo-oophorectomy, compared with 3 percent of carriers who did not undergo the procedure, the researchers report.\n\"One of the main messages of our study is that salpingo-oophorectomy should be part of any management plan for any woman who is found to have these genetic mutations,\" said Rebbeck.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nAccording to Rebbeck, doctors usually recommend that women who test positive for the genes have their ovaries removed at around age 35, but are okay with putting it off until age 40 if they haven't finished having children.\n\"There really isn't anything else that can reduce a woman's risk by this much.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story calls preventive surgery \u201cdrastic,\u201d but it doesn\u2019t provide any details about harms of the procedures. Also, the description of laparoscopic ovary removal makes the procedure seem entirely benign. No mention of how women might think about potential harms such as premature menopause, heart disease, osteoporosis, etc. ", "answer": 0}, {"article": "City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nThis study -- which is the first to suggest that the reduction in risk occurs for low-dose aspirin -- was proposed by City of Hope's Leslie Bernstein, Ph.D., professor and director of the Division of Biomarkers of Early Detection and Prevention, and published online in the journal, Breast Cancer Research.\n\"We already knew that aspirin is a weak aromatase inhibitor and we treat women with breast cancer with stronger aromatase inhibitors since they reduce the amount of estrogen postmenopausal women have circulating in their blood,\" said Bernstein.\nDUARTE, Calif. -- A City of Hope-led study found that the use of low-dose aspirin (81mg) reduces the risk of breast cancer in women who are part of the California's Teacher's Study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all \u2014 and regular use of low-dose aspirin isn\u2019t for everyone. As the Mayo Clinic notes, people with some medical conditions are at greater risk of complications associated with daily aspirin therapy.\nIt\u2019s well known that daily aspirin use can cause serious gastrointestinal bleeding in some people, which is why experts recommend a careful risk-benefit calculation even where benefits are more conclusively established \u2014 as in the prevention of heart disease. It\u2019s irresponsible not to mention those risks in the context of a speculative benefit such as breast cancer prevention.  ", "answer": 0}, {"article": "But many others are tough calls.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\n\"The device is only good for certain lesions, and that's why you have to be a dermatologist to be able to classify and categorize those lesions appropriately,\" said Christy Foreman, director of FDA's Office of Device Evaluation.\nThe Food and Drug Administration on Wednesday approved a first-of-its-kind device, called MelaFind, that makes detailed, digital images of skin growths and uses a computer to analyze them for signs of cancer, offering a sort of second opinion to doctors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s a bit confusing, but the story explains that the device also makes the wrong call too often, giving too many false positives. \u201cHowever, the device did not raise an alarm about non-melanoma growths only about 10 percent of the time; that was still better than doctors in the study who correctly ruled out melanoma in less than 4 percent of such cases, on average.\u201d Just presenting the false positive and false negative rates would have been more helpful to readers.", "answer": 1}, {"article": "Use of multiple hormone-blocking agents was associated with a 27 percent increased risk for heart disease.\nThe finding indicates that androgen therapy is overused because its benefits have not been shown to outweigh its dangers in many cases, said Dr. Nancy L. Keating, associate professor of medicine and public health at Harvard Medical School and lead author of a report on the study published online Dec. 7 in the Journal of the National Cancer Institute.\n\"There is a growing realization that we cannot use androgen deprivation therapy in a haphazard fashion,\" Klein said.\nMONDAY, Dec. 7, 2009 (HealthDay News) -- Diabetes, heart attacks and other cardiovascular problems appear to be more common in men with prostate cancer who are treated with androgen deprivation therapy, which reduces or eliminates the male sex hormones that can promote cancer growth, a new study has found.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story included quantitative information about the harms associated with androgen deprivation therapy. However, it mixed uses of relative risks and absolute risks within the same sentence, which we think can only confuse readers. Excerpt:\u00a0\nWe urge journalists to use absolute risk throughout every story.\u00a0 See our primer on this topic.\u00a0 \nNonetheless, we\u2019ll give the story the benefit of the doubt on this one.\n", "answer": 1}, {"article": "The findings are mixed on substance abuse.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\nAfter practicing mindfulness meditation, she continued to feel anxious at times but told Ms. Logan, \u201cI can stop and observe my feelings and thoughts and have compassion for myself.\u201d\n\nSteven Hayes, a psychologist at the University of Nevada at Reno, has developed a talk therapy called Acceptance Commitment Therapy, or ACT, based on a similar, Buddha-like effort to move beyond language to change fundamental psychological processes.\n\u201cWith the really hard stuff, you need something else, something that allows people to tolerate these very strong emotions.\u201d\n\nIn the 1990s, Dr. Linehan published a series of studies finding that a therapy that incorporated Zen Buddhist mindfulness, \u201cradical acceptance,\u201d practiced by therapist and patient significantly cut the risk of hospitalization and suicide attempts in the high-risk patients.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story alludes to the harms of mindfulness mediation for some patients who have had fewer than 3 episodes of depression (according to one study). The story also notes the general harms of a new practice becoming a fad when there are few standardized training programs, and it has not been studied long enough for all conditions for which it is currently being promoted. ", "answer": 1}, {"article": "Several of Cook's co-researchers work for the company.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nTHURSDAY, May 2, 2013 (HealthDay News) -- An implanted device that monitors brain activity may offer a way to predict seizures in people with uncontrolled epilepsy, a small pilot study suggests.\nThe prospect of being able to predict seizures is \"very exciting,\" he said, in part because it's the uncertainty of the disorder that can dim people's quality of life.\nThere are plenty of questions left, said Dr. Ashesh Mehta, director of epilepsy surgery at the North Shore-LIJ Comprehensive Epilepsy Care Center in Great Neck, N.Y.\n\n\"This study is an important first step,\" said Mehta, who was not involved in the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was careful to explain:\n\u201cBut any benefits need to be weighed against the risks. Besides false alarms and unnecessary anxiety, the implant itself can cause problems. In this study, three patients had serious complications, including one with an infection and one whose chest device moved and caused her pain. Two patients ultimately had the implants removed.\u201d", "answer": 1}, {"article": "There were some weaknesses in the study.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nThe potential for harm is notably absent in the story. Now, the study design was such that toxicity could not be evaluated and as a  result it was not addressed in the publication. However, the story should\u00a0 have noted that the harms of the drug are unclear at the present time. \n ", "answer": 0}, {"article": "Take this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nBut it's not only in the U.S.\n\n\"This is a global epidemic,\" Eckel emphasized.\nFor children, the numbers are also sobering: 20 million kids under age 5 are overweight.\nBy now, you've probably heard all the buzz about the Mediterranean diet, or perhaps you've tried it.\nOther components included: a moderate daily intake of alcohol with meals- mostly from red wine; eating fish, poultry or tree nuts (like walnuts or cashews) weekly; and limiting eating red meat to about twice a month.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t reflect on possible harms that might be associated with consumption of a\u00a0\u2018Mediterranean diet\u2019.", "answer": 2}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the study, 9 out of 99 (9%) of patients in the sham group reported at least one adverse event compared to 14 out of 102 (14%) in the sTMS group. Even though the authors suggest the adverse events were similar between the groups, the story should have reported this.\u00a0 Furthermore, we have no long-term information about problems associated with magnetic pulses in the brain, nor do we know about long-term effects on the primary endpoint, namely headache. Could they worsen over time? ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\n\u201cThe effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect.\u201d\n\n\u201cThe pomegranate people are spending millions to prove what I could have told them in the first place,\u201d she added.\nThe findings were presented at the American Society of Nephrology\u2019s meeting in Denver \u2014 aka Renal Week \u2014 and have not yet been vetted by independent experts.\n\u201cMuch higher than red wine, for instance.\u201d\n\nThe researchers figured an antioxidant-rich diet might help patients with kidney failure, because the level of free radicals in their blood increases as the blood circulates through the dialysis device.\nShe said her team had found no side effects, but added that kidney patients should be aware of the high potassium content in the juice, given the delicate balance of nutrients in their blood, and talk to their doctor if they consider drinking it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job.\u00a0 The story states that the \u201cteam had found no side effects, but added that kidney patients should be aware of the high potassium content in the juice, given the delicate balance of nutrients in their blood, and talk to their doctor if they consider drinking it.\u201d", "answer": 1}, {"article": "Barrow Neurological Institute is part of Dignity Health St. Joseph's Hospital in Phoenix.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release only reports the mild adverse effects, including headache and infection, which occurred in 11.9 percent or 5 out of 42 patients. It was a glaring omission not to report serious side effects that required some of the patients to undergo corrective surgery following the procedure. According to the published study:\n\u201cTwenty-six (61.9%) patients experienced 64 AEs related to the study procedure, of which 7 were serious AEs experienced by 5 patients (11.9%). Four (9.5%) patients required return to surgery: 2 patients for explantation due to infection, 1 patient for lead repositioning, and 1 patient for chronic subdural hematoma.\u201d", "answer": 0}, {"article": "They took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\nStill, the current study should ease concerns raised by earlier results from the WHI trials that an increased risk of breast cancer or heart attacks might translate into higher long-term mortality rates, said Dr. Melissa McNeil, author of an accompanying editorial and a women\u2019s health researcher at the University of Pittsburgh.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nThe current study, however, looked at longer-term data from the WHI study and found no increased risk of death from all causes, or from cancer or cardiovascular issues in particular, associated with hormone use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of outlining the complicated history of findings from hormone replacement studies, and the harms and risks, and uses numbers to explain the risks.\nThere is great nuance in the findings, which can be interpreted differently for women of different ages seeking HRT. Women bring different life risks of cardiovascular disease or breast cancer with them into any discussion of HRT.\nThe conclusion quoted in the story may be less-than-reassuring, but is here:\n\u201cHormone therapy has been in and out of favor \u2013 first it was good for all menopausal women, then it was dangerous for all women,\u201d McNeil said. \u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the study might not have been long enough to detect serious risks with long term use. It says, \u201cIf it works, patients would likely have to take Bryostatin-1 for the rest of their lives. The main adverse event\u00a0was diarrhea.\u201d", "answer": 1}, {"article": "Rydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\nCommon side effects of Rydapt in patients with AML include low levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\n\u201cThe ability to detect the gene mutation with a diagnostic test means doctors can identify specific patients who may benefit from this treatment.\u201d\n\nRydapt is a kinase inhibitor that works by blocking several enzymes that promote cell growth.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release effectively reports possible side effects experienced by AML patients receiving Rydapt, including \u201clow levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\u201d\u00a0 It also warns women who are pregnant or breastfeeding to avoid taking Rydapt.\u00a0 It also points out that the FDA approved the use of Rydapt for other patients with \u201ccertain types of rare blood disorders\u201d and provides a list of possible side effects they might experience.", "answer": 1}, {"article": "\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\n\u201cI think it\u2019s potentially good news, but I don\u2019t think it\u2019s to the point where people should go out and start using it,\u201d said Dr. Ronald C. Petersen, who heads the Mayo Alzheimer\u2019s Disease Research Center in Rochester, Minnesota.\nStill, she said, \u201cThere are things we can all do to postpone (mental) decline.\u201d Keeping medical conditions such as diabetes under control and getting regular exercise are two examples.\nAnd participants who got the hormone shots also felt the effects in their daily life, said Laura Baker, a memory researcher at the University of Washington & VA Puget Sound Health Care System in Seattle.\n\u201cAll you have to do is supplement that hormone and it then will result in a whole cascade of effects that then restore an aging system to a younger system,\u201d said Baker.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits, we wish the story had quantified the side effects observed in the study, but since side effects were acknowledged and since the following caveat was included, we\u2019ll give it a satisfactory score on this criterion:\n\u201c\u2026more work is needed to gauge the long-term consequences of GHRH injections. It\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\n\u201cIs it going to work in the long run and is it going to be safe? That is still unknown,\u201d said Petersen. \u201c", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms of this experimental approach.\u00a0 In the study, there was a failure of detection in one instance because of normally occuring material which gave off the same light as the \"paint\".\u00a0 This would be an example of a false positive test; there may be other instances where something similar could occur. How often does this occur?\nThis is an example of an animal research report being presented as applicable to humans.\u00a0 There is little, if anything, known about potential harms in human subjects.", "answer": 0}, {"article": "Galipeau was not involved in the Porter study.\n\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD.\nMoreover, the signal does not call down the deadly all-out immune attack -- the feared \"cytokine storm\" -- that can do more harm than good.\n\"I think it is a big deal,\" says Jacque Galipeau, MD, professor of hematology and medical oncology at Emory University Winship Cancer Center.\nOne of the molecules, CD19, makes the T cells attack B lymphocytes -- the cells that become cancerous in CLL.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a three-person study, it\u2019s difficult to quantify harms or benefits beyond just describing what happened to each patient. The WebMD story, though, did a better job of presenting the very real side effects of the study, even showing that the treatments for the side effects may have hampered the effectiveness of the cancer therapy. \u201cThe treatment was not a walk in the park for patients. One of the three patients became so ill from the treatment that steroids were needed to relieve his symptoms. The steroid rescue may be why this patient had only a partial remission.\u201d", "answer": 1}, {"article": "Barua is with the Kansas City (Mo.)\n\"It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels,\" Barua and his coauthors wrote.\nMeanwhile, the Food and Drug Administration issued guidance earlier in 2015 advising clinicians about the over-use of testosterone therapy, and pointing to a possible increased risk of heart attack and stroke.\nThe study team looked at national data on more than 83,000 men with documented low testosterone, all age 50 or above, who received care in VA between 1999 and 2014.\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions an FDA advisory about possible increased risk of heart attack and stroke with testosterone therapy. We\u2019ll call this acknowledgment of possible risks good enough for a Satisfactory rating, although many other possible risks exist including exacerbating sleep apnea, skin reactions, and promoting noncancerous growths of the prostate. One of the researchers is quoted as urging individuals to get appropriate screening from a health professional before considering\u00a0testosterone therapy, but the reader does not learn why this is important. Bottom line:\u00a0we know the overall mortality was lower in the group that was treated to a normal testosterone level, so serious adverse events , within the time frame of the study, do not appear to outweigh benefits. However, prostate cancer, for instance, is slow growing and might not have manifested within the time frame studied.", "answer": 1}, {"article": "Larger studies in many more patients are needed before the drug will be available, though, she says.\nThe benefit is small and studies have been inconsistent, says researcher Rachelle Doody, MD, head of Alzheimer\u2019s disease research at Baylor College of Medicine.\nOct. 8, 2012 (Boston) -- An experimental Alzheimer \u2019s treatment slowed memory loss by about one-third in people with mild Alzheimer's , offering hope that the drug can alter the course of the progressive disease.\nWhen the findings of the two studies were looked at individually, patients given solanezumab for 18 months didn\u2019t do better on either a test used to measure patients' symptoms or a measure of how well patients are functioning than patients given a placebo.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story included more detail than the AP story about rates of chest pain, reporting that just over 1% of trial participants taking the active drug reported chest pain, compared to just 0.2% of those in the placebo group. We do take some issue with the description as chest pain when the report describes it as angina.\u00a0 However, this story did not mention the cases of brain swelling and or small bleeding in the brain that were included in the AP report. Nonetheless, we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe study is published in the online edition of Archives of Neurology.\nOct. 10, 2011 -- A small study shows that a new drug being tested for the treatment of Alzheimer's disease reduces the buildup of plaques in the brain associated with the fatal disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than its HealthDay competition in that WebMD actually told us how many people experienced harms in the study.", "answer": 1}, {"article": "CHICAGO (Reuters) - A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said on Sunday in reporting an analysis of the results of a 10-year study.\nParticipants had 10 one-hour training sessions conducted in a classroom setting over five weeks.\nThe program got harder with each correct answer.\nResults of that study, published in 2014, found modest benefits in the reasoning and speed-of-processing groups, but not memory.\nThe institute is part of the National Institutes of Health, which funded the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine any serious harms from using brain games, other than time lost.", "answer": 2}, {"article": "What if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\n\"So right from the beginning you're trying to show that radio waves could activate gas and not harm the human-anything else,\" Stahl remarked.\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment repeatedly states that the treatment has no side effects. This is at least premature, at worst deceptive.\nThe segment should have stated that meaningful clinical outcomes (such as death and quality of life) even in animals have not been demonstrated, that little is known about the long-term effects of the treatment on surrounding tissues, and that the use of nanoparticles in cancer treatment is so new that it\u2019s premature to declare that their use in cancer treatment is without side effects. \nOne researcher interviewed makes clear that the inference that the technique does no harm to surrounding tissue is based only on \"gross inspection\" of that tissue.\u00a0 But the story simplistically states at one point, \"Kanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\"\u00a0 That\u2019s not proof of anything. ", "answer": 0}, {"article": "Zarate and his colleagues had previously demonstrated that ketamine shots helped some patients with treatment-resistant unipolar depression, meaning they did not cycle through manic episodes.\nThe problem in bipolar illness and depression, he explains, doesn\u2019t appear to be that a person has too much or too little glutamate; instead, it\u2019s likely that the way their neurons release and take up the chemical is out of whack.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nKetamine could improve treatment of bipolar illness and depression in a variety of ways, Zarate said; for example, as a means to jump-start standard drug treatment, or as an anesthetic before ECT.\nThe 18 patients in the study had tried an average of seven different drugs for treating their bipolar illness, and were still severely depressed; 55 percent had failed electroconvulsive therapy (ECT), or shock treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify the potential harms. In fact, it minimizes the potential harms by saying there were no \"serious adverse events,\" while listing side effects that\u00a0included anxiety, feeling woozy or loopy, headache, and dissociative symptoms, meaning a temporary sense of disconnection from reality.\" People on ketamine may have a different perception of what is serious. ", "answer": 0}, {"article": "This diet excludes many compounds found in wheat, certain fruits and vegetables, garlic, onions and sugar substitutes.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While a dietary intervention may seem relatively harmless, there are notable risks. Potential nutritional deficiencies and changes in gut bacteria following a low FODMAP diet long-term have not been studied. Some people may also find it\u00a0 inconvenient to be on a restricted diet that prohibits consuming their favorite foods.", "answer": 0}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\n\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n\"The cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\" said Dr. Wanna.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Drilling into your ear to implant a device can involve harm. \u00a0As for harms, we learn of them only obliquely with this phrase: \u00a0\u201cthe non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\u201d \u00a0Are we to presume that the wire electrode implants can be \u201cmore traumatic?\u201d More detail was definitely needed here.\nThe favored \u201cround window\u201d approach is also considered safer given that the news release reports that \u201cthe cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\u201d according to the lead researcher. \u00a0How much harm? We don\u2019t know.", "answer": 0}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "The body naturally synthesizes vitamin D when the skin is exposed to sunlight.\nAt the end of the study, the researchers found no clear difference between the two groups in the average number of days missed from duty due to a respiratory infection \u2014 which included bronchitis, sinus infections, pneumonia, ear infections and sore throat.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\nOn the other hand, a recent study of 162 adults found that those who took 2,000 IU of vitamin D everyday for 12 weeks were no less likely to develop respiratory infections than those given placebo pills.\nVitamin D has been the subject of much research of late, with studies linking low vitamin D levels in the blood to higher risks of type 1 diabetes and severe asthma attacks in children and, in adults, heart disease, certain cancers and depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story cautions that vitamin D can cause problems including nausea, vomiting, constipation, poor appetite, weight loss and even higher blood pressure or heart rhythm abnormalities.", "answer": 1}, {"article": "\"The bottom-line finding of the Alpha Omega Trial is that [omega]-3 fatty acids did not reduce the primary endpoint major cardiovascular events,\" Kromhout said, noting that the ALA finding needs further confirmation.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\nDuring the study, the patients consumed an average of 18.8 grams of margarine per day, which meant ingestion of an average of 226 milligrams of EPA combined with 150 milligrams of DHA omega-3 fatty acids and/or 1.9 grams of ALA.\n\nBy the study's end, almost 14 percent of the heart attack patients had experienced another \"major cardiovascular event,\" with some cases ending in death.\nAt the study's start, the patients were instructed to consume (over a period lasting a little over three years) one of four different types of margarines: one supplemented with omega-3 fatty acids; one supplemented with the plant-derived ALA; one supplemented with both omega-3 fatty acids and ALA; and one with no supplements.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While mentioning that there didn\u2019t appear to be any benefit from the use of fortified margarine, the story neglected to report that there also didn\u2019t seem to be any overt harm from the used of the fortified margarine. Even the absence of harm is worth mentioning.\u00a0 We look for discussions of benefits, harms and costs in all stories and don\u2019t see same often enough. ", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\nAlthough HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects.\n(fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The jury remains out about the potential long-term effects of what some refer to as endocrine disrupters. Readers of this release are told there were no \u201cserious\u201d side effects, but not what the side effects were.\nNor was there any mention of the ongoing scientific debate about the safety of phytoestrogens. Concerns have been raised about tumor promotion in estrogen-sensitive tumors from phytoestrogens (although plant estrogen is actually very weak compared to estrogen used for pharmacologic purposes).", "answer": 0}, {"article": "But for now this category is useful only to researchers.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAs the story makes clear, lab tests and brain scans looking for signs of Alzheimer\u2019s are not ready for clinical use, so it is reasonable to defer discussion of the potential harms of such tests. The story does mention that the revised guidelines do \u201cleave one wondering if a lot more worry will be generated by the notion of \u201cpreclinical Alzheimer\u2019s,\u201d when science and medicine can\u2019t offer anything to ease those fears.\u201d", "answer": 1}, {"article": "WHAT'S NEXT: Researchers said they want to see whether moderate drinking also benefits women with hypertension.\nThe researchers found that people who drank moderate amounts of beer, wine, or liquor had fewer heart attacks, though their risk of death was not significantly different from that of the other subjects in the study.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nOverall, the results suggest that a change in societal messages could spur changes in actual performance.\nBefore the test, one group was exposed to a negative stereotype: They were told that women do not perform well at spatial reasoning.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does mention excessive drinking as a harm (it could raise blood pressure), it does not mention any of the other potential adverse effects.", "answer": 0}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThese areas, called the caudate and the nucleus accumbens, found in the centre of the brain, have previously been linked to food cravings and the motivation to want a food.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\nProfessor Gary Frost, senior author of the study from the Department of Medicine at Imperial, said: \"Our previous findings showed that people who ate this ingredient gained less weight -- but we did not know why.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Even if there were no direct harms/side effects of the supplements, it would have been useful to say so explicitly. It would also be useful to know if there\u2019s a risk from long-term use since there was the suggestion it might have an impact on the body\u2019s microorganisms. It also appears as if the MRI was a form of fMRI which may have carried some risks, however small.", "answer": 0}, {"article": "That's why they compared ketamine patients with patients taking other pain medications.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\n\"While most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite -- lack of a symptom,\" Cohen said.\n\"The approach we used here could be applied to any number of other conditions, and may reveal new and important uses for thousands of already approved drugs, without large investments in additional clinical trials,\" Makunts said.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from taking ketamine. A British Journal of Clinical Pharmacology study of ketamine for chronic pain devoted a lengthy discussion to side effects from clinical ketamine use, dividing them into central nervous system (CNS)-related, cardiovascular and hepatic (liver).", "answer": 0}, {"article": "For more information, please see www.arthrokinex.com\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThe process works by using one's own blood \u2013 specifically the body's own anti-inflammatory proteins and human-growth elements \u2013 to end or ease pain and chronic injuries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release mentioned no potential harms of the treatment, and emphasized multiple times the supposed safety of the treatment as a \u201cnon-drug, non-surgical treatment derived from your own blood.\u201d\u00a0\nBut just because it\u2019s from your body doesn\u2019t mean it\u2019s inherently safe\u2014further study would be necessary to determine the safety and risk of adverse reactions.\nThough probably safe if done in a sterile fashion, there is no information on the long-term impact of this treatment on the arthritic joint.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss adverse events related to yoga or intensive stretching. Yet the authors of the study reported on both. These are important issues, as many patients with chronic back pain fear that becoming physically active will exacerbate their symptoms.\n\n\n\n ", "answer": 0}, {"article": "The average age of children in the study was 7.\n\"The difference in sniffing pattern between the typically developing children and children with autism was simply overwhelming,\" says Noam Sobel of the Weizmann Institute of Science in Israel.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nBut the most immediate question for Sobel is \"whether an olfactory impairment is at the heart of the social impairment in autism.\"\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The problem with any diagnostic tool, including very early-stage diagnostic concepts like this one, is that while they can offer accurate diagnoses \u2014 they may also provide an inaccurate diagnosis. This is particularly relevant, since the release quotes one researcher as saying the work \u201craises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\u201d But here\u2019s the thing: in the event of a \u201cfalse positive\u201d diagnosis of ASD in a very young child, it may take months or years for the diagnosis to be disproven. That could cause unnecessary stress for the patient and family and \u2014 given the expense of ASD treatment for many families \u2014 could impose a significant economic burden as well. The\u00a0damage would be minimized by using the test, as any test should be, in the context of a good clinical evaluation.", "answer": 0}, {"article": "IRE uses strong electric fields that cause cells to die without exposing the tissue to radiation or heat.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nInitial tumor control was achieved in all patients, and during the follow-up period of up to 4 years, the recurrence rates were 0/55 (Gleason <7), 3/117 (Gleason 7) and 10/67 (Gleason >7).\nFor the study, Dr. Stehling and his team of researchers evaluated data from 265 patients with primary (stages T1-T4) and recurrent PCa after surgery, radiation therapy and HIFU.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes several different claims about the superiority of this treatment method to others \u2014 but never brings up the potential of harm.\n\u201cThe patients we have treated in the Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\u201d the release states. [Italics ours].\nThe word \u201cdestroyed\u201d is not typically used in medicine. Even if there is a \u201clow incidence\u201d of side effects, we would like to know what those rare side effects are.\nFurther, the news release provides no information about how side effects were measured (e.g., standardized measures completed by patients, physician assessments\u2013which is not considered reliable), how many men actually completed reports of complications, the median length of follow-up\u2013saying \u201cup to \u00a04 years\u201d is very imprecise. (They could have been followed just 6 months, 1 year, and so on.)\u00a0 Another problem is that the recurrence group\u00a0included\u00a0men who had already been treated with surgery or radiation\u2013which do cause erectile dysfunction and urinary incontinence. To interpret complication data the reader needs to know the level of urinary control and sexual function before the IRE treatment. The release also does not describe how recurrence was defined, whether all men were evaluated, and\u2013again\u2013the median length of follow up.", "answer": 0}, {"article": "Previous studies have found women's monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues.\n\"While overall more men than women smoke cigarettes, women and girls take less time to become dependent after initial use and have more difficulties quitting the habit,\" the researchers write in their study.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nAfter undergoing the brain scans they viewed the photos a second time and reported on a scale from zero to 100 if the pictures triggered cigarette cravings.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned, but it\u2019s also difficult for us to envision what they might be in this case, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "WASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nRisk-based screening is a poor approach.\n\"All women age 40 and over can benefit from annual mammography.\nContact Joy Burwell at 202-263-2971 or jburwell@amplifypublicaffairs.net to arrange an interview with an SBI spokesperson.\nContact Shawn Farley at 703-648-8936 or PR@acr.org to arrange an interview with an ACR spokesperson.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Overdiagnosis and overtreatment aren\u2019t discussed, but these are real and significant issues with mammography.", "answer": 0}, {"article": "That study was funded by the device\u2019s manufacturer, Neuronetics, a company based in Malvern, Pa.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThe technique has been shown to work better than a placebo, but the proportion of patients who show complete relief ranges widely, from as few as 10 percent to as many as 57 percent, according to various studies.\nThe costs of ECT \u2014 typically about $3,300 for four weeks of thrice-weekly treatments, according to AHRQ data \u2014 are covered by most private insurers as well as by Medicare and Medicaid.\nThe procedure, which is more widely used than rTMS, requires two to three treatments a week for three to four weeks and is effective for many patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately addresses adverse effects. It says, \u201cStudies have shown that side effects are few and generally minor, such as headaches and scalp irritations.\u201d In addition, \u201cA few small studies have looked at its effects on cognitive function and found either no effect or slight improvement.\u201d\nInteresting, in the AHRQ report, rTMS vs ECT had about the same number of withdrawals due to adverse effects, so despite the scarier sounding potential adverse effects from ECT, dropouts due to actual adverse effects were about the same.", "answer": 1}, {"article": "He agreed that quicker diagnosis could mean better treatment and outcomes for patients.\n\"By diagnosing diabetes quicker, we can improve outcomes,\" said Courgi, an endocrinologist at Northwell Health's Southside Hospital in Bay Shore, N.Y. \"The current standard is to delay diagnosis with repeat office visits and blood work.\nCurrently, it's recommended that a blood test focused on elevated fasting levels of blood sugar (glucose) or a blood component called glycated hemoglobin (HbA1c) be confirmed with a second blood test at a follow-up visit.\n\"The CDC reports that greater than 52 percent of the U.S. population has either clinical diabetes or prediabetes,\" Bernstein noted.\n\"I'm hoping that these results will lead to a change in the clinical guidelines when they are revised in early 2019, which could make identifying diabetes a lot more efficient in many cases,\" Selvin said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story would have benefited from an exploration of the harms of overdiagnosis and overtreatment. Many of the patients who tested positive in both tests didn\u2019t develop diabetes until a decade or two later. Potentially, patients like that could be treated overly aggressively with drugs that could do them harm.\nLikewise, an accompanying editorial notes that the criteria proposed by the study might miss more people with diabetes than the conventional method of repeated blood glucose tests. In the data studied, simultaneous A1C and blood glucose tests agreed only about 40% of the time, versus 70% agreement for successive blood sugar tests.", "answer": 0}, {"article": "A family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nWhile some people improve with customized diets that avoid certain foods that trigger symptoms, this approach doesn\u2019t help everyone and some emerging research suggests that the condition may also be influenced by processes in the brain.\n\u201cOne component of IBS is increased sensitivity to the functions of the bowels; simply summarized, this means either the nerves taking messages from the bowel to the brain are more sensitive or that the brain is more attentive or reacts in a more emotional manner to the normal messages arising in the bowel, or both,\u201d said Dr. Michael Camilleri, a researcher at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota, who wasn\u2019t involved in the current study.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\n(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are also not addressed. This is particularly problematic for the sections of the piece that deal with antidepressants. For example, the story specifically mentions both tricyclic antidepressants (which have potential side effects ranging from constipation to sexual problems) and selective serotonin reuptake inhibitors (which can also pose health risks). We don\u2019t expect a story like this one to provide an exhaustive overview of risks associated with these classes of drugs, but we do think it should at least acknowledge that there are risks.", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss the potential harm due to the increase in radiation exposure, but was then followed by a quote from the VP of breast health at the company making the device dismissing some of the concern related to the increase in radiation.\nThe article did not mention rates of false positives or false negatives with the new imaging.\u00a0\u00a0It could be that it finds lots of new things\u00a0that\u00a0lead to many more biopsies but not all cancer (i.e. they report the recall rate, but what about the biopsy rate for traditional vs. 3-D?)\nSo despite the headline that addresses false positives, the story doesn\u2019t give any evidence on that question.", "answer": 0}, {"article": "Combining data from 20 clinical trials, which included over 1,000 patients with chronic insomnia, the authors calculated sleep improvements after C.B.T.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nA big part of the difference may be how insomniacs perceive their sleep performance and the negative messages they give themselves about their poor sleep and how it will affect their daily lives.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nIn this way, unless exacerbated by physical causes \u2014 like sleep apnea or restless leg syndrome \u2014 insomnia is a condition of the mind that then infects the body.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no known harm to CBT for insomnia. There are myriad harms to commonly used sleeping medications. Although the story would have been strengthened by explaining those harms (further dissuading people from medication, which is what physicians recommend), the story\u2019s failure to mention harms of medications when the article itself was about CBT seems overly punitive. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "CHICAGO - A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\nHerniated disks are often the source of sciatica, or pain that radiates downward from the lower back into the leg.\n\"We learned that when pulsed radiofrequency is followed by steroid injection, the result is longer lasting and more efficacious than injection only,\" Dr. Napoli said.\nIn some cases, the entire disk must be removed and the vertebra fused together for stability.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release leads with a phrase we find problematic: \u201cminimally invasive.\u201d For many readers this connotes a quick, \u201csafe and effective\u201d intervention as mentioned in the release. But \u201cminimally invasive\u201d can potentially have more complications than a prior \u201cmore invasive\u201d approach.\nNo instrumentation close to the spine or its nerve roots is risk-free. Nerve damage and infection are two potential complications that should have been mentioned.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in describing the side effects seen with Lamisil, a drug approved for this use. Unfortunately it does so with a bit of an apparent bias, \u201c\u2026.If you are willing to risk side effects, \u2026\u201d in its discussion. Although the laser treatments are generally well tolerated, some people have mild pain and a sense of warmth. We would have been willing to give the benefit of the doubt but the suggestion that there are absolutely no side effects associated with the laser treatment leads us to rule this unsatisfactory.", "answer": 0}, {"article": "Cao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\n\"There has been a great deal of interest in understanding the possible benefits associated with common drugs,\" Tamimi said in an emailed statement.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\nTherefore the findings are believed to be very robust, and suggest that aspirin, which is widely available, cheap and has limited toxicity, has the potential to have widespread benefit on cancer mortality for breast, colon, lung and prostate cancer.\"\n\"It is good to remember, though, if a person wants to take a low-dose aspirin, especially if a person has had cancer, they will want to have an initial conversation with their doctor first.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding. Studies have showed an increased risk of both when taking a daily aspirin.\u201d", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big hole. As noted earlier in this review, bariatric surgery is not without risk of complications, particularly in people with multiple morbidities and older age or very young age. It behooved the story to say something about this, including the risks and harms of untreated diabetes or diabetes and obesity in people who have tried everything and failed to resolve either condition.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explores the issue of whether Rituxan may suppress the immune response too much, making the patient vulnerable to other diseases. It also explains how this effect has been observed in the drug Tysabri, a different immune suppressant used for MS.", "answer": 1}, {"article": "First published on September 5, 2007 at 12:00 am\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nWhile surgical robots have been available for most of this decade, few are used to do cardiac bypass surgery, even though that was their focus when the machines were introduced.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to compare key risks\u2013of death, complications, need for additional surgeries,\u00a0infection rates, etc.\u2013of robot-assisted to conventional surgeries. Again, since the article raises the comparison between stenting and robotic surgery, these risks should have been compared too. Because the story uses anecdotes that suggest better outcomes and fewer side effects, the reporter should have looked for data to compare those anecdotes to.", "answer": 0}, {"article": "\"\nIn his study, doubling the length of treament also doubled the risk of endometrial cancer, which affects the uterine lining, to about 3%.\nOxford funded the study, which included more than 6,800 women from 36 countries, While tamoxifen delays tumor growth in some women, it appears to cure others, Gray says.\nThat's because postmenopausal women have the option of tamoxifen or another class of hormonal therapies, called aromatase inhibitors, or AIs.\nOverall, women who take tamoxifen for a decade cut their risk of dying from breast cancer nearly in half, compared with those who don't take it at all, says study co-author Richard Gray of the University of Oxford in the United Kingdom.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give the story the benefit of the doubt.\nGood points:\nRoom for improvement:\nThe story provided only one woman\u2019s tale of side effects.\u00a0 It provided no estimate of how often these occur. And the Young Survival Coalition pointed out another age-specific concern in the statement it released:\nFinally, a particular concern with this study is the impact that this study may have on young women\u2019s family planning.\u00a0 Many young women already wait until they have completed their five-year course of Tamoxifen before trying to start a family.\u00a0 Will this study cause that delay to become 10 years?\u00a0 And, are the modest benefits shown in this study worth that?\u00a0 That is a very personal decision and again, we recommend speaking with your physician.", "answer": 1}, {"article": "\u201cModels are models,\u201d Lin said.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nSome experts in cancer screening and statistics said its novel approach was \u201con shaky ground\u201d and used a \u201ccompletely unverifiable\u201d methodology that they had \u201cnever seen before,\u201d but others praised its \u201cintriguing and innovative approach.\u201d There was one area of agreement, however: \u201cI imagine it\u2019s going to generate some buzz,\u201d said biostatistician Ted Karrison of the University of Chicago.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nAn analysis of two influential studies of prostate cancer screening concludes that the much-debated test \u201csignificantly\u201d reduces deaths from the disease, suggesting that current recommendations against routine PSA screening might be steering men away from a lifesaving procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing from information produced by the USPSTF, the article concluded that the gains in prostate cancer detection \u201ccome at some cost to health, though: For every life saved, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them. In\u00a0other estimates, such \u201coverdiagnoses\u201d outnumber lives saved by 50-to-1.\u201d\nThe one harm that is often overlooked in widely-promoted screening programs is the psychological harm that perfectly healthy people may experience when they have had a \u201ccancer scare,\u201d and that even though their life is unlikely to be saved, the worry, anxiety, depression and angst do exact a substantial life-altering toll that goes unmeasured.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms of treatments mentioned. The article mentions in a general way that \u201cimpotence and incontinence are common following surgery to remove the prostate\u2026\u201d Yet presenting one person\u2019s very rosy experience with the new technology\u2013\u2026\u201dhad no difficulty with either incontinence or impotence\u201d\u2013seems unbalancing. ", "answer": 0}, {"article": "The study appears in the September issue of the journal PLoS Medicine.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nSeveral studies have suggested a role for statins in slowing the progression of disease among patients with rheumatoid arthritis, but others failed to find a protective benefit for statin use.\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nEven though the authors of the research study commented on the risks of statin use in order to place this potential additional use into context, this story failed to include any mention of the potential harms.", "answer": 0}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the weak points in this story \u2013 and in many of the stories we saw on this study, frankly \u2013 was that, while harms or complications were mentioned, they were not defined nor quantified.\u00a0 What harms?\u00a0 And how often do they occur? This story had a quote that \u201cI don\u2019t think we\u2019ve educated [people] well enough\u201d about the possible risks \u2013 but the story itself didn\u2019t do so.\nThe AP story, by comparison, at least mentioned \u201crisks that occur more often with older patients, including complications from sedation, accidental performation of the colon and bleeding.\u201d", "answer": 0}, {"article": "Oct. 6, 2010 -- An extended-release version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal treatment for menopause -related hot flashes .\n\u201cEstrogen and estrogen-progestin drugs are about 95% effective for treating hot flashes,\u201d he tells WebMD.\nResearchers presented findings from two studies of Serada at the NAMS meeting.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nUtian is now an independent consultant and was a co-author of one of the studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nGluten is not a carbohydrate; it\u2019s a mix of proteins found in wheat and its close relatives (including spelt, kamut and farro), as well as in barley and rye.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nIt\u2019s what gives bread its elasticity, but it also sets off the immune system of people with celiac disease, damaging the small intestine and sometimes producing painful and unpleasant symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the strongest aspect of the story and the area where readers are likely to find some value. The story explains that the low-FODMAP diet has drawbacks, since foods high in FODMAPS are thought to stimulate growth of certain bacteria associated with digestive health. We\u2019d add that anything that restricts consumption of fruits and vegetables has the potential to reduce the quality of your diet and potentially impact your health. This is especially true for children. The story rightfully\u00a0stresses that a low-FODMAP diet should be used \u201cto reduce specific symptoms, not as a way to improve health.\u201d", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nFor example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays, he said.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\nIn addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.\u201d Although the release does not go into specific detail about the number of patients who reported side effects, or the degree of severity of the side effects, the list of harms seems adequate for a drug just beginning the clinical trial process.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potentional harms of the vaccine.", "answer": 0}, {"article": "Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nOf those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent.\nThey target a certain protein that has the ability to shut down T cells \u2013 a part of white blood cells that help the body fight infection and disease naturally.\nAs well, at least when used as single agents, these agents tend to confer side effects that patients find much more tolerable than those associated with chemotherapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is one sentence related to harms in the release, but it doesn\u2019t tell us what they are.\n\u201cThere were no treatment-related deaths or therapy discontinuations due to drug-related adverse effects.\u201d\nThe package insert lists the most common side effects as\u00a0fatigue, cough, nausea, diarrhea, constipation, anorexia, arthralgia (joint pain), pruritus (severe itching), and rash.", "answer": 0}, {"article": "But the procedure had never been done in people.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nThe microscopic bubbles \u2014 roughly the size of red blood cells \u2014 had previously been injected into a vein, along with a chemotherapy drug called liposomal doxorubicin and a tracing molecule.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a single patient and the story does mention that \u201cno damage from the ultrasound was visible inside her brain.\u201d But breaching the blood brain barrier is a big deal and likely would entail harms, especially if done repeatedly as would need to be done in many clinical treatments. There\u2019s certainly a risk of bleeding as the news release mentions in a related Q&A. Some discussion of harms/tissue damage or lack thereof seen in animal studies would have been informative.\nThe story does contain information from someone who appears to be an independent voice\u2013Dr. Gordon Li\u2013cautioning the reader that the ability to get drugs into the brain now requires effort to determine \u201csafe doses\u201d of those drugs. \u00a0But that issue is given just a glancing blow \u2014 not enough for a Satisfactory grade here.", "answer": 0}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nA recent meta-analysis done by the same group of researchers found a 27 to 31 percent increased risk of heart attacks in women taking calcium without vitamin D.\n\nMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\n\"There is a lack of consensus at the present time as to what recommendations should be regarding the use of calcium supplements,\" said study senior author Dr. Ian Reid, who fully expected that the new results will have a \"significant impact on recommendations.\"\nTUESDAY, April 19, 2011 (HealthDay News) -- More evidence is emerging that women who take calcium supplements to prevent bone deterioration may, in fact, be risking their heart health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to quantify the potential harms from calcium, but, because the numbers were presented only in relative terms, we feel readers will not be able to adequately assess for themselves whether they need to change their behavior. For example, the story says, \u201cwomen who were randomized to take calcium and vitamin D as part of the study protocol had a modest 13 to 22 percent increased risk of cardiovascular problems, particularly heart attacks.\u201d Then it says, \u201cThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women. Now the increased risk for heart attack was 25 to 30 percent and, for a stroke, 15 to 20 percent.\u201d We\u2019re not sure why a 22 percent increased risk is considered \u201cmodest,\u201d while a 25 percent increased risk is cause for alarm. Some absolute numbers and even an explanation showing the number of women who would have to take calcium regularly in order to see one heart attack would have been good context.", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects were reported in the research; however, the story briefly mentions the ethical and medical concerns that may be associated with a drug that erases memory. ", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"We don't want to send the message to people who have bone-on-bone, with big bone spurs and limited range of motion that they're all of a sudden going to get relief from injecting a little bit of cement into their bone,\" Hepinstall said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\nThe calcium phosphate cement flows into the spongy inside portion of the bone, filling in microfractures and other damaged areas, and it hardens in about 10 minutes' time, said Dr. Kelton Vasileff, an orthopedic surgeon at the university's Wexner Medical Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the story is the harm of overselling the benefits of the procedure. There is no discussion of whether there are other significant harms to consider. Like all surgery, this procedure will have serious risks\u2013both within the joint that\u2019s being injected and throughout the body. (A similar injection into the spinal vertebrae, called vertebroplasty, comes with very serious potential risks.)", "answer": 0}, {"article": "The women were separated into two groups.\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\nStill, \"the observations are consistent with what we have seen with the value of early detection.\nThey were also 32 percent more likely to need surgery to remove the whole breast (mastectomy), and 66 percent more likely to need lymph nodes removed.\nHowever, the study did not prove a cause-and-effect link between earlier mammograms and smaller tumors and less aggressive treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of the harms of earlier or more frequent screening, which have been documented time and time again. More screening can mean more false positives or more finding of breast changes that lead to more testing, such as biopsies, more costs, and more worry.", "answer": 0}, {"article": "The other half went to Weight Watchers meetings, had access to Weight Watchers' online materials and had two phone consultations and follow-up email contact with certified diabetes educators who told them how to modify the Weight Watchers plan to help with their diabetes.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nLeft uncontrolled, the condition can damage blood vessels and nerves, putting people at risk of having a heart attack or stroke.\n\"You can lose some weight and lower your blood sugar - and may even be able to change your medications.\nThe study's 563 participants were all overweight or obese and under a doctor's care for uncontrolled Type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Most interventions pose some kind of potential harms and Weight Watchers is no exception. For some, particularly those without access to a dedicated dietitian as the study participants had, the amount of sodium in a WW points-based meal plan may be too high, or the vitamins insufficient to maintain nutritional needs.", "answer": 2}, {"article": "Many older adults prefer psychotherapy to medication for the treatment of anxiety.\nEditorial: Solving the Geriatric Mental Health Crisis in the 21st Century\n\nIn a related editorial, Eric J. Lenze, M.D., of the Washington University School of Medicine, St. Louis, writes: \u201cTherefore, we are in the midst of the following two unprecedented trends: the aging of the population and the transformation of everything in our lives by mobile technology.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nThe clinical trial demonstrated both treatments reduced symptoms of worry, depression and GAD, but telephone CBT was superior to telephone NST and resulted in a greater reduction of symptoms.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentioned no possible harms from this approach, although in fairness, supportive telephone conversations are unlikely to carry much risk. \u00a0 However, we wonder about\u00a0situations where the telephone therapy sessions may not detect some problems that might surface during a face-to-face consultation.", "answer": 2}, {"article": "Plus, surgical techniques have improved.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nAs a result, surgeons are trying to find remedies for problems that, Byrd said, had received \"no treatment at all\" in the past.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\nDerek Ochiai, a surgeon with the Nirschl Orthopaedic Center in Arlington, who began performing hip arthroscopy six years ago, estimates that he did only about a dozen of the procedures that year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe news story fails to mention potential harms of hip arthroscopy. A recent review suggests the rate of complications for all indications is \u201cgenerally less than 1.5%.\u201d (Clin Orthop Rel Res 2009;467:760-8) Various sources suggest complications include: scuffing of the articular cartilage and chondral surface from instrument breakage and inadequate distraction (separation of the femoral head from the hip socket); iatrogenic dislocation; nerve damage (sciatic, superior gluteal, lateral femorocutaneous); removal of too much labral tissue; removal of too much bone, thus weakening the bone and causing a fracture; damaging the blood supply to the femoral head, leading to avascular necrosis; temporary numbness of the perineum or foot (a distraction neuropraxia); and scrotal necrosis. Although an expert says that the procedure is meant to prevent future arthritis, this is not quantified; without good data on people who did not have the procedure, it is conceivable that arthroscopy could promote arthritis.", "answer": 0}, {"article": "And will they change the quality of sleep in any way?\nUslaner and his colleagues investigated a compound called DORA-22, which has the same mechanism of action as suvorexant, to see how it fared alongside not only Ambien and Lunesta but also diazepam (Valium) in rats and rhesus monkeys.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nThis is the first time in years that scientists have targeted a totally different receptor in the quest to combat insomnia, said Dr. Alexandre Abreu, co-director of the UHealth Sleep Center at the University of Miami Miller School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag.\nWhile the study did not examine the effects of DORA-22 in any detail it did in fact look at level of cognition in the animals studied.\u00a0 While the story notes, \u201cDORA-22 did not lead to the same mental impairments as the other three drugs. Rhesus monkeys and rats performed just as well on memory and attention tasks shortly after being administered DORA-22 as they did on an inactive placebo,\u201d it fails to note that cognition was impaired at higher doses.\u00a0 This is a major error in interpretation of the study results.\nAlthough we would prefer to see potential harms mentioned as high up in stories as potential benefits, this story does highlight questions about harms at the end, so at least those who read the whole story are alerted to the many unknowns.\nBecause of that ending, we\u2019ll give it the benefit of the doubt and grade it satisfactory on this criterion.\n\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about a possible harm (increased cancer incidence) that the statin medications may result in.\u00a0 ", "answer": 1}, {"article": "WATCH: The naked mole rat might help us cure cancer\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nThe US Preventive Services Task Force, which analyzes the best available evidence to create guidelines for doctors, now recommends biennial mammography screening for the general population in women ages 50 to 74.\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nInstead, they note that the benefits of screening will probably be more favorable when screening is directed at people with a high risk of the disease \u2014 such as those with a family history of breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is mainly about harms and the fact that increased breast cancer screening was not associated with lower mortality rates in the study \u2014 suggesting that there is a high rate of overdiagnosis of breast cancer. \u201cThe trouble with overdiagnosis is that while the cancers doctors find wouldn\u2019t have harmed their patients, the treatment and stress that result from the diagnosis probably will,\u201d the story says. The story adds that estimates of the scope of the problem are \u201cfrustratingly broad \u2014 from less than 10 percent to 50 percent or more of women who get screened. In other words, we don\u2019t actually know how bad the problem is.\u201d", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\nThat was longer than we expected, and it's great news for this group of women.\"\nTheir findings are based on the women's T-score, which is a measure of bone density.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did not quantify any harms associated with bone density testing, with osteoperosis or with waiting too long to have ones bones tested.", "answer": 0}, {"article": "Ellis also is a McNair Scholar at Baylor.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\n\"In this particular activation mechanism, the cells develop a subtle mutation within the functional part of the HER2 gene that activates the enzyme,\" said Ellis, professor and director of the Lester and Sue Smith Breast Center, part of the National Cancer Institute-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine.\nThere is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of the drug were mentioned. It was also glossed over that most of the patients in the trial did not seem to have any response to\u00a0neratinib. The release\u2019s only reference to harms was that \u201cNeratinib was well tolerated by most patients.\u201d Other research (including the peer-reviewed paper this release is based on) has shown diarrhea to be a significant side effect of neratinib.", "answer": 0}, {"article": "But therapies have been improving steadily.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\n``We can, once again, get control of virus replication in patients with the most advanced disease who are resistant to other drugs and really have a major impact on the course of disease and on survival in these patients,\" said Kuritzkes, who is a paid consultant to Panacos.\n``We desperately need new compounds with novel mechanisms of action,\" said Eric Freed, chief of the virus-cell interaction section of the HIV Drug Resistance Program of the National Cancer Institute.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss the potential side effects of this new drug, nor does the story provide a caveat that the drug may not live up to its predicted effect in humans. The possibility of a negative interaction with other HIV drugs, or with drugs for co-existing medical conditions is also not mentioned. But this is one of the hazards of reporting on data that have not yet been peer-reviewed (Or have they? The story doesn\u2019t make it clear.) The company and the investigators certainly know what side effects have been experienced so far. Having the company president say that the drug has \u201ca great safety profile\u201d is inadequate. ", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\nTo measure levels of optimism, participants were asked to use a five-point scale to either agree or disagree with six statements, such as, \u201cIn uncertain times, I usually expect the best.\u201d\n\nThe results showed that the most optimistic women \u2013 those in the top 25 percent \u2013 had a nearly 30 percent lower risk of dying from any of the diseases analyzed in the study when compared to the least optimistic participants in the lowest 25 percent.\n\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\n\u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n\nShe said her team plans to focus more on the potential impact of optimism on biological functioning in future research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being\u00a0overly\u00a0optimistic\u00a0can\u00a0put\u00a0people\u00a0into\u00a0harm\u2019s way \u2014 say, thinking they\u2019re better drivers than they really are, and upping the risk of an accident. (There are a number of studies about this very thing.) But that\u2019s a kind of common sense we don\u2019t think needs calling out in a story.", "answer": 2}, {"article": "Flublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective (see Skowronski et al.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\nThe most common side effect from Flublok is pain at the site of injection.\nIn a 2014/15 post-marketing study of 9,000 adults 50 years and older, people who received Flublok were over 40% less likely to develop cell culture confirmed influenza than people who received a traditional flu vaccine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a section on the safety of the new vaccine that offers substantial relevant information, as well as how to obtain more detailed information if desired.", "answer": 1}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nThe prototype pill\u2014dimethandrolone undecanoate (DMAU)\u2014is somewhat similar to the combined female pill, which contains estrogen and a steroid hormone.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the range of side effects found among study participants, though some of the characterizations appear to lack context. For example, the story mentions that some subjects experienced \u201cmild weight gain.\u201d Based on information in the study abstract, the mean weight gain was 1.5 to 3.9 kilograms. Given that 3.9 kilograms is 8.5 pounds, that\u2019s not inconsiderable. i.e., many men may balk at the idea of gaining more than eight pounds in a month. It\u2019s also not clear what sort of weight we\u2019re talking about. Muscle? Fat? Water retention? This may be particularly relevant (and worth articulating clearly) for a medical intervention aimed specifically at sexually active adults.\nBy the same token, the story notes that \u201ca minority of participants did experience decreased libido during the study.\u201d According to the study abstract, eight of the study participants who received the drug experienced decreased libido. Given that only 83 people completed the study, and that some of those study participants received a placebo, that means that more than 10 percent of men who received the drug experienced decreased libido.\nAgain, this seems particularly relevant for a drug aimed solely at people who are planning to have sex. In short, the story did not overlook any of the potential harms discussed in the abstract, but could have done a better job of placing those potential harms in relevant context. How appealing is a birth control pill for men if it makes more than 10 percent of them less interested in sex in the first place?", "answer": 1}, {"article": "The subjects were divided into two groups.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\nFor example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\nAcross both groups, subjects showed no serious adverse events or study withdrawals due to an adverse event.\nIn fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline,\" said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the subjects in the clinical trial did not have any adverse reactions to the device, and that a skin irritation assessment concluded there was no irritation or erythema. However, the study abstract provided by the news release issuer reported that 25% percent of the volunteers experienced itching.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\n\"Certainly this reinforces our belief that sinus surgery increases the quality of life of patients, and I see that clinically as well as scientifically,\" added Dr. Jordan S. Josephson, a sinus and allergy specialist at Lenox Hill Hospital in New York City.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\n\"It's a minimally invasive type of surgery performed with a telescope that goes into the nostril,\" then basically snips away abnormal and interfering tissue while leaving normal tissue behind, Smith explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors did not report adverse effects of endoscopic sinus surgery, the news story should have mentioned that complications can include bleeding, bruising, swelling and infection. \u00a0Rare cases of vision problems, spinal fluid leaks and meningitis have also been reported.\u00a0 If you don\u2019t report harms and you don\u2019t report costs, you\u2019re not telling a very complete story. ", "answer": 0}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nMen with COPD have shortness of breath and often take steroid-based medications for an extended time, both of which increase their risk of low testosterone.\nLow testosterone is common in men with COPD and may worsen their condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known dangers to TRT including raising the risk of prostate cancer but none of the risks are mentioned in the news release.", "answer": 0}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\n\"Although these results are promising, much more research needs to be conducted before we can use scorpion venom components to treat rheumatoid arthritis,\" Beeton said.\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\nIn addition, treatment with iberiotoxin did not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\n\"It was very exciting to see that iberiotoxin is very specific for the potassium channel in FLS and that it did not seem to affect the channels in other types of cells, which might explain the lack of tremors and incontinence,\" Tanner said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release reported that treatment of rats with iberiotoxin \u201cdid not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\nThat\u2019s not quite right. The study itself says it only examined tremors and incontinence, and other adverse effects couldn\u2019t be ruled out.\nAlso, just because a particular adverse effect wasn\u2019t observed in rats doesn\u2019t mean it is safe for humans.", "answer": 0}, {"article": "She said self-exams may not reveal tumors early enough to improve survival.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\n\"By the time a breast cancer is large enough to be detected by self-exam, tumor biology is the most important predictor of outcome, not finding a tumor a few months before it would have become apparent,\" she said.\nDuring the women's health movement of the 1970s, the self-exam gained importance as a means for women to take charge and rely less on a paternalistic health system.\n\"Not only do the trials not find a benefit, the trials demonstrate harm in terms of increased physician visits and benign breast biopsies,\" said Dr. Nancy Baxter, a University of Toronto surgeon who reviewed the evidence on self-exams for the Canadian Task Force on Preventive Health Care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists the downsides of screening via a self-breast exam, namely,\u00a0 over treatment via biopsies for false positives and false reassurance that mammography is not needed. The story appropriately notes a woman\u2019s individual risk is a factor when choosing how and when to be screened. A woman at higher-risk may feel that\u00a0 monitoring tissue changes via self-breast exams is useful.\n\u00a0", "answer": 1}, {"article": "The study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nIn Canada, that\u2019s roughly 3.6 million people.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\nMany of these individuals turn to adaptive devices designed to magnify objects and text, but these devices can be prohibitively expensive, uni-functional and bulky.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release didn\u2019t address harms but we\u2019re not aware of any associated with assistive reading devices.", "answer": 2}, {"article": "Study authors note that the success and sustainability of a post-discharge wound-monitoring protocol requires a dedicated transitional care program and not simply adding a task to the current staff workload.\nThere was an overall data submission rate of 90.2 percent among participants, and submissions were reviewed within an average of 9.7 hours.\nA limitation to telemedicine protocols that call for the use of smartphones is that not every patient has the necessary technology or knowledge to upload images on their own.\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\nThe nurse practitioners responsible for reviewing the submitted images attested to the value of the photos and patient satisfaction, although they also noted it was difficult to find time to review the submitted images on top of an already heavy clinical workload.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t explored. The app mentions that there was one false negative result among the 40 patients studied, but doesn\u2019t explain why this happened or what the consequence was.", "answer": 0}, {"article": "Scientists have developed a simple three-in-one blood test they believe could transform treatment of advanced prostate cancer, helping to extend or save lives.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d\n\nBy testing cancer DNA in the bloodstream, the researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with the drug.\nThey are cheap and simple to use, but most importantly, because they aren\u2019t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing \u2013 offering patients the best chance of surviving their disease.\u201d\n\nThe research was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research.\nProf Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of potential harms of the liquid biopsy itself or of guiding chemotherapeutic treatment decisions based on results of the liquid biopsy.\nWhat about false positives? And false negatives? Erroneous results from a \u201csimple\u201d blood test could lead to a patient stopping the drug prematurely or initiating erroneously. Stories about screening tests must include the false positive and false negative rates for these reasons\u2013they are a real risk.", "answer": 0}, {"article": "Organizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\nBut he said there were other factors as well, like a belief that Lucentis might have been the better drug.\nBut it is approved for another eye disease, age-related macular degeneration.\nAnother got Lucentis, with laser therapy used only after six months and only if needed.\nWith this successful Phase 3 trial, insurers will now be more likely to pay for such off-label use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While the story did include the common side effect of the drug in the study, there were other potentially important complications that were not mentioned.", "answer": 1}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\nThe Science: For decades, parents looking for an over-the-counter medicine to cure a child\u2019s sickness and coughing have turned to syrupy medicines containing dextromethorphan, a popular cough suppressant found in products like Children\u2019s Dimetapp DM and Robitussin DM.\nThe study was carried out by pediatricians at the Pennsylvania State University medical school and supported by a grant from the National Honey Board, an industry-backed agency of the Department of Agriculture.\nThe subjects were randomly divided into three groups: one that received no treatment, another that received one or two teaspoons of buckwheat honey, and a third that received a dose of honey-flavored dextromethorphan.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We appreciate that, at the end of the piece, it includes a section on risks. It says, \u201cThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\u201d We think a number here would have helped. How rare is rare? One in 1,000? One in 1 million? According to the Centers for Disease Control, there are about 110 cases of infant botulism annually. While the cause of the infection is not entirely clear, both honey and corn syrup have been implicated. SInce the story suggests that sweet substances might be useful, the addition of corn syrup to the risks would have been helpful to readers.(see:http://www.bt.cdc.gov/agent/botulism/clinicians/epidemiology.asp)", "answer": 0}, {"article": "ACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nThe exact cause of the disorder is unknown, but certain risk factors make it more likely to occur, including:\n\u2022 Being pregnant with more than one baby,\n\u2022 Having chronic conditions, such as type 1 or type 2 diabetes, autoimmune disease and kidney problems.\nIn those studies using smaller doses, the reduction in preeclampsia risk hovered around 10 percent, he said, but the higher dose in this latest study was linked to a 62 percent reduction in risk.\n\"Preeclampsia is one of the most serious complications of pregnancy, with a high risk of death for the mother and baby,\" said senior study author Dr. Kypros Nicolaides.\nWEDNESDAY, June 28, 2017 (HealthDay News) -- Something as simple as taking a low-dose aspirin every day may protect pregnant women from the life-threatening condition known as preeclampsia, new research suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\u201d To its credit, it also adds, \u201cHowever, as with all drugs, women should talk to their doctor about the use of aspirin in pregnancy before taking up this regimen, because aspirin does increase the risk for bleeding.\u201d", "answer": 1}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\n\u201cThe only difference is it\u2019s kind of a beautiful environment.\u201d\n\nCustomers at Evolved Science shell out anywhere from $325 to $875 for an infusion.\n\u201cThere is not not substantial evidence that vitamin supplements have a large impact on cognitive function,\u201d said Dr. Francine Grodstein, a public health researcher at Harvard who has studied the subject.\nPatients kick back in cream-colored chairs together while they\u2019re hooked up to IVs in the \u201cinfusion lounge.\u201d\n\n\u201cIt doesn\u2019t look like a doctor\u2019s office.\nThe infusion treatments can be traced back to an intravenous supplement known as the Myers\u2019 cocktail, a slurry of magnesium, calcium, B vitamins, and other products developed decades ago by a Baltimore physician.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The statement from the clinic that these IV infusions are safe was unchallenged. There is always a potential harm in an IV administration (infection, vein damage) and yes, receiving worthless treatments for what could be a serious condition is a potential. Also, there was no mention about what kind of testing is done before these treatments are administered, but it appeared to be minimal.", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of even potential harms in the story. Even the accompanying editorial raised one issue: \u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "Still, the ENTs recommend tonsillectomy for sleep-disordered breathing, saying it reduces symptoms in most children.\n\"Completely gone,\" his mom says.\n\"Your child is under,\" says Moran, \"completely under.\n\"It was loud,\" Moran says.\nA year later, Tyler is feeling great.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article failed to mention that calcium and vitamin D supplementation increased the risk of kidney stones. Although the experts quoted were clear that the trial was not a ringing endorsement for the use of these supplements to reduce fracture rate, they also cast the use of these supplements in a light more positive than the current study suggested.", "answer": 0}, {"article": "In studies, clinically-tested, stimulant-free Capsimax was shown to significantly help improve body composition, promote thermogenesis and lipolysis, decrease appetite, accelerate metabolism and increase resting energy expenditure.\n\"Aging is inevitable, but that doesn't mean we can't be active participants in our weight management as we age,\" said Abhijit Bhattacharya, President of OmniActive Health Technologies Ltd., producers of Capsimax.\n\"Because capsaicinoids (the component of hot peppers that gives them heat) are hot, it was imperative that we use an ingredient which the subjects could tolerate,\" said Vijaya Juturu, Ph.D., F.A.C.N., one of the lead researchers on the MR Study.\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that multiple studies have shown the supplement is safe, however, the safety hasn\u2019t been evaluated or demonstrated in this or other research we could find. A search of PubMed found only three studies involving\u00a0capsicum supplementation. All were short-term and none were designed to look at safety.\nWebMD\u00a0says that taking capsicum supplements\u00a0is generally safe for adults if taken for a brief period of time. However, taking large doses for a long period of time can lead to serious harms including liver or kidney damage.", "answer": 0}, {"article": "The DAWN trial included trial locations in the United States, Spain, France, Australia and Canada.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"These findings could impact countless stroke patients all over the world who often arrive at the hospital after the current six-hour treatment window has closed,\" says co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine and director of neuroendovascular service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital.\n\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any specific harms from either approach, nor what the rate of adverse effects was in either group. It\u2019s not enough to state only that there was no difference.\nThe release noted that there was \u201cno difference in mortality or other safety end points between the two groups of patients\u201d in the study (those undergoing clot removal and those getting medical only). But the release could have been much clear about specific \u201csafety end-points,\u201d complications of both the clot-removal procedure and drug therapy; and certainly more information about residual disability in both patient groups.", "answer": 0}, {"article": "Jill adds: \"Anal cancer is on the increase and those of us who have been through what at times was gruelling radiotherapy regimen, welcome this study and the impact it will have on the treatment plans of patients in the future.\"\nThe project's findings however have uncovered a phenomenon suggesting rates of lymph node spread are being overestimated, potentially leading to overtreatment of patients with chemo radiotherapy.\nThis can result in damaging side-effects, and doctors are particularly keen to avoid it in cases where it offers little benefit to the patient at potentially great cost.\nFunded by the Bowel Disease Research Foundation (BDRF) charity, the work has been published in the Lancet Oncology journal.\nShe said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes refers to the harm of over treatment and side effects, but never quantifies them. A quote from a patient refers to \u201cjoint pain and continence issues\u201d suffered by some patients but it\u2019s unclear which treatments were responsible.", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of triggering a manic episode and reports (accurately) that there was no observed difference in the groups studied. The story could have gone further and discussed common harms from antidepressants stacked up against this finding of no benefit \u2013 strong incentive to stop giving antidepressants for bipolar disorder.", "answer": 1}, {"article": "Links will be live at the embargo time http://jamanetwork.\nWho and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\nBottom Line: Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone in women with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release briefly discusses harms. The release says patients who received radiation and lumpectomy had more \u201clocal\u201d recurrences of the cancer, but their overall survival was modestly better than patients who did not have radiation (a 0.27% reduction over 15 years).\nThe release should have given some mention to the harms of radiation treatment, particularly since the potential benefit of radiotherapy was very small.", "answer": 1}, {"article": "Hartmann said doctors could take pressure off women by performing lumpectomies first to eliminate their cancer tumors.\nSuch scans are becoming standard for women who appear to have cancer in one breast, and half the time they raise suspicions about the other breast.\n\u201cOur own impression is that women in some ways are getting sort of scared into having prophylactic mastectomies because of having these uncertain tests,\u201d Leach said.\n\u201cI\u2019m worried about the women who are on the fence and make a very quick decision before really considering the other options or the fact that it is an irreversible procedure,\u201d said Dr. Todd Tuttle, the U\u2019s chief of surgical oncology and lead author of the study in the Journal of Clinical Oncology.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report mentions slightly higher risks of surgical complications and infections. It would have been useful to specify how serious and frequent these outcomes are, but this is not a serious flaw. ", "answer": 1}, {"article": "\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nThe new report, published Friday in the Journal of the National Cancer Institute, is based on real-life observations instead of experiments.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\nThe effect was strongest for gastrointestinal cancers, such as colon cancer and stomach cancer.\nBut he added that it will take scientists a few years to mull over all of the existing evidence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged side effects such as serious stomach bleeds and pointed out that this study didn\u2019t look at overall death rates or side effects.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author of this story makes possible harms of the therapy clear: testosterone therapy\u00a0increased fatty plaque in coronary arteries, a risk factor for heart disease. It also talked about the possible risk of stroke in a subset of men.", "answer": 1}, {"article": "For more information about the symposium, visit www.thoracicsymposium.org.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\nIn terms of toxicity, just over one-third of patients (34.5%) experienced radiation pneumonitis of any grade, with only two patients experiencing grade 3+ pneumonitis.\nResources on Lung Cancer and Radiation Therapy\n\u2022 Digital brochures: Radiation Therapy for Lung Cancer (Spanish version), Plain Talk about Stereotactic Radiation, Understanding Clinical Trials\n\u2022 Videos: Radiation Therapy for Lung Cancer, An Introduction to Radiation Therapy\n\u2022 Additional brochures, videos and information on radiation therapy from RTAnswers.org\n\nABOUT THE SYMPOSIUMThe 2017 Multidisciplinary Thoracic Cancers Symposium, co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and The Society of Thoracic Surgeons (STS), features the latest advances in surgery, radiation therapy, chemotherapy and novel molecular biologic therapies for thoracic malignancies such as lung cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that just over one-third of the 58 patients experienced radiation pneumonitis (inflammation of lung tissue), and that two had cases severe enough to possibly require oxygen or steroid treatment. However, the release does not mention other harms of this sort of radiation treatment, which can include fatigue lasting for several weeks, neuropathic pain, rib fractures and other problems. There is no mention of any measurements of these other radiation effects.", "answer": 1}, {"article": "\"They still drank, but they drank less.\"\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno serious side effects\u201d in the study, but one week of treatment in 10 people isn\u2019t going to provide an adequate picture of the potential harms \u2014 a shortcoming the story should have alerted readers to. In addition, we were a little concerned by the notion that this supplement \u201cmay deliver alcohol to the brain\u2019s reward center faster. So you get an effect sooner; therefore, you don\u2019t drink as much.\u201d Getting people drunker faster may well cut down on the amount of alcohol they consume in a night, but it might also result in unintended consequences like an increase in impaired driving or other risky behaviors. We think the story was too quick to give a free pass on safety without exploring some of these concerns.\nThe nature of a daily habit like drinking demands long-term treatment, thus increasing the time that side effect incidence could accumulate.", "answer": 0}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\nThe MedDiet is also low in dairy, has minimal red meat, and uses olive oil as its major source of fat.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\nLike many researchers, Hardman takes his research home: \"I follow the diet patterns and do not eat any red meats, chicken or pork.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be minimal to no health debits stemming from the Mediterranean diet, assuming one eats in moderation.", "answer": 2}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\n\"\n\nThe Stanford professor and his team screened 120 such proteins that commonly circulate in the blood, and settled on 18 that showed the signature of Alzheimer's.\nThe test initially will be used in research labs, where scientists are trying to learn more about the memory-wasting disease that is one of the most feared consequences of aging.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did acknowledge that there are very few medical treatments for patients once they are diagnosed with Alzheimers\u2019s, it failed to address the burden of such knowledge for the patient and the patient\u2019s family.\u00a0 There could be insurance ramifications, there should likely be\u00a0a consulting component to go hand in hand with the test, and there is the possibility of false positive results.\nThe story did not do an adequate job of addressing the potential harms of this test.", "answer": 0}, {"article": "Patients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nLOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story meets the minimum requirement of this criterion by reporting some of the side effects seen in this drug trial. However, it should have noted that the trial was too small to see less common side effects. Indeed, a trial this small would be unlikely to detect the muscle pain and weakness that cause serious problems for some similar patients when they take statin drugs to reduce cholesterol and heart-related risks.", "answer": 1}, {"article": "But a new study suggests an existing medication may help.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\nFor the new study, Leon-Ferre and his colleagues randomly assigned 150 women who experienced at least 28 hot flashes a week to oxybutynin or a placebo.\nAnd oxybutynin doesn't interfere with the metabolism of tamoxifen, Leon-Ferre said, calling that an important consideration for breast cancer survivors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that side effects included constipation, mild diarrhea, dry mouth, dry eyes, episodes of confusion and difficulty urinating. It\u2019s not noted if these side effects were seen in both the low-dose and high-dose groups. There is also no indication of which side effects were most common or how many women experienced them.\nImportantly, though, the article does note that the long-term effects of the drug aren\u2019t known and that oxybutynin is in a class of drugs that \u201chave been linked with mental decline\u201d and that previous studies have found \u201cthe drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients.\u201d\nInformation on ClincalTrials.gov about the trial suggests this study evaluated two doses in an effort to find an effective dose with fewer side effects.", "answer": 1}, {"article": "Park-Wyllie and colleagues tapped into data on more than 205,000 Ontario women at least 68 years old who had taken the bone drugs.\nHowever, researchers stress the drugs are effective at preventing fractures of the hip or spine, which are much more common in elderly people with the bone-thinning disease osteoporosis.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nApart from atypical fractures, the most serious side effect of the bone drugs is bone death, or osteonecrosis, of the jaw.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of telling the reader how few women suffered the unusual thigh fracture. They further give some context by explaining how those on the drugs reduced their harm from more-typical fractures by 24 percent.", "answer": 1}, {"article": "SILVER SPRING, Md., May 18, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.\nThis is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.\nThe most common side effects of treatment with Tencentriq were fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation.\n\"Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway,\" said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.\nIn all patients, 14.8 percent of participants experienced at least a partial shrinkage of their tumors, an effect that lasted from more than 2.1 to more than 13.8 months at the time of the response analysis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are \u201cimmune-mediated.\u201d We would have liked a bit more context on what this term means for patients.", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similarly, this story doesn\u2019t discuss harms.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the progestin IUD is well tolerated and there were no adverse events in the study, the story makes no mention of any potential harms.\u00a0 The adverse effect outcome measure reported in the study was effects or complications severe enough to suspend treatment. The concurrent GnRH analog treatment does have side effects (temporary menopausal symptoms) that may be important to some women, while not warranting suspension of treatment.", "answer": 0}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned \u2014\u00a0unacceptable when the whole point of the study being covered is to ensure the safety of the new device.\u00a0Known complications of implanted neurostimulation devices include wound infections at the surgery site and breakdown of the device or hardware requiring reoperation. Since these devices have never been studied in advanced heart failure patients, we don\u2019t know if these issues might cause more serious problems\u00a0in these patients than they do in healthier populations where neurostimulation has been tried before.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article fails to mention the small but real risks of total knee replacement, which include blood clots in the leg and lungs, joint infections, and (rarely) death. Because of the risks, costs, and inconvenience of knee replacement, many people prefer nonsurgical remedies. While the story entertains the idea of knee replacement in younger people, such procedures are likely to require another operation during a person\u2019s lifetime \u2013 something not mentioned at all.\u00a0 \n", "answer": 0}, {"article": "Mothers who left the study said they no longer needed support, sought counseling from mental health professionals, or didn\u2019t have time for the phone calls.\nWhile all of the mothers were depressed at the start of the study, at mid-point only 32 percent were at risk for depression, and this declined to 15 percent at the end.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\n\u201cA lot of first-time moms wonder what\u2019s normal, what\u2019s depression, and what to do with the fact that they feel overwhelmed and alone and like their experience looks nothing like the happy moms they see smiling in all of the baby food and diaper commercials.\u201d\n\nBecause postpartum depression is the most common complication of childbirth, it makes sense to explore peer counseling and other interventions that can reach women in rural or suburban areas where access to mental health professionals may be limited, said Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the Center for Women\u2019s Mood Disorders at the University of North Carolina at Chapel Hill.\nTo assess the effectiveness of phone counseling for easing these symptoms, Letourneau and colleagues identified 64 mothers with symptoms of major depression within 24 months after delivery and offered them up to 12 weekly peer support calls.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention could be harmful, but the story does not address that possibility. The peer counselors might be less capable than professionals of detecting suicide risk, for example. Or, the counseling might provoke additional symptoms such as excessive anxiety.", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is almost a throw-away line in the study that says, \" A recent study estimated the epidemiologic impact of DWI-based diagnosis would result in reduced annual TIA incidence (33%) and increased stroke incidence (7%) in the United States.\" Reducing these \"mini-strokes\" by 33% would indeed be a dramatic change, given the number of people who suffer from them, but these are \"warning strokes,\" that can actually force people to change risky behaviors or begin taking the right medications to avoid an actual stroke. Those strokes may have actually climbed by 7% in the theoretical model of a world where diffusion scans were the norm. A 7% increase in strokes could mean an additional 55,650 people suffering a stroke each year, by our count. Again, these numbers would be nice to see in the story.\u00a0", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states, \u201cWomen taking estrogen in pill form saw an increase in HDL or \u201cgood\u201d cholesterol and a decrease in LDL or \u201cbad\u201d cholesterol, but an increase in triglycerides.\u201d But what does that mean? Would an increase in triglycerides be harmful to one\u2019s health? The article does not mention any other adverse effects, but it may have been beneficial to reinforce the notion that the study lacks the absolute numbers and statistical power to claim, \u201cNo significant differences in adverse events.\u201d", "answer": 0}, {"article": "But there are reasons to think aducanumab may succeed where other drugs have failed.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\n\"If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer's disease,\" says Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute in Phoenix.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is clear that the drug\u2019s effects on amyloid plaque are accompanied by potential harms:\nBut there\u2019s a downside. The process of removing plaque sometimes causes fluid to build up in the brain. In rare cases, it can also cause bleeding. These side effects are known as amyloid-related imaging abnormalities, or ARIA.\nWe\u2019re also told that about 20 participants dropped out of because of adverse effects.", "answer": 1}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nAnother 49 women received control acupuncture and 49 received massage.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\n\u201cThe acupuncture protocol we have tested appears effective,\u201d lead researcher Dr. Rachel Manber, of Stanford University in California, told Reuters Health in an email.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Dr. Christina Luedke of Children\u2019s Hospital Boston said she carefully screens teenagers and their families before prescribing a pump.\nThe pumps are used for those with Type 1 diabetes, which accounts for about 5 to 10 percent of all diabetes cases and used to be called \u201cjuvenile diabetes.\u201d The more common form is Type 2, which is often linked to obesity and more often affects adults.\n\u201cWithout appropriate glucose monitoring, the pumps can increase the risk of getting sick more quickly compared to injections,\u201d Luedke said.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall focus of the original research and\u00a0this article was on the potential harms of insulin pump use by adolescents and the need to address safety concerns.\u00a0 Potential causes of adverse events related to patient use and education and device malfunction were appropriately described.\u00a0 This article could have been improved by including the importance of parental oversight in preventing adverse events, particularly since three of the five deaths occurred at times when there was no parental supervision.", "answer": 1}, {"article": "This week an unprecedented travel advisory was given for southern Florida after more than a dozen people were diagnosed with Zika after being bitten by \"homegrown\" mosquitoes.\nTrials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe urgency for a vaccine to protect against Zika infection has intensified as the virus spreads rapidly across Latin America and the Caribbean.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nResults are expected by December and if they are promising, a bigger phase II trial will be launched in Zika endemic countries\n\nThat puts the project ahead of schedule, since the original launch of the phase I trials was expected to start in September, Fauci said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story notes that the killed-virus vaccine is safer than another line of vaccines under development,\u00a0but it does not address the presence or absence of any side effects or potential harms/shortcomings of the new experimental vaccine if and when this vaccine is tested in humans. One extremely important safety concern, for example, will be how it affects pregnant women and fetuses.", "answer": 0}, {"article": "Visual analog pain scores at 6 weeks after the injections improved by a mean 3.8 points or 61.47 percent in patients who had the PRP injections compared to the autologous blood group, a mean 2.5 points or 41.6 percent improvement.\nAnalogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\nBoth groups experienced more improvement at 3 and 6 months after the injections, with no significant in pain scores between the treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no attempt to quantify harms here. After reading this story, one might assume that there\u2019s nothing risky about this procedure.", "answer": 0}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nIn fact, if you look at drawings from Leonardo da Vinci \u2014 or a Gray's Anatomy book from 1901 \u2014 the spine isn't shaped like a sharp, curvy S. It's much flatter, all the way down the back.\nIf you look at an American's spine from the side, or profile, it's shaped like the letter S. It curves at the top and then back again at the bottom.\nIt's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\n\"If you have a lot of fat built up in the belly, that could pull your weight forward,\" Mummaneni says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that an active lifestyle, and strong abdominal muscles, can reduce the risk of back pain. And there\u2019s a lot of evidence to support this. But not all exercises are created equal. Some exercises that people associate with abdominal strength may actually aggravate lower back pain. Full sit-ups can worsen back pain as can bilateral leg lengths. Also, poorly done Pilates or yoga can as well. All require some training. The same is true of a generally active life style \u2014 excessive squats, planks, core strengthening can worsen back pain. Some acknowledgement of that fact would have earned the story a Satisfactory rating here.", "answer": 0}, {"article": "This is relatively new thinking.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\n\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the news release, the study authors say that we need \u201ca careful assessment of the safety and acceptability of early egg and peanut introduction in different populations\u201d before rolling this out widely. What are these safety concerns? The story doesn\u2019t say.", "answer": 0}, {"article": "Before the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nAnd now, a real pill for your unreal illness.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nIn general, there was a 40 percent increase in prostate cancer in men who had no sons.\nMen who had only daughters were more likely to have developed the disease than those who had at least one son, researchers found, and the relative risk of prostate cancer decreased as the number of sons increased.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential risks with the use of Paxil.", "answer": 0}, {"article": "The researchers then cross-referenced this information with health department death records.\nRelated: Severe childhood obesity is on the rise in the U.S.\n\nIt\u2019s recommended that people get 150 minutes (or two and half hours) of exercise each week, based on guidelines from the American Heart Association, the U.S. Centers for Disease Control and Prevention and other medical authorities.\n\u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac University.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\nOne study, published in 2014 in the journal Heart, suggests that in people with existing heart disease, the risk for cardiac arrest and stroke was the same for people who exercised more than an hour a day compared with those who didn\u2019t exercise at all.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job highlighting some of the potential harms associated with vigorous physical activity: \u201cHowever, experts caution that it is possible to overdo it\u201d \u00a0and \u201cmore exercise than two and a half hours a week can actually be unhelpful and even harmful.\u201d\nAn expert in the field not associated with the study provides a bit of common sense to the discussion; \u201cThere are risks that come with a\u00a0weekend warrior exercise schedule, especially for people who aren\u2019t used to being active. \u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac\u00a0University.", "answer": 1}, {"article": "To learn more, visit njhealth.org.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\n\"Ideally, we want to eliminate all staph aureus from the skin of eczema patients,\" said Leung.\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from using the lotion are mentioned.\nCould there be allergic reactions? If the lotion does, indeed, reduce the amount of Staph. aureus on the skin, are there consequences to that? Or consequences to changing the skin\u2019s microbial balance in general?\nAlso, many eczema patients are acutely aware that their skin is not just fragile, but also may have open sores; should a bacterial lotion be applied to broken skin? And does this put them at risk of a bacterial infection that can spread?", "answer": 0}, {"article": "Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\nThey also wore a sensor that tracked their movements at night, including indications of restlessness.\nFor measuring sleep quality, participants wore an armband that measures skin temperature, heat flux, bed temperature and skin moisture levels.\n\u201cImagine this - you are in a confined space and have limited ability to adjust the situation (since you are asleep) while you are possibly surrounded by pollutants,\u201d he told Reuters Health by phone.\n\u201cThis is how things are in bed, covered under duvets or a blanket.\u201d\n\nFor one night of the study, 17 volunteers slept with an open window or internal door.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be no immediate potential harms, but the story mentions indirect ones like extra noise or concerns about security.", "answer": 1}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nThere may also be other benefits linked to omega 3 fatty acids for the fetus as well, in helping nerve development \u2014 that\u2019s why many prenatal vitamins include forms of omega 3 fats.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the researcher\u00a0\u201csays there isn\u2019t much harm in consuming more omega 3 fats;\u201d it adds that high doses of omega 3s, in rare cases, increase the risk of hemorrhage in people prone to bleeding problems. That is just enough to merit a satisfactory rating.\nIt does not mention, however, that omega 3 supplements can cause allergic reactions in people with allergies to either fish or to the plants, seeds or nuts from which the supplements are derived. MayoClinic.org also notes that \u201cthere is not enough information at this time regarding the safety of fish oils when used in amounts greater than those found in foods during pregnancy and breastfeeding,\u201d which suggests that the risks of supplement use could be higher among the most likely audience for this story: women who have been trying to get pregnant.", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Something missing from the studies mentioned were any sort of placebo controls or comparisons to alternative screening techniques. Too much screening can lead to unnecessary surgeries that have their own risks. The story does say, \"the additional polyps found may result in more biopsies, raising costs.\" But it should have also talked about the potential downsides of screening and any potentail side effects from undergoing this procedure.", "answer": 0}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\nThe participants found the Chantix-booze combination increased the unpleasant effects of alcohol and reduced the rewarding aspects of drinking.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that Chantix carries a \u201cblack box\u201d warning and that there are concerns about depression, suicidal thoughts, and the risk of heart attacks and strokes.", "answer": 1}, {"article": "Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nAttaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the news release. Some scientists are concerned that nanotechnology may have toxic effects on the body, especially the lungs.\nDepending on the nanotechnology, other organs may also be at a risk for damage. In particular, some nanoparticles may affect the endocrine system, leading to changes in hormone levels, sexual characteristics, reproduction and development.\nThe news release talks only about the benefits of nanoscience research without any description of its potential harms. Consequently, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "Related: De Niro says 'find the truth on vaccines'.\nAbout 1 in 68 children develop autism in the United States, according to the Centers for Disease Control and Prevention, But as many as 20 out of 100 infants with an older sibling with autism will develop the disorder, said Di Martino.\nRelated: See the special bond between a boy with autism and a deaf shelter dog\n\nThe study results are \u201cvery exciting,\u201d said Dr. Adriania Di Martino, a professor of child and adolescent psychiatry at NYU Medical School.\n\u201cThe earlier we can get biological markers for autism, the earlier intervention can be initiated, and the greater the chance of better outcomes, \u201d said David Kennedy, Ph.D., co-director of the Child and Adolescent NeuroDevelopment Initiative at the University of Massachusetts Medical School.\nThis excess fluid \u201ccould possibly be an early biological marker for autism,\u201d said Mark Shen, the lead author of the article, published in Biological Psychiatry, and a post-doctoral fellow at the University of North Carolina\u2019s Carolina Institute for Developmental Disabilities.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the harms inherent in MRIs for infants. Some of the harms of MRIs have to do with the sedation that is required, which, ironically, may harm the developing brain.\nAlso, as with any screening test, there are the harms of \u201cfalse-positive\u201d and \u201cfalse-negative\u201d results. In this case, a false-positive finding would result in a healthy baby being diagnosed with autism. And for a false-negative result, a baby with autism wouldn\u2019t be diagnosed.", "answer": 0}, {"article": "But light was associated with better driving.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\n(Reuters Health) - - Exhausted shift workers may be safer driving home at night when they\u2019re exposed to bright light before they hit the road, a small study suggests.\n\u201cWe experience severe sleepiness toward the end of the night shift, and this may overlap with our commute time,\u201d said senior study author Dr. Ralph Mistlberger of Simon Fraser University in British Columbia, Canada.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Exposure to light in this way isn\u2019t harmful, so we\u2019ll rate this N/A. However, such a therapy could encourage people to skip on an intervention that would be more effective such as sleep. Or it could inure a false sense of security.", "answer": 2}, {"article": "The rest of the men used a placebo spray.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, this was the most complete story of the three reviewed in discussing side effects: \n\"A total of 6.1% of the men and 6.7% of their partners suffered at least one side effect. In men, the most frequent side effect was loss of erection; it occurred at least once in 3.1% of men. In the partners, the most frequent side effect was burning in the vulvovaginal area; 5% of women reported it at least once.\"", "answer": 1}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nIn their experiments, Kupper and colleagues found that scarification with the vaccinia virus offered much greater protection against smallpox than injecting the vaccine.\nT-cells are located in lymph nodes and blood, as well as in peripheral tissues such as skin and lung.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this approach to vaccination. ", "answer": 0}, {"article": "That also was not significantly different.\nOver the past 20 years, studies showed that if a person having a stroke gets a thrombolytic drug within three hours of when the symptoms start (4\u00bd hours for certain patients), the process can be reversed and a lifetime of disability avoided.\n\u201cFor the stroke field, this is a really big deal,\u201d Walter Koroshetz, deputy director of the National Institute of Neurological Disorders and Stroke, said of the findings, which were presented over three days at the International Stroke Conference in Hono\u00adlulu.\nIf flow isn\u2019t restored quickly, brain tissue and the functions it controls \u2014 movement, speech, cognition \u2014 are damaged or can die.\nIn the Italian study, called SYNTHESIS Expansion, 362 stroke patients were randomly assigned to get either IV tPA or endovascular treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harm was this:\n\u201cmany practitioners think that newer clot-retrieving devices work better than the ones used in the three trials. Because endovascular procedures were shown to be no more dangerous than IV thrombolytics, physicians may continue to perform them and assume the outcomes can only get better.\u201d\nSince no benefit was seen with the invasive clot retrieving devices, we would have liked to have seen some additional information on the adverse events directly related to the placement of the device.", "answer": 0}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nThe disorder, nearly impossible to diagnose until now, is characterized by a cluster of confounding symptoms that include chronic bloating, abdominal pain, gas, and bouts of relentless diarrhea, constipation, or both.\n\"Most IBS patients have been told at one time or another that the disease was psychological, all in their head,\" said Pimentel.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n\"Having an early diagnosis means patients can avoid years of invasive tests and visits to specialists that often leave them with more questions than answers,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100% accurate. A wrong test result may lead doctors to causes that may not actually be the problem. As such it may lead to inappropriate treatments. That\u2019s a harm that should have been mentioned.", "answer": 0}, {"article": "Dr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\n\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that there is \u201cno harm in doing the Mediterranean diet\u201d. However, people still need to maintain appropriate caloric consumption, regardless of the type of diet. Excess calories, even from healthy food, can cause weight gain. What is not discussed in the news story, but is mentioned in the source article is that greater adherence to the Mediterranean diet was associated with lower caloric intake. Also, the addition of daily moderate consumption of wine may be problematic for those who cannot drink alcohol. One to two alcoholic drinks per day has been shown to slightly increase the risk of breast cancer in women. ", "answer": 0}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nAt the end of the study, men who exercised had higher bone density than those who had supplemented their diet with 1000 milligrams of calcium and 800 international units (IU) of vitamin D per day.\nThey measured the men\u2019s bone density before and after the study, which took place over 18 months, but they didn\u2019t look at fractures.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nThe recommended daily intake of vitamin D is 600 IU in adults up to age 70, and 800 IU for older people, according to the National Institutes of Health (NIH).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, the story was all about a finding that might help people avoid the \u201charm\u201d\u00a0of thinking that supplements do more for them than they actually do.", "answer": 1}, {"article": "During the study, Sweden did not fortify foods, nor did kids use a lot of supplements.\n\u201cIf you\u2019re already sufficient, there is not a lot of evidence that taking more supplements will help.\u201d\n\nShe said the teens in the study might have been deficient in folic acid, with levels a few times lower than what\u2019s typically seen in North American kids.\n\u201cLike most studies, it probably raises more questions than it answers.\u201d\n\nIn the U.S., kids aged 9 to 13 should get a total of 300 micrograms of folate a day from food and supplements according to the Institute of Medicine\u2019s \u201cDietary Reference Intakes.\u201d Kids 14 and older and adults are urged to get 400 micrograms a day and pregnant women should get 600 micrograms.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nThe new study is among the first to examine whether folate is tied to school achievements, according to Dr. Torbjorn Nilsson of Orebro University Hospital and his colleagues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms not mentioned. The story could have mentioned the potential for excessive folic acid intake to interfere with vitamin B12 uptake which, though unlikely in a teen population, could mask symptoms of B12 deficiency. But we\u2019ll give it the benefit of the doubt on this.", "answer": 2}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms or potential drawbacks to the surgery, nor does it describe which patients should not get the surgery. The FDA announcement (from which this story is partially based) noted that serious side effects of the surgery included nausea, pain at the device implant site, vomiting, and surgical complications. Less severe side effects included pain, heartburn, problems swallowing, belching, mild nausea and chest pain. In addition, the company disclosed in its announcement that the therapy is not suitable for a wide swath of the patient population including those with cirrhosis of the liver, portal hypertension, enlarged esophageal veins, certain types of hiatal hernia; patients who may undergo magnetic resonance imaging (MRI) or diathermy; patients at high risk for surgical complications; and patients who have a other implanted medical devices such as pacemakers, implanted defibrillators and neurostimulators.\nWe would add that when you start tinkering with the vagus nerve, there could possibly be many adverse effects over time, especially cardiac-related. Twelve months is too short a timeframe to establish these types of harms.", "answer": 0}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\nBut at 25 weeks, the resolution rates were similar in the two groups: 30% of the patched group and 42% of the acupuncture group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This study did not report significant adverse effects with either the patch or with acupuncture. In our view, however, this\u00a0does not absolve the story from at least mentioning\u00a0the potential for harm with\u00a0both treatments.\u00a0The patch, for example,\u00a0has the potential to cause new onset amblyopia in the stronger eye.\u00a0And\u00a0acupuncture might be painful, cause infections\u00a0(though rarely), and disrupt a child\u2019s education due to the need for frequent treatments.", "answer": 0}, {"article": "Researchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, Virginia, screening tests do have potential harms. If we\u2019re ready to raise the possibility of benefits of a hypothetical test, we need to raise the equally unknown possibilities of false positives and false negatives. The authors do not address the risk that follows from misclassification of non-high-risk patients as high risk. These risks include exposure to unnecessary medical interventions, difficulties getting insurance, and other potential impacts on the way they plan their lives.", "answer": 0}, {"article": "Australian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nThe research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all. Again, this is particularly problematic given that denosumab is already on the market and has well-documented potential harms. For example, the websites for both XGEVA and Prolia (denosumab\u2019s current trade names), note that the drug can cause a wide variety of problems, including (but not limited to): severe pain in muscles, bones and joints; serious infections that may require hospitalization; severe allergic reactions; osteonecrosis in the jaw; thigh fractures; and nausea.", "answer": 0}, {"article": "Swan said that she and her colleagues published similar findings last month.\nWEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\n\"We would all like a simple, noninvasive way to predict potential problems with fertility in men, but unfortunately, this one is not ready for prime time,\" said Dr. Elizabeth Kavaler, a urology specialist at Lenox Hill Hospital in New York City.\n\"This is an important paper showing, once again, that anogenital distance is a strong predictor of semen quality,\" said Shanna H. Swan, vice chair for research in the department of preventive medicine at Mount Sinai Children's Environmental Health Center, New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 But this story promotes a \u201csimple\u2026noninvasive way to test testicular function and reproductive potential in adult men.\u201d\u00a0 So presumably one would act on the basis of what this simple test shows.\u00a0 That opens questions about the sensitivity and specificity of this approach \u2013 neither of which are addressed and both of which raise issues of potential harm, overtesting and overtreatment for the man.\nMaybe not so \u201csimple\u201d as described.", "answer": 0}, {"article": "Lakhan tells WebMD in an email that the extracts were administered orally.\nIn the paper, published in the open access journal BMC Neurology, the researchers write that recently introduced therapies of combined THC and CBD have the potential to relieve symptoms and that past reviews have suggested that cannabinoid therapy is beneficial for people with MS.\n\nGenerally, use of the marijuana extracts were well-tolerated in patients, the researchers write.\nThe reviewed studies were published between 2002 and 2007 and included data from nearly 500 people with MS. Five of the six studies analyzed reported significant improvements in spasticity; one study reported no improvement in spasticity.\nThe reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no numbers were provided to give a sense of the scope of the potential harms of taking the extracts.\u00a0\u00a0 All the story said was, \"Side effects vary greatly.\"\u00a0 What were they?\u00a0 How many people had them?\u00a0 ", "answer": 0}, {"article": "Doctor are taking the first steps to move this treatment beyond the world of the elite athlete.\n\"I knew something was wrong, and I knew that I was going to have to take some time to heal,\" Bornstein says.\nThey are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\n\"I was pretty bummed to find out I might be missing the first game, maybe a couple more games,\" Bornstein says.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only said\"\u00a0 \"reported side effects were minor. The biggest complaint so far?\u00a0 Needles hurt.\"\u00a0 Let viewers judge which side effects were minor by naming them and listing how often they happened.\u00a0 Even more important, though, the story should have emphasized that really nothing can be said about side effects when the very preliminary experimental approach is still undergoing clinical trials. ", "answer": 0}, {"article": "Resistant starches also serve as powerful prebiotics\u2014food for intestinal bacteria in the colon.\n\u201cIn my belief, that\u2019s what\u2019s protected them against some of the ravages of the more modern-day high carbohydrate diet.\u201d\n\nLuckily, resistant starch is found in a range of delicious foods.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nThe four pancakes were made from ordinary starch, starch plus whey protein, resistant starch (a tapioca-based starch modified to become resistant\u2014much like leftovers are), and resistant starch with whey protein.\n\u201cAfter you eat a meal that\u2019s principally carbohydrate, the fact that your body can burn a greater percentage of fat as its energy source is very unusual,\u201d he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re rating this N/A since it\u2019s about food choices. However, it is possible that the belief that a food contains resistant starch could paradoxically lead to that food\u2019s overconsumption.", "answer": 2}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nIn what appears to be the first randomized trial of its kind, they found that arterial stiffness was improved by vitamin D supplementation in a dose-response manner in this population, they write in the journal PLOS ONE.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\nNow it's time to do a larger-scale study, particularly in high-risk populations, and follow participants' progress for longer periods, Dong and Raed say.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not delve into the side effects of taking high doses of vitamin D over a long period of time. These side effects include kidney stones, which should have been addressed. The study does note, though, that no side effects were reported in the trial.", "answer": 0}, {"article": ".\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\nIf so, science has some good news for you: Eating hot chili peppers may help you live longer.\nhad lower HDL-cholesterol, lower income, and less education,\u201d in comparison to participants who did not consume red chili peppers.\nThe researchers note that people who ate hot red chili peppers tended to be \u201cyounger, male, white, Mexican-American, married, and to smoke cigarettes, drink alcohol, and consume more vegetables and meats .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0addresses potential harms from eating red hot chili peppers, by quoting\u00a0an expert source warning about discomfort and worsening symptoms\u00a0in people with\u00a0digestive disorders such as stomach ulcers.", "answer": 1}, {"article": "Some people do need supplements.\nCalcium intake from food has been rising, he says, with recent surveys finding averages around 1,000 mg a day \u2014 close to or meeting the 1,000 mg. to 1,200 mg recommended for adults (the higher level is advised for women over 50 and men over 70).\nThe review \u201cis really reassuring,\u201d says Clifford Rosen, senior scientist at the Maine Medical Center Research Institute at the University of Maine.\nCalcium-rich foods, such as milk (300 mg a cup), plain yogurt (400 mg per cup) and kale (100 mg a cup), come with added nutritional benefits.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While we discussed benefits above, the focus of the story is primarily on potential harms. Namely, the story looks at potential risks to heart health associated with the use of calcium supplements. And the story does a fine job here, particularly given the fact that, as one source in the story notes, \u201cThe public has been receiving very confusing and alarming messages about calcium supplements.\u201d Specifically, the story explains that there is some concern that the use of calcium supplements may lead to a build-up of calcium in the arteries, which may contribute to risk of heart attack or stroke. The story then fleshes out the arguments of both sides in this debate, without making any sweeping judgments about which side of that argument is correct. In other words, the story gives readers information without telling readers what conclusions they should draw. In a case like this one, we think that\u2019s the responsible position to take.", "answer": 1}, {"article": "But the F.D.A.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\nYet, he said both are \u201cvery safe and effective, and a heck of a lot better than surgery.\u201d (It entailed ripping out the groin-to-ankle vein with a wire via an incision.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t get specific as to how often harms should be expected with the various treatments discussed, but\u00a0it does mention some of the more common problems that can occur, including recurrence of the varicose vein or\u00a0the creation of new\u00a0varicose veins in the same area. Still, the story goes to significant\u00a0lengths to make readers think this is a benign procedure (including\u00a0a quote about one patient\u00a0feeling a \"a little tiny pinch\"), when long-term consequences of superficial vein ablation on risks of deep vein issues such as clots are unknown.\u00a0\u00a0Overall, because the story didn\u2019t give any sense of the scope of the problems \u2013 how often someone considering the various approaches may experience harms if they do \u2013 we must rule this unsatisfactory. ", "answer": 0}, {"article": "Neuronix received European approval several months ago and has installations in the UK and Germany.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nTEL AVIV (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer\u2019s disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t know how complete is the list of complications reported when the data haven\u2019t been published yet and we\u2019re hearing this only from the company and/or a company-supported investigator.\u00a0 The story stated that \u201cabout 20 percent of patients experience a mild headache but there are no long-term negative effects.\u201d Why would this approach cause headaches?\u00a0 How can you discuss \u201cno long-term negative effects\u201d after short-term results in 6 people?\nThe story should have painted a picture of how incomplete the harms picture is at this point.", "answer": 0}, {"article": "The restrictive diet lasted for five weeks.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\nSince some children have negative physical reactions to certain foods -- such as eczema, asthma and gastrointestinal problems -- that affect different organ systems, it has been suggested that foods may also affect the brain in a way that results in adverse behavior, according to information in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither this story nor the WebMD story we reviewed mentioned that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet.", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It talks about the potential side effects, but it limits that discussion to what the study found in a very small group of men. Are there long term effects from lidocaine exposure that have been found in other studies? Does the body build up resistance to lidocaine? This isn\u2019t a short term problem that can be solved with a few weeks of therapy. It is\u00a0usually a\u00a0life long problem, and the story should be framed that way both in discussing the benefits and the harms.", "answer": 0}, {"article": "Wall Street sees denosumab as a potential blockbuster crucial to Amgen.\nThe studies found denosumab caused eczema in some patients, and a dozen of the women got a serious skin infection, cellulitis, that sometimes required hospitalization for intravenous antibiotics.\n\"Because this drug affects the immune system, the long-term effects on cancer risk or immune function is still unknown,\" she warned, saying she expects FDA will require Amgen to track risks over time if the drug is approved.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nHowever, based on some prior studies, independent experts say denosumab appears more effective at preventing spine fractures than three older pills \u2014 Fosamax, Actonel and Boniva \u2014 and calcitonin nasal sprays, which all use various pathways to slow down cells called osteoclasts that break down bone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Citing the FDA\u2019s review of denosumab, as well as the adverse risks reported in the trials, the story mentions that this drug is associated with an increased risk of skin infections and some tumors.\u00a0 The story also points out that its long-term effects on cancer risk and the immune system are unknown. ", "answer": 1}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms or the safety of the immunotherapy toothpaste in this story. \u00a0Does the product carry the risk of systemic reactions that one might see with allergy shots? Does the toothpaste make you drowsy like some antihistamines? There is no\u00a0statement that the product is FDA-approved, which might help readers gauge its merits.\u00a0 All we are given is the praise of one of the trial\u2019s participants and a comment from the product\u2019s inventor.", "answer": 0}, {"article": "The scans are cheaper, quicker and safer than angiograms.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nThe SCOT-HEART study tracked more than 4000 patients who were referred to a hospital clinic with symptoms of angina - a condition that restricts the blood supply to the heart.\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\nThe research is published in the New England Journal of Medicine and is being presented at the European Society of Cardiology Annual Congress in Munich.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that CTA scans are \u201csafer\u201d than angiograms because CTAs don\u2019t require the insertion of tubes into the body.\nBut no other harms are mentioned and many readers may want to know about radiation exposure and allergic responses to the contrast dye used. \u00a0According to the study,\u00a0 those who did have a CTA scan ended up having more invasive coronary angiograms and coronary opening procedures in the months following the scan. These procedures carry considerable risks.", "answer": 0}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nThe theory behind trying DBS for Alzheimer's patients, Scharre said, is similar to the \"use it or lose it\" principle: If key brain areas can be stimulated to form new connections among cells, it might slow decline.\nAnd there were \"signals\" that it was slowing down two of the patients' decline, said lead researcher Dr. Douglas Scharre, director of cognitive neurology at Ohio State University's Wexner Medical Center.\nIt's \"much too early\" for patients or caregivers to seek out DBS, said Fargo, who was not involved in the study.\nIn the pilot study, side effects included hot flashes, heart palpitations and burning sensations in the skin, which were reversed by adjusting the DBS settings, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t completely drop the ball, stating side effects \u201cincluded hot flashes, heart palpitations and burning sensations in the skin, which were reversed by adjusting the DBS settings.\u201d But any story on an implantable medical device should caution readers about the risks of surgery to both install and remove it and mention that medical devices are not required to undergo rigorous safety tests before they are allowed on the market. The lead\u2019s assertion that the device \u201cmay be safe\u201d neglects the inherent risks of implantable devices.\nThe story left out another known risk of deep brain stimulation: depression. All three subjects were treated with antidepressant medication. Although, as the study authors note, the DBS may not have caused the depression\u2013it is common in dementia, and treating it can improve people\u2019s cognitive and functional abilities. Such as described for patient \u201cLaVonne.\u201d", "answer": 0}, {"article": "Further tests are required before this latest method can be used within a clinical setting.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\nTraining deep-learning models on data from more than a quarter of a million patients, the scientists were able to predict the cardiovascular risk factors that were not previously thought to be present in retinal fundus images.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story offers no mention of potential harms that might arise from using this new approach and since it\u00a0would be\u00a0non-invasive, it is hard to imagine many.\u00a0 But the potential for incorrect assessments is always present as either false-positives or false-negatives and the harms from either of those can be considerable.", "answer": 0}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\nIn contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,\" said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology.\n\"Our hope is that the high potency of this form of treatment will significantly improve treatment of these patients,\" says Dr. Hannan, the principal investigator of the high-risk prostate SBRT trial.\nIn the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does include a paragraph about urinary side effects (among others) for patients in the trial. But the release deliberately seems to try to minimize these. (Editor added italics.)\n\u201cIn addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment. In the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment. Researchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments. Decrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.\u201d\nMany men might find a one-in-four chance of impotence a high price to pay for treatment for early-stage prostate disease. We have to complain that the release does not give us numbers for the harms \u2014 in any way that is meaningful and allows us to compare this new therapy to existing therapies.\nThe phrase \u201cnot necessarily different\u201d is not helpful. The phrase \u201ca small risk\u201d is not giving us a number we can use.\nAs noted above, a substantial proportion of the patients might not have needed treatment \u2014 so that even a \u201csmall risk\u201d of complications would be unacceptable. In the absence of a comparison group, no conclusions can be drawn as to whether this represents a less harmful active treatment option.", "answer": 0}, {"article": "Whitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nThe results, published in the Public Library of Science (PLoS) ONE journal, showed that MSMB is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story detailed the harms associated with the current means of testing for prostate cancer. \u00a0While suggesting that the new MSMB test was able to distinguish between aggressive and non-aggressive prostate cancer, the story did not provide details about how well the test was able to do this. In a nutshell, the story mentioned (though it didn\u2019t quantify) the high false positive rate associated with PSA, but it provided no detail on the relative false positive rate of MSMB. It also failed to mention whether the test failed to pick up on a percentage of prostate cancers that were present. ", "answer": 0}, {"article": "Further,Dr.\nFrank Brown of Dallas, grandfather of six and the owner of Frank\u2019s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or \u201cbad cholesterol.\u201d High levels of LDL cholesterol are strongly associated with heart disease.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\n\u201cIf you take the core patients who are at highest risk, it makes you appreciate how important this drug class is,\u201d said Dr. Amit Khera, Director of the Preventive Cardiology Program and Associate Professor of Internal Medicine at UT Southwestern.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention potential harms at all. If anything, it does just the opposite, saying at one point that an observation of a woman with a genetic variation that naturally confers the effects of this class of drugs suggests that \u201ctherapies aimed at blocking [the protein targeted by these drugs] would not only be effective, but also safe.\u201d That\u2019s a good anecdote about the inspiration for the drug treatment, but it\u2019s problematic in a release that seems to focus almost exclusively on anecdotes. Particularly since the release does not tell readers that both evolocumab and alirocumab have potential adverse side effects. According to the press materials for evolocumab (Repatha), \u201cIn a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha-treated patients.\u201d And the press materials for alirocumab (Praluent) note \u201cPraluent can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital.\u201d What\u2019s more,\u00a0there could be less common, but more serious adverse effects that will only come to light after large numbers of patients take these drugs for long time. There is nothing in the release that says for how long the drug was used. These potential health effects are worth noting \u2014 especially in a release that focuses solely on the use of a new class of drugs.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.\nWhile earlier research has yielded mixed conclusions on the link between cancer and fiber, it would make scientific sense: According to the Chinese researchers, people who eat high-fiber diets have lower levels of estrogen, which is a risk factor for breast tumors.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there are hypothetically potential harms of too much fiber in the diet, this story in this context didn\u2019t need to drill down on them.", "answer": 2}, {"article": "Photophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\n\"The use of the colored glasses in the high school, college or other setting can allow a person to engage in some medically approved activities, while minimizing the risk of symptom exacerbation.\nCINCINNATI--Following a concussion or mild traumatic brain injury (TBI), patients may suffer from light sensitivity or photophobia, making it challenging to return to normal activities.\nA new study from the University of Cincinnati (UC), published online this week in the Journal of Athletic Training, assessed the use of colored lenses in post-concussion patients and found wearing certain color-tinted sunglasses may be a good alternative to dark sunglasses.\n\"We found that 85 percent of patients reporting photophobia had relief of the symptoms with one or more colors-- blue, green, red and purple--with no reported adverse events,\" Clark says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no reported side effects while wearing colored glasses. It recommends against wearing colored glasses while driving since \u201ccertain colors make seeing stop lights or emergency vehicle lights difficult.\u201d", "answer": 1}, {"article": "But two days later, most patients were satisfied.\nOverall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story of possible harms from the use of acupuncture. While the risks may be slight in most cases, they are not negligible. Infection is always possible and some can be serious.\u00a0Also if a patient is not given an actual pain reliever and has to revisit the ER later, that is a harm.", "answer": 0}, {"article": "The most surprising new finding relates to breast cancer.\nI hope it gets across to women, because we are not reversing ourselves.\u201d\n\nIndeed, the investigators emphasized that the results do not change recommendations concerning combination hormone therapy for the two-thirds of menopausal women who still have a uterus.\nA major caveat in interpreting the new estrogen data is that the study used conjugated equine estrogens, which are estrogen compounds derived from the urine of pregnant mares and marketed by Wyeth Pharmaceuticals under the brand Premarin.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\nAn accompanying editorial in the journal was skeptical about the results, arguing that the design of the initiative, which is skewed toward older women and stopped all forms of hormone treatment after several years of use, does not match the way doctors typically prescribe treatment to women in their 50s at the onset of menopause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nKudos to the The Times for parsing risk carefully. Among these: estrogen alone carries different risks than estrogen-with-progestin,\nestrogen-alone for older women is much riskier than for younger women and risks for women who still have a uterus (unlike those who have had a hysterectomy) are also different. Last, but still important, the form of estrogen used in the study is not typically used now, so conclusions about benefits cannot be assumed to follow to the current form (estradiol.)", "answer": 1}, {"article": "To learn more, visit http://www.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nBy measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\nNinety-two percent of the 174 reductions performed with the inferior pedicle technique used a Wise pattern incision, which disrupts the lower suspensory ligaments, and 7.5% used a Boston modification of Robertson technique, which preserves the lower suspensory ligaments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address the incidence of harms with either method.\nBased on our review of the literature on the topic, there are potential complications seen with both techniques including painful scars, wound dehiscence (a surgical complication in which a wound ruptures along a surgical incision), infection requiring antibiotics, and corrective surgery if the original surgery is unsuccessful.\nThe published study does note a variety of side effects and how often they occurred and also states there was no statistical difference between the rate of harms. This would have been good to mention in the release.", "answer": 0}, {"article": "Doctors used the self-learning computer to detect changes in brain scans too subtle for humans to see.\nBritish AI expert Prof Noel Sharkey, from the University of Sheffield, said of the findings: \"This is exactly the sort of task that deep learning is cut out for - finding high-level patterns in data.\nDr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nAs a final test, it was given a set of 40 scans from 40 patients it had never studied before.\nDr Jae Ho Sohn, who worked on the project, said: \"We were very pleased with the algorithm's performance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned. As with all screening tests, there is a risk of a false-positive or a false-negative result. Either can create anxiety, confusion, and incorrect medical treatment.\nRegarding the PET scan itself, the American College of Radiology lists the following:\nThe small circular opening of the scanner can elicit anxiety in some patients that may require sedation or stopping the scan.", "answer": 0}, {"article": "The trial was registered at http://www.\nAbout the Journal of Orthopaedic & Sports Physical Therapy\n\nThe Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae) publishes scientifically rigorous, clinically relevant content for physical therapists and others in the health care community to advance musculoskeletal and sports-related practice globally.\nResearchers at Baylor Scott & White Health in Temple, Texas, found that dry needling, which uses filament needles to stimulate sensitive loci, or trigger points, in the muscles, is as effective as cortisone injection in reducing pain and improving movement problems caused by greater trochanteric pain syndrome (GPTS).\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While no harms were reported in the study, the news release still should have mentioned typical side effects of dry needling such as temporary pain, bruising and post-treatment soreness. The release does mention the \u201cpotentially harmful effects of steroids\u201d but doesn\u2019t say what they are.\nThe concern over potential\u00a0complications from steroid injection seems to be magnified while any potential harms from dry needling is ignored.", "answer": 0}, {"article": "This abstract can be found at sirmeeting.org.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nOne month later, researchers followed the progress of eight patients and found that GAE significantly decreased pain (-58 mm on the Visual Analog Scale), reduced stiffness and increased physical function (-36.3 on the Western Ontario and McMaster University Osteoarthritis Index).\n\"This procedure could have a significant impact in the treatment of osteoarthritis pain as a whole,\" said Bagla.\nInterventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss the potential harms associated with this procedure. The procedure is complex involving the catheterization of\u00a0 \u201cvery small arteries or capillaries within the lining of the knee,\u201d and carries inherent risks of penetrating those blood vessels. Potential complications include bleeding at the puncture site and pain. Long-term complications have yet to be determined but could include failure of the intervention to address the symptoms of knee OA, worsening of the pain in some individuals, and osteonecrosis (a bone disease that results from loss of blood supply to the bone). \u00a0Also yet to be established is the period of time it takes for healing to occur within the joints after the procedure.", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although it discusses the potentially catastrophic side effects of acute treatment,\u00a0the story did not explain that these patients have compromised immune systems following treatment and need ongoing therapy with immunoglobulins for an unknown amount of time. That\u2019s a considerable omission.\nThe New York Times story, which we also reviewed, did a better job on this.\n\u00a0", "answer": 0}, {"article": "[5] UK Biobank http://www.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nUsing these findings, the researchers then developed an easy-to-calculate risk score for an individual's risk of dying in the next 5 years, based on the most predictive self-reported information, including 13 questions for men and 11 for women.\nThe results allow researchers to compare the predictive ability of a large number of health-related risk factors which were formerly studied separately and using different populations, although the predictive ability of risk factors does not necessarily imply they are causally related to the risk of dying.\n\"The Ubble website allows anybody in the UK between forty and seventy years old to calculate their 'Ubble age' and their risk of dying within the next five years compared to the general population, using a simple set of a dozen or so questions,\" says study co-author Professor Erik Ingelsson from Uppsala University, Sweden.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text does offer a brief cautionary note when it quotes from the commentary of a couple of UK scientists in The Lancet issue to the effect that \u201cwhether this will help individuals improve self-awareness of their health status\u2026or only lead to so-called cyberchondria, is a moot point.\u201d Cyberchondria refers to unfounded anxiety concerning the state of one\u2019s health brought on by visiting health and medical websites, so that term seems apt here. And \u201cmoot\u201d conveys the uncertainty surrounding outcomes as, again, the study can offer no evidence. We\u2019ll give a Satisfactory rating, though we wonder if it would have been more effective to say, \u201cit is unclear whether use of this information will lead to actions that will help or harm individuals.\u201d", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of medical risks and hardships of surgery. Along with the usual risks posed by surgery, there\u2019s a risk that lymph node transfer could cause lymphedema to develop in the part of the body where healthy nodes were extracted, according to Breastcancer.org. For many women those drawbacks may outweigh the potential for an uncertain benefit.", "answer": 0}, {"article": "The number could double by 2050.\n\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nMore: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families,\u201d Lambracht-Washington said in a statement.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the vaccine is \u201csafe in mice\u201d and alludes to the fact that it hasn\u2019t been proven safe in humans. It also mentions \u201charmful side effects, such as brain inflammation\u201d with a previous Alzheimer\u2019s vaccine attempt.\nFor that, we\u2019ll give the story credit. But we think it could have better served readers by explicitly cautioning that safety in mice doesn\u2019t translate to safety in humans.", "answer": 1}, {"article": "Nov. 24, 2016.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\n\u201cThe findings need to be validated in a larger trial,\u201d Ley added, \u201cbut they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates.\u201d\n\nIn an accompanying editorial, Elihu Estey, MD, an AML expert at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center in Seattle, noted that AML is not one disease but many, each driven by different genetic mutations.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nWe don\u2019t yet understand why patients with TP53 mutations consistently respond to decitabine, and more work is needed to understand that phenomenon.\u201d\n\nResponses to decitabine are usually short-lived, however, with remissions typically lasting for about a year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly address harms from either decitabine or standard chemotherapy for AML. What are the common harms from chemotherapy and which of these side effects are reduced in decitabine? Because the focus of the release is on the trial results of a drug described as less toxic, we would have liked some context on what reduced toxicity means.", "answer": 0}, {"article": "Nonetheless, the new study is \u201cvery credible,\u201d said Dr. Barnett Kramer, associate director for disease prevention at the .\nAfter all, mammography had improved and, in Norway, each mammogram was independently read by two radiologists, which should make it less likely that cancers would be missed.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\nThe investigators found that women 50 to 69 who had mammograms and were treated by the special teams had a 10 percent lower breast cancer death rate than similar women who had had neither.\nThat means, Dr. H. Gilbert Welch of Dartmouth wrote in an additional analysis in an accompanying editorial, that mammography could have reduced the breast cancer death rate by as little as 2 percent, an amount so small that it is not really different from zero.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story notes that screening mammography exposes women to false alarms scares as well as the risks and harms of treating tumors that actually would not have become life-threatening.", "answer": 1}, {"article": "This study will be presented at a medical conference.\nThe results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nA new study shows men who ate the most foods rich in a group of antioxidants known as flavonoids were 35% less likely to develop Parkinson\u2019s disease than those who ate the least.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms aren\u2019t discussed but we don\u2019t know what they\u2019d be.", "answer": 2}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion about any potential harms associated with the use of plavix. \u00a0", "answer": 0}, {"article": "So which one is right for you?\nIt\u2019s similar to [the exposure from cosmic radiation] you might get on a long airplane flight.\u201d\n\nWhile a growing body of data suggest that virtual colonoscopy is as sensitive as colonoscopy in picking up potential tumors, not all cancer experts agree that it\u2019s a good alternative to the gold-standard scope.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nOr, the images can be combined to generate a 3D view of the colon, allowing the doctors to \u201cfly through\u201d the organ looking for any suspicious growths or protrusions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that virtual colonoscopy \u201cinvolves exposure to a small amount of radiation. But according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk. It\u2019s similar to [the exposure from cosmic radiation] you might get on a long airplane flight.\u201d\nThe USPSTF states:\u00a0\u201cRadiation exposure resulting from CT colonography is reported to be 10 mSv per examination. The harms of radiation at this dose are not certain, but the linear no-threshold model predicts that 1 additional individual per 1000 would develop cancer in his or her lifetime at this level of exposure. The lifetime cumulative radiation risk from the use of CT colonography to screen for colorectal cancer should be considered in the context of the growing cumulative radiation exposure from the use of other diagnostic and screening tests that involve radiation exposure. On the other hand, improvements in CT colonography technology and practice are lowering this radiation dose.\u201d\nWe think that broader context should have been provided to readers.", "answer": 0}, {"article": "In a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\nThe combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cThe combination of the two drugs also led to far higher levels of side effects, such as colitis and inflammation of lung tissue, at 54 percent versus 24 percent for Yervoy alone. Patients were also more likely to stop taking the combination of drugs.\u201d\u00a0 That is useful information but a bit incomplete.\u00a0 The numbers reflect the percentage of patients who suffered grade 3 and 4 side effects and not just colitis and lung inflammation. \u00a0But the story missed the most significant potential harm of all: death. As the paper itself notes, out of fewer than 100 patients who received the drug combination, \u201cThree deaths were related to the combination therapy according to investigator assessment.\u201d That\u2019s worth mentioning.", "answer": 0}, {"article": "Forty-five minutes later, sweating, he was done.\nAt dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\nHis doctor told him absolutely not, saying, \u201cYou are the kind of guy we will read about who dies during the race of a massive heart attack.\u201d Mr. Del Sontro could still exercise, his cardiologist said, but no more than 45 minutes a day.\nTo keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants.\nMr. Del Sontro is all too aware that the cause of his heart disease is a mystery, but he worries that if he fails to eat right and exercise he might make his illness even worse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are several \u201charms\u201d embedded in this story in the way it is framed \u2013 worry, anxiety, and a sense of foreboding. Yet those harms are mostly unexplored in a meaningful way.\u00a0 \u201cBetter\u201d tests won\u2019t help unless they also identify better treatments, and there is little or no critical attention paid to potential interventions here \u2013 just a tossed off one-liner about the women who gets a stent after the first episode of stable angina, and the implied sense that stenting and bypass are used to prevent heart attacks and death.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential harms of Botox treatment, which include a droopy eyelid, muscle weakness, headache, headache, respiratory infection, flu-like symtoms and redness and pain at the injection sites.\u00a0 \nThe risk of these side effects may be reduced if the treatment is provided by a licensed dermatologist. This should have been stated.\u00a0 ", "answer": 0}, {"article": "A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nThe medication was well tolerated, with the main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\n\"Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder,\" says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.\nNew Rochelle, NY, September 25, 2017--A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses possible harms with use of this new formulation of the drug by saying, \u201cthe main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\u201d The study itself offers more detail and a breakdown of what proportion of participants experienced these effects but most were considered to be mild.", "answer": 1}, {"article": "April 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\n\"Herbal preparations are less harsh on the skin due to their anti-inflammatory properties, while our results suggest they can be just as, if not more, effective than chemical treatments,\" she says.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No human testing was apparently done.\u00a0 In point of fact, it\u2019s far too early for the story to talk about either benefits or harms.", "answer": 2}, {"article": "Although we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\nIn the test, the participants closed one eye and placed the other against the RETeval device, which flashed 10 to 20 white or colored lights of various intensity against a white or colored background.\n\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\n\"Since the retina is part of the nervous system, what is happening in the retina is likely reflective of what is occurring in the brain,\" Silverstein said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "What\u2019s known about the safety of this device? And what about the chances of false positives or false negatives? The news release didn\u2019t say. It only quoted a researcher stating the test was performed to be \u201cas noninvasive and quick as possible.\u201d", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths.\nThe researchers assessed each participant's mood, attitude about life, behaviors and spirituality with questionnaires and structured interviews before the first session, seven hours after taking the psilocybin, five weeks after each session and six months after the second session.\nTo measure the changes in attitudes, moods and behavior over time, the researchers administered a questionnaire that assessed negative or positive changes in attitudes about life, mood and behavior.\n\"The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,\" says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a good job here, stating that \u201c15 percent of participants were nauseated or vomited, and one-third of participants experienced some psychological discomfort, such as anxiety or paranoia, after taking the higher dose. One-third of the participants had transient increases in blood pressure. A few participants reported headaches following the session.\u201d Well done.", "answer": 1}, {"article": "Total energy intake was within the normal range.\n\"Our findings indicate that the overriding principle of a healthy diet is not the quantity of fat or carbohydrates, but the quality of the foods we eat,\" says PhD candidate Johnny Laupsa-Borge.\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\n\u2022 The Study is named (FATFUNC) and was performed by researchers at the KG Jebsen center for diabetes research, Department of Clinical Science at the University of Bergen.\n\"We here looked at effects of total and saturated fat in the context of a healthy diet rich in fresh, lowly processed and nutritious foods, including high amounts of vegetables and rice instead of flour-based products,\" says PhD candidate Vivian Veum.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not go into any detail on the potential downsides of a very-high-saturated fat diet.\nFor example: Would most people enjoy and be able to adhere to a diet that includes lots of butter, cream, and cold-pressed oils? Some would no doubt savor such a diet, but others might be turned off.", "answer": 0}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\nAside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nThough the claim was met with some skepticism by other clinicians, the idea that ACell\u2019s powder, which has been approved by the government, could facilitate new hair growth has breathed new life into the race to clone hair.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned harms in passing but did not quantify them. We wish it would have. The problem here is that we are talking about off label use, but, at a minimum, some of the harms related to the other, more established products could have been quantified. Instead, the story gives the harms question short shrift, saying, \u201cOne advantage of Latisse is that it needs to be applied only once a day (Rogaine needs to be applied twice; Propecia is taken once daily), and does not seem to cause reactions in people who are allergic to minoxidil.\u201d", "answer": 0}, {"article": "Scientists think testosterone has some protective effect on the heart.\n\"For the vast majority of men, the benefits of hormone therapy are absolutely clear: it can halt the disease or stop it for years,\" she said.\n\"There is no definitive evidence, though the risk of heart problems is definitely something doctors should consider when prescribing hormone treatment,\" Thun said.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story focuses on one potential harm of hormonal therapies given to men with prostate cancer. And while some specifics are included in the body of the story, the headline and lead of the story paint a much harsher picture of the potential risk than do the actual statistics reported by the researchers.", "answer": 1}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nAll 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.\nJust 10 weekly sessions of the approach, called ImPAT for Improving Pain during Addiction Treatment, had an effect that lasted up to a year in 55 veterans who took part, according to the new results published in the journal Addiction by a team from the VA Ann Arbor Healthcare System's Center for Clinical Management Research and University of Michigan Medical School's Addiction Center.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n\"These results highlight the need for addiction treatment programs to offer a multifaceted approach that doesn't only address substance use but also the other factors that might be driving substance use, including pain,\" says Mark Ilgen, Ph.D., the study's lead author and a VA and U-M psychologist specializing in addiction research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms. But there don\u2019t appear to be potential harms associated with ImPAT, certainly none that stand out relative to other behavioral interventions. So we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Bitop funded a series of studies, now published in prominent scientific journals.\nI was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nThe perfect situation is that the patient inhales in the morning and evening at home.\u201d\n\nThe inhaler has been tested in three small groups of patients particularly at risk from air pollution, due to asthma, COPD and bronchitis, with the positive results due to be published soon, Bilstein said.\n\u201cIt supports the natural barrier.\u201d\n\nWhen inhaled, this helps prevent the damage caused by air pollution particles that can lead to asthma, chronic obstructive pulmonary disease (COPD) and lung cancer, Bilstein said: \u201cDamage cannot occur as strongly and there is less inflammatory response, and so disease progression is reduced.\nBut on the other hand we have to be realistic and in many countries you cannot just switch traffic overnight to electric cars and do other drastic things.\u201d\n\n\u201cIt will take many more years, especially in countries like China, and I think there is an ethical need to provide something to the general population to protect them,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not explained. The comments of one doctor in the story\u00a0suggest that the compound is inert, supporting the notion that there are no harms. But a quick check of a material safety data sheet reveals some concern about the potential for ectoine to produce pulmonary edema if inhaled, in addition to eye and skin irritation.", "answer": 0}, {"article": "The study also found other benefits.\nThe paper suggests that the drug may one day offer a nonsurgical alternative to \"vertical sleeve gastrectomies\" that have become popular in the battle against morbid obesity.\nIn the meantime, basic weight loss advice remains the same: fewer calories in, more calories expended by physical activity.\nResearchers at the Salk Institute for Biological Studies in La Jolla, Calif., reported Monday that they have developed a compound that tricks the metabolism into responding as if a meal has been eaten, causing it to burn fat to make room for new calories.\nNearly 20 years ago, Evans's lab worked to identify the molecular switch that turns on a whole series of bodily responses to eating, including digestion, absorption, the transfer of nutrients by the bloodstream and increased blood circulation, to name a few.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story passes along a claim that this drug would be safer than other treatments. This is irresponsible. Since the drug has yet to be tested in people, it is impossible to know what potential harms might be found later.", "answer": 0}, {"article": "Is that a big difference?\nAlthough the pro-surgery outcome is not a game-changer, Weintraub says it might cause some doctors and patients to consider surgery.\n\"We would hope a study as powerful as this one will inform decision-makers to rethink the direction they're going in,\" the NHLBI's Dr. Michael Lauer told Shots.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\nStudies have been inconclusive, but doctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story, along with the Associated Press we reviewed, failed to mention harms. We did appreciate, though, that NPR noted that \u201cdoctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\u201d", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing blood and injecting blood components into the vagina and clitoris are not without potential risk of pain, infection or other unknown complications. This should have been made clear.", "answer": 0}, {"article": "Newswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\n\u201cWhen there is an abnormality that we can\u2019t feel and are unable to biopsy, we have to find that lesion in surgery,\u201d said Dr. Andrea Madrigrano, assistant professor of surgery at Rush University Medical Center.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nUsing the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms from inserting the radar reflector. It mentions that it is performed on a day separate from the surgery, in a procedure similar to a needle biopsy.\u00a0 Uncommon but potential complications of a needle breast biopsy procedure include pain, syncope (fainting), bleeding, and infection.", "answer": 0}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the AP and the NPR story we reviewed, this story at least provides a bit of information on the early trade off between angioplasty/stent and bypass surgery. \u201cResearchers found that at one year after the procedures, death rates were about the same for surgery and stents, reflecting the higher risk of mortality from the open-heart procedure itself\u2014about 2% for surgery compared with about 1% for stenting. The short-term risk of surgery can affect patients\u2019 treatment decision, especially given the prospect of open-heart surgery and weeks of recovery, compared with a less-invasive angioplasty.\u201d", "answer": 1}, {"article": "The American Heart Association recommends that adults eat less than 1.5 g of sodium per day.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nBy the end of the trial, sixteen people had dropped out of the study, including 10 out of 48 from the seaweed group, according to findings published in the American Journal of Clinical Nutrition.\nThe research group is working on a new supplement that uses 80 percent less alginate, with less sodium, better taste and fewer side effects than the current formula, Astrup told Reuters Health.\nStill, the new results should be treated with caution, according to Dr. Maria Vazquez Roque, who has worked on alginate-based gels at the Mayo Clinic in Jacksonville, Florida, but was not involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear about the unpleasant nature of the supplement \u2013 and how it contributed to study dropouts. And the story mentioned concerns about long term safety \u2013 with some study participants having bloating, nausea, and diarrhea.\u00a0 The story also noted that blood pressure did not drop as much in the supplement group as with placebo, perhaps due to the sodium content of the supplement.", "answer": 1}, {"article": "For more information, visit http://www.\n\"Breast cancer survival is strongly tied to the sensitivity of tumor detection; accurate methods for detecting smaller, earlier tumors remains a priority,\" says Prof. Yehuda Zeiri, a member of Ben-Gurion University's Department of Biomedical Engineering.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nIn fact, typical mammography sensitivity, which is 75 to 85 percent accurate, decreases to 30 to 50 percent in dense tissue.\nNEW YORK April 25, 2018 - A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening methods typically include false positive results, which will require further testing that might include biopsy. The release did not mention this potential harm or any others from the proposed method of testing breath and urine.\nThis is not a 100% accurate test and there is no discussion on what happens when the test is wrong or why the test may not be accurate all of the time.", "answer": 0}, {"article": "The study received no funding from private industry.\nSUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\nThe target nerve bundle, explained Mandato, \"resembles a complex highway crossing with many [nerve] signals and exits going in all directions.\"\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any harms in the story.\u00a0Lead author Dr. Kenneth Mandato commented on the nasal spray as being \u201csafe, convenient and innovative.\u201d Such statements without any mention of the drug\u2019s potential harms gave the story an overly positive spin. Side effects of lidocaine include flushing or redness of the skin and bleeding at the application site. And while the procedure may be \u201d simple\u201d and \u201cminimally invasive\u201d to an interventional radiologist, anyone who\u2019s had these catheters wending into their sinus cavities may not agree.", "answer": 0}, {"article": "Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez Jr. T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, DeVore B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V and Eby CS for the GIFT investigators.\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\n\"It's a widely used anticoagulant, but it causes more major adverse events than any other oral drug.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\nThe School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them.", "answer": 1}, {"article": "What's that like for Mason?\n\"There was nothing we could have done to change that night,\" said Bob Gambuti.\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. Any surgical procedure presents a risk. Since clinical trials of stem cell procedures for spinal cord injury are just beginning, they carry a risk of unforeseen adverse effects.", "answer": 0}, {"article": "See video.\nThe most promising compounds were licensed to Peloton Therapeutics, Inc., a biotech firm co-founded by Dr. McKnight and based at UT Southwestern's BioCenter campus.\nIn the Nature study, researchers compared the two drugs head to head and found that the HIF-2 inhibitor was more active than sunitinib and that it was active against tumors progressing on sunitinib.\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than explaining that some of the kidney cancers were \u2018resistant\u2019 to the drug\u2019s effects, we learn nothing about the potential adverse effects of the new treatment.\nWhile \u201cmice on sunitinib were sickly and lost weight,\u201d the mice on the new drug gained weight, according to the release. That is hardly sufficient information to know whether the new treatment was well tolerated. Perhaps weight gain was due to fluid retention.", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cso far no negative side effects have been reported.\u201d This is insufficient.", "answer": 0}, {"article": "Information on breast cancer is available at cancer.gov.\nThe researchers suggested that the difference in results between low- and regular-dose aspirin may have been attributable to most women taking low-dose aspirin more often than three times a week, even daily, for cardiovascular protection as opposed to more-sporadic use of regular-dose aspirin for pain relief.\nHowever, aspirin can increase the risk for internal bleeding, so women should talk with their doctors before starting a low-dose aspirin regimen, for any reason.\nAbout 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that aspirin can increase risk for internal bleeding, and says that women should consult a doctor before beginning a daily-aspirin regimen. This is satisfactory\u2013but barely\u2013since the magnitude of this potential harm is not mentioned.", "answer": 1}, {"article": "The test was developed at the University of Bradford, UK.\nCo-first author Dr Mojgan Najafzadeh from the University of Bradford said: \"We feel that we've taken it as far as we can in proving that the test works with high predictability for cancer outcome, and IMSTAR are the right partners to improve it still further.\"\nDr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release needed to provide more information on the risks that arise with cancer screening tests\u2013for example, of being told you have cancer when you do not; or the opposite, being told you\u2019re cancer-free when you actually have cancer. There is also the risk of overdiagnosis \u2014 finding and treating non-growing or slow-growing cancer that doesn\u2019t need to be treated.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThis work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.\nIt is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nOur ultimate goal was to enhance the body\u2019s ability to repair itself,\u201d said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tesar provides a cautionary note related to the potential harms of this approach; \u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\u201d Given the stage of research, we think this is sufficient to rate this criterion as satisfactory", "answer": 1}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\nIt now needs to be taken over by some diagnostic corporation before it can launch into something for widespread use.\u201d\n\nWhat needs to be determined is \u201cwhat the sensitivity and specificity would be in a screening population of 100,000 people,\u201d said Dr. Brian Wolpin, of the Dana Farber Cancer Institute.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\nBut, he said, \u201cthis is just a speculation based on the current strength of the study.\u201d\n\nHad such a test been available, it might have save the life of Dr. Teresa Flippo-Morton, a prominent breast surgeon from Charlotte, N.C.\n\n\u201cShe was an expert in oncology,\u201d said Dr. Derek Raghavan, a colleague and president of the Levine Cancer Institute where Flippo-Morton worked.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm from screening and treatment is an important issue \u2014 these are major surgeries (which are best performed by skilled surgeons at high-volume centers) that are associated with mortality rates of around 4% and multiple morbidities. While the test was 100% sensitive and specific in the study, in the real world there will be false negatives and false positives\u2013and possibly indeterminate results. We also do not know whether there is any risk of overdiagnosis (detecting cancers that would never cause a problem).\nBut there was no mention in the story of the potential harms. The logical extension of the approach advocated in this piece is that all people should be screened for pancreatic cancer. If that is what the researchers and the other commentators in the piece believe, then they should also address the issue of unnecessary surgeries, side effects from treatments, and the anxieties caused by mass screening.\u00a0A more reasonable point of discussion in the piece might have been to suggest developing a screening protocol for populations known to be at risk. For example, people who smoke, are obese, or who have diabetes are all more likely to be diagnosed with pancreatic cancer. An\u00a0effective and cost-effective screening program would need to determine which people to target (including whether a person is healthy enough to undergo surgery) and at what age.", "answer": 0}, {"article": "The fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nYet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\nOn the other hand, he said, many women who are Her2-positive do not benefit from Herceptin.\nBut two studies discussed at the oncology meeting found that patients who were considered Her2-negative even using both tests benefited from Herceptin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harms of treatment (i.e. slight increased risk of heart failure in some women).\u00a0 The story also mentions that even women diagnosed as positive are not guaranteed benefit from the drug.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\nWe don\u2019t know what the harm would be, other than consumers pursuing a costly approach for which the evidence base is questioned.\n\u00a0", "answer": 2}, {"article": "But there are other theories about how fluoride works.\nIf you pay out of pocket, a varnish treatment costs from $23 to $55, compared with a filling, which ranges from $86 to $606, according to the American Dental Association.\n\"Prevention has always been a part of the world of dentistry,\" says Richard Valachovic, president of the American Dental Education Association.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fluoride for dental health has been extensively studied for decades and is considered safe, so we\u2019ll file this rating as not applicable to the story.\nBut, as some dentists might point out, there is an argument to be made for discussing one known\u2013though minor\u2013risk: Some people living in areas with naturally high levels of fluoride in their water may experience tooth discoloration or other issues if they are given additional fluoride treatment.", "answer": 2}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "With its clear questioning of the evidence for lice control products, the story infers the harm of spending money on unproven products.", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because of the lack of evidence, it is difficult to quantify the harms. But the story did a nice job of addressing the harms. \"Some side effects have been reported. Because the device uses large electrical bursts, it can trigger fast heartbeats. Four such cases out of about three dozen patients were described in a recent report by Ken Thomson, a radiologist in Melbourne, Australia. AngioDynamics says that these cases have all been treatable and that the company has taken technical steps to minimize such future occurrences. One case reported to the FDA was of a U.S. patient who in July suffered a serious hemothorax, or blood buildup between the chest wall and lungs. The patient had to stay in the hospital for 16 days, and doctors said an artery \"most likely\" was punctured during the operation. AngioDynamics said in the FDA report that such a puncture is a \"possible complication\" of any such operation.\" This is more detail than is provided in most stories, even when there is much more evidence available.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nThe study is preliminary and doesn't prove cause and effect.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nAlready linked to a reduced risk of rheumatoid arthritis, diabetes, multiple sclerosis, and cancer, statins also may help to improve symptoms of psoriasis, researchers report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story failed to note any of the potential side effects of statins.", "answer": 0}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nPrevious research suggests that in a 24-hour period, the average person with type 1 diabetes spends about 10 hours with blood sugar levels too high, and about an hour a day with blood sugar levels too low, according to Aaron Kowalski, assistant vice president for treatment therapies at the Juvenile Diabetes Research Foundation.\nTHURSDAY, April 14, 2011 (HealthDay News) -- In the latest research to test the concept of an artificial pancreas for the management of type 1 diabetes, British researchers report that they were able to improve blood sugar control and reduce the risk of dangerous low blood sugars overnight.\nFor the eating-in portion of the randomized study, 12 of the study volunteers were assigned to consume a medium-sized meal (60 grams of carbohydrates) at 7 p.m., and then another half were placed on the artificial pancreas program during the night, while the other half maintained their standard insulin pump therapy.\nAn analysis of pooled data showed that the overall time that plasma glucose levels were in target \"increased by a median 28 percent\" with the artificial pancreas, said the study's lead author Roman Hovorka, a principal research associate at the University of Cambridge in the United Kingdom.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No risks or harms from statins are mentioned in this story. Statins are a well tolerated class of drugs with a relatively low risk profile, but all drugs carry risks and have side effects. When you start talking about extending statin use to a much larger percentage of the population, those risks become magnified. We felt that some mention of risks was warranted.", "answer": 0}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\n\"It may provide (an opportunity for) both physicians and couples to take a closer look at ways for men to step up to the plate and optimize their reproductive potential,\" said Dr. Robert Brannigan, urologist at Northwestern University Feinberg School of Medicine.\nWhen a couple is struggling to conceive, it's the woman who is usually the first \u2014 and often the only one \u2014 to be poked, prodded and analyzed, experts say.\nAlthough it's not the first ever at-home test, SpermCheck Fertility is the first one to use the lateral flow assay method, Lopez said.\nAlthough it's not a comprehensive evaluation and could give some consumers a false sense of security, the test does provide a starting point while drawing attention to male infertility as a legitimate health concern.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out that the test might lull men into a false sense that they have no fertility problems. \u201cA positive result from the SpermCheck Fertility test could give men a false sense that everything is all right, APA\u2019s Imler said.\u00a0It might even cause some men to delay a necessary doctor\u2019s evaluation, Brannigan said.\u201d\nThe story waited a little too long to make this point, but we were glad to see it included.", "answer": 1}, {"article": "Other researchers will be analyzing economic data.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nStill, he said, the new technology \u201cis potentially transformative.\u201d\n\nFor researchers the information deluge leads to a different problem: how to analyze the data.\nThere are, for example, more than four million recordings of weights and blood pressures and over 60,000 instances when the defibrillators went off, shocking a patient\u2019s heart.\nThey include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention the problem of potential information overload however there was no discussion of actual harm such as inappropriate shocks from implanted defibrillator devices, for example. \u00a0There was no questioning of the accuracy of the data potentially transmitted by devices.\nThis was a far too rosy picture \u2013 almost as if all the data was so terrific that the only downside could be the volume of terrific data.\u00a0 Other things can go wrong as past experience shows when you try to regulate the heart. ", "answer": 0}, {"article": "Investigators evaluated the effect of the USPSTF guideline on the number and distribution of new prostate cancer diagnoses in the U.S.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\n\"Our study was designed to assess the impact of the USPSTF recommendation on screening practices among urologists and primary care providers and the incidence of prostate cancer,\" explained lead investigator Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of not screening is implied to be an increased risk for prostate cancer mortality because diagnoses of high-risk cancers could be delayed. We\u2019ll award a Satisfactory here, although we\u2019d note that we don\u2019t have high quality data supporting this supposition. The PIVOT trial of surgery vs. watchful waiting for men who were mostly screen-detected was negative. \u00a0Only post-hoc analyses showed a potential survival benefit for aggressively treating high-risk cancers. \u00a0One modeling study\u00a0suggested that screening can be associated with net gain of quality-adjusted life years\u2013though the 95% confidence interval also includes a net loss.\nAnother potential harm associated with screening are the adverse effects of treatment (whether necessary or unnecessary). The release notes that \u201cradiation therapy and surgery have a negative impact on quality of life,\u201d but this is somewhat euphemistic as we\u2019re talking about potential for incontinence, impotence, and biopsy-related sepsis as well as death. \u00a0There are hard numbers citing the rates of incontinence and impotence related to prostate surgery, so those certainly could have been cited here discussing harms.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Two harms of treatment, difficulty getting insurance when one has a prexising condition and not wanting to know that one was going to develop this disease, were mentioned in the broadcast.\nBut the story never addressed the issue of false positive test results \u2013 which could be a huge issue.\u00a0 Imagine being told erroneously that you test positive for Alzheimers disease! ", "answer": 0}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\n\"This study shows that basically neck pain will get better on its own,\" said Dr. Victor Khabie, chief of the departments of surgery and sports medicine at Northern Westchester Hospital in Mount Kisco, N.Y. \"It would've been good if they had a no-treatment group, too,\" he added.\n\"We found that there are some viable treatment options for neck pain,\" said Gert Bronfort, vice president of research at the Wolfe-Harris Center for Clinical Studies at Northwestern Health Sciences University in Bloomington, Minn.\n\n\"What we don't really know yet is how to individualize these treatments for each particular patient.\nAll are probably still viable treatment options, but what we don't know is what each particular patient will need,\" Bronfort said, adding that it's possible a combination of treatments might be helpful, too.\nSpinal manipulation is one type of treatment that's offered for neck pain, and it can be administered by chiropractors, physical therapists, osteopaths and other health care providers, according to the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This rating is a close call. The story does warn readers that spinal manipulation can pose \u201crare, but serious risks.\u201d Also, none of the trial participants reported a serious adverse event. But the story could have been more specific and reported that, as the editorial accompanying the research article pointed out, \u201cneck manipulation has a rare but potentially catastrophic risk for vertebral artery stroke.\u201d Also, the story should have at least briefly mentioned some of the harms that can be caused by the pain medications (including acetaminophen, narcotics and muscle relaxants) that were prescribed to some participants.", "answer": 0}, {"article": "Oral and injectable medications are also prescribed.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\n\"Neurologists have been looking for safer ways to administer natalizumab infusions to their patients, but there hasn't been clear data on whether decreasing dosing frequency improves safety,\" says first study author Lana Zhovtis Ryerson, MD, assistant professor of neurology at NYU School of Medicine and an attending neurologist at NYU Langone's Multiple Sclerosis Comprehensive Care Center.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than progressive multifocal leukoencephalopathy (PML) \u2014 the side effect targeted in this study \u2014 the other side effects of natalizumab therapy are not mentioned. The most serious include liver toxicity, and infections from immunosuppression.\nFurthermore, although many other therapies which cause immunosuppression can lead to PML, it might have been helpful for readers to know that natalizumab has proven particularly worrisome in this regard. It\u2019s been pulled from the market in the past because of PML concerns, and it\u2019s recommended by many in the MS field to be used in very limited circumstances.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of treatment, such as anxiety from positive test results and the possibility that patients will fail to follow up on a positive initial screen.\u00a0It also fails to define the potential harm of providing false reassurance \u2013 the risk of false negative results, which is failing to identify an affected infant, which would be of concern to women who are seeking accurate answers.", "answer": 0}, {"article": "The work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nThis disability-specific discovery approach represents a strategy for finding neuroprotective treatments for neurodegenerative diseases that are tailored to repair damage for each disability, one at a time, in contrast to a \"one size fits all\" treatment approach.\nThey hypothesized that while inflammation causes loss of myelin and synapses, it is the decrease in cholesterol synthesis gene expression in astrocytes that explains why lesions do not repair in MS.\nCholesterol does not leave the blood and enter the brain, instead it is made in astrocytes and plays a role in making myelin, the nerve coating, and synapses, the nerve connections.\nInflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not explain whether there are any harms from changing the gene expression in the mice, let alone what the potential harms might be in humans.", "answer": 0}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nHowever, studies so far have come to mixed conclusions as to whether older adults with a high dietary intake of various antioxidants have a lower risk of dementia.\nReactive oxygen species are produced naturally in the body, as byproducts of metabolism; because the brain is an area of high metabolic activity, it is thought to be particularly vulnerable to accumulating oxidative damage over a lifetime.\nThe one-third of study participants with the highest vitamin E consumption typically got 18.5 milligrams (mg) per day, just over the recommended daily intake of 15 mg.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no known harms to eating a diet rich in foods containing vitamin E, but this story goes the extra mile and notes that high vitamin E intake from supplements can cause excessive bleeding.", "answer": 1}, {"article": "Amid a growing body of evidence on the health impacts of the sport, the consensus aims to help current and would-be players maximise the health pros and minimise the health cons of golf, and to guide policy-makers and industry leaders on how best to make golf more inclusive and accessible and so encourage more people from all walks of life to take up the sport.\nCompared with other sports, the risk of injury is moderate, but as it's an outdoor activity, golfers may be more at risk of skin cancer.\nEvidence suggests it may not only be good for mind and body, but also for a long life\n\nThe consensus--one of the first of its kind--comes on the eve of the Ryder Cup, the biennial golf tournament between Europe and the US.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAnd the sport is often perceived as expensive, male dominated, difficult to learn, and not a game for the young or those on the lower rungs of the social ladder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only potential harm from golf mentioned is an increased risk for skin cancer. It\u2019s an important inclusion that prompts us to give a barely passing grade.\nThis nebulous statement is also included: \u201cCompared with other sports, the risk of injury is moderate.\u201d (Rugby and mixed martial arts come to mind).\nWhat\u2019s not mentioned is a host of musculoskeletal injuries related to the repetitive and asymmetric nature of swinging a golf club.", "answer": 1}, {"article": "But the triggers are different for different people.\nThat testing is expensive, it may not be necessary and it could even be harmful, says lead researcher Dr. John Mafi, of Beth Israel Deaconess Medical Center in Boston.\nIt's estimated that every year 12 million Americans go to the doctor seeking help for headaches.\nToday there are a lot more advanced diagnostic machines than there were a decade ago, and more patients are asking to be tested.\nThen the center works with patients to try to identify what triggers their headaches and how they can avoid those triggers in the future.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A strong point of this story is that it does explore the potential harm from unnecessary diagnostic tests. We applaud the mention, as too few stories address this phenomenon, but the facts that are presented to help the audience understand why a test would be harmful are somewhat confusing. The story says:\nMafi\u2019s study did not include patients with tumors or other serious problems that can cause headaches. He only looked at otherwise healthy patients who suffered chronic headaches. And in these cases, repeated diagnostic testing can lead to further unnecessary procedures like biopsies.\u00a0On top of that, exposure to radiation in tests like CT scans adds up over time and can increase the risk of certain cancers.\nIn other words, diagnostic tests could find something like a tumor that is causing a headache or early bleeding in the brain prior to an aneurysm, for example. But those people weren\u2019t part of this study so we have no way to make a true comparison to people who had a test and found a problem versus people who had an unnecessary test.\nThe story should have explained the exclusion of patients with tumors more clearly. The patients here are chronic headache patients, as opposed to people who have developed headache as a new symptom or a new type of headache. Depending on their presentation, the latter two may need a series of tests.", "answer": 1}, {"article": "Dr Fabiansen , the main author of the paper appearing in PLOS Medicine today, underscores the importance of the findings:\n\n\"Previous studies of nutritional supplements have mainly looked at the effect on weight gain.\nThose with the most severe acute malnutrition have more than ten times increased mortality, and those surviving may have impaired development, compared to children without malnutrition.\nThe study was primarily funded by Danida, MSF-Denmark and MSF-Norway, and USAID via the World Food Programme.\nMore than 30% of children in the world have chronic malnutrition.\nSo, I hope we can use the results to provide the best possible treatment for more vulnerable children.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Many people\u2019s first question upon reading about a peanut buttery kind of nutrient supplement might be whether it produced any allergic reaction or other side effects in infants. In fact, it didn\u2019t, but the news release doesn\u2019t tell us that.", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cclinical trials have so far revealed no significant side effects\u201d from vaccine treatments.\u00a0However, we think the story should have included an important caveat: that these are early stage\u00a0trials involving small numbers of patients that\u00a0can\u2019t provide\u00a0conclusive evidence of safety. In addition, it should be recognized that addictions are\u00a0chronic conditions and these vaccine treatments are likely to be long-term as well. Therefore, longer-term adverse effects should be expected, especially for a treatment that interferes with molecules closely related to the body\u2019s natural chemical messengers. The story could have been a bit more circumspect on this point.", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\n\u201cOverall, these are the most exciting data we\u2019ve seen in asthma in 20 years,\u201d said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi.\n\u201cThis asthma data and the data we already have in atopic dermatitis really raises the possibility the scientific community has finally hit upon the key pathway across all these allergic diseases,\u201d George Yancopoulos, Regeneron\u2019s research chief, said in an interview.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter takes it on the lead researcher\u2019s word that the \u201cdupilumab was well tolerated, with side effects similar to placebo. But she cautioned that longer trials are needed to fully assess the drug.\u201d We would have liked to have seen those side effect numbers. Similar to placebo? Does that mean 10 patients in the drug group had side effects and a dozen in the placebo group? Does it mean three and six? Just give us the numbers.\nImportantly, one subject receiving dupilumab developed angioedema, a serious and potentially life threatening allergic reaction presumably due to the drug.\nAnd even the accompany editorial in the New England Journal of Medicine drew attention to safety questions:\n\u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "Has he had any use of prescription painkillers since he started the study?\nIf left unsatisfied, the receptor sends pain signals to the brain - this is withdrawal.\nUnlike methadone, Suboxone can be prescribed by any doctor, even a family physician, so treatment for addicts can now be convenient and discreet.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\n\"I didn't know how bad being on opiates affected me,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The drug has considerable safety issues, yet the story didn\u2019t discuss any of them. ", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include the potential harms of sleep deprivation, which are extensive.", "answer": 0}, {"article": "Get to know how you can help save and improve kids' lives at http://www.\n\"We looked at all of these metabolites in concussed male adolescent patients and in non-concussed male adolescent patients and it turns out that the spectrum is really different,\" explains Daley, who is also Western's Associate Vice-President (Research) and a principal investigator at Western's renowned Brain & Mind Institute.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n\"This novel approach, to use blood testing of metabolites as a diagnostic tool for concussions, was exploratory and we were extremely pleased with the robustness of our initial results,\" says Dr. Fraser, also an Associate Professor in Western's Departments of Paediatrics, Physiology & Pharmacology and Clinical Neurological Sciences at the Schulich School of Medicine & Dentistry.\n\"There is no one metabolite that we can put a finger on but when we looked at all of them, those profiles are different enough that we could easily distinguish concussed patients from non-concussed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned, but they certainly exist. We encourage releases on diagnostic and screening tests to address the potential for false positive (over-diagnosis) or negative results (under-diagnosis) that could have an impact on patient care.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is always a risk of false positives or false negatives with such tests, but the story didn\u2019t address those risks. It did do a good job discussing the harms of overtreating prostate cancer.", "answer": 0}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nFor the study, Loeb's team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.\nPrevious recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\n\"Our study is the first blinded randomized controlled trial to compare the direct and indirect effect of the live vaccine versus the inactivated vaccine,\" said Loeb, a professor in McMaster's Department of Pathology and Molecular Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release makes no mention of possible harms that my follow the use of either the influenza vaccine injections or nasal spray, even though there are well-known restrictions on whom should and should not receive the nasal spray, and potential negative reactions to the injections among some people.", "answer": 0}, {"article": "The first CT scan was OK.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nBut a new study proves there may be a better way to detect the disease \u2014 early enough to beat it\n\nBarton Lazarus is one of the lucky ones.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nA study out today in the New England Journal of Medicine says patients treated in the early stages of lung cancer have a 92 percent chance of surviving 10 years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms \u2013 such as radiation exposure, the harms of biopsies and the consequences of a false positive result.", "answer": 0}, {"article": "She also is studying the health effects of teaching the skills to individuals with type 2 diabetes, women with metastatic breast cancer and caregivers of dementia patients.\n\"Even in the midst of this stressful experience of testing positive for HIV, coaching people to feel happy, calm and satisfied -- what we call positive affect -- appears to influence important health outcomes,\" said lead author Judith Moskowitz, professor of medical social sciences and director of research at the Osher Center for Integrative Medicine at Northwestern University Feinberg School of Medicine.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\nFor the HIV study, which was based in San Francisco, 80 participants (primarily men) were taught a set of eight skills over five weekly sessions to help them experience more positive emotions.\nThe research was supported by grants R01 MH084723 and K24 MH093225 from the National Institute of Mental Health and grant P30 AI117943 from the Third Coast Center for AIDS Research, all of the National Institutes of Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "If the researchers believe the intervention is without harm, the release needed to spell that out. Harms were also not measured or\u00a0disclosed in the study itself, but it\u2019s something we encourage news release writers and journalists to seek to clarify.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no explanation of the potential harms from unnecessary screening, the intervention that\u2019s at the heart of this story. Unnecessary screening can produce false positive results that may lead to anxiety, unnecessary curtailing of activities, and needless treatment and follow-up that can cause harm. We acknowledge that the story does mention the harms from some specific bone density drugs. For example: \u201cBisphosphonates, sold under brand names such as Fosamax and Actonel, are highly effective. But because of some\u00a0possible, rare side effects\u2014an unusual type of fracture of the thigh bone and a deterioration of the jaw bone\u2014the medication often isn\u2019t prescribed for more than five years.\u201d But we\u2019d note that it isn\u2019t clear how one should extrapolate data on potential harms seen in post-menopausal women to men.", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\n\"It's clear that a safe alternative to oral antibiotics could have a huge benefit, and our data show spironolactone may be that alternative,\" said the study's lead author John S. Barbieri, MD, MBA, Dermatology chief resident at Penn.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\nSpironolactone, marketed under the name aldactone, is currently approved to treat high blood pressure, heart failure, and conditions that cause people to retain fluid.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms of the drug other than to say it \u201cmay have a better safety profile\u201d than oral antibiotics. Then again, it may not. Safety was not part of the study. There should be some language about spironolactone\u2019s known side effects, which include an allergic reaction and vomiting, among others listed by the National Library of Medicine.\nIn addition, there can be long-term consequences of lower androgens, such as decreased bone mass following continued use.\n\u00a0", "answer": 0}, {"article": "Eight months later, none of the tumors had come back.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nAn electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains the short term harms associated with the therapy, noting that there were no \u201cmajor complications\u201d and that eight of the 28 patients \u201chad temporary trouble breathing due to a partially collapsed lung, but all got better on their own within a week.\u201d\u00a0 It would help to provide further information about whether those collapsed lungs required additional monitoring or hospitalization days.", "answer": 1}, {"article": "For more information, visit http://www.\nToday, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nFrom 1995 to 2005, according to Science Watch, Hennekens was the third most widely cited medical researcher in the world and five of the top 20 were his former fellows and/or trainees.\nHennekens notes that further research is needed, but that in the future, the use of regular claims-based surveillance for mammography as a source of data may offer some unique advantages over self-reports.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms that might come from more frequent or aggressive screening of older women. As experts at the University of California-San Francisco and Harvard explained following their 2014 review of studies conducted from 1990 to 2014 on risk factors for women 65 and older and the value of mammography for women 75 and older, \u201cDoctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade.\u201d", "answer": 0}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\n\"Whether it's through counselling or medication, girls can manage their symptoms and decrease the risk of further complications such as fertility problems, hirsutism (excessive hair growth) and type-2 diabetes\".\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. While a blood test is a relatively low-risk procedure, this release could have mentioned the risk of under- or over-diagnosis leading to incorrect or no treatment based on reliance of this diagnostic test, if it makes it to the commercial stage.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a brief mention of side effects, so this skirts by as Satisfactory. However, it would have been helpful to explain that about 1 in 10 adults experience nausea, vomiting, or chills. Painful swelling in the injected arm that requires medical treatment is \u201crare,\u201d according to the CDC.\nThe reporter mentions there is no live bacteria, which is good, but probably should also have mentioned there is no thimerosal, a mercury-based preservative.", "answer": 1}, {"article": "Nothing worked.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a great job in not only providing a listing of potential harms, it also provides information on their frequency and impact on the subjects in the clinical trials.", "answer": 1}, {"article": "Cancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point out that a woman would be expected to suffer from post-menopausal symptoms after removal of her ovaries and that treatments are available. \u00a0However, no information is provided about the potential harms related to the surgical procedure.", "answer": 1}, {"article": "Jan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nFor those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The main problem is that there was no explicit statement about presence or absence of side effects. Readers want to know, and since researchers have studied and reported on adverse effects, there should be an explicit mention in a news report. In this case, there was no difference in side effects between the drug group and the placebo group.", "answer": 0}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nCINCINNATI -- Using a person's spoken or written words, new computer tools can identify with great accuracy whether that person is suicidal, mentally ill but not suicidal, or neither.\nThe scientists also noticed that the control patients tended to laugh more during interviews, sigh less, and express less anger, less emotional pain and more hope.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This isn\u2019t covered in the release, but a look at the study leaves open a concerning question for us. Suicide prevention work is sensitive work: It\u2019s tricky for caregivers and stressful for patients, and while the study notes an institutional review board approved the study, it doesn\u2019t make clear how or whether the patients were counseled or debriefed before or after the study intervention (i.e. asking them a bunch of open-ended questions and recording audio of them speaking). This should have been made clear in the study as well as the release. There is also the potential\u00a0harm of a false negative result \u2014 in which case caregivers may receive false reassurance regarding someone who is, in fact, suicidal.", "answer": 0}, {"article": "\"This is hugely promising and very significant research,\" he tells WebMD.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story emphasizes the upside but makes no mention of what could go wrong with an automated system.\u00a0The potential adverse effects of a malfunction, such as hypoglemic shock and death,\u00a0are\u00a0serious.", "answer": 0}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nIf choosing among white chocolate, milk chocolate or dark chocolate, \"I'd definitely go with the dark chocolate,\" said Saposnik, director of the Stroke Research Unit at St. Michael's Hospital in Toronto.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nThe review authors, who found three studies on chocolate consumption and stroke between 2001 and 2009, are scheduled to report their findings at the American Academy of Neurology's annual meeting in Toronto in April.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss the possible harms of higher LDL cholesterol \"or perhaps higher incidence of cardiovascular disease\" from chocolate. But it didn\u2019t provide any evidence.\u00a0 Nonethless we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "(See graphic.)\nThat trend is raising concern that the high-tech exams could cause a small but significant excess of cancers in coming decades and spurring debate about whether the increasingly ubiquitous tests are being overused, exposing millions of Americans to needless risk.\nThe average level of that exposure has increased about 600-fold since 1980, according to a federal report being published this year.\nThe number of Americans undergoing CT scans has increased dramatically in recent years, driving a significant increase in the amount of radiation that many people are being exposed to from medical procedures.\nBut researchers have estimated the risk based on what is considered the best information available about the health effects of radiation -- data collected from survivors of the atomic bombings of Hiroshima and Nagasaki, as well as exposure of nuclear plant and medical workers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harms of radiation exposure due to CT scans. Notably, the story comments on how many excess cases of cancer could be explained by the radiation exposure and that some of the risk is easily avoidable: some scans are unnecessary.", "answer": 1}, {"article": "The third section had participants taking a placebo.\n\"That's the main natural compound in unroasted coffee, and roasted coffee has much, much less of it than unprocessed coffee,\" Vinson said.\nTUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\n\"So while people might have this perception that it's all natural since it's coming from a coffee bean, with supplements in general it's still a buyer-beware market.\"\n\"So we're not talking about something that is interchangeable with the coffee we drink,\" which is produced by roasting beans at a temperature between 464 and 482 degrees Fahrenheit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes a researcher who says weight loss in the study was achieved \u201cwithout side effects.\u201d That\u2019s not good enough \u2013 not without any acknowledgment that a 16-person study can\u2019t tell us very much about the adverse effects of any treatment.\nThe story does make the point that weight loss supplements are not necessarily tested for purity and have been found to contain undeclared ingredients in the past.\u00a0 Although we\u2019d like to see some more detail on what adverse effects might be cause by these spiked supplements (for example: kidney failure, heart problems, etc).\nThe LA Times\u2019 story, by comparison, quoted an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 0}, {"article": "The other co-authors were from the CDC.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\n\"This seems like a no-brainer to screen patients who have any of these additional risk factors,\" said lead author Dr. Matthew O'Brien, assistant professor of medicine at Northwestern University Feinberg School of Medicine.\nThe study was conducted collaboratively with the United States Centers for Disease Control and Prevention (CDC), using data collected every year from a nationally representative sample of U.S. adults.\nThe study was funded by grants R21-DK112066, R01-HL093009 and ULI-TR001422 from the National Center for Health Statistics of the National Institute of Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The considerable harms of overdiagnosis which include the risk of unnecessary followup tests and treatment that can cause adverse effects, are not mentioned. There are both benefits and harms associated with broad based screening programs.", "answer": 0}, {"article": "All participants took calcium and vitamin D as well.\nAccording to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone.\n\"I think that it's really an important important proof-of-concept that you can inject locally and get a response,\" said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nOne report describes the case of an 88-year-old woman who had been taking the bisphosphonate alendronate (Fosamax) since suffering a hip fracture 10 years earlier.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In our opinion, the risks of Forteo are not described in sufficient detail. It does note that Forteo may prompt further spread of bone cancer, but what about the more common side effects? The Forteo prescribing information, for example, lists a number of more common side effects, and it includes\u00a0a black box warning with a broader caution about bone cancer, concluding that this drug should only be prescribed for patients in whom the potential benefits outweigh the risks.\n While this particular study observed no significant differences regarding adverse events, including no serious adverse events, the article should have noted, as the investigators do, that the study was too small to accurately assess safety. Absent such a discussion, the article might be read as implying a green light for safety.", "answer": 0}, {"article": "She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\nHowever, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).\nThe patients were randomly assigned to receive either TAK-875 (303 patients), placebo (61 patients), or another diabetes drug called glimepiride (brand named Amaryl).\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are numbers attached to the potential harms, but there is so little context that it would be hard for readers to make any sense of the numbers. It says, \u201cThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\u201d\u00a0 What does this mean, exactly?\u00a0 What specific types of side effects were experienced, and were some of them severe?", "answer": 0}, {"article": "Learn more at www.cdc.gov/DrugOverdose.\nHaving trained EMS staff to administer naloxone in rural areas will save lives.\u201d\n\nTo reduce opioid overdose deaths, particularly in rural areas, CDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\n\u201cNaloxone is non-addictive, and expanding training on how to administer the drug can help basic emergency medical service staff reverse an opioid overdose and save more lives.\u201d\n\nNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\nAllowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, \u201cDisparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,\u201d published in the American Journal of Public Health.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release\u00a0does not say anything about the potential risks here. The fact that lower level EMS staff have been banned from administering this drug suggests that it could be dangerous. However, the reality is that the risks of intranasal naloxone are not significant, so this should have been mentioned. The risk of an intramuscular injection are also low \u2014 more or less the same as the risk of any injection (minor bleeding, hitting a nerve, etc). The release should have mentioned the lack of risk and perhaps provided context for the strict regulation of naloxone use (which again is more historical than rational).\nPart of what makes the release confusing is that it appears to be advocating for two things. It mentions multiple times that only staff with advanced training are allowed to administer the drug. And it says that \u201cNaloxone can be given nasally to a person suspected of overdose, allowing basic EMS staff to administer the drug without injection.\u2019 But then it also says that \u201cCDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\u201d Perhaps both statements are true, but the release does not make it clear whether the agency\u2019s strategy is focused on the training or the expansion to basic staff.", "answer": 0}, {"article": "Men who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\nA comparison of 2 of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival\n\n(Philadelphia) - High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies.\n\"However, the proportion of men undergoing prostatectomy plus radiation therapy decreased significantly over time and there were trade-offs for the survival advantages,\" said Dr. Lu-Yao.\nSeveral large clinical trials are nearing completion that should validate these retrospective findings of the benefits of primary radical prostatectomy followed by additional therapies such as adjuvant radiation,\" said Leonard Gomella, Chair of the Department of Urology at Jefferson (Philadelphia University + Thomas Jefferson University), who was not involved in this research.\nIn the largest population-based retrospective study to date, Dr. Lu-Yao and colleagues examined the records of 13,856 men in the Medicare-SEER registry diagnosed with locally advanced prostate cancer -- cancer growth that had not yet metastasized to distant sites in the body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a strength. The release stated: \u201cMen who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\u201d\nThe news release also stated: \u201cThe risks of prostate removal, or prostatectomy, are well known and include higher chance of developing incontinence and erectile dysfunction. There are some risks associated with radiation treatment and hormone therapy, but they are less common, and are typically thought to have a lower impact on quality of life.\u201d", "answer": 1}, {"article": "A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nHe says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states VTP \u201conly caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\u201d While it\u2019s good that harms were mentioned, it\u2019s a disservice to patients to downplay their impact with the word \u201conly.\u201d\nFurther, the news release does not give the proportion of patients on VTP who experience adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, the news release glosses over the fact that over 1/3 of subjects needed repeat treatment within 2 years and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the release omit side effects or other potential harms from this type of treatment, it emphasizes the harms of conventional treatment, thus presenting an unbalanced comparison. The conference abstract summarizing the research noted that adverse events included short-term flu-like symptoms that are common to certain types of immunotherapy, as well as temporary reductions in white blood cell counts. In addition to failing to mention these reported harms, the release did not alert readers to potential life-threatening risks of immunotherapy which sometimes do not become apparent until the therapies have been given to many people over many years.\nOf note: a similar experimental immunotherapy trial by the same company (with acute lymphoblastic leukemia rather than AML patients) was halted after some patients died, according to this conference recap. The growing awareness of potential hazards of immunotherapy was recently highlighted in this post on HealthNewsReview.org.\nThe release should have mentioned that the absence of life-threatening complications in this small trial does not prove the treatment is safe.", "answer": 0}, {"article": "In a related editorial, Drs.\nWEDNESDAY, March 2, 2011 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.\nNumbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\n\"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin,\" she added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag.\nWhile the story points out the most common side effects, fatigue and depletion of white blood cells, occurred in both study groups, readers aren\u2019t given any sense of how common these were.\u00a0 In fact, they were quite common: these side effects occurred in 54% of those on eribulin and 40% of patients in the treatment of physician\u2019s choice group.\u00a0 This is why we expect stories to quantify harms.\nTo its credit, the article does note that the most common adverse event that caused women to drop out of the eribulin arm was neuropathy, or numbness and pain caused by nerve damage \u2013 and it notes a 5% study drop out rate.", "answer": 0}, {"article": "Griebling said the American Geriatrics Society includes desmopressin in the Beers Criteria for potentially inappropriate medications for older adults, primarily because of concerns about resulting low blood sodium levels.\nThe researchers also found that those in the higher-dose spray group experienced a \"significant improvement\" in overall quality of life, compared with the untreated group.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\n\"Other researchers have examined the utility and safety of desmopressin for the treatment of nocturia in the past,\" he said.\n\"Nocturia is very common in patients over 50 years old, and can cause significant problems by causing loss of sleep, and injury due to falls,\" said study lead author Dr. Jed Kaminetsky.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes risks of\u00a0using this drug in the elderly, and mentions that it is already on a list of drugs not to be given to the elderly.\u00a0 The story also discusses incidences of low blood sodium levels that sometimes occur with this drug.", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- A minimally invasive treatment for enlarged prostate that limits blood supply to the prostate seems to be just as effective as surgery but without the risk of debilitating side effects, such as impotence and urinary incontinence.\nThe procedure is performed under general anesthesia and involves a hospital stay.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\nPAE can be an outpatient procedure as well.\nOther minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not report on any harms observed in the 67 men who took part in the study reported on.", "answer": 0}, {"article": "Did I feel guilty for potentially contributing to the development of a superbug?\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To its credit, this blog mentions some of the\u00a0most common\u00a0side effects associated antibiotic use such as diarrhea and eczema, and it mentions antibiotic resistance as a problem. However, it failed to put these harms into terms that understandable and useful to readers.\u00a0Clearly, data about the frequency of adverse effects would help readers weigh these downsides against potential benefits. In addition, while the story\u00a0says\u00a0that overuse of antibiotics might be \u201ccreating superbugs that may soon conquer the universe\u201d (a characterization that we understand is meant to be humorous),\u00a0the story should have explained that antibiotic overuse may have\u00a0real implications for children\u00a0who get treated unnecessarily. For example, there is some evidence that the use of antibiotics can lead to colonization of the child\u2019s nasal passages with resistant bacteria which can cause future infections that are\u00a0more difficult to treat. Parents need this kind of information before deciding whether to use drugs\u00a0on an infection that will probably clear up on its own anyway in most children \u2014 and can be effectively treated after a few days with antibiotics if it doesn\u2019t.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states:\u00a0 \nWe wonder how well patients tolerate side effects of headaches, rashes and higher blood pressure. ", "answer": 1}, {"article": "It updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did an adequate job mentioning the harms from zinc. This story did an especially good job providing a range of side effects. \u201cExperts stress that more research is needed before the most effective kind of zinc can be determined, and they caution that in high doses \u2014 more than 40 milligrams per day \u2014 zinc can cause dizziness, headache, drowsiness, increased sweating, loss of muscle coordination, alcohol intolerance, hallucinations, and anemia.\u201d", "answer": 1}, {"article": "AMD, the No.\nAccording to national statistics, the average age at which individuals are given L-DOPA is 67; the average age of AMD diagnosis is 71.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n\"Results suggest a new path forward in our fight against AMD that may even include a strategy to prevent those at risk of the disease from ever developing it,\" said Brian McKay, Ph.D., associate professor, Department of Ophthalmology and Vision Science, University of Arizona.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "At no point does the release mention any harmful effects from taking L-DOPA.\u00a0 And while patients might arguably be willing to face greater risks in order to retain their eyesight, it doesn\u2019t excuse the release for omitting relevant details. L-DOPA has been given to patients for years and the list of possible side effects \u2014 both physical and mental \u2014 is considerable. Patients reading stories or releases touting the possible treatment use of new drugs deserve to know the full story including possible negative effects of the drug\u2019s use.", "answer": 0}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\n\"I just think it's too early really,\" said one, who spoke on the condition of anonymity for that reason.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nHe predicted that information gained from the trial after the results are fully analyzed will have \"important implications for the design of future HIV vaccines.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Were any harms \u2013 besides the lack of protection in most trial participants \u2013 reported in the Thai trial?\u00a0 We don\u2019t know from the story.\u00a0 ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did mention concerns about anxiety and depression; how often these occur and whether the drug increases their prevelance\u00a0are relevant peices of information. It would have been useful to hear how often these side effects occur. ", "answer": 1}, {"article": "Here, Ehlers touches on a broader controversy around games like Project Evo.\n\"If it says 'FDA approval needed' in the business plan, I myself scream in fear and run away,\" says Tim Chang, managing director at Mayfield Fund, a venture capital firm.\n\"And if, at the end of the day, the goal is about improving health, then we may need to revisit the way we are quantifying outcomes.\"\n\"When you look at the percentage of individuals that are playing video games [59 percent] and overlay that with the percentage of individuals that have chronic conditions or need some assistance from the medical perspective [45 percent], the relationship is pretty strong,\" says Willis Gee, director of information technology strategy and innovation at health insurer Cigna.\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. There is strong debate about whether recreational video games affect social development or behavior. Such games certainly can displace physical activity\u2026 playing outdoors\u2026 that is important to the health of children in particular. The story would have been better if it at least mentioned that video games may not be entirely benign.", "answer": 0}, {"article": "Bosl acknowledges that if this is very early research, but he believes if the results are confirmed, it may lead to a safe and inexpensive way to detect autism, which would allow intervention before any autistic behaviors appear.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\nThis will now allow the researchers to evaluate them for autism and then look back at the brain activity patterns of the children who do fit the clinical criteria for autism.\nScientists have known for quite some time now that the earlier a child with autism gets therapy, the easier it is to improve language and behavioral skills.\nOverall, the biggest differences in brain activity were seen at 9 months \u2013 which is much earlier than when a child typically shows behavioral problems associated with autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story quantified the harms.\u00a0The obvious harm is parental anxiety and labeling an infant as having autism when there must be at least some risk of false positives.\nThis was framed as a potential screening test.\u00a0 All screening tests carry potential harms.\u00a0 Journalists often report only on screening tests\u2019 potential benefits.", "answer": 0}, {"article": "For more information, please visit http://www.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms that could arise from taking a garlic supplement although a quick web search shows potential negative side effects including nausea, vomiting and diarrhea. There are also some indications that garlic may lower blood pressure, increase bleeding,\u00a0and possibly irritate the intestinal lining, issues that should be of concern to some who might potentially take this supplement.", "answer": 0}, {"article": "\u201cWhen I told this to my boss, he said there have to be atlases for children from diverse backgrounds.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\nBut they differ in a key way: Whereas the algorithm the NIH uses can predict if someone has a given genetic disorder, the Face2Gene algorithm spits out not diagnoses, but probabilities.\nHowever, the app won\u2019t give clinicians a yes or no answer to the question of, \u201cDoes my patient have a genetic disorder?\u201d\n\nThat\u2019s intentional.\nThe app describes photos as being a certain percent similar to photos of people with one of the 2,000 disorders for which Face2Gene has image data, based on the overall \u201clook\u201d of the face as well as the presence of certain features.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms here, but with any screening test (or \u201creference informational tool\u201d as Face2Gene calls itself), there is a risk of overdiagnosis or incorrect diagnosis, without confirmatory genetic testing. That could be devastating to parents of affected children for example. Even though the company says that the software should not be used as a diagnostic tool, the allure to do so \u201coff label\u201d is there.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nDuring widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\nA camera at the tip shows the inside of the gut, so that unusual cell clumps can be found and removed.\n\u201cFrom a task force perspective, this article alone would not prompt us to look at the screening guidelines.\u201d\nOne in 40 of those younger than 50 years had late-stage polyps, but no one actually had colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms of colonoscopy, such as bleeding and perforation.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nevirapine crosses the placenta. Studies in pregnant women have shown that nevirapine decreases the chance of passing HIV to a child during labor and at birth. Liver toxicity has been observed with long term use of nevirapine in combination with other HIV drugs, though this is not mentioned in the article. Additionally, other studies have shown 20-40% resistance to the drug after taking one dose as a protective measure in labor, yet there is no mention of the rate of resistance in the main study discussed in the article. Nevirapine may be \u201ceasy to take\u201d, but quantification of side effects noted in this and other studies discussed is omitted. Given there is only a 3% absolute reduction in transmission in one study cited, the risks of the drug for newborns and their mothers needs to be discussed. ", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\n\"Sweat contains lots of information related to human health that researchers have not fully analyzed and we found some unexpected chemicals associated with CF,\" he says.\n\"We set out to discover whether there were chemical indicators detected in sweat that could complement the gold standard for CF diagnosis: the sweat chloride test.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms here involve errors in diagnosis. More specifically, the story does not address the specificity or sensitivity of the biomarker testing. And this is important. Specificity indicates how good a test is at ruling out people who don\u2019t have a problem. Sensitivity addresses how good a test is at positively identifying people who actually have the problem. False positives can result in unnecessary treatments and costs. False negatives can result in patients not getting treatments that could help them. And if it\u2019s still too early to tell what the specificity or sensitivity of the tests are, they need to address that.", "answer": 0}, {"article": "\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\nThey removed inactivity as a factor in their study of aging by looking at the health of older people who move quite a bit.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nThis conundrum is particularly true in terms of inactivity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any comment about risks of injury or harms that might result from an active lifestyle riding miles on a bicycle.", "answer": 0}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nParvalbumin is a cause of fish allergies, so we knew that it passed over to the blood, and that this form of parvalbumin is specific for fish\"\n\nShe joined forces with Pernilla Wittung-Stafshede, and together they took the idea forward.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nThere is correlation between certain diets and decreased rates of Parkinson's disease - as well as other neurodegenerative conditions.\nParvalbumin effectively 'scavenges' the alpha-synuclein proteins, using them for its own purposes, thus preventing them from forming their own potentially harmful amyloids later on.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is dominated by suggestions that parvalbumin could help with Parkinson\u2019s and perhaps other neurodegenerative diseases including Alzheimer\u2019s, ALS and Huntington\u2019s but only at the very end do we learn it\u2019s been studied as a a cause of fish allergies.\nIs this the only harm? We don\u2019t know because harms aren\u2019t included.", "answer": 0}, {"article": "Craig Horswill, clinical associate professor of kinesiology and nutrition at the University of Illinois at Chicago, says the study adds to the growing body of evidence that suggests strategies for increasing non-exercise active thermogenesis \u2014 defined as spontaneous activity unrelated to a fitness routine \u2014 are needed to help overcome the detrimental effects of prolonged sitting.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms in the news release. It\u2019s likely that there aren\u2019t many, since low-impact seated activity is good for joints and can still burn some calories. But still, as we say in our review criteria:\u00a0if you\u2019re only hearing about the potential benefits of a test or treatment, run for the hills.", "answer": 0}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\n\"The findings are most important for populations at high risk for cardiovascular disease, such as Type 2 diabetics, who have normal levels of LDL cholesterol, but elevated levels of non-HDL or apo B,\" said Dr. Vladimir Vuksan, research scientist and associate director of the Risk Factor Modification Centre of St. Michael's.\nThe review also indicated that barley had similar cholesterol-lowering effects as oats, which is often the go-to grain for health benefits.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"After looking at the evidence, we can also say that barley is comparably effective as oats in reducing overall risk of cardiovascular disease\" said Dr. Vuksan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are unlikely to be harms for most people if they increased their barley consumption, but upping their daily intake could also lead to gastrointestinal problems in some people. The recommended daily consumption of barley in Canada is 3 grams but the study recommends that it be increased to 6.5 to 7 grams daily. People diagnosed with Celiac disease have most likely already been advised that consuming barley (as well as other foods containing gluten) can cause complications.", "answer": 2}, {"article": "However this does not help them to overcome their fear in the long term.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nOf all patients referred, four-fifths (79%) went on to have dental treatment without the need for sedation and 6% had their dental treatment under sedation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address risks, but CBT carries few risks (if any). In addition, the release states that in this study, patients who needed additional therapy beyond CBT for mental health issues were referred for more assistance.", "answer": 1}, {"article": "; Timothy Lesnick, M.S.\n\u201cWomen with APOE e4, who have a greater genetic risk for Alzheimer\u2019s disease, particularly benefited from this therapy.\u201d\n\nMenopause is defined as occurring 12 months after a woman\u2019s last menstrual period and marks the end of menstrual cycles.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Early in the text, the writer notes that one large, older study\u2014the Women\u2019s Health Initiative at NIH\u2014has found an association between use of estrogen and an increased risk of dementia among women 65 or older. The study highlighted here, in contrast, focuses on women five to 36 months past menopause, individuals predominantly in their 50s. The potential long-term effects of estrogen use by these younger women is not mentioned in the release.\nEstrogen carries a well-known small increase in risk for breast cancer and blood clots, which could have been briefly acknowledged. In addition, the National Library of Medicine states that estradiol, the form of estrogen used in transdermal patches, \u201cincreases the risk that you will develop endometrial cancer (cancer of the lining of the uterus [womb]). The longer you use estradiol, the greater the risk that you will develop endometrial cancer.\u201d Other minor side effects include head ache, breast pain and nausea, among others.", "answer": 0}, {"article": "Bangalore said this is critically important because \"compliance is big issue with our patients.\"\nThe idea that ACE inhibitors are more effective than ARBs was based on comparing studies on ACE inhibitors going as far back as the 1980s and into the 1990s with newer studies on ARBs in the 2000s.\nMost guidelines set forth by the major medical groups suggest starting a patient with an ACE inhibitor first, but the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) considers ACE inhibitors and ARBs to be equal.\nTop health issues to pay attention to in 2016: The rise of personalized diets and medical treatments\n\nFor more health news, you can sign up for our weekly newsletter here.\nThe one difference they found was that ARBs tend to be better tolerated by patients, meaning that they have fewer side effects or result in fewer adverse events.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point to the greater occurrence of a dry cough as a result of taking ACE inhibitors compared to taking ARBs but a quick web search for both drug types shows a much larger list of possible side effects including dizziness, headaches, drowsiness, nausea, vomiting, diarrhea, low blood pressure, weakness,\u00a0and skin rash, as well as increased potassium levels and possible sexual dysfunction. A similar omission is present in a HealthDay story that explained the same research.\nCough is the most common side effect of ACEI that is not generally seen with ARBs. The one other one is angioedema which is more common with ACEI. Otherwise studies show that other side effects are probably similar. This isn\u2019t stated explicitly, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "This new development represents a big step forward in personalised medicine.\nRemarkably, CURATE.AI subsequently identified a ZEN-3694 dose that was 50 per cent lower than the patient's starting dose of the drug prior to CURATE.AI analysis.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\n\"No two patients' profiles are alike, and as a patient's body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an unprecedented advance for combination therapy,\" Prof Ho explained.\nTo overcome the challenges of conventional combination therapy, the NUS team of engineers developed the CURATE.AI platform, which uses the patient's own clinical data - such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "AI is not perfect. AI programs can, and will, make mistakes. What might those mistakes mean in the context of cancer treatment? It\u2019s not clear, and the release doesn\u2019t address this. We know that clinical trials using \u201cCURATE.AI-guided\u201d therapies are underway, and that the patient highlighted in the news release is involved in a clinical trial. But we don\u2019t know how any of those trials are going. Will those trials identify any risks or potential harms? How will medication dosages be adjusted to reduce side effects? That remains to be seen, and the release should not simply ignore the issue. If this single patient\u2019s treatment was sufficient to warrant a news release, any potential harms (or even the absence of potential harms) should also be worth addressing.", "answer": 0}, {"article": "But prior to the present study there was very limited evidence of any cognitive benefits in humans.\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nTreatment with probiotics also resulted in lower levels of triglycerides, Very Low Density Lipoprotein (VLDL), high-sensitivity C-Reactive Protein (hs-CRP) in the blood of the Alzheimer patients, and likewise a reduction in two common measures (called \"Homeostatic Model Assessment\", HOMA-IR and HOMA-B) of insulin resistance and the activity of the insulin-producing cells in the pancreas.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although probiotics are considered to be safe for people who are generally healthy, they have been linked to severe side effects in people with underlying medical problems. According to the National Institutes of Health, the populations most vulnerable to adverse effects from probiotics include the critically ill, infants, and people with weakened immune systems, which often includes elderly men and women. Since this study was conducted in individuals aged 60-95 years with an underlying health condition, safety should have been addressed in the news release. And yet, no explanation of risks or potential harms was provided.\nEvaluation of all treatments, including benign appearing supplements, should include an assessment of harm. ", "answer": 0}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nAfter the study's first six months, 21 percent of the 5-FU group rated the side effects as \"severe,\" and 40 percent rated them as \"moderate.\"\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nIn the absence of such a long-lasting prevention option, he said, the typical approach to caring for patients with a history of prior carcinomas is to monitor for the next cancer and then remove it surgically -- an effective but imposing strategy often called \"wait and cut.\"\nIn addition to Weinstock, the new study has many authors from the VAKCC trial including at each of the study's 12 sites: Boston; Bay Pines, Fla.; Chicago, Ill.; Palo Alto, Calif.; Atlanta; Loma Linda Calif.; Minneapolis; Nashville; Denver; Durham, N.C.; Philadelphia; and Miami.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release describes harms in the following paragraph:\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged. After the study\u2019s first six months, 21 percent of the 5-FU group rated the side effects as \u201csevere,\u201d and 40 percent rated them as \u201cmoderate.\u201d", "answer": 1}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\n\"We are excited that the benefits observed in the early pilot and preclinical research extended to this larger trial,\" says Luke G. Huber, ND, MBA, vice president of product innovation and scientific development at Life Extension.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although adverse effects were reported by by study participants (e.g bone and joint pain, headache, physical weakness and celiac disease), researchers commented in the study that these conditions were not related to treatment, since \u201cno differences were noted in adverse effects between the two treatment groups.\u201d\nBut if there are no side effects, then a simple acknowledgement that \u201cthere were no adverse effects\u201d would still be in order, and the release didn\u2019t provide this.", "answer": 0}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\n\u201cI was in a dire place, but now I can swim and cycle and I am determined to walk.\u201d\n\nHolly Drewry was 21 when she was diagnosed with MS, and her condition deteriorated after she gave birth to her daughter, Isla.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are left unexplained.\u00a0 One source notes that haematopoietic stem cell transplant (HSCT) \u201cis an aggressive treatment that comes with significant risks.\u201d\u00a0 And one patient who received the treatment noted that \u201cI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\u00a0 But none of that illuminates the nature of the risks that someone would encounter.\nThis is the weakest point of the story. This is a treatment with real risks. They way it is presented gives very little insight to the reader about what these risks are.", "answer": 0}, {"article": "Newswise \u2014 Baltimore, Md.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nIt continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.\nAccording to Dr. Vujaskovic, the new deep-tissue thermal therapy equipment, which is made by Pyrexar, will be used to treat cancers of the abdominal and pelvic region, including cancer of the bladder, rectum, cervix, ovaries, pancreas and connective tissue, which are known as sarcomas.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release touts the potential benefits of both therapies, it says nothing about side effects or potential harms. According to the Mayo Clinic, possible side effects of proton therapy include fatigue, digestion problems and headaches. The National Cancer Institute lists possible side effects of hyperthermia, which include burns, blistering, vomiting, and and possible cardiac disorders.", "answer": 0}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe new test, called the xTAG respiratory panel, approved earlier this year by the U.S. Food and Drug Administration, is the most comprehensive FDA-approved virus-panel to date.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nIt tests for a dozen viruses, including several types of influenza, two types of respiratory syncytial virus, or RSV, three types of parainfluenza, adenovirus and even rhinovirus, which causes the common cold.\nAccording to manufacturer Luminex Corp. , Austin, Texas, the viruses in the panel are expected to account for about 85% of the viral illnesses in the U.S. this year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two\u00a0main drawbacks of the xTag test, that it is expensive and can\u00a0take up to a day or two to get the results, are presented.\u00a0\u00a0Expense is an important\u00a0issue given the volume of acute febrile illnesses in children, particularly if this test were given routinely in an outpatient setting.\u00a0 In addition, if the processing time at the specific location is is too long, the test may not have any practical benefit in the treatment decision window.\u00a0\u00a0 ", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\nSince its introduction in 2001, the banding approach has become a popular alternative to \"Roux-en-Y gastric by-pass\" surgery, which involves the literal stapling of the stomach in order to redirect food past part of the small intestine to instigate reduced food absorption as well as a quicker sensation of satiety.\nThe results: 12 years or more later, more than 60 percent of the banding patients said they were \"satisfied\" with their experience.\nTo explore satisfaction levels and the long-term complication history of gastric banding, in 2009 Himpens and his team examined a pool of patients who had undergone the surgery between 1994 and 1997.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information about the harms observed in the study population who had had gastric banding surgery. It says, \u201cHowever, 39 percent of the patients had experienced serious complications, including abnormal pouch expansion (9), band erosion (23) and band infection (1). Another 22 percent experienced relatively minor complications. Almost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery. The procedure \u201cappears to result in relatively poor long-term outcomes,\u201d the researchers concluded.\u201d", "answer": 1}, {"article": "The field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\nThe TST is the most commonly used test to detect TB infection, with about 50 million tests worldwide each year, according to the World Health Organization.\n\u2022 Among participants with HIV, the ability of all three tests to detect TB infection was diminished, though the C-Tb appeared more robust in HIV-infected participants with low CD4 T cell counts.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0is no mention of potential harms with this new test, leaving readers to assume its safety. Although relatively minor, side effects have been noted in previous clinical trials including: \u201cLocal adverse reactions following C-Tb injection included transient itching and discomfort as expected components of the immune response.\u201d\nIn addition, as with most diagnostic tests, there is a risk of false-positive (over-diagnosis) or false-negative (under-diagnosis) results. This should have been mentioned along with data on the test\u2019s reliability. ", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the one major flaw in the reporting from our perspective. Harms are not mentioned anywhere. Threading a catheter into a blood vessel in the brain to retrieve a clot and giving a clot buster are not totally benign procedures. The Australian study did not see any differences in the incidence of bleeding or worsening of symptoms whereas the second study saw a slight but statistically insignificant increase in bleeding in the group who received alteplase and the clot removal. \u00a0Importantly, the study was conducted in centers where there is considerable expertise and availability. \u00a0These results may not be transferable to all hospitals.", "answer": 0}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nPresented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study.\n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen.\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems unlikely that personalizing a weight loss plan could cause significant harm. The most tangible downside is likely to be time and money wasted on a plan that might not be more effective than standard dietary advice. Still, a small risk of complications resulting from repeated blood draws or finger sticks is possible since glucose and insulin concentrations are measured from blood samples.", "answer": 2}, {"article": "She's a breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nSince the new guidelines lean heavily on knowing breast cancer risk, doctors need to redouble their efforts to make sure risk assessments are done for women in their early 40s, they concluded.\n\"We believe formal risk assessment is essential for women ages 40 to 44 in order to identify those who require screening mammography to start at the age of 40, and those who would qualify for screening MRIs and genetic testing,\" Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms (outside of future breast cancer diagnosis) of women receiving a high score on the risk assessment. It is unfortunate because risk does not mean someone will absolutely get breast cancer and some women could receive false positive mammograms with attendant anxiety and risk of unnecessary follow-up tests and procedures.", "answer": 0}, {"article": "The authors declare no other conflicts of interest.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\nThe cohort included 305 patients under 70 years of age, 448 patients ages 70 to 79 years, and 330 patients aged 80 years or more (which included 16 patients aged 90 years or more).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release. The study alludes to harms in a quote, saying:\n\u201cOlder patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\u201d\nOk. So this starts getting at the fact that the treatment itself is harmful. Why not go further and explain to readers and journalists what the risks are from the treatment and how the risks played out with this study?\nKnown harms from this treatment include fatigue lasting 4-6 weeks, neuropathic pain, rib fractures and other risks.\u00a0", "answer": 0}, {"article": "Gille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nNov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It is ludicrous to simply report \u201cThere were no serious side effects\u201d when the only data you\u2019ve reported is two hours of observation of healthy volunteers!\nFirst, were there ANY side effects?\u00a0 If so, what?\nSecond, how many people with diseased arteries (not healthy volunteers) would have to be treated and followed for how long in order to be able to say ANYTHING meaningful about side effects?", "answer": 0}, {"article": "Yet the study suggests the opposite has happened.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nThe study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nThe drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions alternative treatments, but doesn\u2019t address potential harms of changing prescribing patterns. While reducing the risk of overdose may outweigh any potential negatives of taking patients off of a drug, it\u2019s still worth addressing any drawbacks.\nThe story\u00a0also does not explain how concurrent use of benzodiazepines and opioids cause harm (via the combined sedative effect which can lead to respiratory depression).", "answer": 0}, {"article": "For advice, information and support, visit http://www.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nAs part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate - making it extremely difficult to pay attention to walking.\nDr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nParkinson's UK Research Fellow Dr Emily Henderson and principal researcher on the study, based at the University of Bristol, said:\n\n\"With the degeneration of dopamine producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms or side effects but some commonly reported adverse events associated with rivastigmine include dizziness and nausea. It can also cause drowsiness and fatigue which in some patients might actually increase the risk of falling. In addition, this drug has potential interactions with commonly prescribed drugs for elderly patients (such as aspirin, some beta blockers, NSAIDs, and medications for urinary incontinence, among others). This is noteworthy because Parkinson\u2019s disease patients tend to be on multiple medications, increasing the likelihood of falls and of possible drug interactions.", "answer": 0}, {"article": "The heightened connectivity to spirituality has also been demonstrated to curb suicidal thoughts and attempts.\nThe scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nThe study does have shortcomings: For one, the data relied on people self-reporting their habits, so there is a possibility of error there.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nWhile skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u201cThe effects of psychedelics on the developing brain are still largely unknown, meaning they could still pose a threat to people with a predisposition to schizophrenia,\u201d says the story. But it does not add other possible drawbacks cited by the study, such as \u201cfeelings of anxiety, fear, panic and paranoia.\u201d Since potential harm is a big reason these drugs are not widely available, we think this was an issue worth discussing in more detail.", "answer": 0}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nIn the U.S., there are around 50 million men and 30 million women affected by hair loss, which U.K.-based researchers said could be a source of \u201cpsychological distress.\u201d\n\nIn a study conducted on human hair follicles, researchers investigated a drug called Cyclosporine A (CsA), which has been prescribed to treat immune disorders and transplant rejection since the 1980s.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The need to study the safety of WAY-316606 was mentioned, but should have been higher in the story. The story would have been stronger if it had mentioned whether the drug\u2019s safety has been studied previously, and what the results if any showed. It was a missed opportunity to highlight known harms of a drug already on market.", "answer": 0}, {"article": "Ingber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThough there still aren\u2019t enough data to prove the chips are reliable enough to put rodents out of a job, Ingber says it\u2019s only a matter of time; they hope to have them tested and ready for market in two years.\nIt takes up to 15 years and $5 billion for a new drug to make it through testing and earn approval from the U.S. Food and Drug Administration (FDA).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough one. The article does mention limitations, but doesn\u2019t specifically state that conceivably this chip technology could have unforeseen problems \u2014 that it may say everything is ok when it isn\u2019t and that could lead to harm. Given the early stage of this research, it would be prudent to include a caveat about potential for unknown or unpredictable downsides to the technology.", "answer": 0}, {"article": "For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.\n\"Obesity continues to be a problem in America and it is an epidemic rapidly spreading around the world,\" said Reem Z. Sharaiha, MD, MSc, assistant professor of medicine at Weill Cornell Medicine and attending physician at New York-Presbyterian/Weill Cornell Medical Center, the study's lead author.\nThe team also reported that endoscopic sleeve gastroplasty patients customarily left the hospital on the same day of treatment, while laparoscopic sleeve gastrectomy patients stayed for about three days and laparoscopic banding patients for a day and a half.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\nAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for endoscopic sleeve gastroplasty patients and 14.46 percent for laparoscopic banding patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release does state that \u201cresearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\u201d That\u2019s good. However, the release doesn\u2019t tell us what they mean by \u201ccomplications.\u201d Endoscopy, in general, is fairly low risk \u2014 but potential complications can include short-term pain and nausea, infection, organ tearing and bleeding.", "answer": 0}, {"article": "\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\nSenior author Professor Kausik Ray, from Imperial\u2019s School of Public Health, said: \u201cFor the first time, we show that statins reduce the risk of death in this specific group of people who appear largely healthy except for very high LDL levels.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of statins are mentioned, but they\u2019re significant. Taken over many years, let alone decades, those risks become even more significant considerations. The most common side effect \u2014 29% of people on statins report experience it \u2014 is damage to muscles and muscle pain (e.g. soreness, tiredness, and weakness), according to the Mayo Clinic. However, those on placebo report a similar rate of muscle pain and damage. Other, less common side effects (for which there\u2019s also less evidence that statins may be responsible) include liver damage, increased blood sugar or type 2 diabetes, and memory loss/confusion.", "answer": 0}, {"article": "The new study, however, draws from the population.\n\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\nJan. 9, 2012 -- Nicotine replacement therapies such as gums or patches may not help smokers kick the habit long-term, a new study shows.\nThe findings are at odds with clinical trials, Connolly says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nA total of 8,231 men between the ages of 50 and 75 took part in the study, published in the New England Journal of Medicine.\nAll of the men had elevated blood levels of prostate specific antigen (PSA), which indicated an increased risk for prostate cancer.\n\"We know from experience that many of these men are likely to have microscopic prostate tumors that were missed by their original biopsy,\" he says in a news release.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing and quantifying the potential harms of the drug, which are significant.", "answer": 1}, {"article": "Macular degeneration patients often are advised to take certain vitamin combinations that may help stave off advanced disease.\nThe experimental drug, lampalizumab, aims to slow the destruction of light-sensing cells in the retina, creeping lesions that characterize the stage of dry AMD called \u201cgeographic atrophy.\u201d When those cells die, they can\u2019t grow back \u2014 the vision loss is irreversible.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nThe current research sheds light on how that long-suspected immune culprit might be working, and is \u201cthe first suggestion that there may be a treatment for geographic atrophy coming up in the future,\u201d said National Eye Institute retina specialist Dr. Wai Wong, who wasn\u2019t involved in the study.\nWhile there\u2019s no treatment for the advanced dry form, the \u201cwet\u201d form occurs when leaky blood vessels grow under the retina \u2014 and there are several therapies that can help those patients preserve vision.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were no \u201csafety concerns\u201d noticed during the trial. We\u2019re not sure what that means\u2013does that mean there were zero side effects? Or just no life-threatening ones? When we looked at the study, we did see that the drug caused side effects, which might not meet the researchers\u2019 definition of a \u201csafety concern\u201d but could certainly be of interest to patients taking the drug.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no discussion of potential harms, which is unacceptable for a story based on a drug that already has a known risk profile and for which new claims are being made. ", "answer": 0}, {"article": "And patients may need to continue treatment.\nThere are some rare side effects, including severe inflammation, infection and detached retina.\nThree months ago, he noticed his vision was distorted.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nMore than 80 percent maintained their vision and up to 40 percent actually improved their sight significantly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention side effects, such as inflammation, infection, and detached retina.", "answer": 1}, {"article": "(Reuters Health) - A system of automated twice-daily texts and the ability to use text messaging to receive answers to questions about treatment helps relieve some of the stress of chemotherapy for women with breast cancer, researchers at the Fox Chase Cancer Center in Philadelphia reported Monday.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nOne of the patients texted the program 1,217 times.\nEveryone has different information-seeking behavior\u201d and the system can respond to that, Dr. Wen said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There don\u2019t appear to be any harms associated with text messages, barring potential distraction while driving. Hence, this criterion doesn\u2019t apply.", "answer": 2}, {"article": "While this is a small study, the results highlight how thinking outside the box -- in this case using Mozart -- to improve adenoma detection rates can potentially prove valuable to physicians and patients.\"\n\"Anything we can do to get those rates up has the potential to save lives.\nThis was up from a baseline detection rate of 21 percent before the study began.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\nWhen spotted early, potentially dangerous polyps can be removed during colonoscopies, preventing the development of disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No foreseeable harms or side effects in listening to music during procedures.", "answer": 2}, {"article": "The results were also presented at a medical meeting in May.\nThe study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n\"While there is potentially easier insertion that does not require sedation, I still doubt after removal there will be weight loss,\" he said.\nThe findings were to be presented Friday at the annual meeting of the American Society for Metabolic and Bariatric Surgery and the Obesity Society in New Orleans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions these harms:\nAs for side effects, one patient had a bleeding stomach ulcer while taking high doses of pain pills after a knee replacement. Most patients (91 percent) suffered from stomach cramps and nausea, which nearly 100 percent said were mild or moderate.\nThe story would have been stronger if it had warned readers that a study that puts a device in only a couple of hundred people may miss problems that could appear after the device is placed in hundreds of thousands or even millions of patients. The documentation that the manufacturer will give patients lists several serious, even life-threatening, potential side effects, including intestinal and airway blockages. These potential risks should have been noted.", "answer": 1}, {"article": "Moffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nCurrently, there are no studies that have analyzed the long-term effects of neoadjuvant radiation therapy on breast cancer patients.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\nTheir study, published in the June 30 issue of Breast Cancer Research, found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site.\nWith more than 5,200 team members, Moffitt has an economic impact in the state of $2.1 billion.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no comment in the release about potential harms, although the study itself addressed the potential negative impact on healing.", "answer": 0}, {"article": "There are substantial risks.\n\"Unfortunately, for most patients this is not going to be the answer yet,\" says Reardon, who used to work at Duke but wasn't involved in the new research.\n\"We're extraordinarily encouraged by what we see with this data,\" says Mitchel Berger, chairman of neurosurgery at the University of California, San Francisco and director of its center for brain tumors.\nIn addition, the researchers are planning to try the approach on children with brain cancer, as well as other types of cancer, including melanoma and breast cancer.\nBut overall, the median length of survival was 12.5 months for patients treated with poliovirus, compared with 11.3 months for a similar group of patients treated in the past, the researchers report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported \u201csubstantial risks\u201d with the treatment, including \u201cdangerous swelling in the brain that can lead to seizures and other complications.\u201d It reported that one patient had a life-threatening blood clot in the brain that required surgery.\nThe story did not explain how many of the patients in the trial experienced the substantial risks. This was something NBC News handled better (see the review). We can look the other way on the benefits criterion, but the story should have given some estimate of how many people experienced harm from the treatment.", "answer": 0}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\nAlthough the IUD is not yet approved to treat endometrial cancer, it is approved and widely used to treat endometriosis and abnormal uterine bleeding.\n(The disease progressed in one of the women with AEH and four of the women with early-stage cancer.)\nThe authors followed 20 Italian patients from January 1996 to June 2009 with atypical endometrial hyperplasia (AEH), which often precedes the cancer, and 14 women with early-stage endometrial cancer confined to the inner layer of the womb.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story accurately notes that the study reported no adverse effects. The study\u2019s authors reported only on adverse effects that were sufficient to require suspension of treatment.", "answer": 1}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were many stories about this study, and we could not find one that mentioned harms. This is unfortunate because screening tests do produce false positives and people do make choices based on those results. As a clinician in a New York Times piece about the relative weakness of treadmill tests as a predictor of health explained, \u201cIn my own practice I\u2019ve seen people who thought they shouldn\u2019t be exercising anymore because someone put them on a treadmill and got an abnormal test result when in fact there was nothing wrong with them.\u201d\nProviding this information could also be harmful in other ways. It might reassure someone that they\u2019re going to live a long time, and lead them to forego the things that they\u2019ve previously done to be healthy. Or for those at increased risk of dying, it might make them more fatalistic and less prone to take steps to improve their health.", "answer": 0}, {"article": "Additional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\nFor military personnel, internet-delivered cognitive behavioral therapy appears to be an effective alternative to meeting regularly with a therapist, although it is about half as effective as traditional methods, according to results of a study conducted by Daniel Taylor, University of North Texas professor of psychology and director of UNT's Sleep Health Research Laboratory.\n\"The online program can also be done from home rather than at a military behavioral health clinic, which some service members may avoid due to concerns about stigma,\" said Pruiksma, an assistant professor of psychiatry at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).\nIt is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\nIn a previous study of civilians with insomnia, Taylor and his research team discovered that cognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects' use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward, although the subjects weren't required to stop taking their medication.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release. According to the scientific paper, \u201cAEs [adverse events] determined to be related to the research included one patient with an increase in insomnia after primary care physician reduced hypnotic medication and six patients with skin irritation from wearing the Actiwatch.\u201d While these appear to be minimal, releases should still try to address any potential harms.", "answer": 0}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\n\u201cWhat I like about this paper is that it validates the upper-GI route and demonstrates that you can get very good cure rates without doing a colonoscopy.\u201d\n\nThat\u2019s important because colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body and can be complicated for the people most at risk for C. difficile infections, Hohmann noted\n\nKao\u2019s study also showed that people found FMTs far less unpleasant when the poop came in a pill.\n1 in hospitals.\u201d\n\nAccording to the Centers for Disease Control and Prevention, C. difficile infects half a million people in the United States per year and kills 15,000 people.\nWhile the FDA said in 2013 that doctors can try fecal transplants in patients with C. difficile infections, the agency noted doctors should only use FMT for other conditions in clinical trials.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a satisfactory here for including the differences between the two methods of delivery: One source is quoted saying, \u201ccolonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body\u00a0and can be complicated for the people most at risk for C. difficile infections.\u201d\u00a0 It could have gone a step further and reminded readers that a colonoscopy is an invasive procedure with the inherent risks of infection and perforation that obviously aren\u2019t there when taking a pill. The story did not mention the other adverse events described in the paper such as nausea and vomiting, though.", "answer": 1}, {"article": "Over two years, both groups showed steady improvement.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nFor example, some patients can learn to defuse the voices in their head \u2014 depending on the severity of the episode \u2014 by ignoring them or talking back.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s conceivable that changing the standard of care for patients by reducing drug doses may carry some risk. Could some patients\u2019 symptoms be less-well controlled? Then again, drugs are very much overused in this area. And on average the study showed better symptom relief with the lower doses. No harms were documented in the study\u2013no increase in hospitalizations at least. \u00a0So while we can\u2019t give credit here, we won\u2019t ding the story either. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "He applied for funding of the research a few years ago, to no avail.\nMake sure the room temperature is comfortable.\n-- Avoid what are commonly called simple carbohydrates and \"sugary stuff\" at that meal or at bedtime.\n\"When our insulin is very high, we can't get to sleep,\" he says.\nInstead, choose whole-wheat crackers, which can control insulin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms don\u2019t seem to apply in this case. ", "answer": 2}, {"article": "The game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\nWhile some psychotic symptoms can be reasonably well treated with medication, patients often still have debilitating problems with memory and cognitive function, meaning they struggle to get back to work or stay in education.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that there are any potential harms associated with playing the game. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "A reality check on nootropics and other efforts to keep aging at bay\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nThat\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n\nEarly studies attributed a lot of short-term benefits to nootropics \u2014 so much so that in 1983, Russian scientists turned to phenylpiracetam to boost the physical and mental performance of cosmonauts during space flight.\nBurke, who begins each morning with a Bulletproof coffee \u2014 a rich brew of caffeine with dollops of butter and coconut oil \u2014 has created a San Francisco meetup group called Peak Performance \u201cto teach all my friends in the tech space about life hacks so they can kick a--better every day.\u201d\n\nLast spring, 100 people showed up at a Peak Performance event where psychedelic psychologist James Fadiman said the key to unleashing the cognition-enhancing effects of LSD \u2014 which he listed as less anxiety, better focus, improved sleep, greater creativity \u2014 was all in the dosage.\nNgo has experimented with piracetam himself (\u201cThe first time I tried it, I thought, \u2018Wow, this is pretty strong for a supplement.\u2019 I had a little bit of reflux, heartburn, but in general it was a cognitive enhancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are addressed\u2013enough to be Satisfactory for this criteria. But the discussion is confusing. The story initially says nootropics have \u201csupposedly few side effects and low toxicity.\u201d Later it states:\nAs for newer nootropic drugs, there are unknown risks. \u201cPiracetam has been studied for decades,\u201d says cognitive neuroscientist Andrew Hill, the founder of a neurofeedback company in Los Angeles called Peak Brain Institute. But \u201csome of [the newer] compounds are things that some random editor found in a scientific article, copied the formula down and sent it to China and had a bulk powder developed three months later that they\u2019re selling. Please don\u2019t take it, people!\u201d\nIn contrast, consider these unequivocal cautions in a similar Mercury News story last fall, starting in the seventh paragraph:\nResearch into the cognitive benefits of nootropics is still in its early stages, and some experts worry about the long-term health effects of ingesting potent synthetic smart drugs, which are largely unregulated.\nSome users have reported side effects including headaches, upset stomach, insomnia, anxiety and depression.\nDr. Reid Blackwelder, past president of the American Academy of Family Physicians, said it concerns him that customers are ordering such drugs online without consulting a doctor, because some of the substances seem to have a powerful impact on the brain. And much of the research on the cognitive benefits of these substances is supported only by studies using animals, Blackwelder said.", "answer": 1}, {"article": "The biggest variable is patients themselves.\n\"There is, to be honest, some irrational exuberance out there,\" says Daniel Berry, chief of orthopedic surgery at the Mayo Clinic in Rochester, Minn., and president of the American Academy of Orthopedic Surgeons.\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\n\"If you have a brand new sports car and leave it in the garage, it will last forever and you won't have any fun,\" says Thomas Schmalzried, an orthopedic surgeon at St. Vincent Medical Center in Los Angeles.\n\"It got to the point where I couldn't get on my motorcycle anymore,\" says Paul Canter, a picture framer from Los Angeles who had a double hip replacement at 63 last year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article included only general references to the harms associated with knee and hip replacement. It did not specify rates of mortality, blood clotting, infection, and other potential adverse events associated with primary and revision knee and hip replacement operations. These are important issues in this age group since early joint replacement will likely involve more problematic revision procedures down the road. Detailing the complications and adverse events that can be expected in revision procedures would have helped balance the article.\n", "answer": 0}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\nBotox is currently FDA approved for cosmetic use to lessen frown lines, and for medical use to treat a number of conditions including chronic migraines, bladder incontinence, excessive underarm perspiration, and certain types of neck pain and eye issues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible negative side effects. According to MayoClinic.com, possible side effects include \u201cpain, swelling or bruising at the injection site, headache or flu-like symptoms, droopy eyelid or cockeyed eyebrows, crooked smile or drooling, eye dryness or excessive tearing.\u201d In rare cases, the effect of botulinum toxin can spread to other parts of the body and cause botulism-like signs and symptoms.\nThere\u2019s another issue relating to potential harms that should have been mentioned here. Using botox to treat depression is still an off-label use, meaning that\u00a0its safety and efficacy as a treatment for depression have not been established by the FDA.", "answer": 0}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nIt lasts, and the placebo effect doesn\u2019t last once you stop a treatment.\u201d\n\nBut acupuncture believers say it doesn\u2019t really matter whether Western scientific studies find that the treatment has a strong placebo effect.\nBut the real lesson, acupuncture supporters say, is how difficult it can be to apply Western research standards to an ancient healing art.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "      \n\n\n \n\n \nThe article didn\u2019t discuss or quantify potential harms associated with acupuncture. However, potential adverse effects would not likely serve as an obstacle to wider utilization of this treatment. When performed with sterile disposable needles by competent practitioners, acupuncture appears to be a relatively safe treatment approach.\n ", "answer": 0}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\n\"We think it's best to start with CRISPR therapies that involve relatively conservative uses of this powerful tool,\" Dr. Kmiec said.\nThe study was led by Pawel Bialk, research scientist at the Gene Editing Institute, the nation's only CRISPR-focused research initiative situated in a community health care system.\n\"We believe that finding ways to use CRISPR to improve existing treatments will lead to some of the first benefits for patients while we tackle the vital ethical issues around the use of CRISPR for edits that can be passed on through DNA.\n\"This work is another significant step on the pathway to FDA approval,\" said Nicholas J. Petrelli, M.D., FACS, Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t talk about specific harms but it does note that \u201cthe CRISPR application being developed for lung cancer does not involve directly editing a patient\u2019s genome \u2014 only the genes in the tumor.\u201d\nThe release calls this application a \u201crelatively conservative\u201d use of CRISPR and that it might \u201cprovide a level of safety and reliability that is reassuring for patients.\u201d\nThe release would have been better had it explained that there\u2019s potential for viral vectors that are used to carry genes into the body to infect healthy cells as well as cancer cells; the study cites a need for \u201cmore effective delivery methods of these genetic tools to lung tissue\u201d that would eliminate the potential for disrupting normal cells.\nIt would have been helpful to note why this is important: a germ line can be passed on to children while somatic mutations generally can not be passed on.", "answer": 0}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Aside from mentioning that chocolate has a lot of sugar in it, harms are not discussed in the news release. Not only is eating lots of chocolate (stuffed with fat and sugar) likely to increase, not decrease, a person\u2019s risk of developing diabetes, the research paper states that other cocoa components they tested made things worse by decreasing insulin secretion.", "answer": 0}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was discussion of hypothetical harms that might results from eliminating a cache of subcutaneous fat.\u00a0\u00a0It flags this early on by saying, \"Eliminating fat cells without also eating less or exercising more may make fat crop up elsewhere and ultimately do more harm than good.\" However, the story does not\u00a0provide\u00a0any data about whether\u00a0the harms considered have been demonstrated to occur.", "answer": 0}, {"article": "Thursday's discussion focused on its use in preventing HPV-related disease in girls and women, including those as young as 9.\nThe committee's HPV vaccine workgroup is recommending the vaccine be given to girls 11 and 12, and the committee will consider recommendations for females 13 to 26.\n\"We would like to see the FDA mandate some sort of labeling or other mechanism to communicate to health care providers and patients the continued need for regular cervical screening,\" said Amy Allina, program director of the National Women's Health Network.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nAdvocates are recommending the vaccine be given to 11- and 12-year-old girls before they become sexually active, but argue that it is not a license to behave promiscuously, Kaledin reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms, and this is a very important omission. To do this right, you would need to immunize 70 million people. Varicella vaccine has a serious event rate of about 4%. If this vaccine is in the same ballpark, there would be 2.8 million people with serious reactions. Some discussion of possible harms is necessary. ", "answer": 0}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\nThe day the government announced the study results, Westside Medical Imaging of Beverly Hills, Calif., issued a press release saying that the study \u201cshould once and for all settle the controversy\u201d about whether CT lung scans save lives.\nWe\u2019re very frightened some people are going to be harmed because of this.\u201d\n\nA version of this article appeared in print on Nov. 16, 2010, on page D5 of the New York edition of The Times.\n\u201cI\u2019m concerned that some radiologists might be early in that learning curve and some patients may be harmed because of it.\u201d\n\nWhile the study found a benefit to scanning a specific group of high-risk smokers, that doesn\u2019t mean other groups will get the same benefit, says Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York.\nBut the early results also showed a downside of scanning: one of every four lung scans showed an abnormality, which often led to additional worry, radiation exposure from follow-up scans and, sometimes, lung biopsies and even risky surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear on this:\nIn a rarity for such a story, \u201cdownsides\u201d was even in the headline.\u00a0 The third paragraph read:\u00a0 \u201cBut now cancer and screening experts are worried that the limited findings will be used by private screening centers to promote the test to a broader group than was studied. That, in turn, could lead to thousands of unnecessary lung scans, causing excess radiation exposure and unnecessary biopsies and surgery.\u201d", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t addressed. Again, this is unacceptable given that both drugs are already on the market. And these problems can be significant. The potential side effects associated with Bavencio include lung, liver and kidney problems. Potential side effects associated with Inlyta include heart failure and serious or fatal bleeding.", "answer": 0}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\nThis means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\nBoth tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms of such a breath test. If the release is going to discuss potential unproven benefits, it should also mention the potential harms of screening tests including false positives, false negatives leading to over- or under-diagnosis. \nChief among these harms would be falsely labeling healthy people as possibly having cancer and then subjecting them to invasive testing or even treatments that turn out to be unnecessary. Based on the statistics in the study abstract, an 81% specificity suggests that almost one-out-of-five people taking the test would be labeled as possibly having cancer when they don\u2019t. However, the 80% sensitivity suggests that at present about one-in-five people with cancer would be missed. (Computed tomography (CT) screening for lung cancer is about that). The numbers get much worse, as discussed above, when we consider using the test in the general population of people who aren\u2019t likely to have stomach cancer.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The limitations and harms (from false positives, unnecessary biopsies, and unneeded surgery/radiation) from PSA screening and other current diagnostic procedures for prostate and other cancers are\u00a0pretty well known. It\u2019s unlikely that the newer nuclear imaging tests described in this article are without limitations and potential harms as well, including exposure to ionizing radiation, but there is no explicit/direct information about them. Also, finding low-risk cancers could pose psychological and physical harms from over diagnosis and over treatment.", "answer": 0}, {"article": "\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\n\"We were pleased to be involved in the development of CAM2038 and are hopeful that it will serve as another safe and effective therapeutic option for patients with opioid use disorder.\nDuring this period, four challenge sessions were conducted with a randomized hydromorphone dose to determine subjective 'liking' score based on a visual analogue scale.\nThe primary endpoint was met for both CAM2038 doses, demonstrating blockade of the subjective effects of hydromorphone as measured by the Drug Liking Visual Analog Scale.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms was offered beyond saying the drug was \u201cwell tolerated across the course of treatment.\u201d What does that mean? We do not know.\nWe do know that the drug is not wholly benign. Here are some side effects listed by the U.S. government\u2019s Substance Abuse and Mental Health Services Administration: nausea, vomiting, constipation, muscle aches and cramps, cravings, inability to sleep, distress and irritability and fever.\nUntil this is tested in a larger cohort, we do not know the potential array of side effects.", "answer": 0}, {"article": "For more information, visit http://www.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\nNonetheless, since then, there has been a 76 percent decline in the number of prescriptions dispensed from a peak of about 2 million in the last quarter of 2007 to about 531,000 in the first quarter of 2014.\nThe commentary was coauthored by Dianna Gaballa, a fourth-year medical student; Joanna Drowos, D.O., M.P.H., an associate professor of integrated medical science and associate chair of the Department of Integrated Medical Science; and Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean, all in FAU's Charles E. Schmidt College of Medicine.\nThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes results of the EAGLES study, which aimed to address concerns about the potential for Chantix users to experience related neuropsychiatric problems. However, there are significant concerns with both the EAGLES study and with the FDA\u2019s subsequent decision to remove the \u201cblack box\u201d warning from Chantix. Rather than trying to recap all of those concerns in this space, we refer you to a detailed piece by Alan Cassels that was published on HealthNewsReview.org\u2019s blog in January. Suffice it to say, the EAGLES study did not settle the debate over the safety of Chantix \u2014 and that debate warrants some discussion in a release like this one.\nThis release describes harms from smoking and specifically the harms of under-treating smoking. But it doesn\u2019t discuss side effects of Chantix. While those side effects may be much less severe than combusted tobacco smoke that does not excuse their elimination from the news release. Ideally, people are provided enough information necessary for realistic, rational shared decision-making with their doctor about pharmaceutical medications, not false reassurance that there are no risks to this type of treatment.", "answer": 0}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any of the harms associated with the vaccine.\nWhile influenza vaccine is generally safe, there are some potential adverse reactions that are more common with the high dose formulation. According to a news release from Sanofi-Pasteur, the manufacturer of Fluzone, announcing updated prescribing information for Fluzone high-dose in patients 65 and older: \u201cThe most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever. Other adverse reactions may occur. Fluzone High-Dose vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.\u201d", "answer": 0}, {"article": "That aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nAccording to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a big oversight. There was no mention of the risks involved with having surgery in the vicinity of the spine, which could include serious complications such as infection, as well as device failure. The story should have cautioned that medical devices are not required to undergo rigorous safety trials before they are allowed on the market, as we cover in our medical device primer.", "answer": 0}, {"article": "\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since the release\u2019s main source does reference the possibility of these findings leading to future treatment methods, the release really should offer some information about the possible harms of stem cell applications, which include immune reactions and even cancer.", "answer": 0}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nThese results are hugely encouraging, but we need to do more studies.\u201d\n\nFor this study, 48 patients who were diagnosed with a kidney tumor on conventional CT or MRI were imaged with sestamibi SPECT/CT at Johns Hopkins prior to surgery.\n\u201cSestamibi SPECT/CT lets radiologists and urologists \u2018see\u2019 the most common benign kidney tumor, something CT and MRI have not succeeded in doing alone,\u201d says Mohamad E. Allaf, M.D., MEA Endowed Professor of Urology at the Johns Hopkins University School of Medicine.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address harms in terms of reduced harms from adding the imagining technology to standard diagnostic tests:\n\u201cEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\u201d\nHowever, the potential harms from the test itself are not mentioned. Like CT, the test involves the use of ionizing radiation known to increase the risk of cancer. Though often minor, the contrast imaging agents (also called tracers or \u201cdye\u201d) injected prior to the test can cause allergic reactions, headaches, chest pain, dizziness, and other reactions.", "answer": 2}, {"article": "SUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\n\"This is a very good first step, but it's a little scary and we need to move to safer vectors,\" said Dr. Mary Ellen Conley, director of the Program in Genetic Immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tenn.\n\n\"The study shows proof-of-principle that gene therapy with stem cells in a genetic disorder like this has strong potential,\" added Paul Sanberg, a stem cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nThe study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged early on and prominently that one of the study participants developed leukemia, which may have been related to the new treatment. The story probably should have mentioned that other harms might become apparent as these patients are followed further or as more patients are studied. However, we think the study went far enough to earn a satisfactory.", "answer": 1}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\nIt found that the tailored approach could prevent 43 percent more heart attacks and strokes than the simpler, general recommendations used now.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nDoctors generally add their own judgment to that decision as well.\nIt also factored in what\u2019s known about different types of patients\u2019 responses to various blood pressure medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know what the harms would be of the idealized \u201ctailored medicine\u201d approach described in the piece.", "answer": 2}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nPeople who received real acupuncture also showed improvements in their quality of life and ability to exercise, according to researchers from Kyoto University and Meiji University of Integrative Medicine in Kyoto, Japan.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nIt is often marked by a chronic cough and shortness of breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tong-Joo Gan of Duke University hints that there are few downsides to acupuncture, but the story does not specifically point out any harms or side effects from acupuncture. Probably the key point is at the very end where the acupuncturists say don\u2019t try acupuncture first.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms. For example, the story does not mention how many calories are in the drinks and that overconsumption by non-elite athletes could contribute to weight gain.", "answer": 0}, {"article": "New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThe School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.\nThe researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite.\nWith 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "By focusing on proton therapy advantages, and offering little information on which side effects proton therapy does not ameliorate, the release effectively glosses over the fact that proton therapy can still cause a wide array of significant adverse side effects associated with radiation therapy.", "answer": 0}, {"article": "This story has been updated with additional information.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nIn cases of severe depression, that equilibrium gets out of whack, and Sage\u2019s drug is meant to restore it, modulating those GABA receptors to allow NMDA to do its job.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does report that the company said the only problems reported by patients were dizziness or a sedative effect (in both the treatment and placebo groups), it should have specifically cautioned readers that there could be other potential harms that cannot be identified by a one-month test in which only 10 patients received the active drug\u2013notably, if this drug can pass into breastmilk or affect babies in utero. Also, as noted above, the story fails to tell readers that the form of the drug used in this trial is given as an inpatient IV treatment, which carries risks.", "answer": 0}, {"article": "The comparison groups in the experiments varied as well.\nIn the latest look at various treatments, the Cochrane group evaluated studies that examined both pharmaceutical and alternative techniques, including acupuncture, acupressure (a noninvasive variation of acupuncture), ginger, vitamin B-6 and conventional anti-vomiting drugs.\nThere's still no reliable treatment to relieve vomiting and feelings of nausea in early-term pregnant women, according to a review of 27 clinical trials published by the Cochrane Library.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nThe medicine, though never approved for use in the United States, led to birth defects in some 10,000 kids in Europe and Canada.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that most of the studies included in the\u00a0review didn\u2019t include enough information about potential harms \u2014\u00a0\"something everyone would certainly want to know.\"\u00a0\u00a0We\u2019ll call this satisfactory, but we wish it had included at least some information about the harms that were mentioned, such as heartburn in patients taking ginger and drowsiness in patients taking anti-nausea medications.", "answer": 1}, {"article": "An app called Natural Cycles has become the first to be classified as a medical device for use as contraception.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nSo if you could reliably know when you've ovulated as a woman, and then you give that egg two or three days to die, any time after that in the cycle you will not get pregnant because there's no egg to fertilise,\" Dr Susan Walker, a senior lecturer in sexual health at Anglia Ruskin University, told BuzzFeed News.\nAt first she starts to use the app to prevent pregnancy, and when she's ready [to get pregnant] she switches to plan, and usually she gets pregnant quite quickly, because the app already knows her body and cycle.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest harm to using this contraceptive method is getting pregnant. The article reminds readers that\u00a0another risk to using this method of birth control is it does not protect against sexually transmitted diseases, as condoms do. Otherwise, there is only the inconvenience of daily logging of one\u2019s temperature and entering menstrual cycle data.", "answer": 1}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nThe effects included pain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\nThese results show promise in otherwise healthy individuals for a nonpharmaceutical option that appears to have rather minor, temporary adverse effects for some users,\" said Rob Danoff, DO, an osteopathic family physician and program at Aria Health Care in Philadelphia.\nClinical Global Impression responses indicated significantly greater improvement with the RLS device (90 percent) compared with ropinirole (63 percent), the current standard dopamine therapy for RLS.\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports the number of participants who had problems including \u201cpain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\u201d", "answer": 1}, {"article": "What's the point of a runny nose?]\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nThis suggests that AIP-2 might also help humans, since dendritic cells have the same function in us that they do in mice.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article provides some explanation of the potential harms of ingesting live hookworms for therapeutic purposes. It warns against readers \u201ctrying this at home,\u201d especially in the cases of young children and pregnant women. No statement is made about the potential harms of treatments derived from hookworm spit or similar compounds, but at least most readers probably won\u2019t leave this article with the impression that buying hookworms overseas and self-infecting is a great idea.", "answer": 1}, {"article": "Nichols continues to push for funding and advancement for dry eye research and treatment.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nThere is hope for dry eye patients worldwide.\u201d\n\nDiagnosis of dry eye is identified by an eye care professional based on careful evaluation of signs and symptoms, including dryness, discomfort, vision changes and damage to the surface of the eye.\nFocusing her research on all aspects of the eye, Nichols discussed the mechanics of the three layers of the tear film and the importance of each from the cornea outward:\n\u2022 Mucin layer: helps tears adhere to the eye\n\u2022 Aqueous layer or water layer: nourishes and protects the cornea\n\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\n\u201cDry eye is a common complaint to eye care professionals, with millions of U.S. adults experiencing the symptoms of this often chronic disease,\u201d Nichols said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible harms caused by the drug. But the package insert\u00a0for the drug, also known as Xiidra, notes that they exist: \u201cThe most common side effects of Xiidra include eye irritation, discomfort, or blurred vision when the drops are applied to the eyes, and an unusual taste sensation (dysgeusia).\u201d\u00a0 It appears that some of the side effects are the same as the symptoms that the drug is supposed to\u00a0relieve.\u00a0 \u00a0", "answer": 0}, {"article": "Chambers spent two nights in the hospital after her operation in April.\n\"The cost is that you don't have the ability to lift heavy objects,\" Collins said.\n\"The last time I had an injection in my wrist, it was so painful, I thought I was going to have to pull over coming home and have someone else come and drive,\" she recalled.\n\"Some of the newer implant designs save a lot of the bone stock,\" said Collins, who performs about 10 wrist replacements a year.\nUnder low-wear conditions, doctors expect joint prosthetics to last 10 to 15 years, another reason replacement might not be considered for younger people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions a single disadvantage of the operation\u2014that patients can\u2019t lift heavy objects. But any patient undergoing joint replacement faces potential complications such as infection. In one recent study, 52% of patients had a complication after wrist replacement and 44% reported pain one to five years after surgery. (J Hand Surg [Am]. 2003;28:570-6). There is also the possibility of undergoing a second operation for fusion if the implant fails\u2014a risk that persists with newer implant designs as well as old ones. The article does not cite a source for the projected 10- to 15-year life of the device.", "answer": 0}, {"article": "Dr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\nBut what if the researchers put people - fat and thin - on weight-reducing diets and gave them enough leptin to make their bodies think that they were still fat.\nThey also measured thyroid hormone concentrations in the blood and found that leptin reversed the declines in those levels that occurred with weight loss.\nIf people lose weight, they have less leptin.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of any possible \nharms. What, if anything, happened after the study subjects stopped receiving leptin injections?", "answer": 0}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nKhare reached up with a syringe to inject a small dose of ketamine into an IV bag hanging above the chair, then dimmed the lights, pulled the window curtains and asked if she had questions and was feeling OK.\n\nPestikas listened to music on her iPhone and watched psychedelic videos.\nThe trip ends soon after the IV is removed, but Pestikas said she feels calm and relaxed the rest of the day, and that the mood boost can last weeks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said ketamine can cause rapid increases in heart rate and blood pressure \u201cthat could be dangerous\u201d as well as hallucinations. It quoted one expert who said the drug \u201ccan be abused, so we have to be very careful about how this is developed.\u201d", "answer": 1}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\n\"Due to its inherent simplicity, requiring only a blood draw and presenting information to the physician in familiar context using a single number - just like PSA itself - we are quite hopeful in IsoPSA's future utility after further validation studies,\" said Mark Stovsky, M.D., co-author and staff member, Cleveland Clinic Glickman Urological & Kidney Institute.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nBy identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no great harms associated with taking a blood test, but we do know there are harms associated with screening tests. They can lead to false positives, additional tests and over-treatment of low risk prostate (and other cancers) that might never have caused harm.\u00a0Patients may also suffer psychological effects\u00a0if they are confronted with false positive test results. The side effects of\u00a0treatment for these tumors can be serious \u2014 impotence, incontinence and bowel dysfunction. Though one could argue this new test may decrease those harms, it is unproven at this point.\nWe rate this one Not\u00a0Satisfactory.", "answer": 0}, {"article": "For more information, visit acc.org.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\nThe prevalence of obesity among children at the end of three years was 1.1 percent in the group receiving intervention compared to 1.3 percent in the control group.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because the interventions are largely educational and don\u2019t include drugs or therapies, we\u2019ll say that harms are unlikely. But is it theoretically possible that the intervention could have some unforeseen impact on these children that shows up years later? Fear of fat? Anorexia? We won\u2019t penalize the release for not raising the issue,\u00a0but saying something about downstream potential would have added depth and insight.", "answer": 2}, {"article": "Equally important, the response was long-lasting for most patients.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nWhile the TRK fusions occur in only a small percentage of common adult cancers, they occur frequently in some rare pediatric cancers, such as infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer, said Dr. Laetsch, who leads the Experimental Therapeutics Program (ETP) in the Pauline Allen Gill Center for Cancer and Blood Disorders at Children's Health in Dallas.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nTo date, the response to this drug seems to be durable in most patients,\" said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern's Pediatric Hematology and Oncology Division.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any of the specific harms from the drug.\nThis phase 1 safety trial demonstrated only that the drug is sufficiently safe to take to the next level of trials, not to use in practice.\nThe release mentions that \u201cnone of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\u201d This is a key finding of the study and readers would have benefited from a more thorough explanation of the harms. There were seven patients enrolled without the genetic mutation. Four patients experienced a grade 3 (severe) adverse event. No patients experienced a grade 4 or 5 adverse (life threatening) event. These are important results of the study because they support future testing of the drug in larger pediatric populations.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the most serious harm of the treatment, an increased risk\u00a0of atrial fibrillation. Other risks include post-infusion reactions, including fever,\u00a0headache, flu-like symptoms and joint pain.", "answer": 1}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no discussion of potential side effects or harms of this treatment approach, other than the patient\u2019s statement that he has had no side effects. He also called the\u00a0new intervention \u201ca breeze.\u201d\nIn truth, because the drug\u2019s safety is being evaluated\u00a0in this clinical trial, the researchers do not yet know what side effects might occur, a fact the story does not address. Also, there were likely some side effects measured in the animal studies.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release addresses the most common known side effects of the cooling system, which included cold-induced headaches, as well as neck and shoulder discomfort, chills and pain associated with wearing the cooling cap for an extended period of time.\nIt also mentioned another risk: the cold cap could cause chemotherapy drugs to \u201cmiss\u201d an isolated grouping of breast cancer cells in the scalp. However, the release points out that this is \u201cextremely rare.\u201d\nAlthough we would have liked some evidence-backed explanations on the latter harm, we feel the news release does a Satisfactory job here.", "answer": 1}, {"article": "Neither scenario gives doctors an objective indication of the severity of the injury.\n\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"We were looking at different types of brain lesions detected by the CT scans, ranging from mild to serious injuries, and found that the biomarker we tested for actually corresponded to the injuries.\n\"If we could find a simple test that takes the guess work out of diagnosing these kids, that would completely change the way we approach concussions and would certainly give parents greater peace of mind,\" said Papa.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is silent on the potential harms that could result from an easy-to-use biomarker test, especially one that has a 47% specificity (the ability of the test to correctly identify those without the condition). A test with only 47% specificity means that more than half of positive results will be \u201cfalse positives.\u201d\u00a0The release does not address these \u201cfalse positives\u201d at all \u2014 meaning instances in which the test diagnosed a patient as having brain injury when there was no injury. A false positive could result in additional testing, which may create a financial burden, and \u2014 in the case of a CT scan \u2014 poses health risks of its own. Second, the release refers to the possibility of using the blood test to make brain injury diagnoses \u201con the spot.\u201d Quoting one of the researchers who did the study, the release says: \u201cThe idea is to get a point-of-care test that could be used on the field to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play.\u201d However, the journal article the release is reporting on notes that GFAP is detectable in the bloodstream \u201cwithin one hour of injury.\u201d The release does note that such a tool should only be used to \u201chelp\u201d adults make decisions about a child\u2019s health, but this still raises some significant questions. What if a coach, for example, takes a blood test before the GFAP has had time to become detectable in the blood stream? Would that give the coach a false sense of confidence that the child is fine and can re-enter the game?", "answer": 0}, {"article": "\u201cAnd what\u2019s happened with gonorrhea?\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\nDespite the fact that gonorrhea and meningitis are quite different from one another, the bacteria that cause Neisseria gonorrhoeae and Neisseria meningitidis are actually related.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vaccine has potential side effects, and these aren\u2019t mentioned. According to the CDC, more than half of the people who get meningitis B vaccines have mild problems such as headaches or soreness where the shot was given. Fainting, allergic reactions and shoulder pain are less common effects. Also, the vaccine appears to be only moderately effective, meaning people may get infected regardless.\nOverall, not much is known about this vaccine\u2019s safety\u2013whether it\u2019s being used for meningitis or gonorrhea. As Bloomberg News explained, many health experts decry the lack of data on the vaccine. Discussing this issue would have made the story stronger.", "answer": 0}, {"article": "This benefit was independent of other heart risk factors such as advancing age, high blood pressure, family history of heart attack, body mass index, exercise, smoking, and caffeine and alcohol intake.\nDuring the study period, 405 participants had heart attacks.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\nWomen who ate the most blueberries and strawberries were 32 percent less likely to have a heart attack, compared to women who ate berries once a month or less.\nBesides flavonoids, berries also are loaded with other nutrients, including vitamin C, potassium and folate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms, but all health interventions have harms, as well as benefits.", "answer": 0}, {"article": "Half tolerated even twice that amount: a four-peanut dose.\n\"These treatments really have the potential to transform people's lives,\" Vickery said, \"and I have seen it happen firsthand: the sense of relief [families] get when a child becomes desensitized.\"\nIf this ends up being the first approved treatment, if it is covered by insurance and if details of whom it works for best were all worked out and the risks and benefits were clear, \"that would be so amazing, because we haven't really had anything like that before,\" he said.\n\"It's not everything we would hope for, but it's still fantastic to be able to raise someone's threshold from a teeny tiny amount of peanut to a couple of peanuts or more,\" said Sicherer, who believes that other allergy products will be developed in time: \"I can tell my patients that this might be the right thing for them, but if not, we're looking at things that might be easier and better down the road.\"\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes harms through the profile of one patient: \u201cEllis experienced stomach cramps and vomiting multiple times during the study,\u201d and once she had an anaphylactic reaction which required medical attention. And this was a successful patient story.\nThe story also reports that 11% of participants dropped out of the study as a result of side effects.\nHowever, it left out important issues such as the higher dropout rate \u2014 around 20%, mainly due to adverse events \u2014 among those who received the treatment, and unknown long-term effects.", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nTo address this issue, the SPRINT study tapped more than 2,600 volunteers aged 75 and older, assigning half to a target blood pressure of less than 140 mm Hg and half to target of less than 120 mm Hg.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the possible adverse reactions to medications that lower blood pressure, although these are widely known.\u00a0 Nor does the release mention any adverse reactions among the study participants other than those that were used as endpoints for the study \u2014\u00a0myocardial infarctions, strokes and heart failure, for example.\nThe published research article notes that while treatment carried risk of side effects for both patient groups studied, the differences between the serious side effects (low blood pressure, fainting, acute kidney injury) encountered in each group weren\u2019t significantly significant.\nAnother issue not addressed in the release is that these patients were followed very closely by study staff and were examined initially every 3 months. In clinical practice, patients are often not seen that frequently which means that some patients might not get the level of monitoring needed to prevent or treat emerging complications.\nWe were pleased to see that the release cautioned patients to \u201ctalk to their doctor to determine whether this lower goal is best for their individual care.\u201d", "answer": 0}, {"article": "The study is published in the journal BMJ.\n\"Dark chocolate may be a pleasant and effective way of delivering important dietary components that can provide health benefits to the ever increasing numbers of people at increased risk of cardiovascular disease,\" says researcher Christopher M. Reid, PhD, professor of cardiovascular epidemiology and preventive medicine at Monash University in Australia.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nThey did not study actual people eating actual chocolate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the Harvard expert:\n\u201cThe researchers are ignoring some downsides, he says. \u201cThey are ignoring the dangers of too many calories and too much fat and sugar from the chocolate bar,\u201d he says.\u201d\nBut somewhere in this review, we must criticize the story for never offering any detailed analysis of the researcher\u2019s \u201cmodel.\u201d We could do it in the Evidence criterion, but we\u2019ll choose to do it here.\nSurprisingly the model used by these researchers did not account for the adverse effects (weight gain, etc) that might accrue from adding a daily 100 g chocolate bar, which might contain as much as 600 calories (!), to your diet for 10 years.\u00a0 Since the entire underpinning of the story was the validity of the model, this is a weakness in the story. ", "answer": 0}, {"article": "The moderate dose also prompted a drop in the ability to accurately recognize fear in other people's faces, determined by having the participants look at a range of photos, the study found, but it did not affect the ability to perceive the shifting cues in a person's eyes or voice, determined by having the participants listen to a series of audio clips.\nThe study, funded by the U.S. National Institute on Drug Abuse and conducted at the Human Behavioral Pharmacology Laboratory at the University of Chicago, was published in the Dec. 15 issue of Biological Psychiatry.\nThese drugs, which are often used in combination with alcohol, have potentially life-threatening effects, according to the U.S. National Institute on Drug Abuse.\nIn fact, those who took the drug actually rated themselves as more sociable than those taking MDMA.\nMDMA is part of a family of so-called \"club drugs,\" which are popular with some teens and young at all night dances or \"raves.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said that the drug \u201cmight impair a person\u2019s perceptive abilities and thus prompt risk-taking.\u201d\u00a0 Is that the only known risk of taking MDMA?", "answer": 0}, {"article": "As exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nResults of the vaccine were not as good in the other 25 patients.\n\"That time frame is not anything to write home about,\" Gulley says.\nFor them, the median time before the cancer progressed was about two months.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions side effects in a satisfactory way.", "answer": 1}, {"article": "3 Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes; Diabetes Care, July 2011.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\nThe possible role of phentermine has not been established, therefore the possibility of an association between heart valve disease and the use of phentermine alone cannot be ruled out.\nLosing five to 10 percent of total body weight is likely to produce health benefits, such as improvements in blood pressure, blood cholesterol, and blood sugars.3\n\nSome side effects of phentermine that have been reported include pulmonary hypertension, valvular heart disease, palpitations, increased heart rate or blood pressure, insomnia, restlessness, dry mouth, diarrhea, constipation and changes in sexual drive.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release lists nine separate possible side effects of the use of the drug in question and then adds to that the statement that, \u201cThese are not all of the potential side effects of phentermine.\u201d\u00a0 It then offers seven additional paragraphs with cautions, contraindications and warnings pertaining to taking the drug, all under the heading of \u201cImportant Safety Information.\u201d\u00a0 Readers will at least be informed, if not alarmed, after reading.", "answer": 1}, {"article": "\u2022 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer's, compared with controls.\nAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\n\u2022 The first report of certain Alzheimer's-related pathologies in the retina, including vascular amyloid pathology.\nWe look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer's, both in identifying and monitoring those who may be affected by the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is a reference to how other ways of detecting Alzheimer\u2019s are \u201cinvasive\u201d but there is nothing in the release about the possible harms associated with this diagnostic tool. A false-positive diagnosis of dementia or Alzheimer\u2019s would be one such harm.", "answer": 0}, {"article": "\u201cWomen will know pretty quickly if acupuncture will work for them.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\n\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\nHis spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that 4 percent of study participants who received acupuncture actually had twice as many hot flashes (\u201ca 100 percent increase\u201d). That\u2019s good. The release also refers to acupuncture as \u201clow risk.\u201d But that doesn\u2019t mean no risk. According to the Mayo Clinic, acupuncture can cause soreness, minor bleeding or bruising \u2014 and that may be exacerbated for patients who are taking blood thinners. There are also more serious risks involved, particularly if an acupuncture therapist has not been properly trained. Those risks include infection and possible organ damage. Since the release explicitly says \u201cwomen bothered by hot flashes\u2026may want to give acupuncture a try,\u201d it is especially important to be up front about potential risks and the importance of finding a certified acupuncture practitioner (as well as where that certification should come from).", "answer": 0}, {"article": "But the supplement has largely failed to show benefits in human athletes.\nAsked if he would recommend that serious marathon runners add nonalcoholic beer to their diets, Dr. Scherr said, \u201cWhen I look at the results of our study, I would have to answer \u2018Yes.\u2019\u201d\n\nIt\u2019s possible to get large amounts of polyphenols from other foods, he added, like those training-table staples chokeberries and mangosteens, as well as pomegranates and grapes.\nAn analysis of 10 human studies of the supplement presented at the American College of Sports Medicine annual meeting in June concluded that quercetin supplementation \u201cis very unlikely to provide an endurance performance advantage.\u201d\n\nBut the beer experiment did not begin by looking at mice.\nBut, said Dr. Scherr, it almost certainly involves the beverage\u2019s rich bouquet of polyphenols, chemical substances found in many plants that, among other things, \u201csuppress viral replication\u201d and \u201cinfluence the innate immune system positively,\u201d all beneficial for fighting off a cold.\n\u201cFurthermore, it is not possible to drink one to one and a half liters of alcoholic beer per day, especially not during strenuous training.\u201d We all knew that, right?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the study, participants consumed 1-1.5 liters/day of non-alcoholic beer (or a placebo) for 5 weeks total.\u00a0There could be several potential adverse effects such as weight gain from extra calorie consumption, imbalances in nutrients if the liquid replaced other fluids, etc. No potential harms were mentioned.", "answer": 0}, {"article": "Taiwanese scientists say a blood thinner drug based on venom from the Wagler's pit viper was effective in mice, and might prove safer than current anti-clotting meds for humans one day.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A source included a risk of blood thinners in general\u2013 that they can cause bleeding\u2013so the story gets a Satisfactory rating. But the story could have clarified that other potential harms are unknown at this point.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the \"Actavis plc\" name).\n\"In clinical trials, TrueTear\u2122 demonstrated increased tear production upon stimulation of the nasal cavity,\" said John Sheppard, M.D., M.M.\nWARNINGS \n\nDo not apply stimulation around electronic monitoring equipment (eg, cardiac monitors, ECG alarms), in the bath/shower, while driving, operating machinery, during activity in which sneezing/watery eyes may cause risk, areas other than the nose, within 3 feet of shortwave or microwave therapy equipment, around flammable anesthetics mixture (air, oxygen or nitrous oxygen).\n\"TrueTear\u2122 represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,\" said David Nicholson, Chief R&D Officer, at Allergan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We will give the release a satisfactory rating because it includes a list of adverse events and warns that there is no long term safety data. But the side effects are described only in percentages and there is no indication of the severity of the events. Other reports about the device indicate that the news release left out information about adverse events seen in other trials, as well as speculation about potential long term effects.\nAn article published in Clinical Ophthalmology, which describes an experiment that appears to be a precursor to \u201cStudy 2\u201d in the news release, describes three device-related adverse events, including one migraine headache in a patient with a history of migraines, along with two cases of nasal discomfort that lasted a day or two.\nAn article written by a doctor who said he tested the device reports that \u201cThe exact mechanism of action of OD-01 is still under investigation, because there is some suggestion that the device may produce long-term effects. One proposed mechanism is that neurostimulation works to kick-start the system through some form of lacrimal gland remodeling.\u201d Well, if use of the device could cause long term effects, including changes to the glands that produce tears, the release should have mentioned that potential.", "answer": 1}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\n\u201cPublished research shows squeaking is rare compared with other total-hip-related risks like infection, dislocation and leaving patients with uneven leg length.\u201d\n\nBut plaintiffs lawyers, who have already filed scores of lawsuits on behalf of ceramic hip patients, are gearing up to argue that squeaking is not a minor problem for many who experience it.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nSome patients squeak even they are walking normally, like Ms. O\u2019Toole or Michael Mueller, a software executive in Scottsdale, Ariz. Mr. Mueller is so frustrated with squeaks, pain and popping noises for which he blames his ceramic hip that he has displayed his problem on YouTube.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story focuses on one main harm\u2014squeaking in hip implants made of ceramic\u2014and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. ", "answer": 1}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\n\u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have the liver effects,\u201d he said.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\n\u201cPIK3CA mutations are present in many other tumor types,\u201d Hirawat said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes the head of cancer drug development for Novartis as saying, \u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have liver effects.\u201d\nWhat any of this means is not clear. As much diarrhea as compared to what? Were they expecting CNS or liver effects? Do other PI3K inhibitors have those side effects? None of that is spelled out.\nOnce again, we returned to the ESMO news release and abstract to learn more. This told us the most frequent side effects were hyperglycemia, nausea; decreased appetite and rash.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story failed to mention that excess vitamin D is stored in the body and that excessive intake can be fatal.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pushes back against misleading claims of safety and notes that kratom has been linked to at least 44 deaths. It also notes one confirmed instance of fatal kratom overdose, which contradicts one advocate\u2019s statement that \u201cyou can\u2019t take enough to hurt yourself.\u201d", "answer": 1}, {"article": "First published on May 11, 2008 at 12:00 am\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\n\"We know that the data for this is just emerging, but we feel it's a very safe intervention, and it's empowering for families and very reasonable,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article doesn\u2019t discuss the very real risks of the proposed experiment and does not seek out any disinterested expert resource.\u00a0 A hallmark of autism spectrum disorders is problematic social interaction.\u00a0 One can speculate that transfer of affected children out of the home and into a hospital \"clean-room\" runs counter to the effort to improve socialization that is a current, mainstream treatment for the disorders.", "answer": 0}, {"article": "What if, her team began to think, it could come up with a blood test for schizophrenia?\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\nShe recalled her boyfriend at the time searching the web for her diagnosis and saying: \u201cOh God, no.\u201d After that, she kept quiet about her diagnosis, worried it would drive friends away.\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\nFor years, researchers searched, in vain, for concrete signs in the brain that could tell them the difference between, for example, bipolar and depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no potential harms mentioned, and yet screening carries the potential for harm because of false positive and false negative rates that may lead to the wrong intervention.", "answer": 0}, {"article": "Newswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nThough aneurysms can happen anywhere in the body, they most commonly happen in the brain, or in the main vessels that lead to the heart, legs and arms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the new procedure were mentioned. The lone patient who underwent the procedure called it \u201ca difficult surgery\u201d and anticipated feeling better after recovery but we\u2019re not told if the procedure was successful or how long recovery took.\nAs we\u2019ve written, minimally invasive is still invasive \u201cand thus pose potential harms associated with anesthesia, infection, and bleeding.\u201d", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nIt did reduce the severity and duration of colds slightly, but the researchers say the difference was so slight it ended up being pretty meaningless, and not worth the effort or expense of taking all that vitamin C.\n\nPeople apparently protected from colds by vitamin C, Senay said, are those who subject their immune systems to extraordinary amounts of physical stress, such as people who run marathons, or do serious trekking in the winter.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nFor the rest of us, the chances of vitamin C warding off colds is so slight, the lead researcher concludes it \"doesn't make sense to take vitamin C 365 days a year to lessen the chance of catching a cold.\"\nAnd the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report fails to indicate that taking high levels of vitamin C, as some advocates\u00a0suggest, can have serious health consequences, from dental erosion to kidney toxicity. It can also interact with aspirin and other drugs.\u00a0 ", "answer": 0}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly discusses what is, by far, the most common side effect of SDF treatment \u2014 which is that the area of the tooth affected by the cavity becomes darkened after treatment. There are, however, other potential harms. A 2016 paper noted that 3 out of 1,493 patients in studies they reviewed developed \u201ca small, mildly painful white lesion in the mucosa,\u201d which disappeared after 48 hours. However, that\u2019s such a small effect size, that it\u2019s not clear whether the lesions were caused by SDF, so we don\u2019t fault this story for not mentioning it. There can be more significant adverse health effects if SDF is inhaled or swallowed \u2014 including respiratory problems, vomiting and diarrhea. But those effects are only relevant if SDF is not handled properly, so, again, we don\u2019t fault the story for not mentioning it.", "answer": 1}, {"article": "Scientists in Britain say they have developed a blood and urine test that can detect autism in children.\nThey found the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called advanced glycation end-products (AGEs).\nGenetic causes are thought to be responsible for about a third of cases of ASD, while the rest are believed to be caused by a combination of environmental factors, mutations, and rare genetic variants.\n\u2022 Note added 27 February 2018: The UK autism research charity, Autistica, provided the following comment to the Guardian: \u201cThis is a small, early-stage study which may explain one biological difference in autism.\nResearchers at the University of Warwick said the test, believed to be the first of its kind, could lead to earlier diagnosis of autism spectrum disorders (ASD) in children who could then be given appropriate treatment much earlier in their lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although potential harms from blood or urine tests are quite minimal, the story suggests the research findings could lead to routine screening for autism.\nScreening tests are never completely benign; in particular \u2014 in this case \u2014 if a \u2018false positive\u2019 result led parents to believe their child had ASD when they did not \u2026 or \u2026 if a \u2018false negative\u2019 result offered false assurance that there was no ASD present.", "answer": 0}, {"article": "The HSRx product demonstrated superior treatment performance throughout the entire clinical study.\n\"Acne is among the 10 most prevalent human infectious diseases and recent studies show it has a significant long-term psychological impact on many of the 80+% of teenagers and young adults who suffer from it,\" he added.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\n\"Acne is a universal plague,\" said Frank Parise, HSRx Group Chief Financial Officer, citing a recent NASA warning that even the International Space Station harbors germs that can cause the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned. Most OTC acne medications come with a warning to start slowly with small amounts until you know how your skin will react. Common side effects include dryness, redness, peeling, itching, burning, and rashes.", "answer": 0}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When quitting, heavy smokers can experience\u00a0withdrawal symptoms\u2013such as depression, insomnia and decreased heart rate\u2013even if they use nicotine replacement products.\nThe article did refer to \u201cwithdrawal\u201d and \u201curge intensities\u201d and so we\u2019ll considered that sufficient.\u00a0However, the piece would have been stronger had it specifically discussed the withdrawal symptoms mentioned above.", "answer": 1}, {"article": "Ilaris can lower the immune system\u2019s ability to fight infections.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms warranting a borderline satisfactory rating. But the side effects information is similar to that found on product labeling \u2014 it follows the regulatory requirements concerning product labels \u2014 but provides no data on harms from the trials behind the drug\u2019s approval. It could have been more informative with a few more details.\u00a0 In addition, the information on harms appeared to be contradictory. One paragraph says common responses to the drug were minor reactions and susceptibility to colds; the next paragraph lists serious side effects.", "answer": 1}, {"article": "\u201cA.A.\nA.A. and other 12-step programs \u201care not cure-alls,\u201d Dr. Kelly said, \u201cbut I would say at a minimum, they help.\u201d\n\nDr. Edward V. Nunes, a professor of clinical psychiatry at Columbia, said research had demonstrated that certain elements of A.A. were effective.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of the harms of treatment, however, the story notes that A.A. and 12-step programs are not a panacea for alcohol dependence, as they do not work for everyone. The story does cite researchers in the field of addictions research and treatment who note that people often attend A.A.meetings as only one component of their treatment. ", "answer": 1}, {"article": "\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\nThe high-nitrate breakfast included 16 ounces of beet juice.\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from consuming high concentrations nitrates.", "answer": 0}, {"article": "Alexander Technique is a series of posture lessons, devised by a 19th century Australian actor named F.M.\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n\"The whole point is that you understand the process so that you can arrive there yourself,\" says Gray.\n\"The fact of having your arms up and carrying the weight of this instrument and pushing the instrument toward you and so you have this stress, this wall you're pushing against,\" says Rodriguez.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n3.\u00a0\u00a0\u00a0\u00a0 The article did not discuss harms or adverse events. The study did not report any adverse events related to Alexander Therapy. Individuals interested in this this treatment approach might find this information useful, since several other common therapies for chronic back pain\u2014from acupuncture to manual therapies to invasive treatments\u2014do cause adverse events and complications.\u00a0\n", "answer": 0}, {"article": "This post has been updated.\nThe American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nPart of the problem is the common perception that women deserve free mammogram coverage and that the scientific community is basing its decision on cost or rationing, said Lawrence Gostin, a Georgetown University law professor and expert on public health.\nLanguage was included in the spending bill that says any recommendations of the task force related to breast cancer screening, mammography and prevention refers to those \u201cissued before 2009.\u201d\n\nSen. Barbara Mikulski (D-Md.)\nThe U.S. Preventive Services Task Force, an independent panel of experts whose members are appointed by the federal government, issued a final set of recommendations late Monday saying that women between the ages of 50 and 74 should get routine screening once every two years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms briefly in two places. In one place, the story refers to \u201cthe anxiety and potential harm caused by over-diagnosis and false positives,\u201d though it doesn\u2019t explain what over-diagnosis or false positives mean (potentially leaving many readers in the dark). The story also notes that \u201cThe most serious potential harm is unneeded treatment for a type of cancer that would not have become a threat to a woman\u2019s health during her lifetime.\u201d But it doesn\u2019t give readers any idea of how serious this harm might be, or how common this scenario is. In short, the story does enough to earn a Satisfactory rating, but could have (and should have) done more. It\u2019s worth noting that the New York Times piece did a top-notch job discussing harms.\nThe story does, however, make clear that women should be informed consumers, and that \u2014 if well-informed \u2014 women should have the authority to weigh potential benefits against potential harms and make their own decisions about when and how often to get screened. That\u2019s an important point, and one worth making.", "answer": 1}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n\u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention or discuss the potential harms of consuming a daily portion of blueberries or blueberry product. But since it\u2019s difficult to imagine what these would be, we\u2019ll rule this not applicable.", "answer": 2}, {"article": "An experiment with 24 healthy volunteers found that compared with consuming glucose, consuming fructose \u2014 the sugar found in fruits, honey and corn syrup \u2014 resulted in more activity in the brain\u2019s reward regions, increased responses to images of food and a tendency to choose eating a high-calorie food over a future monetary reward.\n\u201cDon\u2019t stop eating fruit.\n\u201cInsulin is released when we consume glucose,\u201d she said.\n\u201cThe pancreas secretes insulin, and insulin drives glucose into cells so that it can be used for energy.\nPage said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not Applicable for this story.", "answer": 2}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story ends with a Duke fitness expert warning that \u201ctoo much caffeine \u2014 such as the high doses found in Zantrex \u2014 could cause jitteriness, anxiety, spikes in blood pressure and rapid heartbeats in some people.\u201d", "answer": 1}, {"article": "Shi's lab has developed a promising live-attenuated Zika vaccine candidate called ZIKV-LAV that had been shown to be safe, non-virulent, and effective in protecting against infection in mice and non-human primates.\n\"During the Zika epidemic, we learned that the virus preferentially infects neural progenitor cells in the fetus, and causes the devastating microcephaly seen in babies born to infected mothers,\" says Pei-Yong Shi, a virologist at University of Texas Medical Branch in Galveston.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\n(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nCo-implanting the virus along with the GSCs also prolonged the median survival time of the treated mice to around 50 days, compared to around 30 days for the untreated mice who received GSCs alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that the treatment had \u201cno health effects on the mice, no weight loss, and no behavioral abnormalities such as loss of appetite, depression, lethargy, or self-injury. The mice also functioned normally in tests for anxiety and motor function.\u201d\nHowever, we interpret \u201charms\u201d to mean harms to humans. The release doesn\u2019t describe any potential harms to humans.", "answer": 0}, {"article": "Quantity surveyor Alex Laws was part of the Newcastle University clinical trial and is delighted with the results of the study.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\nAlex said: \"I was keen to be part of the clinical trial as I know how important research is into helping people with the condition - I previously worked in the medical research field.\nDr Weaver said: \"As the outcomes of heart disease is worse in diabetic versus non-diabetic patients, there is a need to identify additional treatment options.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any side effects or harms to participants from the use of metformin, although a host of minor-to-moderate side effects\u00a0may be routinely seen with this drug. The research paper itself limits discussion of side effects to \u201cany major or severe episodes of hypoglycemia,\u201d which it defines as instances of low blood sugar \u201crequiring intervention of another person to resolve the event,\u201d or any episode of hypoglycemia \u201cresulting in a loss of consciousness.\u201d\u00a0Although none were reported, both instances seem substantively more serious than minor side effects. Gastrointestinal side effects, for example, are commonly reported by patients taking metformin. And there are some relatively commonly found metabolic adverse effects of metformin (metabolic acidosis) that could have been looked for to determine if there is an increased incidence in this \u2018vulnerable\u2019 group.", "answer": 0}, {"article": "In the United States, cervical cancer screening guidelines were changed in November.\nWe're behind in the U.S.\"\n\nThe strategy makes particular sense in less-developed countries, where women could do an HPV test themselves with a \"self swab\" and then send the swab in for analysis, Einstein said.\nDNA testing for HPV, though, does have drawbacks -- namely that it is less specific, meaning it is likely to pick up more false-positives, than a Pap smear.\nFor their study, the Italian researchers compared HPV testing alone with HPV testing plus a Pap smear in 94,370 women aged 25 to 60 years old.\nTUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes the potential harms of HPV DNA testing, most notably the high false positive rate \u2013 or the high number of tests that come back positive that would never progress on to cancer. Positive results require additional testing and follow-up, which in itself isn\u2019t particularly dangerous, but could cause anxiety and requires time off work and additional costs.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms from a cheek swab are unlikely there is a potential harm in framing the genetic testing results as guiding the choice of one antidepressant over another. Patients may focus solely on pharmaceutical options, to the exclusion of non-pharmaceutical ones.\nAntidepressants have well-documented side effects and drug interactions.", "answer": 0}, {"article": "\"We observed that early dietary intervention [with extensively hydrolyzed formula] decreased the frequency of diabetes-associated autoantibodies, which are markers of an ongoing disease process, by about 50 percent by the age of 10 years,\" said the study's lead author, Dr. Michael Knip, a professor of pediatrics at the Hospital for Children and Adolescents in Helsinki, Finland.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\nAfter adjusting the data to try to account for the duration of exposure to one of the study formulas, the researchers found that the extensively hydrolyzed formula reduced the risk of having one diabetes autoantibody by 49 percent, and the risk of having two or more autoantibodies by 53 percent.\nNo one knows for sure what causes this process to begin, but some research suggests that the initial autoimmunity may begin early in life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no real \u201charms\u201d with using formula, either cow\u2019s milk formula or extensively hydrolyzed formula.\u00a0 It appears the latter may be a better choice because there are fewer proteins broken down for digestion.", "answer": 1}, {"article": "LONDON (Reuters) - Scientists in Canada and Sweden have used laboratory-made biosynthetic corneas to restore vision to patients in a small human trial, and shown for the first time that they can help to repair damaged eye tissue.\n\u201cWith further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\u201d\n\nThe cornea is a tiny piece of transparent, film-like tissue that covers the surface of our eyes.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\n\u201cThe results were pretty encouraging and there is great potential here,\u201d Fagerholm said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The last sentence of the story says, \"Fagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\" This is about as much space as any of the stories devoted to the harms. It would have been nice to see a little more detail here, but, if after two years there were not any side effects, this is a satisfactory quantification.", "answer": 1}, {"article": "Also of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\n\"This particular product plays very strongly into where we see the market going,\" he said.\nIt's a key finding, because patients with diabetes usually suffer from more advanced PAD and the blood vessels re-clog faster than for those who do not.\n\"It's a good opportunity,\" Gunderson said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms from the approach.\nAny newly introduced device used in an interventional procedure has inherent risks both from the device itself and from the operator.\u00a0 The procedural complication rate is an important consideration especially since the new device is said to be as good as existing treatmemts.", "answer": 0}, {"article": "The cause of atopic dermatitis is a combination of genetic, immune and environmental factors.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gets an acceptable rating in this category since it mentions that the drug can cause serious allergic reactions and eye problems including conjunctivitis (pinkeye) and keratitis (inflammation of the cornea). It also cautions that people with asthma shouldn\u2019t use the drug since it hasn\u2019t been tested for safety in these patients.\nThe release should also have noted that regulators don\u2019t know if there are any long-term harms associated with Dupixent use. None of the trials exceeded 16 weeks.", "answer": 1}, {"article": "A breakthrough in helping the body to produce more insulin could make tedious injections of the hormone history.\nIn theory, if the same results occur in people, it\u2019s possible that those on the verge of developing diabetes might never progress to develop the disease, since the high blood sugar levels that can cause damage to tissues and lead the body to become less responsive to insulin could be avoided.\nJohn Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nMORE: Half of Diabetes Cases Are Undiagnosed\n\nNow, researchers working with mice at the Harvard Stem Cell Institute report in the journal Cell that they have discovered a hormone, betatrophin, that can prompt the body to generate more insulin-producing beta cells and, if the work is confirmed, the hormone could potentially do away with the need for regular insulin shots.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story speculates extensively about the many benefits a treatment based on this preliminary research might confer. So we think it\u2019s only fair that the story at least mention the possibility that a\u00a0new treatment might also cause harm.\u00a0The researcher quoted in the story suggests that \u201canything that lowers blood sugar can make you healthier.\u201d Besides the obvious exception of hypoglycemia (which can be fatal),\u00a0recent experience with Avandia confirms that drugs which lower blood sugar can\u00a0sometimes have other undesirable\u00a0effects.", "answer": 0}, {"article": "With the discovery of the gene marker Vimentin comes a new way to significantly increase the rate of detection of colon cancer.\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\n\"Our idea was that if you had an inexpensive test that was easy to use and wasn't invasive, you could reach a lot of people and prevent deaths from happening every day of the year,\" Markowitz said.\nThat test, which looks at two different DNA markers (instead of the one marker used by PreGen-Plus), is the one with which Markowitz is more familiar.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a brief pass at discussing harms when it says: \"Compared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often. If results are abnormal, a colonoscopy would still be required.\" But readers should be told how many cancers does the test miss (false negatives)? What is the rate of false positives\u2014and how many people will believe they have colon cancer, when in fact they don\u2019t? How many people will find themselves hospitalized with a serious complication caused by a follow-up confirmatory colonoscopy?\u00a0 ", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\nAnderson say a healthy diet, exercise help ward off its recurrence\n\nA healthy diet and exercise help prevent the return of breast cancer, but meals loaded with fruits and vegetables provide no extra benefit, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms associated with fruit and vegetable consumption, something some might think is unnecessary.\u00a0 But, for comparison, another story by another news organization did quote the lead investigator as saying there were no harms found with eating fruits and vegetables above a certain threshhold. It could have been addressed in this story. ", "answer": 0}, {"article": "The group getting the test began chemotherapy a median of about five months earlier.\nThe new study, done in and nine other countries, compared 265 women who began chemotherapy after their CA125 levels began to rise with 264 women who waited to begin chemotherapy until they had symptoms, like or pain.\nDr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\nDr. Andrew Berchuck, director of gynecologic oncology at , said that while \u201cit\u2019s the American way, sort of, to be aggressive\u201d and treat early, some doctors and patients even now did not start chemotherapy when CA125 rises.\n\u201cBut there are also people who wouldn\u2019t want to go back on chemo unless they absolutely have to.\u201d\n\nDiane Paul, an ovarian cancer survivor and patient advocate in , said that when she was getting the CA125 test, she asked her doctors not to tell her the results, to reduce her anxiety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the major harm of CA-125 testing, which is that it could lead to unnecessary treatment in women who would not benefit from it.", "answer": 1}, {"article": "Ziman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nAntibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nThe problem is particularly serious in Australia, where melanomas were the fourth most commonly diagnosed cancer in 2017 and cause about 1,700 deaths a year, according to the university.\nDr. Jodie Moffat, head of early diagnosis at Cancer Research UK, agreed that a test which finds melanoma earlier could help reduce deaths from the disease, adding that \"melanoma can be more than skin deep, and it's much harder to treat when diagnosed at a late stage after it has spread.\"\n(CNN) Australian researchers have developed an experimental blood test they say is the first blood test capable of detecting melanoma -- an aggressive form of skin cancer -- in its early stages with a high degree of accuracy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like many other stories about screening tests, the reader is not provided with any comments on the potential harms. Even with a 90% sensitivity and specificity (a high mark for such a test), there would be many\u00a0people with both false positive and false negative results. Read more about this issue in our primer:\u00a0Understanding medical tests: sensitivity, specificity, and positive predictive value\nThese cancers are frequently overdiagnosed, so a diagnostic test that finds a lot of low-risk cancers could be harmful by leading to overtreatment. Ideally, we want know that the test is leading to finding early-stage, high-risk cancers that require and would benefit from treatment.", "answer": 0}, {"article": "But CT use continued to soar.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\n\"There are some serious concerns about the methodology used,\" but the authors \"have brought to attention some real serious potential public health issues,\" said Dr. Arl Van Moore, head of the American College of Radiology's board of chancellors.\n\"The CT scan is a wonderful tool for examining internal organs, organs that are below the depth of where a poking finger or a listening stethoscope can hear, and yet don't show up on routine X-rays,\" Dr. Michael Brant-Zawadzki, a clinical professor of radiology at Stanford University tells CBS News.\nMedical radiation now accounts for more than half of the population's total exposure; it used to be just one-sixth, and the top source was the normal background rate in the environment, from things like radon in soil and cosmic energy from the sun.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to flesh out the quantification of the effect under study, namely additional risk of cancers.\u00a0 While the source study reports on \"attributable risk\" of cancer and cancer-deaths due to CT scanning, it would be helpful for the viewer to know what this means in terms of numbers of cancers and risk to the individual.", "answer": 0}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "An ongoing study will evaluate the product over two years.\n\"There isn't a clear diet that prevents you from getting Alzheimer's disease or improves your memory,\" Thies said.\nThe new drink, called Souvenaid, may actually stimulate the growth of new synapses, said the drink's inventor, Massachusetts Institute of Technology scientist Dr. Richard Wurtman.\nIf it appears to have a positive effect, then it may be something that could benefit patients even before definitive symptoms of Alzheimer's appear, Wurtman said.\n\"You are making a judgment without the protections you have when dealing with a medication,\" Thies said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only paraphrased the researchers saying \u201cthere were no serious side effects.\u201d That\u2019s not good enough.\u00a0 What did the data show?\u00a0 What was observed?\u00a0 In how many people?\u00a0 Then let readers or independent observers judge what is serious or not. At a minimum, the percentage of people in the trial with any side effects should be given.", "answer": 0}, {"article": "Among 787 adults who had quit smoking within the previous two years, nearly a third reported having returned to using cigarettes, according to a study published online Monday by the journal Tobacco Control.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nSmokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of the potential harms from taking nicotine, as opposed to quitting without drug therapy. There\u2019s also the question of whether people are doing themselves more harm by continuing to smoke because they failed to quit with the help of a nicotine replacement product. If they had been able to more effectively quit earlier, would they live longer?", "answer": 0}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Sonata is in the midst of an ongoing phase\u00a0II\u00a0clinical trial, designed to assess both effectiveness and safety of the procedure. But the story still makes a good effort to address risks and related concerns. For example, the story states that \u201csuch minimally invasive procedures require a lot of skill to perform safely\u201d and quotes an expert as saying \u201cYou need a really experienced surgeon\u2026.Will it translate to the average ob/gyn?\u201d In addition, the story notes that, while uterine fibroids are rarely malignant, in a small number of cases they can be cancerous \u2014 and \u201cbecause tissue is not removed with the Sonata method, it cannot be biopsied.\u201d\nWith a little more digging, the reporter might have found the Gynecological Surgery paper mentioned above. In that trial of 50 patients, there were 34 \u201cadverse events.\u201d Most were not severe, but incorporating some of that information would have made the story even stronger.", "answer": 1}, {"article": "Powe is due to present the findings Friday at the annual European Breast Cancer Conference in Barcelona, Spain.\n\"The concept of controlling tumor growth by preventing a stress or inflammatory response is not novel,\" said Dr. Cathie Chung, a medical oncologist and an assistant professor of oncology at the City of Hope National Medical Center in Duarte, Calif.\n\nFor instance, other research has found that women with breast cancer who regularly take aspirin, which is an anti-inflammatory, may have a decreased risk of recurrence.\nFRIDAY, March 26, 2010 (HealthDay News) -- Treatment with blood pressure-lowering drugs known as beta blockers appears to help reduce the spread of breast cancer in women, a team of British and German researchers report.\n\"There is more work to be done before you can say whether this relationship is meaningful and will hold up,\" agreed Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.\nIt's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story offered no detailed discussion of side effects of beta blockers. While they are generally considered \"safe,\" the story didn\u2019t explain what \u2013 if anything \u2013 was observed, and it could have at\u00a0 least listed some of the more common side effects, including drowsiness, dizziness and weakness. ", "answer": 0}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nThose parts of the brain soon start to die.\nA drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not good enough.\u00a0 The story only says the drug isn\u2019t without risks, chiefly brain bleeding.\u00a0 How often does this occur?\u00a0 This is a big issue. If even one of the 4 people whose records show they got tPA in this analysis had problems after hospital discharge, that could throw any potential benefit out the window.", "answer": 0}, {"article": "The treatments lasted for six months.\nResearchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was badly incomplete and confusiong in reporting on harms.\nFirst, it inaccurately reported that \u201cthe quality of life for patients on FOLFIRINOX was not as good\u2026.After six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\u201d\u00a0 That\u2019s wrong.\u00a0 The researchers reported:\u00a0\u201cAt 6 months, 31% of the patients in the FOLFIRINOX group had a definitive decrease in the scores on the Global Health Status and Quality of Life scale versus 66% in the gemcitabine group. Significant increases in the time until definitive deterioration in the quality of life were also noted in the FOLFIRINOX group for all functional and symptom scales.\u201d\u00a0 So quality of life was BETTER, not worse in the Folfirinox group.\nAnd the reporting of harms was oddly incomplete.\u00a0 The story stated:\u00a0\u201cAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\u201d\nWhy did the story report that statistic instead some of these easily explained in the journal article:\n75 of those in the Folfirinox group (46%) had neutropenia compared with 35 in the Gemcitabine group (21%) 21 of those in the Folfirinox group (13%) had diarrhea compared with 3 in the Gemcitabine group (2%) 15 of those in the Folfirinox group (9%) had sensory neuropathy compared with 0 in the Gemcitabine group \u00a0 ???", "answer": 0}, {"article": "To study the relationship between berry consumption and heart disease, Cassidy and her collaborators at the Harvard School of Public Health analyzed findings from the Nurses Health Study 2 which includes more than 90,000 nurses in the U.S.\n\"We showed for the first time that a regular intake of substances that are naturally present in red-, blue-colored fruits and vegetables can reduce the risk of a heart attack by about 32 percent in young and middle-aged women [ages mid-40s to 60],\" compared with women who ate berries once a month or less, says study author Aedin Cassidy of the University of East Anglia.\nAt the same time, researchers have monitored the nurses' health to see which diseases they go on to develop, or not.\nWomen With A Berry-Snacking Habit May Have Healthier Hearts\n\nWhen it comes to supernutritious foods, the blueberry has long had a health halo floating over it.\nNow, a new study published in the American Heart Association's journal Circulation suggests eating three servings per week of blueberries and strawberries helps cut the risk of heart attacks among some women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both the HealthDay and TIME articles, the NPR story did not discuss potential harms. But all health interventions have harms, as well as benefits and costs. We looked the other way on costs but not on harms.", "answer": 0}, {"article": "WASHINGTON (Reuters) - Screening smokers and former smokers for lung tumors using three-dimensional X-rays reduced their risk of dying from lung cancer by 20 percent, researchers said on Thursday.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\nIn 2006, Dr. Claudia Henschke of New York Presbyterian Hospital-Weill Cornell Medical Center caused a stir when she published a study saying that 80 percent of lung-cancer deaths could be prevented through widespread use of spiral CT.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story misses the mark completely in its handling of the potential harms of the test.\u00a0It does provide the important caveat that \u201cCritics of the scans fear that smokers may not be motivated to quit if they believe screening can save their lives if they do get cancer.\u201d\u00a0\u00a0It fails to note the relatively high false positive rate (25% to 60%) and the implications on unnecessary additional testing. This is especially disappointing because the NCI press release provided the information.", "answer": 0}, {"article": "For more information, visit http://www.\nIn the accompanying editorial titled, \"Can a Toothpaste Reduce Heart Attacks and Strokes?,\" Joseph S. Alpert, M.D., an internationally renowned cardiologist, noted the importance and timeliness of these findings and commented on how his father, a dentist, had told him even before he went to medical school, that dental health may affect heart attacks and strokes.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nToday, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. While regular toothpastes come with a standard warning to keep away from young children and to avoid ingesting, we aren\u2019t told if the disclosing agents used in Plaque HD\u2019s \u201cTargetol technology\u201d pose any additional harms for people with sensitivity or mouth problems. It would be good to be told either way.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the quoted source and the study authors cautioned that beta blockers carry some side effects and additional research is needed to determine if the drugs\u2019 benefits outweigh their risks for cancer patients. It specifically mentions risks for people with asthma. Other specific harms from beta-blockers for the general population include depression and diarrhea. Beta-blockers may also cause complications for people with diabetes.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\nIn the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.\nIn particular, the researchers compared the ability of all three NAD+ precursor vitamins - NR, niacin, and nicotinamide - to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and health benefits.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are addressed. The news release said there were \u201cno serious side effects with any of the doses,\u201d though there were four cases of potential flushing we address under quality of evidence. But it should have pointed out that no safety data exists on long-term use. Nor is there data on the impact of taking this supplement along with other medications or in greater amounts than the tested doses. Also, the people in this study were all healthy, so it\u2019s unclear what impact this substance might have on people with health conditions. That\u2019s an important point since the researchers plan to study NR\u2019s effects on elevated cholesterol, obesity and diabetes as well as people at risk for chemotherapeutic peripheral neuropathy.\u00a0 Also, just because something occurs naturally in the human body doesn\u2019t mean it\u2019s safe.", "answer": 0}, {"article": "But he also sees a lot of patients who cannot be candidates.\nThat's why Orr saw blank spots where people's noses and eyes should be in their faces, sort of like \"holes in the film,\" says Colby.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nSo when Orr's cousin read about an experimental treatment for macular degeneration, Orr quickly got in touch with one of the researchers, had some basic tests, and before she knew it, she was one of more than 200 patients to have an experimental miniature telescope implanted in her eye.\nAs a result, the Food and Drug Administration plans to monitor safety for at least five years for the next set of patients who receive the telescope.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The fourth sentence talks about the potential harms, a rarity for any health story. In fact, the whole second paragraph should be part of a template for most health writing.\u00a0\"Findings from the clinical trials show that the telescope does improve vision for the majority of patients. Still, there are some concerns about corneal damage, since the telescope is relatively large inside the eye. And the population who might benefit from the new device is somewhat limited. The treatment doesn\u2019t work for those who have had cataract surgery. And for those who catch the disease early on, there may be better options.\" One of our reviewers just printed that out and taped it to his computer screen.", "answer": 1}, {"article": "Women with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nWomen who took such hormones had fewer hot flashes, on average, than women who took soy - and both had fewer than those who took a placebo, or \u201cdummy pill.\u201d\n\n\u201cThe bottom line for someone who is very disturbed by hot flashes, the best treatment is hormones, and the next tier would be soy,\u201d said Dr. Gloria Bachmann, professor of obstetrics and gynecology at the Robert Wood Johnson Medical School in New Jersey.\nHowever, a 2002 landmark study by the National Institutes of Health (NIH) found that such treatments can increase the risk of breast cancer, heart disease and stroke.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate job reminding readers of the risks reported from the 2002 Women\u2019s Health Inititiative study (although we wish it had given the absolute risk data).\u00a0 And it cited what the NIH reports as side effects of soy supplements \u2013 but again without numbers.\u00a0 Adequate nonetheless.", "answer": 1}, {"article": "In 2008, Gao struck out on his own, taking a job as director of a brand-new gene therapy center at UMass.\n\u201cWe are probably in the greatest innovative period of understanding human disease and how to make cures ever.\u201d\n\nThe concept of gene therapy is straightforward, beautiful even: Fix an illness caused by a faulty gene by replacing or supplementing a healthy new copy of the gene.\nAdditionally, the brain is a closed compartment, so the risks of gene therapy are minimized\u2014other parts of the body, the liver or the lungs, say, are undisturbed.\nFor the next 13 years, Gao would work for Wilson, engineering new and better viruses for the therapies, called \u201cviral vectors.\u201d These molecular FedEx trucks can be loaded with healthy versions of genes and deliver them to the correct location in the body.\nThe most promising candidate was adeno-associated virus (AAV)\u2014a virus that grows in the presence of adenovirus but is a completely different type.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one is difficult to evaluate, since most of the current research relates only to animal studies. However, early in the story, the writer reflects on the well-publicized death of a clinical trial participant in 1999 that brought gene therapy trials to an abrupt halt in the United States.\u00a0 Other passages in the story also suggest caution,\u00a0as does a source later in the story, who notes that risk accompanies many therapies. These details are sufficient to indicate there could be significant harms if these methods move into human testing, and that\u2019s enough to rate as Satisfactory. However, it could have been made clearer that researchers\u00a0really don\u2019t know the harms yet.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Clearly elaborated.", "answer": 1}, {"article": "Funding came from the National Institutes of Health and the American Heart Association.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does an excellent job of outlining the exercise regime employed in the study. However, it does not mention that the study specifically recruited subjects between the ages of 45 \u2013 64 who were sedentary. Given that one of the exercise sessions recommended in the study focuses on high-intensity interval training (HIIT) \u2014 and such training does come with potential risks for deconditioned individuals \u2014 it might have been advisable to mention that supervision for HIIT training should be strongly considered.", "answer": 0}, {"article": "Bauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\nThe number of people using a combination of tobacco and e-cigarettes is on the rise, according to Etter, resulting in smokers switching and consuming less tobacco each day.\nBut others in the field of tobacco control disagree, stating that whilst people -- including youth -- may have tried e-cigarettes, the evidence is lacking for their regular use.\nSince their introduction in 2006, e-cigarettes have become commonplace among smokers trying to kick their habit, with a third of smokers trying to quit in the United Kingdom turning to e-cigarettes to aid them, according to one study .\n\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "On the harms possible from e-cigarettes, the story was not as thorough as it could have been. For example, there is a growing scientific literature on known harmful molecules in the vapor.\u00a0Nickel, for instance, is in some ENDS vapor and is known to be harmful in other inhaled scenarios. Concerns have also been raised about the quality of different brands of cartridges and the batteries used in some devices, which have in rare cases been reported to catch fire.\nBut we acknowledge that the story took the time to quote different experts by name and let them make their harms arguments, so we\u2019ll award a satisfactory rating. Jean-Francois Etter, professor of Public Health at the University of Geneva, urged people to see the benefit of e-cigarettes in cutting smoking as outweighing their harms. Another expert argues that while they may benefit adults who are trying to quit traditional smoking, \u201c[they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures. \u201d He adds that \u201cExposure to nicotine can harm adolescent brain development.\u201d", "answer": 1}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nWhen we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\nThe effect remained even after the researchers adjusted for other things that can influence heart-disease risk, such as obesity, high blood pressure, smoking, low levels of physical activity and a family history of heart disease.\nIn the study, researchers from the Harvard School of Public Health and the University of East Anglia in the U.K. analyzed data from 93,600 women ages 25 to 42 enrolled in the Nurses\u2019 Health Study II.\nThe women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both HealthDay and NPR, TIME also did not discuss potential harms. But all health interventions have harms, as well as benefits and costs.\nWe looked the other way and gave a N/A score for no discussion of costs, but we can\u2019t do so with harms.", "answer": 0}, {"article": "The original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the modified vancomycin hasn\u2019t been tested in human trials. As such, it\u2019s not clear what the potential harms may be. The release doesn\u2019t mention this. And there will almost certainly be potential harms, given that conventional vancomycin has a range of potential side effects, from nausea and diarrhea to kidney damage. Could risk of these potential harms decrease if the modified vancomycin can be used in smaller doses to address bacterial infection? If so, that\u2019s something the release could have addressed.\nWe also understand that some side effects would we a trade-off people might be willing to accept if it turns out the drug could prevent death or painful treatments that can come with an overwhelming bacterial infection. ", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe test approximates the average blood glucose levels over the previous 2 or 3 months, based on the amount of glucose that has accumulated on the surface of red blood cells.\nHowever, HbA1c levels increased in the final third of pregnancy, which is consistent with the decrease in sensitivity to insulin that often occurs during this time period.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The blood test itself is virtually harmless, and overall fairly reliable, but results can be skewed by a variety of unrelated diseases and lifestyle factors, resulting in false positives and negatives.", "answer": 0}, {"article": "And there's another potential problem with existing treatments.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nIt's too early to tell if the drug actually works, and it will be years before it's ready to seek federal approval to be prescribed to patients.\nWEDNESDAY, April 21, 2010 (HealthDay News) -- Researchers are reporting that a drug is showing promise in early testing as a possible new treatment for hepatitis C, a stubborn and potentially deadly liver ailment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the main side effect of BMS-790052 in early testing was headache. But considering that this was a phase 1 study designed primarily to collect information about drug safety, we think it\u2019s unfortunate that the story chose to emphasize a secondary test result \u2013reduction in viral load \u2014 and downplay potential safety issues.\u00a0\nThere is also no discussion of the potential harms associated with the\u00a0other experimental drugs that the story suggested would help treat\u00a0hepatitis C. If a story is going to pass long claims that unapproved drugs are\u00a0going to cure hepatitis\u00a0C, we feel it also needs to\u00a0provide\u00a0the full picture of the harms these treatments may entail. \u00a0", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nThe technique is a new use of an approach that many surgeons are already familiar with: the Gillies incision, used for surgical repair of cheekbone fractures.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\nApril 29, 2016 - A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an \"Ideas and Innovations\" paper in the May issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated that \u201cNone of the patients experienced complications, and there was little or no visible scarring.\u201d\u00a0But the published study noted that neurapraxia (a temporary loss of nerve function) lasting several weeks was a risk. Although none of the 19 patients experienced complications, it would have nevertheless been helpful to describe possible risks in the news release. \nMost interventions carry risks, and the Gillies incision used in this procedure is no exception. Complications from the procedure could result in injuries to the wall of the eye and cosmetic deformities, as well as limitations in jaw movement.", "answer": 0}, {"article": "The team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nOur new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nResearch on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As is so often the case with news releases about cancer screening tests, what usually gets highlighted is the sensitivity; in this case, that early stage cancers resulted in a positive test 90% of the time.\nBut what\u2019s not highlighted \u2014 and can cause significant emotional harm \u2014 is that 10% of the time\u00a0the test will be negative in someone who has cancer. That \u201cfalse-negative\u201d result provides false reassurance that there\u2019s no cancer present. In addition, there may be a small number of\u00a0\u201cfalse-positive\u201d tests leading to inappropriate procedures. Readers need to know how often false positive results occur with the test, and that\u2019s something a small study such as this can\u2019t confidently address.", "answer": 0}, {"article": "The report, he added, might quell the craze.\nAs for vitamin D, some prominent doctors have said that most people need supplements or they will be at increased risk for a wide variety of illnesses, including heart disease, and autoimmune diseases.\nAt the same time, vitamin D sales have soared, growing faster than those of any supplement, according to The Nutrition Business Journal.\nIn general, most people are not getting enough vitamin D from their diets, but they have enough of the vitamin in their blood, probably because they are also making it naturally after being out in the sun and storing it in their bodies.\nBut Andrew Shao, an executive vice president at the Council for Responsible Nutrition, a trade group, said the panel was being overly cautious, especially in its recommendations about vitamin D. He said there was no convincing evidence that people were being harmed by taking supplements, and he said higher levels of vitamin D, in particular, could be beneficial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, contrary to the claims of many advocates for increased supplemental vitamin D, there is evidence that\u00a0high levels of vitamin D may\u00a0have adverse\u00a0effects, such as increased risk for fractures and an increase\u00a0in the overall death rate. The story also explained that too much calcium has been linked to increased risk of kidney stones and, more tentatively, heart disease.", "answer": 1}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\nIt may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not told about any of the risks of epidurals.Those risks include a drop in blood pressure (which can complicate an otherwise normal pregnancy), severe headache (in less than 1% of women), slowing of labor due to lying on one side for too long (unless a \u201cwalking\u201d epidural is used, though the procedure is rare), shivering, backache, ringing of the ears, nausea, trouble urinating, and the increased likelihood of interventions like forceps and cesarean section (since it can be harder to push). Epidurals also require a catheter to drain urine, which significantly increase the risk of urinary tract infections.", "answer": 0}, {"article": "Laxminarayan did not dismiss the notion of this type of use out of hand, however.\n\u201cBut if you can select a group with a high incidence rate of syphilis or chlamydia, and you want to try to reduce the rate of syphilis quite quickly in this group of people, you may think that this strategy could be used for a couple of months.\u201d\n\nRates of syphilis in particular have risen steadily in recent years; the rate in 2015-2016 \u2014 8.7 cases per 100,000 people \u2014 was the highest since 1993, the Centers for Disease Control and Prevention reported.\nThere was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nThe overall reduction of all STIs was 47 percent, but that average was dragged down by the fact that doxycycline doesn\u2019t cure gonorrhea.\nThe spread of some sexually transmitted infections could potentially be dramatically reduced by instructing people who have had unprotected sex to take antibiotics within 24 hours after the intercourse, a new study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The body of the story spells out many of the potential harms, but the story would have been stronger if warnings had been included in the headline and lead paragraphs. The headline refers to \u201craising tough new questions\u201d and the second sentence in the story says the strategy \u201ccould spark a controversy.\u201d The potential harms would have been clearer to readers if the headline and lead had bluntly stated that routine use of doxycycline could undermine the effectiveness of antibiotics for a range of infections, not just the sexually transmitted diseases these researchers looked at.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drinking milk is common enough that it hardly warrants an explanation of the associated harms.", "answer": 2}, {"article": "The stem cell procedure is in the earliest stages of development, said Celiz.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nIt's like this material goes over and just taps it on the shoulder and says, 'Wake up, wake up,' and then it starts to repair itself.\"\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential for risks when using stem cells to grow dental tissue.\u00a0As with many reports on new research, this story suffers from its optimism. \u00a0The new material has been tested in cell cultures and has yet to even make it to an animal model, so predicting harms is difficult but it is easy to come up with some concerns: Will this material be as durable as existing fillers? Has the material been tested for long-term safety? If the material fails, how will that impact a subsequent root canal? \u00a0Clearly these questions cannot be answered but\u00a0we think that any good story should point out the unknowns and not just the potential positives.", "answer": 0}, {"article": "One of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n\u201cA prevention tool like a ring could be used discreetly, a woman would have control over it, and it could allow her to keep herself safe from HIV without having to ask a male partner to take on prevention strategies,\u201d Baeten said.\nAdherence is also a big issue for the only other PrEP on the market, a once-a-day pill called Truvada.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would have liked to see some mention of whether there might be any harms associated with this. It is possible that long-term use might pose risks that don\u2019t show up in shorter studies. The story does not even say, \u201cWe don\u2019t know of any harms.\u201d", "answer": 0}, {"article": "Zecuity, which is battery-operated, delivers 6.5 milligrams of sumatriptan over the course of about five hours and can relieve nausea, as well as reduce sensitivity to light and sound.\n\"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill,\" said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.\nAnd 84 percent of patients using the patch were relieved of their nausea, compared with 63 percent of those in the placebo group, according to a company news release.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the story, \u201cThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\u201d We\u2019ll call this adequate for a satisfactory, but it would have been helpful to know how often these adverse effects occurred, especially since the FDA had previously delayed approval of the product based in part on safety concerns. In addition, there was no mention of other adverse effects\u00a0that have been associated with triptan use, such as atypical pain and pressure sensations (e.g. tightness in the chest and throat constriction). The story did mention that triptans can be harmful for\u00a0patients with heart disease or who are taking SSRI antidepressants.", "answer": 1}, {"article": "Ingelfinger, who wrote an editorial published with the study, echoed Montgomery's cautious optimism.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\nIn the study, 10 patients had an episode of antibody-mediated rejection anywhere from two weeks to five months after their transplant.\nThe enzyme is derived from a strain of Streptococcus bacteria, and it essentially chops up the antibodies that would attack the organ.\nNow the new research suggests a simple approach -- an infusion of a particular enzyme hours before the transplant -- could offer a better alternative.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article makes clear the patients were \u201csuccessfully treated\u201d if sensitizing antibodies returned, it does not give any information about side effects, from the enzyme infusion nor the anti-rejection drugs subsequently used.", "answer": 0}, {"article": "(Forget to weigh in or track your meals?\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\n\"The data really does confirm that when you give people tools and help, instead of just preaching to them, it really does help.\"\nSince last May, he has lost about 50 pounds (52, to be exact, but it fluctuates a bit) and his blood sugar has returned to the normal range.\nAdditionally, traditional players in the weight loss space, such as Weight Watchers, now offer some similar incentives, such as personal coaching.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not consider potential harms of the program, but because they do seem relatively minor, we\u2019ll rate this N/A.\nThings we did ponder related to risks of using the app: The study results implied that 25% of participants dropped out, but readers are not told why. Was following the program too difficult or not specific enough? Will this be simply one way for people trying to lose weight to fail and give up on improving their health? Do people get any portion of their money back if things don\u2019t work out?", "answer": 2}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nLaunched in October, its sales touched $2.11 billion in the quarter ended Dec. 31.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms from the drug. What were the drop out rates and adverse drug reaction rates? What was the severity of the reactions? The story does not address these issues.", "answer": 0}, {"article": "For more information on Hologic, visit www.hologic.com.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\nWomen with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\n\"Density creates challenges for conventional mammography by obscuring the images, which often results in additional visits and exams for women,\" said Edward Evantash, MD, board certified OB/GYN and Medical Director for Hologic.\nThe actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no explanations of potential harms of integrating 3D mammography\u00a0into current breast cancer detection or that this technology does not appear to benefit women with extremely dense breasts. It is unclear if this technology could result in false positives (over-diagnosis) or what the negative predictive value of the test is (the probability that subjects with a negative screening test don\u2019t actually have the disease).\nIf these tests lead to over-diagnosis then women face the harms (and costs) of unnecessary treatment.", "answer": 0}, {"article": "Last year 61.5m prescriptions for antidepressants were issued in England.\nThese initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nIt would accelerate our therapeutic interventions and make them more tailored to the needs of the patient.\u201d\n\nBut further clinical research is needed to see if the findings can be applied in a clinical setting, Hallstrom added.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions no potential harms. However, as with all screening tests, false-positive and false-negative results can be harmful in a number of ways.", "answer": 0}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\n\"Getting a diagnosis of dementia can be time consuming and quite frustrating for many people, so it's promising that earlier indicators of cognitive decline are in development,\" said Paul Edwards, Director of Clinical Services at Dementia UK.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nIn the United States, the condition is the sixth biggest cause of death among all adults, according to the US Centers for Disease Control and Prevention, while in the UK it has overtaken heart disease as the leading cause of death, according to the Office for National Statistics.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest risk with a screening test like this is incorrect results\u2013false positives and false negatives, which the story never explains. There is significant harm that can result if a person thinks they are at high risk of dementia when they aren\u2019t, or thinks they\u2019re at low-risk when they\u2019re high risk. These are otherwise known as a test\u2019s\u00a0sensitivity and specificity and they should have been discussed, especially how these unknowns will guide next steps for future research.", "answer": 0}, {"article": "Marji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n\"Many supplements have biologic activity, but before I recommend that people take isolated supplements they need to be tested in humans.\"\nFor the study, Ray's team treated human breast cancer cells with bitter melon extract, which is sold in U.S. health food stores and over the Internet.\n\"When we used the extract from that melon, we saw that it kills the breast cancer cells,\" said lead researcher Ratna Ray, a professor of pathology at Saint Louis University.\n\"The results of this laboratory study are intriguing,\" McCullough said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 You can\u2019t talk about harms from an agent that\u2019s only been tested in a petri dish.\u00a0 But, then again, you really can\u2019t say much at all. Yet they made a news story out of this. ", "answer": 2}, {"article": "Soy may keep breast cancer from coming back\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cThere are probably 30,000 people in the U.S. who never smoked and who have lung cancer.\u201d\n\nLung cancer kills 160,000 Americans a year.\n\u201cAlthough the risks are probably different for American women for developing lung cancer, I do think it is a call to action for more research about how we develop lung cancer,\u201d Patel said.\nMost of the women in the study had never been smokers, and there\u2019s a lot of evidence to suggest that lung cancer is a different disease in smokers versus non-smokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t address harms, but we\u2019re not sure that there are any harms worth mentioning when it comes to soy foods eaten in moderate amounts.\u00a0Hypothetical concerns that soy may promote estrogen-sensitive cancers have not been confirmed in large studies. And the story correctly\u00a0advises readers not to take soy supplements, which deliver a higher dose of soy isoflavones that might potentially increase\u00a0cancer risk. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "What's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nThe study, of 78 people with and without colon cancer, found that those with the disease tended to have a distinct pattern of chemicals in their breath.\nThe idea of using a breath test to catch cancer is not new: Researchers are looking into breath tests for detecting a number of cancers, including lung and breast tumors.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nBut for now, he added, \"this study raises many more questions than answers.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentioned that this test\u00a0would inevitably\u00a0produce\u00a0false-positive results that would lead to\u00a0needless invasive follow-up tests.", "answer": 1}, {"article": "Follow Group Health research on Twitter, Facebook, Pinterest, LinkedIn, or YouTube.\n\"We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,\" Dr. Arterburn said.\nResearch at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression\n\nSEATTLE--Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\n\"A large body of evidence indicates no difference in how effectively the newer antidepressants improve people's moods,\" said Dr. Arterburn's coauthor Gregory Simon, MD, MPH, a Group Health psychiatrist, GHRI senior investigator, and research professor in psychiatry and behavioral sciences at the UW School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With the exception of a mention that some people can\u2019t take buproprion (seizure disorder patients, for example), and the weight gain issue, the release makes no mention of the considerable side effects that accompany antidepressant use, or the often frustrating search patients and physicians must undertake to find an antidepressant that is both effective and tolerable for individual patients. Fatigue, insomnia, increased anxiety, headache and nausea are all fairly common when starting an antidepressant.", "answer": 0}, {"article": "\u201cWhen drugs don\u2019t work, what else is there?\u201d\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nIn September, the journal Pain published the largest-ever clinical trial of spinal cord stimulators, comparing their use with conventional pain therapies, including drugs, nerve blocks and physical therapy.\nThe study, which was financed by the implant maker Medtronic, followed 100 patients who had undergone spinal surgery and had developed chronic pain in one or both legs.\n\u201cSometimes efficacy wanes over time, but I still believe in them,\u201d said Dr. Kaufman, also an assistant professor of anesthesiology at the New Jersey Medical School.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes some annoyances and potential problems with the device (e.g. the \u201cbuzzing\u201d vibration and the need for reoperations to replace dead batteries), but neglects to mention others. For example, the authors of the 2007 trial noted that electrode migration occurred in some 10% of patients and infections in 8%. A 2004 review by a leading group of pain experts noted that complications occur in about one-third of patients. Additional problems included pain near the site where the device is implanted, tears of the membrane that surrounds the spinal cord (the dura), and malfunctioning equipment. (Pain 2004;108:137-47)\u00a0 ", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The first line of the story says that this cream \"promises instant anti-impotence with no side effects.\" It also quoted a researcher:\u00a0 \"Our initial studies show that it is safe to use multiple times.\"\nWhat does that mean? \nThe story should have at least briefly mentioned that \"safety\" in ten rats does not automatically equate to safety in people. \u00a0\nAll drugs have side effects. \u00a0\u00a0", "answer": 0}, {"article": "This week, specialty insurance administrator Magellan Behavioral Health Inc. issued medical necessity guidelines for TMS treatment and will provide coverage effective Jan. 1.\n\"Generally speaking, just because a device, procedure or medication has been approved or is deemed to be safe by some entities does not mean that it is automatically covered,\" BlueCross BlueShield spokeswoman Kelly Allen said.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\n\"When this large magnet pulses repetitively, it causes an electromagnetic field which then passes through the skull and stimulates the brain tissue itself,\" said West, explaining a cascading effect that results in the interior nerve fibers connecting better.\nSaid West: \"Typically, when Medicare starts to cover something the excuse of experimental and investigational is no longer valid.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t provide any specifics about potential harms of the treatment, \u00a0We are told, \u201c\u2026treatments are more effective than medications with far fewer side effects,\u201d \u00a0\u201c\u2026but for the most part, it is safer in general than taking a medicine. You\u2019ve got less seizure risk than taking a medicine. You\u2019ve got less side effects than taking a medicine.\u201d \u00a0Exactly what are the risks and how often do they occur? \u00a0Here is a listing of side effects from \u00a0the NIMH website:(http://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml )\n\u201cSometimes a person may have discomfort at the site on the head where the magnet is placed. The muscles of the scalp, jaw or face may contract or tingle during the procedure. Mild headache or brief lightheadedness may result. It is also possible that the procedure could cause a seizure, although documented incidences of this are uncommon. A recent large-scale study on the safety of rTMS found that most side effects, such as headaches or scalp discomfort, were mild or moderate, and no seizures occurred.\u00a0Because the treatment is new, however, long-term side effects are unknown.\u201d", "answer": 0}, {"article": "The petitioners filed the results of that study in October.\nInstead, they were consuming corn masa flour products, because that was the staple grain in that diet,\" says Cynthia Pellegrini, senior vice president of public policy and government affairs at the March of Dimes.\nThe rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the FDA\u2019s worry that a chemical used on corn flour could interact with the corn masa flour. It quotes the FDA which says:\u00a0\u201cThe FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\u201d It would have been nice for the story to explain more clearly what concerns are raised \u2014 this seems pretty vague \u2014 but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "ZURICH (Reuters) - Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited benefits.\n\u201cThe modest absolute clinical benefit of canakinumab cannot justify its routine use in patients with previous myocardial infarction until we understand more about the efficacy and safety trade-offs and unless a price restructuring and formal cost-effectiveness evaluation supports it,\u201d wrote Dr. Robert Harrington, chair of the Stanford University School of Medicine, in an editorial in the New England Journal of Medicine.\nHe downplayed critics who said the benefit was small, saying that one large subgroup in the so-called Cantos trial had shown a 27 percent reduction in cardiovascular risk.\n\u201cSome have wondered whether a particularly high-risk subgroup could be identified where canakinumab\u2019s current price can be justified,\u201d he said.\nNovartis had said in June that the drug met its goal in the study but details were only unveiled at European Society of Cardiology meeting in Barcelona.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "From the get-go, readers are told there are risks to keep in mind. This was entirely absent from the TIME story we reviewed.\nThat said, we wish this Reuters story had discussed the harms more in-depth\u2013how frequent were they? How severe?", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention the increased risk of strokes with Lucentis. The story should have also mentioned risk of inflammation and infection from injection into the eye.", "answer": 1}, {"article": "\u201cThese results have pushed me toward the idea.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\n\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nJ. David Gangemi, director of the Institute for Neutraceutical Research at Clemson University, said he found the study interesting, but added, \u201cI think that many of the people who have dedicated their careers to clinical trials in studying these effects are not at all convinced from this analysis that there is this large reduction in incidence and duration of disease.\u201d\n\nDr. Gangemi is the senior author of a 2005 study, published in The New England Journal of Medicine and included in the review, that found no benefit in the herb.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0points out\u00a0that the herb has some side effects, and quotes a physician mentioning the most common one (a rash, especially in children) and the most important contraindication (pregnancy).\u00a0It also points out that the study did not take potential harms into account, alerting readers to the possiblity of others\u00a0not mentioned here.", "answer": 1}, {"article": "Cardiac arrest involves the abrupt loss of heart function, breathing and consciousness.\n\u201cOnce a victim has sustained a cardiac arrest with little or no blood supply going to the heart or brain, the time to reestablishing blood flow with oxygenated blood is critical,\u201d said Dr. Lenworth Jacobs, director of trauma and emergency medicine at Hartford Hospital in Connecticut.\nUnlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention studied here involves a last-ditch emergency effort to revive a person who is dying. There are some potential harms if the resuscitated person survives, and the story didn\u2019t mention those, but given the measured approach of this story and the nature of the research, we feel this one is N/A.", "answer": 2}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nFor more information, please contact: \n\nJoel Winston \n\nPublic Relations Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nj.winston@qmul.ac.uk \n\nTel: +44 (0)20 7882 7943 / +44 (0)7970 096 188\n\n* Research paper: 'Changes in the Frequency of Airway Infections in Smokers who Switched to Vaping: Results of an Online Survey'.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nSenior author Professor Peter Hajek from QMUL said: \"There is no doubt that e-cigarettes are much safer than conventional cigarettes, but smokers are still led to believe that they're dangerous.\nThe results, published in the Journal of Addiction Research & Therapy, show that 66 per cent of respondents reported an improvement in respiratory symptoms, 29 per cent reported no change and 5 per cent reported worsening.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes a researcher saying it\u2019s \u201cmisinformation\u201d to tell smokers that vaping is dangerous. That\u2019s just not true. E-cigarettes contain nicotine, which can harm fetuses and adversely affect brain development. They also contain a host of other chemicals, including some potential carcinogens and lung irritants, which have not been adequately studied. The relative amount of harm from vaping versus smoking remains uncertain.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the only significant adverse event for those on estriol was irregular menses. It could have gone into more detail, perhaps, but this passes muster. The point is that estriol is essentially a weak form of estrogen that has been shown in previous studies to be fairly safe, and whatever risks exist are likely outweighed by benefits in women with MS.", "answer": 1}, {"article": "Now Dr.\nIn the four-month study, the group randomly assigned to receive intranasal insulin twice a day either improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\nOne hallmark of Alzheimer\u2019s disease is reduced metabolism in the brain, which shows up on scans as less use of glucose, the fuel for brain cells.\nAnd conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\nFor years, the study\u2019s principal investigator, Suzanne Craft, has studied insulin\u2019s effects in Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story references potential adverse effects, and notes that this study was too short and small to reliably document the potential harms of treatment. However, it didn\u2019t mention the adverse effect data \u2014 limited though it may be \u2014 that was reported in the study. Adverse events were more common in the insulin-treated groups and were reported by 72% of patients receiving\u00a020 IU\u00a0of insulin,\u00a068% receiving\u00a040 IU, and\u00a057% receiving placebo.\u00a0The most commonly reported adverse event was a stuffy nose, but headaches and nosebleeds were also more common with insulin treatment.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain that the use of MRI technology might result in 'false signals'.\u00a0 It should have explained that this means that some patients who did not have clots that could cause a cardiopulmonary embolus\u00a0would have been treated as if they did.\u00a0 There was no discussion about the harms associated with this treatment; nor was there any discussion of the mental anguish that might accompany the diagnosis in the absence of the condition.\nSimilarly \u2013 the story included no discussion of the possible harms associated with the Angiojet.\u00a0 Although it appears, from the summary of safety and effectiveness data filed with the FDA, that the risks of bleeding complications, heart attacks, and death are less with the Angiojet than with the treatments for large deep vein thrombosis with which it was compared, there was no discussion of the harms associated with this device in the story.", "answer": 0}, {"article": "Omalu found traces of the disease in the brain of legendary Pittsburgh Steelers player and pro Hall of Famer Mike Webster in 2002.\nWhile it is hoped that this will be one avenue to help detect the disease in the living, McKee believes that it will just be one part of a larger process.\nHowever, there is a potential bias in that study, as relatives of these players may have submitted their brains for diagnosis due to clinical symptoms noticed while the players were alive.\nMore exposure to football increases likeliness of CCL11\n\nThe paper evaluated the brains of 23 deceased football players with CTE, and compared them to the brains of 50 deceased people diagnosed with Alzheimer's disease and the brains of 18 deceased non-athletes.\n\"This is an inflammatory marker that may be non-specific and may not be diagnostic of CTE,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a story is going to speculate about the potential clinical benefits of a new research finding (and this one does), the story should also discuss the harms. It\u2019s worth pointing out, for example, that any test such as\u00a0this would produce false-positive and false-negative results. Such results could cause unnecessary concern and anxiety and perhaps the loss of a lucrative career \u2014 or false reassurance that nothing is wrong when a degenerative process is underway.", "answer": 0}, {"article": "Even so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to do one thing helpful for readers. It provided a comparison, of sorts, of different coconut parts. It says, for example, that \u201d\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated. A tablespoon of butter, by comparison, contains 102 calories and 11.5 grams of fat; 7.3 of those grams are saturated.\u201d But it provides no context about what this means. We read this and assumed that we should avoid all coconut oil products and stick with butter, but the story hypes coconut oil and coconut milk so much that readers are likely to miss this nuance.\n\u00a0\nOne quote in the story refers to calories, but the matter of high-calorie food of any sort, including coconut oil, contributing to obesity is not explained.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of \u201charm\u201d does not appear to be relevant here. Individuals may find text messages to be annoying, of course, but the study itself notes that participants \u201coverwhelmingly\u201d reacted positively to the intervention. That doesn\u2019t make it into the story.", "answer": 2}, {"article": "The research is so early that the drug hasn't been named.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nThe current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says study participants who took the drug exhibited \"few side effects.\" But what were those side effects and how serious were they?\u00a0The story doesn\u2019t say. While the implication here is that the drug seems to be safe \u2014 a conclusion that we can\u2019t really draw based on a small, early phase test \u2014 the story does include a\u00a0cautionary quote from an expert about the need for additional testing to demonstrate safety.\u00a0It also noted that patients taking this drug might still need to be treated with interferon, which many individuals can\u2019t tolerate because of side effects. A close one, but we\u2019ll call it satisfactory.\u00a0\u00a0", "answer": 1}, {"article": "A limitation of the study was its small sample size and short follow-up period.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in the release. Laser treatment can produce such irritants as \u201cdry eye\u201d and temporary visual halos, and a small number of patients have experienced increased eye pressure and the development of cataracts. These harms are apparently rare, but they deserve attention. The published study noted that there were few adverse effects and they were minor, but that the small sample size and length of follow-up were not adequate to make any firm statement about harms.", "answer": 0}, {"article": "In drafting its updated colon cancer screening guidelines, the USPSTF reviewed data on several screening strategies.\n\"Evidence convincingly shows screening for colorectal cancer works, but not enough people are taking advantage of this highly effective service,\" said Owens, a general internist at the Veterans Affairs Palo Alto Health Care System and a professor at Stanford University.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nFor this older group, the USPSTF recommends that decisions on screening be made during consultations between the patient and his or her doctor.\nThe USPSTF notes that only one-third of eligible adults in the United States are screened for colon cancer, and more need to take advantage of this effective method of prevention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have mentioned some of the potential harms of screening, ranging from anxiety over a worrisome result to bleeding, colon perforation, sedation-related events and other problems. Also, since the story specifically included comments lauding colonoscopy, it should have also mentioned that colonoscopy accounts for most of the serious harms caused by colon cancer screening.", "answer": 0}, {"article": "Turner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention side effects, but the study itself reported that adverse effects included nausea, diarrhea, and weight loss. In addition, there are some concerns that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners. It\u2019s worth noting that this absence of potential harms in the story is particularly problematic, given that a key goal of the study was to determine whether high doses of resveratrol are safe. Moreover, weight loss is already a significant concern among Alzheimer\u2019s patients, so anything that would exacerbate that is definitely worth paying attention to.", "answer": 0}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nLONDON (Reuters) - Exposure to bright light can raise testosterone levels and lead to greater sexual satisfaction in men with low sexual desire, according to the results of a small scientific trial.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any potential risks. Light therapy is generally safe, according to the Mayo Clinic, but mild side effects could include eyestrain, headaches, nausea, irritability, and agitation. Light therapy poses special risks for people with certain medical conditions or on medications such as antibiotics that can cause skin or eyes to be sensitive to light, and it can trigger mania in people with bipolar disorder.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nIn their study, funded by the Italian Ministry of Health, the investigators recruited three men and 11 women, ages 22 to 65, with obesity as shown by a body mass index (BMI) of 30 to 45 kg/m2.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\n\"We need new safe and effective therapies for obesity,\" said principal investigator Livio Luzi, M.D., professor and head of endocrinology at the IRCCS Policlinico San Donato and the University of Milan in Milan, Italy.\n\"These changes suggest a beneficial effect of dTMS on both weight loss and change in microbiota composition,\" Luzi said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Specific risks are not discussed, though it\u2019s mentioned that dTMS is currently approved in the U.S. for treating major depression and is being studied in other countries for treating neuropsychiatric disorders. Unlike deep brain stimulation, this technique does not require an operation or implantation of electrodes, so we can deduce that the potential harms are lower than other neurostimulation procedures. Nevertheless, a brief\u00a0mention of harms would give readers a sense of the risk-benefit balance should dTMS rise in popularity and availability in the coming years.", "answer": 0}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nNormally, our immune cells are good at killing invaders like bacteria but bad at fighting cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give this story a barely satisfactory rating because it does report that there were treatment-related deaths and side effects\u00a0including \u201cflu-like symptoms and confusion.\u201d But no other numbers or side effects are mentioned\u2013though there were many more\u2013and the story doesn\u2019t elaborate that CAR-T therapy can be fraught with unpredictable\u00a0problems.\u00a0Interviewing a patient who experienced these problems would have made the story more reflective of the true experience of receiving CAR-T.", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial.\nDeveloped by IceCure Medical (Caesarea, Israel/Memphis, TN), specifically for breast applications, the IceSense3 Cryoablation System\u2122, has a long history of successful treatment of benign breast fibroadenomas.\nIts effectiveness in breast cancer has been proven in a number of smaller studies, including a recent American College of Surgeons Oncology Group (ACOSOG) trial and extensive long-term ongoing, unpublished studies in Japan.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most we get is that patients felt \u201cminimal discomfort.\u201d But could ICE3 leave cancerous tissue behind without a clinician knowing? And are there any other side effects? We aren\u2019t told, and this seems strange given that the \u201ccosmetic\u201d benefits are so well-known and touted so frequently in the text. The National Cancer Institute does describe a few potential harms of cryoablation (which they classify as a type of cryosurgery), including hemorrhaging and bad interactions with chemotherapy. These probably should be mentioned in the release.", "answer": 0}, {"article": "This posed a conundrum.\nBut the downsides to getting a vaccine are extremely minimal, and flu shots may still be helpful in reducing some illness and saving lives, which is why public health experts say you should get vaccinated anyway.\nIn kids, the highest-quality evidence \u2014 a randomized controlled trial \u2014 suggests the vaccine works well enough: On average, if you give six kids under the age of 6 a flu shot, you can expect to prevent one case of the flu.\nThe flu shot is designed to protect people against three or four strains of the A and B viruses that researchers believe will be most common that year, leading to the nasty fevers, headaches, coughs, and runny noses that make many people miserable in the fall and winter.\nAs Roger Baxter, the co-director of the Kaiser Permanente Vaccine Study Center, told me, \"Flu vaccines are not a panacea, and do not prevent all cases of flu, even in the best years, when there are no manufacturing problems and the match is perfect.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the risks of negative reactions to getting a flu shot usually center on inflammation at the site of the injection, a comparatively minor side effect.\u00a0 It emphasizes that given such a minimal risk, there are very few harms for getting this protection, minimal though it may be in some years.", "answer": 1}, {"article": "Three trials had used zinc acetate lozenges and found that colds were shortened on average by 40%.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release falls short in its description of harms of the recommended treatment. Sucking on zinc lozenges can have a number of minor but unpleasant side effects, like\u00a0leaving a metallic\u00a0taste in your mouth, and, less commonly, vomiting, stomach cramps, and diarrhea. The article warns that certain other ingredients in lozenges can cause zinc not to be absorbed. However,\u00a0it would have been better to spell out that zinc can interfere with the absorption of some classes of antibiotics, making those medications less effective as well.", "answer": 0}, {"article": "2013: New guidelines could have far more Americans taking statin drugs for cholesterol\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nThe new guidelines, published in the Journal of the American Medical Association, suggests that people ages 40 to 75 who have one or more risk factors \u2014 such as high cholesterol, high blood pressure, diabetes or smoking that put them at a 10 percent or greater risk of having a heart attack or stroke in the next 10 years \u2014 should be on statins.\nIn contrast, the ACC and AHA recommend that people with a 7.5 percent or greater risk take the drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentions\u00a0\u201cmuscle pain and\u00a0cataracts [and] an increased risk for diabetes in women.\u201d This is sufficient, but the story would have been stronger if it had discussed frequency of these side effects, and mentioned the more serious (and thankfully more rare) risks of rhabdomyolysis and muscle breakdown.", "answer": 1}, {"article": "But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death.\n\u201cI\u2019m done with you guys bullying us.\u201d\n\nThen, she took out a bag and dumped the contents on the table: nine months of cancer drugs prescribed to her son, Landon, who was 4 at the time.\nWhile cannabis is legal in many U.S. states, the drug is still classified by the Drug Enforcement Administration as a Schedule 1 narcotic (along with heroin and cocaine), which make it very difficult for scientists to conduct clinical trials on people.\nWhen Riddle made the decision to give her son cannabis, the information on its safety and efficacy was (and still is) limited to anecdotal accounts, a handful of case reports and lab studies published in obscure medical journals.\nThe latter two\u2014which included OxyContin, morphine and Ativan\u2014were prescribed to help Landon cope with the side effects of cancer treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms of long term treatment with cannabis oil. Also, it does not clearly explain that early discontinuation of conventional treatment might increase the risk of relapse.", "answer": 0}, {"article": "One pain specialist not involved with the study saw the benefits of this procedure.\n\"The results of this study are very significant,\" said Dr. Kiran Patel, director of neurosurgical pain at Lenox Hill Hospital in New York City.\nAlso, the procedure isn't covered by all insurance companies, so out-of-pocket costs to patients can be very high.\n\"In certain patients who have not gotten relief from other treatments, this therapy may give sustained pain relief and may allow them to reduce opioids for at least 18 months and perhaps longer,\" said lead researcher Robert McCarthy.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the procedure \u201cwas not without complications. Five patients needed to have the wires implanted again, two patients had them removed because they were infected, and one had the device removed because of a complication.\u201d\nThe story didn\u2019t describe the complication, which was a foot drop. It could have also gone a step further by cautioning that the FDA often does not require new medical devices to prove that they are safe or effective in order to be used in people.", "answer": 1}, {"article": "Cholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\nDr Lesley-Ann Martin at the Institute of Cancer Research in London, where the research has been carried out, said: \u201cDuring the course of treatment, ER-positive breast cancers, that are \u2018fed\u2019 by oestrogen, often become resistant to standard hormone therapy.\nThe scientists say the findings are boosted by two studies which found the over-activation of certain genes linked to cholesterol production were linked with a poorer response to the anti-cancer drugs.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins are among the most commonly prescribed drugs in the U.S. but do carry risks including muscle damage, diabetes and memory loss. This isn\u2019t addressed in the story.", "answer": 0}, {"article": "Kappelmann, N et al.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\nThe research was mainly funded by the Wellcome Trust, with further support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nInflammation can also occur as a result of the immune system mistaking healthy cells for infected cells and attacking the body, leading to autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers note that \u201csome existing drugs can have potentially serious side effects, which would need to be addressed.\u201d\u00a0 Because each of these drugs differ, consideration of the side effects of each would be something a patient should consider based on the benefits and evidence.\nThe side effects of anti-inflammatory medications can be serious. They may increase cancer risk and through suppression of the immune system, increase susceptibility to infection. The release would have been stronger had it offered more specifics about potential harms.", "answer": 1}, {"article": "So why weren't they all cured?\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\n\"Bedwetting is multifactorial even within these groups, and eventually we should be able to pinpoint the cause for every single child,\" Lakshmanan said.\nExactly how sleep apnea results in bedwetting is not fully understood, but hormonal changes may play a role.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big omission in the story. Any story about surgical procedures needs to address the potential harms from surgery.The basic risks of surgery, including infections, bleeding, and complications of anesthesia should have been mentioned.", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that either product poses any particular harms. We\u2019ll rate this Not Applicable. However, it\u2019s worth mentioning that just like no one is sure if these devices help, we also don\u2019t know if they hurt. For example, using these products\u00a0may give false reassurance and lead individuals to stay glued to their devices even longer than they currently are \u2014 perhaps exacerbating an existing problem.", "answer": 2}, {"article": "LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test will enable women with ovarian cancer to be referred to gynaecological surgeons who specialize in the care of women with ovarian cancer, while patients with a benign tumor will not have to travel to specialist centers.\n\u201cThe vision is that a woman who has been diagnosed with having an abnormal pelvic mass will have a simple blood test and from that we will deduce whether or not she has cancer and if she does which drug would be most suitable for her,\u201d he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the rate of false positive diagnoses in the pilot studies described here were quite low, they still occurred.\u00a0 The story would benefit from directly addressing that and other possible debits of the test.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told that\u00a0experts fear that these tests could lead to unnecessary surgery or delayed diagnosis, and that\u2019s sufficient for a Satisfactory rating.\nThe story could have delved into a bit more of the specifics: What is the evidence\u00a0for these concerns? What are the false positive and false negative rates? These details are\u00a0useful\u00a0because the point of the story is that clinicians are not using these tests to try to improve outcomes of ovarian cancer patients. \u00a0Are the possible debits\u2013or\u00a0uncertainties driven by lack of clinical data\u2013contributing to these decisions?", "answer": 1}, {"article": "The designer of that treatment, Dr. Katherine A.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\nThe delivery virus, carrying a good version of the human gene for the clotting agent known as Factor IX, was prepared by researchers at St. Jude Children\u2019s Research Hospital in Memphis.\nThe virus has a propensity for making liver cells its target, which is good for the therapy because these cells are the natural producers of Factor IX.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions serious problems with other delivery viruses and that liver cancer had been observed in mouse studies.\u00a0 The description of the one patient\u2019s decline \u2013 and the fact that he can\u2019t be injected again with the same virus \u201cbecause his immune system is now primed to attack it\u201d was also important.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nThe next step in the research is to understand exactly how oxytocin changes brain circuitry to improve social behavior, and to document how related treatments might be used to boost established social learning interventions.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n\"We found that following oxytocin treatment, parents reported their child to be more socially responsive at home, and our own blind independent clinician ratings also supported improved social responsiveness in the therapy rooms of the Brain and Mind Centre,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release briefly describes the symptoms reported in the children taking part in the trial. The common side effects were thirst, urination and constipation.\nOur reviewers thought it should be pointed out that the risks and long-term effects of treating children with oxytocin are unknown.", "answer": 1}, {"article": "These differences in risk were statistically significant.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nIndeed, most physical activity guidelines are the same for the middle-aged adults as for the elderly, even though it is estimated that over 60% of the elderly are unable to achieve this same level of exercise.\nDuring that follow-up their level of physical activity was monitored and categorised according to five levels of MET-h values per week: <1; 1-3.74; 3-75-7.49 (equivalent to brisk walking for up to 150 minutes per week, and the recommended activity level); 7.5-15; and >15 MET-h per week.2 Mortality and cardiovascular events were recorded over the follow-up period and associated with exercise levels.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. David Hupin comments, \u201cThe level of physical activity in the elderly was negatively associated with mortality rate in a \u201cdose-dependent\u201d way.\u201d He also adds, \u201cEven a little [exercise] is good, and more may be better.\u201d\nBut exercise is painful for many older adults with arthritis or other physical ailments, and can also lead to falls, which aren\u2019t mentioned. We\u2019re not saying this is a major omission, as the release does emphasize the benefits of low doses that are less likely to cause harm. But it\u2019s still not up to our standard.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the harms of hormone therapy, which include a higher\u00a0risk of heart disease, stroke and breast cancer (but see \"quantification of benefit\" criterion below).", "answer": 1}, {"article": "Politi said a serving of walnuts is about 14 halves, which adds up to 180 calories.\nAfter one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned is that walnuts can cause weight gain because they are high in calories. Because walnuts are a common food, there are no real expected harms except for those who are allergic to them.", "answer": 1}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nWhile kidney cancer can have symptoms such as back pain and bloody urine, it's difficult to detect early, said Lee, who said about half of these tumors are found when people undergo X-rays for other reasons.\nIt even represents an advance over conventional laparoscopic surgery, which requires separate incisions for devices that can grasp and sever the cancer, as well as an endoscope that provides illumination and a view of the target area, said Marvin Guiles, director of engineering at Cambridge Endo, who worked on the instruments with Lee.\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\nBesides providing an entry point, the trocar makes a seal at the incision point to prevent the leakage of carbon dioxide, which is pumped into the abdomen to give the surgeon more space in which to work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential \"mishaps\" but what does that mean? How often do they occur? How often will the surgeon need to revert to open surgery? What are the long-term risks?", "answer": 0}, {"article": "The study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nWhile it seems almost silly to worry about potential harms of eating more fruits and vegetables, the story does not include caveats that would help readers see how misinterpretation of the study results might cause harm. The story mentions that \u201cstudies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\u201d It should have pointed out that an earlier round of observational studies of fruit and vegetable intake similar to this one produced rampant enthusiasm for beta-carotene, but then actual experiments had to be cut short because some participants taking the supplements had higher rates of lung cancer. Any story about potential benefits of specific components of foods should clearly remind readers that in some cases supplements containing these same components have been shown to be useless or even hazardous.", "answer": 0}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nBecause of serious side effects, the drug -- Lemtrada (alemtuzumab) -- is approved in the United States only for patients who have failed other treatments.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nAlso, when the immune system rebuilds itself, \"a significant number of people, about 40 percent, will develop another autoimmune disease,\" Giovannoni said.\nBy the study's end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of infections (including herpes), the need for monthly blood and urine tests for four years after the last dose, the risk of developing \u201canother autoimmune disease,\u201d such as\u00a0Graves\u2019 disease (a thyroid disorder) and a bleeding/bruising disorder called idiopathic thrombocytopenic purpura.\nWe\u2019d have preferred to see a statement that\u00a0long-term harms have not been determined, but this is otherwise a satisfactory description of the harms.\nAlso, the drug was initially refused approval by the FDA\u00a0for safety reasons, a very revealing\u00a0fact that would have provided patients with some context on how serious the side effects are.", "answer": 1}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\n\"And if we can use those as novel targets for, let's say, nasal sprays or medications, we may be able to treat people like Judy without surgery,\" Metson says.\n\"The next time she gets a cold,\" he says, \"her membranes are not going to swell and block the sinuses the way they have in the past.\nBecause I think it's made enough of a difference that I'm glad I did it,\" Foreman says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers off-handedly to the possibility of\u00a0\"poking through to the brain or into the orbit of an eye,\" but it fails to explain that these events are very rare but real risks of the surgery. While extremely unlikely, it\u2019s possible for surgeons to accidentally\u00a0damage\u00a0the optic nerve, resulting in blindness, or to puncture the base of the skull, resulting in cerebrospinal fluid leakage. Other less serious,\u00a0but more common complications are also possible. The story didn\u2019t mention\u00a0any of them.", "answer": 0}, {"article": "This study is really a proof of concept.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\n\"Every individual has a breath print that differentiates them from other people, depending on what's going on in their body,\" explained study lead author Dr. Raed Dweik, a staff physician in the department of pulmonary, allergy and critical care medicine with the Respiratory Institute at Cleveland Clinic.\nIn the new study, to gauge how well the noninvasive breath test could identify heart failure, the team collected exhaled breath samples from 41 patients who had been admitted as in-patients to the Cleveland Clinic.\n\"That's what makes the new field of breath testing so promising, because it is non-intrusive, so there is no risk involved,\" Dweik said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story misses the mark here. It quotes a researcher saying \u201cthere is no risk involved.\u201d Even if there is no direct physical harm from breathing into a testing device, there could be substantial harm caused by actions based on the test results\u2026 including unnecessary hospitalizations and treatments or, conversely, delays in potentially beneficial treatments.", "answer": 0}, {"article": "ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Here again, the release and abstract include specific rates of treatment-related adverse events, but only buried deep in the text and without important context or explanation. It is not enough to glibly pass off higher rates of serious side effects as \u201cmanageable\u201d and \u201cconsistent with known safety risks.\u201d The release states that there were grade 3-4 adverse events in 68% of the patients receiving atezolizumab in addition to chemotherapy, compared to 57% of the patients receiving chemotherapy alone. But there is no explanation of what these numbers mean. Grade 3 usually means severe and a grade 4 adverse event is typically life-threatening. There is also no mention in the release itself of the finding that 20.4% of the immunotherapy patients suffered \u201cserious\u201d treatment-related adverse events, compared to 10.5% of those who received only chemotherapy.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "CPR, when performed by training medical personnel or bystanders, carries risk including broken ribs, internal organ damage and cognitive deficits. These risks are especially high for those with chronic or terminal diseases, or whose arrests already have lasted long enough to cause brain damage. The urge to \u201chelp\u201d among bystanders is powerful and praiseworthy; and Good Samaritan laws not only recognize the impulse as humane but also protect those who give aid. But a story so positive about \u00a0CPR\u2019s benefits has some obligation to alert victims and potential helpers alike of the risks as well as the benefits.", "answer": 0}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nSo the researchers use infrared light, delivered by an extremely fast-pulse laser.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nThe pulses are so fast, Dr. Kessel said, that two photons hit a target molecule simultaneously, with the same effect as if UV light was used.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t say much about potential harms when all that\u2019s been reported is an experiment on 9 human organ donor lenses.\u00a0 But the story didn\u2019t even capture what the authors wrote:\u00a0", "answer": 0}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nAt some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no information about possible harm. In general, we might expect a news release about this kind of study to include the most common side effects found at rates considerably higher than placebo. Here those side effects include insomnia, dry mouth, and nausea. The rate on insomnia, which occurred in 14-15% of patients on drugs and <2% on placebo, is especially cogent, as it\u2019s a symptom that can really affect people\u2019s lives.", "answer": 0}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\n\"It's like you're in a parking lot,\" Hyman says.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nWhy Doctors Are Trying A Skin Cancer Drug To Treat A Brain Tumor\n\nMaryAnn Anselmo feared for the worst when she was diagnosed with a brain tumor called a glioblastoma in late 2013.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article describes only one side effect of vemurafenib, the drug that targets the BRAF mutation in cancer. (\u201cShe\u2019s lost some peripheral vision, though she\u2019s been able to compensate.\u201d) However, the piece does link to the NIH-run MedlinePlus description of the drug, including a full list of side effects and other important information\u2013for a cursory online story, this is helpful and very responsible.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned weight regain as well as some of the side effects that occur with the use of this device. \u00a0For a more complete discussion, it should have included information about how frequently these occur.", "answer": 1}, {"article": "The study published online May 16 in Circulation: Arrhythmia and Electrophysiology.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\n\"What we know is that the PROTECT AF trial enrolled more patients and has longer follow-up at this time and this allows greater statistical certainty,\" said Dr. James Freeman, assistant professor of cardiology and first author on the paper.\nNew Haven, Conn.-- A new study by a Yale researcher may support the use of a device for patients suffering from irregular heart rhythms.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible drawbacks to use of the Watchman device.\nBut federal regulators have made clear that they have concerns. In a letter dated March 13, 2015, the Food and Drug Administration told the manufacturer, Boston Scientific, that its approval was\u00a0contingent upon the submission of periodic reports on the safety of the device.\n\u201cThe primary safety endpoint is treatment of the patient without the occurrence of life-threatening events as determined by the Clinical Events Committee, which would include events such as device embolization requiring retrieval, bleeding events such as pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion and any bleeding related to the device or procedure that necessitates an operation,\u201d the letter says.\nIt also notes that the device maker agreed to carry out a study to assess \u201cwhether the rates of safety and effectiveness during the early commercialization of the WATCHMAN device in the United States are consistent with the premarket findings.\u201d", "answer": 0}, {"article": "Dr.\nThe practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\nThere\u2019s a lot of hope for getting a stool-based test.\u201d\n\nPromising results for the blood-based tests were reported this week at a meeting in Barcelona, Spain.\nBut the blood-based test may have a similar problem, since a positive signal could come from cancers anywhere in the body.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two tests the Times reported on were done on blood and on stool, which, in theory, should not harm anyone during the screening. But there is potential for harms as a result of screening. The story states that with the Exact Sciences DNA test \u201c12 percent of the time the patient will be given a false alarm.\u201d\u00a0 And, regarding the Epigenomics blood test, the story states that \u201cmore false positives could be generated so you could end up doing more harm than good.\u201d", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this story puts forth the idea that certain foods (especially coffee and wine) are good for microbial diversity\u2013and that\u2019s a health claim\u2013there should be an acknowledgement that\u00a0these foods also can carry harms. There was no mention\u00a0of the size of the dose\u2013how much coffee? How much wine? And people may take that lack of dosing to mean whatever they want, including having more than is beneficial and veers into unhealthy or dangerous.", "answer": 0}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nMany researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\nStatins are not risk-free.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned potential harms associated with the use of statin medication though didn\u2019t provide any insight about how commonly these occur. Is it 1 in 10?\u00a0 1 in 100?\u00a01 in a million? \u00a0", "answer": 0}, {"article": "However, for a study that lasts this long, \u201cthose are acceptable numbers,\u201d noted Arber.\nStill, the results are \u201cvery promising,\u201d Arber told Reuters Health by e-mail, adding he is now working to identify people who could benefit from the drug without experiencing the side effects.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\n\u201cThe findings in this study don\u2019t necessarily make that decision any easier,\u201d said Dr. Andrew Chan of Massachusetts General Hospital and Harvard Medical School, who did not participate in the research.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If we were tough on the \u201cevidence\u201d criterion grade, we go a little easy on this one.\nThe story notes that Celebrex users were more likely than the placebo group to develop polyps once they stopped taking the drug, and it quantifies this risk appropriately in absolute terms. However,cardiovascular risk \u2014 which is the main concern with this drug \u2014\u00a0is described only in\u00a0relative terms. The story states\u00a0that those treated with the drug had a 66% higher risk of serious cardiac disorders. Although we acknowledge that this is a picky point,\u00a0the story should have\u00a0reported the absolute rate of these problems in both groups and the associated difference in risk. This would have helped\u00a0readers understand how common cardiovascular events were in the study overall and how concerned they should be about the increased risk in the Celebrex group.\nNonetheless, because of the overall handling of harms and repeated mention of safety concerns, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "The muscle into which needles deliver vaccine is not nearly as active immunologically.\nFlu patch may take sting out of your fears\n\nIn what would be a boon for needle-phobes of all ages, researchers have developed a skin patch that vaccinates against the flu and could be available in five years.\n\"We've now demonstrated a technology that can enable painless, self-administered flu vaccination,\" said Mark Prausnitz, a professor in the Georgia Tech School of Chemical and Biomolecular Engineering and leader in the research.\n\"It's a technological approach that makes a lot of sense,\" said Dr. Jan Drutz, a general pediatrician at Texas Children's Hospital who calls needle-phobia common in both kids and adults.\nIn the study, one group of mice received the influenza vaccine from traditional hypodermic needles; another group received the vaccine through the dissolving microneedles; and a control group received the microneedle patches not containing any vaccine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, but since these are likely to be minimal and we\u2019re at such an early stage in development, we\u2019ll call it not applicable. We think we\u2019re being lenient here (but we were with the AP story as well) because any new drug delivery system runs the risk of causing some harms and side effects \u2013 things that can\u2019t be known before human testing \u2013 and a point the story could have made. ", "answer": 2}, {"article": "His research group is making plans to try the technique on patients with advanced ovarian cancer and sarcomas \u2014 rare tumors that arise from connective tissue in bones and muscle.\nThree years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nThe study, published Monday in the Proceedings of the National Academies of Science, contributes to hopes that a tumor-fighting strategy called immunotherapy can slow, halt or even reverse the growth of a range of cancers \u2014 and do so with fewer dangerous side effects.\nThe approach outlined in the new study by researchers from the Fred Hutchinson Cancer Research Center in Seattle identifies several ways to make it better, said Dr. Cassian Yee, the study's senior author.\nThe key is to identify specific cancer-fighting cells already circulating in the blood of patients and make thousands of copies of them in the lab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\n\u201cCurrently, the T cells have limited staying power and often die off before their work is done. Doctors give them a boost by administering a growth factor called interleukin-2. But at high doses, it can cause dangerously low blood pressure, breathing problems, kidney failure and heart arrhythmias.\nYee\u2019s group showed that by choosing T cells more selectively, patients can get by with much lower doses of interleukin-2, making the treatment less toxic.\u201d\nBut we\u2019re not told what side effects were observed in the 11 patients in the study. In reality the study originally involved a high dose (3 subjects) and low dose (8 subjects) IL-2 arm.\u00a0 The high dose arm was closed by the Data and Safety Monitoring Board prematurely due to unacceptable toxicity.\n\u00a0", "answer": 0}, {"article": "This research was supported by Gilead Sciences.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nDaily treatment with the antiviral drug tenofovir during the third trimester of pregnancy reduced the mother-to-child transmission rate of hepatitis B (HBV) from 18 percent to 5 percent, according to the findings of a clinical trial led by researchers from NYU Langone Medical Center and published on June 16 in the New England Journal of Medicine.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms. It states that \u201ctenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.\u201d\u00a0 It also says that researchers \u201cfound no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\u201d\u00a0 Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment.", "answer": 1}, {"article": "The survival benefits were restricted to men under 65.\n\"Our findings show that some tumors that are considered to be low-risk at diagnosis do pose a threat to life, especially if they are not surgically removed,\" the study authors write.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nNow, a Swedish study suggests that radical prostatectomy \u2014 complete removal of the prostate gland \u2014 is better than \"watchful waiting\" for the treatment of younger men with low-risk prostate cancer.\nThis is important, because experts believe many prostate tumors found by PSA are likely to be slow-growing \u2014 perhaps so slow they will never cause a problem before the man dies of something else.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information comparing the rate of all cause mortality in the two groups; it also indicated that more men in the group that didn\u2019t have surgery had hormone therapy. \u00a0To be balanced, the story should have indicated\u00a0that there are commonly occurring side effects from surgery to remove the prostate such as incontinence and sexual problems.\nThe competing HealthDay and AP stories, by comparison, did a better job of this.\nThe story would have been better if it had indicated that for men with prostate cancer, taking hormone therapy means that the cancer has progressed; further providing readers with insight about the absolute rates at which men in the two groups needed hormone therapy would have provided a more complete picture.", "answer": 0}, {"article": "This data can be sent to a mobile phone.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\n\"This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,\" Kalantar-zadeh said.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published study mentions \u201cno reported adverse events,\u201d but the news release does not address harms.\nHarms are relevant since we\u2019re guessing many readers might be wary of swallowing an electronic transmitter and hope \u201cthis too shall pass\u201d (without incident).\nAnother harm that isn\u2019t mentioned is the risk of false-positive findings that may\u00a0lead\u00a0to unnecessary antibiotic treatment for some people. Such treatment poses risks to individual patients and contributes to the growing problem of antibiotic resistance.", "answer": 0}, {"article": "Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\n\u201cChronic kidney disease now affects about 10% to 13% of the adult population and substantially increases risks of cardiovascular complications and early death,\u201d said Prof. Strippoli.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any harms. Some of the \u201cclassic\u201d dietary recommendations have a small harm profile (potassium, protein), and this is also not discussed.", "answer": 0}, {"article": "Another took part in an exercise program.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nBut soon that level of activity often comes to a crashing end and patients can relapse dramatically, even becoming bedridden for several days or longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no attempt to quantify harms, even though harm rates were mentioned in the study. It does talk about the potential harms, though, in quoting a physician who treats chronic fatigue patients in Salt Lake City.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\n\"This suggests that MRI finds breast cancers that also mammography would find, but MRI detects them earlier, and it finds the cancers which, if MRI had not been done, would have progressed to interval cancers.\"\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not state any potential harms of MRI screening. False positives from MRIs aren\u2019t uncommon and can lead to anxiety and additional invasive testing. That\u2019s harmful for patients.\nWe\u2019d like to see news releases and stories start to acknowledge potential harms, particularly since the country is moving toward more universal breast cancer screening with MRI.\nOver the past few years, studies have been coming out noting concerns about the gadolinium (a heavy metal) contrast material that is used during breast MRI. The contrast is necessary to demonstrate areas of increased tissue vascularity (the state of blood vessel development and functioning). Recent reports note that gadolinium may deposit in the brain. We do not know the long-term significance of this. The FDA is studying the effects \u2014 if any\u2013 on \u201crepeated use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI).\u201d", "answer": 0}, {"article": "Among them: bringing out Lipovitan Junior, a caffeine-free version for children.\nBut another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\nThe study found that test subjects given 5-Hour Energy experienced \u201cenergy\u201d for about 40 minutes longer than when given Red Bull or Monster Energy, though it was not clear from court papers whether that difference reflected the energy shot\u2019s higher levels of caffeine.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly\u00a0acknowledges that energy drinks have been linked to\u00a0reports of deaths and\u00a0injuries that may be related\u00a0to their high caffeine content, and there was an online link in the text to a previous story about these concerns. We\u2019ll call this good enough for a satisfactory. However,\u00a0considering that FDA reports\u00a0suggest that 18 deaths and more than 150 injuries\u00a0may be related to energy drinks, we don\u2019t think the story captures the full scope of the potential problem.\u00a0This deficiency was nicely described by Paul Raeburn at the Knight Science Journalism Tracker, who\u00a0noted that\u00a0in a 2,000-word piece, there was ample room\u00a0to do \u201ca more thorough job of reminding offline readers why these drinks have provoked concern.\u201d\nAdditional comment about kids and teens and use of these drinks along with alcohol would have strengthened the article.", "answer": 1}, {"article": "Autism has always been a tricky disorder to diagnose.\n\"Why some toddlers with ASD get better and develop good language and others do not has been a mystery that is of the utmost importance to solve,\" Eric Courchesne, one of the study\u2019s authors and co-director of the University of California-San Diego's Autism Center, said in a statement.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nIn an article published Thursday in the journal Neuron, scientists at the University of California-San Diego have found that children with autism spectrum disorder, or ASD, with good language outcomes have strikingly distinct patterns of brain activation as compared to those with poor language outcomes and typically developing toddlers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided no description of potential harms from this scanning approach. The chief potential harm would be a false positive or false negative scan. If the scan is wrong, that may trigger unnecessary additional anxiety or false reassurance for parents regarding their child\u2019s likely outcome. It may also lead parents and doctors to implement the wrong kind of therapy for autistic children. The researchers on this study have suggested that\u00a0non-verbal therapies may be more appropriate for the children whose scans suggest they are not \u201clanguage-ready\u201d (and vice-versa). But if the scan is wrong, these children may be offered the wrong kind of treatment \u2014 possibly leading to a worse outcome than if they hadn\u2019t been scanned at all.\nThe story also could have noted some of the challenges involved with getting MRI images on young children. MRI scanners make loud banging noises which can be frightening to children and sedation is sometimes required. \u00a0The researchers in this study were able to do the scans while the children were asleep, which didn\u2019t require sedating the children.", "answer": 0}, {"article": "And the study had one particularly unexpected outcome.\nThe advantage of a passive sensor is \"these things are done kind of autonomously so you don't need to do much except check when the resting heart rate starts coming up,\" Clue's head of scientific research, Dr. Vedrana H\u00f6gqvist Tabor, told BuzzFeed News.\nThe devices also showed that resting heart rate spiked shortly before ovulation began, according to the Berlin company, which presented data from the small, preliminary study at the European Society of Human Reproduction and Embryology's annual meeting this month.\nAnd while resting heart rate can be a tell-tale sign of ovulation, Lea von Bidder, CEO of Ava, says consumers shouldn\u2019t rely on that measurement alone if they\u2019re serious about getting pregnant.\nBut Don't Think Of This As Birth Control Even though Clue\u2019s marketing director happened to find out she was pregnant from her Fitbit, the point of the study was to demonstrate that it's possible to use Fitbit as a conception tool, not as a pregnancy test, H\u00f6gqvist Tabor said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear what any potential harms might be in this case, though one possibility is that some women may delay taking steps to diagnose possible fertility problems in order to use this technology. Another possible \u201charm\u201d is the bother and cost of using this device by\u00a0women who would become pregnant anyway without any problem.\nWhile the story doesn\u2019t address those issues, we give kudos to the story for addressing another possibility: that women may use the technology to track their ovulation cycle in order to avoid becoming pregnant. The story tackles this issue head on.", "answer": 1}, {"article": "But the mind is a powerful thing.\nAnd in a large Italian study of people who complain of gastrointestinal problems, the authors conclude that NCGS is slightly more common than celiac disease, putting it at a prevalence of a bit above 1 percent of the population.\nThe second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nThe authors found that 40 percent of patients on the entirely gluten-free diet reported a continuation of symptoms, compared with 68 percent of those who had consumed gluten.\nIf you don\u2019t have celiac disease or a wheat allergy and are experiencing distressing gastrointestinal symptoms after eating gluten \u2014 lack of satisfaction with your stool consistency, for example \u2014 there is something like a 1 in 30 chance that the gluten is potentially responsible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address the fact that adopting a gluten-free diet can pose nutritional risks. As a Harvard Medical School post notes, \u201ccutting out [gluten-containing] products may mean you\u2019re reducing your fiber intake from whole grains, or missing out on vitamins that you\u2019d normally get from fortified foods.\u201d For example, a 2000 study that compared the diets of a healthy control group with celiac disease patients who had gluten-free diets found that, among other things, \u201cthe diet of the [celiac] patients was unbalanced, with a higher percentage of energy as fat and a lower percentage of energy as carbohydrates.\u201d Children would likely be most impacted by nutritional deficits from a restrictive gluten-free diet.", "answer": 0}, {"article": "The worms were getting rave reviews.\n\"At age 11, I developed this condition, called alopecia areata, where I lost my hair,\" says Velasquez-Manoff, a science writer in Berkeley, Calif. \"It started in patches, but eventually I lost it all.\"\nThe bottom line: \"The proportion of patients who improved with the worms was no different than the proportion of patients who were improved with placebo,\" says Dr. Stephen Hanauer at Northwestern University Feinberg School of Medicine, who was involved with one trial.\nWhen you first meet Moises Velasquez-Manoff, the first thing you notice is his hair \u2014 or the lack of it.\n\"They basically ride your bloodstream back through your heart, into your lungs,\" where they hang out for a while, Velasquez-Manoff says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says one person found that having worms in his body \u201cwasn\u2019t pleasant,\u201d and he experienced diarrhea and cramps. But potential risks are not adequately addressed. According to a story in The New York Times Magazine, for example, severe whipworm infection can result in anemia, clubbed fingers and stunted growth in children.", "answer": 0}, {"article": "THURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\nAll had already undergone at least one failed drug regimen.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nAtrial fibrillation accounts for between 15 percent and 20 percent of all ischemic strokes, with stroke risk rising fivefold among patients with the condition as compared to healthy men and women, the release noted.\nFor more on irregular heartbeats, visit the U.S. National Library of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms. ", "answer": 0}, {"article": "Dr. Wheeler has authored over 200 peer-reviewed articles a number in top tier journals.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThrough its partnership with the New Mexico Cancer Care Alliance, an \u201cexemplary national model for cancer health care delivery,\u201d the UNM CCC offers access to more than 175 clinical trials to New Mexicans in every part of the state.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nOne of the premier cancer centers nationwide, the UNM CCC has more than 125 board-certified oncology physicians, forming New Mexico\u2019s largest cancer care team.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention harms, and that\u2019s a troubling omission in a summary of a study devoted to a drug\u2019s safety and efficacy. The published study states the following:\n\u201cSerious adverse events related to vaccination occurred in five (0\u00b72%) of 2877 women in the vaccine group and eight (0\u00b73%) of 2870 women in the control group.\u201d", "answer": 0}, {"article": "\u201cWhy not open it late?\nLike a lot of things in medicine, however, when you actually test it in an organized way, in a randomized, controlled trial, you find out it doesn\u2019t work.\u201d\n\nHe added, \u201cIt will change what I do.\u201d\n\nIn an editorial accompanying the study in the journal, two other cardiologists say that late angioplasty may still be worthwhile for some patients.\nThe ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nThe findings may come as a rude surprise to many cardiologists, who have come to believe that opening a blocked artery, even days or weeks after a heart attack, is bound to be good for patients.\nAlthough angioplasty is not open surgery, it is an invasive procedure with risks, and the researchers wanted to know if there was any reason to put these patients through it when they seemed to be on the road to recovery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms associated with the use of drug coated stents were presented in this story.\u00a0 The reader needed to infer that a harm associated with stents was the propensity of the artery to \"close again\".\u00a0 Ideally, a story should mention both the frequency and severity of adverse effects.\u00a0 But since the focus of this story was on a study showing that the rates of heart attack and death were comparable for different approaches\u00a0 (\"either heart medicines only or balloon treatment and stents with heart medicines\"), we consider this as satisfactory. \n\u00a0\n\u00a0", "answer": 1}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nAlthough the study can\u2019t prove that getting a scan caused the extra medication use, the gap could not be explained by differences in risk factors for heart disease, such as cholesterol levels or smoking.\nBy contrast, it\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer.\n\u201cPhysicians cannot easily ignore diagnoses made with screening tests because it is impossible for them to determine whether their patients have real disease or pseudodisease,\u201d Lauer notes.\n\u201cOverdiagnosis is threatening to become an increasingly important public health problem because of the enthusiasm for and proliferation of unproven screening tests,\u201d Lauer writes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the competing Wall Street Journal story, this story was clear about the potential harms: \u201cit\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer. And the dyes used to enhance the images cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nExisting therapies for excessive underarm sweating, also called axillary hyperhidrosis, offer limited effectiveness and can be expensive.\nOral medicines can be used to systemically limit sweating.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, and given the lack of details on what the topical medication is made of, it would be difficult find out via independent research.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nSiliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We could have rated this release unsatisfactory on this criterion, since no numbers are given about the extent of the problems found in the trials. But we\u2019ll give it the benefit of the doubt because of the extent of discussion on potential harms \u2013 despite the absence of numbers.\nThe release mentions that completed suicides occurred in patients treated with Siliq during clinical trials, which is why the drug\u2019s label will include a boxed warning. Although the release states cause and effect hasn\u2019t been established, some patients \u2014 especially those with a history of depression \u2014 seemed to show an increased risk for suicidal ideation and behavior.\nThe release uses language that may confuse readers\u00a0about harms. In one place it says \u201cA causal association between treatment with Siliq and increased risk of suicidal ideation and behavior has not been established\u201d and in the next sentence claims that \u201cBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Black Boxed warning\u2026.\u201d\nPatients may also experience more infections, or allergic/autoimmune conditions, as Siliq targets the immune system. Other side effects associated with the drug include joint pain, headache, fatigue, diarrhea, throat pain, nausea, muscle pain, injection site reactions, influenza, low blood cell count and fungal infections, the news release adds.\nAlthough we would have liked to have seen some numbers indicating how often these side effects occurred, and clarity about whether or not they were observed, we believe the news release does an adequate job addressing harms, as a significant chunk is devoted to this issue. This is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "But such evidence often does not pan out in human studies.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\nBut the guidelines do recommend metformin first.\u201d\n\nFor patients with Type 2 whose doctor started them on a drug other than metformin, he said, \u201cI certainly would encourage people to talk with their doctor.\n\u201cPlain old metformin given in the same dose as we do for Type 2 diabetes doesn\u2019t seem to be a breakthrough for cancer, at least for pancreatic cancer.\u201d\n\nMany other metformin clinical trials are underway for breast, colorectal, endometrial and other cancers.\nSo much metformin is taken in the United States \u2014 some 72 million prescriptions were written for it in 2013 \u2014 that a recent study found higher trace levels of it (presumably from the urine of people taking it) in Lake Michigan than of any other drug, including caffeine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The implication of this story is that metformin may help others besides those with type 2 diabetes. Other groups mentioned in the piece include those with type 1 diabetes, polycystic ovary disease, dementia, cancer and simply those who are aging (ie. everyone). The only side effect mentioned is stomach upset. So one could arguably conclude that everyone should be on this medicine. Not mentioned are the potentially dangerous side effects of metformin. Specifically it should not be given to those with acute or chronic kidney disease (a condition that commonly goes undetected). It can induce lactic acidosis which can be serious, even life-threatening. This is so well known that metformin is commonly held when patients are admitted to the hospital with an acute illness.", "answer": 0}, {"article": "Accessed October 2013 from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.jsp [5] Flum, D. R., et al.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\n[3] The risk of death is about 0.1 percent[4] and the overall likelihood of major complications is about 4 percent.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release reports that one trial participant had a gastric ulcer and almost all reported mild to moderate cramping and nausea, the release doesn\u2019t warn readers that this sort of balloon could cause serious, even fatal, complications including esophageal tears, intestinal blockages that require surgery, life threatening allergic reactions, heart attack, cardiac arrest or airway blockage. The FDA approved a package insert that lists these potential risks (see page 11 of the Patient Labeling). The release should have also mentioned the most important risks.", "answer": 0}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cWhile additional study and longer follow-up are necessary to confirm the optimal dose for single-fraction HDR brachytherapy, we are optimistic that the single-treatment approach can eventually become a standard practice for prostate cancer treatment.\u201d\n\nFor more information or a copy of the full study, contact ASTRO\u2019s media relations team at press@astro.org.\n\u201cIt is becoming apparent that patients may be treated definitively for their prostate cancer in as little as a single day with a minimally invasive outpatient procedure,\u201d said lead study author Daniel J. Krauss, MD, a radiation oncologist at Oakland University\u2019s William Beaumont School of Medicine in Royal Oak, Michigan.\nThe median patient age was 63 years (range 43-73), and 91 percent of the patients presented with stage T1 disease.\nWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release provided detailed information on harms: \u201cWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%). No patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity. Rates were similarly modest for long-term side effects. Six patients (10.3%) experienced chronic grade 2 urinary toxicity and one patient (1.7%) experienced grade 3 chronic GI toxicity that subsequently resolved. No patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.\u201d\nBut given that many oncology experts would consider the treatment unnecessary, any level of toxicity\u00a0could be considered unacceptable.\nThe lay reader would have benefited from a description of what \u201cgrade 2 or grad 3+\u201d levels of toxicity means.", "answer": 1}, {"article": "The key asset Pfizer wanted?\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nA few weeks ago, the Food and Drug Administration granted Tesaro\u2019s drug fast-track approval status \u2014 and this new data will support its registration applications to both the FDA and the European Medicines Agency, Tesaro CEO Lonnie Moulder said.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\nIn recent days, the researchers behind three PARP drug contenders threw down preliminary data during the European Society for Medical Oncology conference in Denmark.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story about the side effects or harms traceable to either the three new drugs, or to the one approved drug also mentioned for the treatment of ovarian cancer.\u00a0 A quick web search yields a host of possible side effects, including nausea, anemia, fatigue, joint pain and many others. Especially with stories touting potential new drugs, information should be provided about potential harms the medications may present, not just the positive results of taking the drug.", "answer": 0}, {"article": "The American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\n\"Anytime you can take someone who comes into the hospital after having cardiac arrest, who may not ever wake up, and you can potentially change that to someone who can wake up and become back the person they were the day before, it's an amazing thing,\" says Dr. David Likosky, a neurologist.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\nIn medicine, in general, we have many very expensive treatments that may make a marginal difference \u2014 treatments that are potentially painful, that cost a lot,\" Likosky says.\n\"Every time I hear this story, I get goose bumps,\" Cowles says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms that might be associated with hypothermia treatment after a heart attack.\u00a0 There was no discussion of\u00a0conditions or medication use that might lessen or eliminate the benefit that this treatment might confer.\nAlthough one of the clinicians said \"ice packs can do the job\", there have been some studies to suggest that the percentage of surviving patients is lower in the group whose temperatures went too low.", "answer": 0}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All surgeries carry the potential for harms. None of the harms were discussed in this story.\nThe story does not provide a true picture of the process involved in the two patients.\u00a0 Prior to the 8 hour transplant procedure, the patients underwent harvesting of leg hair, \u201c\u2026once or twice daily for a variable period of 6 weeks to 6 months before surgery.\u201d", "answer": 0}, {"article": "\"WE FOUND THAT [TYLENOL] IS INEFFECTIVE ON BOTH PAIN AND DISABILITY OUTCOMES FOR LOW BACK PAIN\" A 2015 systematic review of high-quality evidence, published in the BMJ, found that acetaminophen didn't seem to help most sufferers of chronic low back pain, and that it barely alleviates pain in people with osteoarthritis.\nThe study also noted that patients on acetaminophen \"are nearly four times more likely to have abnormal results on liver function tests compared with those taking oral placebo.\"\nNow, Moore was referring here to acute pain that strikes after a specific event, like a surgery, a cut, or a burn, but his message was simple: Ibuprofen seems to work best, followed by acetaminophen, and then aspirin.\nEither the outcomes in studies are badly defined, the studies have too few participants to say anything concrete, or many people in the studies actually seem to have chronic headaches as opposed to the ordinary ones the researchers are allegedly studying.\nThere's also some evidence that NSAIDS may increase the risk of psychosis and cognitive impairment in the elderly, so doctors may avoid prescribing these drugs for older patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story comprehensively describes the harms from each drug based on different uses and patient populations. We especially liked this quote:\u00a0\u201cDon\u2019t believe that just because something is over-the-counter, it\u2019s safe.\u201d", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is another example of a story about a screening test that didn\u2019t provide any information about the potential harms associated.\u00a0 While there are those who believe that the hs-CRP alone warrants drug treatment, this is not a universally held view.\u00a0 While the statins are relatively safe, they are not without potential side effects and are relatively expensive for the twenty plus years of potentially unnecessary treatment", "answer": 0}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis can make a difference to other patients, so I am glad to be the first one helping them with my experience.\u201d\n\nAs soon as the donor kidney was reattached to the patient, it turned ruby-red and started to pour out urine, indicating that it was functioning well.\n\u201cIt behaved like a normal kidney, despite it being an extended criteria donor kidney.\u201d\n\nHe points out blood tests within 48 hours showed that the kidney was removing wastes and excess fluid from the blood normally.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nThe technique, unique solution, and device are part of a Phase I clinical trial at Toronto General Hospital (TG), University Health Network (UHN), assessing the safety of the device, with subsequent phases examining its efficacy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplantation poses a number of risks, from infection to rejection of the donor organ to the kidney failing to work normally. The release refers to the phenomenon known as \u201csleepy kidney,\u201d in which a newly transplanted organ takes some time before it begins functioning. However, it doesn\u2019t address other health risks in a meaningful way, not does it offer any insight into how the new technique may affect those risks. Could ex vivo organ perfusion reduce those risks? Increase those risks? We\u2019re not told.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\"The biggest problem we face in preventing stroke in patients with atrial fibrillation is that almost half of patients don't take any blood thinner at all,\" Bernstein said.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nLOS ANGELES, Feb. 19, 2016 - A new medication reverses the blood-thinning effects of the anticoagulant dabigatran in patients suffering a brain bleed, potentially limiting the extent of bleeding, according to research presented at the American Stroke Association's International Stroke Conference 2016.\nIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that idarucizumab \u201cdoesn\u2019t seem to carry with it any tendency to increase clotting,\u201d but does not tell readers anything else about potential harms. Could idarucizumab contribute to other problems? Readers don\u2019t know. Even if there are no health risks associated with idarucizumab, it\u2019s important to tell readers that. And, according to the Praxbind website, there are potential adverse effects.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention harms of transplant at all. Harms could include those from surgery itself, like problems with anesthesia, infection, and bleeding, and harms also include life-long effects of immunosuppresive therapy, which increase risk for infection, involve taking drugs every day for the rest of your life, and have other side effects. The story paints a very rosy picture of transplantation and is not balanced. One patient who is donating her kidney claims it\u2019s \u201cjust a 3 inch incision,\u201d which minimizes what\u2019s involved, especially for the donor. Often, donors have more pain post-operatively and a longer recovery period than the recipients. Plus, this quote minimizes other potential harms to the donor, such as what happens if her one remaining kidney fails? ", "answer": 0}, {"article": "He was not involved in the research.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explicitly discuss harms from a potential \u201csniff\u201d test by dogs or machines imitating dogs.\u00a0 It does discuss contradictory research on whether cancer-sniffing dogs can achieve high accuracy. The obvious \u201charm\u201d of inaccuracy is that a patient goes untreated for cancer, or conversely, is exposed to invasive testing because of a false positive. Without early detection by dogs, patients are already getting exposed to tests such as computer tomography and bronchoscopy.", "answer": 0}, {"article": "\"But my question here is, 'Is there a real benefit?'\"\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n\"So if there's no targeted treatment to follow up on the results of this kind of scan, then it's just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does something worse than failing to quantify the potential harms of MRIs. It allows an autism activist to say, \"I\u2019m always glad to see there\u2019s more autism research underway, and there\u2019s certainly no risk to having an MRI.\" No risk? At the very least there is the potential for MRIs to lead to unnecessary procedures. A recent study showed, for example, that there was a direct correlation between the availability of MRIs in an area and the number of back surgeries. The study\u2019s authors concluded, \"if increased MRI availability is associated with increased early use of low back MRI as well as with subsequent use of low back surgery, both of which have questionable clinical benefit, then widespread MRI diffusion may put patients at risk of a decrease in the quality of care they receive.\" Another risk is for renal injury when MRI is performed with contrast dye.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story\u2013although weight loss medications were discussed.", "answer": 0}, {"article": "Side effects among patients taking the drug were similar to the placebo group.\n\"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease,\" said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.\nAnd, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last,\" he added.\n\"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder,\" Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cSide effects among patients taking the drug were similar to the placebo group.\u201d Dr. Alessandro Di Rocco also agrees with this statement, since the \u201ccompound is apparently well tolerated without significant side effects.\u201d However, the story could have been more thorough in letting the reader know exactly what those side effects are.", "answer": 1}, {"article": "Stanford\u2019s Department of Medicine also supported the work.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nOver the 24-week duration of the latest trial, 109 participants received ixekizumab every two weeks; 94 received placebo injections every two weeks; and 111 alternated every two weeks between getting injections of ixekizumab and the placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn that \u201cfew serious adverse events were reported for patients receiving the drug, or the placebo\u201d but a close reading of the actual abstract shows that 7 percent of patients taking the drug every two weeks (versus 3 percent on placebo) had serious adverse\u00a0events. If the absolute effects on benefits are reported why are not the absolute effects of the harms? We think it is important to at least list the major adverse events that occurred during the trial.", "answer": 0}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cThis was far greater than expected.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\nMen got a good result but women got a fantastic result,\u201d he said.\nIt is the leading killer of women in the United States, claiming more women each year than men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the use of the device.", "answer": 0}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\n\"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients,\" said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.\nBut the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.\n\"This gives us some confidence that annual PSA screening is going to soon become a thing of the past,\" said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference.\nDutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential for harm associated with adopting any of the\u00a0aspects of prostate cancer testing and treatment covered in the story were not clearly or completely discussed.\nFor example \u2013 what are the consequences of a surgeon not being proficient with robotic surgery?\nWhat are the side effects for the medication Avodart? How often are they seen?", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\n\"Psoriasis and psoriatic arthritis are chronic inflammatory conditions that can be quite uncomfortable and often painful for patients, so any treatment that might reduce symptoms may improve quality of life,\" says lead study author Soumya Reddy, MD, an assistant professor of medicine in the division of rheumatology at NYU Langone, and co-director of NYU Langone's Psoriatic Arthritis Center.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\n\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\nResults were even more pronounced in those with severe disease activity, with scores falling from 7.7 before surgery to 5.7 after for patients with severe psoriasis, and from 8.2 to 4.8 after surgery for patients with severe psoriatic arthritis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Sadly, no harms related to bariatric surgery were mentioned, nor were the likelihood of complications due to the surgery and the rate of reversals that are often necessary.\nPsoriasis is an important problem but clearly bariatric surgery would not be a first-line treatment for the condition. The trade-offs in terms of risks of complications and required lifestyle changes after bariatric surgery are critical considerations for a patient hoping to reduce their psoriasis symptoms.", "answer": 0}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nThe result: The relative risk for squamous cell carcinoma was found to have dropped by 15 percent among those Danes who had filled more than two NSAID prescriptions, compared to those who had filled two or less.\nThe researchers pointed out that the NSAID-cancer connection could be affected by a range of lifestyle factors they did not account for, such as an individual's specific skin type or sun exposure patterns.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the harms associated with long-term use of aspirin, including bleeding in the gastrointestinal tract and brain. The suggestion that \u201cmost\u201d people are already taking aspirin for cardiovascular disease prevention is also potentially misleading, since regular aspirin use is recommended primarily for those at higher risk of heart disease.", "answer": 0}, {"article": "She told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nBefore the surgery, she could only make out the biggest letters on the first few lines.\n\"Since I was a child, I hoped that in America, one day maybe there would be a cure for my disease,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a small hole that formed in one eye, thought not to be clinically meaningful.\u00a0 There is also not enough emphasis that this is a short term (weeks to months) trial and that problems (or improvement)\u00a0may well develop after a delay. The story also did not mention the past history of deaths which have been associated with some gene therapy trials. \u00a0", "answer": 0}, {"article": "\u201cIt\u2019s really recommended to replace white rice with the same amount of brown rice or other whole grains.\u201d\n\nThe researchers who did the study analyzed rice consumption among 39,765 men and 57,463 women who participated in the Health Professionals Follow-up Study and the Nurses\u2019 Health Study I and II; participants in the three groups ranged in age from 26 to 87.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\nAnd those who eat white rice on a regular basis \u2014 five or more times a week \u2014 are almost 20 percent more likely to develop Type 2 diabetes than those who eat it less than once a month.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms discussed, but both of these food choices are safe and likely to be well tolerated. ", "answer": 2}, {"article": "Wolchok says manufacturers of both drugs (Genentech's vemurafenib and Bristol-Myers Squibb's Yervoy), which also funded these studies, have agreed to work with researchers to study how these drugs are tolerated by patients when taken together, giving doctors even more possible treatment options.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\nForty-eight percent of patients on vemurafenib had substantial tumor shrinkage that lasted for more than a month, compared to 5.5% of patients in the chemotherapy group.\nPatient advocates like Tim Turnham, executive director of the Melanoma Research Foundation, are thrilled because \"the incidence of melanoma is going up all over the world and the treatment landscape has been terrible.\"\nPatients on vemurafenib saw the drug work within 72 hours and 84% of the patients were still alive after six months, compared with 64% of patients getting dacarbazine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a single word about potential harms, as opposed to a New York Times story, which described \u2013 variously for the two drugs:\nAgain, is this not worthy of at least a line?", "answer": 0}, {"article": "Doctors, however, are unlikely to rush to change clinical practice.\n\u201cThis may also be why the rate of major cardiovascular events during follow-up was no lower in the fatty acid groups than in the placebo group.\u201d\n\nAll the men and women in the Dutch study were aged between 60 and 80 and had suffered a heart attack roughly four years previously.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nDespite the overall negative results, researchers did find there was a reduction in repeat heart attacks and other cardiovascular events in women who took ALA margarine, although this was not statistically significant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We always think harms should be addressed \u2013 even the absence of harms.\u00a0 Consumers need to be educated that no product making health claims is cost-free or harm-free.\u00a0 The story did not mention that there did not appear to be any differences among the various groups in terms of harms. \u00a0But since there were no differences, we\u2019ll simply rule this Not Applicable. ", "answer": 2}, {"article": "With 25 years of specializing in natural phospholipid research, development and production, Lipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data, technical quality and safety to meet the growing demand for natural cognitive health solutions.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\n\"Based on these strong results, we improved the formulation and applied for a patent in the US market,\" explains Rutenberg.\nUp to 80% of women report having some symptoms prior to menstruation.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no description of potential harms. The company CEO is quoted saying there are \u201cno reported side-effects.\u201d\nHowever, a look at a commonly used scientific database for CAM product ingredients reveals there are side effects associated with phosphatidilserine, the active ingredient found in the product. Those include nausea, gastric distress and insomnia. There also may be an increased risk for acquiring infectious diseases, such as bovine spongiform encephalopathy (mad cow disease) if the phosphatidilserine is derived from bovine cortex, according to the database site.", "answer": 0}, {"article": "The blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\nAbout 28,000 die of it, making it the most common cancer and second-leading cancer killer among men.\nMen at high risk for prostate cancer, such as African Americans and those with a family history of the disease, are the most likely to benefit from PSA screening.\nBut the panel concluded that the evidence remains inconclusive for those men as well.\nBut it remains unclear whether that translates into a reduction in the death rate from the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without quantifying the frequency, the story mentioned the common side effects of treatment for prostate cancer.", "answer": 1}, {"article": "The team of scientists at Imperial was funded by Cancer Research UK.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nAs well as breast cancers, cancers such as acute myeloid leukaemia and small-cell lung cancer are particularly transcription-dependent, so ICEC0942 may work well for these too, especially where they have become resistant to other treatments.\nThe discovery of the drug was spurred by an initial meeting between Professor Anthony Barrett, from the Department of Chemistry, and oncologist Professor Charles Coombes from the Department of Surgery & Cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms that might preclude this treatment from coming to market.\nFrom other examples of cancer drugs, it is most\u00a0likely that there\u00a0would be some undesirable effects and the release could have at least acknowledged that harms are unknown.\u00a0  ", "answer": 0}, {"article": "Is a drug really needed for what seems like a trivial use?\n\u201cIt is reversing the epinephrine.\u201d\n\nThe label for the hypertension drug phentolamine contains warnings about heart attacks and occlusion of blood flow to the brain.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nOraVerse does the opposite, dilating the blood vessels and speeding up blood flow so the anesthetic can be carried away.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that when used for high blood pressure the drug can cause heart attacks and occlusion of blood vessels in the brain. \nBut the report does not challenge the drugmaker\u2019s claim that those side effects would not apply for this use of th drug. And again, since the data is unpublished it is a leap of faith to accept this conclusion. ", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n\n\nThe story does warn of risks. However, it doesn\u2019t tell readers how common they are. In fact, the researchers reported that 85 percent of patients reported at least one adverse event and that problems (including hospitalizations) occurred often enough in the first few weeks after treatment that it was only when researchers disregarded those treatment-related problems that they saw a net benefit during the first year. The researchers say their longer-term follow-up indicates patients report ongoing benefits according to some of the research measurements, but the story should have pointed out that the potential gains come only after enduring several weeks of recovery and elevated risk.\n", "answer": 0}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions re-operation due to infection and pain, mechanical failures and discomfort as harms of the implanted device.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that no serious side effects have been reported.", "answer": 1}, {"article": "\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nNor do the study authors advise drinking as a cure for arthritis.\nAlcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nThe association was seen in both men and women, though it was stronger in males.\n\"This actually isn't a new concept.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms of alcohol consumption. ", "answer": 0}, {"article": "Abstract 375: Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.\n\"Image-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\" said Raman.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated, \u201cResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\u201d\nSince this was a safety trial, we expected more detail on what those expected side effects were.\nWere \u201cexpected side effects\u201d the same as those observed in patients getting T-VEC for melanoma? Are the flu like symptoms the worst?", "answer": 0}, {"article": "The test means having kids measured before a season starts, to establish a baseline.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\n\"I wasn't worried,\" Aldrich says, \"until my doctor and my mom were, like, hinting that if this happens again I probably won't ever be able to play soccer again.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe broadcast does not mention potential harms of using the Impact system. Testing could cause an athlete needless anxiety. Unnecessarily withholding an athlete from play increases inactivity and the risk of depression. It is unclear who owns the sensitive information and how it is protected.\u00a0 And it is unclear whether the recommendation to wear headgear might make head-to-head collisions more dangerous for other players. \n", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative data indicating that the rate at which blood clot formation occurred after implanting the new stent was comparable to the rate with one of the currently available drug-eluting stents. \u00a0However there was no information about how the harms with this new stent compared with bare metal stents or no stent at all.", "answer": 0}, {"article": "Researchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\n\u201cIn a sense it\u2019s a necessary micronutrient and we need it, but we might be (in) a situation where we have enough \u2014 we might even have too much.\u201d\n\nSelenium is found in meat, bread, and some nuts.\nLast week, a review of prior studies suggested that selenium probably doesn\u2019t help prevent cancer, but might be linked to an increased diabetes risk at high doses (see Reuters Health story of May 11, 2011.)\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that high levels of selenium have been linked with\u00a0increased risk of type 2 diabetes. It notes that no serious side effects were reported with selenium use in this particular study, but it\u00a0should have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use. It might also have noted that selenium supplements have the potential to cause a rare syndrome called selenosis when taken at very high doses.", "answer": 1}, {"article": "\u201cWill these peptides actually induce tolerance in people?\nIf the approach succeeds in human studies, it may one day lead to more targeted treatments not only for multiple sclerosis but also for other kinds of autoimmune disorders, including type 1 diabetes and rheumatoid arthritis.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nThe study was funded by grants from the National Institutes of Health, the Myelin Repair Foundation, the Juvenile Diabetes Foundation, and the Australian government.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unfortunately, the story bounces from an older approach, using white blood cells, to the use of microparticles.\u00a0 So, it is easy to get the wrong impression of results.\u00a0 Harms were not addressed in the results of the study using microparticles.\u00a0 Dr. Miller\u2019s quote, \u201c\u201dThere [were no side effects], there was no re-triggering of disease, and we actually showed that immune responses in patients were decreased,\u201d were related to the ongoing and unpublished study using white cells as carriers.", "answer": 0}, {"article": "In this first-in-humans trial, she is Patient No.\n\u201cThere\u2019s a lot that still needs to be worked out.\u201d\n\n[Here\u2019s what you need to know about immunotherapy]\n\nComplications can be lethal; one clinical trial was briefly halted in July after three young adults died of brain swelling.\nIt\u2019s too soon.\u201d\n\nScientists have wanted for decades to marshal the immune system to vanquish cancer, but their attempts have mostly been frustrated.\nHer mother added, \u201cWe just need this to work and to stay working.\u201d\n\nNCI\u2019s Fry is careful not to make any promises about an extended remission.\nIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale or will produce the lasting remissions that everyone hopes to see.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses potential harms. Early on, the it notes that \u201ccomplications can be lethal,\u201d and refers to a study in which several patients died due to brain swelling. Much lower down, the story refers to one patient\u2019s \u201cintense immune reaction that followed treatment,\u201d involving a fever of 106 degrees Fahrenheit. Those aren\u2019t all the risks, but it\u2019s some of the major ones.", "answer": 1}, {"article": "Jessie Quinn of Sacramento was 36 years old when loss of appetite, weight loss, some eye issues and finally pelvic pain sent her to the emergency room in 2010.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\n\u201cWe can find cord-blood donors for 99 percent of patients who cannot find a donor.\u201d\n\nQuinn was hospitalized for 30 days, and she said the recovery was difficult but relatively uneventful.\n\u201cHe decided he would be focused on being the patient and said, \u2018Do whatever you have to do with me because I want to walk my girls [who were then 12 and 16] down the aisle.\u2019 \u201d\n\nOn advice of their hematologist, the Gordons traveled to Hutchinson, which has established a national reputation as a bone-marrow transplant center, but quickly discovered there was no good donor match.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely raises the risk of cord blood transplantation and the risk of standard cancer therapies throughout the piece. For example, it says, \u201cBecause each umbilical cord produces only a tiny number of stem cells, umbilical-cord transplants take longer to work than standard transplants, which makes patients more likely to get fatal infections. And if cells from several umbilical cords are used, the chances of immunity problems increase.\u201d\nWe do wish that the story made it clear earlier on that the new approach is preceded by intensive chemotherapy and the inherent side effects it entails.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is pretty clear on this, noting early on that \u201crecent studies have found increased rates of complication such as blood clots that travel to the lung, an increased need for blood transfusions, and a higher risk of death with the bilateral procedure.\u201d Later the story refers to two different studies. One, published earlier this year, found \u201cincreased overall complications and risk of subsequent surgery within 30 days\u201d for patients who had the bilateral replacement. The other, published in 2014, found that \u201cbilateral patients were at increased risk of both minor and major in-hospital complications as well as death.\u201d Again, it would have been great to include links \u2014 or citations \u2014 for the relevant studies.", "answer": 1}, {"article": "Lehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nDec. 1, 2011 (Chicago) -- An experimental treatment that involves spinal injections of ozone gas and steroids relieved pain in over two-thirds of 327 people with back problems related to a herniated disc.\nIn the study, 119 people (37%) reported no pain at six months.\nStudies suggest that ozone therapy works by reducing inflammation, shrinking herniated discs, and relieving pressure on the nerves bringing pain signals to the brain.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that no side effects were observed and that a small percent of patients had more pain after the injection.\nBu the story does not talk about the potential risks of ozone gas to individuals as well as the environment. Ozone is a toxic gas and one would expect that the benefit of its use as a medical treatment would need to be clearly demonstrated prior to recommending it as a routine treatment option. Even if that is done, one would want to know that this gas can be safely generated and administered without causing toxicity to those administering it and to the environment itself. In this context, the mention of no risks seen in the study needs to be taken with considerable caution.", "answer": 0}, {"article": "They were so sure cancerous nodes had to come out that they said the study was unethical and would endanger women.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\nIt is not known whether the findings also apply to women who do not have radiation and chemotherapy, or to those who have only part of the breast irradiated.\nThe complications \u2014 and the fact that there was no proof that removing the nodes prolonged survival \u2014 inspired Dr. Giuliano to compare women with and without axillary dissection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses several harms from lymph node removal, and shows that the difference in survival for women who had nodes removed and those who did not was not significant. \u201cIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit. They were also more likely to have lymphedema.\u201d", "answer": 1}, {"article": "Propping open clogged arteries with a tiny wire-mesh tube called a stent is no better at reducing the risk of heart attack or death in patients with stable heart disease than treatment with medications, according to a large new study that challenges routine use of a procedure that rapidly became standard medical practice.\nThe study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not having a heart attack or in imminent danger of having one.\nSuch patients constitute at least one-third of those undergoing the 1.2 million angioplasties performed each year, and perhaps as much as 85 percent.\nSome cardiologists who specialize in the procedures, however, argued that the study did not focus on the sickest patients who are most likely to benefit, and that the main purpose of angioplasty in many is to alleviate chest pain, not to prevent heart attacks.\nThe findings could also help fuel a resurgence of bypass surgery, which has become far less common with the rise of angioplasty.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states the procedure is considered \"safe\" but that it does carry some risks.\u00a0 However, what those risks are and their frequency or severity is not discussed.\u00a0 ", "answer": 0}, {"article": "Last Wednesday, the F.D.A.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nand Medicare to devise a plan to restrict the device\u2019s spread to places where doctors had sufficient skill to implant them safely.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions several risks of the procedure such as stroke risk and paravalvular leak, but hard numbers are missing. How many patients undergoing TAVR or conventional valve surgery suffer strokes? How common is leakage? All the story provides are generalizations: \u201cThere is some question about whether the process of inserting the new valves loosens debris that can cause strokes. One large study found a higher stroke rate in patients receiving valves without surgery compared with those receiving valves with surgery. Another large study did not find this effect. The valves also tend to leak slightly around the edges. New designs are ameliorating this problem, but not solving it.\u201d\nWe\u2019ll reward the story here for at least mentioning some potential risks. But it is disappointing that such a lengthy report includes only one-sided, glowing patient reviews of TAVR. Why is there not a single account of any patient who suffered a stroke or other serious complication?\nTo the article\u2019s credit, it also raises the issue of limited evidence about the valves\u2019 durability: \u201cFor now, evidence of the procedure\u2019s effectiveness exists only for the sickest patients and there are only five years of data on how long the valves last.\u201d", "answer": 1}, {"article": "The testing is done under medical supervision.\nBut the only way to confirm that it was safe for Jula to eat egg was to take the food challenge test.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\n\"If the symptoms were treated with just Benadryl or another antihistamine, they were considered mild or moderate.\nNow, a new study sheds light on the effectiveness of a test called a food challenge to determine whether a person can tolerate a food they once reacted to.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story explains, patients who experienced either mild or serious allergic reactions to the oral food challenge were treated with antihistamines or epinephrine respectively. For the 86% of patients who passed their food challenges with no adverse reactions, no harm was involved.", "answer": 1}, {"article": "This suggested the test could be used to tell the conditions apart.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n\u201cMoving forward, our goal is to formally validate our findings with a larger sample size that includes both adults and children for future use in the clinical arena.\u201d\n\nArticle reference: Danielle Fortuna, D Craig Hooper, Amity L Roberts, Larry A Harshyne, Michelle Nagurney, Mark T Curtis, \u201cPotential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders,\u201d PLOS ONE, DOI: 10.1371/journal.pone.0205501, 2018.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\n\u201cWe have many tests for making diagnoses, but the ones that conclusively indicate infection can often take more time than we\u2019d like, especially in cases of childhood meningitis or encephalitis,\u201d said Mark Curtis, MD, PhD, Associate Professor of Pathology, Anatomy and Cell Biology, who also works as a hospital pathologist.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Getting a \u201cspinal tap\u201d to extract a sample of CNF is nothing to sneeze at.\nAlso called a lumbar puncture, the roughly 45-minute procedure involves inserting a needle into a patient\u2019s lower back, navigating it between two spinal vertebrae, and barely slipping the tip into a sac near the spinal cord. This location allows a doctor to suck out the nervous system\u2019s fluid, which is shared from the brain case down through the spinal cord.\nBut during or after the procedure, there\u2019s up to a 25% chance that fluid will leak into nearby tissues and trigger headaches, according to the Mayo Clinic. Dizziness, nausea, and vomiting up to two days after the procedure can also occur, and the headaches can last as long as a week. Back pain can be an issue, too, as can bleeding at the site of the puncture.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm of treatment mentioned was that the patient interviewed for the story feels a little sleepy in the afternoon after treatment. \u00a0However the experience of a single individual cannot be considered sufficient information on the possible harms associated with a treatment.", "answer": 0}, {"article": "Both studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story at least mentioned potential harms and that \u201cit remains to be seen if the drug is safe for long-term, intermittent use.\u201d\nBut we think it is inadequate to simply state that those on the drug had \u201csignificantly fewer side effects.\u201d\u00a0 What does \u201csignificantly fewer\u201d mean?\u00a0 And what were they?\nBoth stories we reviewed could have talked a bit more about the experimental nature of this drug and the problems seen in the past with hormone-regulating drugs.", "answer": 0}, {"article": "Both the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\n\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any possible harms from adding pecans to the diet. A brief mention of nut allergies and the high fat and calorie content of nuts would be appropriate in a release advocating daily pecan supplementation.", "answer": 0}, {"article": "Loyola's department of urology is ranked 39th in the country by U.S. News and World Report.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe study is titled \"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomized, phase 3, non-inferiority trial.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that patients who had robot-assisted surgery spent more time in the operating room than those having open procedures (seven hours vs. six hours). It also reports overall rates of adverse effects (67 percent in the robot group vs. 69 percent in the open group), along with listing the most common problems: urinary tract infections and intestinal obstructions. It would have helped if the release had pointed out that these complication rates were not statistically different.", "answer": 1}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Along with failing to evaluate the evidence, the story completely skips the numbers attached to any harms. One study on the foam therapy does spell out the different side effects, although most of them appear minor. Perhaps most troubling to people looking mainly to get rid of unsightly veins is that 51 out of 166 people treated reported that their skin had changed color. So, perhaps, patients are trading one problem for another. It\u2019s information that, at a minimum, should be included. The story says, of the surgical approach, \u201cThe surgery can cause bleeding, bruising, nerve injuries, scarring and infection, and legs may have to be wrapped with bandages for several weeks.\u201d It needed to at least note some of the harms associated with the other approaches.", "answer": 0}, {"article": "Researchers then rated them using a well-validated scale that measures aggression and agitation.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nThen the researchers re-randomized those who did not respond to placebo to receive either drugs or placebo, and found similar encouraging results for the drug combination.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, despite the fact that significant side effects occurred during the study, and in more than one or two people \u2014 most frequently falls, diarrhea, dizziness, and vomiting. The drug is also well known to have significant side effects on heart rhythm \u2014 hence the exclusion of patients with heart rhythm problems \u2014 and also to raise the levels of commonly used drugs such as digoxin and some of the SSRI class of anti-depressant/anti-anxiety drugs.", "answer": 0}, {"article": "Vitrakvi will run further tests of the drug's safety and effectiveness.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\n\"Today\u2019s approval marks another step in an important shift toward treating cancers based on their tumor genetics rather than their site of origin in the body,\" said FDA Commissioner Scott Gottlieb, M.D.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. An FDA news release mentioned fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and elevated enzyme levels that might indicate liver damage. The FDA said patients should have regular liver tests and warned against treating women who are pregnant or breastfeeding because of potential harm to their fetus or baby.", "answer": 0}, {"article": "Alyssa Gold had planned on getting married by age 26 and having kids by age 30 \u2014 but life worked out differently.\nIt\u2019s now being called the \u201cbaby deadline test.\u201d\n\n\u201cThere are some young, healthy women who are living their lives in shape and taking very good care of themselves who might not know that their reserve strength of their ovaries is lower than it should be.\u201d said Dr. Joshua Hurwitz a reproductive endocrinologist and infertility specialist with Reproductive Medical Associates of Connecticut.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\n\u201cIf I had waited until I met my husband and we were trying now to have a child it would be a very different story.\u201d\n\n\u201cEven the best AMH level in the world is not a guarantee for someone going forward or even right now but they are good indicators for fertility,\u201d said Hurwitz.\n\u201cIt's a question of having the knowledge and awareness of keeping your options open.\u201d\n\nThe test is a simple blood analysis that usually costs less than $100.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, though they exist. To name a few, women may act upon the test results\u2013for example, undergoing invasive and expensive treatments like egg retrieval and freezing\u2013when those actions may have not been necessary. Or they may experience anxiety over test results that show low levels of the hormone, and consider themselves \u201cinfertile\u201d when that is not at all certain.", "answer": 0}, {"article": "IRE was successfully administered to all patients.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nSAN DIEGO, April 24, 2015 /PRNewswire/ -- University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife\u00ae System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.\nIt is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are alluded\u00a0to, e.g. \u201c[19] percent sustained complications with a median grade of 2 (range 1-3),\u201d but they\u2019re not discussed or explained in sufficient detail. What\u2019s a \u201cmedian grade 2\u201d complication? It would have helped this release to cite, for example, the\u00a0American Cancer Society\u00a0on the side effects of\u00a0ablative therapies for pancreatic cancer. Generally, according the ACS, those harms can \u201cinclude abdominal pain, fever, nausea, infection, and blood clots in nearby blood vessels\u201d with a\u00a0potential for serious complications.", "answer": 0}, {"article": "Doctors numbed the lower half of O'Brien's body.\nTraditional knee surgery cuts through muscles and tendons.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nScar tissue from previous surgeries and arthritis were removed before she was fitted with the prostheses which will act as her new knee.\nFive hours after surgery she said she was feeling great.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms resulting from this procedure.", "answer": 0}, {"article": "No relationship was observed between exercise and later anxiety, but the researchers did find a link between exercise and later depression.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\nBut when it comes to mental health benefits, \u201cthe majority of the protective effect comes from the first one or two hours of exercise each week,\u201d said study author Samuel Harvey, associate professor of workplace mental health at the Black Dog Institute and the University of New South Wales, in an email.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this N/A since the risks associated with light exercise are fairly minimal. However, we think it\u2019s always a good idea to discuss the potential harms of an intervention. In this case, the story implies that very light and infrequent exercise provides this benefit. Does this encourage people to exercise less and to then lose out on other health benefits of more exercise? Injuries are also an issue for those going from no to some exercise.", "answer": 2}, {"article": "Peer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nDr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms from the test are not explained. The primary medical risks from the use of such a test would stem from inaccurate identification of an individual\u2019s risk of addiction. This could lead to individuals identified as being at low risk potentially being less careful about their use of opioids, leading to addiction; conversely, inaccuracy could identify an individual as being at higher risk when, in fact, they were at low risk and would benefit from being prescribed opioids.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No track record to discuss.", "answer": 2}, {"article": "Imagine plopping six cups of coffee grounds on the heads of patients just before they are wheeled into the operating room to have nose or throat surgery?\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\n\"The basic assumption is that, after registration, the spatial relationships between the patient's head and the fiducial markers remains constant,\" said Patrick Wellborn, the graduate student who is making the presentation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the cap is \u201cnoninvasive\u201d but doesn\u2019t say whether there are any potential harms. Silicone allergies are purportedly rare, but they do exist.\nThe news release is silent on the issue of potential harm which is movement from anatomic landmarks. We aren\u2019t sure that the lower error rate seen with the coffee cap is really an advantage. \u00a0An earlier publication from the group concluded:\nOur results show that our granular jamming fixation prototype reduces registration error by 28%-68% (depending on bump direction) in comparison to a standard Brainlab reference headband.. Indeed the method appears to be better than the headband approach but it is unclear how it performs in comparison to anchored fiducial markers.", "answer": 0}, {"article": "Of the 52, 30 had prolonged symptoms and 22 had short-term symptoms of mild traumatic brain injury.\n\"It's frustrating for both parents and physicians that we can't accurately and objectively predict how long a child's concussion symptoms might last, what those symptoms are likely to consist of and when it might be safe for them to return to sports or school,\" said Hicks, who, as a practicing pediatrician, has routinely cared for kids with concussions.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\nFor the study, Hicks and his co-authors looked at 52 patients between the ages of 7 and 21, with an average age of 14.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not directly address potential harms. The harms with screening tests are false-negative results\u2013in this case, concluding a child doesn\u2019t have a concussion when she really does\u2013and false-positive results\u2013concluding a child needs treatment when she doesn\u2019t.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of this mystery substance aren\u2019t addressed. The story quotes a dermatologist who says \u201cthe best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\u201d But how does a dermatologist \u2014 or anyone \u2014 really know since the company won\u2019t say exactly what\u2019s in its product?", "answer": 0}, {"article": "The study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nIn many cases such big reductions were achieved even though the patients were already taking statins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentioned the drugs could cause memory problems and that long-term safety must still be assessed. The story would have been stronger if it had mentioned the actual rates of memory problems found in the studies. Some mention of the side effects seen with monoclonal antibodies used for other purposes would also have been useful.", "answer": 1}, {"article": "Each received a book detailing her prescribed diet.\nThe findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\n\"This is the best study so far to compare popular diets,\" said Walter Willett, chair of the department of nutrition at the Harvard School of Public Health, because of its size, duration and the small number who dropped out.\nThe latest findings add to a growing body of evidence that the high-protein Atkins diet does not cause the harmful heart and artery effects long feared by many researchers.\nThe study by Stanford University researchers compared the Atkins approach with three others: the standard low-fat, reduced-calorie regimen long recommended by many physicians and weight-loss experts; the Zone, a reduced-carbohydrate approach developed by author Barry Sears; and the very low-fat, high-carbohydrate regimen created by Dean Ornish.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a concern with the Atkins diet that it would result in increased LDL cholesterol but that the study did not find this to be the case.\nThe article on which the story was based reported on the reasons people did not complete the study; there were no serious medical harms found.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\nCHICAGO (Reuters) - U.S. researchers are closing in on an accurate test for autism, a finding that could lead to earlier diagnosis and treatment.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One would think from reading these stories that getting an MRI is as harmless as taking a shower. Neither this story nor the CNN story explained the real psychological and physical impacts of brain scans. For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. If this test is to become useful it would need to be conducted early in a child\u2019s life. This should have been conveyed to the reader.", "answer": 0}, {"article": "Still, little is known about its cause.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re on the fence here. We\u2019re not suggesting that breastfeeding causes serious harm to mother or child, except perhaps in some cases of infectious disease transmission. However, breastfeeding isn\u2019t always the peaceful scene of contentedly suckling infant often portrayed in the media. Cracked nipples, nipple pain, engorgement, mastitis (breast infections) are not uncommon and can reduce breastfeeding success. In addition, breast milk is low in vitamin D, and exclusive breastfeeding may increase the risk of rickets. Some acknowledgment of these issues could potentially encourage steps to prevent and address these problems, which would be beneficial.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0mentions potential harms from screening, namely \"serious health risks from examining and treating tumors that may not be harmful.\"\u00a0 The story could have been clearer about what some of these risks are (like undergoing unnecessary surgery with all of its risks and anxiety to the patient), but it appropriately mentions that screening may have harms, which is often overlooked.\u00a0 ", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned.\nThe FDA said side effects of Gilenya in pediatric trial participants were \u201csimilar to those seen in adults,\u201d with the most common being headache, liver enzyme elevation, diarrhea, cough, flu, sinusitis, back pain, abdominal pain and pain in extremities.\nThe FDA added there are other serious risks with the drug including slowing heart rate, infections including a rare brain infection, vision problems, swelling and narrowing of the blood vessels in the brain, respiratory problems, liver injury, increased blood pressure and skin cancer, as well as potential harm to a developing fetus.", "answer": 0}, {"article": "That protein is known as an epidermal growth factor receptor (EGFR) kinase.\nIt's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nThe scientists say in the news release that not only did they find that a compound called WZ4002 can slow tumor growth, but that it is possible to \"selectively target the drug-resistant mutant EGFR in tumors, with relatively less effect on the normal EGFR in health tissues.\"\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed, nor is it mentioned that the safety profile in humans has yet to be established. The article would have done well to continue the Dr. Eck quote from the\u00a0press release\u00a0to include his acknowledgment that \"we still have much to learn about their potential liabilities,\" referring to this new class of compounds.\nThe \"hope\" that the compound will have fewer harms than currently available drugs appears to be based largely on in vitro\u00a0data.", "answer": 0}, {"article": "The women ranged in age from 49 to 83 years.\n\u201cAs dark chocolate contains more cocoa and less sugar than milk chocolate, consumption of dark chocolate would be more beneficial.\u201d\n\nLarsson and her colleagues, whose findings appear in the Journal of the American College of Cardiology, tapped into data from a mammography study that included self-reports of how much chocolate women ate in 1997.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nAccording to Larsson, flavonoids have been shown to cut high blood pressure, a risk factor for stroke, and improve other blood factors linked to heart health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Close call here, but the story goes a step further than WebMD when discussing the possible\u00a0adverse effects of consuming too much chocolate. In addition to warning that chocolate has a lot of fat, sugar and calories, it explicitly notes that eating too much of it\u00a0\u201ccould be counterproductive.\u201d WebMD offers no comparable warning and suggests that eating more chocolate than\u00a0was\u00a0consumed in this study would\u00a0result in similar\u00a0health benefits.", "answer": 1}, {"article": "Rather, the study was designed to determine whether H.R.T.\n\u201cWomen today have so many options \u2014 a wide array of doses, from low to traditional, and ways to use them.\u201d In addition to pills, there are patches, gels and sprays applied to the skin.\noptions and select the best treatment for women 45 and older with menopausal symptoms, the North American Menopause Society has developed a mobile app, MenoPro, for iPhone/iPad and Android devices.\nBut now, new research suggests that the benefits of short-term hormone treatment to control life-disrupting menopausal symptoms outweigh the risks \u2014 as long as the treatment is started at or near menopause.\nFor women without a history of cancer, blood clots or heart disease, most professional medical societies concerned with women\u2019s health now recommend treatment for menopausal symptoms for up to five years using therapy that combines estrogen and progesterone and even longer for those who take estrogen alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is trying to compensate for bad communication in years past, and so we believe it should meet a high standard when communicating the perspective it says is \u201cnew.\u201d\nHere is one harms statement that could use more careful writing and more numbers. The italics were added by us:\n\u201cIn an analysis in 2013 in the American Journal of Public Health, Dr. Philip M. Sarrel and his co-authors calculated that, based on reduced death rates among women taking only estrogen in the W.H.I. study, avoiding hormone replacement resulted in the premature deaths of 18,601 to 91,610 women in the decade after the study\u2019s release.\u201d\nThere is a lot of leeway between 18,000 and 90,000. The claim of deaths due to misinformation begs for a more accurate description of the equation used in the 2013 paper, as well as limitations of the analysis. It would also be\u00a0important to explain why this recommendation differs from that of the independent U.S. Preventive Services Task Force, which still recommends against the use of HRT for the prevention of chronic diseases. Their recommendation includes a\u00a0detailed description of harms and benefits on their web site.\nThe entire story is about the \u201charm\u201d possibly done by the warning years ago that hormone replacement therapy had been hyped inaccurately as a cure-all. But the story is remarkably silent on the potential \u201charm\u201d that still exists from hormone replacement for some women under some circumstances. The point that every woman should calculate her own personal risk versus benefits with her physician seemed buried.", "answer": 0}, {"article": "The study was funded by the P.J.\nFor example, according to the researchers, those with systolic blood pressures below 140 millimeters of mercury and no calcium had an event rate of 12.7 events per 1,000 person-years, and similar people with systolic blood pressures between 140 and 159 millimeters of mercury had an event rate of 13.6 events per 1,000 person-years.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\n\"We can predict that about 15 out of every 100 people with a particular risk score will die of a heart attack, but the equations don't tell us which of those people will be one of the actual 15; they don't give us personalized information,\" says McEvoy.\n\"If a health care provider wants to target blood pressure in a patient with traditional heart disease risk factors and above-normal blood pressure, he or she can look at coronary artery calcium to help with tiebreakerlike decisions,\" says J. William McEvoy, M.B.B.Ch., M.H.S., assistant professor of medicine and member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states: \u201cThe scans use radiation, so there is a very small cancer risk for susceptible individuals.\u201d While the mention of cancer risk is laudable, we aren\u2019t clear what\u2019s meant by \u201csusceptible individuals.\u201d Also, it does not mention that CT scans are not recommended for pregnant women due to possible risk to the fetus. In addition, harms can also arise from medications prescribed to treat these calcium scores.", "answer": 1}, {"article": "Therefore, Ulrik Dalgas is not recommending that all multiple sclerosis patients throw themselves into intensive physical training regimes without first seeking professional advice.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\nBut the fact that physical training also seems to have a protective effect on the brain in people with multiple sclerosis is new and important knowledge,\" says Ulrik Dalgas.\nNew research shows that resistance training protects the brain in persons with multiple sclerosis, which may delay the development of the disease\n\nIn the past, multiple sclerosis patients were advised not to exercise for fear of exacerbating the illness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out that MS patients were advised against exercise in the past for fear of exacerbating the condition. But only positive effects correlated with the study are addressed in the release, with no mention of potential harms. Weight training and other types of exercise have the potential to cause injury, which might be more likely in MS patients with reduced muscle function, impaired balance, or other issues. Consequently, we give the news release, a Not Satisfactory rating here.", "answer": 0}, {"article": "Besides M.D.\nMore than half of the women in the study came from Houston.\nStudy participants were grouped as low, medium or high risk based on how much their CA-125 levels changed over time.\nIn the last decade, hopeful of finding a better test, ovarian cancer researchers have invested much time in the investigation of other biomarkers and technologies.\nThree of the eight turned out to have benign tumors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions false positive results and unnecessary exploratory surgery as potential harms of the test.", "answer": 1}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 We don\u2019t know what harms there might be in mice on metformin, but we shouldn\u2019t have to wonder!\u00a0 After all, we weren\u2019t the ones writing about \"strong\" benefits of metformin in mice! ", "answer": 0}, {"article": "In a new paper published on May 31 in the journal PLOS One, researchers from Duke believe they have found a better way.\nWhile more than 4,000 American women die of the disease each year, the mortality rate has dropped more than 50 percent in the past four decades, largely due to the advent of well-organized screening and diagnostic programs.\n\"We recruited 15 volunteers on Duke's campus to try out the new integrated speculum-colposcope design,\" said Mercy Asiedu, a graduate student working on the project in Ramanujam's lab.\n\"The mortality rate of cervical cancer should absolutely be zero percent because we have all the tools to see and treat it,\" said Nimmi Ramanujam, the Robert W. Carr, Jr., Professor of Biomedical Engineering at Duke.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No possible harms are described. While it is difficult to imagine how this device could cause direct harm, screening and diagnostic tests always involve the possibility of harm from false-negative and false-positive tests. A brief mention of this was warranted.", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will rate the story as satisfactory because it does clearly point out that the surgery is hazardous, sometimes triggering a stroke, and that some patients die soon after the procedure. However, the story reports stroke and death rates at the lower end of the ranges reported in medical literature. The story says a major task force report estimated the risk of stroke and death within 30 days after surgery as less than 3 percent overall, but up to 5 percent at some hospitals. However, the lower figure in that task force report uses data only from clinical trials, which typically involve highly skilled surgeons and have better outcomes than typical clinical care. That report also said that some observational data indicates a risk of stroke and death of almost 7 percent at some hospitals. The evidence review mentioned above concludes that the 30-day risk of stroke and death is 7 percent in clinical trials of carotid endarterectomy.\nThe story does warn readers that few hospitals and surgeons publish their individual results.\nThe story would have been stronger had it mentioned that there are harms that can occur if we started screening anyone, regardless of whether they had symptoms. As the USPSTF explains, \u201cFor the general primary care population, the magnitude of benefit is small to none. Adequate evidence indicates that both the testing strategy for carotid artery stenosis and treatment with [surgery or stenting] can cause serious harms.\u201d", "answer": 1}, {"article": "Blakeway says she often has success combining acupuncture with Chinese medicine.\nThis was the second time a so-called \"female Viagra\" failed to make it on the market; in 2004, an FDA panel said no to Intrinsa, a testosterone patch meant to hormonally help women with a lack of desire for sex.\n\"There hasn't been much action in this area, and that certainly has to come up when a company is thinking about dumping money into researching a drug for female sexual dysfunction,\" says Phyllis Greenberger, president of the Society for Women's Health Research, which received money from Boehringer Ingelheim, the company that makes flibanserin.\nYou can find a practitioner through the National Certification Commission for Acupuncture and Oriental Medicine, or if you prefer a medical doctor, visit the website of the American College for Advancement in Medicine, where you can put in your ZIP code and find a doctor who specializes in integrative medicine.\n\"If your sexuality has been lying dormant for a while, then it's going to take a while to wake it up,\" Blakeway says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is growing\u00a0recognition that many alternative treatments, despite being \"natural,\" can produce serious side effects. But this story doesn\u2019t even nod in the direction of harms, despite discussing approaches, including vaguely described \"herbal combinations,\" that\u00a0may carry unknown risks.\u00a0Notably, the FDA has repeatedly warned consumers against herbal dietary supplements marketed for sexual dysfunction, as these have been shown to contain Viagra or similar substances that can cause harm in some patients and can\u00a0interact uNPRedictably with other medications.", "answer": 0}, {"article": "The rate for 413 volunteers given placebo treatment was 7.7 percent.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\nA second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of the drugs, potential false positives from screening, deaths during the study, and impact of such a prophylactic protocol on antibiotic resistance are not discussed.\u00a0 \nThe\u00a0study publication\u00a0mentions adverse reactions due to local irritation of the nose or skin, which resolved after treatment was discontinued.\u00a0 \nWe believe harms always warrant at least a brief mention. ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nThe new study, published in the journal Neurology, tested the effects of Botox injections on MS-related arm tremors, which affect up to two-thirds of people with MS.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nRight now, there\u2019s no good way to treat MS arm tremors, said Nicholas G. LaRocca, vice-president of healthcare delivery and policy research at the National MS Society.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\nMuscle weakness was the most common side effect in this study, van der Walt said. It affected 42 percent of the study patients, though it went away within two weeks.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\nAnd 7% to 9% will be told they should have a biopsy because of something suspicious that turns out not to be cancer, the researchers concluded.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The piece states that the researchers noted that \u201c\u2026false positive recalls may cause inconvenience & anxiety and biopsies can cause pain and scarring.\u201d", "answer": 1}, {"article": "The study was presented Monday at the annual meeting of the American College of Cardiology in Orlando, Fla.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\n\"The triple pill approach is an opportunity to 'leapfrog' over traditional approaches to care and adopt an innovative approach that has been shown to be effective.\"\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports: \u201cThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\u201d\nWhat were those side effects, how severe were they, and at what rate did they occur? The story doesn\u2019t say.\nWhile the news release doesn\u2019t say what specific side effects were observed, there are array of potential side effects with blood pressure medication that the story could have mentioned, such as nausea and fatigue.", "answer": 0}, {"article": "The study was supported by the National Institutes of Health and the National Science Foundation.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\n\"While more research is needed, the hope is such a tool could one day be used on the sidelines to help determine more quickly whether an athlete needs further testing.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harmful effects, most notably false positive and false negative results, of the ultrasound procedure are not mentioned. A false positive could result in unnecessary follow-up tests and treatments while a false-negative result could lead to an athlete resuming on-field play too soon, greatly increasing their risk of head injury complications and severity.", "answer": 0}, {"article": "\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not quantify whether there is any reduction in progression-free survival or \u201ccure\u201d rate with reduced radiation. The release also does not quantify what is meant by the words \u201creduced radiation.\u201d Is it half of normal doses, or reduced frequency but the same dose?\nThere may be potential harms in reducing a therapy aimed at a cure, but the release does not address this except in vague terms:\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee. \u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.", "answer": 0}, {"article": "For more information, go to UHhospitals.org.\nA new investigational delivery method for localized vaginal estrogen therapy that utilizes an applicator free softgel to alleviate moderate-to-severe vaginal pain during intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), received high rates of patient satisfaction among post-menopausal women, according to post-trial survey results published in the journal Menopause.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Neither the news release nor the original study on which it reported provided any detailed information about the safety of the investigational drug, other than to say that the estrogen product used has been shown to be \u201csafe and effective.\u201d\nThe product being discussed may offer a lower dose of estrogen than other currently available alternatives, but nonetheless, full disclosure requires some discussion of potential risks.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nHowever, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics.\nThese questions addressed in a new study by researchers from Charit\u00e9 - Universit\u00e4tsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.\nSo far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics.\n\"We were surprised to see that, after six months, two thirds of participants continued to use self-acupressure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release leaves the impression that there were no ill effects, but the study summary itself notes that some women in the acupressure group experienced bruising, nausea, dizziness or chest pressure.\nAccording to the study, 15 participants experienced an adverse effect.", "answer": 0}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\n\"But it wasn't until 20 years later that we were able to find drugs that directly target the underlying cause of cystic fibrosis,\" says Fred Van Goor, who led the team at what is now Vertex Pharmaceuticals that developed Kalydeco.\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\nAs a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story. We think that it\u2019s especially important to include information about harms when you feature a patient who describes the benefits of the drug by saying\u00a0\u201csomething huge had happened. It was just something I had never felt in my life before.\u201d\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nA1C levels on average decreased to 7.5 percent from a baseline of 8.3 percent in the group on pump therapy, but decreased to just 8.1 percent in the group receiving multiple injections.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention any potential harms of insulin pumps, even though the researchers reported that two patients were hospitalized because of infections at the site of the pump insertion.", "answer": 0}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nNonetheless, the odds of survival are about the same for weekend and weekday admission for stroke, the study found.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\nA total of 543 weekend stroke sufferers got the drug versus only 229 weekday stroke patients.\n\u201cAnyone who thinks they are having a stroke should seek care at a hospital immediately.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of the serious risks associated with tPA therapy.", "answer": 0}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\nView a new year's message from Dean Golden for 2019\n\nPlease take a moment to watch a special message from Robert N. Golden, MD, dean of the University of Wisconsin School of Medicine and Public Health, in which he reflects on 2018 and looks ahead to 2019.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release does note that the study population was limited to post-menopausal women due to the effect of Lupron on sex steroid production, it does not mention potential harms associated with the drug combination among post-menopausal women or possible interactions with other drugs that may be used by this population. The study itself found that\u00a077 of 109\u00a0patients or (71%) experienced at least one adverse event. Three serious adverse events (2 cases of gastrointestinal hemorrhage and one case of deep vein thrombosis) were judged to be potentially related to the drug.\nEmphasis on or exaggeration of potential benefits, coupled with minimizing or totally ignoring harms, have been hallmarks of a majority of the ~2,000 news stories that we\u2019ve reviewed in the past 9 years. \u00a0News releases could help turn news stories in a different, more helpful, more complete direction. \u00a0That\u2019s our hope and expectation with this new feature of reviewing health care news releases.", "answer": 0}, {"article": "He divided a group of rats into galantamine and donepezil cohorts.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n\"At the doses shown to reduce nicotine self-administration, the AChEIs did not make our animals sick,\" Schmidt said.\n\"We're very interested in screening potential efficacy of anti-addiction medications in our models,\" said Schmidt, a professor in Penn's School of Nursing and Perelman School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that people may become ill when taking the AD drugs. A source is quoted in the release says, \u201cWe know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and that this will limit their compliance.\u201d", "answer": 1}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "This press release contains forward-looking statements.\nStatements in this press release that are not purely historical are forward-looking statements.\nIn comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\nMRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy.", "answer": 1}, {"article": "Simmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None were mentioned.\u00a0The other side of the early identification/screening coin is that labeling a child with a mental illness early on and with minimal evidence also has adverse effects with regards to self-image and development.", "answer": 0}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\n\u201cWhat we are all about is making cognitive care part of primary care.\u201d\n\nMore than 5 million Americans have Alzheimer\u2019s disease, the leading cause of dementia.\n[Scientists are cautiously optimistic about progress toward finding treatments for Alzheimer\u2019s disease]\n\n\u201cLook, there is a late-life tsunami of late-life cognitive decline coming at us, and health-care providers are standing on the beach,\u201d said Charles J. Duffy, a neurology professor at the University of Rochester Medical Center who founded the company.\nThe federal government\u2019s approval to market the device comes as Alzheimer\u2019s researchers everywhere step up the pursuit for easier and more inexpensive ways to identify dementia in its earliest stages.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA approved this test on the basis of \u201clittle risk.\u201d But we really aren\u2019t told anything about what those risks are. Here\u2019s what the FDA had to say: \u201cThe risk of a false positive result may result in result in the clinician conducting a more detailed and extensive medical work-up to determine if a subject actually has cognitive impairment that would not be expected for his/her age and educational level. The risk of a false negative result would also be considered minimal. Clinicians would still be responsible for conducting a diagnostic work-up for patients presenting with cognitive impairment symptoms regardless of the Cognivue device result.\u201d\nOne thing both the story and FDA neglect to mention is that a\u00a0false positive can produce patient/family anxiety regarding a devastating condition with no effective treatments. We\u2019re not sure that qualifies as \u201clittle.\u201d", "answer": 0}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\n\"Floaters often arise as the vitreous -- a gel-like substance that fills the eye -- contracts and pulls away from the back of the eye,\" explained ophthalmologist Dr. Naomi Goldberg, who reviewed the new research.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\n\"Greater confidence in these outcomes may result from larger confirmatory studies of longer duration,\" the study authors wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms by saying, \u201cThere were no differences between the two groups in harmful side effects, according to the study.\u201d\nBut that\u2019s not enough\u2013What are the potential risks? The small size of the study (52 patients) makes it hard to exclude the possibility of side effects. As with any new surgery, doctors will have to learn how to do the procedure. Would you want to be an eye doctor\u2019s first patient to get the new procedure?", "answer": 0}, {"article": "His physical therapist quickly diagnosed it as tennis elbow.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\nIn addition to tennis players, Bishop sees the injury in gardeners with their shovels and trowels; painters with brushes; and golfers with clubs.\n(Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FlexBar is probably safer than some other commonly used treatments for elbow pain such as steroid injections. However, the story doesn\u2019t really address safety, except to say that\u00a0traditional hand weights can sometimes make tennis elbow pain worse (and by implication, that the FlexBar won\u2019t). While this isn\u2019t a major concern of ours, we think\u00a0it\u2019s probably premature, based on a single 21-person\u00a0study,\u00a0to suggest that the FlexBar is safer than other noninvasive approaches to treating tennis elbow.", "answer": 0}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\n\"If you received a placebo and you have a 74% chance of having symptoms go away or improvement [of illness]\" \u2013 compared with the 80% in the antibiotic group ... \"as a parent, how impressed are you about a 6% difference?\"\n\"More young children with a certain diagnosis of acute otitis media recover more quickly when they are treated with an appropriate antimicrobial agent,\" Klein wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although we\u2019re tempted to give this story a pass for providing a detailed list of potential harms and a better explanation of why limiting antibiotic use can be beneficial (it can \u201cincrease the chance the future use of antibiotics will be effective\u201d), the expectation here is that the story will provide a quantitative estimate if available. These figures were easily obtainable from the original studies, and should have been provided.", "answer": 0}, {"article": ", and receive monthly highlights by signing up at http://www.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of preterm birth are explained, but nothing is said about the possible harm of the drug \u2014 even to pregnant mice and fetuses.", "answer": 0}, {"article": "He hopes to make periodontal treatment a standard part of treating prostate disease, much like cardiac patients are often encouraged to visit their dentist before undergoing heart procedures and a dental checkup is advised for women who are pregnant or considering pregnancy.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nBut even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly assumes readers will understand there is potential harm from untreated gum or prostate disease and that is probably reasonable. It might have described the risks and limitations of repeated PSA screening and biopsies (which can lead to false-positive results and unecessary treatment), but we don\u2019t think that was an essential part of this analysis. Nonsurgical treatment of periodontal disease has a low potential for harm, something the release could have mentioned. The release does point out the risk to heart patients and pregnant women of untreated periodontal disease.", "answer": 1}, {"article": "Participants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\nTo conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\n\"Sleep is part of our own nature's defense against illness,\" says Dr. M. Safwan Badr, former president of the American Academy of Sleep Medicine and chief of the division of pulmonary, critical care and sleep medicine at Wayne State University School of Medicine in Detroit.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\n\"It's almost alarming how strong the effects are,\" says Aric Prather, an assistant professor in the department of psychiatry at the University of California, San Francisco and lead author of the study, published Monday in the journal Sleep.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the increased risk of getting a cold with not enough sleep \u2014 with the attendant sometimes debilitating symptoms that are all-too-familiar to many. But mainly the story is advocating for more sleep \u2014 and could there be risks to getting more sleep or trying to stay in bed for 8 hours if you\u2019re only hardwired to sleep for 6 hours? That\u2019s unclear, but the story could have clarified that although more sleep is associated with fewer colds, that doesn\u2019t necessarily mean that increasing your amount of sleep will reduce the number of colds you get. Proving that would require a different study. We\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "Of those followed, 151 participants developed pancreatic cancer.\nUsing information from the VITamins and Lifestyle study, Dibaba and the other co-authors analyzed an enormous trove of data on over 66,000 men and women, ages 50 to 76, looking at the direct association between magnesium and pancreatic cancer and whether age, gender, body mass index, non-steroidal anti-inflammatory drugs use and magnesium supplementation play a role.\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"For those at a higher risk of pancreatic cancer, adding a magnesium supplement to their diet may prove beneficial in preventing this disease,\" Dibaba said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release encourages people to add magnesium through their diets and through supplementation but doesn\u2019t tell them what the recommended daily allowance is. In the United States, the current magnesium recommended intakes are 400-420 mg/day for men and 310-320 mg/day for women.\nExceeding the recommended levels of magnesium through supplementation can cause side effects. Although these are not likely to be life-threatening, excessive intake of supplemental magnesium is harmful to\u00a0 individuals with impaired kidney functions. In addition, magnesium can interfere with certain medications so patients should always consult with their doctor before adding a supplement.\nFrom WebMD: \u201cDoses less than 350 mg per day are safe for most adults. When taken in very large amounts, magnesium is POSSIBLY UNSAFE. Large doses might cause too much magnesium to build up in the body, causing serious side effects including an irregular heartbeat, low blood pressure, confusion, slowed breathing, coma, and death.\u201d", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lays out a few harms of hormone blockers \u2014 which it notes is also called chemical castration in men \u2014 including hot flashes, breast growth and sexual problems.", "answer": 1}, {"article": "Not so.\n(Canes were OK.)\n\nHalf of the participants got a health education program involving regular in-person sessions and some stretching exercises, while the other group was told to aim for 150 minutes of aerobic activity as well as strength, flexibility and balance training both at the study's facilities and at home.\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\nThe authors called on medical schools to \"start preparing students to prescribe exercise as effectively as they prescribe statins, and for health systems to support physicians in addressing inactivity just as they provide support in addressing other health risks.\"\nAn editorial accompanying the study, by the University of California, San Francisco's Patricia Katz and the University of South Carolina's Russell Pate, also noted that people who engage in physical activity have a lower risk for heart disease, diabetes, certain cancers, depression, cognitive impairment and functional decline.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story basically recommends physical activity for the elderly, which most experts would support. But the study in question focused on \u201csedentary people between 70 and 89 years old who had some functional limitations, but who could walk about a quarter of a mile in 15 minutes or less, unassisted by another person or a walker. (Canes were OK.)\u201d\u00a0 There is obviously a great deal of variation in a population that broad and many included in that age bracket may also have balance, pain or stability\u00a0issues that might preclude jumping into a similar program.\u00a0\u00a0We would have been happier if the story focused early on any new program of physical activity being clearly linked to an initial consult with the person\u2019s physician.\u00a0 While the story does mention at the end that the authors of an accompanying editorial advised physicians that, \u201cPrescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\u201d that seemed insufficient compared to the consequences of physical-activity-induced injury among the elderly.", "answer": 0}, {"article": "In fact, the only clue TMS treatment contains magnets at all is that patients must remove any jewelry and stow their credit cards (to prevent demagnetization) before treatment.\nThe most common, not surprisingly, are headaches.\nHope for both groups may have arrived through an unlikely source: magnets.\nA physician then tests the machine to see how much power is needed to affect the patient\u2019s reflexes.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are a feature of this story.", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\n\u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nUntil lately, such patients have had only one surgical option: ankle fusion surgery, in which the worn-out part of the joint is removed and the bones are permanently locked together with screws and plates.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\nAn estimated 50,000 people a year experience end-stage ankle arthritis, in which the ankle cartilage has worn away completely, causing painful bone-on-bone contact and some level of disability.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presents some risks, i.e. replacement failure, loosening, slow healing, infection\u00a0and amputation.\u00a0 It\u00a0also mentions that not all individuals are appropriate candidates for surgery.\u00a0 It could have provided numbers for how often these harms occur.\u00a0 Nonetheless. we\u2019ll give it the benefit of the doubt on this criterion and grade it barely satisfactory. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article focuses on the associations between hormone use, heart disease, and the ages at which women begin using hormones. It does not mention other known harms of hormone use. For example, the statement, \"This new analysis tells us that hormones have no or very little risk for women when started within 10 years of menopause\" is not accurate; there IS an increased risk of breast cancer if used for more than a few years.\u00a0", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We particularly like how the article treated this criterion. It is made clear early in the story that aggressive medical treatment in premature babies may be a double-edged sword, since \u201cthese infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.\u201d\nWe also like the fact that the article differentiates between survival and a \u201cfunctional, fully participatory life.\u201d An independent pediatrics professor, Dr. Elizabeth Rogers, is quoted as saying she wouldn\u2019t change her clinical practice based on the research because \u201cthe risks of poor outcome outweigh the possibility of a really good outcome for families,\u201d especially for babies born at an early gestational age.", "answer": 1}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nJune 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. Statins do have side effects, contrary to their glowing press. And, although the story does say that more study is needed, it makes no mention of the fact that cancer patients may be taking a host of other drugs that could interact poorly with statins.", "answer": 0}, {"article": "The panel that issues those guidelines is currently reviewing its recommendations, he said.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe five-year \"disease-free\" survival rate was 83.9 percent in those who did not have the more aggressive surgery compared with 82.2 in those who did, the researchers reported.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported that the study found no benefit for the more aggressive full axillary lymph node dissection (ALND)\u00a0among the 900 women studied with T1 or T2 breast cancer.\u00a0 Because ALND poses risk of infection and lymphedema, more patients would be harmed by continuing the currently recommended treatment.\u00a0 While the article mentions the potential complications of ALND, it does not quantify the incidence of infection or of lymphedema after ALND. Women should be told how often this occurs.", "answer": 0}, {"article": "They kept a food journal throughout, and the researchers biopsied their fat tissue.\n\u201cWe discovered that the patients who exhibited higher amounts of were the patients who had a very strong improvement in cholesterol, in glycemia, in waist to hip ratio and also a reduction in different parameters in both cardiovascular disease and risk factors.\u201d\n\nHigher levels of , the findings suggest, seem to have favorable effects on health.\n\u201cOur diet and deteriorated microbiota are really a major piece of the puzzle in trying to understand why Western diseases are rising like crazy.\u201d\n\nSonnenburg says that when researchers try on mice what many of us do on a regular basis\u2014eat food depleted of dietary fiber\u2014their gut microbes behave erratically.\nBoth groups of people lost the same amount of weight, but the high- group had a stronger decrease in visceral fat than the others, says study author Patrice D. Cani, PhD, professor and group leader of the Metabolism and Nutrition Research Group at Universit\u00e9 Catholique de Louvain in Belgium.\nIt\u2019s increasingly clear that the composition of your gut bacteria likely influences your risk for many health problems, from obesity and type-2 diabetes and even certain autoimmune diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss risks associated with increasing your intake of dietary fiber. However, that\u2019s likely because there are few (if any) health risks associated with increasing fiber in your diet. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In presenting the lack of harms associated with even the high doses of antigen needed to trigger the desired immune response, the article included an important caveat about elderly individuals typically faring worse than the healthy young people tested.", "answer": 1}, {"article": "The IVC required cross-clamping in 24 cases.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nRenal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms in a comment by the lead surgeon who describes complications from the procedure as \u201crelatively minor\u201d but it could have just as well have said \u201crelatively serious\u201d for all the insight the phrase gave us about harms and risks from the robotic surgery. The surgeon also is quoted saying \u201ceven with a minimally invasive approach, the surgical management of severe cancers in mostly elderly patients will likely involve complications.\u201d Again, we are not told what those complications are and their impact on the patient.", "answer": 0}, {"article": "This trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nHowever, yoga has been predominantly evaluated for breast cancer, and research on its role in alleviating prostate cancer patients' side effects has been lacking, largely due to the perception that men would not be willing to participate in this form of holistic exercise.\nFurthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether anyone felt that yoga may have caused any harms. Injuries from the practice of physical yoga (as opposed to meditative) are, in fact, quite common, although most are minor and include pulled muscles and sprains but can extend to more serious injuries such as a ruptured disk in the lower back.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the final paragraph, the story mentions that BMP is linked to more complications, particularly difficulty swallowing in surgeries done high on the spine.\nBut the story didn\u2019t explain how big were the potential harms.\u00a0 According to the results of the study, the use of BMP in anterior cervical fusion is associated with a 51.4% higher complication rate compared to patients who did not receive BMP (7.09% vs. 4.68%, respectively).\u00a0 However, these data were not presented in the story. ", "answer": 0}, {"article": "Merck said trial results would be presented at an upcoming medical meeting.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When you\u2019re simply passing along information spoonfed to you by a drug company, you\u2019re not likely to explain or quantify the potential harms. \u00a0And, indeed, Reuters didn\u2019t even nod in the direction of discussing harms.\nMerck\u2019s news release unhelpfully said the \u201csafety profile of Keytruda in this trial was consistent with that observed in previously reported studies.\u201d\nIn our 6 tips for writing about immunotherapy, we note that harms of immunotherapy drugs \u2014 which can include serious adverse effects such as diarrhea and pneumonitis \u2014 are often downplayed", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article addressed the safety issue of of the three diets, which was a main outcome of the research study.\u00a0 There had been concern among medical and health professionals that low carbohydrate diets like the Atkins Diet, which allow large amounts of meat and cheese, could cause harmful increases in LDL (\"bad cholesterol\") and increase the risk of heart disease.\u00a0 An important message of this article is that alternative dietary approaches can be safe and beneficial to reduce serious health risk of overweight and obesity.", "answer": 1}, {"article": "\u201cThe state of the science will be changing relatively quickly, so we\u2019ll have to keep looking at this.\u201d\n\nRight now, the American Cancer Society (ACS) and other medical groups recommend that women start Pap tests at age 21 or three years after they become sexually active, whichever comes first.\nThe problem with that higher false-positive rate is that it could lead to needless biopsies and other tests, or treatment to remove abnormal-looking tissue.\nUsually, the immune system clears the infection, but persistent infection with certain strains of HPV leads to cervical cancer in some women.\nBut there are still questions about the effects of HPV screening, and \u201cmore complete evidence\u201d is needed before it becomes widely used, Whitlock and her colleagues write.\nIt has not been clear exactly how HPV testing, or liquid-based Pap tests, measure up against standard Pap tests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained the impact that false-positive tests might have if the HPV testing became routine. More women could have unnecessary biopsies to remove tissue that was not cancerous.", "answer": 1}, {"article": "Massage Therapy May Rub It Out\n\nLow back pain is second only to cold symptoms when it comes to complaints that send people to the doctor.\nAfter 10 weeks, the results were dramatic: Nearly two-thirds of the patients who received either type of weekly massage said their back pain was significantly improved or gone altogether.\n\"We found that both types of massage were equally effective in helping people improve their function and diminish their symptoms,\" Cherkin says.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\nIn some cases, researchers report, the benefits of massage lasted for six months or longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t mentioned but it would have been easy to cite what the study reported: that adverse events, mainly increased pain, was uncommon (4-7%) in those treated with massage. Even saying that massage is generally a safe treatment would have been fine.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One shortcoming of the story:\u00a0 no discussion of harms from Abraxane.\nHere is the data from the Calgene press release:\n\u201cThe most common grade \u2265 3 treatment-related adverse events in the study for ABRAXANE plus gemcitabine vs. gemcitabine alone were neutropenia (38% vs. 27%), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). In the ABRAXANE plus gemcitabine arm, the median time to neuropathy improvement was 29 days. There was no difference in serious life threatening toxicity (4% in each arm).\u201d", "answer": 0}, {"article": "So far, the FDA is erring on the side of caution.\n\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nDr. Mina Fazel, child psychiatrist at the Oxford University Children\u2019s Hospital, says, \u201cIt\u2019s complicated, because you\u2019re giving antidepressants when you\u2019re very worried about that young person\u2019s mood.\u201d Essentially, the moment when it seems most necessary to prescribe the drugs may also be the moment when the patient is most at risk of suicide.\nUntangling this cause and effect has thus far eluded researchers, though there is some evidence to suggest that antidepressants spark a chemical reaction in the brain that does in fact increase the risk of suicide.\n\u201cThey\u2019re not better than nothing,\u201d he said, \u201cand there\u2019s quite clear evidence that they\u2019re more dangerous than nothing.\u201d He arrived at this conclusion after applying the customary dose of skepticism doctors are taught to apply when translating research findings to clinical practice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some harms and uncertainty associated with antidepressant use in young people whose brains are not fully developed, including an increased risk of suicide.\nBut, unfortunately, the story goes\u00a0beyond the evidence, and includes erroneous information.\nThe story says: \u201cSince 2004, the FDA has advised\u00a0that antidepressants not be prescribed to individuals under 24 due to the increased risk in suicidality.\u201d This is not true\u2013the FDA did not make such a blanket statement\u2013they note the increased risk of suicidality, but leave it up to physicians to weigh the possible risks vs possible benefits.\nIt also says: \u201cFDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\u201d But, FDA doesn\u2019t address brain development in their evaluation of drugs.\nThe story then says: \u201cresearch on antidepressants suggest they negatively affect brain plasticity\u00a0and memory\u201d and cites two rather dated animal studies that that don\u2019t seem well described by the story.\u00a0\u00a0Antidepressants do seem to affect brain plasticity, but in a good way, as opposed to stress. We\u2019re aware of no adverse effects on memory documented in humans with antidepressant treatment (although depression adversely affects memory).\nAlso, the reference the author cites for antidepressants sparking a chemical reaction to increase the risk of suicide is about psychosis, not suicide, at least as far as we can tell from the abstract.", "answer": 0}, {"article": "Newswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nA rare and aggressive form of skin cancer, MCC, is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The same study named in the release shows that multiple patients had side effects from the drugs. These are not mentioned in the release.\nThe side effects occurred in two patients who developed lymphopenia (abnormally low white blood cells), one who had an increase in blood creatine phosphokinase which could indicate muscle inflammation or damage, and other disorders.\nThere were also \u201cserious treatment-related adverse events\u201d in five patients, including enterocolitis [inflammation of the small intestine and the colon], infusion-related reaction, aminotransferases [enzymes related to the liver] increased, chondrocalcinosis [calcium deposits in cartilage], synovitis [joint inflammation], and interstitial nephritis [inflammation of the kidneys].", "answer": 0}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the potential harms of treatment, which may be an increase in false-positives,\u00a0unnecessary biopsy, and anxiety.\u00a0 False positives may decrease with additional screening, such as an MRI, or when ultrasound is done annually.\u00a0 The high rate of false positives with mammography plus ultrasound meant that only about 1 in 10 women with cancer suspected on combined screening turned out to have cancer when biopsy was done,\u00a0whereas about 1 in 5 women with abnormal mammograms alone actually had cancer. ", "answer": 1}, {"article": "He presented the findings here at the annual meeting of the American Academy of Dermatology.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201csome in the study reported temporary tenderness, redness, numbness and bruising.\u201d That\u2019s all it said.\nThat raises more questions than it provides answers.", "answer": 0}, {"article": "Biologics are genetically engineered proteins derived from human genes.\n\"This is the single most effective drug we've had in psoriasis, ever,\" says Kenneth B. Gordon, MD, a dermatologist and clinical associate professor at the University of Chicago's Pritzker School of Medicine.\nThe result: The thick, red, flaking skin lesions that are characteristic of psoriasis cleared up in about three times as many patients who got briakinumab as those who got methotrexate.\n\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\nAt that time, the company said it wanted to evaluate the \"next steps\" for briakinumab and might try for approval again at a later date.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Weaker than the competing HealthDay story on this point.\u00a0 This story only reported \u201cpatients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\u201d\u00a0 Then, in the second last sentence of the story, it added that serious adverse events occured in 9/1% of briakinumab group and 6.1% of methotrexate group.\u00a0 But HealthDay actually quantified what they were \u2013 the number of serious infections and the number of cancers.\nIt\u2019s inadequate for WebMD to throw in a line \u201cmore cancers\u201d while failing to provide any numbers or details.", "answer": 0}, {"article": "This news release is available in French.\n\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out some precautions people need to take before exercising. The study\u2019s lead author explains that patients should use \u201creleaver medication\u201d (sic) before they exercise and adds they should take the time to cool down afterward. He also says people could exercise indoors during the winter months, since cold air provides another trigger for asthma symptoms. It would have also been helpful to note that any physical activity triggers asthma symptoms in some people. In these cases, patients may have to take medicines before they exercise. The National Heart, Lung and Blood Institute recommends easing into physical activity with a warm-up period and also wearing a mask or scarf over the mouth when exercising in cold weather. More detail would have been appreciated here, but we feel the news release had enough for a Satisfactory rating.", "answer": 1}, {"article": "The review identified a handful of drugs that \u201care probably effective and should be considered for migraine prevention.\u201d These include the antidepressants amitriptyline (Elavil, Endep or Vanatrip) and venlafaxine (Effexor); the beta blockers atenolol (Senormin or Tenormin) and nadolol (Corgard); and for menstrual migraines, naratriptan (Amerge) and zolmitriptan (Zomig).\nIn a summary of the guidelines written for patients and their families, this is how migraines are described:\n\nPreventive treatment involves taking a seizure drug and a beta-blocker every day to reduce the frequency, severity and duration of migraines.\nNeurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs, according to Dr. Stephen D. Silberstein, a neurologist at the Jefferson Headache Center at Thomas Jefferson University in Philadelphia.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nIn addition, an herbal remedy derived from a family of plants called Petasites or butterbur was found to be effective, according to the review.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story was not specific enough on this point, it reminded readers that all drugs \u201ccan have side effects or interact with other medications.\u201d\u00a0 It didn\u2019t mention how serious they might be or how often they might occur. We\u2019ll give the story the benefit of the doubt however since the list of drugs is long and the incidence and severity of the side effects is complicated\n\u00a0", "answer": 1}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nParticipants in the trial reported minor side effects such as dry mouth and constipation, however at higher doses, some participants did complain about some psychiatric side effects.\nPhentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story \u2013 while not quantifying harms \u2013 did a better job in discussing harms than the LA Times story, so we\u2019ll give it a satisfactory score. It reported:", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says up high that patients who fell outside the guidelines had a \u201chigher risk of dying in the hospital and of complications from the implantation.\u201d But there are no numbers provided. In fact, there are more percentages provided in this story about the stock prices of the various device makers involved than there are about the harms or benefits. This is the Wall Street Journal, of course, but we still thought some additional numbers about harms or benefits would have been helpful to any reader.", "answer": 0}, {"article": "Sarah Steven, Keiren G Hollingsworth, Ahmad Al-Mrabeh, Leah Avery, Benjamin Aribisala, Muriel Caslake, Roy Taylor.\n\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nProfessor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\n\"The bottom line is that if a person really wants to get rid of their Type 2 diabetes, they can lose weight, keep it off and return to normal.\nIn addition, the team found that even patients who have had Type 2 diabetes for up to 10 years can reverse their condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might arise from this approach. There are risks that come with very low calorie dieting \u2014 which was done for 8 weeks according to the release. Potential harms of extreme dieting should have been mentioned including whether there were any health issues in the 30 patients over the six months study period.\nThe most common side effect of very low calorie dieting is gallstones, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Minor, short-lasting side effects include fatigue, constipation, nausea and diarrhea. The Institute recommends that patients following a very low calorie diet that results in rapid weight loss should be monitored by a doctor.", "answer": 0}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nThe new study, involving more than 15,000 high-risk patients, did not find any overall benefit and even suggested the combination may be dangerous for some patients.\nAgain, while those receiving the supplements had lower homocysteine levels, they were no less likely to have another heart attack or a stroke, or to die from heart disease.\nAnother study presented at the cardiology meeting did surprise researchers when it did not find any benefit to combining the blood-thinner Plavix with aspirin for preventing heart attacks, strokes or deaths in heart patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any harms associated with consumption of vitamin B supplements, although such harms would occur from vitamin B intake unlike that studied, so this gets a satisfactory grade. ", "answer": 1}, {"article": "The goal isn\u2019t to make every trace of inflammation disappear, the scientists stress.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\n\u201cThere was no boundary, apparently.\u201d\n\nIn the study, Furman and his colleagues analyzed blood samples from 100 young and old people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t addressed at all \u2014 and there are potential harms associated with drinking, as the story says, \u201cmore than five cups of coffee a day.\u201d As the Mayo Clinic notes: \u201cEven among adults, heavy caffeine use [more than around four cups of coffee per day] can cause unpleasant side effects [including fast heartbeat and muscle tremors]\u2026.Some people are more sensitive to caffeine than are others. If you\u2019re susceptible to the effects of caffeine, just small amounts \u2014 even one cup of coffee or tea \u2014 may prompt unwanted effects, such as restlessness and sleep problems.\u201d", "answer": 0}, {"article": "The device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nSince the cardiologist began work on the project about a decade ago, the defibrillator he helped design has gone through several iterations.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nAlthough the researchers pointed out in their journal article that \u201cthe initial experience includes several cases of problems such as lead migration, lead dislodgement, and inappropriate sensing,\u201d the story does not refer to any potential harms.", "answer": 0}, {"article": "GlaxoSmithKline is charging up to $98,000 for a six-month treatment course of Arzerra, a drug approved in late October for chronic lymphocytic leukemia, which strikes about 15,000 Americans a year.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\n\u201cIt creates these huge ethical quandaries about trying a drug that has a modest benefit for the average patient at enormous expense.\u201d\n\nFolotyn is given by a rapid intravenous procedure once a week for six weeks out of every seven.\n\u201cIt\u2019s a very aggressive disease, and patients right now have no options,\u201d said James V. Caruso, the chief commercial officer for Allos, a 17-year-old publicly traded company based in Westminster, Colo., that has no other drugs on the market.\nGenzyme\u2019s Clolar for pediatric leukemia costs about $34,000 a week, though the company says that only two weeks of treatment are typically needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug\u2019s cost, it would have desriable to provide a brief comment on the toxicity of the drug as well.\u00a0 The addition of the information would help the reader place the value of the drug into a better perspective.\u00a0 According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug", "answer": 0}, {"article": "The screening phase of the trial lasted about seven years.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\nThe guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, eliciting protests from breast cancer experts and advocacy groups who argued the recommendation for fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story briefly discussed a few of the harms associated with mammograms, specifically the stress and anxiety caused by false positive results; however, it should have also mentioned the harms associated with unnecessary treatment of cancers that may not cause problems or be life-threatening.  Also, focusing on this issue of the \u201cstress\u201d for women who receive a false positive result puts too much emphasis on these psychological harms. Counterposing \u201cstress\u201d to \u201clives saved\u201d, though valid, is not persuasive.\n\u00a0", "answer": 0}, {"article": "The study found none.\nThe number of hot flashes among the women taking Lexapro, which is also known as escitalopram, dropped to about five on average after eight weeks--a 47 percent decrease or about 4.6 fewer hot flashes per day, the researchers reported.\nAmong those taking a placebo, the number of hot flashes dropped to 6.43 per day, a 33 percent decrease of 3.2 fewer hot flashes per day.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the competing WebMD coverage at least mentioned the possibility that this drug could cause adverse effects, this blog post does not\u00a0acknowledge any potential downsides of treatment. We have a lot of good data on the adverse effects of antidepressants, and the story could easily have brought in\u00a0summary data from other studies, rather than relying simply on 8 week data from a relatively small number of women. Giving results from a single study, while ignoring data from hundreds of other relevant studies involving thousands of patients, is a frequent problem in reporting. See the WebMD review for a more thorough discussion of why this is important.", "answer": 0}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n\"One of the improvements in outcome for ALL overall has been using methotrexate in a more intense fashion, by giving higher doses,\" said senior investigator William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, director of the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders at NYU Langone and director emeritus of NYU Langone's Perlmutter Cancer Center.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\n\"The improvement in cure rates for ALL over the last few decades, for the most part, has not come through the introduction of new medications, but through using existing medications in new ways, in terms of their dose and schedule,\" Dr. Carroll said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone \u201cwere at much higher risk for a debilitating bone condition called osteonecrosis,\u201d although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well.", "answer": 1}, {"article": "The current study sets the stage for clinical trials in humans.\n\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\n\"These dogs have the type of mutation found in the majority of patients with this disorder, so this approach could lead to a sustained gene therapy in people.\"\nThe National Institutes of Health (grants HL064190 and HL63098), the Howard Hughes Medical Institute and the Pennsylvania Department of Health supported this study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms in a couple of places, as in this excerpt:\n\u201cThe FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\u201d\nand in a quote by the lead researcher:\n\u201cBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\u201d\nBut as this study was done in canines, we would have liked a bit more detail on how harms might\u00a0 manifest in human clinical trials.", "answer": 1}, {"article": "During the sessions they received suggestions for mental imagery designed to minimize the intensity of their hot flashes, such as images of a cool place.\nThey are linked to declining estrogen levels, but it remains unclear just why the sudden lack of estrogen sends the body into thermal mayhem, and why some women are more affected than others.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any possible harms or side effects of the alternative therapy. It does, however, mention that hormone therapy comes with its own risks. The LA Times article, by comparison, correctly states there is no known risk of hypnosis.", "answer": 0}, {"article": "But he also emphasized the structured nature of the program tested in his study.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\nOn average, the effects of the mindfulness program were comparable to what's been seen in studies of sleep medications and \"talk therapy,\" said study leader David Black, an assistant professor of preventive medicine at the University of Southern California, in Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions risks in the context of sleep medication, saying that sleeping pills \u201ccan have side effects that are particularly dangerous for older people \u2014 such as dizziness and balance problems that can lead to falls, and problems with attention and memory.\u201d By implication, the story is saying that the meditation showed no side effects. (For example, did it make it harder for any of the participants to sleep?) It would have been nice to have that issue clarified.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did provide potentially useful information about the kinds of people who should avoid consumption of probiotic containing foods. However, the story did not contain sufficient information about the nature of the evidence demonstrating this to be true. \u00a0Have there been any studies done comparing outcomes of people with \u2018weakened immune systems\u2019 (whatever that includes) who have and have not consumed probiotics?\nAnd while the story did mention that it is common for people who have begin to consume probiotic containing foods to experience uncomfortable bloating, it failed to report on more serious risks associated with probiotic use.", "answer": 0}, {"article": "By eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per.\nBut the responsibility should also be shared by society, argues University of Southern Denmark professor of biophysics, Ole G. Mouritsen, who has authored several books on seaweed as food.\nFor example, dried and granulated seaweed can replace some of the flour when producing dry pasta, bread, pizza, snack bars, etc.\n\"It is difficult to determine how much seaweed a person should consume to benefit from its good qualities.\nWe think this knowledge should be available for society and also be put to use\", says Mouritsen.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are some vague references to harms in a list of bullet points at the end of the release. We do not think this satisfies the criteria but, instead, creates more confusion. It says:\nWhat is one to make of that?", "answer": 0}, {"article": "So why does acupuncture seem to work?\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\nSome women -- I would say probably about 15 percent -- have such severe hot flashes that they even refuse to take medications that can cut their risk for cancer or cancer recurrence by 50 percent, simply because they can't handle the hot flashes,\" Vito explained.\n\"And I've actually had patients who have had acupuncture with good success, so I'm not surprised by the finding,\" she added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t mentioned at all. The Mayo Clinic notes that risks associated with acupuncture range from soreness to infection to organ injury. Further, the clinic warns that some patients are at higher risk than others, such as patients who have pacemakers or bleeding disorders.", "answer": 0}, {"article": "But definitively proving these benefits is challenging, requiring years of costly research.\n\u201cBy opposing one group of muscles against another, it stimulates osteocytes, the bone-making cells.\u201d\n\nMost experts argue that it\u2019s difficult, perhaps impossible, for adults to gain significant bone mass.\nIf you don\u2019t fall, you greatly reduce your risk of a serious fracture.\u201d\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides insight into the downsides of bisphosphonate therapy but says nothing about the potential dangers of yoga. It is true that, done correctly, yoga is not likely to produce significant injuries. However, the subjects in the study were not supervised nor was their positioning for each of the poses determined. Incorrect alignment can cause joint strain and joint and injury. In fact, the Times itself has previously reported that yoga can wreck your body!", "answer": 0}, {"article": "In clinical trials, a plant-based diet lowers total cholesterol by 12.5 mg/dL.\n\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\n\"The first place to start is by building meals around nutrient-packed, plant-based foods, which fit into nearly every cultural template, taste preference, and budget.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms but does suggest registered dietitians and the menus found in federal recommended dietary guidelines could help people transition to a plant-based diet. There is mounting evidence that plant-based diets may be associated with reduced risk for many health conditions, as long as one eats a balanced diet and in moderation. We\u2019ll rate this one Not Applicable.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy, which is caused by elevated blood sugar levels damaging the blood vessels of the retina and affects approximately 7.7 million Americans.\nThe standard Medicare per-injection costs of the three anti-VEGF drugs evaluated in the study are about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin).\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nothing is reported about adverse effects either locally in the eye or systemically. While these drugs are standard treatments, a line about potential for infection or other potential harms should have been included. Information about completion rates and reasons for dropouts would also have been welcome.", "answer": 0}, {"article": "But testimonials are not scientific proof.\nMark Crislip, an infectious-disease doctor in Portland, Ore., who recently wrote about dry needling for Science-Based Medicine \u2014 a website critical of alternative medicine \u2014 says the version practiced by physical therapists doesn\u2019t \u201ccome with the mystical baggage that accompanies acupuncture.\u201d But he says it may well be a \u201ctheatrical placebo.\u201d\n\nWhat do published studies say?\nFor now, here\u2019s what consumers should know:\n\nPhysical therapists say it is not, \u201cthough superficially, it may look the same,\u201d says Justin Elliott, vice president of government affairs for the American Physical Therapy Association.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nWhile some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We like that the story called out risks specifically, which is something we don\u2019t see often. It says, \u201cNeedling can produce minor bleeding and some soreness, but in trained hands, and with the use of sterile needles and gloves, \u201cit\u2019s a very safe procedure,\u201d Briggs says.\u00a0In rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\u201d\nThe story would have been stronger if it had quoted a source with no vested interest in discussing risks. Also, it\u2019s worth pointing out that these risks are real whether \u201ctrained hands\u201d do the procedure or not.", "answer": 1}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nThat doesn't tell the whole story.\nBut those who said they took the drug at least 9 out of every 10 day had a 73 percent lower risk.\nSome insurers might pay, but some might balk.\nThere's one other thing, the CDC says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several clear points were made about harms:", "answer": 1}, {"article": "\u201cThis is still investigational and requires more research.\n(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nThe stent \u2014 a tiny wire mesh tube similar to those used to prop open heart arteries \u2014 was placed in the internal pudendal artery, which supplies blood to the penis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story explained that there were no adverse events reported up to three months later but that risks may become evident much later. That\u2019s an appropriate and important reminder.\nBut the story didn\u2019t go far enough in providing available context.\u00a0 The coronary stents are well known to have problems with clotting \u2013 generating a new generation of more expensive \u201ccoated\u201d stents and the need for prolonged treatment with expensive oral medications to prevent clotting. The story could have addressed this \u2013 extrapolating that coronary artery complications could occur in penile arteries is not unreasonable. However, the trade-offs of stent risks \u2013 protecting the heart vs. protecting erectile dysfunction are quite different (and implicitly equating them smacks of another element of disease-mongering).", "answer": 0}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\n\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\n\u201cIt was 41 times per hour that I would stop breathing,\u201d says Turner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the main side effect from the device is \u201cthat people can wake up with a sore tongue.\u201d We\u2019ll give this a barely passing satisfactory. (What about people who may have suffered adverse reactions or complications from surgery?)", "answer": 1}, {"article": "Dr. Durado Brooks, director of colorectal cancer at the American Cancer Society, agreed.\n\"You would intuitively think that the G variant would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case,\" Smits said in a statement.\nThe search for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a \"Holy Grail\" of colon cancer research.\n\"This suggests that there may be two different mechanisms that affect telomere length and that set up susceptibility to cancer,\" she said.\n\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story kept piling up the accolades \u2013 \u201cone more advantage\u201d and then \u201canother benefit is\u2026\u201d but in the end the story was all benefits and no harms. The New York Times story, by comparison, addressed false positives.", "answer": 0}, {"article": "The other half got a heart health education program.\nThe Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although evidence increasingly shows that patients with heart failure benefit from\u00a0physical activity, exercise is not without risk. Some patients with heart failure may experience worsening symptoms or cardiac arrhythmias related to exercise. There\u2019s also the potential for falls. The story should have noted that in this study, tai chi did not provoke any adverse events and seemed to be very safe for this group of patients with mostly mild heart failure.", "answer": 0}, {"article": "Caution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nTUESDAY, Jan. 12, 2010 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds.\n\"The sequence is that when you do the randomized trial, you don't get the same effect,\" Lipton said.\nBut the evidence is not sufficient to support routine use of angiotensin receptor blockers to prevent Alzheimer's disease, Wolozin said.\nA similar but smaller protective effect was found for a related drug, lisinopril (Prinivil, Zestril), which blocks production of the active form of angiotensin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One harm was mentioned \u2013 \"There are potential hazards, such as too-low blood pressure that can lead to damaging falls.\"\u00a0 That\u2019s an incomplete listing, but we\u2019ll give the story the benefit of the doubt in at least nodding in the direction of potential harms. ", "answer": 1}, {"article": "For more information, visit http://www.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nFor the study, researchers analyzed data in the National Inpatient Sample (NIS) database of more than 75,000 adults who underwent either laparoscopic or open fundoplication for GERD between 2000 and 2013.\nCHICAGO (January 26, 2017): Patients with gastroesophageal reflux disease, known as GERD, who undergo laparoscopic anti-reflux operations compared with traditional \"open\" operations suffer fewer postoperative complications, experience faster recovery, and incur lower health care costs, according to study results published online as an \"article in press\" on the Journal of the American College of Surgeons website, ahead of print publication.\n\"Surprisingly, in 2003, 12 years after the first laparoscopic anti-reflux operation was reported, only 25 percent of all the anti-reflux operations were performed laparoscopically in the U.S.,\" Dr. Schlottmann said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release names complications associated with both types of surgery for GERD, while stating that patients undergoing laparoscopic procedures encountered fewer of them: \u201cpostoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\u201d", "answer": 1}, {"article": "This new way of testing fetal DNA seemed to have already become fairly common where Seitz used to live, in Washington, D.C.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\nUntil the new testing technology came along, the only less invasive option was for an expectant mother to get an ultrasound, plus have her blood tested for specific proteins.\nIt's only been on the market since October 2011 and is not regulated by the Food and Drug Administration \u2014 the FDA does not regulate this type of genetic testing service.\n\"Patients need to understand that while this is better, it is not a diagnostic test, and I think the companies have done a great job in putting this material out,\" he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited several harms associated with the new screening tests, including the risk that some women may terminate a pregnancy based on the screening results alone without follow up diagnostic tests. It also noted that the tests can pick up minor genetic abnormalities that might previously have gone unnoticed.", "answer": 1}, {"article": "Why use the traditional approach if the laparoscopic technique is better in some ways?\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe study \"confirms what a lot of surgeons who do both procedures know already,\" Brunt said.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\n\"It's not one-size-fits-all,\" said Dr. L. Michael Brunt, a professor at Washington University in St. Louis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that the less invasive surgery might not be appropriate for patients who face increased risk from general anesthesia, including the elderly or those with multiple health problems. We\u2019ll rule this satisfactory, but the story could also have noted that the less invasive procedure produced a higher rate of operative complications than the standard procedure (6% vs. 2%).", "answer": 1}, {"article": "LONDON (Reuters) - Scientists have developed an eye implant that allowed three blind patients to see shapes and objects within days of treatment in a trial and say the device could become routine for some kinds of blindness in five years.\nAfter the light detection stage, it uses the eye\u2019s natural image-processing functions to produce a stable visual image.\nHe could even read a clock face and differentiate between seven shades of grey, the researchers said.\nOther types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\n\u201cWe have shown that people can be provided with enough useful vision for daily life,\u201d he said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on the implant requirements for the device\u00a0nor the potential downsides associated with this surgical procedure.", "answer": 0}, {"article": "With this new approach, SD-101 is the match that starts the fire.\"\n\"We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready,\" said Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\n\"We are really starting to understand the science of how immunotherapies work in patients,\" said Ribas, who is also the director of the Parker Institute for Cancer Immunotherapy Center at UCLA.\nIn UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time\n\nA UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin cancer, live longer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a dose-escalation study that was conducted to determine the safest dose. This means the focus was symptoms and side effects. And the news release states that. Yet, none of the symptoms or side effects patients in the study experienced are described in the news release. This is a major deficiency of this release.", "answer": 0}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nIn addition, \"at a certain point in time, the cells don't respond anymore to the hormonal therapy,\" said Dr. Debasish Roychowdhury, head of oncology medicines development at GlaxoSmithKline.\nBut chemotherapy medicines, which often are given intravenously, attack healthy cells as well as cancerous ones, causing nasty side effects such as vomiting and hair loss that limit how much of those medicines can be given.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nIt's also been approved for that use in the 27 European Union countries and several others.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that Tykerb can damage the liver and harm a fetus.\u00a0 But that\u2019s an incomplete listing.\u00a0 Tykerb can cause rare but very serious problems with heart failure and pulmonary toxicity. The drug can also cause diarrhea, skin rash, swelling, redness, pain and or peeling of the skin on the hands and feet, anemia, nausea and vomiting \u2013 along with a host of less common side effects. The story was way off in this regard. ", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story hints at false alarms from the use of PET scans, this is insufficient information on the harms of scanning. What would a \u201cfalse alarm\u201d entail? What does it do to a person who receives this news? ", "answer": 0}, {"article": "\u00b7\nAt the heart of the debate is this: The only rigorous clinical trial of the device -- which is approved to treat severe epilepsy -- failed to demonstrate effectiveness in alleviating depression.\nThe pocket-watch-sized device is billed as \"a pacemaker for the brain,\" the newest cutting-edge treatment for as many as 4 million adults whose severe depression is not relieved by psychotherapy, drugs or even shock treatments.\nIn its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nLast month committee chairman Charles E. Grassley (R-Iowa), whose panel issued a report highly critical of the agency's approval of VNS, said he was concerned that patients and their doctors were not being adequately informed about the risks of VNS, which include cardiovascular problems that can be life-threatening.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Very thorough discussion of potential harms. The story mentions cardiovascular problems that can be life-threatening. It says the device must be replaced every five years or so when the battery runs low. The story also profiles a patient who \u201cfrequently lost her voice while she was talking and felt a persistent constriction in the back of her throat. Both are common side effects of VNS treatment.\u201d It states that \u201cWorsening depression and suicide attempts were reported by one-third of patients in one study funded by Cyberonics, according to data presented to the FDA.\u201d The story also suggests that while the device generator may be removed from the chest of a person who wants to stop VNS use, the \u201celectrodes in her neck must remain forever; doctors tell VNS patients that removing them is too risky because tissue grows around them As a result, VNS recipients cannot undergo a full body MRI or therapeutic ultrasound.\u201d", "answer": 1}, {"article": "Elder's team found the right amount of sleep and stress reduction at the start of the trial predicted successful weight loss.\nIn fact, although diet and exercise are the usual prescription for dropping pounds, high stress and too little sleep (or too much of it) can hinder weight loss even when people are on a diet, the researchers report.\nAnd the factors that promote health -- eating well, being active, not smoking, sleeping enough, controlling stress, to name a few --promote all aspects of health,\" he added.\nTUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\n\"If sustained, the dietary choices made by people undergoing short sleep could predispose them to obesity and increased risk of cardiovascular disease,\" the researchers wrote in an American Heart Association news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was reporting on the impact of getting adequate amounts of sleep on weight loss. \u00a0While there was no overt discussion of the harm of obtaining adequate amounts of sleep, there doesn\u2019t appear to be any harm involved in adequate sleep.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the procedure, which should be a factor in weighing the risks and benefits of any intervention.", "answer": 0}, {"article": "and Premal H. Thaker, M.D., M.S.\nAlthough further study is needed, these results highlight the importance of adrenergic receptor-\u03b22 (ADRB2), a signaling pathway important to ovarian carcinogenesis and targeted by NSBBs (versus the ADRB1 pathway targeted by SBBs).\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nAn estimated 21,290 new cases are diagnosed, and some 14,180 women die from the disease each year in the U.S., according to the American Cancer Society.\n\"The ability to show improved survival using nonselective agents - which inhibit a specific stress pathway - is the culmination of years of research into ovarian cancer biology and pathogenesis.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms at all. Side effects can range from diarrhea to depression, may trigger asthma attacks in asthmatic patients, and can cause complications for patients with diabetes. Some of these side effects may seem relatively inconsequential when compared to EOC mortality, but they\u2019re worth mentioning.", "answer": 0}, {"article": "A protein present on tiny particles released by cancer cells may provide a way to detect pancreatic cancer in its earliest stage, when prospects for successful treatement are best, according to a study by researchers at the University of Texas M.D.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nAs a result, 80 percent of pancreatic cancer is diagnosed in later stages, when surgery is no longer an option.\nPancreatic cancer has one of the lowest survival rates of any cancer, with only 4 percent of patients surviving five years after diagnosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the story neglect to mention harms, it asserts that the still-to-be-developed test is 100 percent accurate. But as the competing stories on this study pointed out, that figure is based on testing in a very small number of people under favorable conditions. We now know from many decades of increased use of screening tests that these tests are fallible and there\u2019s no reason to to expect a new test would not offer up false positives and negatives when used in a broader population. Inconclusive and incorrect tests can lead to more invasive tests, increased patient anxiety and expensive and debilitating surgeries.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. On one hand,\u00a0the story does address harms from false-positive tests: \u201cJust as important, the tests were remarkably good at avoiding false-positive signals, which would needlessly alarm women and lead to riskier and more-invasive tests to confirm a diagnosis. For both types of cancer, the PapSeek test\u2019s \u201cspecificity\u201d \u2014 its ability to accurately recognize the absence of disease \u2014 approached 100%.\u201d\nYet\u00a0the story glossed over the high false-negative rates and how a patient might (incorrectly) interpret a result \u2014 i.e. by testing negative, they may wrongly believe they do not have a uterine or ovarian cancer.", "answer": 0}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\n\"It seems that migraine surgery patients can recover function and ability to cope with pain very well after surgery, in stark contrast to what has been shown in other pain conditions,\" Dr. Austen and coauthors write.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"Pain questionnaires used in the evaluation of better-understood and more common pain syndromes have not been applied to migraine surgery,\" Dr. Austen and coauthors write.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is perhaps one of the most egregious omissions of the news release: not mentioning any potential harms of a surgery that directly impacts the nerves and muscles of the face. While the method of this surgery is not included in the news release, a look at the Mass General web page where the lead author works describes the surgery as a \u201crelease\u201d of nerves in the eye, forehead, back of head, and nasal regions. Depending on the extent of the surgery, a patient may be required to undergo anesthesia in an operating room. The risks are not mentioned on this page either, but a look at the risks of the similar brow-lift procedure shows that complications may include facial nerve damage or paralysis, infection, and scarring.", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Use of Avodart\u00a0is associated with increased risk of sexual side effects and a small increase in heart failure risk. The story didn\u2019t mention these potential problems.", "answer": 0}, {"article": "Participants in the higher seafood consumption group ate an average of two seafood meals per week.\n(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\n\"This study helps show that while cognitive abilities naturally decline as part of the normal aging process, there is something that we can do to mitigate this process,\" says Martha Clare Morris, ScD, a Rush nutritional epidemiologist and senior author of the paper.\nThe participants were recruited from people already taking part in the Rush Memory and Aging Project, a study of residents of more than 40 retirement communities and senior public housing units across northern Illinois, plus older adults identified through church groups and social service agencies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study population in this specific study was made up of older adults (mean age of 81.4 years old). There are few, if any, risks associated with eating one seafood meal per week for older adults. However, the release might have warned that both the FDA and the EPA, while encouraging pregnant and breastfeeding women to consume two to three servings of fish weekly, now recommend that they choose fish that is low in mercury (which include salmon, shrimp, pollock, tuna (light canned), tilapia, catfish, and cod).", "answer": 2}, {"article": "In investigating how BCG administration produces its beneficial effects, the research team identified a mechanism never previously seen in humans in response to treatment with any drug - a shifting of the process of glucose metabolism from oxidative phosphorylation, the most common pathway by which cells convert glucose into energy, to aerobic glycolysis, a process that involves significantly greater glucose consumption by cells.\nIn August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of \"America's Best Hospitals.\"\nParticipants in the placebo group and in a comparison group of patients receiving no treatment experienced consistent HbA1c elevations over the same eight-year time period.\nBut by the end of that short, 20-week trial, there was no reduction in HbA1c, the established measure of blood sugar levels over time.\nThat reduction was maintained over the next four years, with treated participants having an average HbA1c of 6.65, close to the 6.5 considered the threshold for diabetes diagnosis, and with no reports of severe hypoglycemia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the vaccine are mentioned.\nIt\u2019s been given to humans since the 1920s and side effects, including allergic reaction to this live vaccine, have been well documented. It should be avoided in anyone with decreased immune function.\nOf note, a\u00a0 point is made that in those study subjects who received the vaccine, there were \u201cno reports of severe hypoglycemia.\u201d", "answer": 0}, {"article": "\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\nThe final product, which is administered intradermally (between the layers of the skin), comprises patient-derived dendritic cells genetically modified with an adenovirus to produce parts of the HER2 protein.\n\"We are using a vaccine approach to generate an immune response to HER2, which is found at high levels on and drives the growth of several types of cancer, including breast, ovarian, lung, colorectal, and gastroesophageal cancers.\n\"Moving forward, we would like to investigate whether we can increase the proportion of people who benefit from treatment with the vaccine by combining it with checkpoint inhibitor therapy,\" he added.\nOne patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the release was some injection site discomfort. The release also mentioned that the patients were tested to see if there was cardiotoxicity (heart dysfunction or muscle damage) and none was found.", "answer": 1}, {"article": "\"This suggests there may be a benefit of treatment, even in this age group.\"\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the article does mention some harms of aggressive treatment, impotence and incontinence, it doesn't provide readers with any context around how often these occur or how troubling men may find these.\u00a0 There are qualitative statements telling readers that\u00a0quality of life can be affected, but overall, the seriousness of treatment side effects seems to be minimized.\u00a0 ", "answer": 0}, {"article": "Since amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues that can only be established in a much larger trial.\u00a0 The need for a larger trial was mentioned, but no hint of unestablished potential harms.", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that \"There was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\" \nBut the story did not provide a clear picture of the view from patient perspective about how the two treatment approaches differed.", "answer": 1}, {"article": "\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\nWe focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.\nThe CGI-I is a standardized assessment tool that allows clinicians to rate the severity of ADHD illness, change over time and efficacy of medication.\nDr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\nThere are patents supporting Shire's overall ADHD franchise in the U.S. that extend to 2029.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The adverse effects are clearly listed and equated with those of other amphetamine drugs. The adverse effects that occurred in more than 5 percent of the subjects included decreased appetite, headache, insomnia, irritability, nausea, weight decrease and dizziness and were similar to those observed with other amphetamine compounds.", "answer": 1}, {"article": "To do this, all of the study volunteers were given all three tests.\n\"This device is interesting and warrants a further look, but it still needs to be perfected and the researchers need to figure out its niche,\" said Dr. Jennifer Appleyard, chief of allergy and immunology at St. John Hospital and Medical Center in Detroit.\n\"The electronic nose discriminates between patients with asthma and healthy subjects and its performance is increased when combined with FENO,\" wrote the Italian team led by Dr. Paolo Montuschi of the Catholic University of the Sacred Heart in Rome.\nDr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nWEDNESDAY, April 7, 2010 (HealthDay News) -- Using an artificial breath-sensor system dubbed the \"electronic nose,\" Italian researchers were able to spot more cases of asthma than with traditional diagnostic tools.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there appears to be little risk of harm from the new\u00a0testing procedure itself, the\u00a0story makes no mention of the\u00a0downside that can accompany\u00a0a faulty diagnosis\u2013whether a false positive or negative. False positive tests (diagnosing asthma when the patient has another disease) and false negatives (failing to diagnose asthma) can have significant consequences.\u00a0A brief comment on the potential harms associated with a faulty test would have been helpful.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\nOne large federally funded study found the coronary calcium score a better predictor of coronary events like a heart attack than the traditional Framingham Risk Score, which considers age, cigarette smoking, blood pressure, total cholesterol and HDL, the \"good\" cholesterol.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\n\"Do you put this 50-year-old who has this family history on a statin medication with potential expense (and) side effects for the next four decades of his life, or do you further refine how far at risk he is?\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, this story mentions harms, yet generally misleads readers. While the story emphasizes potential long-term benefits of screening, there is no mention of the downstream risks of tests and treatments triggered by the initial screening scans. For example, someone found to have a high coronary calcium score may be referred for an invasive coronary angiography exam, which in rare cases can cause serious injury or death. This story fails to point out the typical downsides of screening, especially for low-risk individuals who are less likely to gain important benefits.", "answer": 0}, {"article": "(\"Primary insomnia\" means that medical problems, medicines, or other substances have been ruled out as a cause of sleep difficulties.\n\"The theoretical concept is correct, in that we do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep,\" Kohler said.\nThe most effective treatment is cognitive behavior therapy, which involves changes such as avoiding cigarettes, alcohol and caffeine before bed, and getting plenty of bright light in the morning but turning off the TV, computer and dimming the lights during a wind-down period, among other techniques for improving \"sleep hygiene.\"\nWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn't have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping) .\nThe basic answer in this preliminary study, is yes, it seems to work, and it works in two ways,\" said Buysse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of what would appear to be a question many people would have:\u00a0 didn\u2019t wearing a cap that is presumably connected to some water supply actually interfere with anyone\u2019s sleep? Did the control group patients wear a cap?\u00a0 If so, did it make it harder for them to sleep?", "answer": 0}, {"article": "The study was temporarily halted in 2008 because of concerns over ethics and patient safety.\n\"A definitive answer on chelation therapy will take much additional research,\" Gervasio Lamas, chief of the Columbia University division of cardiology at Mount Sinai Medical Center in Miami Beach, Fla., said in a statement.\nIn a statement after the study was presented, Antman, a cardiologist at Boston's Brigham and Women's Hospital and professor of medicine at Harvard Medical School, added, \"Intriguing as the results are, they are unexpected and should not be interpreted as an indication to adopt chelation therapy into clinical practice.\"\nGary Gibbons, director of the National Heart, Lung, and Blood Institute, says the study was a \"breakthrough\" not for proving that chelation works, but for \"establishing that this chelation therapy regimen can be administered in a safe manner in the context of a clinical trial.\"\nIn response to such concerns, researchers revised their consent forms \u2014 the documents that explain a study's risks and benefits to patients \u2014 which had failed to mention the risk of death in chelation therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chelation is risky and\u00a0dangerous, and\u00a0notes that at least 30 patients have died from off-label chelation therapy since the 1970s. But then it quotes the\u00a0director of the National Heart, Lung, and Blood Institute calling the study a \u201cbreakthrough\u201d \u2013 not for proving that chelation works, but for \u201cestablishing that this chelation therapy regimen can be administered in a safe manner in the context of a clinical trial.\u201d Without some data or an explanation, readers are going to have a hard time\u00a0reconciling these\u00a0contradictory views about the safety of chelation. And since the NHLBI quote ends the piece, it\u2019s the take-home that may have the biggest influence on readers.", "answer": 0}, {"article": "A video in which Professor Probert explains how the machine works can be found here\n\"The Odoreader has a 30 metre column that enables the compounds in the urine to travel through at different rates thus breaking the sample into a readable format.\n'The use of a gas chromatography (GC)-sensor system combined with advanced statistical methods towards the diagnosis of urological malignancies', published today in the Journal of Breath Research, describes a diagnostic test using a special tool to 'smell' the cancer in men's urine.\nProfessor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nProfessor Probert said: \"There is an urgent need to identify these cancers at an earlier stage when they are more treatable as the earlier a person is diagnosed the better.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release speculates about potential benefits, but never acknowledges that the test might have downsides similar to the PSA test. False-positive results could lead to unnecessary biopsies and take a psychological toll on men who are tested \u2014 the release should have mentioned this.", "answer": 0}, {"article": "Bolstered by stories like Ham's, doctors are experimenting with marijuana as an addiction treatment in Massachusetts and California.\n\"It's hard to argue against anecdotal evidence when you are in the middle of a crisis,\" said Patricia Hymanson, a York, Maine, neurologist who has taken a leave of absence to serve in the state House.\nThere are some promising findings involving rats and one 2014 JAMA study showing that states with medical marijuana laws had nearly 25 percent fewer opioid-related overdose deaths than those without, but even a co-author on that study said it would be wrong to use the findings to make the case for cannabis as a treatment option.\nPeople are dying and, as a result, we ought to use things that are proven to be effective,\" said Dr. Richard Saitz, chair of the Department of Community Health Sciences at the Boston University School of Public Health.\nTired of feeling \"like a zombie,\" the 37-year-old mother of two decided to quit cold turkey, which she said brought on convulsions and other withdrawal symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some known or suggested harms of chronic marijuana use, yet there was not much\u00a0mention of those harms in this story. \u00a0The one harm mentioned is a significant one: marijuana also can\u00a0be addictive.\nHowever, the article didn\u2019t mention others risks of inhaling marijuana, such as lung disease,\u00a0as well as effects on motivation, and other cognitive\u00a0issues, especially when the dose isn\u2019t being well controlled when smoked.", "answer": 0}, {"article": "But such drugs tend to be extremely expensive.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\nThe cells do have a drawback: they destroy healthy B-cells as well as cancerous ones, leaving patients vulnerable to certain types of infections, so Emma and the other patients need regular treatments with immune globulins to prevent illness.\nThe altered T-cells \u2014 called chimeric antigen receptor cells \u2014 are then dripped back into the patient\u2019s veins, and if all goes well they multiply and start destroying the cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some of the adverse effects of treatment in great detail, and mentions that patients treated successfully have compromised immune systems and must undergo ongoing therapy\u00a0with immunoglobulins. The story could have noted that we have\u00a0little idea what kind of long-term challenges these patients might face as a result of the alterations made to their immune systems.", "answer": 1}, {"article": "Related: What Really Helps Knee Pain?\n\"It erased all of that.\u201d\n\nThe outpatient procedure typically takes about 40 minutes, is performed with local anesthesia and doesn\u2019t require an incision.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\nThe three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.\n\"The arthritis was so bad that I could barely step down without severe pain.\u201d\n\nBecause she wasn\u2019t eligible for a knee replacement she tried cortisone injections, physical therapy, medications \u2014 nothing relieved her pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are identified.\nHowever, we think it would have been worth pointing out that there is little scientific\u00a0literature about applying this old technology to a new\u00a0part of the body. So, it\u2019s unclear what the eventual risks are.\nAlso, the article is not quite clear what radiofrequency ablation is doing: killing nerves, for at least 6 months. There could be permanent loss of nerve sensation, or maybe the nerves will grow back years later, either normally or in an altered state (which has happened in some other medical and surgical situations).", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t include any discussion of potential harms that could be attributable to \u2018Mediterranean diet\u2019 adherence.", "answer": 2}, {"article": "For further information about the company go to creativemedicaltechnology.com.\n\"The CaverStem\u2122 procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis,\" said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company.\nAccording to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n2013 Jun 9;11:139. https://www.ncbi.nlm.nih.gov/pubmed/23758954\n\nOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms of the stem cell treatment. Although stem cell clinics often tout the safety of stem cells because they come from within the patient\u2019s own body, that does not mean that there are no risks to stem cell procedures. Only one stem cell procedure (a blood-derived stem cell treatment used for treating cancer and blood-illnesses) is currently approved by the FDA. All other stem cell therapies in the U.S. are experimental and unregulated by the government, including this\u00a0CaverStem procedure. On his blog, UC Davis stem cell scientist Paul Knoepfler reminds patients seeking stem cell therapy that every medical procedure has side effects. \u201cDifferent kinds of stem cells have variable risk profiles,\u201d writes Knoepfler, \u201cbut if someone tells you that the stem cell treatment they are selling has no risks then that is a big red flag and I would walk away.\u201d\nGiven the small number of men tested and the limited duration of follow-up, it is difficult to deem that this is a safe treatment.", "answer": 0}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nFive had no more attacks, 14 had an improvement in their condition, and only one person had a worsening of symptoms.\nThirty-five study participants had this form of vertigo.\nThey then moved each patient's head forward and shook it from side to side for about 15 seconds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the diagnosis of a suspected new form of vertigo so possible false diagnoses are a possible harm. And, the unnamed medication likely carries side effects.", "answer": 0}, {"article": "\"Wow!\"\nUltimately, the drug might be used by around 3,000 patients worldwide, if approved, and Schoenebaum expects it would be command a very high price, perhaps $250,000 a year.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nThe foundation has championed the development of drugs, including VX-770, and has provided $75 million to Vertex to get the medicine this far.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes the CF Foundation president saying there were no significant side effects.\u00a0 But even the press release  reported some numbers for discontinuation rates and severe side effects, so we wish the blog had as well.  ", "answer": 0}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\nOur hope is that much will be learned from the sharing of useful information and personal experiences based on the medical and health topics of the blog.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nDrinking more than four cups of coffee may lower the risk of some head and neck cancers, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least this story did what the WebMD story didn\u2019t do in discussing some of the potential harms from drinking a lot of coffee. ", "answer": 1}, {"article": "It was published Tuesday in JAMA, the journal of the American Medical Association.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nFor the problem-solving therapy, people were asked to create a list of the things that matter most to them in their lives and brainstorm on how to incorporate those things into daily life.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\nThey next were asked to categorize problems and worries into \"manageable\" and \"unmanageable\"; the main focus in problem-solving therapy is to tackle those problems that are considered manageable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms, but there are few potential harms associated with the relevant interventions\u2013other than temporary discomfort, stress or anxiety that can come along with addressing difficult feelings. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"Where's the money going to come from?\n\"I can certainly understand why people are concerned about linking these -- it's clear we're going to have to carve billions out of the health-care system,\" said Thomas Herzog, chairman of gynecologic oncology at Columbia University New York Presbyterian Hospital, speaking on behalf of ACOG.\nThe American College of Obstetrics and Gynecologists (ACOG) recommended the change after concluding that more frequent testing did not catch significantly more cancers and often resulted in girls and young women experiencing unnecessary stress, anxiety and sometimes harmful treatments because of suspicious growths that would not cause problems.\nThe Obama administration distanced itself from the breast exam guidelines announced Monday by a federal task force, saying the panel does not set government policy or determine what services are covered by the government.\nBut in this case, if anything, we're taking money out of our own pockets.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes in paragraph two the potential harms of over-screening\u2013that the testing led to stress, anxiety and some unnecessary treatments. \nThis point is emphasized by a quote in the following paragraph.\u00a0 ", "answer": 1}, {"article": "These conditions included generalized, social, and separation anxiety disorder as well as having a parent with bipolar disorder.\n\"This raises the possibility that treatment-related increases in brain activity during emotional processing may improve emotional processing in anxious youth who are at risk for developing bipolar disorder,\u201d said fellow co-author Dr. Jeffrey Strawn, a professor in UC's Department of Psychiatry and Behavioral Neuroscience, as well as director of the Anxiety Disorders Research Program, in a statement.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\nAccording to the Anxiety and Depression Association of America, 80 percent of children with a diagnosed anxiety disorder and 60 percent of those diagnosed with depression do not receive treatment.\nSome mental health professionals have suggested that mindfulness exercises can help bridge the treatment gap, and there is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms. However, that may be because there are few (if any) risks associated with cognitive therapy for anxiety disorders. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\nAccording to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\n\"The benefits of aspirin outweigh the harms for most people in their 50's who are at risk of cardiovascular disease but not at increased risk of bleeding.\nWhile taking low-dose aspirin daily can help prevent heart troubles, doctors note that it also increases the risk of bleeding in the stomach and intestines, and strokes caused by bleeding in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained, and that\u2019s sufficient to rate as Satisfactory.", "answer": 1}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe thought was that since high PSA levels are correlated with prostate cancer, rapidly rising levels of PSA, called \"PSA velocity,\" from one year to another would also be an indicator of prostate cancer.\nBut when they factored in other things that can influence risk, including a family history of the disease, being older, being black, PSA level and results of a digital rectal exam, there was virtually no association between PSA velocity and biopsy outcome.\nBut the National Comprehensive Cancer Network and American Urological Association guidelines do recommend biopsies based on high PSA velocities, even in the absence of an elevated PSA or a suspicious digital rectal exam, according to background information in the study.\nAnd many internal medicine and primary-care doctors, in part because of fears of litigation, do order biopsies based on fast-rising PSA levels, Brawley said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The competing AP story was much better on this point, reporting that using rising PSA levels, 1 in 7 men would have a prostate biopsy as compared with 1 in 20 men based solely on high PSA level. This suggests that change in PSA level results in 13/20 unnecessary prostate biopsies.\nThe story could have provided more detail on some of the possible complications resulting from prostate biopsies.\nIt did mention anxiety from tracking PSA levels over time. ", "answer": 0}, {"article": "The quality of life survey measured overall functioning (physical, emotional, cognitive, etc.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\nBut a study led by a Loyola Medicine thoracic surgeon has found just the opposite: Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\nFollowing surgery, all patients were surveyed at 1 month, 4-5 months, 7-8 months and 10-11 months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All interventions carry risks, and the news release does not mention any potential harms that may accompany major surgery. These include complications related to anesthesia \u2014 including blood clots and pneumonia, infection at the incision site, fluid build-up under the skin, bleeding, scarring and nerve damage.\nAs mentioned in the \u201cbenefits\u201d section, the news release also does not point out the patient subgroups who did not experience a marked improvement in their quality of life.\nFor these reasons, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "More trials need to be done of this unique treatment, she added.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will score this story as meeting the minimum requirement of this criterion because the story did briefly note that \u201cthe reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins,\u201d which would imply to alert readers that the number wasn\u2019t zero. However, the point of the trial was to find a way around side effects that statins cause some patients, so it is irksome that the story fails to point out that a trial this small probably wouldn\u2019t have detected the statin-caused problem, and that much larger trials will be needed to rule out similarly uncommon problems with this new drug.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nWashington, DC--For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\nFounded in 1916, the Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology.\nIn contrast, the rate of fractures rose four-fold in the control group as some of those women were diagnosed with osteoporosis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention potential harms at all. Given the wide range of potential side effects from growth hormone use \u2014 from headache and joint pain to weight gain and weakness \u2014 this is a significant oversight.", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the estrogen-only part of the Women\u2019s Health Initiative was stopped early because the women taking estrogen had an increased risk of stroke. (But it also could have mentioned that possible harm again as a factor that women should consider when deciding about therapy for their menopausal symptoms.) Blood clots, another possible side effect of estrogen therapy, are mentioned only briefly.", "answer": 1}, {"article": "The negatives?\nIt was overpowering.\u201d\n\nRobison\u2019s TMS research team was led by Harvard neurologist Dr. Alvaro Pascual-Leone, who supplies an introduction to \u201cSwitched On.\u201d In a separate interview, Pascual-Leone says Robison\u2019s book demonstrates how small changes in brain function, however temporary, can have a life-changing impact.\n\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0does describe harms that affected the man highlighted in this piece. While that\u2019s important for understanding his story, the descriptions provided do not help the reader determine how common these harms may be nor\u00a0the severity of the negative aspects identified. Studies of TMS for the treatment of other disorders\u2013for example, depression\u2013could have been cited to establish common risks and side effects.", "answer": 0}, {"article": "Schubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nThe precise cause of fibromyalgia is unknown \u2014 there are no physical signs, such as inflammation and tissue damage in the painful area \u2014 but some researchers believe the disorder involves problems in how the brain processes pain signals.\nBut, he explained, pain and emotions are \u201cconnected in the brain,\u201d and emotional factors may act to trigger \u201clearned nerve pathways\u201d that give rise to pain.\nThat is important because it is possible for patients to benefit from simply receiving attention from a healthcare provider, or being part of small-group sessions with other people suffering from the same condition, for example.\nThat is not to say that the pain people with fibromyalgia feel is \u201call in their head,\u201d stressed Dr. Howard Schubiner, of St. John Health/ Providence Hospital and Medical Centers in Southfield, Michigan.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll grade this one not applicable because the story didn\u2019t mention any potential harms of psychotherapy \u2013 which is understandable since these are generally thought to be small.\u00a0 But there are some theoretical risks which the story could have mentioned.\u00a0 ", "answer": 2}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes potential harms from the vaccines: \u201cThe level of serious adverse events was higher in the placebo group than either vaccine group, and \u2018most of the serious adverse events were attributed to malaria.'\u201d", "answer": 1}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n\u201cWhat we\u2019ve found is that your risk of having an aggressive cancer if you\u2019re in the high group is about 40%, and if you\u2019re in the low group, the risk of having an aggressive cancer is only about 7%,\u201d Tomlins says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While alluding to problems with the PSA test, the story did not cover any potential problems that might arise with the experimental test. \u00a0Although this test may potentially improve the accuracy of a man\u2019s risk estimate, there was still a fair amount of overlap and uncertainity. \u00a0The story did not report the proportions of cancers that were low and high risk. \u00a0Finding a low risk cancer could be considered a harm because many are considered overdiagnosed. \u00a0Missing a high risk cancer also causes harm.\nThis new test was suggested to eliminate the problem that arises because \u2018it\u2019s up to the patients and their doctors to figure out what to do next\u2019 when an elevated PSA level is detected. \u00a0However \u2013 even if this new test were available \u2013 it would still be up to patients and their doctors to determine what next steps to take.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explains possible harms from using the devices by soliciting opinions from the Heimlichs, the namesake of the famous Heimlich maneuver:\n\u201cAny action that delays use of the Heimlich maneuver or complicates the rescue can be deadly.\u201d\nTo balance this perspective, the article also discusses the use of these devices as a backup to other standard procedures:\nThe LifeVac and the Dechoker are both intended to be used if standard rescue treatments fail, the companies say. One person can get the device while another person starts the Heimlich maneuver, suggests Sean Pittman, Dechoker\u2019s director of strategic development.", "answer": 1}, {"article": "Abraham is a consultant for the company.\nThe research team tested the safety and effectiveness of a transvenous phrenic nerve stimulator made by Respicardia Inc. Much like a pacemaker, it sends a regular signal telling the diaphragm to breathe during sleep.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\nUnlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains this short phrase \u201cwithout causing serious side effects\u201d in reference to potential harms. We find that inadequate considering that CSA is serious condition that occurs in already very ill people. Presumably, they would be susceptible to a range of risks for side effects from the surgical placement of the device.\nThe release also states that 10 study enrollees were \u201cexcluded due to non-study related medical issues or deaths, exiting the study or missing visits,\u201d and \u201cAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\u201d\nWe think a discussion on why some patients exited the study (was it due to intolerance?) and some details on \u201ctherapy-related discomfort\u201d were warranted here.", "answer": 0}, {"article": "The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.\nIn a study of 2,000 men in the Chicago area, \"we found it to be more accurate than the tests now available, and it also seems to identify the more aggressive prostate cancers,\" he said.\nThe presence of circulating cells can indicate spread of the cancer to other parts of the body, but they are so rare that they are invisible to current technology.\nThe new PSA test is given twice a year, along with a digital rectal exam to determine the size of the tumor, and a yearly biopsy.\nBut it was a small study, and \"it will take another year or two to get enough cases to nail down the predictive index,\" Veltri said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not provide insight about the individuals who were incorrectly diagnosed in the study reported on. \u00a0What percentage of men had aggressive tumors that the test failed to detect? \u00a0And what percentage of men received treatment because the test identified them as having aggressive tumors but actually did not need to be treated?", "answer": 0}, {"article": "\u201cOnce you finally understand what is driving the disease we can develop therapies that are more effective,\u201d she said.\n\u201cThat is a drug that can take a while to work, so if the person has time I would rather give him essentially two shots on goal rather than one.\u201d\n\nFor advanced patients who need a quick response, he would use vemurafenib first.\n\u201cWe don\u2019t know what dacarbazine did to the ipilimumab, but we do know even in the presence of dacarbazine, ipilimumab still produced a durable response and extended survival.\u201d\n\nDoctors said taken together the new studies offer new options for patients.\n\u201cWhat was interesting about this study was not only was it the second one to show a benefit,\u201d but that the improvement \u201ctook place even in the presence of dacarbazine chemotherapy,\u201d Dr. Jedd Wolchok of Memorial Sloan-Kettering Cancer Center in New York, who presented the study at the meeting, said in a telephone interview.\nCHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned only skin rashes and joint pain from vemurafenib, but the story didn\u2019t explain, as the New York Times did, that 38% of trial participants had to stop taking the drug or lower the dose because of side effects. And there wasn\u2019t a word about side effects from ipilimumab.", "answer": 0}, {"article": "The drug was also granted a priority review.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nIn clinical trials, the most common side effects reported by participants taking Nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state).\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that Nuplazid has a \u201cBoxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.\u201d Other harms observed in the very brief (6-week) trial are swelling due to the accumulation of excessive fluid in the tissue, nausea\u00a0 and confusion. The release would have been stronger had it given us an idea of how common or rare these side effects are.", "answer": 1}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nAt the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Direct harms from a simple saliva test seem improbable at best, given its non-invasive nature.\u00a0 But the competing HealthDay story pointed out that even a saliva test could produce false positives that could cause real anxiety in patients, something that clearly could harm them.\u00a0There is also the potential for false negative results, which would falsely reassure patients about their status. Even an accurate positive finding could cause harm, since it would inform people about their risk of a future condition without giving them the ability to do much about it.", "answer": 0}, {"article": "Restless legs syndrome causes a person to feel a powerful urge to move his or her legs.\n\"Treatments for restless legs syndrome is now frequently advertised direct-to-consumer, and thus while this may enhance awareness it may result in patients seeking treatment for milder or other conditions not well-studied,\" he explained.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\nThe medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\nThe researchers found that 61 percent of those taking dopamine agonists showed at least a 50 percent improvement in their symptoms, compared with 41 percent of those taking an inactive placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists adverse effects commonly seen with both classes of medication discussed in the story. It adds, \u201cUp to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit.\u201d", "answer": 1}, {"article": "The study was recently published in the journal Spine.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\n\"With low back pain, there are many reasons people don't get better,\" added Perle, also a professor of clinical sciences in the College of Chiropractic at the University of Bridgeport in Connecticut.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\n\"In short, no single therapy is better than another, although some individuals are likely to have more success with one therapy than another,\" said study author Sidney Rubinstein, a research fellow at VU University Medical Center in Amsterdam.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any review of a treatment should discuss both the benefits and risks of the treatment. \u00a0The story focused entirely on the comparative effectiveness of manipulation, and ignored discussion of potential harms and adverse effects.\nMany people are scared away from spinal manipulation for low back pain over the potential risk of serious complications such as cauda equina syndrome, paralysis, and death\u2014or the exacerbation of a disc herniation. However, as the new systematic review pointed out, serious complications related to manipulation for low back pain are extremely rare.\n\n \n", "answer": 0}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fainting and abnormal potassium levels were mentioned as harms of treatment, though there was no indication of how common these harms might be. Another harm not mentioned was that it is known from other studies that labeling someone as \u2018hypertensive\u2019 can severely affect their quality of life (self perception). ", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\n\n\u2022 Effectiveness shown in tests on ovarian and bowel cancer\n\u2022 Developed by researchers at the University of Warwick\u2019s Warwick Cancer Research Centre\n\u2022 New drug could be cheaper to produce and less harmful to healthy cells\n\nTests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.\nCommenting on the drug\u2019s benefits when compared to existing platinum-based drugs, such as Cisplatin, Professor Sadler says:\n\n\u201cPlatinum-based drugs are used in nearly 50% of all chemotherapeutic regimens and exert their activity by damaging DNA and cannot select between cancerous and non-cancerous cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story promises so much of this compound, including that it could be\u00a0less harmful to healthy cells than existing treatments. But it\u2019s hard to know what side effects might exist because the drug has apparently never been tested in animals or humans. The release does mention the many side effects associated with existing chemotherapies, but we wish there had been a caution: \u201cThere may be side effects with FY26 that remain to be discovered.\u201d", "answer": 0}, {"article": "This is the first to correct an inherited genetic mutation.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\n\"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed,\" said Jennifer Luddy, a spokeswoman for Express Scripts.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nThe company's offer of unusual payer models, including rebates and installment payments, will \"help ensure patients' individual financial situation does not hinder access to treatment,\" da Silva said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms of the therapy. We do think the story should have mentioned that we don\u2019t know much about the long-term effects and safety of using this technology, however.", "answer": 1}, {"article": "And it is mainly a disease of older people.\n\"They did well and beat their lung cancer,\" Adusumilli says, proving that when it comes to surgery for early stage lung cancer, age should not be a limiting factor.\n\"We shouldn't allow numerical age to be the deciding factor,\" Lichtenfeld says.\nHis cancer had not spread, and Adusumilli told him there was a good possibility the cancerous tissue could be completely removed and he could go back to leading a normal life.\nOlder adults are more functional, both physically and mentally, than ever before, and he says the medical community needs to adjust its thinking about what treatments older cancer patients can tolerate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article admits the conventional wisdom is that older patients don\u2019t tolerate surgery for lung cancer, but from headline to the final sentence\u00a0the NPR story is about older lung cancer patients thriving, based on a personal story and and experts\u2019 opinions. There is no meaningful discussion of the harms of surgery.", "answer": 0}, {"article": "Information on ongoing trials is available at www.clinicaltrials.gov.\nFor a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014, subsequent reports on Form 10-Q and 8-K, and other filings by the company with the U.S. Securities and Exchange Commission.\nThe median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS.\n\"These findings confirm that VYXEOS provides the first opportunity we've had in decades to extend survival for patients with high-risk AML,\" added Gail Roboz, M.D., Professor of Medicine and Director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York.\nCelator's pipeline includes the lead product, VYXEOS\u2122 (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin being studied for the treatment of acute myeloid leukemia; CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release noted that serious harms from the drug were comparable to the standard therapy and listed the adverse events including infections, febrile neutropenia, bleeding, cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nOne word of caution about the harms. The study was not blinded (according to its listing on ClinicalTrials.gov) and these adverse effects may have been subjectively\u00a0found, potentially biasing the results. \u00a0We are not given enough information about this in the news release.  ", "answer": 1}, {"article": "Medtronic has also noted such effects in Infuse\u2019s warning label.\nThe high complication rate was seen in 2006 data..\n\n\u201cI would have hoped that this sort of surveillance would be a routine part of F.D.A practice,\u201d Dr. Deyo said.\nThe use of a bioengineered protein should be \u201cdiscontinued either permanently or until further information becomes available regarding how to use it safely,\u201d said Dr. Thomas A. Einhorn, chairman of orthopedic surgery at Boston University.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nThe research team based its report on records collected through a database known as the Nationwide Inpatient Sample, which gathers information from 20 percent of the nation\u2019s hospitals.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe harms associated with the use of bone-growth proteins in fusions to treat upper spine pain are the headline of the story \u2013 and the study it is based on. The story specifically notes that patients have reported life-threatening complications, including difficulty breathing and swelling of the neck.\nThe story would have been better if it had included some explanation of the number needed to treat in order to see an additional case of harm.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\n\"Let's say 10,000 women in the world were going to die of breast cancer that developed in their 40s,\" Brawley tells WebMD.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\nThe American Cancer Society (ACS) still recommends that women start screening in their 40s -- but only if they are fully aware of the possible harms as well as the possible benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention the risk of false positives and how this could affect whether women would still be inclined to get mammograms as they get older.", "answer": 1}, {"article": "THURSDAY, June 28, 2012 (HealthDay News) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.\nNone of the patients had responded to metformin alone.\nThey added more research is needed to confirm their findings.\nThe patients on linagliptin also had fewer heart attacks and strokes compared to those being treated with glimepiride.\nThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was inadequate/incomplete quantification of the harms.", "answer": 1}, {"article": "The findings were presented at the San Antonio Breast Cancer Symposium.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nTumors shrank in one-third of women with metastatic breast cancer given T-DM1, says Ian Krop, MD, of the Dana-Farber Cancer Institute in Boston.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does mention that all the women experienced side effects. It left out some potential harms and didn\u2019t quantify any specific adverse events, simply noting that side effects were \"typically the fatigue and nausea often seen with chemotherapy.\" The Genentech press release mentions and quantifies severe adverse events that were not mentioned here, including low platelet levels in about 6% of patients.\u00a0\nThe article does describe a death that occurred during the trial, although see the \"sources\" criterion for a comment about the outside source that provided the interpretation. Especially because it doesn\u2019t present how many women were enrolled in the trial, the article needs a truly outside expert\u2019s interpretation of this death. In general, more discussion and quantification of the harms would have matched the quantified benefits.\nAlso not noted are the potential risks associated with Herceptin, a component of T-DM1. For instance, this drug is associated with\u00a0cardiac toxicity;\u00a0while the risk of heart failure may at present not be a dominant concern in the treatment of metastatic breast cancer, the risk could become more relevant if T-DM1 were truly able to increase lifespan. Other\u00a0black box warnings\u00a0of Herception not mentioned include the potential for serious infusion reactions, sometimes fatal.", "answer": 0}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the risks of breast reduction surgery, which are considerable: infection, bleeding, blood clots, nerve and muscle damage, plus the risks associated with anesthesia. \nFurther, the story fails to mention a risk of great importance to younger women: inability to breastfeed.\u00a0 ", "answer": 0}, {"article": "But investors had been anticipating a bigger effect.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nThere were fewer cases of pancreatitis, which has been viewed as a potential problem, but more cases of pancreatic cancer, although the difference was not statistically significant.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nVictoza is only the second diabetes drug to show such heart benefits, after Eli Lilly (LLY.N) and Boehringer Ingelheim\u2019s pill Jardiance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of mentioning the side effects of Victoza, even pointing towards whether effects were statistically\u00a0significant. One omission was that the story did not mention the higher incidence of gallstone disease, a side effect that was highlighted as significant in the paper.", "answer": 1}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\nParents were surveyed the day before treatment about the severity of their child's symptoms.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that almost half of the children who were treated with VapoRub reported side effects including skin irritation or a burning sensation, while none of the children in the other groups reported any side effects.", "answer": 1}, {"article": "Earlier this year, dementia overtook heart disease as the leading cause of death in England and Wales.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nThe technique, known as optogenetics, allowed the scientists to artificially cause groups of neurons to fire in unison by pulsing light into the brains of the mice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This potential treatment is still in mouse trials, so there\u2019s not a lot that can be said at this point about potential harms. The author quotes the researchers, who pointed out that the lights as they were used in the trial \u201cwould not be offensive at all for people to have in the background.\u201d", "answer": 2}, {"article": "Recipients were at most seven years older or younger than the donors.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nThe study is in the Clinical Journal of the American Society of Nephrology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplants vary in success rates according to many factors. There is no mention of harms that might come to a patient from receiving a kidney from a much older deceased donor. Or the harms that an older donor might face compared with a younger donor.", "answer": 0}, {"article": "+ Total fat loss was much greater when participants combined diet plus walking (about 16 pounds) and diet plus weight training (about 17 pounds).\nThe findings, \"Effect of Exercise Type During Intentional Weight Loss on Body Composition in Older Adults with Obesity,\" appear in the November issue of the journal Obesity.\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address harms. We believe the release should have encouraged seniors, especially those with documented cardiovascular disease, to be assessed by a physician before starting a new exercise program.\nThis example of an exercise readiness questionnaire covers some of the considerations that seniors should discuss with a physician prior to embarking on a new exercise regimen.", "answer": 0}, {"article": "\u201cWhat about long-term safety issues?\u201d he asked.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\nNEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story actually quantified the harms, but they both noted there were side effects. This story did a better job, though, by noting that the only dose that seemed to work also seemed to produce the most side effects and by raising the issue of long-term safety concerns. It also was the only story to answer the question that readers surely would have when reading about an illegal narcotic being used as medicine. Did these patients feel high as a result? This story says that most did not. Because of the additional information and context, the rating here is satisfactory.", "answer": 1}, {"article": "He started taking a daily dose of aspirin a couple of years ago as the results of his study emerged.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\n\"This is definitely the first time that research has shown that long-term aspirin use can reduce the risk of deaths due to cancer,\" Dr. Asad Umar of the National Cancer Institute's division of cancer prevention tells Shots.\nRothwell says the \"sensible time\" to start taking aspirin \"would be before the risk of cancer starts to rise, at about 45.\"\n\"So I think in the fullness of time, preventing cancer will be seen to be the main reason for taking aspirin in healthy individuals,\" Rothwell says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the few stories to put a number to the potential harms. \u201cBut aspirin carries risks. The biggest is stomach bleeding, although it also raises the risk of brain hemorrhage. Daily aspirin doubles a person\u2019s gastrointestinal bleeding risk to about 2 in every 1,000 people a year. But Rothwell says this bleeding hazard is \u201cdrowned out\u201d by the cancer benefit.\u201d", "answer": 1}, {"article": "Carlson notes that many cognitive intervention studies last one year or less.\nThe research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe study was supported by the Johns Hopkins Neurobehavioral Research Unit, the National Institutes of Health's National Institute on Aging (P01 AG027735-03), the Alzheimer's Drug Discovery Foundation and the Johns Hopkins Epidemiology and Biostatistics of Aging Research Fellowship (NIA T32AG000247).\nThe same things that benefit us at 5, 10, 25, 35 - contact with others, meaningful work - are certain to benefit us as we age.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Due to the nature of the intervention\u00a0 \u2013 which was volunteering in a school setting \u2013 it\u2019s difficult to imagine harms occurring. There was no mention of harms in the release, but we won\u2019t penalize the release for that omission.", "answer": 2}, {"article": "Straiton didn\u2019t respond to emails seeking comment.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\nThis procedure, known as a transcatheter aortic valve replacement, is done by threading a catheter to the heart through a small incision in the chest or from the large artery in the groin - it doesn\u2019t require cutting open the chest.\nSurgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nThe condition tends to develop with age and can lead to chest pain, shortness of breath, fatigue and heart failure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story portrays this procedure as minimally invasive and less risky than traditional surgery, but does not describe any risks.\nAlthough TAVR is considered to be lower risk than surgeries that cut open the heart, it\u2019s long-term durability is unknown because the procedure has only been approved in the U.S since 2011.\nMinimally invasive TAVR is still risky. The rate of death within 30 days ranges from 1 to 4%, for example, and it increases the risk of a stroke or heart attack, in addition to other potential vascular and valvular complications, according to UpToDate.com.", "answer": 0}, {"article": "Vincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\nThe study of acupuncture as a remedy for hot flashes was sparked by reports from women who had undergone the ancient Chinese therapy for other problems and reported that their hot flashes seemed to moderate.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nThat requirement has hobbled other alternative treatments, including the herb red clover and vitamin E supplements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that women in the study reported no adverse effects.", "answer": 1}, {"article": "\u2022 Keep up to date with Tenovus Cancer Care by following them on Twitter @tenovuscancer or Liking their page on Facebook http://www.\nThe choir leaders play a huge part of course, but so does the support of the other choir members, the inspirational programme and uplifting songs.\nThere is a link between high levels of inflammation and serious illness.\nThe study also found that those with the lowest levels of mental wellbeing and highest levels of depression experienced greatest mood improvement, associated with lower levels of inflammation in the body.\nIt's really exciting and could enhance the way we support people with cancer in the future.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms but it\u2019s very unlikely there\u2019s any harm in this activity.", "answer": 2}, {"article": "They estimated the scans done in 2007 will cause 29,000 cancers.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\nBy comparison, the average American is exposed to about 3 millisieverts of radiation a year from ground radon or flying in an airplane \u2014 a level not considered a risk to health.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly describes the harm of radiation exposure from CT scanning. The story could have also mentioned that excessive CT scanning can also lead to unecessary follow-up testing and/or procedures for suspicious findings that turn out to be benign.", "answer": 1}, {"article": "Walnuts, that is.\nAnd a study of men attending a fertility clinic, published in May by the journal Human Reproduction, found that high intake of omega-3 fats was linked to more normal sperm size and shape, while high intake of saturated fats was related to lower sperm concentration.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nWalnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Eating walnuts isn\u2019t harmful per se, but they are\u00a0packed with fat and protein,\u00a0and so they\u00a0should be eaten in moderation. The\u00a0amount participants in this study were eating (2.5 oz per day)\u00a0provides about 450 calories and is more than the amount of nuts that is generally recommended for daily consumption (1.5 oz).\u00a0It could\u00a0lead to weight gain if\u00a0not counterbalanced by\u00a0decreased intake of other\u00a0foods. The story\u00a0should have mentioned this.\u00a0 Of course the California Walnut Commission, which partially funded this study, would love to see people eat as many walnuts as possible.\u00a0 Why was the studied designed with this level of walnut consumption?", "answer": 0}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nThere were no reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar, the company said.\nOramed uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states that there were \u201cno reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar.\u201d", "answer": 1}, {"article": "The higher dose yielded greater reductions in amyloid levels, the study showed.\nThe big question is whether or not reducing amyloid levels has any effect on the symptoms or progression of Alzheimer's disease, said Dr. Patrick Lyden, chief of neurology at Cedars-Sinai Medical Center in Los Angeles.\nIf any of these drugs make it through the pipeline, it also needs to be determined who will get them, including whether the drugs will be given to prevent Alzheimer's in patients at high-risk of the disease or to treat it once it's started.\nThe leading theory of Alzheimer's disease is that an imbalance in the production or clearance of the amyloid plaque in the brain initiates a cascade of events that lead to dementia, explained Dr. Neelum Aggarwal, an associate professor of neurological sciences at Rush Alzheimer's Disease Research Center at Rush University Medical Center in Chicago.\nIn the United States alone, there are 5.4 million people with Alzheimer's disease, and the numbers are expected to increase to 13 million by 2050, when approximately three of every five people over the age of 85 will have Alzheimer's disease, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A strict application of this criterion warrants an unsatisfactory score.\u00a0 HealthDay only discussed \u201cpotential for serious side effects\u201d but didn\u2019t report how often they occured.\nWebMD, by comparison, gave specifics that two of six patients receiving the highest dose \u201cdeveloped possible findings of vasogenic edema, or fluid collecting in the brain tissue, as well as micro-hemorrhages.\u201d\nTo its partial credit, HealthDay did discuss several potential side effects, but why not report what was actually observed in the study you\u2019re reporting on?", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We liked the fact that the potential downsides of the bioabsorbable stent were included in the story.\u00a0The story notes that the bioabsorbable stent is thicker and may require patients to be on potent anti-clotting drugs, thus exposing the patient to a risk of bleeding. The story also notes that previous studies have shown a low rate of complications. We would have liked to have seen some information about the complications seen.", "answer": 1}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nFor far too long, though, coffee has been considered a vice, not something that might be healthy.\nThe first reviewed 20 studies, including almost a million people, and the second included 17 studies containing more than a million people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story warns that adding sugar and fat to coffee may negate any potential health benefits. The story also mentions \u201cjitteriness\u201d and the fact pregnant women should limit consumption, but doesn\u2019t describe the potential harms of excess caffeine in pregnancy that have been well described in the literature. And there are a number of studies suggesting that caffeine seems to trigger symptoms in people with anxiety disorders. More generally, what about the research on the ill effects of coffee on insomnia,\u00a0or urinary incontinence.\u00a0or dependence? \u00a0What about withdrawal headaches and the problems of \u201cstopping\u201d coffee drinking? \u00a0We\u2019ll give the benefit of the doubt here as we usually do on borderline calls, but the exploration of harms was not nearly as thorough as the coverage of benefits.", "answer": 1}, {"article": "The answer, said Wang, is \"We just don't know.\"\nThis is the first time that a combination of testosterone and a synthetic progestin called Nestorone has been tested as a gel that could be applied topically.\nAlthough men have sometimes received a bad rap for not being willing to assume responsibility for birth control, Dr. Joseph Alukal, an assistant professor of urology at NYU Langone Medical Center, in New York City, thinks this reputation may be somewhat undeserved.\nUp to 89 percent of the men who received the combination formulas saw their sperm concentrations plunge to less than 1 million sperm per milliliter, versus just 23 percent of those receiving only testosterone.\nThe results of the study, funded by the U.S. National Institutes of Child Health and Human Development, were presented at the recent Endocrine Society annual meeting, held in Houston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions acne as one of the problems seen with men taking the hormone gel, adding that we \u201cjust don\u2019t know\u201d what the long-term side effects might be.\nWhile this comes close to meeting the standard, there are actually quite a few other known risks (some quite serious) associated with the administration of testosterone, which is one of the two hormones contained in the test gel. As the Mayo Clinic website explains, testosterone therapy may:\nThe story should have mentioned some of these risks.", "answer": 0}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quantified harms are not as pertinent since this a blood test. However, one could infer indirect harms, the false positives and false negatives, from the data provided.", "answer": 2}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nIn clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\n\"But because suicide is a life-threatening event we thought it was important to provide this information in the product label.\"\nHis mom now believes that Singulair cost him his life.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is fundamentally about alleged harmful side effects of the drug, so this criterion is clearly established. ", "answer": 1}, {"article": "The hypotensive effect was dependent on time.\nThe maximum systolic BP lowering effect of melatonin falls between 3:00 and 8:00 in the morning, the time of the highest risk of heart attacks and strokes.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is clearly a downside to any supplement use, particularly in older people who may already be on multiple interacting medications.\nAlthough melatonin is probably safe for many adults, according to the University of Maryland Medical Center, a physician should be consulted before taking melatonin if you\u2019re already taking medications for high blood pressure, antidepressants and blood thinners, among others.\nA Web MD article states that melatonin can worsen symptoms in those suffering from bleeding disorders, diabetes, and seizures, and, perversely, may increase blood pressure levels in individuals taking medication to control those levels. Given the availability of melatonin supplements, ignoring the downsides for individuals with these common health problems is significant.", "answer": 0}, {"article": "Although the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nThere are no laboratory tests to diagnose migraines, depression, bipolar disorder and many other ailments of the brain.\nFurther, the researchers found that the technique was powerful enough to distinguish people who were extraordinarily alike.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of discomforts or potential dangers associated with MRIs.", "answer": 0}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "Tasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\nThe condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\nThey have gained nearly 8 percent since December 18.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. Even a brief discussion with a specialist or generalist who prescribes the similar drug ramelteon would have yielded some information about possible harms.", "answer": 0}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms weren\u2019t addressed at all. While lidocaine is most often used to numb sunburn, bug bites, and other skin pain, the Mayo Clinic\u00a0describes it as a last resort for relieving topical pain in kids under the age of 3. Lidocaine can be toxic when ingested by children when used for oral pain relief during teething. The FDA has tracked some cases of seizures and even death linked to use of the drug.", "answer": 0}, {"article": "If you'd like more information about the ONCOblot\u00ae Test, please visit http://www.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\nDallas, Texas -February 4, 2016 - MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot\u00ae Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot\u00ae test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the ONCOblot test itself involves just drawing a blood sample, the results of the test could produce life-threatening harms if it overdiagnoses people. In other words, a person told they have tested positive for these biomarkers for mesothelioma might start treatment too early or unnecessarily. Mesothelioma treatment is notably damaging. Let\u2019s put the study into perspective: there were a total of 32 people enrolled (17 with known malignant mesothelioma and 15 without). Hardly a large enough sample size on which to make the claims made. Although as we noted previously, early detection does offer a small survival advantage, it comes at a cost. The American Cancer Society notes that chemotherapy for mesothelioma can cause hair loss, mouth sores, loss of appetite, nausea and vomiting, diarrhea, increased risk of infections, easier bruising or bleeding, fatigue and long-lasting nerve damage. Radiation treatment also can cause many of the same problems, as well as lung damage. Combining radiation and chemotherapy often makes side effects worse.\nIt won\u2019t be known whether starting treatment earlier offers any benefits to people at risk for mesothelioma, but it is certain that treating more people earlier would cause more treatment-related harm.", "answer": 0}, {"article": "The researchers split the participants into two groups, one that received drug treatment and one that took placebo pills.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n\"The positive result was only marginally significant, and the negative result was clear,\" said Dr. Thomas McGlashan, a professor of psychiatry at Yale and the study's lead author.\n\"It's a pessimistic trade-off, the weight gain and other side effects for what looks like a modest delay in the acute psychotic episode,\" said Dr. Steven Hyman, a professor of neurobiology at Harvard.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions primary harms of treatment as weight gain seen in this short-term trial, but there is no mention of the long term side effects or safety of Zyprexa. Diabetes and complications of the metabolic syndrome have been noted in many patients taking newer anti-psychotic medications like Zyprexa. This may be a result of the significant weight gain from the drugs. The FDA has issued an additional warning about patients developing hypoglycemia and diabetes as a result of taking Zyprexa: http://www.fda.gov/medwaTCH/SAFETY/2004/zyprexa.htm", "answer": 0}, {"article": "Rabe has published reviews showing that delaying clamping for 30 seconds, or squeezing the umbilical cord to get the blood out faster, is also better for premature babies.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\nIn 2011, he published a study of 400 healthy, full-term babies showing that those clamped later fared better; the new study of 263 of those children extends those findings by nearly four years.\n\"The most important thing for parents to be talking with their provider about is how will we adapt to the delivery as it emerges,\" she said.\nHis previous research has shown that babies whose cords were clamped a few minutes later than usual were 90% less likely than others to have iron-deficiency anemia when they were 4 months old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not talk about potential harms to the newborn, such as jaundice, although it does mention the original rationale for quick cord-clamping, to limit the blood loss to the mother.", "answer": 0}, {"article": "The original MCE study was conducted between 1968 and 1973 at seven different long-term care facilities.\nWhile the diet rich in vegetable oil did lower cholesterol levels over the 4-5 year study period, compared to a control group (who continued to eat saturated fat daily), the researchers found no change in the rate of death from heart-related ailments.\nIt\u2019s unclear whether the corn oil or corn oil margarine consumed by the participants contained artery-clogging trans fats or hydrogenated vegetable oils that are now associated with heart disease, or whether the patients had a history of heart disease or genetic risk.\nThe new report, which analyzed 40-year-old data from the Minnesota Coronary Experiment, found no association between lower cholesterol levels and longer life, suggesting that reducing the amount of saturated fat in the diet isn\u2019t enough to reduce risk of death from heart disease.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention in the study (eating more unsaturated fat)\u00a0is unlikely to cause adverse side effects, risks, or\u00a0complications, so we\u2019re rating this\u00a0N/A.\u00a0The story did point out the surprising association between lower cholesterol levels and increased risk of death, though that could have been\u00a0explained more clearly.", "answer": 2}, {"article": "Biomarkers of inflammation were measured at the beginning and end of the study.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\nEditor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\nResults of the randomized, controlled clinical trial -- which involved more than 200 overweight, postmenopausal women who had insufficient levels of vitamin D at the beginning of the study -- are published online ahead of the July print issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because some of the participants were vitamin D-deficient and the dose of vitamin D provided was modest (2000 IU/d), this was a tough call. But supplementation is often so misunderstood, overhyped and oversold that some statement cautioning readers to pay attention to the specifics of this study and not apply its recommendations to everyone seems prudent.", "answer": 0}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study.\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention harms, such as missing an injury due to a false negative or having a false positive result that leads to unnecessary and potentially expensive follow-up tests and treatments.\nWith 100% sensitivity there will be no false negatives, but that is a suspect result. It\u2019s not clear what actions are (or are not taken) as a result of this test so it is hard to assess potential harms.", "answer": 0}, {"article": "\u201cAnd it might be of some help.\u201d\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story used terms like \"no harm\u2026safe\u2026and apparently has few downsides.\"\u00a0 Well, which is it?\u00a0 No harm or few downsides?\u00a0 And if the latter, then how few and of what kind?\u00a0 This is too vague and confusing. \nThis may also be an area in which products that are not as tightly regulated as prescription drugs carry a potential downside.\u00a0 Again, it\u2019s hard to get real information about purity, quality standards and bioavailability for supplements.\u00a0 ", "answer": 0}, {"article": "There\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\nIt detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\nWASHINGTON (Reuters) - It may be possible to predict which women will develop a dangerous complication of pregnancy called pre-eclampsia weeks before they ever show the first symptoms, an international team of researchers reported Monday.\n\u201cIf we can bring the rates of maternal deaths in undeveloped countries down to the rates in developed countries, by being able to determine which women are at the greatest risk for developing pre-eclampsia, then it has that potential to save thousands of lives,\u201d Baker said.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The preliminary nature of the research makes it difficult to accurately assess potential risks associated with the diagnostic test. At the same time, high in the story the lead author touts the huge potential benefits of the research. \"Such a \"metabolic fingerprint\" test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\" With all screenings and \"early warning sign\" tests there are opportunities for overtreatment and potentially harmful treatment, this should have been addressed in some fashion. For example, the main treatment right now for preeclampsia is magnesium sulfate. As the Preeclampsia Foundation, which is quoted in this story, points out on its website, \"Nevertheless, magnesium sulfate, is not a benign drug and must be used by a skilled health care provider with appropriate support facilities. Overdoses can and do occur.\"", "answer": 0}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable, as the potential harms of eating eggs are minimal. In just a line, though, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol). Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "\"Observing this, we asked ourselves if it was possible to pharmacologically induce immune quiescence with medication that was better assured of reaching the point of infection,\" said Ho.\n\"We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission,\" said Emmanuel Ho, a professor in the School of Pharmacy at Waterloo.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that the news release opens with\n\u201cScientists at the University of Waterloo have developed a new tool to protect women [emphasis added] from HIV infection\u201d\nit might lead some interested women to ask about side effects.\nThe question of harms is never addressed. That\u2019s a huge oversight given that the device is implanted and there are many risks associated with such procedures: pain, bleeding, infection, the device becoming dislodged, follow-up surgeries to remove the implant.\nNo potential risks are mentioned.\nIn addition, if the device is not effective in comparison to existing preventive strategies then there\u2019s a potential harm in relying on the device and acquiring HIV.", "answer": 0}, {"article": "But there are still a lot of unanswered questions about immune therapy.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\nIn addition to melanoma and lung cancer, this brake-release approach has been shown effective in early trials against bladder, kidney, head and neck cancers, and some blood cancers.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms associated with Opdivo, despite the fact that the Bristol-Myers Squibb release notes a variety of possible adverse side effects (and that 41 percent of patients receiving Opdivo had adverse reactions). These possible side effects included immune-mediated pneumonitis (i.e., lung inflammation \u2014 including fatal cases), hypothyroidism, colitis, and hepatitis, among others.", "answer": 0}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nThe secretions, he added, pour from the base of the appendix into the right side of the colon and are \u201cvery sticky\u201d and can obscure polyps.\nAbout a third of the colonoscopies were done by general internists and family practitioners who might not have had the experience to do the test well.\nAfter the test, patients can ask whether the doctor got to the right side of the colon and how that was documented.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of perforations, missed cancers and \"unpleasant\" preparation as the risks/side effects of colonoscopy.", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\n\"The results of the Phase 2 study suggest that MM36 represents a potentially safe, effective and well-tolerated non-steroidal treatment for mild-to-moderate atopic dermatitis,\" said Linda Stein Gold, MD, director of clinical research, Department of Dermatology at Henry Ford Hospital and co-author of the article.\nThe randomized, double-blind, vehicle-controlled study in 121 patients showed that MM36 demonstrates a statistically significant effect on the primary endpoints versus vehicle as measured by improvement in IGA score (Investigators Global Assessment) and percentage change in EASI score (Eczema Area and Severity Index).\n\"We believe these Phase 2 results demonstrate compelling evidence of MM36's capacity to be a leading topical PDE4 inhibitor and are aggressively developing MM36 for atopic dermatitis in the US.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published research report clearly reports that some subjects experienced a worsening of symptoms, or no real change, but the release fails to mention any data on side effects. According to the study, the harms were about the same in the high dose group and the placebo, but were greater in the low dose group (and that difference was statistically significant).", "answer": 0}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t give the details behind a physician\u2019s comment that \"there are relatively few downsides to trying statins\" and that statins are \u201crelatively safe.\" For the reader, who may not know much or anything about statins, what does that mean?\u00a0 What are the downsides?\u00a0 And how often do they occur? \nAlthough uncommon, statins may cause muscle soreness/damage or elevated liver enzymes.\nIn a shared decision-making environment, one would simply spell out the facts and let the reader/consumer/patient decide what \"relatively few\" and \"relatively safe\" means to them.\u00a0 ", "answer": 0}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\nHe said it was \u201chard to believe\u201d that soy would have an effect on these women.\n\u201cIt is something they need to gauge, is it worth the risk?\u201d Wong told Reuters Health.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a brief mention of harms that the National Institutes of Health list for soy supplements, but no mention of side effects experienced by women in the study.", "answer": 1}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nThe Mediterranean and DASH diets do not specifically recommend these types of vegetables, but the MIND diet study found that including greens in addition to other veggies made a difference in reducing the risk of Alzheimer's.\nBut the MIND diet also differs from those plans in a few significant ways and proved more effective than either of them at reducing the risk of Alzheimer's.\nEven those who didn't stick to the diet perfectly but followed it \"moderately well\" reduced their risk of Alzheimer's by about a third.\nAt least two servings a week can help, and researchers found six or more servings a week provide the greatest brain benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Following any of these three diets is better than the normal, high fat, salt and red meat standard American diet and even moderate adherence to these diets is thought to be heart healthy and perhaps brain healthy, too.", "answer": 2}, {"article": "These high and low phases are often so extreme they interfere with everyday life and work.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the side effects from lithium, saying, for example, \u201cBut it is very toxic \u2013 at only twice the right dose it could kill a patient, Churchill said \u2013 and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\u201d We\u2019d rather have hard data \u2013 e.g., if 100 or 1,000 people with bipolar disorder took lithium for five years, how many would be expected to die from lithium toxicity?\u201d\nWe would have liked to have seen some side effect information for ebselen. Instead, the story states that the drug \u201cmay be a swift answer\u2026since it is already known to be safe.\u201d Data, please?", "answer": 0}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n\"The idea is that all the surgeon will have to do is remove the pieces with a vacuum,\" says researcher Mark Packer, MD, of Oregon Health and Sciences University in Portland.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not discuss potential harms of femtolaser surgery or mention any adverse effect data reported in the studies\u00a0being discussed.\u00a0(Given the brevity of the presentations, it is perhaps not surprising that potential harms were not mentioned.) While there are no data for the use of the femtolaser in cataract surgery, the risks associated with its use are well described when used in vision correction surgery and could have been mentioned here.", "answer": 0}, {"article": "GW Pharmaceuticals funded the clinical trial.\n\"Cannabidiol should not be viewed as a panacea for epilepsy, but for patients with especially severe forms who have not responded to numerous medications, these results provide hope that we may soon have another treatment option,\" says lead investigator Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone Medical Center.\nIn addition to Dr. Devinsky, the co-authors in this study were: J. Helen Cross, PhD, FRCPCH, Linda Laux, MD, Eric Marsh, MD, Ian Miller, MD, Rima Nabbout, MD, Ingrid E Scheffer, MD, PhD , Elizabeth Thiele, MD, and Stephen Wright, MD on behalf of The Cannabidiol in Dravet Syndrome Study Group.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is clear in mentioning the side effects of the use of this drug in the study: \u201cSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity. The most common side effects in the CBD group were vomiting, fatigue and fever. Eight participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.\u201d", "answer": 1}, {"article": "And another mainstream expert is much more disapproving.\nWith names like SmartBrain Technologies and the Learning Curve Inc., they offer equipment purported, respectively, to \u201cpump the neurons\u201d and \u201cmake lasting changes in attention, memory, mood, control, pain, sleep and more.\u201d\n\nThe Food and Drug Administration regulates all biofeedback equipment as medical devices.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\n\u201cHe still has some symptoms, but he is much more manageable.\u201d\n\nWhether such results can be achieved with other children is a matter of debate.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story the benefit of the doubt on this criterion because it did at least mentions that there are potential harms, but the story would have been better if it had given more detail about the type and frequency of harms. It should have also clearly noted that risks exist even when a treatment is supervised by a skilled practitioner.One of the potential harms raised is this uNPRoven treatment may be favored over proven options like behavioral therapy and medication. \u00a0The story mentioned readily available neurofeedback packages while at the same time had stern warning from a society spokesperson that people can have seizures or anxiety attacks if they use equipment that they get from ebay and use without supervision. No information about how commonly problems such as these occur. ", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThe drug, Kybella, is a form of synthetically derived deoxycholic acid, which the body produces naturally to help absorb fats.\nThe most common side effects included swelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nThe Food and Drug Administration on Wednesday approved a new treatment for adults with \"moderate-to-severe fat\" below the chin, known as submental fat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the FDA\u2019s warning that \u201cthe new drug can cause serious side effects, including trouble swallowing or\u00a0nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\u201d It then lists side effects, which\u00a0included \u201cswelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\u201d\nThis is sufficient for a Satisfactory rating. But the story could have could have mentioned a key concern cited by the FDA in the second sentence of its news release: \u201cUsing Kybella for the treatment of fat outside of the submental area is not approved and is not recommended.\u201d A reworded version of that warning is repeated twice more in the news release.", "answer": 1}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n\"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments,\" Borges says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "According to the original study, 30% of the patients had to have their treatments \u201cinterrupted,\u201d usually due to effects on liver function, although the study says the drug treatment was \u201calmost always\u201d re-initiated, and no one had to be removed from the drug entirely. None of these problems was mentioned in the news release, which also offers no specific information about the frequency or severity of side effects.", "answer": 0}, {"article": "\u201cThe findings were exciting,\u201d she said.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The National Center for Complementary and Integrative Health says relaxation techniques such as deep breathing exercises \u201care generally considered safe for healthy people, although there have been a few reports of\u00a0negative experiences such as increased anxiety. People with serious physical or mental health problems should discuss relaxation techniques with their health care\u00a0providers.\u201d\nIt\u2019s also possible that some people with serious disorders may not seek other proven treatments in the belief that deep breathing will help them.", "answer": 0}, {"article": "JACC is ranked No.\nIn addition, as many as 20 percent of people hospitalized with a heart attack report symptoms of depression, while patients with heart disease have three times the risk of developing depression compared to the general population.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nThis research also demonstrates the positive effects of exercise for all patients, including those with depressive symptoms,\" said study author Arshed A. Quyyumi, M.D., co-director of the Emory Clinical Cardiovascular Research Institute in Atlanta.\nThe College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t delve into harms but we\u2019ll rate this Not Applicable since the release doesn\u2019t give us any specifics on the types of exercise the study volunteers took up. Some exercises are riskier than others.", "answer": 2}, {"article": "\u201cBut difficulty with navigation is increasingly recognised as one of the very earliest symptoms.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\n\u201cBy pinpointing those who are beginning to lose their navigational skills, we hope to show that we can target people at a much earlier stage of the condition and one day become far more effective in treating them.\u201d\n\nThe discovery that loss of navigational skills was associated with Alzheimer\u2019s disease was made several years ago by Chan and colleagues based at several centres in the UK.\n\u201cThe entorhinal cortex is the first brain region to show degeneration when you get Alzheimer\u2019s, and that is where we shall be focusing our research,\u201d said Chan, whose work is funded by the Alzheimer\u2019s Society.\n\u201cIt is usually thought memory is the first attribute affected in Alzheimer\u2019s,\u201d said project leader Dennis Chan, a neuroscientist based at Cambridge University.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The big risk here, as with any screening test, is incorrect results. Even if the study hasn\u2019t happened yet, and important data sets like sensitivity and specificity can\u2019t yet be quantified, they should be addressed in the story. What are sensitivity and specificity? Sensitivity measures how often a test correctly generates a positive result for people who have the condition that\u2019s being tested for. Specificity measures a test\u2019s ability to correctly generate a negative result for people who don\u2019t have the condition that\u2019s being tested for. In other words, there are two possible harms inherent in diagnostic and risk assessment tools: the failure to identify someone who has Alzheimer\u2019s; and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. Either mistake can have significant costs \u2014 financial and personal \u2014 for patients.", "answer": 0}, {"article": "\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nAlthough many patients take drugs like statins and medicine to reduce their risk of stroke, surgical treatment of severe blockages in the carotid artery has been shown to be more effective than medical therapy alone in preventing ischemic strokes caused by a buildup of plaque in the arteries.\nIt included 2,502 patients at more than 100 in the United States and Canada, who were randomly assigned to receive either surgery or stenting over a period of nine years.\n\u201cWhat this trial has done overwhelmingly,\u201d he said, \u201cis shown that in , with the very skilled surgeons and physicians performing stenting, the outcomes were extremely safe.\u201d\nThe trial included patients who had suffered a stroke or a ministroke and those who were asymptomatic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the LA Times coverage,\u00a0this story gives us the key\u00a0essentials regarding what happened to patients in both studies and their risk of major complications such as stroke or heart attack.", "answer": 1}, {"article": "One study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We thought that NBC did a better job detailing some of the potential harms from statin use, but we give the Times credit here for framing the story as a discussion of risks vs. benefits and making it clear that experts critical of the new guidelines believe that they \u201cwould lead millions of additional people to take statins, exposing them to potential side effects such as\u00a0muscle pain\u00a0or damage with little to gain.\u201d", "answer": 1}, {"article": "On the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\n\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\nThe question then becomes finding out what your risk of heart attack is in the first place, which your doctor can help with.\nOne recent study has suggested that despite the increase in bleeding ulcers from aspirin, the reduction in heart attacks might make the cheap drug cost-effective for men over 45.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201caspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d", "answer": 1}, {"article": "For more industry information, health research and recipe ideas, visit =.\nFolsom, Calif., (May 11, 2015) -- A new animal study from Beth Israel Deaconess Medical Center, Harvard Medical School, led by Dr. Christos Mantzoros, indicates that a diet containing walnuts may slow colorectal tumor growth by causing beneficial changes in cancer genes.\nColorectal cancer is the third most common type of cancer worldwide and is second to only lung cancer as the leading cause of death in Western Countries.1 Diet has been shown to be a modifiable risk factor in preventing many types of cancer, including colorectal cancer.\n\"While future studies are needed, we're optimistic of the role of miRNAs as biomarkers of disease and prognosis, and may demonstrate a potential therapeutic target for colorectal cancer treatment.\"\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The limited study did not appear to investigate potential harms, and the release didn\u2019t comment on them. For humans, consumption of too many calorie-dense walnuts could precipitate weight gain. But the equivalent of two ounces a day doesn\u2019t sound like it could be very harmful. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cShortly after that he told me I could relax and that I did a good job and they had retrieved the clot and just to relax and I immediately started trying to move my arm.\u201d\n\n\u201cA patient will come in, they can't speak, they can't move half their body,\u201d says neurosurgeon Dr. J Mocco, of Mt.\nThe intravenous drug is very effective for smaller clots, but it often fails to break up larger clots and is usually most effective when given within 4.5 hours after the first symptoms.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\nIt was an ordinary morning for Stefan Reisch as he was driving to work, when out of nowhere, it seemed to hit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from any aspect of the treatment studied. This is a major oversight in any story, but especially one dealing with a surgical procedure.", "answer": 0}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nAnd they consider themselves lucky.\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\nNow that's trickier.\nSusan Mueller, a mother of two in Ithaca, N.Y., bought shares in a dairy farm so she could pick up her raw milk and yogurt at a drop-off point closer to home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned safety concerns associated with consumption of raw milk, especially by individuals who may have heightened vulnerability. \u00a0(The story also included comments from people who are fans of raw milk who claim these concerns are overblown.) However, this is one area where this story could have been improved. \u00a0Raw milk has the potential to make people quite ill, especially children (which was mentioned in the story) but also pregnant women, those whose immunity is compromised as well as the general public. \u00a0It should have included more information about infection rates among people consuming raw milk.", "answer": 0}, {"article": "Johansson and her colleagues used data from nationwide Swedish health registries to compare pregnancies between nearly 600 women who had given birth after bariatric surgery and more than 2,300 women who hadn't had the surgery but had the same BMI.\n\"The number of women who are obese in early pregnancy has increased dramatically over the last decades,\" said study author Kari Johansson, a postdoctoral researcher and nutritionist at Karolinska Institute in Stockholm.\nWEDNESDAY, Feb. 25, 2015 (HealthDay News) -- After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, a new study suggests.\nBecause obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\nWhile various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines' absorption of calories and nutrients from food.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story uses relative ratios to express the possible negative effects of bariatric surgery (e.g. \u201cthe weight-loss surgery group was twice as likely to give birth to babies considered small for their gestational age, and their pregnancies were also of slightly shorter duration.\u201d), which misses critical information needed to understand the clinical or real world significance of these results. What was the overall percentage of babies considered small in each group, and was this a small or a large number? How worried should people be about this? Another concern is that the story didn\u2019t emphasize or quantify the more important harmful outcomes. There was a higher rate of stillbirths and neonatal deaths in the surgery group (1.7% in the postsurgery group and 0.7% in the control group) which, while not quite statistically significant, provides cause for concern. \u00a0We think readers would be most interested in this \u2014 more deaths among babies of women who had bariatric surgery. But the story mentions merely \u201ca slight bump in the rate of stillbirths.\u201d", "answer": 0}, {"article": "Foods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email.\nResearchers found the antioxidant activity of dark chocolate and cocoa powder was equivalent to or higher than that found in some other so-called \u201csuper fruit\" powders or juices, including acai berry, blueberry, cranberry, and pomegranate.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Starting with the headline, this story extols the\u00a0health-promoting\u00a0properties of the antioxidants found in chocolate, and it isn\u2019t until the last sentence that we receive\u00a0a hint of a warning about\u00a0potential downsides of chocolate, such as high saturated fat\u00a0and total calorie content.\u00a0The story states, somewhat euphemistically, that dark chocolate is a \u201cpotential superfood to be enjoyed in moderation.\u201d The story should have cautioned that you will have to limit yourself to\u00a0just\u00a0a small square of chocolate per day \u2014\u00a0a fraction of a standard chocolate bar, and much less than what the average person consumes as a snack \u2014\u00a0to achieve any potential health benefits. If you eat any more,\u00a0the weight gain caused by the additional calories will most likely negate any benefits from the health promoting antioxidants.", "answer": 0}, {"article": "DePaolo pointed out, \u201c[Elagolix] doesn\u2019t have the pronounced side effects some of the other compounds have.\u201d That\u2019s because, he said, it doesn\u2019t drive down estrogen levels as severely.\nThe success of surgery also depends on finding a skilled and experienced surgeon, and there\u2019s always the risk of surgical complications.\nMany women in the trial experienced the symptoms of menopause \u2014 hot flashes, headache, insomnia \u2014 and researchers have also found the drug causes bone loss.\nMood swings and night sweats were less common, and one woman in the trial died by suicide (though there\u2019s no indication that the medicine was a cause of her death).\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause.", "answer": 1}, {"article": "Each carries problems.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\nCurrent methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might come from use of this new approach.\u00a0 And while the story claims that the new technique \u2014 shear wave elastography (SWE)\u00a0\u2014 is non-invasive, there are clear harms that can come from false negatives or false positives with any screening technique.", "answer": 0}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\n\u201cPatients and their health care providers should discuss the benefits and risks of Siliq before considering treatment,\u201d said Dr. Julie Beitz, director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research, in an agency press release.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\nThis small difference is significant, says Dr. Richard Fried, a member of the National Psoriasis Foundation medical board, since responses to drug treatments can vary dramatically from person to person.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a strong point for the story. In the\u00a0second paragraph, it states that the drug will be sold with a \u201cblack box warning\u201d because of \u201can association with suicidal thoughts and behaviors\u201d among those who took it. It goes further, later on, by saying, \u201cThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\u201d\nAs well, the story spends at least two additional paragraphs discussing the link between use of the drug and suicide, and finally, it cites its effect on the immune system and how it should not be taken by people with some chronic conditions, such as Crohn\u2019s disease.\n(For more on the checkered history of this drug\u2019s side effects as noted in\u00a0clinical trials, see this same criterion in our news release review for the FDA approval of Siliq.)", "answer": 1}, {"article": "\"Thanks to our results, radiotherapy is recommended to many rectal cancer patients.\"\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\nThese hypotheses have now been tested in a study in which rectal cancer patients were randomly assigned to three different treatment arms:\n\u2022 Delayed surgery with short-course (5x5 Gy) radiotherapy followed by surgery after 4-8 weeks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. The news release refers to harms/adverse effects from radiotherapy at least four times but does not name even one potential harm, so we\u2019re rating it unsatisfactory for the omission. \nAccording to the study, the most common postoperative complication was infection, which occurred in 18 percent of patients. The study also mentions bowel obstruction and pelvic abscesses. About 7 percent of patients whose surgery was delayed were hospitalized for radiation toxicity.\nThe news release (and the abstract of the journal article) avoid a thornier question. Could delaying surgery after radiation treatment of rectal cancer increase the chance that rectal cancer will come back? The study found rectal cancer recurred in 2.8% of patients an average of 19 months after delayed surgery and in 2.2% of patients an average 33 months after\u00a0surgery at the usual time. The small\u00a0difference seems to\u00a0favor the usual\u00a0timing of surgery. The authors take a scientifically valid\u00a0position that if the difference in rate between options could have happened up to 5 percent of the time by random chance, then the new\u00a0option is \u201cnoninferior\u201d to the standard treatment, as is the case here.\u00a0It is quite possible that cancer outcomes are slightly worse for the new timing of treatments, but justified by a much bigger improvement in complication rate. The absolute difference in local cancer recurrence is only 0.6% (with a large margin of possible error) whereas surgical complications were reduced by an absolute 12% (41 vs. 53%).\nThe study notes that one potential drawback of delaying surgery is that it delays the start of chemotherapy in\u00a0 regimens that include chemotherapy after a tumor has been removed. But it says chemotherapy could be more effective if administered before surgery, so a delay would present an opportunity to administer chemo. Whether that would help patients would need to be determined by another research study.", "answer": 0}, {"article": "While the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nAt least five years would need to pass before such a declaration would be considered.\nFifteen other patients who got the same treatment died.\nThey are alive, with no evidence of cancer, 18 months later.\n\"I have every expectation that we can get it to work better.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms or side-effects that have been experienced with this form of treatment. ", "answer": 0}, {"article": "Few of the programs studied, though, included exercise.\n\u201cIt took people less time to lose 10 pounds\u201d on a high-fat diet-and-exercise program, about 45 days on average, than the 70 days it took for those who exercised and followed a high-carbohydrate, low-fat diet constructed using guidelines from the American Heart Association, said Kerry J. Stewart, director of clinical and research exercise physiology at Johns Hopkins University School of Medicine and lead author of the report.\nAnd like most of the recent studies about the health effects of low-carbohydrate diets, \u201cthese are very short-term results,\u201d said Dr. Dena Bravata, an internist and research associate at the Center for Primary Care and Outcomes Research at Stanford University, who was not involved with this experiment but has conducted dietary studies.\nAt the start of the program, the volunteers all had healthy blood vessels, as determined by a blood-pressure cuff test in which researchers tighten the cuff, release it and track the resulting gush of blood to the volunteers\u2019 fingertips.\nWith the memory of Memorial Day cheeseburgers and bratwursts still lingering, many of us may be relieved to hear that a new study suggests that a meaty, high-fat, Atkins-style diet can do more than contribute to rapid weight loss.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there were no harmful effects on the blood vessels observed in either group. \u00a0However \u2013 since people in the study were reported to have healthy vessels to begin with, combined with the short amount of time they were followed, it is very unlikely that any change would be seen. \u00a0So it is really insufficient evidence about lack of harm.\nThe story lacks perspective on the problem of knowing whether a treatment is safe or not. We need thousands of people in a clinical trial to determine cardiovascular safety, not 46.", "answer": 0}, {"article": "But there are still hurdles to clear.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nIt\u2019s by no means a cure for migraines, but it should be enough to merit Food and Drug Administration approvals if the companies can replicate those results in larger trials, according to Eric Schmidt, a securities analyst at Cowen and Co.\n\nEach treatment is now in late-stage development, targeting the roughly 38 percent of migraine sufferers who, like Novak, have at least four headache days per month.\n\u201cI felt like my life was being stolen from me.\u201d\n\nCollectively, Americans miss about 113 million workdays each year because of migraine.\nSo far, the four drugs have performed similarly in clinical trials, and analysts expect the contenders will have to compete on price to grab market share.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the companies has reported \u201cserious side effects,\u201d according to the story, which does go on to note that the studies so far have been short-term, 12-week trials and that an understanding of the impact of the drugs \u201cwill take years.\u201d\nHowever, we find this lacking. Even if there weren\u2019t \u201cserious\u201d side effects, readers still want to know what the potential downsides are, and surely there were noted side effects that would have to be weighed against the benefits.", "answer": 0}, {"article": "(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\nBuprenorphine is commonly known by the the brand name Suboxone, and naltrexone is sold under the brand name Vivitrol.\nIf a person is using opioids and takes naltrexone, it can induce a feeling of withdrawal.\nThey all chemically bind to the opioid receptors in the brain to help dull pain and, in some people, provide euphoria.\nThey report good outcomes, avoiding heroin use,\" Lee said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both Vivitrol and Suboxone have side effects that are not compared\u2014or even mentioned\u2014in this story.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article mentioned overuse of the treatment, there wasn\u2019t an explicit mention of the type of harms associated with using hyperbaric therapy.", "answer": 0}, {"article": "A hijab, a turban, a beard: What aren\u2019t you seeing?\nNewsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nHere\u2019s how he got out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One expert is quoted saying, \u201cBut in general, the kind of exercise we\u2019re talking about is certainly not going to hurt.\u201d But suggestions for incorporating techniques such as walking backwards would seemingly come with some risk, especially in an unsupervised location.", "answer": 0}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nAfter a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\n\"Once these symptoms can be identified and measured, it\u2019s possible to develop technology and devices that help humans manage their symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed, and there\u2019s no study to suggest what those might be. But presumably the physical harms here would be minimal, given that thousands if not millions of people wear vibrating smart watches without any known ill effects.", "answer": 2}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\nIt's the same technology used since the 1980s to blast kidney stones, an application called lithotripsy, but for foot problems doctors use less intense shock waves.\nIn high-impact activities like running, the forces even exceed the actual weight because it's so concentrated in a narrow spot where the fascia attaches to the heel bone.\n-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\n\"The stretching, the icing, the taping -- I do all these little pieces of help for my body, and it responds,\" Firestone says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of side effects is the report of some bruising for\u00a0two days afterwards. Potential risks of this treatment include discomfort soon after the procedure. And then there is the possibility that the procedure may make the condition\u00a0worse. Some information acknowledging the risks \u2014 even if they are minor and temporary \u2014 is always appropriate.", "answer": 0}, {"article": "Leading the way is the University of Texas M.D.\nThe greatest promise seems to involve blood and microscopic cancers, but targets for immunotherapies in clinical trials range from lymphoma and brain cancer to cancers of the breast, prostate, colon and lung.\nThe idea is simple: Instead of poisoning the cancer and causing grueling side effects, it signals the patient's immune system to attack malignant cells, much as the body does with viruses and bacteria.\nThey say the greatest strides are being made against cancers where the immune system can fight them in manageable stages, such as in the blood or lymph nodes.\nAround the country, about 140 immunotherapy trials are under way, some of them the final hurdle before they go up for Food and Drug Administration approval.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that \u201cimmunotherapy\u2019s great appeal is its nontoxicity\u201d and that a patient has had no side effects. This is not enough information on the harms of treatment.", "answer": 0}, {"article": "The new analysis was published online Monday in Archives of Internal Medicine.\nWhile the difference in results for real versus fake acupuncture was small, it suggests acupuncture could have more than a psychological effect, said lead author Andrew Vickers, a cancer researcher at Memorial Sloan-Kettering.\n\"Perhaps a more productive strategy at this point would be to provide whatever benefits we can for our patients, while we continue to explore more carefully all mechanisms of healing,\" he wrote.\nThe military has used it to help treat pain from war wounds, and California recently passed legislation that would include acupuncture among treatments recommended for coverage under provisions of the nation's new health care law.\nThe results \"provide the most robust evidence to date that acupuncture is a reasonable referral option,\" wrote the authors, who include researchers with Memorial Sloan-Kettering Cancer Center in New York and several universities in England and Germany.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says acupuncture is \u201crelatively safe,\u201d but doesn\u2019t specify that safety can be improved by selecting licensed\u00a0practitioners. It also does not mention\u00a0that acupuncture is associated with rare reports of serious adverse events, most of which seem to occur with unqualified practitioners.", "answer": 0}, {"article": "This determined the most effective treatment frequency.\nOne can expect the effects to be similar to exercise therapy,\" said Dr. Tatsuya Kondo, who lead the research.\nThe heat shock response (HSR) is activated as a response to stress in the human body, but its function decreased in those with type 2 diabetes.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\nA research team from Kumamoto University, Japan has found that by restoring the function of HSP72, the main protein of HSR, improved glucose-related abnormalities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The belt device is claimed to be well tolerated, but no details on potential harms are given. The release notes: \u201cThe team found that a suitable combination of mild electrical stimulation (MES) with heat shock (HS) activated HSP72 more efficiently.\u201d What is the electrical stimulus and how uncomfortable is it? \u00a0Exactly what is a delivery of heat shock? What temperature is used? And finally is the device battery operated or is it a plug in? \u00a0All of these unanswered questions seem relevant to understanding the device.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nThe researchers also found that surgeons who have done fewer than 20 of the robot-assisted procedures can achieve \u201cacceptable operating times.\u201d Keeping surgeries shorter is a goal because it usually means fewer complications.\nAnd while the robot-assisted operation is now the \u201cdominant approach\u201d to this surgery in the US and is gaining popularity in other wealthy nations, there\u2019s still too little information on how patients fare after the surgery, Dr. Declan G. Murphy of the Peter MacCallum Cancer Center in Melbourne, Australia and his colleagues write.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story provides readers with some potentially interesting questions to raise with a doctor (e.g. how many of these surgeries have you done using this equipment; is this approach the best for the type of cancer I have, i.e. early or more advanced). \u00a0The story mentions in passing potential harms such as impotence and incontinence, referencing a study published in October. \u00a0\nHowever \u2013 the story did not really follow-up on one of the key issues it raised. \u00a0For example, the story mentioned that a surgeon will have to do 80 procedures with this equipment to ensure that they don\u2019t leave any cancerous tissue behind. \u00a0The story could have completed this thought and indicated the ramifications of leaving cancerous tissue behind in terms of health consequences.", "answer": 1}, {"article": "Anderson estimates Jardiance could boost Lilly\u2019s earnings per share by 8 percent on average across 2016 to 2020.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nIn calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study\u2019s main goal.\nZinman noted that Jardiance, like other SGLT2 drugs, causes weight loss and reduced blood pressure, besides lowering both blood sugar levels and body fat, and also reduces swelling, which all help the cardiovascular system.\nThat has not been the case with all things in diabetes,\u201d said David Marrero, president of health care and education at the American Diabetes Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t mention any harms associated with Jardiance, a type of SGLT2 inhibitor. Some mention of potential adverse effects is always appropriate in stories about new drugs.", "answer": 0}, {"article": "Driscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nThose who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nary a mention of the potential risks of caffeine, particularly in an older population. Caffeine is associated with\u00a0headaches, tachycardia (rapid heart rate), and anxiety to name a few.", "answer": 0}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nThe associated pain can last months or even years.\nCalled Zostavax, the shingles vaccine is made by Merck.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that earlier research identified side effects of the vaccine, including redness and pain at the injection site. But an inquiring story would have asked about side effects in the new study.\n", "answer": 1}, {"article": "Powerful chemotherapy and radiation treatments for cancer can impair a woman's fertility.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely mentions the risk \u2013 which it says is not increased \u2013 of a return of cancer. Since that\u2019s likely the main concern with this procedure, we\u2019ll go ahead and award a Satisfactory. But we\u2019d add that women who have\u00a0their own ovarian tissue removed and then reimplanted in a new surgery could potentially have complications of\u00a0those procedures (all surgeries carry some risk). No such complications are addressed in the study that\u2019s the basis for this story, and it\u2019s not clear if adverse effects (beyond cancer recurrence) were tracked by the study authors. We wish the story had asked about, and covered, those potential harms.", "answer": 1}, {"article": "But some pain experts defend the value of the diagnostic tests.\nSkipping the diagnostic nerve blocks can save $10,000 in medical costs.\nPatients don't care much about the finer points of diagnostic accuracy.\nIn doing so, they may weed out patients who would actually benefit from treatment, according to the study.\nCoping with an aching back isn't easy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms incurred or avoided. ", "answer": 0}, {"article": "The timing of treatment also mattered.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\n\u201cThe percentage of attacks for which TENS is sufficient as sole treatment and allows sustained pain relief remains to be determined,\u201d Schoenen cautioned.\nWhen researchers excluded the lowest pulse width, they found 64 percent of people in the other active treatment groups had at least a 50 percent pain reduction two hours after treatment, compared with 26 percent of people in the placebo group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects are minimal but worth mentioning \u2014 and this story doesn\u2019t lay them out. Some users can be allergic to the sticky pads of a TENS system, and those with heart conditions, metal implants, epilepsy, or other\u00a0neurological conditions might be poor candidates for it.", "answer": 0}, {"article": "These included 1 percent who had blood clots and 1 percent who suffered bleeding.\n\"The practical implication is the possibility to incorporate Avastin with any chemotherapy regimen in the frontline therapy of metastatic non-squamous lung cancer,\" he added.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\nFor the study, Crino's team studied Avastin in more than 2,200 patients with advanced or recurrent non-squamous non-small-cell lung cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story reported on the potential harms associated with the addition of this drug to a treatment regimen. \u00a0Without information about what a patient might gain \u2013 it is hard to know whether the risk of these harms is worth the potential benefit. And the story could have provided more details about the severity and impact of the harms.\u00a0 Nonetheless, we give it a satisfactory on this criterion. ", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story illustrates how hard it can be for a parent to enforce cognitive rest.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The CCTA test was reported as a non-invasive alternative to angiography. \u00a0But there was no mention of the harms associated with this test which includes radiation exposure, which is higher than that associated with angiography; the potential for allergic reaction to the material injected to allow the vessels to be seen; and the potential for there to be harms from following up on something seen on the CCTA which turns out to be nothing.\n(A sad, but fascinating case report can be found in the Archives of Internal Medicine Dec 14, 2010)", "answer": 0}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nEight of the 32 got ipilimumab alone, 23 got ipilimumab plus a vaccine called gp100, and one got the vaccine alone.\nThe team found that in patients whose cancer initially progressed while on ipilimumab, whose who were reintroduced to the drug had a disease control rate of 65 to 75 percent, compared to zero in the patient who got the vaccine only.\nCHICAGO (Reuters) - An experimental cancer drug showed early promise at helping patients with advanced melanoma that had spread to the brain, according to a summary of data from a mid-stage study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not give any details about side effects. It is worth noting that the abstracts themselves fail to provide much details about treatment harms, which is one of the problems with basing a news story on medical meeting abstracts.", "answer": 0}, {"article": "So what if it were possible to know before treatment which men might be more likely to suffer complications?\n\u201cThis is still not nearly good enough, yet\u201d he said.\nThis kind of work is important not just for prostate cancer, but all cancers.\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\nIf they can, then doctors really will be \u201cable to assign patients to treatments and see if we maintain the same level of control of cancer and lower the incidence of complications,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable; given that this is still an unproven strategy, there are no data for harms.", "answer": 2}, {"article": "COLUMBIA, Mo.\n(March 10, 2016) - Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\nUsing the Surveillance, Epidemiology and End Results (SEER) program database, Pokala and his research team studied 364 patients who underwent a salvage radical prostatectomy surgery after unsuccessful radiation treatments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention or explain any harms that might be associated with these surgeries. This strikes us as especially disappointing because some of the side effects of surgery are known to influence patient decisions about treatment. The two side effects that get the most attention are incontinence and impotence.\nThe researcher is quoted acknowledging the fear that patients have, but does not offer any measures for post-surgical outcomes related to quality of life. We found that disappointing.\n\u201cBecause radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\u201d Pokala said. \u201cHowever, this study shows that it is a viable treatment option. This can bring a renewed hope and peace of mind to men living with prostate cancer.\u201d\nHarms for either surgery or radiation alone such as urinary, bowel, and sexual dysfunction, can adversely affect quality of life. The literature suggests that salvage prostatectomy can cause even more worrisome complications such as damage to pelvic structures, blood clots, and bleeding. \u00a0Unfortunately, these data are not available in the SEER database so the authors could not assess\u2013an important\u00a0limitation of the study.", "answer": 0}, {"article": "\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nAs measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nThe treatment, dubbed Early Start Denver Model or ESDM, offers a child 20 hours a week of one-on-one treatment with a trained therapist.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\nTheir brains light up when they look at pictures of objects, but not when they look at faces.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any potential harms in this story. It is very possible that the therapy itself does not have any actual side effects, but we always think the risk profile of a therapy is worth a mention.", "answer": 0}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\n\"This study is the first to compare the cancer-fighting potency of plant- versus marine-derived omega-3s on breast tumour development,\" said the professor in the Department of Human Health and Nutritional Sciences.\n\"Seeing the significant benefits omega-3s can have in combatting a highly aggressive form of breast cancer means omega-3s will likely be beneficial for other types of cancer.\"\nThere are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some fatty and farm fish contain significant levels of mercury, PCBs, and other contaminants and experts recommend limiting their consumption and avoiding them entirely if you\u2019re pregnant. That isn\u2019t mentioned. The release also conveys an endorsement of fish oil tablets, which can have side effects such as heartburn, nosebleeds, hot flushes, leg cramps, nausea and bad breath.", "answer": 0}, {"article": "For more information, visit http://www.aaojournal.org.\nAbout OphthalmologyOphthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed, clinically-applicable research.\n\u201cWhile we cannot totally avoid developing cataracts, we may be able to delay their onset and keep them from worsening significantly by eating a diet rich in vitamin C.\u201d \u201cGenetic and Dietary Factors Influencing the Progression of Nuclear Cataract,\u201d Yonova-Doing, et al.\nFor more than 120 years, we have been educators, innovators and advocates for the public and our profession to ensure the highest-quality medical and surgical eye care.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of harms that may come with increasing the amount of Vitamin C one consumes in their diet. While mega doses of Vitamin C supplements are known to be harmful, this release and study stress that the focus here is on obtaining Vitamin C through food sources.", "answer": 2}, {"article": "Frustrations included warning alarms and problems at the insertion point of the device.\n\"The promise in the near term of these technologies is not only to help us reduce significantly the risk of long-term diabetic complications, but also to reduce the risk of having a catastrophic hypoglycemic event, and further help people with diabetes live easier,\" Aaron Kowalski, research director of the JDRF's Artificial Pancreas Project, said during the teleconference.\nA symposium on advances in the technology -- co-sponsored by the American Diabetes Association and the JDRF -- is slated for Sunday as part of the American Diabetes Association's annual meeting, in Orlando, Fla.\n\nFor people with type 1 diabetes, controlling their blood sugar levels is a full-time job.\nIn the first report, Dr. Roman Hovorka, a principal research associate in the department of pediatrics at the University of Cambridge, reported that the technology can significantly improve overnight blood sugar control in adults without the fear of developing hypoglycemia.\nSUNDAY, June 27, 2010 (HealthDay News) -- New research suggests that artificial pancreas technology can help diabetics gain greater blood sugar control overnight, even when they have eaten a big meal or had wine for dinner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The investigator is quoted as saying that \"We reduced hypoglycemia by half.\" There\u2019s a dissonant choir of problems with this statement. First, it\u2019s not clear from the sentence\u2019s placement in the article if this result came in the prior study with children or in the current study with adults. (The rest of these points assume the latter.)\nSecond, the article doesn\u2019t identify the comparator group (those who just used the insulin pump), so a relative result is meaningless. So when the claim is made, \"We reduced hypoglycemia by half,\" readers should be told \"half of what?\" \nThird, the fact that they used a relative risk reduction figure, not an absolute one, is important because this study was so short and small, using relative risk reductions masks the weight (or thinness)\u00a0of the evidence, especially when we don\u2019t have the statistical significance. \nFourth, we\u2019re not sure what data the investigator\u2019s statement of reducing \"hypoglycemia by half\"\u00a0is based on. In\u00a0the\u00a0abstract, it\u2019s says that the time spent below target glucose was approximately half but\u00a0the difference was not\u00a0statistically significant, no doubt due to the small power and short duration of the study. If our interpretation is correct, the story\u2019s author has touted a benefit that\u2019s insignificant, statistically speaking.\nFifth, it should\u2019ve been clearer about what \"reduced hypoglycemia\" mean? The total time spent below target glucose range \u2014 which averaged out over the course of the study \u2014 is different than a (severe) hypoglycemic event, which some readers may read in this result. How dangerous is it to spend any time below the target range, if only temporary and possibly briefly? In other words, is it a harm or an efficacy issue? In the\u00a0abstract, we read about 1 serious case of hypoglycemia \u00a0with the insulin pump, 0 with the closed-loop system; but again, with 12 patients using each for a night, statistically we\u2019re not sure what that tells us.\u00a0\nRegardless of the true intent of this statement, and the true harms that occurred in the study, an independent analysis may have clarified such confusions.", "answer": 0}, {"article": "\u201cI wouldn\u2019t say it\u2019s a cure.\nSo, that these results were so positive for something that\u2019s very safe is an impressive accomplishment.\u201d\n\nRecent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis.\nAnd Dr. Gloria Yeh, a Beth Israel Deaconess internist and co-author of the editorial, said others \u201cwill say, \u2018It\u2019s too slow, I can\u2019t do that.\u2019 \u201d\n\nBut she said it offered a \u201cgentler option\u201d for patients deterred by other physical activities.\n\u201cI was used to being treated in a condescending manner because they couldn\u2019t diagnose me: \u2018She\u2019s menopausal, she\u2019s crazy.\u2019 \u201d\n\nBefore the study, \u201cI didn\u2019t know tai chi from a sneeze,\u201d said Ms. Petersen, who has diabetes and other conditions.\nThe fibromyalgia study involved the yang style of tai chi, taught by a Boston tai chi master, Ramel Rones.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0A big point of the story is that tai chi would be a much less onerous therapy with no harmful side effects. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The journal article on which the story is based clearly discussed this. ", "answer": 0}, {"article": "The Company's website can be accessed at http://www.\nThe investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\nIn the randomized studies, 44 men started on 12.5 mg of oral enclomiphene citrate daily, with 25 men being up-titrated to 25 mg; 42 men received a topical 1.62 percent AndroGel; and 41 men received a placebo.\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release\u00a0did not include any mention of adverse events from the trial in question. \u00a0We always look for an explicit discussion of potential harms. Excerpts from the\u00a0journal manuscript:\n\u201cThere were 53 (21%) men in the studies who had adverse events\u00a0considered by the investigators to be possibly, probably, or definitely related to the study drug. None of these were severe and none were serious\u2026.\nOther than a\u00a0road traffic death, the only death was in the ZA-304 study. This was a 59-year-old Caucasian with secondary hypogonadism who was treated in a \u2018blinded\u2019 fashion with 12.5 mg enclomiphene citrate for 34 days before an ischaemic stroke\u2026.His high number of risk factors and limited exposure made it highly unlikely that the study medication was the cause of his death in the opinion of the investigator.\u201d\nRegarding the researchers\u2019 statement that none of the adverse events were severe or serious, we always think that\u2019s in the eye of the beholder \u2014 the patients, who, of course, are not heard from.\nBut what we\u2019re reviewing is the news release, which is silent on potential harms.\nOur reviewers noted that the FDA has issued a safety alert to add information to labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone. If enclomiphene raises testosterone levels it\u2019s hard to accept the investigator (with a possible financial conflict) dismissing the possibility that the drug caused the stroke.", "answer": 0}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\n\"Health systems should invest in developing electronic health records systems that prompt providers at the point-of-care when screening is needed and when it can be postponed,\" study senior author Joshua Fenton, an associate professor of family and community medicine at UC Davis, said in the news release.\nMeanwhile, it was common among women at low fracture risk, such as younger women without osteoporosis risk factors,\" Amarnath said in a journal news release.\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention a potential harm common to all screening tests \u2014 the risk of a false-positive result that can lead to more tests and unnecessary treatment. And while the dose they provide is small, DXA tests do involve\u00a0radiation exposure. The story makes no mention of any possible downside to that exposure.", "answer": 0}, {"article": "The results were published in January in Nature Medicine.\nCurrently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t include a discussion of actual safety results of the study drug, although this is the primary goal of the study. \u00a0Was this safe? \u00a0Were there any adverse events? The discussion about \u201cresistant virus\u201d found in some patients is not well described. Was this a resistance identified at the beginning of the trial or related to use of 10-1074?", "answer": 0}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nStill, \"a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease,\" he said.\nThe scans aren't risk-free: They frequently mistake scar tissue from an old infection or some other benign lump for cancer, leading to unnecessary biopsies or surgery that in turn can cause a collapsed lung, infection or other problems.\nSome previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\nThe NCI said it is not clear that all smokers should get the scans, which are not risk-free.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story points out that such scans can produce false positive results, lead to further tests and treatments that don\u2019t always benefit patients and have their own risks, and that CT scans expose people to radiation that may raise the risk of other types of cancer.\u00a0 It explains that the NCI is \u201cstill compiling the rates of false alarms and other risks\u201d\u00a0but estimates could have been drawn from past research.\n", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\nand made by DexCom, is said by some researchers to be a bit more accurate, as is a third device, from Abbot, which has not yet been approved.\nThat night, however, the sensor kept beeping me awake, nearly every hour, warning that my glucose level was too high.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Through one man\u2019s story-telling, harms are described and included malfunctions with the machine leading to recalibration or inserting new catheters, trouble relying on machine recommendations for insulin dosages, potential for infection at the injection site, and inconvenience of being awakened or disturbed by the beeping or buzzing alarm. Of course, it\u2019s not clear whether these are the only harms, but they seem reasonable. The story could be improved by reporting on actual harms reported in clinical trials. ", "answer": 1}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nThose who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report in Annals of the Rheumatic Diseases.\nSome have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chondroitin is not associated with the dangerous side effects seen with NSAIDs, but we were left wondering: What were the\u00a0adverse events seen with this supplement?", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nThe study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the researchers\u2019 claim that there were no adverse effects to the oxygen treatment. \nBoth the study and the article fail to address potential future harms, and this should have been discussed. The story barely receives a \"satisfactory\" rating under this criterion. \nThis is one area where an independent perspective would have been helpful. ", "answer": 1}, {"article": "Please visit http://www.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\nWe calculated the population-attributable risk for American men over 60 and estimated that 34 percent of lethal prostate cancer would be reduced if all men exercised to the point of sweating for at least three hours a week,\" Kenfield said.\n\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms. But the lifestyle choices at issue here are (for the most part) so broadly defined that it would be difficult to say what the harms would be. What harms are associated with eating tomatoes, avoiding processed meats, or not smoking? We\u2019ll rate this one not applicable.", "answer": 2}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\n\"This is not a new test, but these results emphasize the importance of looking at this marker in addition to the traditional risk factors,\" said Dr. William Zoghbi, past president of the American College of Cardiology and head of cardiovascular imaging for Houston Methodist Hospital.\nIn this new study, doctors referred 9,715 healthy patients in the Nashville area between 1996 and 1999 to a cardiology outreach screening program provided by the military's Tricare Healthcare System.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\nIf a plaque bursts, a blood clot can form on its surface, blocking blood flow and causing a heart attack, according to the U.S. National Institutes of Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms of CAC testing. It fails to tell readers that the researchers noted in their article that for every 10,000 people screened, about 12 would develop cancer. That means that subjecting 100 million adults to this test would be expected to result in 120,000 additional cancers.\nEven if that cancer burden were deemed acceptable, patients sent for additional testing (such as catheter imaging) or prescribed drugs or procedures would be exposed to the risks and costs of those tests and treatments.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to\u00a0point out\u00a0that in terms of serious side effects (renal, cardiovascular, or cerebrovascular events), or of people discontinuing treatment because of side effects \u2013 there was no difference between those being treated or those who received the placebo.\u00a0 The story neglected to discuss the side effects commonly seen in the study participants given the treatment; there was a higher incidence of fever and musculoskeletal pain in those infused with the drug.\u00a0 \n\u00a0", "answer": 0}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nIn the study, Dr. Roy Taylor, professor of medicine and metabolism at Newcastle University, and his colleagues randomly assigned nearly 300 people to either a weight management program or their usual treatments, including diabetes medications.\nBut in a paper published in the , researchers in the UK describe a landmark study in which people with diabetes went into remission\u2014just by losing weight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the very restricted diet were not mentioned. Were there any problems resulting from months on the liquid diet? Did subjects have trouble adhering to the restrictions?\nThere were quite a few side effects during treatment. According to the study, during the intervention, most common side effects/complaints were constipation (56%), headache (45%), increased cold sensitivity (44%), dizziness (42%). These tended to dissipate over time.", "answer": 0}, {"article": "Carissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\n(The advocacy group Autism Speaks has posted videos to help parents see the signs of autism)\n\nThe earlier a child has been identified as having autism, the earlier behavioral therapies can be applied to lessen the impact of the disorder later in life.\nCurrently there's no biologic test for autism, so pediatricians look to see if a child is meeting certain developmental milestones as well as signs and symptoms of autism.\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\nWhile previous studies using different types of scans have been able to identify people with autism, Lange says, \"no one has looked at it [the brain] the way we have and no one has gotten these type of results.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The same as with the Reuters story, CNN mentioned no harms in this story.\u00a0For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. The biggest harm, though, is the potential for false diagnoses, which should have been addressed.", "answer": 0}, {"article": "I am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\nIt is the first trial of its kind in the world.\nThe oscillation kills the cancer cells while preserving the healthy tissue, avoiding the nerves and urinary sphincter.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nThe shells seek out and saturate cancerous cells, and their advanced vibrational properties are then harnessed to cause the tumorous tissue to pulse with extreme temperature when light is applied through a laser specifically designed to excite the particles.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harms discussed are those in relation to competing treatments.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The AP report provides no details on potential harms. The New England Journal of Medicine study reported mostly minor side effects of the vaccines and one serious complication attributed to the nasal spray\u2014hospitalization for acute inflammation of the tissue surrounding the heart and great vessels (acute pericarditis). It's also worth noting that pericarditis has also been reported (rarely) with the inactivated vaccine.", "answer": 0}, {"article": "Your skin vs. the sun: A sunscreen pill?\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nThe basics: Almost everybody would love to have a \"healthy\" bronze glow, but almost everybody now also understands that the sun isn't our friend and that our skin needs to be protected from its stealthy attacks.\nWe've long assumed sunscreens will do the trick, but then came reports that the vitamin-A compound (retinyl palmitate) integral to many of them could actually be making us more melanoma-prone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of Fernblock are mentioned. If the long-term safety is unknown, an acknowledgement of that or the potential harms of taking any herbal supplement would have sufficed.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed the increase in colorectal cancer incidence that has been observed.", "answer": 1}, {"article": "\u2022 Shepstone et al (2017).\n\"If the SCOOP screening strategy was taken up in exactly the same way as in the study in all UK women aged 70-85 years, we estimate that the strategy could prevent up to 8000 hip fractures per year in the UK.\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\nProfessor Eugene McCloskey, of the University of Sheffield, said: \"Low-cost screening with FRAX among the older population could result in effective, targeted intervention to reduce the human and socioeconomic burden of hip fractures.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this news release addresses effectiveness of a community screening effort rather than a treatment, harms are likely to be few. However, we think potential harms deserved some attention.\nHarms could arise from medication complications \u2014 which for bisphosphonates (the most commonly used drug class for treating osteoporosis) can paradoxically include atypical fractures. This is a risk calculator, so we\u2019re not as concerned about over-diagnosis. The expectation is that the risk information should be incorporated into discussions of treatment options. The bigger concern would be under-diagnosis \u2014 how many fractures occur in women whose FRAX score is low and then don\u2019t go on to bone density scanning (DXA) so the opportunity to diagnose and treat osteoporosis is lost.", "answer": 0}, {"article": "Wiese thinks the vitamin study sounds promising.\n\"It's safe, it's almost obscenely inexpensive, and it's already widely commercially available,\" Dr. Diona Damian, the senior author of the study and a professor of dermatology at the University of Sydney, told HealthDay.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\nResearchers say vitamin B3 gives skin cells an energy boost -- \"turns back on the immune system,\" in Agus's words -- helping them repair the damage.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told via the study\u2019s author that twice-daily nicotinamide is \u201csafe,\u201d but that it\u2019s \u201cnot something we\u2019d recommend at this stage for the general population.\u201d The author\u2019s\u00a0claims to safety can\u2019t be verified without a look at the actual study data (which haven\u2019t been published yet), but since the references we\u2019ve consulted generally support the idea that adverse effects are minimal, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "In 2013, it was 12.6.\n\"There is a fear among clinicians that if you ask questions about suicide, you are giving the patient an idea that this could be an option,\" says Espiritu, \"and if you ask about guns or pills, that you are giving them some hints on how they can carry out a plan.\"\n\"I recall one time with my psychiatrist, who kept trying to encourage me and help me find ways of coping, and I can remember saying, 'I don't believe there's hope, I don't see it, I don't feel it, I need you to hold on to that for me because it's not there,' \" she recalls.\nWhile the homicide rate in the U.S. has dropped 50 percent since the early 1990s, the suicide rate is higher than it was a decade ago.\n\"There is no question that the message I got from Day 1 is that they knew they could help me, and they would help me,\" Lynn says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story looks at an overarching strategy for identifying and treating depression; screening patients to identify those at risk and then pursuing \u201cappropriate care.\u201d While individual drugs or other treatment options can have potentially adverse side-effects, the story does not attempt to evaluate specific courses of treatment. For that reason, exploring the potential harms associated with individual treatment options doesn\u2019t seem relevant in this case.", "answer": 2}, {"article": "Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life.\nNational Health and Wellness Survey: The Global Health and Wellness Report - 2014.http://www.kantarhealth.com/docs/ebooks/global-health-and-wellness-report.pdf.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\n[1]\n\nAccording to Dilip Shanghvi, Managing Director, Sun Pharma, \"We are happy to see the early onset of action and strong efficacy results for Seciera\u2122.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does acknowledge harms by saying, \u201cAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category,\u201d that offers no useful information for readers as to what those adverse events are, or how troublesome they might be to those using the product. The U.S. National Library of Medicine lists these possible side effects from cyclosporine ophthalmic: \u201cburning, itching, stinging, redness, or pain of the eyes, overflow of tears, red eyes.eye discharge, blurred vision or other vision changes, feeling that something is in the eye.\u201d", "answer": 0}, {"article": "The FASEB Journal, June 2018.\nBOSTON (June 11, 2018) -- A new study conducted at the University of California, Davis found that two cups of mangos a day had beneficial effects on systolic blood pressure among healthy postmenopausal women.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nIn the study, 24 healthy postmenopausal women consumed 330 grams (2 cups) of mango daily for 14 days.\nSystolic blood pressure (the upper number in blood pressure readings) indicates how much pressure your blood is exerting against your artery walls when the heart beats.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Mangoes are a fruit. Eating fruit is generally a good idea \u2014 as long as it is part of a balanced diet. The \u201cbalanced diet\u201d part is missing from the release. Mangos are not inherently unhealthy, but they do contain a significant amount of sugar. So, if one is going to increase one\u2019s mango consumption, that should be offset by reducing other sources of sugar in the diet. Adding two cups of mangoes a day at 214 calories is not insignificant unless calories are cut back elsewhere in the diet. To be clear, we don\u2019t think mangoes need a warning label \u2014 but a simple note that mango consumption should be incorporated into a balanced diet would have been valuable.\n\u00a0", "answer": 0}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\nThere is extensive research in this field and I hope that it eventually will come up with a result.\nThe researchers have also tested the method on ten Swedish Parkinson\u2019s patients, in both medicated and unmedicated states.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms, though the study itself says that the intervention resulted in increased nausea in two patients.", "answer": 0}, {"article": "Moffitt is the No.\n\"These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint,\" said Brian J. Czerniecki, MD, PhD, Chair of the Department of Breast Oncology at Moffitt Cancer Center.\nIn order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.\nThe study was published in the December 13th online issue of Clinical Cancer Research and was supported by funds received from R01-CA096997, P30-CA016520, Pennies-in-Action\u00ae, and the Henle Foundation.\nThis suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that the vaccines were \u201cwell-tolerated and patients only experienced low-grade toxicities. The most common adverse events were fatigue, injection site reactions, and chills.\u201d\u00a0 The release would have been better if it had told us how often these side effects occurred in the patient volunteers.", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nShe told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends more time playing down potential risks than it does addressing what risks are posed by Orbera. Risks are summed up with a line that says: \u201cThe most common side effect of installing the balloon is nausea that lasts a few days.\u201d It also says that patients are kept under \u201cmild to moderate\u201d sedation when Orbera is put into the stomach. The story adds that Orbera eliminates \u201crisks involved with more invasive options,\u201d effectively playing down the risks associated with sedation. The story also doesn\u2019t address risks such as \u201cvomiting, abdominal or back pain, acid reflux, influence on digestion of food, blockage of food entering the stomach, bacterial growth in the fluid filling the balloon which can lead to infection, injury to the lining of the digestive tract, stomach or esophagus,\u201d etc. \u2014 all of which are discussed on Orbera\u2019s website.\nHowever, the most problematic line in the story related to harms states: \u201ceven if the balloon were to pop, the saline would be absorbed and pose no harm to the patient. The balloon would be removed in the same way it is at the six month mark.\u201d Readers might think that this mean a popped balloon in the stomach is a trivial event. However, Orbera\u2019s directions for use \u2014 which are also available online \u2014 note that \u201cBowel obstructions have been reported due to deflated balloons passing into the intestines and have required surgical removal. The risk of obstructions may be higher in patients who have diabetes, a dysmotility disorder, or who have had prior abdominal or gynecological surgery, so this should be considered in assessing the risk of the procedure. Bowel obstruction can result in death.\u201d Not necessarily such a trivial event after all.", "answer": 0}, {"article": "Devenish manufactures pre-mix and special feed for pigs, poultry, cattle, sheep, equine, game, companion animals and aquaculture.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nThe findings were presented by Professor Alice Stanton of The Royal College of Surgeons in Ireland:\n\n\"Greater consumption of oily fish has long been linked to a reduced incidence of heart attack, stroke, diabetes and cancer and improved brain health, vision, muscle and joint health,\" said Professor Alice Stanton.\n\"International guidelines recommend eating oily fish at least once per week, however, many people do not eat fish at all and less than 20% of the world's population have optimal omega-3 PUFA levels.\n\"Omega-3 enriched chicken and eggs offer consumers an attractive alternative to eating oily fish or to the lifelong taking of supplements, with the potential for substantial health benefits,\" Professor Stanton said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the release a Not Applicable in this category since the study involved eating a moderate amount of chicken and eggs in their normal diet.\u00a0 Based on what little the release actually tells us about the trial, it\u2019s hard to see where people would be harmed from eating this amount of these particular foods.", "answer": 2}, {"article": "For more information, visitwww.asmbs.org.\nThetreatment involves patients swallowing a capsule that quicklydissolves in the stomach to reveal a deflated gastric balloon inside.With a thin catheter attached to the device, but long enough toremain outside the patient\u2019s mouth, a physician fills the balloonwith fluid (550 mL) to about the size of a grapefruit.\n\u201cOur findings demonstrate that Elipseprovides individuals and their caregivers with a safe, effective, andnon-invasive weight loss intervention that does not require surgery,endoscopy, or anesthesia.\u201d\n\nResearcherspresented interim results for the first 34 patients of a multi-centerstudy that showed individuals lost an average of 22 pounds after fourmonths or 37 percent of their excess weight.\n\u201c Likeother gastric balloons, the mechanism of action of Elipse is likelymultifactorial and includes increased satiety from the reduction ofavailable space in the stomach, delayed gastric emptying, and changesin hormones that control hunger and appetite,\u201d saidRam Chuttani, MD*, study co-author and director of Endoscopy andchief, Interventional Gastroenterology at Beth Israel DeaconessMedical Center in Boston.\nInaddition to Dr. Chuttani, study authors of the abstract entitled,\u201cThe First Procedureless Gastric Balloon: A Prospective StudyEvaluating Safety, Weight Loss, Metabolic Parameters and Quality ofLife,\u201d include, Evzen Machytka MD, PhD, Martina Bojkova MD, TomasKupka MD, and Marek Buzga MSc, PhD from the University of Ostrava,Ioannis Raftopoulos MD, Andreas Giannakou MD, and Kandiliotis IoannisMD from the Iatriko Medical Center, and Kathy Stecco MD, Samuel LevyMD, and Shantanu Gaur MD, from Allurion Technologies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives only a very brief mention of harms, citing nausea and vomiting as the most common adverse events reported. However, with a catheter patients might experience irritation in their esophagus or stomach (which could lead to bleeding or ulcers) or infection from bacteria surrounding the balloon. A concern for this type of balloon, which is intended to deflate, would be improper deflating and obstruction of the intestine \u2014 a potentially serious complication.", "answer": 0}, {"article": "It was a struggle at first, but by the end of the trial he was able to complete the action three out of five times in a 10-minute period.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nThe study builds on previous work in which humans have been able to move computer cursors and robotic arms using their own brain signals, and a study in which monkeys with paralysed arms were able to move them again thanks to a similar intervention.\nThis is the first time a person with paralysis has regained movement in their hands and individual fingers using signals from their brain.\nThat could come from better electrode designs or looking for different signals that are more stable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even if the technology is experimental and only tested on one patient, the\u00a0story should have included some discussion of risks of the implantation surgery and the implant itself.", "answer": 0}, {"article": "Collaborating with Dr. Bickelhaupt and Jaeger were Frederik Bernd Laun, Prof. Dr., Wolfgang Lederer, M.D., Heidi Daniel, M.D., Tristan Anselm Kuder, Dr. rer nat, Lorenz Wuesthof, Daniel Paech, M.D., David Bonekamp, M.D., Alexander Radbruch, M.D., Stefan Delorme, Prof. Dr., Heinz-Peter Schlemmer, Prof. Dr., Franziska Steudle, and Klaus H. Maier-Hein, Ph.D.\n\nRadiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wis., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of over 54,200 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nFor the analysis, a software algorithm was developed for lesion characterization, and imaging features were extracted using a kurtosis-based radiomics model.\nThe technique, known as diffusion kurtosis imaging, provides a picture of breast tissue on a microstructural level.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\n\"This might also improve the efficiency of reporting,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No specific description is provided of potential harms. One potential harm is that this technique still misses some malignant lesions.", "answer": 0}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\n\"While I recognize there is no place like home, should there be the need for urgent or medical care the question is will that be available to the patient when they're in the setting of their own home,\" Padgett said.\nAccording to research done by the American Academy of Orthopaedic Surgeons, there are no significant differences between either approach in recovery outcomes six months after surgery.\nThere are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story a Satisfactory rating on this criterion because it includes comments from a surgeon who warns about the risk of serious complications during the first night after surgery.\nHowever, the most prominent voice in the story is a surgeon who dismisses those concerns by saying, \u201cif the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital. It really doesn\u2019t make sense.\u201d\nWe\u2019re not given any information or data that proves this \u201cdoesn\u2019t make sense,\u201d though.\nWe also think potential harms that could have been included are falling at home due to dizziness, or otherwise not being adequately prepared for managing under major surgery.", "answer": 1}, {"article": "There\u2019s ample reason for caution.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nAccording to a new study, a medication, ancetrapib, appears to simultaneously raise the level of HDL \u2013 sometimes called \u201cgood\u201d cholesterol- and to lower the level of LDL, or \u201cbad\u201d cholesterol.\nTo try to provide final answers, Merck is launching a study \u2013 called REVEAL \u2013 to follow 30,000 people, in several countries, over four years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nReaders of this story are likely to conclude that anacetrapib is safe. They aren\u2019t told that what the researchers actually reported is that based on their statistical analysis, they are at least 94 percent sure that the drug doesn\u2019t cause the 25 percent increase in cardiovascular events that was seen in experiments with a similar drug, torcetrapib. That \u201cpromising\u201d drug was yanked from testing.\nThe story did report the dangerous turn taken in trials of torcetrapib, but it could have done a better job of explaining to readers that while researchers breathed a sigh of relief that the same sort of hazards weren\u2019t seen in this trial of anacetrapib, the safety picture is still only short-term and sketchy.", "answer": 0}, {"article": "The study was presented Monday at the annual meeting of the American Society of Hematology in Atlanta.\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\nTUESDAY, Dec. 12, 2017 (HealthDay News) -- Physical activity appears to help people with lymphoma survive their disease.\n\"Therefore, since physical activity behaviors can be modified, physicians should counsel patients and survivors on the importance of physical activity and encourage them to maintain and, if possible, increase their level of physical activity.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In general, we feel that it is important to discuss potential risks even if those risks are minimal. In this case, you\u2019re talking about a group of people with a very serious illness taking very serious drugs\u2013what should they know about the risks of increasing their physical activity?", "answer": 0}, {"article": "BLOOMINGTON, Ind.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\nAs one of the largest analyses on the risks and benefits of ADHD medication, the study drew on anonymous health care data from 146 million people with employer-based health insurance in the United States from 2005 to 2014.\n\"Many factors can influence who receives ADHD treatment, including socioeconomic factors, health care access, the strength of support networks and disorder severity,\" Quinn said.\nThe larger number of people in the two more recent studies -- as well as the use of U.S. patients in the new analyses -- strengthens this earlier evidence.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not make any mention of potential side effects of stimulants used to treat ADHD. Common side effects include headache, upset stomach, increased blood pressure, dizziness, decreased appetite, insomnia and dry mouth.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nThe study found the average time for recurrence of the tumor was 16.6 months, up from the previous six months.\nIt was only open to those with a particular protein \u2014 present in one-third to two-thirds of glioblastomas \u2014 and those who were tumor free after surgery and radiation.\nThe response was better with the highest dose of Temodar.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of whether the vaccine had any effects other than appearing to lengthen the time needed to observe cancer recurrence.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were a couple of openings for this story to better characterize the potential risks of this investigational procedure. At one point, the story says that the treatment \"doesn\u2019t come without risks,\"\u00a0but the only downside subsequently mentioned is that \"People will have to be trained to use the technique.\" Later,\u00a0an anchor says more directly, \"You are actually destroying some tissues in the lungs. Do they know anything about potential long-term complications?\" But the reporter responds that the treatment \"doesn\u2019t seem to limit pulmonary, lung function at all.\"\u00a0Faced with the\u00a0lack of any long-term data on how patients do with this procedure, we feel it would have been appropriate to at least discus the potential for adverse consequences or emphasize the uncertainty of the current evidence. Instead, the \"breakthrough\" framing came across as cheerleading. ", "answer": 0}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\n\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All the claims are qualitative. That alone would earn an unsatisfactory rating, but the article goes further. Harms are not only presented without quantities, they are described in a vague, unclear, and overly optimistic way. We\u2019re told, in general, that the safety studies \"came out clean.\" That\u2019s overly simplistic without any further detail; even placebos are associated with harms in studies. Then there are the specific issues.\n First, consider the potential cancer risks. The only data described are, it seems, from short-term animal studies. The cancer risks that hung over Exubera were not revealed until after it was yanked from the market, and ultimately the association to Exubera wasn\u2019t definitive. To say that Afrezza holds an advantage over Exubera for these reasons based on short-term animal data is unsubstantiated.\n\nSecond, pulmonary function. The pulmonary function problems for Exubera are detailed as one of its major flaws, with the implication that they contributed to its ultimate failure. In the second-to-last paragraph, the VP acknowledges that Afrezza \"may have\" pulmonary harms; however, \"once people stopped taking Afrezza, this effect went away.\" In several\u00a0studies\u00a0of Exubera, lung function declines were also reversible after people stopped taking it. Without providing any evidence, the article\u2019s general coloring of Afrezza safety being superior to that of Exubera is speculative and wholly inappropriate.", "answer": 0}, {"article": "U.S.\nForward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements.\nStem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell\u2122, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.\nUSRM has been a part of more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.\nForward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release\u2019s statements (mentioned above) refer to positive outcomes and mention no adverse effects, readers can\u2019t draw any conclusions about the safety of the procedure, given it\u2019s a single case study and a short-term follow-up.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nTo assess the impact of acetaminophen use on children's asthma, AsthmaNet investigators studied 300 children, aged 1 to 5 years old, who had mild, persistent asthma, defined as symptoms on more than 2 days out of a week but not daily.\nThe purpose of AsthmaNet is to develop and conduct multiple clinical trials that explore new approaches in treating asthma from childhood through adulthood.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by asthma exacerbation rate, number of days of asthma control, need for \u201crescue\u201d medication and unscheduled medical visits for asthma, as the news release points out. As mentioned above in the \u201cQuantify Benefits\u201d section, this release\u00a0does not lay out any supporting quantitative data for these benchmarks. It only states, \u201cThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\u201d\nFor these reasons, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "The researchers also made a secondary discovery.\n\"The finding supports the idea that omega-3s, and specifically DHA, are preferentially protective in obese postmenopausal women,\" Manni said.\nThe protection likely comes from the fatty acids' anti-inflammatory effects, said Dr. Andrea Manni, professor and division chief of endocrinology, diabetes and metabolism, Penn State College of Medicine.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nIn the current study, the combination of Lovaza and a half recommended dose of Raloxifene at 30 milligrams, was superior to the individual treatments in reducing triglycerides and LDL -- \u201cbad\u201d -- cholesterol and increasing HDL -- \u201cgood\u201d -- cholesterol.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release fails to mention harms at any point and, while a widely consumed, readily available supplement like omega-3 fatty acids isn\u2019t likely to cause major problems, it is not free from side effects that are worth mentioning. The research paper itself points to more than a half-dozen participants in the study who withdrew because of adverse effects including hot flushes, leg cramps and\u00a0nausea. Readers rightly deserve to know possible negative impacts found in research studies.", "answer": 0}, {"article": "TUESDAY, March 8, 2011 (HealthDay News) -- Acupuncture may help reduce the severity of hot flashes and other symptoms of menopause, according to a small study.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\nThe findings were published online March 7 in Acupuncture in Medicine.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe U.S. National Women's Health Information Center has more about treating menopause symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms \u2013 only a discussion of benefits.", "answer": 0}, {"article": "It's the first study to specifically examine...\nJennifer Corbett Dooren has details on Lunch Break.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of harms and we\u2019re not sure what they would be.", "answer": 2}, {"article": "For more information, recipes and facts about pasta, please visit http://www.\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nWashington, DC (May 17, 2017) - Pasta is a convenient, nutritious, easy-to-prepare meal for families.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from increased pasta consumption. The problem is not with pasta\u2019s nutrients but with potentially filling up on high-calorie pasta and excluding other healthy foods (not named in the release) from your diet.", "answer": 0}, {"article": "An \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n\"It does appear that resveratrol was able to penetrate the blood brain barrier, which is an important observation.\nThe highest dose of resveratrol tested was one gram by mouth twice daily -- equivalent to the amount found in about 1,000 bottles of red wine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions resveratrol\u2019s most common side effects, which include nausea, diarrhea and weight loss. It would have been helpful to know how commonly these effects occurred. It also lists loss of brain volume as an effect, but states it could interpreted as either a benefit (since it could have reduced inflammation) or harm.", "answer": 1}, {"article": "Gonzalez said the new trial addressed a serious medical need.\n\"This clinical trial moves us significantly closer to preventing strokes and death in high-risk populations,\" said Keith Black, MD, professor and chair of the Department of Neurosurgery.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\n\"Even under the best current treatments, ICAD carries high rates of recurrent stroke and death, compared with other causes of stroke,\" he said.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms criteria with the following statement:\u00a0 \u201cTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\u201d\nWhile we\u2019ll award a borderline satisfactory, we wish that the release had cautioned that a study of 52 people is incapable of identifying harms that might occur with a larger and broader sample of patients.", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not adequately address potential adverse events and harms related to the Botox injections. The journalist offered a fairly standard list of Botox side-effects but then soft-pedaled by offering the reassuring viewpoint of a consultant for the manufacturer.\nThere is no mention that twice as many adverse events occurred in the Botox group than the placebo group in both clinical trials.\nAnd the story did not address the fact that long-term side-effects and adverse events may differ from those it describes. These clinical trials described adverse events that occurred over a matter of months. Yet those with chronic migraines might have Botox injections every 12 weeks for years and decades. It is possible that the number of adverse events might grow with increasing usage.", "answer": 0}, {"article": "Dr. Venditti is assistant professor of psychiatry at University of Pittsburgh Medical Center's Western Psychiatric Institute and Clinic.\nBut those who did undergo lifestyle changes showed such notable results that Pitt offered to enroll all 159 participants, including Mr. Held, in a lifestyle modification program.\nFirst published on October 29, 2009 at 12:00 am\n\nCorrection/Clarification: (Published Oct. 30, 2009) The educational position of Elizabeth M. Venditti was reported incorrectly in this story as originally published Oct. 29, 2009, \"Pitt program to prevent diabetes shows promise.\"\nThe blood-sugar level for a healthy adult, measured as milligrams of glucose per deciliter, is generally 70 to 100 mg/dl.\nMore than 24 million people in the United States have diabetes, which is a main cause of kidney failure, heart disease, stroke, limb amputations and new-onset blindness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the side effects of metformin, which include gastro-intestinal side effects that can inhibit compliance. A serious condition, lactic acidosis, is a rare but significant side effect.\n\u00a0", "answer": 0}, {"article": "Rothwell and his colleagues published their findings Dec. 7 in the online edition of The Lancet.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nTwenty years after first beginning a low-dose aspirin program, death risk dropped by 10 percent among prostate cancer patients; 30 percent among lung cancer patients (although only those with adenocarcinomas, the type typically seen in nonsmokers); 40 percent among colorectal cancer patients; and 60 percent among esophageal cancer patients.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential side effects of aspirin mentioned in the story \u2014 \u201cbleeding and stroke\u201d \u2014 are relegated to the last line of the story and are given nowhere near the prominence they deserve. For one thing, \u201cbleeding\u201d doesn\u2019t convey the seriousness of potentially fatal\u00a0gastrointestinal\u00a0hemorrhage that can result from daily aspirin. Second, the story didn\u2019t make any attempt to quantify these risks so that they can be balanced against benefits.", "answer": 0}, {"article": "In the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nJan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nThe findings are published in TheJournal of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wasn\u2019t thorough enough in its exploration of potential harms. The only adverse effect noted is the potential loss of libido discussed in the last line of the story. At one point, the story seems to dismiss the\u00a0potential for harm by noting that\u00a0 \u201cno serious adverse events were reported\u201d in the study.\u00a0However, minor adverse effects take on greater importance when a drug provides only a modest benefit over placebo \u2014 which is the case with this medication.\u00a0The study should have provided more detail on what harms were observed (even \u201cminor\u201d ones), and how frequently. Lexapro, when used for depression, commonly results in gastrointestinal disturbance such as nausea, vomiting, loose stools, and indigestion. A variety of\u00a0other adverse effects are possible, including include difficulty sleeping and headaches. It is quite conceivable that an increase in these\u00a0problems might outweigh the small benefit associated with the reduction in hot flashes, so the story\u00a0should have provided this information.\nAnother issue not addressed by the story is the potential for uncomfortable withdrawal symptoms when stopping this medication. This point is particularly relevant to make here because Lexapro hasn\u2019t been extensively studied in women who are healthy and don\u2019t have symptoms of depression. We know that some people with depression experience withdrawal symptoms after they stop taking the drug, but we don\u2019t\u00a0have much evidence on what happens to healthy non-depressed people when they stop taking it.\u00a0The risk of a discontinuation syndrome increases the longer\u00a0antidepressant therapy lasts, so an 8-week study may not capture the problems that women\u00a0may experience with longer-term use of Lexapro for relief of hot flash symptoms. The story could have mentioned that\u00a0women should never abruptly stop taking an antidepressant\u00a0medication like Lexapro, as this can increase the risk of\u00a0more severe withdrawal symptoms.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although highlighted in the NEJM paper describing the neratinib trial, the news release doesn\u2019t mention that 38% of patients receiving the drug experienced severe diarrhea, requiring a change to the trial protocol.\nA related NEJM editorial also noted that a\u00a0phase 3 trial including trastuzumab, pertuzumab and neratinib (compared to standard of care trastuzumab and pertuzumab) could result in significant side effects when added to chemotherapy, and they raise concerns of over-treatment of a large number of patients.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states both the severe and mild side effects of taking this drug. We\u2019ll rule this Satisfactory since there was a good-faith attempt to address the criterion. However,\u00a0while the array of side effects are listed they are not quantified. We do not know what proportion of those taking the medication get each side effect. Nor do we know how severe they are, or how many stopped the medicine die to the side effects. More detail would have been welcome.", "answer": 1}, {"article": "Researchers report these findings in the journal Archives of General Psychiatry.\nThe research builds on a 2006 Lancet Neurology study that followed patients for a median of 5.2 years, beginning with a group of 137 volunteers with mild cognitive impairment.The new study is important because of the long follow-up period, according to Adam Brickman, assistant professor of neuropsychology at Columbia University School of Medicine, who was not involved in the research.\nThe results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer's disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.\nA new study suggests that biomarkers found in cerebrospinal fluid (fluid that surrounds the spinal cord and brain and acts as a protective cushion) could predict who would develop Alzheimer's disease 90% of the time among patients with mild cognitive impairment, a condition characterized by measurable memory problems.\nAs scientists gain more insight into predicting Alzheimer's, aging adults may struggle with the question of whether they want to know their risk, especially since there's still no cure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did make several stabs at touching on harms, reporting:\n\u201cSome of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer\u2019s disease during the longer follow-up.\u00a0 That suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer\u2019s disease, researchers say.\u201d\nAnd it did end with this:\n\u201cAs scientists gain more insight into predicting Alzheimer\u2019s, aging adults may struggle with the question of whether they want to know their risk,\u00a0 especially since there\u2019s still no cure.\u00a0 Some people want to enroll in clinical trials as soon as they start showing symptoms; others would rather be ignorant of their status since there is no cure.\u201d\nWe think these could have been framed more clearly as potential harms, but we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "The other groups showed no significant change.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\nStudies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that some earlier studies found that caloric restriction was linked to memory decline. \nBut it fails to mention one very important practical warning relevant to the study populations: That older patients are at increased risk for malnutrition, and should not restrict their caloric intake without medical superivision.\u00a0\nFurther, it\u2019s not known whether caloric restriction is safe for slightly overweight or normal weight adults regardless of age.\u00a0 ", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms associated with hormone replacement therapy. These are well documented in multiple studies and include a heightened risk of breast cancer and other types of cancer.", "answer": 0}, {"article": "Even More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nThe study did find negative effects in children whose mothers drank moderately: this was defined as not having more than 3 to 6 British units of alcohol per week or more than 3 to 5 units on a single occasion.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not put a number to the \"increased levels of behavior problems and lowered cognitive performance among children.\" It should have.", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this treatment.", "answer": 0}, {"article": "A video of him walking with and without aid of the system can be found here: https:/ .\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\n\"I lifted my knee like I was high-stepping.\nWith the technology switched on, he covered far more ground and his pace was twice as fast during his 30-week study.\n\"We try to time the pattern to stimulation so that it's integrated with their ability.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms, such as the risk of infection from implanted electrodes.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\nThe Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned.\nA bone density scan is a non-invasive and safe test, but the news release is silent on the issue of harms from false-positive or false-negative results \u2014 either of which could lead to over- or under-treatment.", "answer": 0}, {"article": "The hospital recently received the green light from federal authorities to start the first ever human trial of DBS for stroke, and plans to announce Tuesday that it will perform the procedure as soon as an initial patient is identified.\n\u201cDespite advances in physical therapy and acute treatment of stroke there are still too many people who live with long term disabilities, and new technologies are needed,\u201d said Dr. Andre Machado, the chairman of the Cleveland Clinic Neurological Institute who is leading the trial and will perform the procedures.\nThey found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nClose to 800,000 Americans have a stroke each year and estimates suggest about half of those people will be disabled from it.\nAbout 87% of all strokes are this type.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Near the end, the story does mention that \u201cDBS is a type of brain surgery, and comes with risks like bleeding, infection and need for more surgeries\u201d so it earns a Satisfactory rating. It also points out some harms may be unknown. But we would have been happier if the risks were not buried in the last paragraph of the story by which point, odds are, some\u00a0people would have stopped reading.", "answer": 1}, {"article": "Here is how I would think about asking the question instead: What is the easiest way to reduce my chance of death?\nThe ideal measure would combine the length of time spent exercising with the amount of energy expended \u2014 basically, we want to figure out a way to credit people who walk at half the speed for twice as long the same amount as those who walk faster for less time.\nBut since the people in the studies are of different ages, researchers can\u2019t just look to see whether they have, say, a 2 percentage point lower risk of death in a given year, since that lower risk would mean a lot more for someone who is 30 than for someone who is 90.\nConsider, for example, the many posts on The New York Times\u2019 Well blog on the topic (walking versus running, the \u201cright dose of exercise,\u201d \u201cwalk hard, walk easy\u201d), all of which focus on the relative benefits of walking versus jogging versus running.\nAn energy expenditure of 1.19 METs per day (the lowest-energy-expenditure group in the second study here) means about 20 minutes of running a 12-minute mile, three times a week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even moderate jogging carries health risks \u2014 more for some people than others. Running can cause joint problems, shin splints, and aggravate lower back strains, among other things (it\u2019s done all three things for at least one of our reviewers). And people with heart disease, arthritis, asthma, diabetes, lung disease, kidney disease or other serious ailments should consult a physician before embarking on an exercise regime \u2014 even a low-impact one \u2014 because they are at higher risk of incurring more serious health problems. Any story that effectively encourages readers to engage in moderate exercise several times a week (which is laudable), should also caution readers about the potential risks involved and how to begin such an exercise regime safely.", "answer": 0}, {"article": "\u201cIn the last 60 years of depression research, all the treatments have focused on similar mechanisms of action.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\nIn his editorial, Dr. Nelson notes that SAMe is typically not covered by insurance companies, and that although the cost is relatively low, it is still more than the drug co-payments required by most health plans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It only tells us that long-term safety in this setting is unknown. Since the study\u2019s benefits were presented, safety results should\u2019ve been mentioned too.\u00a0The study itself states that there were no serious adverse events, the SAMe and placebo groups had similar rates of discontinuation due to intolerance, and the SAMe group had a statistically significantly greater increase in blood pressure when lying down, an effect which \u201cif confirmed in future studies, may be of clinical relevance.\u201d\u00a0\nAt least, it could\u2019ve discussed if there are potential harms associated with SAMe in general. The editorial states that SAMe, like most antidepressants, carries a warning that it may induce mania in patients with bipolar disorder. This study was too short and too small to detect adverse events that emerge from longer-term use. ", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nThere\u2019s some evidence that when students sleep better, they perform better in school as well.\nBeing tired in the morning can be a dangerous distraction while on the road.\nWhen teens want to sleep in on a school day, they\u2019re not being lazy.\nMore work needs to be done to confirm these findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some drawbacks\u00a0associated with delaying school start times, and the story does a good job of discussing them.", "answer": 1}, {"article": "Newswise \u2014 DURHAM, N.C. -- Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn\u2019s disease, according to a study led by a Duke Health researcher.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\nJaffe led one of two clinical studies that formed the basis of the FDA\u2019s approval and was senior author of the study appearing Sept. 8 in the New England Journal of Medicine (NEJM).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms covered in the study were glossed over in the release, in particular by this sentence: \u201c[P]atients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\u201d\nGiven what was left out, we\u2019ll mark this one unsatisfactory.\nWhat\u2019s not mentioned is that 16% patients in the adalimumab group dropped out compared to less than 7% in the placebo group. We also learned that some of the adverse events that triggered dropout weren\u2019t included in the release: \u201cAdverse events leading to discontinuation of participation in the trial were more common in the adalimumab group and included choroidal neovascularization, blurred vision, reduced visual acuity, fatigue, malaise, and suicidal ideation.\u201d\nSomething simple\u00a0that the release could have characterized about the\u00a0adalimumab treatment\u2019s harms, but didn\u2019t: it had three times the rate of \u201cadverse events\u201d and twice as many serious adverse events.\nIncluding any of these numbers \u2014 and some of the harms that taking corticosterids like prednisone can cause (the best we get is \u201cmany unwanted side effects\u201d) \u2014 would have put the harms and benefits of the adalimumab treatment into clearer context.", "answer": 0}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says about the whole class of drugs to which Keytruda belongs, \u201cThe new drugs are less toxic and more precise than standard chemotherapy. But they are not free of side-effects. Some are severe and can damage the lung, colon, liver, kidneys, hormone-producing glands and the brain, the FDA says.\u201d", "answer": 1}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nDrug recipients could blow out more than 10% more air from their lungs compared with patients who were not taking the drug, and were about half as likely to have a \u201cpulmonary exacerbation\u201d or a worsening of their lung disease that often requires hospitalization.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not make any reference to harms. Although the journal article reporting the trial findings says that the patients receiving the active drug generally had fewer problems than those in the placebo group and that the adverse effects were not serious enough to cause people to stop taking the drug for more than a short period, the editorial points out that this trial does not prove that long term use of this drug is safe. The story should have told readers that patients will probably need to take the drug their entire lives and that further tests are needed before long term safety questions can be answered.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\nThe diet is aimed primarily at people with irritable bowel syndrome, a common condition in which abdominal pain and irregular bowel habits \u2014 with diarrhea, constipation or both \u2014 can wax and wane for years.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the diet is restrictive, in the sense that it asks patients to eliminate a wide array of foods eaten in a normal diet (before cautiously adding them back later in the process). It also hints that because of all the unknowns with this relatively new, not-fully-researched diet, \u201cit\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\u201d", "answer": 1}, {"article": "One for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nThere is the risk of infection or a puncture of the vagina or uterus while inserting the hysteroscope.\nThe nonsurgical approach uses a hysteroscope -- a camera-tipped instrument -- to thread two small wires through the vagina, cervix and uterus and into the fallopian tubes.\nThere is very little bleeding, and no stitches are needed to close the tiny openings (one on each side).\nAs with tubal ligation, there is also an increased risk of ectopic pregnancy -- a pregnancy that develops outside the uterus.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the possible harms of Essure. The story should have pointed out that, because the procedure is new, long-term safety is not known.", "answer": 1}, {"article": "MORE: How Better Habits Can Make Your Day\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\n\u201cThis at-home test was created to meet the needs of couples who are considering and just planning on starting a family, those currently having trouble conceiving,\u201d says Herr, and \u201ceven those men who are just curious about their sperm count.\u201d\n\nWould-be virile men \u201cjust curious\u201d about their sperm count?\nWhile it\u2019s just as likely that infertility is related to the male half of the couple, only 20% of men in duos struggling to make a baby get a sperm-count analysis early on or at all, according to data from SpermCheck Fertility, which earlier this month announced the availability of its at-home screening test for men.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The specificity of the test was not discussed; it was 94% according to FDA documents. It\u2019s only half the story to tell what the sensitivity was.\u00a0 Sensitivity doesn\u2019t tell you about false-positive results, and specificity does not tell you about false-negative results. Why not report both?\nIn addition, a test that tells you about sperm count doesn\u2019t necessarily tell you anything about sperm quality \u2013 another part of the picture. So any man who truly wants the complete picture would need to see the doctor anyway.\u00a0 This isn\u2019t exactly a \u201charm\u201d but it is part of the reality that a news story should have reported \u2013 or else men may feel drawn in by the story\u2019s promotional tone, not realizing the full ramifications of the \u201cdebut\u201d of this \u201cfirst at-home test.\u201d\n\u00a0", "answer": 0}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nSo in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed -- the tumor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harmful side effects, or side effects at all, is made. The original paper does indicate that side effects were minor and that most negative effects were either unrelated or due to disease progression rather than the treatment.\u00a0 However, a line indicating that most side effects were minimal would have been welcome. It would also have been reasonable to mention that virus- delivered therapies have been shown to have potential side effects that warrant caution, and that there is some worry that healthcare workers and others could be infected by these viruses. (though this one seems safe, at least from the studies performed to date).", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It seems that harms to the mice were not discussed in the research paper (not surprising as the mice were all killed as part of the study) that\u2019s the basis for the story. A brief search didn\u2019t turn up anything overly concerning regarding the harms of ginger, but then again, it\u2019s not clear what the dosage given to the mice would translate to in human terms. A high-enough dose of anything can be dangerous. But while it might have been helpful to mention harms to humans attributed to powdered ginger, this may also have propagated the questionable notion that the findings are applicable to humans. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Both involve radiation.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nFor the new study, the researchers analyzed test results from 1,867 patients, who had both types of scans performed within six months of each other over a 10-year period, to see if their CT scans showed osteoporosis as well as the DXAs.\n\u201cObviously it\u2019s something we need to worry about, but if you apply it to a population that\u2019s suitable for diagnosis you wouldn\u2019t run that risk,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that both DXA and CT scans involve radiation, although it would have been helpful to note that the radiation exposure is much higher with CT scans.\nMore importantly, it addressed the risk of \u201cincidentaloporosis\u201d \u2013 or incorrect osteoporosis diagnoses that arise when doctors are looking for something else.\u00a0 We wish, though, that the story had added a line to drive home the point of the potential harm from such overdiagnosis.\n\u00a0", "answer": 1}, {"article": "Yet, the researchers' risk assessment questionnaire was equally poor.\n\"If you think about your car, you have to run your gas tank all the way down before the red light goes on, and that's similar to the way we're screening for iron deficiency,\" said Deepa L. Sekhar, physician and associate professor of pediatrics.\nHowever, the only risk factor significantly associated with iron deficiency without anemia in young women in this study was having had a period for more than three years.\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\nThe researchers then looked at potential iron deficiency risk factors in this group, including the age when they started menstruating, as well as their race and ethnicity, poverty status, food insecurity, tobacco or nicotine use, dietary information, body mass index (BMI) and physical activity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening is not without harms. The release does not mention any potential harms or downsides from identifying more teens with iron deficiency, or pre-anemia. Would a positive screen result in iron supplementation or a change in eating habits? Some research has suggested that mild iron deficiency is protective.\nIron supplementation is associated with constipation and too much iron is harmful to the liver, heart and other organs. A harm to society might be more financial drain on an already strained health care system if widespread screening were adopted.", "answer": 0}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThe researchers tracked the women's progress for a median of more than nine years (half followed longer, half less).\n\"We wanted to look at early stage disease, and those patients typically don't get radiation after mastectomy,\" she said.\nAmong the exceptions are those whose cancers are too large, or those who have different cancers in the same breast.\nThe findings, published online Jan. 28 in the journal Cancer, are especially strong for women over 50 with hormone-sensitive cancers, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of possible harms from either treatment. \u00a0In particular, there was no mention of the possible long-term dangers of radiation.", "answer": 0}, {"article": "Researchers agree there is a strong genetic component.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As\u00a0discussed above, the story doesn\u2019t attempt to quantify the harm of false-positive or false-negative diagnoses. It also doesn\u2019t explore the potential harm of labeling someone with borderline symptoms as having autism.\u00a0In addition,\u00a0it has now become clear that MRI with contrast is associated with kidney damage.\u00a0Physicians now check kidney function in all patients prior to an MRI and must weigh the need for the images vs the very small (but tangible) risk of kidney damage.", "answer": 0}, {"article": "And Medicare has established a registry to see how well large-scale screening works.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\n\u201cThe only way to prevent lung cancer or reduce your risk,\u201d Dr. Gould said, \u201cis to stop smoking.\u201d\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story devotes considerable space to explaining the potential problems invoked by false positives, again with facile use of numbers. The one narrative offered in the story elaborates on this element by focusing on an elderly retiree whose scan unearths a \u201chot spot\u201d on her lung that, after considerable angst and pain caused by diagnostic procedures, was found to contain no cancer.\nAnother harm that could have been added is that the screening x-ray involves radiation, which may cause cancer itself. Though the scan is \u201clow dose\u201d, it isn\u2019t \u201cno dose,\u201d and we know that screening not only will prevent death from cancer, but it will in fact be the cause of some of the cancers.", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harms. ", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Medical Center at Dallas, agreed.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\n\"But for many people, this kind of drug might absolutely be of great help, by doing something that helps the regulation of these appetite hormones and the regulatory pathway,\" she said.\nAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nice job mentioning side effects in the third sentence, followed by a paragraph later in the story\u00a0that spells them out: \u201cBut patients in both drug groups faced a higher risk for side effects, including diarrhea, headache, fatigue, nausea/vomiting, concentration and memory difficulties, anxiety, and depression-related symptoms.\u201d\u00a0 While we wish the story had quantified how much higher the \u201chigher risk\u201d really was, we\u2019ll give it the benefit of the doubt for the things it did satisfactorily.", "answer": 1}, {"article": "Some health experts argue that would be too costly.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\n\"Few of the kids actually experience sudden death while they're in class or at home,\" says Thomas Debauche, a Houston cardiologist.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nApart from a passing reference to costs, there is no discussion of the potential downsides to screening, which are numerous and include overtreatment of benign abnormalities, unnecessary exclusion of children from sports and other health-promoting physical activities, and creation of undue anxiety in children who have no reason to worry about their hearts.\u00a0\u00a0 \n1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes the most common side effect of the newer sublingual drops treatment and the rare risk of serious side effects from allergy shots. The article could have been strengthened by including information on the side effects of OTC and prescription drug treatments.", "answer": 1}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\n\u201cCertainly, this is something we now discuss in more detail with our patients, some of whom have declined CTCA.\u201d\n\n\u201cIt was striking for me that health status was very much related to receiving a (treatable) diagnosis or excluding such a diagnosis, rather than experiencing angina symptoms per se,\u201d said Dr. Paula M. C. Mommersteeg from the Center of Research on Psychology in Somatic Diseases, Tilburg University, The Netherlands, who has investigated associations between personality traits and coronary artery disease symptoms.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nPeople who have coronary artery disease ruled out by the scan benefit, and so do those with severe blockages diagnosed, while those who have moderate artery disease confirmed may only become more anxious after the scan, researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes a cautionary quote about the type of patient who might end up feeling worse after CTCA testing. The story would have been better if it noted that this type of scan can inadvertently find suspicious shadows, especially in the lungs, which may then lead the patient into further, possibly invasive, testing. The story could have also included some reference to concern about harms from X-ray radiation.", "answer": 0}, {"article": "\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it?\nOne of the most prominent claims, that POM can decrease arterial plaque by 30 percent, was taken from a single pilot study that included just 19 people and was funded by the makers of POM.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThe federal government doesn't require companies to vet health claims with the agency before plastering them on product packaging (as long as the claims are accompanied by a disclaimer about their uncertainty).\nAccording to a study by the FTC, this halo effect can even lead people to overlook warning statements -- about the high sodium content of a product, for example.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story perhaps could have mentioned that too much POM juice might contribute to obesity and related health risks such as type 2 diabetes. But we can\u2019t really fault it for not discussing\u00a0the harms of pomegranate juice, because there really aren\u2019t any direct adverse effects that have been well established.\u00a0(The same is not necessarily true for antioxidant supplements, which may well be harmful in some cases.) We\u2019ll call this one not applicable.", "answer": 2}, {"article": "It is the combined effect of surgery and chemotherapy that works best.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms. For example, there is no discussion of the risks associated with aggressive surgery to remove ovarian cancer tumors. As the Mayo Clinic notes on its site, ovarian cancer surgery \u201cgenerally involves removing both ovaries, the fallopian tubes, the uterus as well as nearby lymph nodes and a fold of fatty abdominal tissue (omentum) where ovarian cancer often spreads.\u201d All surgery poses some risk, and this surgery is extensive. Chemotherapy also poses risk. In addition, the release stresses a specific order in which treatment should be given. It states \u201cwomen should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\u201d While the surgery first technique may well have greater chances of survival, reducing tumor bulk with chemotherapy first reduces the peri-operative complications. This trade-off is not discussed.\nWhen a news release is explicitly advocating for a very specific standard of treatment, it\u2019s important to articulate the risks as well as the potential benefits, so that healthcare providers and patients can make informed decisions.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is very safe, however there are some potential undesirable side effects that were reported in the study and that should have been mentioned.", "answer": 0}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\n-For women 30 and over, a test for the virus, HPV, is better than a Pap smear for predicting cervical cancer risk, and those who test negative on both can safely wait three years to be screened again.\n\"The answer is, it could hurt a lot,\" said Dr. Allen Lichter, chief executive of the American Society of Clinical Oncology.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the strengths of the piece, that it takes harms head-on in a screening story, instead of assuming that early screening could do nothing but prevent disease and death. The story does a good job quantifying the harms for some of the screenings mentioned and, for others, explains that the studies did not address harms. It says in its third bullet point,\u00a0\u201cScreening women with no symptoms for ovarian cancer with a blood test and an ultrasound exam is harmful. It didn\u2019t prevent deaths and led to thousands of false alarms, unneeded surgeries and serious complications.\u201d Later, the story becomes more specific, saying, \u201cAfter 13 years, there were no major differences in ovarian cancers found or deaths from the disease. Screening found only 212 cancers while giving 3,285 false alarms that led to 1,080 unneeded biopsy surgeries and 163 serious complications.\u201d", "answer": 1}, {"article": "However, one expert was not sold on this new drug.\n\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\n\"What's most impressive about this two-year clinical trial is how unimpressive it is,\" said Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine.\nWEDNESDAY, July 14, 2010 (HealthDay News) -- A weight-loss pill called lorcaserin not only helps people drop pounds but does so with few side effects, new industry-funded research reports.\nAlso, it does not have the same problems as the previous weight-loss drugs, Fen-Phen (Phentermine), Acomplia (rimonabant) or Meridia (sibutramine), which had been associated with heart problems, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give this a barely satisfactory score. This story is the only one of the three that we reviewed on this study that buries the fen-phen connection. And none of them take the time to spell out how much damage fen-phen really caused. As with the other stories, it breezes past any side effects or other long-term problems by saying, \"(the) team noted that for those taking lorcaserin, there was no increase in heart valve problems as had been seen with the discredited diet drug Fen-Phen. However, common side effects included headache, dizziness and nausea.\" Although, unlike the other stories, it points out about a competing drug, \"FDA briefing documents posted online Tuesday acknowledged Qnexa\u2019s effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\" \nBut, again, connected with our \"Evidence\" criterion comments above, was the study rigorous enough to answer tough questions about safety? We wish the story had explored this more deeply. Can we be sure this drug is safe, since so many prior weight loss drugs fell down on this point?", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes the potential harms of screening. The story describes the radiation exposure from CT\u00a0as being equivalent to that of a mammogram. It is\u00a0not clear where this information comes from. CT scans generally have many times the\u00a0amount of radiation exposure of x-rays. There is also no discussion of the harms caused by false positives, which may lead to unnecessary biopsies, which may lead to further complications. ", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\nmentions harms and the frequency of surgical complications in this study, however, the discussion is limited when compared to\nthe discussion of untreated hernias. Does not mention the harm that a hernia can recur even with the surgery (1.4% in this\nstudy.) The most significant harm reported may be the one case of nerve injury, which was not mentioned in the story. While\nthe story states 20% had complications, three of them life-threatening, readers could have used more detail.", "answer": 0}, {"article": "A week later, under no medication, participants returned to repeat the experiment.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\n\"We have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,\" explains Professor Bach.\n\"When we talk about reducing fear memory, we are not talking about deleting the memory of what actually happened,\" explains lead author Professor Dominik Bach (UCL Wellcome Centre for Neuroimaging, Max Planck UCL Centre for Computational Psychiatry and Ageing Research and University of Zurich Division of Clinical Psychiatry Research).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "One of the investigators is quoted acknowledging the challenges inherent in using drugs like doxycycline to prevent PTSD, but there is no mention in the release about the many serious adverse side effects and drug interactions that come with the use of tetracycline antibiotics.\nDoxycycline has been tried\u00a0long-term for aortic aneurysms (as a matrix metalloproteinase or MMP inhibitor, the same reason it was tried here)\u00a0and as an antibiotic for acne, recurrent urinary infections and other conditions. Although generally considered safe to use, over a long term it can cause allergic rashes, antibiotic resistance, changes in friendly gut bacteria,\u00a0possible weight gain and other problems.", "answer": 0}, {"article": "One major trial was carried out at Queen Mary University of London (QMUL) in the United Kingdom and published in the journal Hypertension.\nThe first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\n\"The possibility of using a natural product, rather than another pill, to help lower blood pressure, is very appealing,\" adds Dr. Amoils.\nDuring the 4 weeks in which they were taking the juice, patients in the active supplement group, whose beetroot juice contained inorganic nitrate, experienced a reduction in blood pressure of 8/4 millimeters of mercury (mmHg).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It may be reasonable to think that taking large amounts of nitrates for long periods of time is safe, but are we really sure? It\u2019s perhaps also worth mentioning that people should get their nitrate from foods, not supplements.\u00a0Cases in the medical literature have documented confusion between inorganic nitrate (found in beets) and \u00a0synthetic organic nitrate or nitrite (e.g. nitroglycerin or amyl nitrate). The latter agents cause potent dilation of the blood vessels at low doses and can precipitate fatal cardiovascular collapse.", "answer": 0}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nIf this had not happened, \"the benefit of aromatase inhibitors over tamoxifen would probably have been somewhat greater,\" they surmised.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nA separate analysis by the same group, also published in The Lancet, looked at bisphosphonates, which are typically used for osteoporosis.\nResearchers at Sheffield University found that in postmenopausal women during the first 10 years after diagnosis of breast cancer, the drug could reduce the risk of death by 18 per cent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t really addressed in this report, except for the last sentence, which states the \u201cmain side effect of aromatase inhibitors is an increase in bone loss and fractures.\u201d\nBut aromatase inhibitors also carry the risk of exacerbating menopausal symptoms (including sexual side effects and sleep problems) and of serious muscle and joint pain, which has caused some women to stop taking the drug in the past.\nBisphosphonates long term can cause bone fractures (paradoxical \u2013 they build bone but not always normal bone) and rarely can cause jaw osteonecrosis (\u201cbone death\u201d). This is more common after dental work, but can also happen sporadically and is devastating.\nSince these details are missing in the report, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "It hopes setting such a standard would also help prevent teenagers who experiment with tobacco from becoming addicted.\nThe FDA estimates that setting such a standard would help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers by the year 2100.\nWASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe FDA will continue to take enforcement actions against companies that inappropriately target children, including through the promotion of e-cigarettes, Gottlieb said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention possible harms of introducing low-nicotine cigarettes, namely that it might encourage current smokers to smoke more to get their usual dose or make people think the cigarettes aren\u2019t as harmful, so they aren\u2019t as cautious about intake. In that scenario, smokers would be inhaling more of the toxic smoke that causes damage to the lungs. We think it\u2019s important to share with readers if researchers have looked into this, and if it\u2019s indeed a concern, as NPR did.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\nDuring the procedure, doctors collect a participant\u2019s blood-forming stem cells, give the participant high-dose chemotherapy to deplete the immune system, and return the participant\u2019s own stem cells to rebuild the immune system.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does the bare minimum here, stating:\n\u201cThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections. Three participants died during the study; none of the deaths were related to the study treatment.\u201d\nStill, we think more could have been said about the side effects of chemotherapy. For example, How many patients experienced them and how bad were they? And the news release does not say how long treatment and recovery takes. The process by which the deaths were categorized is not given and leads to uncertainty about whether these patients may\u00a0have died as a result of the immuno-suppression of their bone marrow.", "answer": 1}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As mentioned in the section on benefits, the release does not explain how the test results might be used. If the intent is to steer people identified as being at higher risk toward more testing or treatment, then the release should have mentioned the risk of doing more harm through overtreatment.\u00a0", "answer": 0}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nThere are no guidelines requiring bariatric surgeons to warn their patients, although recently professional societies of plastic surgeons and bariatric surgeons have begun holding seminars to discuss the idea.\nGavin Dry, a Seattle plastic surgeon wrote last month in a Plastic Surgery newsletter, \"I have seen a dramatic increase in the number of [surgical] revisions required by massive-weight-loss patients.\"\nThe American Society of Plastic Surgery (ASPS) has formed a task force -- D'Amico is a co-chair -- to alert doctors to the higher risks involved and teach them new techniques.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article details what are described as \u201chuge scars\u201d after surgery, along with \u201ca long and painful recovery\u201d. Contouring is described as \u201criskier\u201d and \u201crequiring longer recovery time\u201d than bariatric surgery, though again \u2013 there was no quantification provided. The artilce mentions that some patients will have revision done to improve upon the original contouring procedures. Again, no data were given on how common this really is, other than to say that it, in the view of one plastic surgeon, it has \u201cdramatically increased\u201d.", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentions the heightened risk of further damage from activity in the days and weeks after a concussion, and the unknowns/uncertainties of this risk.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\nHowever, screening ultrasound examinations have higher rates of false positives, meaning more cases of positive screenings where no cancer is present.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors mentioned that whole breast screening ultrasound produces high rates of false positives, there was no information provided about the rate of false positives for the abbreviated breast MRI.", "answer": 0}, {"article": "WEDNESDAY, Aug. 25, 2010 (HealthDay News) -- Swedish scientists report that they've successfully implanted \"biosynthetic\" corneas in 10 patients, potentially paving the way for more accessible treatment for those with cornea-related vision problems.\n\"This is true cutting-edge work and brings an exciting new option to the repertoire of corneal transplant surgeons,\" he said.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\n\"However, there is a shortage of good quality corneas that can be used for transplantation.\"\nFor more about corneal transplants, try the U.S. National Library of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that there were no adverse side effects. It should have been clear that the patients were followed for two years.", "answer": 1}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\nN-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\n\"Addiction goes along with virtually every psychiatric disorder at a higher percentage than it does in the general population\" said Peter W. Kalivas, Ph.D. the senior author on the article and chair of the Department of Neuroscience at MUSC.\nAs the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion, with an annual economic impact of more than $3.8 billion and annual research funding in excess of $250 million.\nVeterans in the study had low rates of substance use during the trial, and the study found little effect of medication on use, perhaps due to the fact that all participants were receiving SUD treatment and exhibiting low levels of use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release explains that the drug used \u201cdoes not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician\u2019s supervision.\u201d However, the published study notes a higher incidence of adverse events in the N-acetylcysteine treated group that in those treated with placebo (66.7% vs. 47.1%). N-acetylcysteine can cause \u201cnausea, vomiting, and diarrhea or constipation. Rarely, it can cause rashes, fever, headache, drowsiness, low blood pressure, and liver problems,\u201d according to WebMD.", "answer": 0}, {"article": "But the scientific evidence has been slim.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nDo melatonin supplements really help people sleep?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from the use of melatonin were mentioned. (It may be problematic for those taking warfarin or individuals with epilepsy.)", "answer": 0}, {"article": "New drug may help MS\n\u201cEven if it doesn\u2019t work, it\u2019s going to be another step down the road.\u201d\n\nIn autoimmune disease, the body\u2019s immune cells mistakenly attack and destroy healthy tissue.\nThe idea would be to \u201cintroduce\u201d the myelin to the T-cells at the same time they were \u201cmeeting\u201d the healthy tissue, and educate them to leave the myelin alone.\n\u201cIf this works, it is going to be absolutely fantastic,\u201d said Bill Heetderks, who directs outside research at the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health, which helped pay for the research.\nIt\u2019s also clear the approach would not repair any damage already done by the disease, so the best candidates would be patients having their very first symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explore potential harms, which is too bad. As the story points out, mice do have much shorter life spans than humans, and if humans have to be on this type of therapy for the long-term there are many potential risks involved.", "answer": 0}, {"article": "\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nThen they injected the cells into rats that had heart attacks and tried to manipulate the cells with a toy magnet.\n\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of even potential harms \u2013 just how \"remarkably simple\" it could be to enhance treatment effectiveness.\u00a0 ", "answer": 0}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this is a follow-up report focused on newly released data, a discussion of the potential harms of the vaccine is not necessary.", "answer": 2}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n(Because women have two copies of the X chromosomes, the other one can compensate, so they may carry the disease but not suffer from it.)\nAnd its effects lasted; after a year and a half, the longest patient follow-up, the therapy was continuing to work.\n\u201cPeople were planning their lives around hemophilia, and now they are doing activities that they weren't before,\u201d George said.\nThe hemophilia study \u201cis small but very promising, and it gives me the sense that gene therapy for hemophilia B is going to be at our disposal in no time, maybe a few years from now,\u201d said Aric Parnes, who is associate director of the Boston Hemophilia Center at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and wasn't involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does not address harms directly\u2013and should have\u2013it does note that one of the worrying side effects of gene therapy\u2014spurring the body to attack itself\u2014was not present in this study.", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nA corresponding Scientific Exhibit, by lead author Nima Eftekhary, MD, an orthopedic surgery resident, and senior author Vigdorchik, called, \"The Spinopelvic Relationship: A Stepwise Approach to Ensuring Stability in High-Risk Dislocation Patients Undergoing Total Hip Arthroplasty\" also was selected by the AAOS Central Program Committee as one of the three Best Scientific Exhibits at the 2018 AAOS Annual Meeting.\nA novel risk assessment tool helps identify which patients undergoing total hip replacement may be at higher risk for an implant dislocation after surgery, according to a new study from researchers at NYU Langone Health and described in the Best Poster in the Adult Reconstruction Hip at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting in New Orleans.\nMore than 310,000 hip replacements are performed in the United States each year, and an estimated 2.5 million Americans are currently living with hip replacements.\n\"There were significantly fewer dislocations in the high-risk group once all of our patients were analyzed through our new treatment algorithm,\" explains study co-author Aaron J. Buckland, MD, an assistant professor of orthopedic surgery in the Division of Spine Surgery and director of spine research at NYU Langone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any risks associated with hip replacement surgery in general, nor does it address potential harms specific to dual mobility cups, which are described in the release as the recommended approach to reduce risk for dislocations. The release notes that dual mobility cups may carry risks \u201cif implanted unnecessarily\u201d but doesn\u2019t describe or quantify those risks. Of note, there is some concern that this type of replacement joint may release higher levels of metal ions than conventional joints when implanted in younger, more active patients.\nAs presented, the only downside of these newer devices are the increased cost. It would be helpful to know if there are any other risks. Newer devices may have some risk simply due to not having long-term experience with them. Current hip replacement devices have been shown to work for 20+ years. It will take considerable time to know whether the same may hold for these newer devices.", "answer": 0}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented the data on the combined outcome of being re-hospitalized or dying from cardiovascular problems, indicating that this occurred in a higher percentage of patients taking the combination of a PPI and Plavix than in those taking Plavix alone. \u00a0The story then went on to say that it appeared that this was due to an increase in re-hospitalization rather than cardiovascular death.\nIt would have been more informative to simply present the data on the individual endpoints of rehospitalization and revascularization \u2013 both of which were higher in the group taking the medication combination; but that dying of any cause did not differ among the two groups.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Cardiac side effects are reported as less serious than those seen in patients who were treated with Herceptin and chemotherapy. However, this comparison with Herceptin is not a fair one. In trials of Herceptin, the incidence of cardiac problems was about 4% at 3 years, so the reduction to 2.5% with lapatinib appears to be an improvement, but there is not enough information in this story on length of time patients took lapatinib and Herceptin to get those figures (and whether those are statistically different). Although long-term cardiac problems are less of an issue for metastatic patients, this side effect is potentially a big issue for early-stage breast cancer patients \u2013 a group of women for which this drug is already being tested as an alternative to Herceptin. ", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\nThe use of anti-VEGF treatment rather than laser for PDR could help prevent these symptoms.\u201d\n\nAdditionally, the need for vitrectomy surgery was lower in the Lucentis group (8 of 191 eyes) than in the laser group (30 of 203 eyes).\n\u201cThese findings will change the available treatment options for patients with PDR.\u201d\n\nDiabetic retinopathy damages blood vessels in the light-sensitive retina in the back of the eye.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that one study volunteer in the Lucentis group developed an eye infection and stated that \u201cserious systemic adverse events,\u201d namely cardiac arrest and stroke, occurred at similar rates among the two groups undergoing the two different procedures. We\u2019ll rate that satisfactory for the disclosure although the release might have gone even further by mentioning the other side effects named in the study including inflammation and elevated intraocular pressure which occurred in both treatment groups.", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nIn addition to the soy protein, nuts and whole grains, participants in the diet were encouraged to eat peas, beans and lentils.\nThe study was published Tuesday in the Journal of the American Medical Association.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the safety of the diet. The study paper notes that there were some potential allergic reactions in the portfolio diet group.", "answer": 0}, {"article": "; Vladimir Lomivorotov, M.D.\n\"About a third of all patients undergoing bypass surgery will develop atrial fibrillation, putting them at higher risk for cardiovascular complications,\" said Jonathan S. Steinberg, M.D., senior study author and Adjunct Professor of Medicine at the University of Rochester and Director of the Arrhythmia Institute in the Valley Health System in Ridgewood, New Jersey.\n\u2022 In the 30 days following surgery, those who received Botox injections during heart bypass surgery had a 7 percent chance of developing AF, compared to 30 percent chance in patients who received saline.\nAtrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story appropriately points out that there were no additional harms seen in the group injected with the botulinum toxin compared to those who received saline other than those associated with the surgery.\n\u201cNo complications from the Botox injections were reported,\u201d according to the release. \u201cBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\u201d", "answer": 1}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "Sometimes patients get stents when they have no pain at all, just blockages.\nBut they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nOther estimates are far higher.\nHeart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions there are potential harms, including death.", "answer": 1}, {"article": "So who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nCephalon soldiered on, giving FDA more data.\nWell, the Food and Drug Administration.\nBut today the company said its response fell short.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Solid job reviewing most common side effects and links to other, rare but life threatening problem.", "answer": 1}, {"article": "The study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nFor example, before groundbreaking work by Dr. John Marshall at UVA in the past, no one knew that ulcers were from bacteria.\nWomen are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\n\"If you look at cancers in women, about a fifth of all cancer deaths would be prevented if we had women at normal body weight in the U.S.,\" said Susan C. Modesitt, MD, of the University of Virginia Cancer Center.\n\"The study results demonstrate that there is a huge alteration, but I don't even know what to say about that, except it is really new and intriguing area to look at in the link between obesity and cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms or risks in the release. Bariatric surgery has many well-documented short- and longer-term risks.\u00a0According to the Mayo Clinic, risks associated with the procedure may include excessive bleeding, infection, blood clots, and leaks in the gastrointestinal system, to name a few. Long term risks of the procedure include bowel obstruction, vitamin deficiencies and malnutrition, and stomach perforation.", "answer": 0}, {"article": "This is something the study\u2019s authors readily acknowledge.\nHe added, \u201cI want patients and their doctors to use caution in applying this.\u201d\n\nA few pain patients will still benefit from opioids\n\nOne of the study\u2019s implications is that opioids actually aren\u2019t a good treatment for chronic pain.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\nMaybe the opioids themselves caused problems that negatively impacted function or quality of life, \u201csuch as constipation, fatigue, poor sleep, and depressed mood.\u201d It\u2019s possible that opioid dose reduction also resolved what\u2019s known as opioid-induced hyperalgesia, \u201ca paradoxical response in which patients receiving opioids become more sensitive to painful stimuli.\u201d\n\nOr, the researchers suggested, the observational studies simply showed reverse causation \u2014 \u201cthat is, patients successfully tapered opioids because pain severity decreased.\u201d\n\nThe findings do not mean that doctors can now simply yank patients off opioids and expect them to get better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms are addressed right away: Come off opioids too quickly, and patients can suffer by having little recourse to deal with chronic pain. Some even resort to illicit drugs or commit suicide.\u00a0One of the study\u2019s authors is also quoted as recommending doctors and patients to exercise caution if tapering is being attempted, and another explains that not all patients respond the same way (and do poorly with tapering).", "answer": 1}, {"article": "Any HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nThe researchers say the technology, although still in the early stages, could allow patients to regularly monitor their virus levels in a similar way to diabetes patients checking their blood sugar levels.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The physical harms are pretty obvious, as the story\u2019s comparison to a diabetes blood sugar test makes clear: Patients need to get a spot of blood onto the sensor. But the more important harm isn\u2019t discussed here, where a simple \u201cthis isn\u2019t ready for the field\u201d statement would have covered. More than 11 in 100 HIV-positive people getting a false-negative test is not very comforting; they could be misled to think their anti-retroviral therapy is still working when it might not be.", "answer": 0}, {"article": "Trials of medications for treating mental illness typically don\u2019t include people younger than 18, Amminger noted, while starting minors on these medications is \u201calways very difficult, and always quite controversial.\u201d\n\nBut if future research bears out the current findings, he added, fish oil promises to offer a safe way to help prevent psychosis in at-risk people, and could also potentially be used to prevent or delay the onset of chronic depression, bipolar illness, and substance abuse disorder \u2014 all of which are far more common than psychotic illness.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\n\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nPeople taking fish oil also showed significant reductions in their psychotic symptoms and improvements in function, while they were at no greater risk of adverse effects than people taking placebo capsules.\nTo investigate whether omega-3 fatty acids might help prevent psychotic illness, they randomly assigned 81 at-risk individuals, 13 to 25 years old, to take 1.2 grams a day of omega-3s in fish oil capsule form or a placebo for 12 weeks and then followed them for another 40 weeks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While fish oil supplements are generally recognized as safe, the story could have told readers about potential side effects which can be gastrointestinal and include blood clotting problems, particularly for people taking blood thinners.\u00a0 ", "answer": 1}, {"article": "The drug is approved for metastatic melanoma patients who show no response to other treatments and for advanced squamous non-small cell lung cancer (NSCLC) with progression on or after chemotherapy.\nWhile median progression-free survival appeared similar between treatments (4.6 months and 4.4 months with nivolumab and everolimus, respectively), when researchers explored a delayed progression-free survival benefit at six months, they reported 15.6 months with nivolumab and 11.7 months with everolimus.\nWe have a real opportunity to change clinical practice for patients when other therapies have failed,\" said principal investigator Padmanee Sharma, MD, PhD, professor, Departments of Genitourinary Medical Oncology and Immunology and scientific director of the Immunotherapy Platform, part of MD Anderson's Moon Shots Program.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\nThe study included 821 patients with advanced RCC across 151 sites in 24 countries in North America, Europe, Australia, South America and Asia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that there were \u201cfewer treatment-related adverse events, including fatigue and nausea, and improved quality of life with nivolumab.\u201d But that\u2019s not really a satisfactory accounting of the harms of treatment. As the\u00a0article in the NEJM notes, \u201cTreatment related adverse events of any grade occurred in 319 of the 406 patients (79%) treated with nivolumab and in 349 of the 397 (88%) treated with everolimus.\u201d The release should have given readers more insight into what these harms are and how often they occur.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states: \u201cPossible side effects are less severe than for chemotherapy, but serious problems can include blood and bone marrow cancers. Common side effects include nausea, fatigue, respiratory infections and blood count problems.\u201d\nAlthough this would be a rare concern, the FDA also says: \u201cLynparza can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception. Women taking Lynparza should not breastfeed as it could cause harm to a newborn baby.\u201d", "answer": 1}, {"article": "\"This is a very safe agent and has been around for a while,\" said Cancer Prevention Research editor-in-chief Dr. Scott Lippman, chair of thoracic head and neck medical oncology at the University of Texas M.D.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\nIn the September issue of Cancer Prevention Research, researchers report that metformin was associated with a substantial reduction (up to 73 percent) in the number of tumors mice developed when they were given a common carcinogen found in tobacco.\nThe researchers thought metformin's possible cancer-lowering properties suggested the need for clinical trials to investigate whether the drug might help prevent tumors in smokers at high risk of developing cancer.\nA second study, this one a randomized controlled trial involving a very small number of humans (23), found that patients with an early form of colorectal cancer who were treated with metformin did see a decrease in possible cancer-related growth, compared with participants not taking the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least the story noted, \"no one knows if metform in safe in non-diabetic populations but some clinical trials are starting to look at the issue.\" ", "answer": 1}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\n\"While these compelling results come too late for those who lost their lives during West Africa's Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless,\" said Dr Marie-Paule Kieny, WHO's Assistant Director-General for Health Systems and Innovation, and the study's lead author [4].\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\n[1]\n\nThe vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release also accurately quantifies the harms associated with this vaccine, noting that more than half of those vaccinated reported mild side effects, including short-term headaches, fatigue and muscle pain. The release also\u00a0identified two serious negative reactions (a high fever and an allergic reaction) associated with the vaccination and a flu-like illness that might have been a result of the vaccine.\u00a0This is a particularly strong point of the release in that many releases on drug/vaccine studies don\u2019t quantify the adverse event rates very clearly or completely.", "answer": 1}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\n\"This is the first randomized clinical trial looking at the effect of magnesium supplementation on symptoms of depression in U.S. adults,\" says Tarleton.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nThe researchers at the University of Vermont's Larner College of Medicine conducted an open-label, blocked, randomized cross-over trial involving 126 adults in outpatient primary care clinics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release made no mention of potential harms of magnesium supplements although it notes the treatment is safe on two\u00a0occasions. \u00a0The actual results, however, were not quite as straightforward. The authors noted in the published study, \u201cThe most common reason for a negative response was that \u201cmagnesium did not help mood\u201d (46%), followed by side effects (20%). The most common side effect, diarrhea, was reported by 8 participants. In addition, the published study notes that people with gastrointestinal disorders or\u00a0kidney disease could not participate in the study since high levels of magnesium are not safe for these patients.\u00a0", "answer": 0}, {"article": "Experts are still divided as to whether raising HDL levels will actually result in any meaningful improvements in clinical outcomes.\nAlthough the trial was primarily designed to look at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual meeting in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and cut LDL, HDL's evil twin, almost in half.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\nTo assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.\n\"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery,\" said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that anacetrapib did not show the type of harmful effects (including higher blood pressure and higher rates of cardiovascular problems and death) seen in trials of a similar drug, torcetrapib, which was pulled from testing. However, the story does not make it clear that this trial was designed to detect harms that were at least 25 percent more common in the treatment group than in the placebo group\u2026 so it was not powerful enough to rule out side effects that were less common than that threshold. ", "answer": 0}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\n\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThe only other factor found to make a significant difference to the children's amount of body fat was their level of physical activity.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nA healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no warning that in rare cases vitamin D overdoses can cause calcium to rise to harmful levels, which can weaken bones and cause kidney stones and other problems. Some of the reported cases have been linked to manufacturing errors which meant the drops given to children contained far more vitamin D than listed on the label.", "answer": 0}, {"article": "Not willing to trust my luck a second time, I got the new vaccine.\nAnother difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nYears ago when I went to bed with what had been a daylong gnawing irritation on one side of my back, I awakened in the middle of the night with the thought, \u201cI have shingles.\u201d First thing in the morning I got a prescription for the antiviral drug acyclovir, which halted progress of the disease.\nIt also reduces the risk of PHN by 86 percent, and it appears to be longer lasting than Zostavax, which starts to lose its protection after three years.\nInstead, it leaves them with deep, searing nerve pain \u2014 a condition called postherpetic neuralgia, or PHN \u2014 that can last for months or years and has no treatment or cure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author tells her personal story and a few common harms. She notes that \u201cthe shot itself is painful and can cause a sore arm for a day or two. Some people develop immune-related side effects like headache, fever or an upset stomach that last less than three days, according to the manufacturer, GlaxoSmithKline. My only reaction beyond local soreness was an acid stomach for a day or two.\u201d\nThis is a good start, but the story didn\u2019t recognize that significant adverse effects are actually more common than the benefits, making the story imbalanced.\nThe study shows that the severity of the side effects of the vaccine were much more intense than what the Times implies. In it, 17% of the patients injected with the vaccine, versus 3% on placebo, had \u201cgrade 3\u201d symptoms. These are defined as symptoms that \u201cprevented normal everyday activities.\u201d The absolute rate therefore is 14% or a NNH (number needed to harm) of seven. While the author of the Times story might not have been that sore after the vaccine, according to the data in the trial, for every seven persons injected with the vaccine, one person will have \u201cgrade 3\u201d symptoms and have difficulty functioning in everyday activities.", "answer": 0}, {"article": "(With HIV, 50 to 60 percent is about the efficacy range researchers hope for.)\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nResearchers from the National Institutes of Health and Johnson & Johnson at the International AIDS Society conference in Paris Monday morning presented data on a clinical trial of what\u2019s called the \u201cAd26-env mosaic vaccine.\u201d\n\nThe mosaic vaccine was developed using a computer algorithm to analyze HIV data from around the world and select a range of HIV sequences to include in a shot.\n\u201cIt\u2019s a step forward toward getting another candidate into trial that could have some promise.\u201d It\u2019s too soon to say if and when the mosaic vaccine might work to prevent the virus from spreading in humans, he added.\nThe other HIV vaccine in human testing, the HVTN 702 candidate, is a newer version of the only other HIV vaccine to show any efficacy in humans, called RV144.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the Ad26 vaccine was the \u201cbest tolerated\u201d of several approaches, but doesn\u2019t tell us what may have occurred in people who didn\u2019t tolerate it so well. The potential indirect harms of\u00a0a vaccine program could also have been mentioned. The vaccine is expected to work only about 50 to 60 percent of the time, according to the researchers. If people feel less pressure to employ other proven measures to control HIV (condoms, etc) because of the vaccine, then it\u2019s possible some harm could occur due to false reassurance.", "answer": 0}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nDr. Schaefer pointed out that the kind of fish consumed is important.\nEating fish is not a guarantee of having high levels of DHA.\nOther dietary intake and genetic propensities probably account for the rest.\nHigh intakes of fish oil can cause excessive bleeding in some people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms from fish oil consumption and included speculation on potential harms from fish consumption.", "answer": 1}, {"article": "This was especially true in the left hemisphere regions of the brain responsible for language.\nTUESDAY, June 26, 2012 (HealthDay News) -- Electroencephalogram (EEG), a test that shows the electrical activity of the brain, might be used to spot autism in children, a new study suggests.\n\"Although autism is still principally a clinical diagnosis, this study ... may allow for a new approach to classifying children with autism and may even assist in the early identification of affected children at a younger age,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York in New Hyde Park, NY.\n\"They then looked at the extent to which brain activity from one region was synchronized with brain activity from another region,\" a phenomenon known as \"EEG coherence,\" said Dawson, who was not involved in the research.\nIn the new study, Dr. Frank Duffy and Dr. Heidelise Als compared EEG measurements of nearly 1,000 children with and without autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nor is it clear what the potential harms might be. The rise in autism diagnoses has been controversial in part because once a child is put \u201con the spectrum\u201d they may be treated differently by the educational system, not to mention other kids.\nIf EEG is used inappropriately and \u2018overdiagnosis\u2019 is a concern, this could be a problem.", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "What happened?\nBut we were surprised by how healthy he seemed seven months later, in August 2008, when we visited with him and his wife Marianne at their home in Erie, Pa.\n\n\"I must say you look like a completely different person to me.\nUsing his wife's pie pans and what he knew best - radios - Kanzius, a former radio executive, built a machine in his garage that he hoped would zap cancer cells without the horrible side effects you get with chemotherapy and radiation.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\nDr. Curley thought there was so much promise in Kanzius' invention, he began conducting his own research with the machine, using tiny bits of gold nano-particles that are so small, thousands of them can be injected into a single cancer cell.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe underlying premise of this device is that it cooks cancer cells by heating metallic nanoparticles. If the nanoparticles used in this approach collect in normal tissue, those tissues could also be cooked by the radio waves.\n The researchers wrote in an article in the journal Cancer in 2007 that while rabbits in their tests did not appear to suffer any irreversible toxic effects, the safety of this approach in humans \u201ccannot be assumed.\u201d The portrayal of this experimental device as lacking potential harms is inaccurate.", "answer": 0}, {"article": "While a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\n\"Having a test like this shortens the time of suffering, it shortens the time of investigation and accelerates getting the patient directly to treatment.\"\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100 percent accurate, and a false positive test can lead to additional diagnostic testing that can cause harm as well as unnecessary treatments. The story could have mentioned this.", "answer": 0}, {"article": "No woman who had a mastectomy developed breast cancer during the three years of follow-up testing.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nCHICAGO (Reuters) - Women with mutations in the well-known BRCA1 or BRCA2 genes who have their breasts and ovaries removed are much more likely to survive than women who do not get preventive surgery, U.S. researchers said on Tuesday.\nAccording to the American Cancer Society and the International Agency for Research on Cancer, 1.3 million new breast cancer cases are diagnosed around the world every year and it kills 465,000 women annually, making it the leading global cancer killer of women.\n\u201cMost of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery,\u201d Kaklamani said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story mention psychological issues facing women who undergo mastectomy and early menopause that results from ovary removal, but the brief reference to harms and lack of important details understates the trauma, side effects and complications that preventive surgery causes women.\u00a0 There are also potential harms from the increased surveillance, for example, with ensuing biopsies. ", "answer": 0}, {"article": "Warren says he wishes the solution were as simple as just taking folic acid.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n\"This is another piece of evidence that supports the beneficial uses of folic acid during pregnancy,\" said Halladay, who was not connected with the study.\n\"It is possible that folic acid ... might provide protection against other neurodevelopmental disorders like autism,\" said Zachary Warren, director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University, who was also not involved in the study.\n\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are hypothetical, but plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story should have mentioned this.", "answer": 0}, {"article": "\"Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?\"\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\nIn 73 of those 285 patients, or 25.6 percent, MRI identified at least one additional cancer in a different quadrant of the breast than the index cancer, or the cancer detected by mammography and/or breast palpation.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote near the top of the release notes that some women may be overtreated. But the release provides no specifics about what that means. In the case of an MRI-detected additional cancer, it could mean an unnecessary mastectomy. We\u2019ll give a borderline satisfactory rating here, although more detail would have been welcome.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although some potential harms are mentioned, none are quantified.\nThe story states that NRT products \u201chave amassed a strong safety record\u201d but we never get any details on that record.\nWe wish the story had delivered a deeper exploration than one health behavior specialist saying, \u201cThere really doesn\u2019t appear to be any great harm.\u201d And a British regulatory proclamation that \u201cthere are no grounds to suspect appreciable long-term adverse effects.\u201d\u00a0 Statements like \u201cdoesn\u2019t appear to be\u201d and \u201cno grounds to suspect\u201d could be haunting some day.", "answer": 0}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The extra olive oil consumed by participants amounts to more than 500 kcal per day, which could cause weight gain if not balanced by a similar reduction in other food intake. Weight effects weren\u2019t reported here and may not have been a problem in this study. But these were Spaniards already accustomed to consuming a lot of olive oil, vegetables, fruits, and legumes. We don\u2019t know if adding a lot of olive oil to the diets of Americans would yield the same results.\nBut the story makes no mention of this or other possible harms linked to the diet. If there really are none, that would have been nice to know and would have strengthened the story.\nSo too would have been a discussion of why, according to the study, more than 25% of the 447 participants \u201crefused to undergo a second procedure or abandoned the study for different reasons.\u201d", "answer": 0}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nIn neither study did patients actually live longer, and there was a high rate of side effects, including high blood pressure and internal bleeding.\nSince then, it has also been approved as a treatment for certain types of lung, kidney and brain cancer.\nShe had it removed, went through a round of radiation and chemotherapy, and was symptom-free for the next nine years.\nThe morning after her midnight meal, Gilbert was on the pavement again, window-shopping with daughter Neely in Soho and Chinatown.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that Avastin is associated with serious side effects, such as high blood pressure and internal bleeding; however, it did not provide data on how many women in each treatment arm experienced these side effects. ", "answer": 0}, {"article": "The investigators compared weight changes in gastric bypass surgery patients to weight changes in more than 5,300 obese veterans who had no weight-loss surgery or formal weight-loss treatment.\n\"This study suggests that patients interested in bariatric surgery, especially gastric bypass surgery, should be able to lose a significant amount of weight and keep that weight off for a very long time,\" said study researcher Matt Maciejewski.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\nBased on the new study findings, Gould said, \"I think a patient who is young and who has a long way to go may want to think about these results, and all other things being equal, might pick a gastric bypass for the long-term weight loss.\"\nWhile other research has found that weight-loss surgery is the most effective treatment for obese patients, there is less data on long-lasting effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms. Bariatric procedures can lead to an array of complications that are worth considering. And on the flip side, it\u2019s worth noting that research also has\u00a0indicated that\u00a0bariatric surgery can both extend quantity and quality of life when compared to not having surgery.", "answer": 0}, {"article": "\u201cThe No.\n\u201cIt would be incorporated into these dreams where I was tied up, like in the movie \u2018Alien.\u2019 It was more difficult to sleep with that thing on than to just get through the night with the apnea.\u201d\n\nMr. Bleck got rid of the machine after he discovered Provent.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nUnlike C.P.A.P., Provent is not covered by Medicare and most major insurers, though some doctors say they expect that will change in the near future.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in this story.\nBoth the Provent device and the sham device were very similar in design and use.\u00a0 Both were adhesive \u201cbandaids\u201d place over the nostrils and both restricted exhalation through the nose (although the sham device did so less).\u00a0 Although the device was shown to have no side effects in the published study, about 16% of those using the Provent device stopped doing so by month 3 (as compared to 13.6% who used the sham device).\u00a0 That means about 1 out of 6 patients using the nasal \u201cbandaids\u201d stopped doing so relatively soon.\u00a0 The reasons for stopping were not provided but we can assume that discomfort was at least one of the reasons.", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nThe results: continual muscle and fat measurements revealed that the group that took no fish oil supplementation lost an average of just over 5 pounds; the supplement group lost no weight.\nAnd then with chemotherapy, there is some inflammation that's detrimental to the heart and muscle, as it can cause muscle breakdown.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The independent perspective from the Texas dietitian did include this: \u201cBut I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot. Much much more than any recommended dietary allowance, along the lines of two to three servings of fish per week.\u201d\u00a0 But neither that comment nor any other line in the story explicitly mentioned the possibility of harm from the mega doses. Is it possible there could be interactions with drugs the lung cancer patients were taking?", "answer": 0}, {"article": "Saxon and her team reported their observations in the Nov. 22 online edition of Circulation.\n\"It's highly likely the reason these patients did better is that they were receiving earlier diagnoses, and they were also empowered to take charge of their own health care more,\" Saxon said.\n\"So we don't really know what it all means, and it's inappropriate to suggest that we could, based only on this compilation of data.\"\nBut, Prystowsky continued, \"this analysis does show two impressive things: one, that patients who are not super-selected for a trial do well with these devices from a mortality standpoint; and two, that patients who had home-monitoring had better outcomes.\"\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The fact that the story could be entirely about surgically implanted devices and never acknowledge that surgery has risks or that the devices themselves have risks is odd, to say the least.", "answer": 0}, {"article": "The brain controls how long we live.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nTo test whether the decline in stem cells was causing ageing, and not itself a result of old age, the researchers injected mice with a toxin that wiped out 70% of their neural stem cells.\n\u201cThe mechanism is partially due to these cells secreting certain miRNAs which help maintain youth, and the loss of these leads to ageing\u201d said Cai, whose study is published in Nature.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the potential harms that might arise from this approach. Since this has never been tested in humans, we have no idea what they risks are. The story needed to point this out.\nTheoretically, the stem cells would have to be delivered into human brains via injections, which would make the intervention incredibly risky and possibly a non-starter. In the original paper, the stem cells were injected into the hypothalamus of the mice using viruses as \u201cvectors.\u201d The researchers used lentiviruses, which are used often as vectors for research, but can be deadly in humans. Some discussion of this hurdle also was warranted.", "answer": 0}, {"article": "For more information, go to www.bayer.us.\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\n\"Data show that the use of effective, long-acting birth control methods including intrauterine devices \u2013 or IUDs \u2013 have helped to reduce unintended pregnancies in the United States but we still have a long way to go,\" 2 said Anita L. Nelson, M.D., Professor and Chair, Obstetrics and Gynecology at Western University of Health Sciences, Pomona, Calif. \"Kyleena is highly effective at preventing pregnancy and may be an appropriate choice for women who want a low-dose, non-daily birth control method.\"\nThe trial was a multicenter, multi-national, randomized, open-label study conducted in 11 countries in Europe, Latin America, the U.S. and Canada.\n\"With the approval of Kyleena, women have an important new birth control option that provides pregnancy prevention for up to five years,\" said Dario Mirski, M.D., Senior Vice President and Head of Medical Affairs for the Americas, Bayer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release goes into this at length, which is good. What would have been even better would have been for the release to compare the likelihood of potential side effects for Kyleena with the likelihood of side effects for other products on the market.", "answer": 1}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story covers directions for Hello, Peanut!\u2019s use in great detail, and also emphasizes that if a baby develops a reaction, parents should discontinue use and contact their pediatrician. The story also discusses potential harms of the product specifically in terms of unintended use. Quoted sources worry that consumers might mistake the product as a cure for peanut allergies as opposed to a preventative tactic. Feeding the product to a child with an existing peanut allergy would likely cause an allergic reaction.", "answer": 1}, {"article": "Individuals in the strategy-based reasoning training showed a greater change in cortical thickness and connectivity compared to individuals who received the knowledge-based training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\nThese brain changes can interfere with brain network communication and the cognitive functions those networks support,\" said Dr. Kihwan Han, research scientist at the Center for BrainHealth and lead author of the study.\n\"For people with chronic TBI, they may have trouble with daily tasks such as creating shopping lists and resolving conflicts with others for many years after the injury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed. While presumably there is little risk from participating in brain training, cognitive training can have its downsides. Harms such as the time investment, frustration over speed or lack of progress, costs, etc. could have been mentioned.", "answer": 0}, {"article": "Cerebral palsy is a common yet understudied neurodevelopmental problem in the U.S.\n\"Many of the signals that we pick up are based on immune system shifts--meaning the way a person's immune system responds to external stress events.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\n\"This is an example of the kind of innovation that can happen when people with different skill sets collaborate.\nThe researchers identified a strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms that might arise from the use of such a test. A blood draw is a low risk procedure; the real potential harm comes from over- or under-diagnosis and that should have been clarified.", "answer": 0}, {"article": "This is really about patient care.\n\u201cThe femoral artery is the traditional route, but when we go in through a vessel in the wrist, we see less bleeding, fewer complications, less pain and discomfort, higher patient satisfaction, shorter hospital stays, and lower costs.\u201d\n\nPatients may undergo coronary angioplasty \u2014 also called percutaneous coronary intervention (PCI) \u2014 to alleviate chest pain or shortness of breath.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nBut with advances we have in technology and equipment, those challenges are rapidly decreasing.\u201d\n\nThis work was supported by a grant from Vita Solutions, a subsidiary of The Medicines Company, for whom Amin has provided consultation; and by the National Institutes of Health (NIH), grant numbers UL1TR000448, KL2TR000450, TL1TR000449 and 1KM1CA156708-01.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not discuss any possible downsides associated with the new technique. Although the disadvantages of using the wrist rather than the groin approach\u00a0are minor and perhaps not clinically relevant for most people, it would have been better for the release to at least mention them.", "answer": 0}, {"article": "\"How bulging is the eardrum?\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nTo do a correct diagnosis, says Dr. Alejandro Hoberman of the University of Pittsburgh, the doctor needs to be able to see the child's eardrum, which may mean cleaning out earwax first.\n\"It is a two- and sometimes a three-person operation to see the eardrum,\" says Hoberman, who led the US study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possibility of antibiotic resistance is raised but never quantified in any way. Other harms are not mentioned. This is a significant omission. Both studies list adverse events, and the Finnish study saw a large number of children with adverse events. As the authors note, \u201cAn adverse event occurred in 85 children (52.8%) in the amoxicillin\u2013clavulanate group and in 57 children (36.1%) in the placebo group (an increase of 16.7 percentage points with amoxicillin\u2013clavulanate\u201d. Of those who received the drug, 77 had diarrhea, 17 had vomiting and 14 had eczema. There also are harms from not taking the drugs, which were not mentioned.", "answer": 0}, {"article": "What does that mean?\n\"Although it's promising, we really have to see the benefit long-term to justify the cost,\" she added.\n\"The experimental therapy, focusing on functionality, not using pain as a reliable symptom, and not as a guideline to adapt movements or activities, leads to better treatment outcomes,\" Malfliet said.\n\"These positive effects were found until the last follow-up measurement at one year after treatment,\" Malfliet said.\nThey should \"learn to put pain into the right perspective, should remain active or increase their activity levels gradually, and should avoid fear of moving,\" said Malfliet, of Vrije University Brussel in Belgium.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although physical therapy and a 12-week program of education about the origins of pain designed to reshape people\u2019s understanding of the pain pathway are not likely to cause harm, it would have been useful to know if any experimental treatment subjects dropped out, failed to finish the program, or felt worse than those in the control group. There is also the potential in such studies for \u201cvictim blaming,\u201d or imposing the onus of attitude change on pain patients. Some of the comments of the principal investigator in the article (i.e. patients \u201cshould learn to put pain into the right perspective and\u2026avoid fear of moving\u201d) may impose additional burdens on some pain patients.", "answer": 0}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nAdditionally, participants were not assigned to eat walnuts or other foods, and were just asked about their dietary choices.\nAdditional research is needed to better understand how diet and lifestyle choices can help maintain our health and well-being as we age,\" said Dr. Grodstein.\nBetween 1992 and 2008, the women were asked questions about their physical function, including their ability to perform basic activities of daily living.\nThis new paper prospectively examined the association between the dietary habits of the participants and subsequent impairment in physical function.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As we stated in a recent review of a news release about walnuts and heart health, a brief mention of nut allergies and the high caloric content of nuts would be appropriate.", "answer": 0}, {"article": "Breaking the diet with so much as a few cookies can cause seizures to flare up.\nThough its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention any harms associated with the diet. In the particular study reported on, the side effects in the children studied included constipation, vomiting, lack of energy, and hunger. \u00a0In addition, there have been reports of more serious side effects occurring after longer term use of the diet.", "answer": 0}, {"article": "That\u2019s called secondary prevention.\nWe know that taking aspirin will prevent a first heart attack and a first stroke, but we also know that aspirin can cause serious bleeding, mainly in the gastrointestinal system and, more rarely, in the brain.\nHe was the principal investigator of the Physician\u2019s Health Study, which was the first to demonstrate that aspirin prevents a first heart attack in men, and the Women\u2019s Health Study, which was the first to demonstrate that aspirin prevents a first stroke in women.\nBy Charles H. Hennekens: After more than 25 years of research on aspirin for primary prevention, we are not much further along than we were after the landmark findings from the Physicians Health Study in 1988.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As above, Hennekens gave a description of the absolute harms involved in aspirin, particularly related to gastrointestinal bleeding, and several of the other sources also discussed this important harm.", "answer": 1}, {"article": "The paper, co-written by Hayes and four colleagues from UCL and Oxford University, concluded that: \u201cLithium remains an important treatment for individuals with bipolar disorder.\u201d It accepts that \u201cthere is clear evidence that its use is associated with a number of adverse events.\u201d\n\nHowever, it adds: \u201cThese risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options.\u201d\n\nThe researchers studied a nationally representative sample of 6,671 patients across the UK who were treated for bipolar disorder between 1995 and 2013.\nThat means that people end up in hospital more often than they need to and end up achieving less in their lives than they could do if they were on lithium.\nWhile 15%-20% of those on the three other drugs were more likely to gain more than 15% of their body weight, just 10% of those on lithium put on the same amount of extra pounds.\nThose on olanzapine added the most weight and experienced high blood pressure as a result.\nBut lithium\u2019s reputation is largely misplaced and based on the experiences of patients from the 1960s to the 1980s who were given too large a dose of the drug, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in outlining the side effects seen with the four drugs in question and provides them in context.", "answer": 1}, {"article": "\u201cThis outcome is more than we hoped for.\nThe bottom line is we now have clear evidence that lowering inflammation through this pathway lowers rates of heart attack and stroke with no change at all in cholesterol.\u201d\n\nAbout a quarter of people who have heart attacks will have another heart event even if they keep their cholesterol at recommended levels.\nWhile the connection between heart disease and cancer may not seem obvious, Ridker says that many people who have had heart problems, like those in the study, are former or current smokers, since smoking is a risk factor for heart attacks.\nThe cancer data is still preliminary, and needs to be confirmed with additional studies, but it\u2019s encouraging, says Dr. Otis Bradley, chief medical officer for the American Cancer Society, who was not involved in the study.\nIn recent years, doctors have started to focus on inflammation \u2014 the same process that makes cuts red and painful \u2014 as an important contributor to a heart attack.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hardly a word about the real and unknown harms of the drug, which are more carefully outlined in a Reuters piece. The TIME article emphasizes the positive news\u2013that anti-inflammatory drugs like the one described in the trial may well represent the future of substantial reductions in heart disease and cancer mortality. But there are caveats that needed much attention not paid in this story.", "answer": 0}, {"article": "By doing so, it can save the lives of some men who would otherwise have died of the disease.\"\nHowever, he believes that with the results of the new 14-year study, \"it feels ethically difficult not at least to inform all men over the age of 50 about PSA and its possibilities.\nHowever, since the benefit of PSA screening requires at least 10 years to be borne out, it still seems questionable to test PSA for men over 70, the researchers noted.\nThe argument over whether PSA screening saves men's lives or merely leads to the overdiagnosis of very slow-growing cancers (with attendant worry and overtreatment) has bedeviled the medical world for years.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although reporting that \u2018just 12 men would need to be diagnosed with prostate cancer in order to save one life\u2019 the story neglected to follow though and examine the harm done to the other 11 men. \u00a0There are psychological consequences of a cancer diagnosis. \u00a0In addition, it wasn\u2019t just that men were diagnosed with prostate cancer that affected the chance that they would die from prostate cancer \u00a0\u2013 at least some of these men also received treatment for prostate cancer. \u00a0There was no discussion of the possible harms that are a consequence of prostate cancer treatment.\nThese are not easy issues, but the story did not mention that the number needed to screen to prevent one cancer death was 293.\u00a0 Those who were screened and got a false positive, perhaps leading to unnecessary followup testing like a biopsy, experienced harms. ", "answer": 0}, {"article": "The researchers tested the therapy in a small group of patients with Addison's disease.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nProfessor Brian Walker, Head of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison's disease and congenital adrenal hyperplasia.\"\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the research article from which this release stems notes that \u201cadverse effects will need to be compared not only for metabolism and obesity but also for immune suppression and osteoporosis,\u201d the release makes no mention of possible harms.", "answer": 0}, {"article": "I see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gives no sense of what could go wrong if this technology malfunctions and delivers the wrong dose of insulin while someone is sleeping.\u00a0The consequences could be fatal. \u00a0", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of the potential harms of drinking large quantities of coffee and tea.\u00a0 There are always tradeoffs. This is worth at least a line. ", "answer": 0}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n\"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients.\n\"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor,\" said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms. Even though the researchers said in their meeting abstract that the therapy had \u201can excellent safety profile\u201d in this trial, the story should have pointed out that patients have been harmed and some have died during experiments using other types of gene therapy.", "answer": 0}, {"article": "The study was conducted in Brazil because of Voltarelli's interest in the experiment.\nThe study suggests a new avenue for treating the intractable disease, in which the immune system destroys insulin-producing beta cells in the pancreas.\nLOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nThe patients, who ranged in age from 14 to 31, were treated with drugs and hormones that prompted the body to produce hematopoietic stem cells and send them from the bone marrow into the bloodstream, where they were extracted by a special machine.\n\"We all realize that without addressing the problem at the level of the immune system, we'll never really beat Type-1 diabetes,\" said Dr. Francisco Prieto, who treats diabetics in Elk Grove, Calif., and wasn't involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states the new treatment is not without risks and that patients are prone to infection.\u00a0 However, there is no description of how severe this harm might be (could lead to death) or how frequently these occurred in the study.\u00a0 So, although harms are briefly mentioned, they are not adequately developed or appreciated. This is not a minor issue, as stem cell transplant can be associated with very signficant risks of infection, organ failure and even death.\u00a0 \nAs an example of what can be left out in a shortened version, this line about potential harms appeared in the original LA\u00a0 Times story, but was left out of the Boston Globe version we reviewed: \"Burt's research group at Northwestern has performed 170 stem-cell transplants to treat a variety of immune system disorders, and two patients have died from the treatment.\"", "answer": 0}, {"article": "What does that mean for men today?\nThose with a higher PSA velocity \u2014 the level rose more than a count of 0.35 a year \u2014 had a 54 percent survival rate, while those whose PSA rose more slowly had a 92 percent survival rate.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nIt diagnoses prostate cancer that's going to actually cause harm,\" said Dr. H. Ballentine Carter, urology chief at Johns Hopkins University, who led the research published Tuesday in the Journal of the National Cancer Institute.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention that screening itself is associated with harms, such as physical pain from subsequent biopsies, anxiety, and problems related to a false positive (a false alarm) screening result.\u00a0 While the story does mention that many experts believe too many men are undergoing side effect prone treatments for prostate cancers which would never harm them,\u00a0 those treatments or side effects are\u00a0 not mentioned.\u00a0 The treatments\u00a0commonly include surgery or radiation, both of which can cause problems with impotence/erections, bladder control, and bowel functioning. The side effects are not inconsequential and happen to a significant number of men (sexual problems seem to occur in a majority of treated men).\u00a0 The reader doesn't have any context for how serious or frequent these may be.\u00a0 ", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Story says \"few eye-related complications\" were reported in the Lucentis group, but didn\u2019t say what few means or what they were.\u00a0 We don\u2019t think that\u2019s quite adequate. ", "answer": 0}, {"article": "The controls have had twice the death rate from aging-related diseases like heart failure and diabetes.\n\"There is no data on non-obese humans,\" said Eric Ravussin, chief of health and performance enhancement at the Pennington Biomedical Research Center at Louisiana State University.\nIt was probably preserved by evolution because it saved people from starving to death when food was scarce, but it is the bane of dieters because it means that the more weight they lose, the harder it is to keep reducing.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\n\"There's never been a study like this one,\" said Dr. Evan Hadley, director of geriatrics and clinical gerontology at the National Institute on Aging, which paid for the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article does a good job of highlighting the weight regain that occurs when peoples\u2019 adherence to a dietary program that provides all the food ends. However, there was no mention of potential side-effects or harms of long-term calorie restriction such as decreased testosterone, muscle mass or bone density.", "answer": 0}, {"article": "\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nTomatoes are rich in the antioxidant lycopene.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\nDuring that time, 67 men had a stroke.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from eating tomatoes.", "answer": 2}, {"article": "Dr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nThe CDC says colonoscopy may also be recommended for people experiencing stomach pain, aches or cramps that don't go away, unexplained weight loss and blood in the stool.\n\"We'll have both the computer and the doctors working in tandem to find polyps and find cancers,\" Kaufman said.\nColorectal cancer is the second leading cause of death among the combined group of men and women who have cancer, according to the National Institutes of Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions radiation exposure and the potential for the need for a follow up colonoscopy if a suspicious lesion is found. In reality almost one third of routine colonoscopies identify a suspicious lesion that is either removed or is biopsied. That means that roughly one in three people undergoing a bowel preparation for a CT colonoscopy will need to undergo a second round for removal or biopsy of a suspicious lesion. That is a significant downside that should have been emphasized in the story.", "answer": 0}, {"article": "To find out, they studied 79 adults with chronic insomnia.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nThe key ingredient in the therapy, according to lead researcher Dr. Daniel Buysse of the University of Pittsburgh School of Medicine, was a simple, somewhat counter-intuitive lesson: \u201cWhen you are sleeping poorly, the most important thing you can do is spend less time in bed.\u201d\n\nInsomnia affects about one in every five Americans, rising to one in three among the elderly, and has been linked to a range of physical problems, from accidents to hypertension.\nWhile brief behavioral treatment for insomnia is not yet generally available, Monk told Reuters Health in an e-mail that his team hopes their findings will be \u201can important first step in that process.\u201d\n\nIn the meantime, Neylan offers insomniacs some advice: \u201cIf you\u2019re not ready to fall asleep, don\u2019t lie down in bed and try to force yourself to sleep.\nYet the time and resource-intense strategy \u2014 usually involving between six- and eight hour-long appointments with a clinical psychologist - is not widely available and its cost, generally hundreds of dollars, is prohibitive for many.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWe won\u2019t hold this story to this criterion because neither the journal article on the test nor an accompanying commentary noted any adverse events. However, the story could have pointed out that a trial this small generally would miss all but the most common problems. Also, the story could have pointed out that until further evidence is developed, it is not know for certain how this type of intervention compares with alternatives. If it turns out that for some people this treatment is less effective than alternatives, then prescribing it would mean leaving them at greater risk of being harmed by insomnia.", "answer": 2}, {"article": "Treatment continued at least until the birth of the baby.\n\"The data suggested that for most of the symptoms we looked at, duration of symptoms was less when mothers received DHA.\nMONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\nDr. Jennifer Wu, an obstetrician and gynecologist at Lenox Hill Hospital in New York City, said, \"We've been recommending DHA intake in pregnant women for brain and nervous system development, and this study suggests another good reason to take DHA.\"\nThe effects seemed to be strongest early on after birth,\" said study senior author Usha Ramakrishnan, an associate professor in the Hubert Department of Global Health at the Rollins School of Public Health at Emory University in Atlanta.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that the babies whose mothers had recevied prenatal supplementation with DHA had bouts with vomiting or rashes that lasted longer than the babies born to mothers in the control group.\nThe story mentioned that the women in the study had low DHA intake which was also the case for women in the US. \u00a0This appears to be an overstatement of the need for DHA supplementation for women in the US and the story should have touched on whether excessive DHA consumption might have potential consequences for pregnant women such as bleeding or problems with vitamin E levels.\nIn addition, the comments by Dr. Wu suggested that women use this supplement along with prenatal vitamins even though this particular study did not begin supplementing until 18-22 wks. A large randomized clinical published in JAMA showed some adverse outcomes among the female infants exposed in utero (not males), namely lower language scores and lower adaptive behavior scores.\u00a0 We don\u2019t know why the story chose to interview Dr. Wu, but perhaps her comments needed to be addressed by other expert perspectives as well.", "answer": 0}, {"article": "Campbell is one of only 14 people in the United States participating in an FDA-approved study of an artificial retina -- a microchip implanted in the eye to stimulate damaged cells.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"Being able to repair, in some way, a function that has been lost is a very exciting thing,\" Del Priore said.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\n\"Patients were able to do things that we would not have anticipated with so few electrodes,\" Mech said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention any potential harms, including risks of the surgery and whether remaining vision, or retinal and surrounding tissue, could be damaged. ", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nIt promotes all kinds of growth in the body and brain, but if you have excess IGF1, it may put you at risk for cancer,\" said Baker, who added that people with Alzheimer's disease tend to have low levels of IGF1.\n\"This was an impressive study showing how GHRH can have a positive effect on cognitive function,\" Zonszein said.\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle.\nAs levels of growth hormone-releasing hormone (GHRH) decrease with age, so too do other hormones stimulated by GHRH, such as growth hormone and insulin-like growth factor 1.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned spiked insulin levels.\u00a0 But it didn\u2019t mention any of the side effects reported in the study:\n\u201cAdverse events primarily consisted of local skin reactions (redness, itching, or stinging) and increased arthralgias. Other adverse events reported, although less frequently, included gastrointestinal upset, numbness or tingling in the hands, weight gain, and fluid retention. Although increased fluid retention can potentially precipitate or exacerbate symptoms of congestive heart failure and hypertension, coronary adverse events were not observed in our study.\u201d", "answer": 0}, {"article": "Older adults with diabetes can look for yoga classes designed specifically for older people and those with chronic medical conditions.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\n\u201cIn our study the effect of yoga on BMI (body mass index) and blood sugar control was marginal,\u201d Hegde, the lead researcher on the work, told Reuters Health in an email.\nThe findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This does not actually address what is known about any potential harms of the type of yoga reported on. \u00a0The story could have mentioned that the study mentioned that there were no adverse events reported during the 3 months of yoga classes but that about 5% of those assigned to the yoga classes dropped out and were not included in the final analysis.", "answer": 0}, {"article": "It also helped her plan, she said.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nDr. Diana Bianchi, executive director of the Mother Infant Research Institute at Tufts Medical Center in Boston and the lead author of the sex-determination report, said, \u201cA very important aspect of the study is how this advances prenatal care.\u201d\n\nBut there are potential concerns too, she said, including that women may spend more than $250 for the tests when they don\u2019t have insurance for prenatal care.\nShe was not unhappy, she said, but \u201cit was like the baby boy disappeared.\u201d\n\nWhen the Lewises complained to Acu-Gen\u2019s president, they were told, \u201cWe are very sure that genetically you are having a male,\u201d she said, reading a transcript of the conversation, which they recorded.\nThe tests are not regulated by the Food and Drug Administration because they are not used for medical purposes, a spokeswoman said, but the agency is investigating the explosion of home genetic tests like these and genome-sequencing kits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story lists potential harms. These range from inaccuracy, because the tests are unregulated and the laboratories don\u2019t have to meet medical standards, to the potential for abortions based on fetal gender.", "answer": 1}, {"article": "\"This is not that.\nThe incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\n\"The injectables aren't going to go away,\" commented Dr. Scott S. Zamvil, a professor of neurology and faculty member in the program in immunology at the University of California, San Francisco.\nThe findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.\nThe lead study author is Dr. Giancarlo Comi, director of the department of neurology and the Institute of Experimental Neurology at the Scientific Institute and University Vita-Salute San Raffaele in Milan, Italy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThe study found that to date, the new drug appears to be both safe and well-tolerated.\u201d It also says, \u201cAdverse events, including serious events, were comparable to those in the placebo group, according to the researchers. The incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\u201d (That Comi paraphrasing also appears to be lifted directly from an American Academy of Neurology news release.) We would have liked to have seen some actual numbers attached to those adverse events. This is important context for readers.", "answer": 0}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cThe weight that it takes them one year to lose is typically back in two months,\u201d often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that bariatric surgery \u201cis also much safer nowadays than it was even a decade ago.\u201d It also refers to the \u201cwell-documented safety and effectiveness of bariatric surgery.\u201d But there are still potential harms, such as bleeding, infection and \u2014 in rare cases \u2014 surgical problems that can be fatal. After surgery, there also is the long-term risk of nutritional deficiencies.\nIf a story aims to offer a complete picture of bariatric surgery it needs to address all aspects, including risks. And if the risks are low, articulate how low those risks are. This allows readers to make more informed decisions about their personal health.", "answer": 0}, {"article": "\u201cDiet is a complicated business,\u201d he said.\n\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cIf the goal is to prevent hypertension\u201d with lower sodium consumption, said the lead author, Dr. Jan A. Staessen, a professor of medicine at the University of Leuven, in Belgium, \u201cthis study shows it does not work.\u201d\n\nBut among the study\u2019s other problems, Dr. Briss said, its subjects who seemed to consume the smallest amount of sodium also provided less urine than those consuming more, an indication that they might not have collected all of their urine in an 24-hour period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of this story was avoiding harm by eating too much (or too little) salt. \u201cThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\u00a0And while those eating the most salt had, on average, a slight increase in systolic blood pressure \u2014 a 1.71-millimeter increase in pressure for each 2.5-gram increase in sodium per day \u2014 they were no more likely to develop hypertension.\u201d It does a great job presenting the numbers in absolute terms.", "answer": 1}, {"article": "Physical function of their knee also improved, based on an index used to judge the effects of osteoarthritis, Bagla added.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nOnly 13 had undergone the procedure by the time of Monday's annual meeting, and only eight had made it to the one-month follow-up, Bagla said.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\n\"Perhaps we can demonstrate and prove patients do not need to be on these medications and can alternatively go through a minimally invasive procedure like this to reduce their knee pain,\" Bagla said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the lead researcher saying \u201cthere were no adverse events related to this treatment\u201d and no side effects were expected because the procedure \u201conly blocks additional blood flow to the knee, rather than cutting it off altogether.\u201d\nIn a preliminary study such as this with almost no follow-up, we think the above statement is inappropriate. There is so little known about it to say \u201cno side effects are expected\u201d is hubris, and the story should have pointed that out.", "answer": 0}, {"article": "But the limit is tricky to impose.\nSher's ethics board said OK.\n\n\"And she went ahead and had a baby at 57 years of age without any problems whatsoever,\" Sher says.\n\"I guess there's a big assumption that most women that need to do this [are] career, successful, rich women,\" she says.\n\"My best friend and I made a pact together that at age 38, if we were both still single, we were going to have a child on our own,\" says Robyn Ross.\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are risks of pre-term pregnancy because of in-vitro fertilization. There are risks to babies from being one of multiples \u2013 such as twins or triplets. These risks are just as important to discuss and weigh as the risks that the story puts forward as reason for this high-tech solution \u2013 having \u201cold\u201d eggs as a woman of 40 years. Yet the story does not discuss these.", "answer": 0}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nThe city's survival rate is 12 percent, and it is expected to improve with a citywide cooling program adopted last July, said Dr. David Keseg, the Columbus EMS medical director.\nFor example, patients treated in large, urban teaching hospitals have better odds than those treated elsewhere, according to research from the University of Pennsylvania School of Medicine published last month.\n\"In the past, we thought this was a hopeless cause,\" said Dr. Michael DeGeorgia, UH's director of neuro-intensive care and a proponent of cooling therapy.\nThe therapy is targeted to patients stricken by ventricular fibrillation, an electrical disturbance that causes the heart's pumping chambers to quiver instead of pump.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of treatment. \u00a0The story ended with a plea to provide people who would otherwise die, with something. \u00a0However since there was no discussion of outcomes with people who were and were not provided this treatment, it is not possible to know whether there are any harms of receiving this treatment. Survival with brain damage could be increased, which could be considered a harm worse than death in some cases.\u00a0 What do the data show? ", "answer": 0}, {"article": "\u201cOne avocado has around 200 to 250 calories.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\nIt\u2019s tough to test diets in real life, because people eat so many different things, but the team controlled what everyone ate, feeding them carefully calibrated diets.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\nAnd so the current message is to replace saturated fat with unsaturated fat, and in so doing, consume a moderate-fat diet, not too much, and also not too little,\u201d Kris-Etherton told NBC News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explicitly states that \u201ctoo much of a good thing can be harmful,\u201d explaining that avocados are high in calories. The story quotes a researcher associated with the study as saying that people should not simply add avocados to their current diets, but find a way to incorporate the avocado into their diets without increasing overall calorie consumption. That\u2019s the best discussion of this issue that we\u2019ve seen in any of the four stories we reviewed on this topic.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nSome harms were mentioned, but oddly the story then referred to this hormone therapy not causing harms associated with chemotherapy. The story does not mention other harms linked to hormone therapy, such as osteoporosis, fractures, diabetes, and heart disease.  We aren\u2019t provided any information on these outcomes or cause of death. Since these results were presented at a medical meeting (which means it is likely the full data have not been reviewed by independent experts) and because the trial was halted early, there is much that remains unknown.", "answer": 0}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of elevated liver function test results. However, it does not explain\u00a0 that women commonly experience abdominal pain, headaches and nausea with this drug.", "answer": 0}, {"article": "The CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nThe study, called TDF2, followed 1,200 uninfected heterosexual men and women between the ages of 18 and 39 years in Botswana, Africa.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\n\u201cWe are in a critical moment in HIV prevention research,\u201d said Robert Grant, M.D., M.P.H, of the Gladstone Institutes and the University of California at San Francisco.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that the\u00a0primary source was a press statement (the results haven\u2019t been published yet), the story provided about as much information about potential harms as could be expected. In one of the studies, the story notes that the\u00a0safety monitors\u00a0saw no evidence of safety concerns. The story also notes that subjects taking the active drug in the the other study\u00a0reported nausea, vomiting and dizziness.", "answer": 1}, {"article": "The company\u2019s shares were up 22.6 percent at $4.28 in mid-morning trade after touching a high of $4.90.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this a just-passing satisfactory score because side effects were briefly mentioned: \u201cno serious side effects were observed in the study.\u201d Still we\u2019d like to see mention of less serious side effects, especially for a birth control intervention, because they\u2019re often a significant factor in women\u2019s choices.", "answer": 1}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\n\u201cWe need to do the next steps to understand what is in the young plasma.\u201d\n\nPlasma is the liquid part of blood, with the red cells and immune cells removed.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nLater, because it was taking so much time and effort, they cut the trial to just nine people and all nine knew they were getting the real thing \u2013 a unit of plasma, once a week for a month, from healthy young men under the age of 30.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of harms anywhere in this story. Transfusions are invasive procedures and carry with them certain unpredictable risks.\u00a0 While the story does say at the end that any eventual product would be cleansed of components that mandate blood-type matching, there is no other discussion related to potential harms.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\u00a0 \u201cThe agency says patients treated with the new system experienced a slightly higher incidence of neurological side effects, including convulsions and headaches, than patients receiving chemotherapy.\u201d\nWhat does slightly higher incidence actually mean?\nWhat is the baseline incidence \u2013 in actual numbers?\nAnd how much higher was the incidence with the new system?\nGive the numbers and let readers/consumers decide what\u2019s \u201cslightly higher\u201d and what that might mean in their own lives.", "answer": 0}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\n\"A lot of time, people come in and say they or a family member has a tremor, and they believe it's Parkinson's disease,\" said Wright, who also was not involved in the study.\n\"This can be very challenging, especially during the early stages of the diseases and if the responsible doctor is not a neurologist specialized in movement disorders,\" said Dr. Oskar Hansson, lead author of the new study, a neurologist and an associate professor at Lund University in Sweden.\nBecause spinal fluid is not easily obtained by a primary care doctor, this diagnostic test is not very useful, so Hansson developed a blood test and investigated its accuracy in the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the experimental test were not discussed. One important potential harm here is that there may be a much higher false-positive or false-negative rate once you use this test in the general public. For now, it\u2019s only been tested in controlled situations where the health status of the study participant was known.", "answer": 0}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nThe team argues that while they do not yet know if these findings would be same in humans, it could lead to new treatments to prevent cognitive decline in older people: \u201cCannabis preparations and THC are used for medicinal purposes,\u201d they write.\nOlder mice treated with THC performed to the same standard as young mice that had not been given the drug.\nThis is a challenge faced by anyone wanting to develop a therapy for a human disorder such as dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report might have mentioned if any or all of the test mice sustained any ill effects (physically or mentally) but it did quote a scientific expert about the potential adverse effects for humans using cannabinoids.", "answer": 1}, {"article": "So when the government advisory panel \u2014 the U.S. Preventive Services Task Force \u2014 recommends against routine PSA testing, it\u2019s making a judgment call.\nIn other words, it tells us what the current U.S. population would look like if today we faced the same risks that Americans faced in the \u201980s; it finds we\u2019d have roughly 25,000 U.S. men diagnosed with advanced-stage prostate cancer each year compared to just 8,000 today.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nThe same European trial that found lower cancer mortality with PSA testing also found that, to save just one life through screening, an extra 37 men would need to be diagnosed with prostate cancer and treated.\nThen, if the patient does have cancer, the available treatments for it \u2014 surgery, radiation, as well as other options \u2014 also have side effects, chief among them impotence, incontinence, and urinary incontinence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "WebMD\u2019s story quantified the potential harms in a more helpful way.\nWe also take issue with the statement that it is an \u201calbeit small risk of sexual dysfunction and urinary leakage from eventual treatment.\u201d\nThe discussion of harms was incomplete.", "answer": 1}, {"article": "The positive results surprised even Stagl.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nThe women felt better one year after the course, five years later, and \u2014 according to a new study published last month in the journal Cancer \u2014 an average of 11 years later.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss possible harms associated with participating in this stress management program, although the harms are likely to be minimal.\u00a0In theory, the program could have heightened anxiety about the breast cancer diagnosis by focusing on it frequently over the 10 weeks of the group. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\nThe low-level laser causes \u201cfat to seep out of a cell, almost like a balloon being struck by a needle,\u201d said Ryan Maloney, medical director for Erchonia Medical.\nDr. Kinney doesn\u2019t have a Zerona or a Zeltiq cooling device, though in the case of the latter, he said, \u201cit is well documented that freezing fat tissue aggressively enough can lead to fat necrosis,\u201d or, fat dying, over a few months.\nNonetheless, a brochure for Zerona states patients can collectively \u201close up to 9 inches without the pain or down time of surgery.\u201d Nationwide, medical spas, chiropractors, cosmetic surgeons, plastic surgeons and dermatologists now offer Zerona for $1,700 to $3,800 for six sessions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to point out the potential harms of these devices.\u00a0\n The devices claim to be based on scientific principles involving the cellular destruction of lipids and their elimination from the body. This is serious metabolic stuff, presumably with serious potential risks. The story fails to acknowledge this. ", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Researchers at Georgia State analyzed clinical data from a large cohort of breast cancer patients treated at Northside Hospital in Atlanta from 2005 to 2015.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\n\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\nThis higher incidence of tumor recurrence can contribute to a poorer prognosis,\" said Nikita Wright, first author of the study and a senior Ph.D. student in Dr. Ritu Aneja's laboratory in Georgia State's Biology Department.\nDespite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not discuss any harms of\u00a0providing cancer treatment in this order\u2013chemo first, surgery second.\u00a0 We\u2019re not aware that neoadjuvant chemotherapy is more harmful than standard treatment but it\u2019s a valid question and the release would have been more helpful had it clearly stated that one way or the other.", "answer": 0}, {"article": "CHICAGO --- Soon you can seek mental health advice on your smartphone as quickly as finding a good restaurant.\nThe preliminary study did not include a control arm, so it's possible that some people who enrolled in the trial would have improved anyway, partly because they may have been motivated to try something new, Mohr said.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\n\"We designed these apps so they fit easily into people's lives and could be used as simply as apps to find a restaurant or directions,\" said lead study author David Mohr, professor of preventive medicine and director of the Center for Behavioral Intervention Technologies at Northwestern University Feinberg School of Medicine.\nMost apps designed for mental health typically offer a single strategy to feel better or provide too many features that make them difficult to navigate.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there\u2019s little harm associated with using any app on the face of it, relying on an app instead of seeking professional help could be harmful. The release should have acknowledged this, and done a better job of explaining who is most likely to be helped by a smartphone app and which individuals have symptoms severe enough to warrant seeking professional medical assistance. There are many different types of depression that range in severity. The National Institute of Mental Health describes several \u2014 seasonal affective disorder, persistent depressive disorder, major depressive disorder, psychotic depression, postpartum depression.\u00a0 ", "answer": 0}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nThe researchers do not make any recommendation in their study about whether women who suffer from PMS should increase their intake of essential fatty acids or, instead, consult with their doctor.\nThe supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were few side effects and mostly \u201cmild.\u201d But what were they?\u00a0 And what does \u201cmild\u201d mean?\u00a0 After all, PMS has a range of symptoms as well.\u00a0 So did this story really help women think about the tradeoffs?\u00a0 Nonetheless, since the story at least mentioned harms, we\u2019ll give it the benefit of the doubt \u2013 barely.", "answer": 1}, {"article": "Epclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\n\u201cThis approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,\u201d said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA\u2019s Center for Drug Evaluation and Research.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nFor patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the most common side effects of Epclusa are headache and fatigue. It also explains that Epclusa carries a warning that \u201cserious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\u201d The FDA also warns that certain drugs may reduce the amount of Epclusa in the blood which would reduce its effectiveness.", "answer": 1}, {"article": "But scientists also realized it could have other uses.\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\nSo we thought maybe there was a connection\u2014that FSH could have direct effects on adipose tissue.\u201d\n\nIn the study, published in Nature, scientists injected the antibody into mice that had had their ovaries removed (mimicking menopause) and mice that had been fed on a high-fat diet.\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not tell readers whether the antibody experiment had any adverse effects on the health of the mice, much less what potential there may be for harms in humans. Again, we know that there have been no human studies yet, so it is impossible to say what potential harms have been found in human subjects. However, it is worth \u2014 at the very least \u2014 specifically acknowledging this point. And one could do more, such as asking about the various roles that the FSH plays in the human body (which likely vary across sex, age range, etc.).", "answer": 0}, {"article": "\"People are different.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\nThe report, funded by the U.S. National Heart, Lung, and Blood Institute, is published in the Sept. 19 online edition of the New England Journal of Medicine.\nSUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms in the study aren\u2019t quantified. How often did they occur? It tells us that the long-term safety needs to be studied, and it gives us good points about safety concerns that have been raised about Severent. (The AP article we reviewed mentions the safety concerns that have been raised about Spiriva.) We think safety information from this study, including the rates of serious events, could\u2019ve been mentioned if not quantified.", "answer": 0}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 We don\u2019t know what the harms of strawberry consumption would be.", "answer": 2}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nThe standard of care for detecting such blood-borne infections is blood culture, but this takes days to complete, only identifies pathogens in less than 30% of patients with fulminant infections, and it is not able to detect toxic fragments of dead pathogens that also drive the exaggerated inflammatory reactions leading to sepsis.\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nAnd it can more specifically identify patients who have excessive inflammation due to systemic infection, rather than other causes,\" said Donald Ingber, M.D., Ph.D., the Wyss Institute's Founding Director, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This test may have harms that warrant mention. It is possible that this test could mislead doctors, just as any test that isn\u2019t perfect could. It wasn\u2019t 100 percent sensitive. So the 15 percent who had a normal test but turned out to have sepsis could have been sent home inappropriately. Or antibiotics could have been delayed where they otherwise might not have. Similarly, it wasn\u2019t 100 percent specific either, so some patients may have received treatments they didn\u2019t need or weren\u2019t given ones that they should have been. A researcher is quoted saying that he envisions this as an add-on to current tests, but until it is studied prospectively in real practice settings, one can\u2019t be sure if it will help more than it may harm.", "answer": 0}, {"article": "Whoopi Goldberg recently stepped in with a new line of medical marijuana\u2013based edibles and bath products (of questionable effectiveness) aimed at this underserved market.\nIn an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nBased on these studies, Nachum is trying to get Food and Drug Administration approval to market Livia as a menstrual pain reliever.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would normally look for some statement about potential harms but in this case we don\u2019t think the requirement is applicable: TENS, when used according to directions, have a low harm profile.", "answer": 2}, {"article": "For more industry information, health research and recipe ideas, visit http://www.\nIn addition to providing omega-3s, walnuts also deliver a convenient source of fiber (2 grams per ounce) and protein (4 grams per ounce).\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\nWalnuts are the only nut that provide a significant amount (2.5 grams per one ounce serving) of alpha-linolenic acid (ALA), the plant-based form of omega-3s.\"\nThese factors are major contributors to heart disease risk, and reducing them is a critical step toward a healthier heart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A brief mention of nut allergies and high caloric content of nuts might be appropriate here since walnuts are being recommended as a daily health supplement for people with Type 2 diabetes. Diabetics and cardiovascular disease are often comorbidities of being overweight.", "answer": 0}, {"article": "The researchers are continuing the treatments and compiling data.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\nCollaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release cites concerns that UFE \u201cmay cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries\u201d as the reason the procedure isn\u2019t more widely used. This is a bit hard to interpret by the layperson and it isn\u2019t until later in the release\u00a0that we learn this essentially means there are risks of infertility associated with conventional UFE.\nThe release should have spelled out the known complications, which, in addition to infertility, include pelvic pain, fever and vaginal discharge, all of which are usually temporary. Death from an embolism (an artery blocked by blood or an air bubble or some other foreign body) following the procedure has been reported but is extremely rare.\nAlso, one of the reported findings\u00a0is fairly misleading:\nComplication rates were 14.6 percent for partial UFE and 23.1 percent for conventional UFE.\nThe original research article discloses that this observed difference is not significantly significant.", "answer": 0}, {"article": "In all, 1,139 volunteers were involved in these trials.\nThe meta-analysis in the Journal of Nutrition, an assessment of the combined evidence from all 19 RCTs, focused on whether consumption of flavanol-rich cocoa products was associated with improvements in specific circulating biomarkers of cardiometabolic health as compared to consuming placebos with negligible cocoa flavanol content.\nThe authors therefore concluded, \"Our study highlights the urgent need for large, long-term RCTs that improve our understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.\"\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\n\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We think that you can\u2019t have a release that talks about how \u201ctempting\u201d the results of a new chocolate-is-good-for-you story without talking about the countervailing wind that is the high calorie count of so many chocolate products. If everyone starts having a chocolate milkshake at lunch after reading this study, our obesity epidemic is going to be even worse.\nThe release included a quote from the study author who noted that \u201cthe findings from the current study apparently shouldn\u2019t be generalized to different sorts of chocolate candies or white chocolates, of which the content of sugar/food additives could be substantially higher than that of the dark chocolate.\u201d\nBut that didn\u2019t go far enough. We think there was an opportunity here to discuss the real health implications of adding cocoa flavanols to the diet in whatever form it might take.\nOnly 37% of all releases we\u2019ve reviewed are graded satisfactory on harms. The discussion on an intervention\u2019s harms needs to start somewhere, and a news release is often the headwaters of the news stream.", "answer": 0}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nBoth Japanese and American flu patients were included in the trial.\nRead more at The Wall Street Journal.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nThe flu virus spreads through the body by invading cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a significant oversight of the story.", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "By greatly overstating the proportion of patients at risk of heart valve disease in the large UK cohort study, the news article fails to provide balanced information about the frequency and seriousness of harms. (See \u201cDisease mongering\u201d above.) Nevertheless, the two research studies taken together reaffirm the strongly held suspicion that these drugs have the potential for causing valvular disorders.\u00a0", "answer": 0}, {"article": "The trial was funded by Pfizer.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nIn the trial, researchers from 144 research centres in 17 countries followed 521 women allocated to receive either palbociclib and fulvestrant, or a dummy pill and fulvestrant.\nThe combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.\nProfessor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release downplays a number of side effects named in the journal article. According to the news release, the drug combination apparently has few severe side effects. The news release identifies a drop in white blood cell count as a common, but non-severe, side effect. But when we looked at the study\u2019s table of side effects we found a considerable number of grade 3 or 4 (more serious) adverse events. Some of this is confusing to interpret. For example, the study says that grade 3 or 4 adverse events\noccurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group. The most common grade 3 or 4 adverse events were neutropenia [low white blood cell count] (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anaemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).\nThe study later says,\n\u201cSerious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.\u201d\nThe study may be drawing a distinction between \u201cserious\u201d and \u201csevere\u201d events and including or not including grade 3 events in these different tallies. Regardless, the\u00a0release misleads by omission when it calls severe side effects \u201crare\u201d while not mentioning these relatively common less-severe effects. And that\u2019s leaving aside the issue of grade 1 and 2 side effects that appeared to be quite common and more frequent in the experimental treatment group. The study notes, for example, that \u201cInfections, fatigue, nausea, anaemia, thrombocytopenia,\u00a0alopecia, rash, and stomatitis, among others, were also\u00a0more common in the palbociclib group.\u201d", "answer": 0}, {"article": "The harvested blood stem cells are then put back into the patient.\nAs a result of the immune-system suppressing drugs, most of the patients in Gu's study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nJune 11, 2012 (Philadelphia) -- In an early study, an experimental stem cell procedure helped 15 teens with type 1 diabetes stay off of insulin injections for about 1.5 years, on average.\nWe need to better understand the biology behind the treatment and follow patients for long-term side effects,\" Robert E. Ratner, MD, chief scientific and medical officer of the American Diabetes Association, tells WebMD.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\nAs a result of the immune-system suppressing drugs, most of the patients in Gu\u2019s study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nMost of those side effects disappeared within two to four weeks, and unlike in previous studies of the experimental therapy, none of the patients developed infections, pneumonia, low sperm counts, or organ damage.\nStill, patients have to be followed for years to ensure they do not develop known long-term complications of immune-suppressing drugs, including tumors and infertility, Gu says.", "answer": 1}, {"article": "That test ruled out a safety problem similar to the one that felled RotaShield, an earlier rotavirus vaccine developed by Wyeth, a drugmaker in Madison, N.J.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nBut it is also drawing new manufacturers into the vaccine market, which many drug companies had abandoned in the 1980s and 1990s, citing too little profit.\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author states that this vaccine appears to be safer than the previous one, however there is no evidence provided to support this claim. Although not statistically significant, there were more cases of intusussecption with the vaccine in the trials.", "answer": 0}, {"article": "Italian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nWhile most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The largest gap in this story is its failure to mention potential harms.\u00a0 In particular, it fails to mention the concern about potential adverse effects on disease outcome, a concern clearly stated in the editorial and in the original article.\n", "answer": 0}, {"article": "Trulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cWith the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.\u201d\n\nAccording to the National Institutes of Health, an estimated 42 million people are affected by constipation.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We rate this Satisfactory because the release includes the restrictions on pediatric use and the risk of severe diarrhea. The release would have been even better if it had mentioned how often the volunteers experienced side effects and the full scope of side effects.", "answer": 1}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nThe researchers believe that TXA could have even wider uses, such as reducing brain bleeds after brain injury.\nThe drug, tranexamic acid (TXA) is cheap, widely available around the world and easily administered, experts said.\n\"Everybody wants to be creative, but you have to look at the data, and they used TXA,\" Levy said.\nAlthough there was some worry that TXA might lead to more heart attacks, strokes or clots in the lungs, the researchers observed no such increase among patients getting the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story correctly\u00a0states that the researchers observed no increase in clots in the patients receiving TXA, earning enough for a satisfactory. However, we wish it had included, as the AP did,\u00a0a caveat regarding the difficulty of identifying clots\u00a0in\u00a0trauma patients who subsequently die.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story says the company reported a \u201cside effect profile consistent with the drug\u2019s currently approval label\u201d, it did not tell readers what that means. The most important adverse event reported in other studies of Vascepa is joint pain, affecting up to about one in 25 patients. The story does not mention warnings about possible allergic reactions in people allergic to seafood or interactions with anti-clotting drugs, which many heart patients take.", "answer": 0}, {"article": "LONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that that no serious adverse events were reported in the trial. It would have been useful to note that 12 weeks is too little time to determine how an asthma drug might affect patients over decades of use.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nCompared with the control group, the children scheduled for adenotonsillectomy were more likely to be hyperactive by their parents' estimates and more likely to experience behavior problems and sleepiness at school.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms associated with the surgery. The harms, although rare, include infection and respiratory complications, and are more common in children with obstructive sleep apnea, the target population in this story.", "answer": 0}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nIn new research that could suggest a road to cure, scientists at Dana-Farber Cancer Institute and Boston Children's Hospital have found that CML stem cells die in response to inhibition of a protein called Ezh2.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\nIn laboratory experiments, the Dana-Farber/Boston Children's researchers found not only that Ezh2 is overabundant in leukemia stem cells but that it helps them survive and give rise to full-fledged CML cells.\nAlthough second- and third-line targeted therapies can often return the disease to remission, some patients don't benefit from these drugs or develop severe side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are mentioned for imatinib, but never detailed. And this is a major oversight that would have benefited the\u00a0crux of the release (i.e. a need for alternatives to imatinib-like drugs). One 2010 study\u00a0assessed a flotilla of side effects, including muscle cramps, nausea, diarrhea, headaches, abdominal pain, joint pain, and more in greater than 10% of patients who take it for CML. But it also notes\u00a0a rare few can be \u201csinister\u201d in less than 1% of patients: heart\u00a0damage, kidney failure, muscle degeneration, secondary cancers, and even\u00a0cerebellar edema, which can cause fainting, seizures, and even put someone into a coma.\nThe side-effects of Ezh2 inhibitors also aren\u2019t noted since it seems\u00a0the most promising one is still in clinical trials. Since the new drug hasn\u2019t been tested in humans there is really no way to gauge side effects but all cancer drugs have them, often very serious ones as noted above.", "answer": 0}, {"article": "The pediatric trial opened the following spring with Emily.\n\u201cThe efficacy takes care of itself, but safety takes a lot of attention.\u201d\n\nOne of the most common side effects is called cytokine release syndrome, which causes high fever and flulike symptoms that in some cases can be so dangerous that the patient ends up in intensive care.\n\u201cI said, \u2018Surely, this has been tried on kids somewhere else in the world,\u2019 \u201d recalled her father, Thomas Whitehead of Philipsburg, Pa. \u201cBut Steve said, \u2018Nope, some adults got it, but that was a different kind of leukemia.\u2019 \u201d\n\nAfter she received the therapy, Emily\u2019s fever soared, her blood pressure plummeted, and she ended up in a coma and on a ventilator for two weeks in the hospital\u2019s intensive care unit.\n\u201cNobody was hoping for zero cancer.\u201d\n\nThe pioneering therapy administered to Ludwig and a few other adults at the University of Pennsylvania hospital paved the way for clinical trials with children.\n\u201cThis is truly pushing the envelope and at the cutting edge of science.\u201d\n\nThe biggest concerns, however, center on safety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe revved-up immune system [that results from the CAR T-cell treatment] becomes a potent cancer-fighting agent but also a dangerous threat to the patient. Serious side effects abound, raising concerns about broad use.\u201d The story then goes on to discuss those potential harms more thoroughly.\nOrdinarily, this would be sufficient for a Satisfactory rating. But given the severity and frequency of serious, life-threatening events, the story needed numbers: What percentage of patients in the trial experienced a serious immune reaction? How many died?\nThere are also plenty of unknowns with a new cancer treatment, such as lack of data on long-term prognosis.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\nThere have been concerns that abnormal findings on Doppler ultrasound may prompt doctors to sometimes unnecessarily intervene \u2014 by, for instance, performing a cesarean section.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that there has been concern that the use of Doppler ultrasound might increase unnecessary interventions, including cesarean section deliveries in cases where it is not actually needed. It says the studies indicated that Doppler ultrasound appeared to lead to better decisions about cesarean sections and inductions of labor. ", "answer": 1}, {"article": "This is when estrogen plummets, and estrogen helps protect bone health.\nThe report identified possible benefits of screening, but noted that there is no solid evidence \u2014 in the form of randomized trials, medicine\u2019s gold standard \u2014 comparing fracture rates of patients who have been screened with those who have not been screened.\nThe safety of one of the most popular types of medication used to lessen the risk of fractures \u2014 bisphosphonates, such as Fosamax and Boniva \u2014 has also been questioned.\nThe US Preventive Services Task Force, which sets standards on disease prevention and primary care, suggests that all women get a bone density screening by age 65, or by 60 if a patient might be at high risk for fractures.\nBut in September, a different group of scientists used the same database and concluded in an article in the British Medical Journal that bisphosphonates appeared to double the risk of esophageal cancer after about 5 years of use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": " \nThe article provided substantial information about potential side effects such as cancer of the esophagus and thigh fractures related to the use of bisphosphonates. However, it would have been useful for the article to also report the conclusion of the US Preventive Services Task Force that bisphosphonates are not consistently associated with serious adverse events.\n  \u00a0", "answer": 1}, {"article": "For more information about the School of Medicine, see http://www.\nThe time to the first exacerbation also was higher with mepolizumab than placebo, but only in the high eosinophil group.\n\"These patients already have been given every treatment we have to offer them and are still having flare-ups that significantly interfere with their quality of life and can lead to deterioration in lung function and higher mortality,\" said Sciurba.\nThe patients with high eosinophil counts who received mepolizumab had a statistically significant 18 percent lower rate of moderate/severe exacerbations (1.4 per year compared to 1.7 per year) than those in the placebo group.\n\"There is significant variation between patients in the cells and other proteins responsible for lung inflammation, so there are actually many different subtypes of COPD,\" said Sciurba.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t describe any possible side effects from the use of mepolizumab, even though there are several. They include headaches, back pain, fatigue and flu symptoms, urinary tract infections, abdominal pain, itching, eczema, and muscle spasms.\nTo its credit the release does say that the side effects encountered from the drug and the placebo were similar. \u201cThe safety profile of mepolizumab did not differ from placebo in either trial,\u201d it says.", "answer": 0}, {"article": "This discovery won the Nobel Prize in 2006.\nAs reported online March 21 in Nature, this is the first time the process, known as RNA interference (RNAi), has been shown to work in humans.\nAnd there were other challenges, not the least of which was how to get the siRNAs into the appropriate cell and then make sure they did what they were supposed to do.\n\"They're basically putting an instruction booklet into the cell saying, 'We don't want this protein expressed for now,'\" explained Gregory Adams, co-leader of the developmental therapeutics program at Fox Chase Cancer Center in Philadelphia.\n\"Now you can go selectively at proteins involved in the disease and not have off-target effects,\" explained Mark E. Davis, lead author of the paper, and professor of chemical engineering at CalTech in Pasadena.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story paraphrased the researchers. \"The precision of the process is crucial to limiting side effects.\"\u00a0 But it never discussed what even the potential side effects of this approach might be.\u00a0 It would have been relatively easy for the story to have included a few words about the potential downsides, including \"off target\" side effects during an exaggerated immune response or the shuttinf off of non-targeted genes resulting in adverse outcomes. ", "answer": 0}, {"article": "While Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\n\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, there is no information in the story about side effects, patient exclusions, or other potential harms of Tecentriq or the chemotherapies included in the cocktail.\nAlso, the common talking point around immunotherapy includes the claim that it is less toxic than traditional chemotherapy, so why would a person take both, instead of just one or the other? What does that do to the side effect profile?", "answer": 0}, {"article": "The artificial nutrition is infused directly into the bloodstream.\n\"We found that the current practice of feeding children in an early stage does not contribute to their recovery\", says lead author Professor Greet Van den Berghe from KU Leuven / University Hospitals Leuven.\n\"On the contrary, the children who had built up a nutritional deficiency after receiving little to no feedings had fewer infections, less organ failure, and a quicker recovery than children who had been fed through the IV.\nTherefore, the method that is applied worldwide is to artificially feed these children during the first days of their stay in intensive care.\nThe effect was present in everyone, regardless of the type of disease, the children's age, or the hospital in which they were staying.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study report goes into substantial background detail about potential harms of malnutrition and overfeeding, and the release \u2014 although without specific data \u2014 more or less describes the concerns. The release could have been strengthened even more if it had informed readers about the rigorous informed consent obtained from parents, and the efforts to maintain basic nutrient levels in all the children.", "answer": 1}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nIn 2012, the Department of Veterans Affairs said it would not cover costs of service dogs for veterans with post-traumatic stress disorder, citing \u201ca lack of evidence to support a finding of mental health service dog efficacy.\u201d The department is now in the midst of a multiyear study on the topic, which could lead to government funding for these pooches.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nStill, they cautioned that \u201cthis study does not answer whether pet dogs have direct effects on children\u2019s mental health or whether other factors associated with acquisition of a pet dog benefit their mental health.\u201d\n\nIt was a classic case of conflating correlation and causation, which Herzog says is common.\nEarlier this year in the Journal of Applied Developmental Science, an introduction to a series of articles on \u201canimal-assisted intervention\u201d said research into its efficacy \u201cremains in its infancy.\u201d A recent literature review by Molly Crossman, a Yale University doctoral candidate who recently wrapped up one study involving an 8-year-old dog named Pardner, cited a \u201cmurky body of evidence\u201d that sometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call for us: Harms are discussed, but briefly and anecdotally. The brief portion comes in the same quote mentioned above, noting that the body of evidence regarding therapy animals \u201csometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress\u201d (emphasis added). A little more information there would be welcome.\u00a0There\u2019s also the issue of immunosuppressed patients coming into contact with therapy animals, and possible harm to the animals, who could be over-worked or subjected to aggressive or harmful treatment from even well-meaning people.\nStill, some harms are at least acknowledged.", "answer": 1}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nWEDNESDAY, May 3, 2017 (HealthDay News) -- A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.\nThe first two trials looked at more than 1,100 patients with moderate to severe ulcerative colitis who had failed with conventional treatment or treatment with newer \"tumor necrosis factor antagonist\" drugs, such as Remicade (infliximab).\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nHowever, in all of the trials, more patients taking Xeljanz suffered from infections, such as shingles, than those receiving placebo, researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Over the course of three paragraphs, the story discusses a variety of adverse health effects experienced by patients participating in the clinical trials, including infections, nonmelanoma skin cancer, \u201cheart problems,\u201d and an increase in cholesterol levels.\nAs with benefits, the story compares the number of adverse health events in those taking Xeljanz with the number of adverse events in those taking placebo \u2014 which is useful for helping readers place the risk in context.", "answer": 1}, {"article": "High-risk tumors are more aggressive and thus more likely to eventually kill the patient.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\nThe chances of the cancer spreading to the bone were reduced while PSA (prostate-specific antigen) blood levels -- thought to be a marker for cancer's advance -- were also better controlled.\nIn looking at the records of more than 5,000 men with prostate cancer, 2,000 of whom were taking aspirin or another blood-thinning drug, researchers presenting at the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego report that the risk of dying from the cancer was reduced by more than half.\nMONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does mention that aspirin comes with risks, including stomach bleeding, so it might barely meet this criterion. However, the mild warning minimizes the risks in some frail or elderly individuals, where gastrointestinal bleeding can be lethal. The story left out a comment from the researcher that anticoagulants increase the potential for rectal bleeding in patients treated with radiation, which seems like an important consideration for men diagnosed with prostate cancer. Calling aspirin \"pedestrian\" in the first line is inadequate in the context of potential harms.\u00a0 There\u2019s nothing \"pedestrian\" about the catastrophic bleeding that may occur in some people.\u00a0 ", "answer": 0}, {"article": "The image that worked best for Ellison showed a field.\n\"The hope for neurofeedback is that after training ends, the benefits that resulted from training will persist -- that in some sense there's been more enduring change in the child's ability to focus and attend and to regulate their behavior,\" he says.\nFor kids who got neurofeedback, he says, \"The ability to speed up the car and steer it was contingent on maintaining your brain waves in a more favorable ratio.\"\n\"There has been a need for some time to have the kind of carefully controlled study that would provide more definitive answers for parents and for the field,\" he says.\nSo the approach remains promising but unproved, says David Rabiner, a researcher at Duke University who writes a newsletter about treatments for ADHD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to discuss\u00a0any potential harms of neurofeedback treatment.\u00a0The most prominent of these is\u00a0that patients\u00a0could forego other treatment approaches that have better supporting evidence and are more likely to reduce symptoms.\u00a0There is also some evidence that\u00a0neurofeedback can cause seizures or make\u00a0symptoms\u00a0worse in some individuals with psychological disorders.\u00a0In addition, the need for frequent treatments may necessitate taking a child out of school.", "answer": 0}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\nCost is one hurdle, with the vaccine sometimes costing up to $200 for people whose insurance doesn\u2019t cover it.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not address potential harms. This study did not report adverse events, but the clinical trial that led to approval of the vaccine reported more than a third of participants had redness and pain after getting a shot. Although the original clinical trial (partially funded by the vaccine maker) concluded that adverse events were generally mild, the story still should have addressed this point.\u00a0 ", "answer": 0}, {"article": "Updated reports on data from the North American \"Daisy\" and \"Violet\" studies were made by Krychman and other researchers at this week's annual meeting of the American College of Obstetricians and Gynecologists in San Francisco.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nNearly half of women taking flibanserin (and nearly a third of women taking placebo) reported at least minimal improvement in \"bothersome decreased sexual desire.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0provided statistics on common side effects including\u00a0daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia.\u00a0 These side effects resulted in 15% of those\u00a0taking flibanserin vs 7% taking placebo withdrawing from the study.", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nCoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.1\n\n\"Allergan is committed to advancing innovation for CoolSculpting\u00ae to meet the needs of patients seeking non-invasive aesthetic treatments,\" said David Nicholson, Chief Research and Development Officer at Allergan.\nIn the U.S., the CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm.\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS\u00ae, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017.\nAn 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CoolSculpting.com states the procedure is proven to be a safe and effective. However, there are risks associated with this treatment. The addendum to the release does contain information about potential harms so we rate this as Satisfactory.\nAccording to CoolSculpting\u2019s patient safety document, subjects may have redness, blanching, bruising, tingling and stinging immediately after the procedure. One to two weeks after treatment, patients could also experience cramping, numbness, skin sensitivity and \u201csensations of fullness.\u201d In addition, cold exposure to certain nerves may cause tongue deviation, lower lip weakness, dry mouth and a decrease in saliva production. Some rare side effects include late-onset pain, first and second degree frostbite, fainting, nausea, dizziness, nodules in the treatment area and hyperpigmentation. Some patients have even experienced \u201cparadoxical adipose hyperplasia,\u201d meaning they experience the reverse reaction and end up with more fat cells in the area.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms.", "answer": 0}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nIt takes about eight minutes to place the balloons, and about 14 minutes to remove them, according to Dr. Jaime Ponce, medical director of the bariatric surgery program at Hamilton Medical Center in Dalton, Ga. Ponce was the principal investigator of the clinical trial on the ReShape system.\nWEDNESDAY, July 29, 2015 (HealthDay News) -- The U.S. Food and Drug Administration's approval of a temporary, implanted balloon device for weight loss may have many wondering how -- and how well -- it works.\n\"It's going to be effective for short-term weight-loss,\" Roslin said, \"but there is still an overwhelming question whether these devices provide any long-term benefit for obesity.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that\u00a0nausea that made some patients drop out of the study, and explained that\u00a0gastric ulcers were seen in the stomachs of more than one-third of patients. Since the device appeals to a consumer who \u201cdoes not qualify\u201d for medical obesity treatment and has only temporary benefit, we believe the story should have quoted at least one critic.\nGiven that the patients in this study are those who \u201cdo not qualify\u201d for the medical management of obesity, one might raise questions about the ethics of\u00a0an intervention that isn\u2019t medically indicated. Given the temporary nature of the device, the risks should\u00a0be expected to\u00a0outweigh the benefits \u2013 especially since the benefits in turn, unless marked behavior changes are permanently undertaken, will, by definition, be temporary. This can be viewed as\u00a0an extreme intervention in the name of non-medically necessary weight loss \u2013 the kind of approach that runs the risk of encouraging people to pursue all sorts of nonsensical, and, at times, dangerous diets and interventions.", "answer": 1}, {"article": "For more information, visit http://www.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories.\nA nationally representative analytic sample suggests that the consumption of fresh pears should be encouraged as part of an overall healthy diet\n\nPORTLAND, Ore. - Dec. 8, 2015 - It's National Pear Month and the perfect time to enjoy juicy, sweet pears.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study looked at a possible association between pear eating and obesity but the protocol did not have a way to determine harms of eating or not eating the fruit. In any case, it\u2019s hard to imagine any.", "answer": 2}, {"article": "The panel withheld a recommendation about tuna, second only to shrimp in popularity in the United States.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\n\u201cSo why would the proposed 2015 dietary guidelines recommend that pregnant women eat more of it?\u201d\n\nBut Dr. Steve Abrams, a panel member involved in the seafood recommendations and medical director of the Neonatal Nutrition Program at Baylor College of Medicine, said that while women need to be aware of the types of fish they are eating, the evidence is strong that fish consumption by mothers is good for the brains of their babies.\nFish is rich in omega-3 fatty acids, B vitamins, iodine, selenium and vitamin D. And numerous studies show that the nutrients in fish are particularly important for brain development in fetuses and nursing infants.\nThe point is that you should have a variety of types of seafood and not limit yourself to one type, and variety includes canned tuna.\u201d\n\nAlice Lichtenstein, senior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University said the panel hasn\u2019t suggested that pregnant women eat more tuna.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does discuss the aforementioned 2005 study, which found that a baby\u2019s score on visual recognition memory tests was affected by the amount of mercury in the mother during pregnancy, so we\u2019ll give it a pass. However, the story would have been better if it had \u2014 even briefly \u2014 addressed the full suite of possible health risks associated with mercury exposure during pregnancy. Also, the story discusses the findings of the 2005 study by referring to mercury measured in parts per million, but discusses mercury levels in tuna in terms of micrograms per ounce. It would have been great if the story had used the same units of measurement in both cases, so that readers could understand the significance of the 2005 study\u2019s findings in regard to levels of mercury actually found in tuna. (A back-of-the-envelope calculation finds that if six ounces of tuna contains 60 micrograms of mercury, the mercury is present at a level of about 0.35 parts per million. But the story could have cited an expert.)\nIn addition, while the story does briefly discuss the advantages of eating fish, it does not really address the potential harms of not getting adequate amounts of omega-3 fatty acids or other nutrients found in tuna and other fish.", "answer": 1}, {"article": "Of those taking an inert pill, or placebo, 91 percent did.\nIf you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\n\nDr. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society cautioned, however, that \u201cone has to be cautious in interpreting these results,\u201d partly because \u201cbased on what they show, there is no overall change in survival.\u201d\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nPut another way, the risk of cancer returning in the original or the opposite breast was 34 percent lower in women on 10 years of letrozole compared with those who stopped after five.\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "First, we applaud the story for recognizing\u00a0the difference between absolute and relative benefits.\nBut because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nThe story also clearly understands that the absolute benefit of the treatment must be weighed against the side effects:\nAromatase inhibitors cause side effects in some women, especially night sweats, hot flashes, and sexual dysfunction. Women receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\nOne thing that would have made this even stronger: Including the rates of the different side effects.", "answer": 1}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms from both CBT and antidepressants. While promoting the advantages of CBT over medications, the release discusses some harms from antidepressants (\u201cconstipation, diarrhea and dizziness\u201d) but didn\u2019t touch on the more serious harms associated with SSRIs, particularly when going through withdrawal.", "answer": 1}, {"article": "She notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\nFollow-up studies of the women who remain alive--who now number 35--continue, the researchers say, to track the impact of trastuzumab on overall survival time even after tumor progression.\nThe difference, Fader says, may be that these patients have been heavily treated in the past, are more likely to have overall poorer health and are more likely to have mutated or heterogeneous tumors, or tumors with different levels of HER2 expression.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not addressed. This trial was relatively small, with only 58 patients, and the relevant journal article notes that the trastuzumab \u201cwas well tolerated\u201d by study participants. However, because trastuzumab is already in clinical use for treating other cancers, we know that it is associated with some risks. And those risks are not insignificant. For example, Herceptin\u2019s manufacturers note that the drug \u201ccan result in sub-clinical and clinical cardiac failure\u201d \u2014 and that is in addition to more common, but less severe, adverse reactions.\nAlthough practices vary, patients need to be monitored with an echocardiogram while on trastuzumab.\nSometimes patients with existing heart problems may be precluded from getting this drug. The abstract, but not the release, addressed risks but only in part, when it states: \u201cToxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.\u201d", "answer": 0}, {"article": "But his thoughts were out of control.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\n\"I think it's actually one of the biggest advances in psychiatry in a very long time,\" says Dr. Martin Teicher, an associate professor of psychiatry at Harvard Medical School and director of the Developmental Biopsychiatry Research Program at McLean Hospital.\nScientists still aren't sure why ketamine works, but there's evidence that it encourages the brain to rewire, to alter the connections between cells.\nAnd it has all been possible, he says, because for the past six years he has been taking a drug called ketamine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms in the story. The Johnson & Johnson news release cited in the story lists a number of side effects: \u201cThe most common treatment-emergent adverse events (>10%) reported in the esketamine group were metallic taste, nausea, vertigo, dizziness, headache, drowsiness, dissociation, blurred vision, paraesthesia (tingling sensation) and anxiety.\u201d\nA recent journal article that was not mentioned in this story reported side effects so severe that all the participants quit taking an inhaled form of ketamine.", "answer": 0}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nRepeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\nParticipants received increasing doses of ketamine over a period of five weeks, with doses optimised for each individual participant using a new dose-titration approach developed by Professor Loo's Sydney research team and collaborators.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release doesn\u2019t say how widespread side effects were in the study population, it does mention some of the side effects and it\u2019s clear to readers that ketamine is not a trouble-free drug.", "answer": 1}, {"article": "\"Are they normal variations?\nIf proved effective, it could become the norm for identifying heart conditions that put one in 10,000 people at risk when doing top-level physical activities, researchers say.\n\"The saddest day for me had to be the day of (baseball) try-outs,\" Jordan says.\n\"One of our goals is to advance the field \u2026 in areas either untouched or unappreciated as being important,\" Towbin says.\nFor decades pediatricians and family physicians have sought a more effective way to identify young athletes at risk of dying while playing the sports they love.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that of the first 500 high school athletes enrolled in this heart screening study, four were advised to drop out of sports and 22 more were told they needed lifetime monitoring. However, the costs and consequences of these recommendations are not addressed. How much does reduce physical activity increase other health risks, including obesity? Does a detection of an \u201cabnormality\u201d on this sort of test mean that these children may have difficulty getting life or disability insurance\u2026 or even health care coverage, if pending insurance reforms are repealed? Will they be barred from certain careers because they have been labeled as having abnormal heart conditions?\nBased on figures from the National Federation of State High School Associations (NFSHSA), if the rate of abnormal test results reported by these researchers were applied nationally, about 100,000 teens a year would be told they need lifelong monitoring and another 15,000 would be kicked out of high school sports activities. These are important consequences that the story should have addressed.\nNote: the NFSHSA reports almost 8 million high school students participate in sports (which means about 2 million new students begin each year).", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\nAs for Nima, Sundvor said, \"We're doing a huge amount of testing and one thing we want to be sure of before we start shipping is that we're 99.9 percent accurate.\"\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website.\n\"Small enough to fit into your pocket along with your keys and mobile phone or a small clutch,\" said Sundvor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without any evidence one way or the other about the \u201cmini chemistry test\u2019s\u201d accuracy, it\u2019s hard to know if there might be any false positive or negative readings, and thus any harms from eating food that has more gluten than the test user thinks. The story doesn\u2019t discuss this.", "answer": 0}, {"article": "Veridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\n\"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells,\" said Robert McCormack, Veridex's head of technology innovation and strategy.\n\"It is appropriate to view announcements such as the one today with enthusiasm, but recognize that we must temper that excitement with the realization that there is still much research to be done to determine the true impact of this test on the treatment of patients with cancer.\"\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\n(CNN) -- Johnson and Johnson will partner with Massachusetts General Hospital to develop and market a blood test that could find a single cancer cell circulating in a person's blood, the company said Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms, not even the obvious possibility that this sort of test could detect cells that don\u2019t actually present a serious health threat or aren\u2019t susceptible to treatment. It perpetuates the myth that early detection is always beneficial and turns a blind eye to the harms of overtreatment.\nBy comparison, see what Dr. Susan Love said on the ABC News website:\n\u201cHaving the cells in the bloodstream does not necessarily mean that the cancer will spread and kill you. Just because you find them does not mean you know what to do with the information. \u2026We all have cancer cells in our body that are dormant,\u201d Love said. \u201cWe need to be careful not to over react to the presence of cancer cells when the treatment may actually be worse than the cure.\u201d \n\u00a0", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of potential harms or side effects from the use of electro-acupuncture, which like traditional acupuncture, is considered to be of relatively low risk.\u00a0 But neither is without risk entirely, given that infection is possible along with bleeding or other injury.\u00a0 Electro-acupuncture is not suggested for people with heart problems, strokes, seizures or epilepsy, nor should it be used by patients with cardiac pacemakers since the small current used can disrupt the function of these devices. These risks should have been included in the release.", "answer": 0}, {"article": "Some of the complaints related to the placement of the device.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nIn a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\n(Reuters) - Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company\u2019s Essure permanent birth control device has been placed properly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of TVU are not addressed. Unlike the HSG, TVU does not emit ionizing radiation, which could potentially make it safer. However, some women do not tolerate TVU, which can last 45 minutes long, well. In addition, as the news release (but not the Reuters story) acknowledged, some women experience spotting or infection following a TVU test.", "answer": 0}, {"article": "(Editing by Jon Loades-Carter)\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\n* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story stated:\u00a0 \"The treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling. The drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\"\u00a0 Well, what does generally well tolerated mean?\u00a0 And what\u2019s happening at the lower doses?\u00a0 This is confusingly incomplete.\u00a0", "answer": 0}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\nUnless you have some other reason to stop them, you should take statins right up to the morning of surgery.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of taking a statin are not addressed, even though they carry side effects, and these effects may have been a reason people stopped taking them before surgery.\nAlso, as\u00a0implied in the news release from The Society of Thoracic Surgeons, patients may have been told to stop their statins by a doctor\u2013why is that sometimes the case? Was it because of a potential perceived harm? This context isn\u2019t provided.\n(It appears, for example, that drug labels for statins used to recommend stopping them before surgery because of the risk of muscle breakdown, known as rhabdomyolysis. There\u2019s some indication that doctors have been slow to catch up with newer guidelines that state statin use should be continued.)", "answer": 0}, {"article": ".\n\"This could provide doctors with an important tool for simply and accurately diagnosing those patients, particularly children, and making sure they are treated properly.\"\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms of this screening tool. Just to mention one hypothetical case, it is possible that caregivers relying on the blood levels alone may err and fail to test in other ways for brain injury. In general, medical tests have two potential harms. The first is that the test does not demonstrate the presence of injury when in fact there is one. This would lead to under-diagnosis. The second is the test demonstrates the presence of injury when it does not exist. That would lead to over-diagnosis. While obvious, the report should have included some caveats to its otherwise glowing comments.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. We don\u2019t know what the harms of eating cherries might be.", "answer": 2}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nThe study involved the most common type of breast cancer \u2014 early stage, without spread to lymph nodes; hormone-positive, meaning the tumor\u2019s growth is fueled by estrogen or progesterone; and not the type that the drug Herceptin targets.\n\u2018\u2018There is no chance that for these patients, that chemotherapy would have any benefit.\u2019\u2019\n\nDr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications.\nThe test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story the benefit of the doubt here. It mentions that adding chemo exposes patients \u201cto side effects and other health risks,\u201d but it doesn\u2019t detail what those effects are. Two other people mentioned in the story refer to \u201ccomplications\u201d and chemo being \u201cnot pretty,\u201d but the story does not elaborate on these comments. The National Cancer Institute lists a slew of side effects from undergoing cancer treatment, such as bleeding, fertility problems and hair loss.\nOn the flip side, researchers mentioned it\u2019s possible that patients in the low risk group could experience relapses in the future, and it\u2019s unclear if early administration of chemo would have helped in these cases. We address this point in the \u201cQuality of Evidence\u201d section, since researchers addressed this as a study limitation in their paper.", "answer": 1}, {"article": "Using space age technology in the Sports Ready clinic at Medway Park, Gillingham, Dr Karen Hambly, an international expert on knee rehabilitation, works with clients who have been given the all clear to start to return to sporting activities but may have concerns about moving from being a patient with an injury to being an athlete again.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\nHealthy cartilage that covers the bone surfaces in the knee joint transfers these high loads from the lower leg to the upper leg.\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\nWhen people run, the load on their knee joints can be up to five times greater than when walking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential harms.", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms found in the studyu of ustekinumab. ", "answer": 0}, {"article": "Sacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes.\nBut because West Virginia has one of the nation's highest rates of death from heart disease, since 2000, the state has offered free, universal cholesterol screening to all fifth-graders enrolled in public schools.\n\"The weight of the child, his waist circumference and whether he has siblings who are overweight would help to select a group that is at greater risk of having high cholesterol,\" he says.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story mentions neither the potential harms of statin drug treatment that have been reported in studies of adults nor the fact that the safety of these drugs has not been studied in children.", "answer": 0}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of side effects that may accompany long-acting contraceptive methods, nor of those associated with the birth control pill/patch/ring.\u00a0While effectiveness in preventing pregnancy is a paramount concern, women also weigh side effects in making a decision about which method to use.", "answer": 0}, {"article": "\"If your immune system has been educated by the vaccine to recognize the tumor cells, we think it will allow the immune system to take care of any individual [cancer] cells trying to set up shop,\" explained Dr. Elizabeth Mittendorf, a surgical oncologist at the University of Texas M.D.\nThe researchers then conducted a variety of tests to gauge each woman's immune system response.\nPhase 3 studies are needed before the vaccine could be approved.\nThe women received monthly injections for six months.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study did not discuss any potential side effects of the current vaccine.", "answer": 0}, {"article": "He struggled to sleep.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states:\nSide effects including anxiety, headache, fatigue, muscle tension, and insomnia, were generally minor and limited to the days following the MDMA sessions.\nReaders might have concerns regarding the long-term consequences of pharmaceutical grade MDMA, but this is unknown. The article does make it clear that the MDMA-assisted psychotherapy model used in the study only involves taking the drug on 2-3 occasions.\nAlso, the article anticipates that some people may (and already do) turn to street sources of MDMA (aka \u201cEcstasy\u201d or \u201cMolly\u201d) to self medicate. It\u2019s made clear that this could could be dangerous, or even fatal, since street sources can be laced with other psychoactive drugs.", "answer": 1}, {"article": "This was a phase 2 trial.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\n\"Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3.\"\nMore than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.\nIniparib inhibits a pathway that helps repair DNA; researchers call it the poly(ADP-ribose) polymerase (PARP) pathway.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the researcher believed the drug was well-tolerated, the article should have included information about demonstrated side effects, even minor ones.\u00a0 The author also should have noted if the study was powered to detect differences since the study cohort was so small.", "answer": 0}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\nBut the big caveat, researchers say, is that it\u2019s not clear that the downsides of pot smoking are worth it.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\n\u201cWe can\u2019t say anything about long-term effects,\u201d Corey-Bloom told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included the important quote, \u201cWe can\u2019t say anything about long-term effects.\u201d\nAnd, short term, the story reported that the study found some patients had fatigue and dizziness.", "answer": 1}, {"article": "Recent research indicates that vitamins C, E and zinc can help vision.\n\u201cBut we are also interested in lifestyle habits and what we can do to make a difference.\u201d\n\nGlaucoma is the second leading cause of blindness worldwide, according to the World Health Organization, affecting an estimated 58 million people.\n(Reuters Health) - People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.\nCompared to coffee, soft drink and iced tea drinkers, study participants who consumed a cup or more of hot caffeinated tea daily had 74 percent lower odds of having glaucoma, the study authors report in the British Journal of Ophthalmology.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Only potential harm to be considered would be those people who respond to this study by abusing caffeinated tea thinking that more consumption might offer more protection from glaucoma. Excess caffeine can have deleterious health effects. Not including this unlikely scenario in the story seems reasonable.", "answer": 2}, {"article": "\u201cI\u2019m amazed,\u201d she said.\n\u201cThe virus infection causes a very potent inflammation response and that response causes brain swelling.\u201d\n\nThe cancer drug Avastin is used in low doses to control the swelling, the team said.\n\u201cThe most important thing is, it sets up a secondary immune response and really destroys the distant tumor cells.\u201d\n\nThe very first patient was Stephanie Hopper, who was diagnosed with a glioblastoma when she was just 20.\n\u201cThe big question is, how can we make sure that everybody responds?\u201d\n\nThe Duke team compared their 61 volunteers to similar past patients who did not get the treatment.\n\u201cVirtually all patients, no matter what you treat them with, are dead within in two years.\u201d\n\nAbout a third of all brain tumors are gliomas, according to the National Brain Tumor Society.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the NPR story that we also reviewed, NBC did a good job of spelling out harms, stating 19% of patients had \u201cnotable adverse events\u201d and more than a quarter experienced brain damage affecting speech and communication. Again, though, we think it\u2019s better to give readers the absolute number of adverse events \u2013 how many out of how many?", "answer": 1}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\nIn 2000, the U.S. Food and Drug Administration approved tenecteplase for use after a heart attack, Arora said.\nThe researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a feared complication of clot-busting stroke drugs: often-fatal brain bleeds, which it said occurred in 1% of patients regardless of which drugs they received. It did not say that one of the two patients in the study who had a brain bleed died from it.", "answer": 1}, {"article": "In humans and many animals the lateral sleeping position is the most common one.\nIn the paper, \u201cThe Effect of Body Posture on Brain Glymphatic Transport,\u201d Dr. Benveniste and colleagues used a dynamic contrast MRI method along with kinetic modeling to quantify the CSF-ISF exchange rates in anesthetized rodents\u2019 brains in three positions \u2013 lateral (side), prone (down), and supine (up).\nBy using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\nTheir colleagues at the University of Rochester, including Lulu Xie, Rashid Deane and Maiken Nedergaard, PhD, used fluorescence microscopy and radioactive tracers to validate the MRI data and to assess the influence of body posture on the clearance of amyloid from the brains.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of changing one\u2019s sleeping pattern is not addressed. While there are people with certain health conditions that can\u2019t sleep on their side, it doesn\u2019t seem like an applicable criteria for rating this release.", "answer": 2}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\nThe UV LED device also emits a much narrower band of UVB light and thereby decreasing likelihood of skin damage that can occur when the skin is exposed to higher wavelengths of UV radiation.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\n\"The potential of digital UV technology for phototherapy is enormous,\" said Dr. Robert C. Walker, RayVio's CEO.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms, although only to discuss how it would reduce risk compared with sunlight exposure. It states: \u201cA vitamin D3 producing UV LED device could be used on skin areas that experience less exposure to sunlight such as upper legs and arms and abdomen and back thus minimizing risk for developing non-melanoma skin cancer. The UV LED device also emits a much narrower band of UVB light and thereby decreasing likelihood of skin damage that can occur when the skin is exposed to higher wavelengths of UV radiation.\u201d\nAlmost all interventions are associated with potential harms, and light therapy is no different. Although light therapy is considered generally safe, it may cause eyestrain, headache, nausea, irritability or agitation, and mania, euphoria, hyperactivity or agitation associated with bipolar disorder. Specifically, UV light can cause eye and skin damage, as well as increase one\u2019s risk of skin cancer.\nSince harms from UV LED aren\u2019t addressed in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "While the mechanism behind the vision-cognition relationship isn\u2019t well understood, Zheng said, worsening vision can discourage people from brain-stimulating activities like doing crosswords and engaging with other people.\nWhile mental function at one check-up was also related to vision at the following exam, the effect of vision on subsequent mental function was significantly stronger.\n(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\n\u201cIf you\u2019re aging without good vision, not only are you giving your brain less stimulation, you might be altering your brain at a structural level,\u201d she said in a phone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the debits of traditional eye exams are minor, more substantive \u201cfixes\u201d of vision problems mentioned in the story (such as cataract surgery) do bring with them possible risks.", "answer": 0}, {"article": "The marketing materials suggested it already had.\n\u201cThe images sort of sell themselves.\u201d\n\nMuch of the criticism focused on the data the task force had used to make its decision, which consisted largely of the results from prospective, randomized clinical trials conducted in the United States.\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\nEarly data from Rafferty\u2019s trial showed that the same group of women who did benefit from 2-D digital benefited even more dramatically from 3-D. (It\u2019s worth noting that this is not a small group of people.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author does mention that a woman who has both 2-D and 3-D imaging, the protocol with the most benefit, would receive twice the radiation of 2-D imaging alone.\u00a0 While this is still under the FDA\u2019s permitted limit, the piece should also mention that patients need to consider\u00a0total radiation exposure from increased use of all high-tech diagnostic imaging equipment.\nIn addition to providing no evidence of improved sensitivity and specificity of 3-D imaging, the piece doesn\u2019t even mention the possibility of over-diagnosis and over-treatment of very early stage breast cancers that may never have needed treatment.\u00a0 Thus a woman may be harmed physically, emotionally\u00a0and financially because of over-treatment.", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harm in this case would be that, by avoiding whole-brain radiation, a patient may shorten his or her life. The story addresses this. For example, the story does a good job of articulating differences in overall survival for those who received whole-brain radiation and targeted therapy versus those who only received targeted therapy \u2014 and it gets bonus points for explaining that the observed differences in survival time were not statistically significant. The story also quotes one source as saying that there are some circumstances in which whole-brain radiation may still be beneficial.", "answer": 1}, {"article": "Hare was not involved in the study.\n\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no side effects from the treatments. We would have liked to have seen more detail on how long the patients were followed (we\u2019re only told that 8 have been followed for one year) and the types of side effects one might expect with this type of therapy. The subjects underwent cardiac surgery during which time cardiac tissue was recovered and the stem cells were injected into the heart via a catheter.\u00a0 Each procedure carries the potential for harm.\u00a0 In reporting on such a small, short-term study, we think the potential for harm is worth at least a line. ", "answer": 0}, {"article": "Streicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nAccording to the FDA, which looked at three clinical trials of Addyi that included about 2,400 women, about 10% more patients treated with Addyi reported meaningful improvements in satisfying sexual events, sexual desire, or reduced distress compared to women taking a placebo.\n\"The data presented in this review suggests that the meaningful change caused by flibanserin is minimal,\" according to the team of Dutch researchers.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\n\"While it is unclear how strongly politics influenced the decision, it is clear that the science was weak,\" they wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We learn the drugs have side effects but nothing about the fainting, falls and somnolence that are known side effects of the drug.\nThe patient with the testimonial is\u00a0quoted saying: \u201cI should be able to choose whether the side effects are worth the benefit.\u201d\nWe agree. But we also agree that anyone reading this article should get a sense of what those side effects are likely to be\u00a0and how often they occur.", "answer": 0}, {"article": "For the new analysis - the first of its kind - the research team looked at dietary data from 160,191 women and assigned inflammation scores based on 32 food components that the women reported consuming in the three months prior to their enrollment.\nBut in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\nOne possible explanation included in the study: The women with lower inflammation scores were more physically active as a group and therefore were at a slightly greater risk of falls.\nThe Dietary Inflammatory Index - developed to assess the quality of diet from maximally to minimally inflammatory based on nutrients consumed - helped them accomplish that.\nThe lower bone density to start could be because women with healthier diets are more likely to be of a smaller build, Orchard said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release but it\u2019s hard to envision harms that could occur from an improved diet.", "answer": 2}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes a serious side effect of low blood sugar and tells readers that the number of low blood sugar episodes with the new drug is lower than that for older drugs. Yet, this could be a serious complication and the actual rate of this complication is not reported. The story does describe actual rates of some side effects for the new drug when combined with an existing drug (metformin). These included diarrhea (10% of participants) and nausea (8% of participants). The story describes sore throat, headache, and runny nose as \u201cless common,\u201d with no quantification. Yet the story does not mention side effects for the new drug individually, so readers don\u2019t know whether these side effects reported may be related to the existing drug metformin. The story also claims that there appear to be no big safety problems, which is probably a premature statement given the relatively long lag time often needed to see safety problems. ", "answer": 0}, {"article": "What are the limitations of IVM?\nAlthough ICSI is safe and effective, the bigger concern is if a patient going through IVM doesn\u2019t use ICSI, Shastri said.\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nAlthough there are different protocols for IVF, and there aren\u2019t any randomized controlled trials that have compared IVF and IVM side by side, studies that look at standard IVF cycles show a significantly higher pregnancy rate than IVM, Shastri said.\nSince IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article notes that for \u201csome women\u201d the hormone injections required for IVF (and presumably IVM as well) can be \u201cdownright dangerous,\u201d it doesn\u2019t say exactly how they are dangerous, what the dangers are, or what the dangers are of the rest of the IVF/IVM procedure in terms of fetal outcomes\u00a0or biological/psychological tolls on women.", "answer": 0}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests the drug\u2019s side effects are milder than those of standard chemotherapy. But the source of this assessment is a member of the study team who is a consultant to the drug maker. \nThere is no description from an independent source of the drug\u2019s safety profile.\u00a0 ", "answer": 0}, {"article": "The study did not follow people over time.\nDr. Fiore, who has reported receiving payments from drug makers, said that \u201cthere are millions of smokers out there desperate to quit, and it would be a tragedy if they felt, because of one study, that this option is ineffective.\u201d\n\nIn the new study, conducted in , the researchers followed a representative sample of 1,916 adults, including 787 people who said at the start of the study that they had recently quit smoking.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\n\u201cSome studies have questioned these treatments, but the bulk of clinical trials have unequivocally endorsed them,\u201d said Dr. Michael Fiore, director of the \u2019s Center for Tobacco Research and Intervention and the chairman of the panel that wrote the guidelines.\nMotivation matters a lot; so does a person\u2019s social environment, the amount of support from friends and family, and the rules enforced at the workplace.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\nIn a systematic review of the available scientific literature a team from Cardiff University's School of Medicine found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment (average study follow-up length over 5 years).\nThe team's review looked at all of the available data including five randomised trials and forty two observational studies of colorectal, breast and prostate cancers.\nProfessor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nThe study identified five healthy behaviours as being integral to having the best chance of leading a disease-free lifestyle: taking regular exercise, non-smoking, a healthy bodyweight, a healthy diet and a low alcohol intake.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only risk of harm in the release is a passing mention of intestinal bleeding in cases of colorectal cancer.\nBriefly mentioning the handful of other risks would have greatly improved this release. Even small doses (80-325 mg) of aspirin can reduce the body\u2019s ability to clot wounds, and consequently promote bleeding. Giving aspirin to patients being treated for cancer may be presumed to increase bleeding risk, especially if the patient has low platelets as a result of chemotherapy.\nSome people are also allergic to aspirin, which can complicate asthma. A regular dose of aspirin can also increase the risk of bleeding stomach ulcers.\nImportantly, 21 out of 36 studies included in the meta-analysis of aspirin and the three cancer types had no data on bleeding.", "answer": 0}, {"article": "Source: Brightling C, et al.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nAs the researchers tracked the participants over the course of 12 weeks, they found that those taking the drug saw a decrease in their sputum eosinophil reading from an average of 5.4 percent to 1.1 percent.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nThe drug, known as Fevipiprant (QAW039), was shown to reduce asthma symptoms as well as inflammation, and it improved lung function and repaired airway linings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No serious adverse effects were reported in trial participants who took fevipiprant, a fact the story does not mention. The story also should have mentioned\u00a0mentioned that it remains to be seen whether fevipiprant is safe over decades of continuous use, which is typical for as asthma drug, as well as for patients of various ages and health conditions.", "answer": 0}, {"article": "Eight foods account for 90 percent of all reactions: milk, eggs, peanuts, tree nuts, soy, wheat, fish and shellfish.\nFor those plagued with peanut allergies, protection may eventually come in the form of a patch worn on the skin, a new study suggests.\nThe FDA recently warned people with peanut allergies to avoid foods containing ground cumin, after traces of peanut powder were found in the ground spice.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story handles this aspect well, by noting side effects of the patches and explaining the difficulties experienced by two participants forced to drop out of the study.", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nHowever, recent research suggests colic may linked to an immature immune system struggling with bacterial imbalances in the gastrointestinal tract, and that high levels of E. coli bacteria in particular may contribute to colic symptoms.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\nTo test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Probiotics are generally regarded as safe for healthy children. Nevertheless,\u00a0the mechanism through which these bacteria work are not well understood, and there have been\u00a0reports of severe infections attributable to probiotics in\u00a0critically ill or immunocompromised patients.\u00a0We don\u2019t necessarily think the story needed to get into this level of detail about potential adverse effects,\u00a0but some comment about the general safety (or lack thereof) of this probiotic strain should have been provided", "answer": 0}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nMany studies have shown it doesn\u2019t take a whole lot of adjustment to greatly lower the risks.\nProstate cancer survivors who eat a typical American diet loaded with red meat, cheese and white bread are far more likely to see their cancer come back and kill them, and they\u2019re more likely to die sooner of any disease than patients who eat a healthier diet, researchers reported Monday.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We won\u2019t flag the story for not discussing the potential harms a Mediterranean style of eating \u2014 which don\u2019t really merit much discussion.", "answer": 2}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of risks or harms of the experimental approach, but part of the function of a phase 2 trial is to evaluate harms. Not only does each drug in the experimental cocktail include its own risks (including increased risk of heart attack and stroke, nerve damage, blood clots, low white blood cell and platelet counts, fatal spikes in blood pressure), but the effect of the combination of drugs could exacerbate the harms or even create new ones. While multiple myeloma patients may be aware of and acknowledge the risks of individual drugs as part of standard treatment, the unknowns of the experimental drug combination should have been pointed out in the release.", "answer": 0}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\n\"Our hope ... is you might be able to give a single dose of a chemotherapy agent and within a day or two figure out whether the tumor is going to respond,\" says Dr. Michael Graham of the University of Iowa.\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\nsaid Stevens, 48, of La Jolla, Calif. \"Your whole life is in sort of a limbo.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report should have mentioned the radiation doses used in PET scans. While these are not large\u2013about the amount of a typical X-ray\u2013they are worth noting. \nPET scans are not indicated for women who are pregnant.\u00a0 \nIf multiple PET scans were to become part of a treatment or diagnositic protocol the radiation dose could become significant. \nIn addition, there is no mention of the possibility that a scan might erroneously identify a treatment as ineffective, causing an unwarranted and harmful change in the treatment approach.", "answer": 0}, {"article": "PhD candidate Alexandra Wade says the new MedDairy diet challenges popular perceptions of what is considered healthy.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nAnd if you\u2019re one of the thousands of people seeking to improve your cardiovascular and cognitive health \u2013 look no further than the MedDairy diet.\u201d\n\u2022 Cardiovascular disease (CVD) is a major cause of death in Australia, with 43,477 deaths attributed to CVD in Australia in 2017.\nIt also includes 1-2 servings of dairy foods (700-820mg calcium), which is less than half the dairy recommended by the Australian National Health and Medical Research Council (NHMRC) for older Australians.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms from a dairy enriched diet.\nSince the release is encouraging greater dairy consumption, including up to 4 servings of cheese a day, it would be important to mention that there are potential harms from consuming more saturated fats found in many dairy products.", "answer": 0}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions harms indirectly by citing a lack of irritation or allergic reactions among those test subjects that used it. This at least clarifies the findings about some of the obvious potential harms, so we\u2019ll rate this Satisfactory.\nBut, we do think the the story could have pointed out that long-term effects are still unknown. For example, what happens if you get some of this in your eye?", "answer": 1}, {"article": "However, the N.Y.U.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe test is so simple and inexpensive that any coach or parent potentially could administer it, the study\u2019s authors believe, and any league afford to provide it as a way to help evaluate and safeguard players.\nThe most commonly recommended sideline test is the Standardized Assessment of Concussion, a multipart examination during which athletes are asked to name the date, describe how they feel, memorize and recall lists of words, and do jumping jacks and other tests of coordination.\nThe Standardized Assessment of Concussion had performed rather miserably, correctly identifying only two of the concussed athletes, missing 10, and finding that three of the uninjured control athletes had supposedly sustained a concussion, since their scores had declined compared with their baseline (almost certainly, the study\u2019s authors believe, because these young athletes were physically tired).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quoting a researcher, the story suggests that parents and coaches should \u201cabsolutely consider\u201d using the test. However, the small number of young athletes tested and the testing that occurred under the supervision of research personnel (who won\u2019t be on the sidelines of youth sports games to train parents and volunteers doing this test on their own) all suggest that it would be inappropriate to state that this test has in any way been shown to be safe.\u00a0Only testing in a large number of students with potential injuries, across a range of ages, backgrounds and sports, with attention to measuring cognitive outcomes in a uniform fashion could lead to this test being demonstrated to be\u00a0the\u00a0same or better than current practice. In addition, we\u2019d note that a potential harm of this test is that it could give parents and coaches a false sense of security. There is no evidence that any of this actually prevents\u00a0young athletes from developing long-term cognitive impairment. While this is true for current practice as well as for this new test, seeing children getting tested on the sidelines more frequently might give false reassurance. One could argue that the safest thing\u00a0for a concerned parent is to avoid contact sports that are prone to involve head injuries.", "answer": 0}, {"article": "He and his colleagues plan to report their findings Tuesday at the Radiological Society of North America annual meeting, in Chicago.\nAnd though surgery safety has \"largely improved,\" Napoli pointed to the risk for bleeding and infection, the need for a minimum two- to three-day hospital stay, the high cost, and the fact that some patients ultimately realize little benefit.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nStill, Park noted that diagnostic uncertainty can undermine the ability of surgery to get at the true source of a patient's pain, given that \"the problem with low back pain is that there are many causes of it, and physicians have trouble identifying the cause of pain.\"\nFor the study, the Italian investigators compared 128 lumbar herniation patients who underwent a single 10-minute round of CT-guided pRF with 120 patients who received one to three rounds of steroid injections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss the harms of this treatment. It\u2019s full of language \u2014 \u201ca simple zap to the spine,\u201d \u201cscalpel-free,\u201d \u201cnoninvasive,\u201d \u201cless risky\u201d \u2014 that might mislead readers into being falsely assured.\nA procedure that introduces instruments close to the spine and makes contact with major nerve roots carries risks of infection and nerve damage. Those should have been mentioned.\nThe story does say that \u201cdiagnostic uncertainty can undermine the ability of surgery to get at the true source of a patient\u2019s pain.\u201d However, we think the story should have underscored the point that low back pain is often treated unnecessarily. Even if a herniated disk shows up in imaging \u2014 which is common \u2014 it might not be the cause of a patient\u2019s pain. That opens the possibility that some patients will undergo a procedure that won\u2019t help them, but could do harm.", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\nIts multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging.\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\nCollectively known as the genitourinary syndrome of menopause (GSM), the various genital and urinary problems associated with menopause have created a market for new therapies and treatments to help women regain sexual function and bladder control.\nFounded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned and extremely relevant based on this June, 2018 publication by the FDA:\nFDA warns against use of Energy-based devices to perform vaginal \u2018rejuvenation or vaginal cosmetic procedures\nThis includes \u201cprocedures intended to treat vaginal conditions and symptoms related to menopause, urinary incontinence, or sexual function\u201d\nSide effects listed include: \u201cvaginal burns, scarring, pain during sexual intercourse, and recurring/chronic pain.\u201d", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any harms of treatment with Byetta.\u00a0 Every medication will have some potential side effects and these are not described.\u00a0 ", "answer": 0}, {"article": "\u201cI prescribe them all the time,\u201d she said.\nThere are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\n\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nSo the challenge is to keep it off long term.\u201d\n\nWhile a 5 percent weight loss may not seem like a lot, \u201cthat is the point where there is a very significant reduction in the risk of diabetes,\u201d said Dr. Louis Aronne, a professor of metabolic research at Weill Cornell Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story kept referring to weight loss drugs as a group, the story focused mostly on lorcaserin, including a\u00a0three-year study that showed lorcaserin didn\u2019t increase the risk of bad heart events versus a placebo in patients at high risk of heart disease. However, the story didn\u2019t mention side effects and uncertainty about long-term use of that drug.\nAn accompanying editorial to the lorcaserin study said that the drug \u201cmay best be used on a cautious basis according to the needs of individual patients,\u201d and mentioned uncertain safety of its long-term use as well as side effects such as headache, fatigue, dizziness, diarrhea, and nausea that led some patients stop using it.\nOther research has raised concern about an increased risk of depression and other side effects that might outweigh lorcaserin\u2019s benefits.", "answer": 0}, {"article": "MORE: A Cheaper Way to Quit Smoking?\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nWhile smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\nA new study on nonsmokers found that six months of treatment with nicotine patches restored long-term memory performance to 46% of normal\u2014 while placebo patients experienced a 26% decline in recall during the same treatment period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\u00a0 \u201cThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\u00a0 However, patients on nicotine did lose a few pounds, which is a known side effect.\u201d The study also reported a small drop in systolic blood pressure in subjected treated with nicotine \u2013 an unusual finding which the story did not report.\nWe like that the story, unlike the MSNBC piece, noted that \u201cnicotine might enhance the cancer-causing properties of other substances.\u201d", "answer": 1}, {"article": "And we were thrilled to see such a huge impact.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\nHospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nBut it also includes how much suffering a patient wishes to bear, effects on the family, and legal, insurance and religious issues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses a few\u00a0potential side effects, at least to the same extent as discussed in the related journal article \u2014 namely, the need to wear a catheter for a few days after treatment, and issues in some patients related to ejaculatory volume. It also talked about the need for more long-term data.\nThat said, it would have been helpful to specifically address other potential treatment side effects\u2013bleeding, infection, etc.", "answer": 1}, {"article": "But given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nMaybe people who drink coffee have some genetic, psychological, or behavioral trait (drinking fewer sugary beverages?\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nThen the researchers, led by Dr. Frank Hu of the Harvard T.H.\nGut Check is a periodic look at health claims made by studies and by newsmakers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This STAT story explained the slightly increased risk of death in those participants in the current study who drank\u00a0very high\u00a0amounts of coffee,", "answer": 1}, {"article": "Michael Hoffer, M.D., an otolaryngologist and concussion expert at UHealth - the University of Miami Health System and lead investigator, has been using the goggle for two years, recruiting study participants from the emergency rooms of University of Miami Hospital and two military hospitals.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\n\"With accurate and timely diagnosis, which is possible through this technology, patients could receive better treatment faster.\nMild traumatic brain injury is typically diagnosed through physical exam findings.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms that may be associated with the goggles. Almost every health care intervention carries risks, although the severity may vary. The main potential harms are those\u00a0arising from a false positive or false negative test. This could lead to unnecessary treatment or exclusion from play in the first case or no treatment for an injury in the second and potential for much more severe effects from a second head injury. \nSince harms weren\u2019t even addressed, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\nStatements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release skimmed over the harms associated with the procedure. As discussed in a previous review, there are adverse effects attributable to this procedure, including the risk of tearing an artery which could cause bleeding in the brain.", "answer": 0}, {"article": "The other half were given only medication: drugs to lower cholesterol, control blood pressure and prevent clotting.\nBut most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\n\"You are not putting yourself at risk of death or heart attack if you defer,\" and considering the safety worries about heart stents used to keep arteries open after angioplasty, it may be wise to wait, said Dr. Steven Nissen, a Cleveland Clinic heart specialist and president of the College of Cardiology.\n\"Even though it goes against intuition, the blockages that are severe that cause chest pain are less likely to be the source of a heart attack than segments in the artery that are not severely blocked,\" said Dr. David Maron, a Vanderbilt University cardiologist who helped lead the new study.\nIf that does not help, they can consider angioplasty or bypass surgery, which unlike angioplasty, does save lives, prevents heart attacks and gives lasting relief of chest pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study mentions the risk of clotting with drug-coated stents, this is not adequate information on harms. Furthermore, the study does not mention any possible harms of medication.", "answer": 0}, {"article": "Cole's own research deals with fish oil, which is relevant because fish is a component in the Mediterranean diet.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nWhen Scarmeas' group looked at the individual components of the diet, they found a stronger association between the overall diet and brain damage prevention than with any individual food in the diet, suggesting that the combination all of the elements may be producing the effect, Scarmeas said.\nIt is complicated in general to compare the benefits of a particular diet with the benefits of not following a different food regimen.\nIt would be easier for people to focus on adding particular elements to their diets -- for example, by taking fish oil capsules -- rather than trying to readjust their eating habits altogether.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of harms, but we\u2019re not sure of any from this diet \u2013 so we judge this criterion Not Applicable in this case. ", "answer": 2}, {"article": "Pereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\nWhile the case study is only an example of the phenomenon occurring in a single person, previous reports have observed the same kinds of reductions in blood pressure in people getting deep brain stimulation for pain, though researchers had believed that the blood pressure benefit was directly tied to the degree of pain relief the person experienced.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nThough his pain eventually returned after four months, his doctors report that their patient\u2019s previously uncontrolled blood pressure has remained normal for nearly three years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A tough call here. While the report is much more detailed than HealthDay about the potential risks of treatment, it features a clumsily worded quote from an expert who calls the risks of this surgery \u201ctiny, but important.\u201d\u00a0The use of the word \u201ctiny\u201d here tends to minimize the risks associated with the\u00a0procedure, which can be very serious.\u00a0A 2% risk of stroke\u00a0in patients undergoing the procedure (as reported on this UCSF Dept of Neurosurgery\u00a0FAQ about DBS) strikes us as\u00a0somewhat\u00a0more than \u201ctiny.\u201d", "answer": 0}, {"article": "MONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nAspirin is less effective than warfarin, but carries a lower risk of bleeding for patients with atrial fibrillation and one risk factor for stroke.\nThis increases the risk for blood clots that can cause stroke.\nThis may simplify how physicians make decisions and also improve patient care.\"\nIn people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms from long term or short term use of apixaban.", "answer": 0}, {"article": "The other three people served as the control group.\nWEDNESDAY, Jan. 11, 2012 (HealthDay News) -- A new type of stem cell treatment for people with type 1 diabetes appears to help re-educate rogue immune system cells, which allows cells in the pancreas to start producing insulin again.\nThe treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.\nThe concept is very intriguing, and the treatment seems to be so simple and so safe,\" said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute, University of Miami School of Medicine.\n\"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To claim a treatment is safe after testing it in only a dozen patients at a single hospital in China is to ignore the long history of treatments that appeared to be beneficial after initial tests, then later revealed serious, even lethal, harms. Even though the researchers declare the treatment to be safe in their journal article, journalists should be skeptical of such broad claims that are based on such slim evidence. There is a vast gulf between stating that 12 individuals did not appear to be harmed during a 40-week trial and proclaiming that a treatment would be safe for millions of patients over the course of decades.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter makes clear the serious risks of surgery, including death rate, and their\u00a0frequency not well-known. \nIt would have been useful to include the risks of death and serious side effects\u00a0for the more invasive intestinal surgery likely to be used on diabetics. The story states that one reason for the decline in bariatric surgery risks generally is\u00a0increased use of the\u00a0less invasive procedure. ", "answer": 1}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nBut the procedure can have complications, which should be considered carefully by doctors and patients, said Arbelo, a senior specialist in the Cardiovascular Institute at the Hospital Clinic of Barcelona in Spain.\n\"Catheter ablation is a valid alternative for the management of atrial fibrillation with a satisfactory success rate,\" said study lead researcher Dr. Elena Arbelo.\nIn addition, 45 percent of patients who had a successful procedure were still taking antiarrhythmia drugs 12 months later.\nAfter the procedure, patients with two or more risk factors for stroke should be prescribed oral blood thinners, while those with no risk factors don't need them, Arbelo suggested.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out the caveats that should be remembered when considering ablation.\u00a0 It explains some of the complications that can occur, and that the procedure may only be a short-term fix.\nHowever, there was definitely a missed opportunity to dig more deeply, and report the scope of the harms as clearly as the benefits. For example, the story didn\u2019t explain 1 out of 10 people had to go back for a repeat procedure during the study. Nor that there were 280 in-hospital complications (7.8%) and 577 complications over the 12 month follow-up (16.3%). Some of the complications were quite serious, including 47 perforations of the surrounding heart tissue.", "answer": 1}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nHowever, Zamboni suggests that the disease instead is the result of blocked blood veins \u2014 leading to inflammation, which, in turn, causes the immune system to attack nerves in the brain and spinal cord.\nThese discrepancies, and growing public controversy, prompted the National Multiple Sclerosis Society in the U.S. and the Multiple Sclerosis Society of Canada to take Zamboni's claims seriously.\n\"Even if the treatment is not useful for patients with MS, I don't think that we can abandon the idea of vascular involvement in MS,\" Zivadinov says.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions life-threatening blood clots are a risk of the procedure, and notes that people have died from the surgery. It also quotes an expert who calls the procedure \u201cunsafe.\u201d It would have been nice to have some statistics on adverse effects to help readers weigh these risks for themselves, but it may be too early in the game to expect this kind of systematic data.\u00a0At this point in the development of an experimental treatment, the priority for a story like this is to make sure potential harms are given adequate emphasis\u00a0\u2014 something this story accomplished\u00a0handily.", "answer": 1}, {"article": "Arjmandi was to present the findings Tuesday at the Experimental Biology meeting in Washington D.C.\nTUESDAY, April 12, 2011 (HealthDay News) -- Eating apples every day may be good for your cardiovascular health, new research suggests.\nShe said that 25 to 30 grams of fiber daily is the recommended intake, and she suggested increasing your current intake by about 5 grams daily each week to give your body a chance to get used to the increased fiber.\n\"The pulp of an apple gets to be a very viscous gel-like substance that grabs cholesterol and pulls it out of the body.\nFoods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t think of any potential harms, and the story stated that \u201cDespite the addition of several hundred calories a day to their diet, the apple-eating women didn\u2019t gain weight over the course of the study. In fact, they lost an average of 3.3 pounds.\u201d ", "answer": 1}, {"article": "protection.\u201d\n\nAlgenist literature touts alguronic acid\u2019s superiority to hyaluronic acid, retinol and vitamin C, among other anti-aging ingredients, in encouraging elastin synthesis and cell regeneration.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nIn Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the story, which is too bad given that this product is apparently uNPRoven, both in labs and in the marketplace. Many would assume that there is no possible harm that could come from applying a natural product containing a seaweed compound. While that may indeed be true, there is no evidence to support that lack of any comments about potential harms. Since there are no data available about its use in premarket testing and the product has yet to reach the market, it would have been reasonable to point out that the potential harms of alguronic acid are unknown at the moment", "answer": 0}, {"article": "Avoiding the drill has the advantage of preserving and extending the life of the natural tooth.\nBut the third is a decay that is not so advanced, and Dr. Jin-Ho Phark, her dentist, is going to use a treatment he's testing that involves no drilling -- \"which is nice because many patients don't like the sound of the drill, and the feeling or the pain that might be associated with it,\" Phark says.\n\"We aim to treat these intermediate lesions -- not the very early ones, but the intermediate ones -- where usually, as a dentist, you are not sure whether you should make a filling or not,\" Paris says.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story does not mention any harms from this product, so we would typically rate it as Unsatisfactory. However, a review article published last year on this sort of sealant also did not mention any side effects. The article did mention that there was a great deal of variation in how these products are used in different countries indicating that there is no clear consensus on how they should be used.\nReference:Sealants in Dentistry: Outcomes of the RCA Saturday Afternoon Symposium 2007Caries Research 2010;44:3\u201313http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000271591&Ausgabe=253776&ProduktNr=224219&filename=000271591.pdf", "answer": 2}, {"article": "\"D.C.I.S.\nThe concern is that many women would have to take tamoxifen or raloxifene for a few to benefit.\nYet that distinction was not pointed out in the news release, and, Dr. Lichtenfeld noted, it was \"de-emphasized\" during the news conference.\nAs for blood clots, there were 141 in the 9,726 women on tamoxifen and 100 in the 9,745 on raloxifene\n\n\"Women who took raloxifene did get uterine cancer, and they did have blood clots,\" Dr. Lichtenfeld said.\n\"The hope is that at some point we'll be able to pinpoint who really is at high risk of breast cancer and then we'll know what to do,\" Ms. Visco said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides sufficient information on the harms of raloxifene compared to tamoxifen. The story does explain that one downside of raloxifene is that it does not appear to reduce the risk of ductal carcinoma in situ (DCIS), which tamoxifen does. There is one error in the story \u2013 about 50% of DCIS will progress to invasive cancer, not 10% as stated in the story.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nThe femoral artery, approximately the width of a pinkie, presents a direct route to the heart; to a physician, it's a straight stretch of freeway that can be navigated easily.\nOnly 1 percent of the 1.2 million cardiac catheterizations performed annually in the United States are done through the wrist; the newer approach is often preferred for patients who are extremely obese or have poor leg circulation.\n\"There's a lot of buzz about this right now,\" he said of radial procedures, which account for about 150 of the 8,000 cardiac catheterizations done at his hospital annually.\nIn the cath lab, he noted, \"time is money\" and radial procedures are \"among the most challenging things we do.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that arterial spasms tops the list of complications with this procedure and indicated that it was particularly problematic in \"little old ladies.\"\u00a0 Beyond this, the story did not give the reader any idea of how common this sort of problem was, making it difficult for readers to evaluate.", "answer": 0}, {"article": "To move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nUsing magnetic resonance imaging (MRI), the pulses were targeted at a specific brain area in the temporal lobe, which is associated with language (the exact area is the crossing of the projection of the ascending branch of the left lateral sulcus and the left superior temporal sulcus)\n\nAfter 2 weeks, the patients were re-evaluated.\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\nThe researchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded ('significant response' was defined as a more than 30% decrease in the Total Auditory Hallucinations Rating Scale score).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "TMS is generally regarded as a low-risk treatment. That does not, however, make it a no-risk treatment. According to the Mayo Clinic, the use of TMS to treat depression can have side effects ranging from headache and lightheadedness to (in rare cases) seizures and hearing loss. We don\u2019t think the release needs to include a laundry list of potential risks, but it does need to address the risk of potential harms in some meaningful way \u2014 even if it is only to highlight that there is a low risk of significant harms.", "answer": 0}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThe paper is entitled, \"Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.\"\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n\"During the treatment of metastatic prostate cancer, physicians will now be able to use AR-V7 status to determine when a patient's cancer has become resistant to androgen receptor directed therapy and will respond better to chemotherapy, enabling the patient to live longer.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The potential risks of blood tests are minor, although the potential of a false result could have serious consequences if it leads to a patient getting an ineffective or potentially harmful treatment.", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a small bit of information on harms at the bottom of the story for one of the two drugs: pain at the site where the ointment is applied in a small number of individuals. This squeaks by with a Satisfactory rating.\nBut, a reader will be hard pressed to find any information about the possible long-term harms of the injectable drug of interest here\u2013this is concerning because these types of drugs are known to have serious\u00a0side effects like increased infection or even cancer risk, as this Nature Review\u00a0article notes.\u00a0We\u2019re not looking for an exhaustive list, but some acknowledgment that possible long-term harms are plausible and haven\u2019t been studied would have been helpful.", "answer": 1}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cThe field is exploding, and this would be another arrow in the quiver that oncologists use.\u201d\n\nImlygic is part of a new group of immune-stimulating viral therapies that could change how cancer is treated and managed.\nIt\u2019s being developed in combination with other immunotherapies, where we think there\u2019s a little more of a commercial opportunity, but we still need to see more data.\u201d\n\nImlygic is approved for skin tumors that are inoperable in patients whose cancer has returned following surgery.\n\u201cBut short of that, this might be like diabetes, where we can control it and people live normal lives.\u201d\n\nImlygic is based on a form of the herpes simplex virus that commonly causes cold sores.\nIn 2011, the California biotech giant Amgen bought BioVex \u2014 and the rights to Imlygic, known generically as talimogene laherparepvec, or T-VEC \u2014 in a deal worth up to $1 billion.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a close call, but we think the story downplays the significance of the harms attributable to these drugs. The story quotes a researcher who calls one drug \u201clow-toxicity\u201d and lists 3 adverse effects, but does not say with what frequency they occurred. According to the linked study, 11% of patients developed grade 3 (severe) and 4 (life-threatening) adverse events related to the treatment. We don\u2019t think that\u2019s what readers have in mind when they hear \u201clow-toxicity.\u201d", "answer": 0}, {"article": "\"Therefore, we are currently working on devising treatment strategies to obtain the same beneficial effects in AD humans using low doses of calcineurin inhibitors that result in minimal or no immunosuppression, thus limiting possible undesired side effects.\"\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\n\"These data clearly show that the prevalence of dementia and Alzheimer's in our transplant patient group is significantly lower, in fact almost absent, when compared to national data from the general population,\" said senior author Luca Cicalese, professor in the department of surgery.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\nAs part of the medical care for transplant recipients, any evidence of memory impairment or dementia is immediately noted and monitored, as it can limit treatment compliance among these patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does point out that preventive treatment with anti-rejection drugs suppresses the immune system. \u00a0But exactly what does that mean? \u00a0What are the implications of this effect? The release does not provide any description of the potential problems that could occur. And that is not the only issue with these drugs. Both tacrolimus and cyclosporine have an extensive its of side effects.", "answer": 0}, {"article": "\"Unfortunately, there are side effects with a catheter.\nWEDNESDAY, June 1, 2016 (HealthDay News) -- If you find yourself hospitalized, you've got a one in five chance of needing a urinary catheter -- raising your risk for a urinary tract infection.\nThe program Saint helped develop -- called the \"bladder bundle\" -- includes protocols, checklists, training and information-sharing that help doctors and nurses reduce catheter use and prevent infections.\n\"A lot of patients and families don't realize that there are problems with a urinary catheter, so they may request them because they think it will allow patients to stay in bed,\" Saint said.\nAn intervention that focuses on changing the culture in hospitals to make them more responsive to the problem of infection control -- one that involves \"rallying around a focused problem and ensuring team-based solutions -- is integral to improving infection control in hospitals,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed in this story, but improved caretaker education on when and when not to use a catheter, and how to insert one while reducing the risk of infection, doesn\u2019t seem to warrant it.\u00a0\u00a0Although there may be some harms from this \u201cbundle,\u201d the study itself was not set up to look for them.", "answer": 2}, {"article": "Another group, the Council for Responsible Nutrition (CRN), which represents the dietary supplement industry, also had reservations about the study.\nIn a statement, Douglas MacKay, CRN's vice president of scientific and regulatory affairs, said that \"there is a large body of previously published evidence, as well as ongoing trials, which suggest that ginkgo biloba is effective for helping to improve cognitive impairment in older adults.\"\n\"Measuring the effect of ginkgo in a big trial in older people, we didn't see any effect of the drug on slowing down or delaying normal age-related changes of cognition,\" said lead researcher Dr. Steven T. DeKosky, vice president and dean of the University of Virginia School of Medicine in Charlottesville.\nOver more than six years of follow-up, the researchers found no evidence that ginkgo delayed or prevented normal declines in memory, language, attention, visuospatial abilities or executive functions, such as anticipating outcomes and adapting to changing situations and thinking abstractly.\n\"The good news is it appeared that it was fairly safe; the bad news was it didn't seem to do anything at least as far as trying to slow down the cognitive changes of aging.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the study found that ginkgo was safe and no serious side effects were noted. But it could have noted that the National Center for Complementary and Alternative Medicine states that \"Side effects of ginkgo may include headache, nausea, gastrointestinal upset, diarrhea, dizziness, or allergic skin reactions. More severe allergic reactions have occasionally been reported.\" ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of treatment, i.e. increased risk of advanced prostate cancer and fatal prostate cancer were mentioned.\u00a0 However, the source article for this story included estimates of the frequency with which these normally occur, so the story could have included this information and provided a more informative picture.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms in its lead sentence, referring to \u201csuch serious side effects as sudden bone fractures.\u201d As noted above, the entire story is essentially about comparing the benefits and risks of bisphosphonate use for treating osteoporosis. The story does a good job of discussing potential (and serious) side effects such as sudden fracture of the femur and osteonecrosis of the jaw. However, the story doesn\u2019t mention the less serious (but more common) side effects such as heartburn or other gastrointestinal problems.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The original AP story mentions that the vaccine may not be very effective and may be considered overtreatment in otherwise healthy younger smokers.\u00a0 But the NY Daily News cut out that part in what it published.\u00a0 Neither version mentioned potential side effects of the vaccine, which might include pain if adminstered via the muscle, and allergic reaction, though this is rare. ", "answer": 0}, {"article": "He said the group was planning additional research into the potential health effects of regular fasting.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\nIt appears to be that fasting is causing some major stress, and the body responds to that by some protective mechanisms that potentially have a beneficial long-term effect on risk of chronic disease.\u201d\n\nDr. Horne noted that patients shouldn\u2019t take up fasting without discussing it first with their doctor.\nThe study showed only an association between fasting and better heart health, which means it\u2019s possible that fasting may not have a direct effect but might just be more common among people who are healthier to begin with.\n\u201cThe first study we did was not a chance finding,\u2019\u2019 said Dr. Benjamin D. Horne, director of cardiovascular and genetic epidemiology for Intermountain Healthcare, a health services and managed care firm in Salt Lake City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only discussion of potential harms of fasting was this: \u201cAny fast should include water because dehydration can raise risk for stroke.\u201d\u00a0 Over what period of time?\u00a0 What\u2019s the evidence base?\u00a0 In what kinds of people? What could happen if people at risk for cardiovascular disease, such as diabetics, fast?\nEven the previous line in the story suggests a broader issue than that when it said \u201cfasting is causing some major stress.\u201d\u00a0 What does that mean, and what are the broader implications for potential harms?", "answer": 0}, {"article": "The paper \"Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening\" is available at: https:/\n\nTo request a copy of the study, please contact: Daniel Luzer\n\n daniel.luzer@oup.com\nAn HPV test, in which doctors test a cervicovaginal specimen for the presence of the nucleic acids of carcinogenic types of HPV, is more sensitive than the Pap test (a microscopic examination of exfoliated cells) for detection of precancers.\nThe HPV test captures the known cancer causing viruses, but there are gynecologists who believe that there may be unknown cancer causing viruses and so continue to do the Pap smear (plus HPV testing).\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\nThe accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly explain the harms of cancer screening. The release addresses the harm of omitting one test, but this wasn\u2019t enough to meet our standard.\u00a0The release states that HPV is \u201cmore sensitive than the Pap test for detecting precancer.\u201d But it doesn\u2019t discuss the flip side, which is that many pre-cancers may not go on to become cancer even though all are treated.", "answer": 0}, {"article": "Longo, the NEJM editorialist, says he'd be more convinced if the placebo patients had received infusions of white blood cells that had been exposed just to the general immune-stimulating part of the Provenge treatment, without the prostate antigen part.\nDeep in the data is further mystery.\nThat's better than the only other approved treatment for such advanced cancers.\nNobody yet knows just how to explain these results.\nAfter decades of dreaming about getting patients' immune systems to fight cancer, immunotherapy is finally here.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms found in the studies. ", "answer": 0}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\n\"This is the first instance of therapeutic regeneration,\" says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute.\nHe says while nature abounds with examples of spontaneous regeneration of limbs or tissues - like a salamander's new tail or a human liver regrowing to full size if partially damaged - doctors have not been able to help patients regrow heart tissue.\nA total of 25 patients participated in the clinical trial, which was designed to determine if it was safe to have cells grown from one's own heart tissue injected back into the heart.\nIn patients who received the cell transplant, Marb\u00e1n says about half of their scar tissue dissolved and the reduction in scar size appears to get bigger after the first six months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story at least mentioned harms. Another story on the study, by WebMD, did not. This one says, \u201cAfter 12 months, researchers report only one patient appeared to have a serious side effect that may have been connected to the experimental cells.\u201d Competing coverage discussed a broader group of patients who had bad outcomes, although it is not clear that all of those outcomes were a result of the treatment. Pinpointing the cause of a side effect can be tricky, and given the lead researcher\u2019s financial interest in this stem cell therapy, we think stories should err on the side of providing more information about potential harms.", "answer": 1}, {"article": "Women were defined as light drinkers if they had no more than one or two drinks a week.\n\"Our results suggest that children born to mothers who drank at low levels were not at any risk of social or emotional difficulties or any risk of emotional impairments compared to mothers who did not drink,\" Kelly tells WebMD.\nIn the U.S., pregnant women are strongly advised not to drink at all, says Eva Pressman, MD, director of maternal/fetal medicine at the University of Rochester, N.Y.\n\nPressman points out that women who are light drinkers during pregnancy tend to be from households with relatively high incomes.\nIn the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\n\"What we tell women is that we don't know of a safe threshold for drinking alcohol during pregnancy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to quantify the harms of drinking too much alcohol. The whole study was about whether alcohol harms kids, and this should have been quantified in some way.", "answer": 0}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\n\u201cThe unexpected presence of the Alzheimer\u2019s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer\u2019s disease pathology is active and detectable earlier than has heretofore been envisioned,\u201d Geert De Meyer of Ghent University in Belgium and colleagues wrote.\nCurrently, only an autopsy can confirm that a person has Alzheimer\u2019s, a fatal and incurable deterioration of the brain that affects more than 26 million people globally.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nLast month, experts at the National Institute on Aging and the Alzheimer\u2019s Association proposed new guidelines for diagnosing Alzheimer\u2019s even before patients have symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention any potential harms of either the spinal tap procedure itself or from the interpretation of the test results. The spinal tap harms include pain and bleeding. The harms of the test could include insurance or employment discrimination, as well as the consequences of mistaken diagnoses.", "answer": 0}, {"article": "The benefits were still seen after a year.\n\"Both acupuncture and traditional medicine have a place in treating fibromyalgia,\" said Dr. Alexander Rances, an acupuncturist, pain management specialist and attending physician at North Shore University Hospital in Manhasset, N.Y.\n\n\"A combination of Western as well as traditional Chinese medicine probably offers these patients the best possible therapy,\" he said.\nMONDAY, Feb. 15, 2016 (HealthDay News) -- Acupuncture may help ease pain and improve quality of life for people with fibromyalgia, a new study suggests.\n\"Although it was allowed for the participants to continue with the pharmacological [drug] treatment they were taking beforehand, when the study was finished, the patients who received individualized acupuncture were taking less medication than the group on sham acupuncture,\" Vas said.\nFor the study, Vas and colleagues randomly assigned 153 patients diagnosed with fibromyalgia to individually tailored acupuncture or simulated acupuncture.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of potential harms from the use of acupuncture although the research paper clearly\u00a0identified some \u201cmild adverse events\u201d affecting participants. These included headaches, pain and bruising at the acupuncture sites, and an aggravation of some fibromyalgia symptoms. While these are far from serious harms, readers deserve to know that they are possible outcomes.", "answer": 0}, {"article": "Smoking was defined as having had one or more cigarettes in the last week.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\n\u201cFinding a way to help infants exposed to smoking and nicotine in utero recognizes the unique dangers posed by a highly advertised, addictive product and the lifetime effects on offspring who did not choose to be exposed.\u201d\n\nIn a previous study, the authors had shown that 72 hours after birth, babies of mothers who smoked had better lung function if their mothers were randomized to vitamin C (500 mg/day) during their pregnancies compared to those born to mothers who smoked and were randomized to placebo.\n#Nosmokingduringpregnancy.\u201d\n\nAbout the American Journal of Respiratory and Critical Care Medicine\n\nThe AJRCCM is a peer-reviewed journal published by the American Thoracic Society.\nIn \u201cOral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial,\u201d Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from vitamin C use.\u00a0Since some readers may take license with these preliminary findings \u2014 and think more vitamin C is better (ie. improve their infant\u2019s lung function) \u2014 the potential harms of vitamin C should have been included.\nPeople can have allergic reactions to vitamin C at even low doses. At higher doses it can be problematic in people with kidney disease, and could be detrimental to fetuses.", "answer": 0}, {"article": "Related: How to Lose Weight and Keep it Off?\nFor those who just can\u2019t give up grains (or regular eating), a new study indicates that being less restrictive is actually better for your waistline.\n\"I was really impressed that they still saw almost a two kilogram weight loss during that last period at the end of the four months,\" she tells Newsweek.\nKrista Varady, an outside researcher who studies intermittent fasting (not the same as intermittent dieting) and weight loss at the University of Illinois, believes the results were significant.\nPaleo has a devout following who swear by its protein-heavy meals, while intermittent fasters believe that forgoing food for hours on end (which varies, but can include skipping meals for an entire day), provides the best results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this N/A since it\u2019s hard to imagine harm from restricting a third of normal calories for two week cycles over 16 weeks.", "answer": 2}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nGiven the current understanding and strength of evidence supporting the importance of nutritional supplementation during pregnancy, \u201cit is impossible to imagine that these results, on their own, should change current practice,\u201d they write.\nResearch indicates that ASD most likely develops in the womb and that a mother\u2019s diet during pregnancy could have an influence.\nMore boys are diagnosed with the condition than girls.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms \u2014 or lack of harms, if that\u2019s the case \u2014 from taking multivitamins or extra iron were mentioned in the release.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although uterine cancer and blood clots are mentioned as harms of treatment, there is no mention of how often they occur. Other harms such as cataracts and stroke are not mentioned.", "answer": 0}, {"article": "The study was funded by MD Anderson's HPV Moon Shots Program and the HPV Anal Cancer Foundation, the E.B.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This news release makes no mention of potential harms. According to the Chemocare.com website, more than 30 percent of patients on nivolumab may experience fatigue, low white blood cells, low sodium, shortness of breath, musculoskeletal pain, decreased appetite and cough.", "answer": 0}, {"article": "\u201cWe are saying forget about stimulating an immune response.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe leukemia patients in the Phase I trial had to be treated with an immunity-boosting drug since the targeted molecule, CD-19, is also present on certain normal immune-system cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gave short shrift to potential harms. The WebMD story stated more plainly that patients suffered debilitating side effects and, in one case, had to be treated with steroids that may have hindered the effectiveness of the cancer therapy.", "answer": 0}, {"article": "They also put tested at against petroleum jelly and regular moisturizer on 22 people with dry, flaky legs.\n\u201cRubber alone would not be that strong.\u201d\n\nIn this case, the catalyst is platinum-based and it turns the gel into a thin, stretchy sheet.\n\u201cMany people have tried to do this, and the materials that have been available up until this have not had the properties of being flexible, comfortable, nonirritating, and able to conform to the movement of the skin and return to its original shape.\u201d\n\nThey screened about 100 compounds before settling on polysiloxane, a silicone-based gel.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n\u201cFor now, there is no magical cream that can make you look younger.\u201d\n\nOlivo will work first to develop the product to deliver drugs to the skin \u2013perhaps allergy or eczema medication, or long-lasting sunscreen, MIT said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells us that\u00a0\u201cRepeated daily wear resulted in no report of irritation or other adverse events resulting from the XPL use.\u201d That\u2019s at least a nod toward discussing potential harms, so we\u2019ll consider this Satisfactory.\nBut, we think the story would be stronger if it had been more specific about what \u201crepeated\u201d meant. We\u2019re also wondering about things that could inevitably occur with regular use, like the product getting into the eyes.", "answer": 1}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms in this statement: \u201cThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\u201d\u00a0 But that is by no means enough. More than a third of the patients in the study developed gait problems or numbness, or both, that in some cases persisted for 12 months. Others developed ataxia, unsteadiness and weakness that was persistent. The release seems to go overboard in downplaying these adverse effects and amplifying the positive outcomes. Releases should never cherry-pick the data from a study.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one\u2019s a close call that we ultimately ruled unsatisfactory. The story is enamored with the greater accuracy that \u201creal-time\u201d imaging should provide for surgeons, but it doesn\u2019t acknowledge that the scalpel cuts both ways. With increased visibility, there\u2019s a greater chance that these scans will turn up so-called \u201cincidental findings\u201d \u2014 problems that no one was looking for and that could well be meaningless to the patient (for example, a slow-growing tumor that would never pose a real risk to the patient). Cutting based on such findings may, in fact, increase morbidity and mortality.\nThe story does get credit for thoroughly explaining the potential risks associated with MRIs. However, the story does not address the risks associated with CT scans at all. CT scans require exposure to a significant amount of radiation, and patients can suffer allergic allergic reactions to the contrast dyes.", "answer": 0}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\nCHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nThe test represents a first in the rapidly developing field of \u201cliquid biopsies,\u201d which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers.\n\u201cFor any given test, the rate of false positives causing unnecessary alarm and false negatives that provide false security should be known,\u201d said Dr. Keith Stewart, an oncologist who heads Mayo Clinic\u2019s Center for Individualized Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The competing Bloomberg story gave a nod to false positives and false negatives, but Reuters really explained why these tests could lead to harms. The story says, for example, \u201cPatients might be attracted to a less-invasive test for colon cancer, but if it is less effective, it might result in more cases of colon cancer, not fewer.\u00a0Another concern is that the tests may pick up on markers that are never destined to be cancer, something already known to occur in blood tests for prostate cancer\u201d.", "answer": 1}, {"article": "Citing World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nThe device, made of both synthetic and animal tissue, is driven by two miniature electric motors.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\nIt is operated by a microcontroller and powered by electromagnetic induction through the skin or through a plug implanted behind the patient\u2019s ear.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 something that must be discussed with any artificial heart device. ", "answer": 0}, {"article": "This study wasn't long enough.\nIn addition, we are testing if this approach can be used in treating other leading causes of blindness, such as macular degeneration and glaucoma,\" said Zhang.\nHe also pointed out that the study involved infants, and that adults -- the most common cataract patients -- have a different regenerative capacity of lens epithelial stem cells.\n\"The study's stem cell engineering has led to the regeneration of transparent lens tissue in children, showing that the concept offers a potential therapeutic approach,\" Daniels wrote.\nA certain kind of stem cell, called endogenous stem/progenitor cells, when left intact, then begins to repopulate the damaged lens and essentially grow a new, healthy lens.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss short- or long-term harms that may arise from this new approach.\u00a0It may be too soon for researchers to determine potential long-range harms from this approach, but saying that would have offered readers some perspective.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that various organizations and experts consider the chemical/medicinal treatments to be highly safe as well as effective.", "answer": 1}, {"article": "The other half received sugar pills.\nIn a new study, the protein-inhibitor drug rilonacept (Arcalyst) appeared to markedly lower the risk of gout flare-ups during the first few months of treatments aimed at lowering uric acid levels.\n\"Well-tolerated drugs that reduce the risk of gout flares when initiating uric-acid lowering therapy could make patients more likely to continue important long-term treatments that control gout,\" Schumacher said in the release.\nThe researchers wanted to learn if rilonacept could lower this short-term risk for by neutralizing a specific target protein -- interleukin 1 or IL-1 -- before it initiates inflammation.\n\"But there are a number of patients who can't take a less expensive alternative, such as nonsteroidal anti-inflammatory drugs, because of their kidney function or ulcer disease,\" Becker noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The standard line about \u201cappears safe and well tolerated\u201d is all we hear about harms.\nEven the news release did better than that, stating: \u201d Common adverse events included infections reported in 15% of the rilonacept group compared with 26% with the placebo.\u201d", "answer": 0}, {"article": "MORE: Losing Focus?\nIn fact, in 2005, more than 500 brain researchers signed a petition (albeit an unsuccessful one) to protest a scheduled lecture on the neuroscience of meditation by the Buddhist spiritual icon, the Dalai Lama, at a major conference organized by the Society for Neuroscience.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Though it doesn\u2019t explicity report on harms, the story does imply that meditation \u201ccan\u2019t hurt you,\u201d which we\u2019ll agree is an accurate sentiment. Any harms are likely to be indirect \u2014 i.e. choosing meditation (a possibly ineffective treatment) over something that is more proven.\nHowever, the story whiffed on the important indirect harm of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants.\nAll interventions have costs.\u00a0 All interventions have harms.\u00a0\u00a0 All health care new stories \u2013 in our opinion \u2013 need to report on both.", "answer": 0}, {"article": "Regular aspirin use can also cause side effects, like stomach bleeding and ulcers.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only listed stomach bleeding and ulcers as side effects of aspirin.\u00a0 The story also failed to include information about often it occurs.\u00a0 However as this is a story about prevention of Alzheimer\u2019s disease, it should have mentioned that the bleeding risks associated with aspirin use increase with age.", "answer": 0}, {"article": "\"His mood improved.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\nThis will allow researchers to develop more robust data and expand the scope of the study, including a focus on specific clinical factors that may impact how patients with dementia engage with and respond to apps.\n\"Our preliminary results are a first step in developing much-needed empirical data for clinicians and caregivers on how to use technology such as tablets as tools to enhance care and also for app developers working to serve the technologic needs of this population.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addressed harms by saying \u201cresearchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\u201d", "answer": 1}, {"article": "Meditation consisted of sitting with eyes closed for about 20 minutes twice a day.\n\"One of the reasons we did the study is because insurance and Medicare calls for citing evidence for what's to be reimbursed,\" Schneider said.\n\"In addition, since this study was conducted at a single center and the primary [change in heart attack, stroke and death] was not statistically significant without adjustment for other factors, more studies and replication of these findings are needed,\" he said.\n\"This is a whole new physiological effect on top of conventional treatment,\" said lead researcher Dr. Robert Schneider, director of the Institute for Natural Medicine and Prevention in Fairfield, Iowa.\nAfter more than five years of follow-up, the researchers found those who meditated saw significant reductions in blood pressure and anger compared to those receiving health education.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Same observation we made in reviewing the TIME.com story: An important indirect harm is that of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants \u2013 less than $18,000 annually.\u00a0 The story didn\u2019t address this.", "answer": 0}, {"article": "THURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\nOther research has found that healthy women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.\nAfter five years, about 400 women in each group either died or had recurrences.\nSince the current study was presented at a meeting, its findings should be considered preliminary until published in a peer-reviewed journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported on the incidence of a serious side effect among the women taking zoledronic acid.", "answer": 1}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nOur intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\nWe think the drug must at least diminish the food-seeking drive, which correlates to an increased caloric intake in patients.\u201d\n\nZafgen, founded in 2005, is backed by investors that include venture capital firms Atlas Venture of Cambridge and Third Rock Ventures of Boston.\n\u201cThe efficacy of Beloranib looks very promising,\u201d said Dr. Merlin G. Butler, director of research and genetics at the University of Kansas Medical Center in Kansas City, Kan., and a principal investigator for the clinical trial there.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article discloses the possible side effects of beloranib related to blood clotting along with the caveat that Prader-Willi patients are predisposed to clotting issues. Two deaths out of 100 patients is a significant issue, even if they can\u2019t be linked definitively to the drug, so it\u2019s good that this is a focal point. But the story mentions no other adverse effects that were observed in the study, and it should have. We\u2019ll give the benefit of the doubt and hope for improvement next time.", "answer": 1}, {"article": "The shorter treatment duration encouraged McCartney to have brachytherapy.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\nAlthough standards depend somewhat on doctors' preferences, candidates for breast brachytherapy typically have early-stage tumors with a margin of healthy tissue around the tumor site after removal and minimal or no migration of cancer cells to nearby lymph nodes.\nBecause the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most important potential harm of brachytherapy would be a lack of efficacy\u2013that is, a patient would choose it due to its greater convenience, despite what could be a lower success rate. Given the lack of long-term data on efficacy available, this is a significant shortcoming.\u00a0 \nThe article does not acknowledge other potential harms of brachytherapy when used for breast and prostate cancer.\u00a0\u00a0 ", "answer": 0}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\n\"Perhaps the program fosters better mental health in the children, which in turn leads to better eating,\" he said.\nAt the study's start, about one-third of the Head Start kids were obese or overweight, compared to 27 percent of those on Medicaid and less than 20 percent of kids not on Medicaid.\n\"Even though children in the Head Start group began the observation period more obese, equally overweight, and moreunderweight than children in the comparison groups, at the end of the observation period the initially obese and overweight Head Start children were substantially less obese andoverweight than the children in the comparison groups,\" the authors wrote.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in this article. However, it is difficult to ascertain possible risks or harms in a case like this.", "answer": 2}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\n\"Unless you can be sure your biopsy has hit the most aggressive part that's in the prostate, you can't be sure\" how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\nDoctors at first were leery of it until studies in more groups of women proved its value, and the same may happen with the prostate test, said Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer.\n\"We're not giving patients enough information to make their decision,\" said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco.\nA new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the potential limitations of the new testing approach.\n\u201cUnless you can be sure your biopsy has hit the most aggressive part that\u2019s in the prostate, you can\u2019t be sure\u201d how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\n\u2026\nUCSF just got a federal grant to see how men choose treatments and whether this test might sway them.\n\u201cWe throw all these numbers at them. Are they really going to make a better decision?\u201d Cooperberg said.", "answer": 1}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story did mention some of the common side effects that occur following gastric bypass surgery, it actually neglected to mention some of the serious side effects of surgery.\nIn addition, since the story was about the impact of gastric bypass surgery on diabetes, it also should have mentioned that resolution of diabetes is not guaranteed to be permanent and reoccurs in as many as 30 out of 100 people who had improvement.", "answer": 0}, {"article": "None did.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\nMeanwhile, in Philadelphia, radiologists examined the scans and calculated how much plaque was present in the patients\u2019 brains and, independently, used a computer to analyze the amount of plaque in the scans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0Although the story did mention that the test involved a radioactive tracer, there was no information about the level of radioactivity exposure involved in the test or whether there were any adverse events reported with the use of this particular dye.", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nHowever, a new study shows the use of novel anticoagulants for AF prescribed on an \"as-needed basis\" guided by diligent pulse monitoring, can be a safe and effective alternative to lowering overall risk of stroke.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\nPHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions the bleeding harms that come with taking anticoagulants, a harm that increases with chronic use. However, the release suggests that the therapy was proven safe when that wasn\u2019t clearly established.", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nThe story demonstrates an all too familiar bias with regard to screening tests; there are no down sides.\u00a0 A couple of words of caution (again the CNN story got it right) about the implications of testing and test results would have been useful.\u00a0 If, for example, the fMRI and DTMRI scans are as accurate as this study indicates, might treatment be withheld from children who do not have the brain scan results that promise likely improvement?", "answer": 0}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\nHeart defects and other health problems are also common, according to the March of Dimes.\nOlder mothers are more likely to give birth to Down syndrome babies.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\nThe new test eliminates the risk of miscarriage, Patsalis said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues still not determined after such a small study.", "answer": 0}, {"article": "The first problem we solved was: how do we make the hand move electronically?\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n\"We quickly found out this is much less about fitting in and feeling normal, and much more about expressing yourself,\" Petresky said.\nThe UCF project started when Albert Manero, an engineering doctoral student, heard a story on the radio about one of the inventors of the 3-D printed hand.\n(CNN) By the time Cynthia Falardeau read about Alex Pring, a little boy who got a battery-powered robotic arm last summer, she had made peace with her son Wyatt's limb difference.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of how well these 3D printed prosthetics fit onto the patient\u2019s bodies. Surveys of people with prosthetic arms indicate that many users have problems with skin irritation, blisters and upper body pain. This story did not mention any of the potential problems that are common among users of prosthetic limbs.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cBut the study showed an increase in the number of device- or implantation-related complications within 30 days of implant: 118 among 888 patients with the new device, compared to 61 of 898 in the standard defibrillator group.\u201d This is beyond what the LA Times did, and we think it is adequate for this score.", "answer": 1}, {"article": "His team\u2019s new approach aims to change that with a simple and inexpensive at-home test option.\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\nAs things stand now, men have to provide samples \u201cin these specific rooms in hospitals under so much stress and embarrassment,\u201d the study\u2019s principal investigator, Hadi Shafiee, PhD, told CBS News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t discussed, and there\u2019s a significant one: a man receiving a false-negative test (he believes his sperm count is too low, when it\u2019s actually normal) or a false-positive (his sperm count is low, but a test tells him it\u2019s normal) \u2014 and telling his partner this incorrect information. For a\u00a0couple that\u2019s trying desperately to conceive, that could be crushing news or deceptive false-hope. Any news story about a new screening test should discuss the false-negative and false-positive rates.\nFor example, a story at LiveScience\u00a0captures these well, telling readers that about 98% of people with no training could detect abnormal sperm samples from a fertility clinic with the new device. The sensitivity of the test\u2019s ability to actually detect a sample with a low sperm count was 99.3%, but only 89.4% of normal-sperm-count samples were correctly read by the device. This means more than 10% of men with a normal sperm count might be lead to believe their numbers are abnormal.", "answer": 0}, {"article": "For more information, visit http://www.\n\"This is a well-designed trial that demonstrates how a prebiotic could potentially help combat one of the most prevalent and costly conditions afflicting children in the developed world -- overnutrition -- by targeting the gut microbiome,\" said Geoffrey A. Preidis, MD, PhD, a member of the AGA Center for Gut Microbiome Research and Education scientific advisory board.\nBased on four-month intervention data, the annual projected body weight increase in the prebiotic group would be 3 kilograms (6.6 pounds), within the expected healthy range, whereas the projected increase in the placebo group was 8 kilograms (17.6 pounds), almost triple the expected yearly weight increase.\n\"Powdered fiber, mixed in a water bottle, taken once a day is all we asked the children to change, and we got, what we consider, some pretty exciting results -- it has been fantastic,\" added Raylene A. Reimer, PhD, RD, professor and researcher in the Faculty of Kinesiology at University of Calgary, who led the study.\nPrebiotics reduce body fat in children who are overweight or obese by altering their gut microbiota, according to new research published in Gastroenterology, the official journal of the American Gastroenterological Association (AGA).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote indirectly suggests that the prebiotics are \u201cnon-invasive\u201d but that doesn\u2019t tell us a lot. Bloating and gas are often at least a temporary problem. It would have been useful to know how well children in the study tolerated the supplement.\nAnd if the parents of children with obesity are not changing their diet (avoiding high fructose corn syrup, excessive prepared foods, and overfeeding), and letting the supplement do the work, that\u2019s not teaching kids to eat healthily, which is an unintended consequence.", "answer": 0}, {"article": "[2] This number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.\nProfessor Hilkka Soininen, Professor in Neurology MD, PhD from the University of Eastern Finland, who headed the clinical trial as part of the LipiDiDiet project, said: \"Today's results are extremely valuable as they bring us closer to understanding the impact of nutritional interventions on very early AD (pre-dementia) which we are now better at diagnosing but unable to treat due to a lack of approved pharmaceutical options.\n\"This is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early.\n\u2022 Academy of Sciences of the - Institute of Physiology\n\nFor further information on the European LipiDiDiet study and consortium, visit: http://www.lipididiet.eu\n\u2022 A Clinical Trial investigating the effects of Fortasyn Connect (Souvenaid) in Prodromal Alzheimer's Disease: Results of the LipiDiDiet study H. Soininen, , M. Kivipelto, T. Hartmann for the LipiDiDiet study group (2016), presentation held at 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy,\n\u2022 The World Alzheimer Report 2015: 'The Global Impact of Dementia'.\nThe initiative benefits from funding provided by the 7th Framework Programme (FP7- 211696) of the European Commission, and follows on from previous projects in the field of dementia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know the possible risks associated with drinking an amalgam of different food products. And this release provides no insights. Previous studies have suggested that the nutritional product is well tolerated and did not appear to cause any harms. That being said, we think that this should have been noted in the report.", "answer": 0}, {"article": "Overall, more than half of people who run will experience some sort of injury from doing so, while the percentage of walkers who will get hurt is around 1 percent.\nYou're also more likely to trip and fall while running than you are during a walk.\nThere's even evidence that running can have positive effects on tension, depression, and anger.\nIt was immediately apparent that running can lead to more injuries, and the risk goes up as running programs get more intense.\nStudies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story does a very good job of quantifying the potential risks of running and of comparing the likelihood of injury from running to those for walking.", "answer": 1}, {"article": "Franks says thalidomide can help an additional 75% of patients achieve remission.\nThe majority of the patients (60%) had the most common subtype of lupus-related skin disease, known as discoid lupus erythematosus, which is characterized by red, scaly patches that can scar.\nIn a small study from Spain, lupus patients showed dramatic improvements in skin lesions while taking the drug, lenalidomide (Revlimid), and most relapsed soon after they stopped taking it.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not found in the current study (probably due to small sample size and short follow-up period), lenalidomide may lead to progression of full-blown lupus \u2013 and the story appropriately mentioned this. Birth defects were also mentioned as possible side effects of using lenalidomide.", "answer": 1}, {"article": "An ancient herbal remedy is getting fresh attention this cold and flu season.\n\"There is not enough research about whether [elderberry] works in children and there is also isn't enough information about the proper dose in children,\" Dr. Anna Minta of Johns Hopkins Children's Center told CBS News.\nThe Brennan family in Glen Rock, New Jersey, believes it works..\n\n\"So we give the kids, and we take it ourselves, elderberry every morning right after breakfast,\" Kevin Brennan told CBS News.\nThe Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nOne small study found an elderberry extract called Sambucol could shorten the duration of flu symptoms after a person gets sick by about 3 days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit here for making it clear that raw elderberries are poisonous. However, the story is about commercially-prepared elderberry extract, not raw berries. There was no discussion of possible harms of extracts. While the few clinical trials of elderberry extract did not report adverse events, the story could have at least noted that supplements are exempt from most FDA regulations. The lack of inspections and independent quality control checks means that consumers are almost entirely dependent on the internal procedures of manufacturers. Thus, there is no independent guarantee that the potentially poisonous elderberries are being properly prepared.", "answer": 1}, {"article": "Other Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nOf 108 patients so far evaluated by bone scan, 21 had complete resolution, and 61 had partial shrinkage of metastatic bone lesions, which can lead to bone fractures, severe pain and eventual death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said \u201cSide effects of cabozantinib included fatigue, high blood pressure and hemorrhage\u201d but it never explained how often these were seen.\u00a0 In 1% of patients?\u00a0 10%\u00a0 All of them? ", "answer": 0}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\nThis is especially true if a student doesn't have access to other meals during the school day.\nThere's less supervision by parents and less structure.\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that care was taken not to give these snacks to children who had nut allergies.", "answer": 1}, {"article": "The test measures five chemicals in the breath.\nEach year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\nThis method is expensive, invasive and has some risk of complications,\" study author Dr. Sheraz Markar said in an ECC news release.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself\u2013if an exhaled breath is all it involves\u2013is unlikely to carry immediate harms. But with any lab test used to detect disease, the potential harm is if the test fails the patient\u2013by either flagging them as having cancer when they don\u2019t, or flagging them as not having cancer when they do. The first scenario can cause anxiety and lead to extra, unnecessary testing, and the second means the cancer is going untreated. We always hope to see a nod to this in any story about testing, and it\u2019s why we often say \u201cthere is no such thing as a simple medical test.\u201d", "answer": 0}, {"article": "The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.\n\u201cWith our latest results, we believe that brexanolone, if approved, could provide relief for women with a range of postpartum severity.\u201d\n\nThe paper, published in The Lancet, includes a new integrated analysis of results from three double-blind, placebo-controlled trials that took place at 30 sites in the U.S., including UNC\u2019s Perinatal Psychiatry Unit.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\nIn the brexanolone trials, we saw patients starting to feel better within days,\u201d said the trial\u2019s academic principal investigator, Samantha Meltzer-Brody, MD, MPH, director of Perinatal Psychiatry Program at the UNC School of Medicine.\nThe first statistically significant reduction in depression severity with brexanolone injection relative to placebo was observed as early as 24 hours after dosing.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains one somewhat vague sentence on harms.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\nReaders would also be interested in details on whether the drug is safe for nursing infants. That\u2019s not mentioned.", "answer": 1}, {"article": "http://www.\nAmsterdam, July 3, 2017 - Doctors should consider radiosurgery earlier for patients with severe facial pain, according to a new study in the International Journal of Radiation Oncology*Biology*Physics (the \"Red Journal\") - the official journal of the American Society for Radiation Oncology (ASTRO).\nThe article is \"Stereotactic Radiosurgery for Trigeminal Neuralgia Improves Patient-Reported Quality-of-Life and Reduces Depression,\" by Rupesh Kotecha, Jacob A. Miller, Sujith Modugula, Gene H. Barnett, Erin S. Murphy, Chandana A. Reddy, John H. Suh, Gennady Neyman, Andre Machado, and Sean Nagel.\nWhile this can reduce the pain, it makes patients drowsy and tired, and they report feeling drunk.\nThe researchers analyzed patients' answers before treatment and at each follow-up appointment, and found that patients reported an improved quality of life and lower rates of depression after radiosurgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It would be most useful to know why radiosurgery is typically a \u201csecond line treatment to be used following the medication\u201d and so one wonders if this is due to the harms involved with this type of surgery which can include fatigue, skin problems, and difficulty swallowing, none of which are mentioned in the news release. At a minimum, if there weren\u2019t any side effects among the patient volunteers, the release could have stated that there weren\u2019t any. Additionally, since the treatment involves radiation and radiation can promote cancer, the study should have mentioned this and why or why not it is an issue with this specific treatment.", "answer": 0}, {"article": "It\u2019s better to avoid fatty food altogether.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nIn a study published in the American Journal of Cardiology, scientists from the National Heart and Lung Institute at Imperial College London calculated that the reduction in heart disease risk offered by a statin could offset the increase in risk from eating a cheeseburger and a milkshake.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to ding the story for not actually calculating the potential harms, given that the piece is based on an editorial. In all, we think the story did a fair job pointing out the problems with using statins as a subsitute for exercise and a healthy diet. It could have at least mentioned some of the side effects of long-term statin use.", "answer": 1}, {"article": "Preventive treatment has not changed much over the last three decades.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nIn addition to Rimer and Asplin, authors on the paper include Giannis Mpourmpakis and his graduate student, Michael G. Taylor, of the University of Pittsburgh; Ignacio Granja of Litholink Corporation, and Jihae Chung, a UH graduate student working in Rimer's lab.\n\"If it works in vivo, similar to our trials in the laboratory, HCA has the potential to reduce the incidence rate of people with chronic kidney stone disease.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call. The release notes that some people are unable to tolerate the side effect of citrate and it says that safety studies of hydroxycitrate are needed, but there is no discussion of what potential harms the proposed treatment might pose.", "answer": 0}, {"article": "Neurontin causes sleepiness, and soy extracts can produce gastrointestinal troubles.\n\"There's a lot of hype around trying things that we haven't proven effective and, sadly, we haven't proven they're safe,\" said Dr. Heidi D. Nelson, the first author of the journal article and an internist and professor at the Oregon Health and Science University.\nThe drugs include the antidepressants Paxil (paroxetine), Effexor (venlafaxine), Prozac (fluoxetine) and Celexa (citalopram), the blood pressure drug Catapres (clonidine), and the seizure drug Neurontin (gabapentin).\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\n\"I wouldn't encourage the mindset of putting women on these drugs thinking they're going to be on them for life,\" he said, adding that patients should try the drugs for a few months and then try to stop.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions side effects of the non-hormonal treatment under study, as well as the risks associated with hormone replacement therapy. There is no mention of the incidence of these side effects. However, this was a meta-analysis of 43 studies, so side effects varied by medication and each study. ", "answer": 1}, {"article": "\"Now we get into the speculation part, right?\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nResearchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\n\"One option certainly is over these three decades we have become much better at treating the cardiovascular risk factors that come with overweight and obesity.\"\nThe BMI has been vilified as a poor measure of an individual's health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job describing why some people with low BMI might be at higher risk of dying\u2013 i.e., they may be suffering from cancer or another disease that could cause weight loss.", "answer": 1}, {"article": "The therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\nOne lost much of her abdominal wall to infection and just died in misery.\u201d\n\nAnother risk is that the surgery may be done unnecessarily.\n\u201cI\u2019ve had to say my goodbyes to everybody,\u201d Mr. S. said the day before the operation.\nThe incision was sewn up around the tubes so the chemotherapy would not leak.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that one study showed that \u201c8 percent who got the surgery and Hipec died from the treatment itself.\u201d\u00a0 And it stated:", "answer": 1}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nAt the start of the study, they drank, on average, 11 standard drinks daily.\nExperts said the drug is likely to appeal to heavy drinkers who would rather seek help from their own doctors, rather than enter a rehab clinic to dry out.\nThe drug, Topamax, works in a different way than three other medications already approved for treating alcoholism.\nIt's unclear how many relapsed after quitting the pill.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention some of the unpleasant side effects that people taking the drug experienced; although it did not provide information about how frequently they occurred, it mentioned that 20% of the people dropped out of the study which provides a composite of sorts.\u00a0 ", "answer": 1}, {"article": "\u201cShould he take a statin?\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\n\u201cFinasteride has to be recognized as the first clearly demonstrated way to prevent prostate cancer with any medication or any oral agent at all.\u201d\n\nFinasteride has had its ups and downs.\nBut the reality is that people are being operated on.\u201d\n\n\u201cWe are trying to avoid a diagnosis to avoid a prevention whose value is disputed,\u201d he said.\nIn the meantime, GlaxoSmithKline, which has a patented drug, Avodart, to reduce the size of men\u2019s prostates, has a study asking whether its drug can prevent prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did raise an important question about harms:\u00a0 \"Should healthy men take a drug for the rest of their lives to avoid getting and being treated for a cancer that, most often, would be better off undiscovered and untreated?Is it worth risking a chance that unanticipated side effects may emerge years later if millions of men with no prostate problems take this drug\u2026\"\u00a0 Although the balance of the story was out of whack \u2013 citing more proponents of using the drug than opponents \u2013 we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Partial replacements are also cheaper, say researchers from Oxford University.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\n\u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible,\u201d said Dr Rafael Pinedo-Villanueva, the co-lead researcher and NDORMS senior health economist, who is funded by the National Institute of Health Research Oxford Biomedical Research Centre and the Medical Research Council.\n\u201cFor patients and the NHS to see the benefits of partial replacements, we need the buy-in of surgeons, who would need to feel comfortable performing a greater proportion of their knee replacements as partials,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What risks are associated with getting either surgery? The story simply doesn\u2019t tell us.\nWhen considering harms, one needs to keep in mind the side effects of surgery, the recovery from surgery, how they function after recovery and then whether there are differences in the need for subsequent procedures.", "answer": 0}]